<SEC-DOCUMENT>0001055726-22-000034.txt : 20220510
<SEC-HEADER>0001055726-22-000034.hdr.sgml : 20220510
<ACCEPTANCE-DATETIME>20220510155907
ACCESSION NUMBER:		0001055726-22-000034
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		72
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220510
DATE AS OF CHANGE:		20220510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		22909382

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ino-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:500251c5-f1ff-4b5f-bcb3-245f4230a461,g:c147bae2-ade6-4d52-bd96-82e99e7a58d2,d:5cd930e6c7ce444abb7f72171f50164c--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ino="http://www.inovio.com/20220331" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ino-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180L2ZyYWc6NzA0YzNhZmQ2YjJhNDVhNmE5Y2RjOGQ3ZGI4NTNjNzQvdGFibGU6YzlkOGFkYmQzZWU0NGFhNjkwZDY3Yzc2YjZiOTVlYzkvdGFibGVyYW5nZTpjOWQ4YWRiZDNlZTQ0YWE2OTBkNjdjNzZiNmI5NWVjOV8xLTEtMS0xLTMxNjky_113148a0-daff-49e5-bbb6-3c21fd52b5c2">Mar 31, 2022</ix:nonNumeric><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180L2ZyYWc6NzA0YzNhZmQ2YjJhNDVhNmE5Y2RjOGQ3ZGI4NTNjNzQvdGFibGU6YzlkOGFkYmQzZWU0NGFhNjkwZDY3Yzc2YjZiOTVlYzkvdGFibGVyYW5nZTpjOWQ4YWRiZDNlZTQ0YWE2OTBkNjdjNzZiNmI5NWVjOV80LTEtMS0xLTMxNjky_007d5b7e-ba37-4057-9c1f-bb9b26c24e54">false</ix:nonNumeric><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180L2ZyYWc6NzA0YzNhZmQ2YjJhNDVhNmE5Y2RjOGQ3ZGI4NTNjNzQvdGFibGU6YzlkOGFkYmQzZWU0NGFhNjkwZDY3Yzc2YjZiOTVlYzkvdGFibGVyYW5nZTpjOWQ4YWRiZDNlZTQ0YWE2OTBkNjdjNzZiNmI5NWVjOV82LTEtMS0xLTMxNjky_680041c5-4c00-44f2-9b58-ff74258a8463">2022</ix:nonNumeric><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180L2ZyYWc6NzA0YzNhZmQ2YjJhNDVhNmE5Y2RjOGQ3ZGI4NTNjNzQvdGFibGU6YzlkOGFkYmQzZWU0NGFhNjkwZDY3Yzc2YjZiOTVlYzkvdGFibGVyYW5nZTpjOWQ4YWRiZDNlZTQ0YWE2OTBkNjdjNzZiNmI5NWVjOV83LTEtMS0xLTMxNjky_cd776983-f742-4168-8cde-5a399f3c31d7">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180L2ZyYWc6NzA0YzNhZmQ2YjJhNDVhNmE5Y2RjOGQ3ZGI4NTNjNzQvdGFibGU6YzlkOGFkYmQzZWU0NGFhNjkwZDY3Yzc2YjZiOTVlYzkvdGFibGVyYW5nZTpjOWQ4YWRiZDNlZTQ0YWE2OTBkNjdjNzZiNmI5NWVjOV85LTEtMS0xLTMxNjky_e29a1fc4-3b83-48f4-9b7d-36da11d9e589">0001055726</ix:nonNumeric><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180L2ZyYWc6NzA0YzNhZmQ2YjJhNDVhNmE5Y2RjOGQ3ZGI4NTNjNzQvdGFibGU6YzlkOGFkYmQzZWU0NGFhNjkwZDY3Yzc2YjZiOTVlYzkvdGFibGVyYW5nZTpjOWQ4YWRiZDNlZTQ0YWE2OTBkNjdjNzZiNmI5NWVjOV8xMC0xLTEtMS0zMTY5Mg_c60e6f0c-400e-4986-a6a1-b1157d55452f">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ic3d2aff6e7174cf6990e9cce3126b3d2_D20210101-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNC0wLTEtMS0zODcxMw_3e7c1e5d-af94-4a9d-8491-3f37d7a30ea0">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="if641e7664fea4b26986aea56c1df79ee_D20190219-20190301" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182NC9mcmFnOmQxMDYzYTAyMmY3YTQwNzQ5NjdjZGVhMTdlY2MxNGI4L3RhYmxlOmM5ZWQ1NDhiNjZhZjRiZjA5NmZkZjNjNTZkYmYwODc4L3RhYmxlcmFuZ2U6YzllZDU0OGI2NmFmNGJmMDk2ZmRmM2M1NmRiZjA4NzhfMi0xLTEtMS0zMTY5Mg_baa924e4-6443-4be4-aff4-b2f5f9f93f01">0.1858045</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i3b8f0e3e81bb46f2b223a270fb1bfb13_D20191226-20191226" decimals="10" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182NC9mcmFnOmQxMDYzYTAyMmY3YTQwNzQ5NjdjZGVhMTdlY2MxNGI4L3RhYmxlOmM5ZWQ1NDhiNjZhZjRiZjA5NmZkZjNjNTZkYmYwODc4L3RhYmxlcmFuZ2U6YzllZDU0OGI2NmFmNGJmMDk2ZmRmM2M1NmRiZjA4NzhfNy0yLTEtMS0zMTY5Mg_4b8c2e80-8f79-4ea2-b95f-ead0b2dda7e7">0.0002147766</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ino-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia337f4f8221049bdafddfe7f7f369002_I20220509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21d5e20142404b77b5d380c961472ef1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae8b8138e63644098dfe464495c5f147_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00d50bf6cf7f4ad2a522a955df7010fd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i998a91031a25433790f82a700988c0b4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5b13173d5de4d16982a5e2c1dfbfd2e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec9fd62a63dd428f8b7307aa6489cfd8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i804e05de6cd241ee8b38b4028e3fa675_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48c5a28f11784bc08ca5f019b88b0a82_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic94dcc9ceaba4c73bf5498290cc2a8f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c094866746944c190a5cb5e6ec38207_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a5ff34a96be4b01892682db87c0bb82_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3d2aff6e7174cf6990e9cce3126b3d2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a5dd7608edd4c9b81f794075e1bf7c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia20aee050b564621b0904ff547d1603d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8a58b7a2eeb4d1b8fa8e40ba25ea392_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8289efe5fbaf48509196fa46a48e5ffc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4a41317c5a64ca1abb762b294f27a77_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie499a30eb95c4720b752a618011da9de_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie50284eae13a4b7db5e6261db6e0f911_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic282ad05383d4cf390606ef8b610a75a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33a11834f7f947429f551d48915db764_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id541689a86584fd08a1e5666a6539c27_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09c58eec38c84e9ba577bfb58d9de2c6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib931e527febe494c96c6bff98a6bc8c8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i197e743baebd4a54a1f59b2ead228a4b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a964ed0569a4e2687266fee8d3eb2cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic378134c645a455f8c29cf425649d9b4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7fbf9be64024e8389236deb05644f9a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37a14c64016b44eeb0df3bd03a9c7261_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01903000ca0941ae93dc226d9b97e700_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c88a6a27b9e44eeba42ab6a651cc57c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i495f9f8bba37406aa957bb1fa1bb6b82_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i706e11fcf7b840a68346dcb076a72fe7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b4db7184a6e4d539bd893221daa7b6b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib17ceb956c2f426eb2b764885c99a7e2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f8d19094f794192baacd56f29fcdae7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a7141f817b64eedaa3b9d245abc6c8f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafaea1518ae5419386ac2efc6b2ba187_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd921433e3a44903b67d69cd507b789c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2676a854bc50429cba33013cd2fd88be_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2af437e174542f6a96a9dd371a8e151_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13070eb515fa45c694edb66f1cadcb21_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5188e2afa230429fab7f59ddf2c594b3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdd8f1364df749e5b75e252f613f37c5_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5998790341a8497ba20d32d62e49492c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9acea0aaff494ae8956e27ef9faf34c6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:OtherCounterpartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib186138d47d74be9a37ef0b9377767e2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:OtherCounterpartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dd96d739d1d4c6ba7fd44457e650877_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i200d0433fb874ceca8d01b4202a59cf7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d5059c8d38048299da6be38015206d8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96212faeb6564d55b7a90168c62339d7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifea821ceda2b46c5ba64c5b0a9ebf7eb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3b77e32e0d54bbe98f98ad16cfdcced_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d2dabcc2e274335be3e08c2ede5ec0e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15f4645750d14b1d8727f373d9bfec66_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35afa32f29f843dabd62652947f0eeb1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dd02c8047614f899869c90b0070ab8d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11ad7b0c63c34318904c5962edc5336c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c1de2f49204499c821a49656c3c3db0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i256e22e1c0a840458b2307e674601335_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c26ca99f7cb4cacbac0e8bc0ed494ed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a46ac477e0c44908926cbfd89796968_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>ino:position</xbrli:measure></xbrli:unit><xbrli:context id="ie327610064114130b6724b61e0aa0b11_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a7a4020c94941b4b6acc78d93b58453_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i471805632a1c4b1497d106f7f6d32bc1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a3922f5859d40ef8c8a2487c7e981b6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bad7403c49c468b8ceafcdd73d058f4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i910199c871b24e7281edfe262f9e595c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcdd3d9daef249babdd7610c465d9861_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fd176d27ac94f388085f5b57e2f24cd_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6e6180b331b4e71ba67ae40963d4a03_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc7f88e09b444751aad08e36afbd151d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7763d94f5b7e483eb2aa063bff3f4fc5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37fe9e79f04d4894a64245d5e39a5f1e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if05223ae01d645f69bb34279da86b5c0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib091b9b6d4f644349ae9a24d2bdc827b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf2144065280473599c7afda89ad1694_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d6412688827466ca20d0eb89182015c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20a3ba1b8f6c4fdbbc57d85e7c759c66_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62d964321f9c49ba80f2d28a540dfb8e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05e130a7d4404dcf9c53ef79a503f2d8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aee826afc7f4bb584c9baec2cacd2ff_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02b127be22eb4b9a9750afaa61f1ec0f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae1ff7cfb12549c794647cdbfea00698_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50d2be785b7e4c0eb3075ccc1b52f222_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ab217ecf956405d9cf37acb90fb804c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i735216c789474c09b2396fda353fb55e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib92f6424c666449486766a5d1d0e1832_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a4147a900d44007bcbaff1d2000a812_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i922d453abb054b1c959336166486250e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a00852361e24abdb75f61f00ba8440e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0927a0eab1d4d2ea57f80d09385ab14_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2346a1c5f64c47f39444b2604e34bec9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff609476032e4fd5850ace07b081d978_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4df03a74cdb1441981e64076b32bf6cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf4907bded604daa8b4f90733b4960a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic01a2bc151f341de9e5bc9ca12685bd1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4acf182b26a44980bccfb7dc1c75de40_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10431da7c03644c9875fb73a741719db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cee4483f4e345c08e931ecf9ad3260d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaca2ffe0ede4c7292c889e48dba76a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0768b2ff10a94d04af660988ce14766c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia45b882b6c5449a098b1e8921b30765f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fc8c9fb3dda470585109a269277aa90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddcca9c2136e4da798d1e5a739c72a2b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id97388b64a184cbab4a4fa6e23803d1c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4284e75eeec74588b5ab75d6c01392cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia11026ef96064c518d5053ab32d38a62_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5133a9aa6b974cd6be58671085bc9222_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ffc37c7b05544bb97a430265cc2bef9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd3476330236483c98b0ec3070d9e333_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i937bf2eba10942f6be46a1071b4f10d7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ac1da597f7b4340893eba51de04ad26_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i851991d1186f468b82660c9a9ba18e50_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3175c5ab2f0d46d7883309efb700f354_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72f5235c51804466877805e8fd527626_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ee1c54551f24453a3c895ffdc0bfe2e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f93349007644f839f68fbed0c369c0d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b2a0788492e40989bb27421d1bd2073_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic060851ec89c42658d3355959c413ec0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6fece0d322b434c8593f46a8150a928_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia23c27fd3cb34cb7ac69f9e4e67b758a_I20190301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="if641e7664fea4b26986aea56c1df79ee_D20190219-20190301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-19</xbrli:startDate><xbrli:endDate>2019-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>ino:day</xbrli:measure></xbrli:unit><xbrli:context id="i89c242d635e34cc2882b5b395b26a546_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11fba970b3414270a4d7e4804a06e0e9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if239e019c41f41df87d6fabeb16a8209_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93f4fe9cdb954509a29e6972a23d8717_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie10fbf5fad8743a6b390d426979d8a2f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3c3bc6efec5497d8d3e271600131a3b_I20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="krw"><xbrli:measure>iso4217:KRW</xbrli:measure></xbrli:unit><xbrli:context id="i257d1ac432f142b299c0fe356311ee8a_D20191226-20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-26</xbrli:startDate><xbrli:endDate>2019-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7987401764743bca11a6fcb90ae347c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide3610d56f684b5fbb8f7fff6ee33eee_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cd8ee10514043399860125bd7812d5e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b8f0e3e81bb46f2b223a270fb1bfb13_D20191226-20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-26</xbrli:startDate><xbrli:endDate>2019-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee0415add3154b6c8fca72404d201bb7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e2be23d00d345b6bed7ade8e6494fc7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a881011504441e1a9c61a374bf1ccf4_D20211109-20211109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-09</xbrli:startDate><xbrli:endDate>2021-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e2f4f4898364123a256c32ca33facc9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief33ee4c2f9d472ca203587fdd030959_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49690b96047544fa998f0502891752a4_D20210125-20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-25</xbrli:startDate><xbrli:endDate>2021-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d07fc0fc7734f8d9a8aaf0c1d8877ec_I20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i506a7271caec452a979fcd2973d994a3_I20160513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74e4addc1ab747f6b371d1e28eef2596_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c114109f3fb4d2e9bd8f37900a7cf35_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7964dc3a17e4cfb80c440f5e98914ba_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53998403d9a644378e830ed35dde9174_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74c8f3b2f8074de68c07442296de5eda_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e593faba088418ca3470ba0e2ef170a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1f7c31d501f484e8655d8e19138ea45_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eeb39a62cfd45a19b16ff2f77b29ea0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d5160a767ac4bafba1dc028690dde9c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64c8814591c9419e86db1db17a0446e7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i450d92211f544cdc985d06e7fed62e63_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6079656cc273434d86458c6aebd9dc67_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i404ce3ef99524755b77883e75ca4a739_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f5a82e0fe634a5cb2409168cbd8cd88_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5454fcab37d841f7875d94376e14df0d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5244cd2065d44efa8be7f4b42dc1fef1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i131de56e723d441a8b4d29a66a9f0297_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieccf6f95500841c6a3689f60a52eee48_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1c041808f3c4fcdad3091644d6b6568_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12c8e38f5a5d4faf8e21cca6e3048613_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i466990d2769740b4be6de242e03e8e59_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82e293c63e7b45f497259112c8856cf3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaec0500407e4460af3ae9824374aa5f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91452942e5e5451087ce0e121faae465_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c416618392046e181d9a033a06b4af3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2ec2de8f8e64ef6b6eb20c42e3919e2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fdb61060a19450e8b33f7efaa1f435d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76d9cb0a9e604a1d89a1ce39c1ba9ed3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fb6f216bfa54b49a624c469d5203ec1_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i491165f321fa4e9eba5d2778f326ed0d_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie37803101927413c9caf0a2b10452612_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0505907c69774e2f9b14cd272f6e78ab_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i113857f5676c45c8985e00527eadd700_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54c2b2722e924db1b3ff26d952a3e88e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a14a4908e804611b1eb9dc197afef27_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic38879a67ed2417892b510c2282934e9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i154ff5c5f70146429ef3ca2399396227_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c89ed0e5b044d7e82c20c40f333fc2a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0034e9c906a24164ba01742d7b986684_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9fe7623f5234877ba048ec3fbd39a69_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic40026348a73461d8f5be933afc8a40e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i598d38fe89f5401ebb28138691b4da4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93b7902a9abb40beb532a03c0df4ed2d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ic80593d7532d4f61b66a6152e7a7552b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bf07160649541bca2512ad124da7853_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if296892e17fa4a3996048fd9a773bb41_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d671d2113a6459188a02276cfc2a5f6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>ino:agreement</xbrli:measure></xbrli:unit><xbrli:context id="ia01bf7e261dd4db5917be920fa366418_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2db1017a46a040d6861a567a358dcdd1_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8516f2c2e834670831af151ddee24ed_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bcc9760314f413bba4b5e3b026f2e41_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9818436ba9fe436cb6d8b574154f1b3b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e370c4fb7ad47f09d71f49dcf34f2f7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i071ee78b7166461a9fbde479b660be3e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i506a148e81644d5482e7e9eebdf0b1d5_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2be74ba561d442db493dddcc92ebd3e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b96bf9a8fc445eaba5ecb1d140390f6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e1c9fb9467945ab9163eda017d1f2da_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f8f17f12161403fafe2948a7f9f402f_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i152a732fccdd4dbdb5a4fc5c6458a1ec_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9442dd1633e455b91a66f5a6ab2ce25_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32bf53bd03c54fc1a9176c9e8bd73481_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b14e2287928438d88d281f85c7278a8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bfa9631ac274759b1b56aef9adc496f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5ba8467f8d240158db11dd9beaae7e2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5e81165a16440ebb8326d8a24d15995_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2b5bc317c764378a3de78871886838c_D20190801-20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92f8729b1391467aa54b6475bbefade5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6295923acaed47d1956bd75c6c4c0edd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b11763ebe53429599cade53585833b6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie62aeb4d7cf747aeb6d6d6c6296bfe0a_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e16f9f97cb444ca9d3dba5ea73d1d90_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4518574f497f4fa2a453bf07d6721aa2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1204bafe5467488693dda8b9e96a2774_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17c519d2d2f7427e8cf34e5097504c60_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA2000DeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c0779eaba8941deac45ec2a70e681f7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA2000DeviceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ee8e99d45ce4685bcbfe7aa1f6ef9ac_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74796e39acc84dc198e9df9ff90b38c2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2125ae0ebb6c4ac58e7f4bb7948cf2ee_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76c6ab34cb86461fbeae30681dd72330_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a59d1c482204129ace354f666e93b3c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9287e5231b0c44c2a4df39c192522f21_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ef6b938867e49d4b6bea20f92003696_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief31b251d6394afd8f91a7cc96c6f6f0_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i358168d3fb3e4081afe3f8f55ae73934_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2998f9f06ab149b7a5203f1dd82fad31_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i072b718ce60743018ae014282340909c_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35c4e31704a040e18096a49a219271b0_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdd6b2404d2348d6be3af54fee60364d_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b0adeeead5e4699a63cb480fc0a0ac3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7af4410be8f148b5b8314f57ad7a668d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iade08220a0f74869bcb1f820413ac244_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1f4de57b99d45e7878e83e0a961478f_D20200601-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39108879adec43dd9ce939da4a9133c8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i240a06710e7f499c92f922af74aa1d72_D20200601-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94cd371c1e2a482189fbcd1fa606ce5b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99ae48f06acb4be0999de4734437d7de_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37c604731df5488385ee8ef0f5eaa642_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic757f5e350bb42269e2c1e8b10f57ef6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc03d9886d82421ebbc554d6ea904cd3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6bb6660938e47b0a2d5df1338384e35_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c48be9a581248328538c7ec76130395_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c076c415b0c4d348c148ffabebaa199_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic58ffceb77ce4063a7894330d50f5c66_D20220401-20220421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3ee9fcf6611452784c45ad678fced93_I20220421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-21</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5cd930e6c7ce444abb7f72171f50164c_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:33.333%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTEz_d5cf483f-b60f-4bb4-86a2-4c4d3ce07235"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTEz_d78f3682-4bc5-4b90-91c5-906d0ef857a5">10-Q</ix:nonNumeric></ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGFibGU6MTcyN2NiM2NkMzcwNGMyZGE3NTY5MDc2NzA2MzMwMjkvdGFibGVyYW5nZToxNzI3Y2IzY2QzNzA0YzJkYTc1NjkwNzY3MDYzMzAyOV8wLTAtMS0xLTMxNjky_4d1dfd9e-14fe-4e8b-8f6c-b0af110d0328">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.465%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGFibGU6ZjJkMDNiYTBmOTYyNDVmYmFkYzk2NTliNGYxN2YxNWUvdGFibGVyYW5nZTpmMmQwM2JhMGY5NjI0NWZiYWRjOTY1OWI0ZjE3ZjE1ZV8wLTAtMS0xLTMxNjky_19101b24-f067-48b7-8ca8-548cbda5fd68">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">       FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">COMMISSION FILE NO.&#160;<ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTE0_38eee5d7-2636-44b1-a798-01ba5a2aebeb">001-14888</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:186.00pt"><tr><td style="width:1.0pt"></td><td style="width:184.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><img src="ino-20220331_g1.jpg" alt="ino-20220331_g1.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:204px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTIw_5a326a8a-e71f-4d55-ace6-9e675222c79b">INOVIO PHARMACEUTICALS, INC.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.276%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.260%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGFibGU6MGY0OGExNGZkYzQyNDQ2Yjg1M2M2ZmQxMjkwNDViYjkvdGFibGVyYW5nZTowZjQ4YTE0ZmRjNDI0NDZiODUzYzZmZDEyOTA0NWJiOV8wLTAtMS0xLTMxNjky_1bea5435-e996-438d-8d4d-e04c80ffc3f1">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGFibGU6MGY0OGExNGZkYzQyNDQ2Yjg1M2M2ZmQxMjkwNDViYjkvdGFibGVyYW5nZTowZjQ4YTE0ZmRjNDI0NDZiODUzYzZmZDEyOTA0NWJiOV8wLTItMS0xLTMxNjky_522422ee-cab4-42d2-8379-fca5faf9b6ab">33-0969592</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTIx_2f82e584-3b95-4726-a45a-d5aae1ee0791">660 W. GERMANTOWN PIKE, SUITE 110</ix:nonNumeric>  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTIy_9f7ce997-9a14-4a2e-b049-ed9f34d05383">PLYMOUTH MEETING</ix:nonNumeric>, <ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTE1_ec78e188-8442-48b6-bb54-afffa2795fc6">PA</ix:nonNumeric>  <ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTE2_fd5eaad4-6747-4143-bd28-0cac6925083f">19462</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">REGISTRANT&#8217;S TELEPHONE NUMBER, INCLUDING AREA CODE: (<ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTIz_fc094a2c-1bb3-47f2-abea-2064c6ea29c8">267</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTI0_185137ff-2cb8-40de-81f8-916c4ebcb35b">440-4200</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(B) OF THE ACT:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.069%"><tr><td style="width:1.0%"></td><td style="width:41.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGFibGU6NTA5NTIwNDFhYmIzNDFiODgwMzc1NzY3OTIyOWViZmMvdGFibGVyYW5nZTo1MDk1MjA0MWFiYjM0MWI4ODAzNzU3Njc5MjI5ZWJmY18xLTAtMS0xLTMxNjky_617e16bd-0548-4a14-958e-8352e9e7b14c">COMMON STOCK, $0.001 PAR VALUE</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGFibGU6NTA5NTIwNDFhYmIzNDFiODgwMzc1NzY3OTIyOWViZmMvdGFibGVyYW5nZTo1MDk1MjA0MWFiYjM0MWI4ODAzNzU3Njc5MjI5ZWJmY18xLTEtMS0xLTMxNjky_a87ad73b-7916-4264-92a4-4e1803f50fdd">INO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGFibGU6NTA5NTIwNDFhYmIzNDFiODgwMzc1NzY3OTIyOWViZmMvdGFibGVyYW5nZTo1MDk1MjA0MWFiYjM0MWI4ODAzNzU3Njc5MjI5ZWJmY18xLTItMS0xLTMxNjky_373af2f3-9d57-4ffa-83ed-24c7b9b8108d">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:33.333%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTE3_1e87fe85-a8d5-4cda-90f1-763a186df520">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTE4_056bd5a0-5a56-4216-8bf7-c7e5098e9802">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.867%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.077%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.490%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGFibGU6MTlkY2UxMmM5Yjg4NDcwNmIzZjhkOTdiYTE4MTJkMDAvdGFibGVyYW5nZToxOWRjZTEyYzliODg0NzA2YjNmOGQ5N2JhMTgxMmQwMF8wLTAtMS0xLTMxNjky_72cb8942-a7b5-46d8-9927-50cbe73558e4">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGFibGU6MTlkY2UxMmM5Yjg4NDcwNmIzZjhkOTdiYTE4MTJkMDAvdGFibGVyYW5nZToxOWRjZTEyYzliODg0NzA2YjNmOGQ5N2JhMTgxMmQwMF8yLTQtMS0xLTMxNjky_b670b75e-2973-4c24-8efb-4172e4c67b65">&#9744;</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGFibGU6MTlkY2UxMmM5Yjg4NDcwNmIzZjhkOTdiYTE4MTJkMDAvdGFibGVyYW5nZToxOWRjZTEyYzliODg0NzA2YjNmOGQ5N2JhMTgxMmQwMF80LTQtMS0xLTMxNjky_ab8d6c71-67e9-4780-981c-16be296f4c52">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTE5_29607103-1b9b-4313-93b5-2fed5ae24e10">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">        &#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-top:3pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares outstanding of the Registrant&#8217;s Common Stock, $0.001 par value, was <ix:nonFraction unitRef="shares" contextRef="ia337f4f8221049bdafddfe7f7f369002_I20220509" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTAw_27fb1473-cdcc-4222-9fad-0d2194d6bed4">229,041,114</ix:nonFraction> as of May&#160;9, 2022.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:186.00pt"><tr><td style="width:1.0pt"></td><td style="width:184.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5cd930e6c7ce444abb7f72171f50164c_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 10-Q</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarterly Period Ended March&#160;31, 2022</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:81.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_13">Part I.  Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_13">Item&#160;1. Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_16">a) Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_16">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_19">b) Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_22">c) Condensed Consolidated Statements of Comprehensive</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_22"> Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_25">d) Condensed Consolidated Statements of Stockholders' Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_28">e) Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:42.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_31">f) Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_31">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_103">Item&#160;2. Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_103">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_121">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_121">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_124">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_124">31</a></span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_127">Part II.  Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_127">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_130">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_130">32</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_133">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_133">33</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:24.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_148">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_148">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_151">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_151">58</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_10"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows and prospects. These risks are discussed more fully in Item 1A. Risk Factors herein. These risk factors include, but are not limited to, the following:</span></div><div><span><br/></span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable.</span></div><div style="margin-bottom:5pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We have limited sources of revenue and our success is dependent on our ability to develop our DNA vaccines, DNA immunotherapies, dMAbs and electroporation equipment.</span></div><div style="margin-top:5pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional capital to develop our DNA vaccines, DNA immunotherapies and dMAb programs and electroporation delivery technology. </span></div><div style="margin-top:5pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">None of our human vaccine candidates or our immunotherapy and DNA encoded monoclonal antibody product candidates have been approved for sale, and we may never develop commercially successful vaccine, immunotherapy or DNA encoded monoclonal antibody products.</span></div><div style="margin-top:5pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have modified our COVID-19 vaccine strategy to develop our vaccine candidate as a potential heterologous booster for other available vaccines, which will result in new and added risks and may not be successful. </span></div><div style="margin-top:5pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There can be no assurance that our COVID-19 vaccine candidate will ever be granted an Emergency Use Authorization by the FDA or similar authorization by regulatory authorities outside of the United States if we were to decide to apply for such an authorization. The option of seeking an Emergency Use Authorization may no longer exist for our primary vaccine candidates, and if we cannot obtain such authorization or, if granted, it is terminated, we will be unable to sell our vaccine candidate and instead will be required to pursue the biologic licensure process, which is lengthy and expensive.</span></div><div style="margin-top:5pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">DNA medicines are a novel approach, and negative perception of the efficacy, safety, or tolerability of any investigational medicines that we develop could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals.</span></div><div style="margin-top:5pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we and the contract manufacturers upon whom we rely fail to produce our electroporation devices and product candidates in the volumes that we require on a timely basis, or at all, or fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our electroporation equipment and product candidates.</span></div><div style="margin-top:5pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer.</span></div><div style="margin-top:5pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have agreements with government agencies, which are subject to termination and uncertain future funding.</span></div><div style="margin-top:5pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation. </span></div><div style="margin-top:5pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face intense and increasing competition and steps taken by of our competitors, such as the introduction of a new, disruptive technology, may impede our ability to successfully commercialize our DNA medicines.</span></div><div style="margin-top:5pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection. </span></div><div style="margin-top:5pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5cd930e6c7ce444abb7f72171f50164c_13"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I.  Financial Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;Financial Statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i5cd930e6c7ce444abb7f72171f50164c_16"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:74.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNC0xLTEtMS0zMTY5Mg_f521b5f6-69c9-4ff8-b944-affa11be7224">59,009,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNC0zLTEtMS0zMTY5Mg_9a334c61-51f7-49b4-9af4-d4f05256941c">71,143,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNS0xLTEtMS0zMTY5Mg_9f50a367-d606-40db-bb9f-77974dd04088">301,384,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNS0zLTEtMS0zMTY5Mg_bd23b132-76a8-4bb6-91e2-25b25e9cf2bc">330,170,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNi0xLTEtMS0zMTY5Mg_74ac9446-7e86-44c3-b3e6-1444a0be4d72">4,003,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNi0zLTEtMS0zMTY5Mg_d1dcd2c0-a2f5-4d4b-a9f0-621e9184b9f7">5,466,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNy0xLTEtMS0zMTY5Mg_d584e7ef-26e6-4250-adf3-d2a6e2d3bc0b">3,487,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNy0zLTEtMS0zMTY5Mg_ff353c41-43e6-4f10-80ab-900d4a350759">2,565,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfOC0xLTEtMS0zMTY5Mg_96bce83f-74bd-42a1-9f0c-dd04cdca8b2a">31,946,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfOC0zLTEtMS0zMTY5Mg_a0d95bdf-ee61-4788-854a-664a0afaab52">38,836,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfOS0xLTEtMS0zMTY5Mg_5d5b0bf9-02a3-4b4c-b8df-1f9c263c5296">75,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfOS0zLTEtMS0zMTY5Mg_862ba108-f0e7-479f-ac1d-159061944e0d">261,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTEtMS0xLTEtMzE2OTI_5fa9f1be-ea96-4b9d-ad21-d0e4ad565304">399,906,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTEtMy0xLTEtMzE2OTI_563fcbec-ae05-45c2-9ee5-db474f178cfe">448,444,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTItMS0xLTEtMzE2OTI_63fcf12e-59be-402f-9dad-864684877f3f">16,696,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTItMy0xLTEtMzE2OTI_54ebd978-d78f-40a1-a066-cd36d8511297">17,453,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTMtMS0xLTEtMzE2OTI_be1ab8dd-5f48-4e2d-874c-80fc0c7f2514">3,369,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTMtMy0xLTEtMzE2OTI_3d21f4be-fb27-4106-bdf4-9540140eb61f">3,906,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTUtMS0xLTEtMzE2OTI_da57016d-463c-4fe4-b62b-003a79efe9b3">2,499,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTUtMy0xLTEtMzE2OTI_2f8cb186-e10a-41e6-b20f-97264c1e8d79">2,626,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTYtMS0xLTEtMzE2OTI_7f4107a4-82b2-464c-9fa0-d0a8b5469a6f">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTYtMy0xLTEtMzE2OTI_2e1f3967-daaa-452b-9013-580af7afdd4b">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTctMS0xLTEtMzE2OTI_e147b23d-7a63-42ab-abc4-056dacd5905e">11,251,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTctMy0xLTEtMzE2OTI_1b800068-ade4-45ff-a4e8-5497ee5f8afb">11,571,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTgtMS0xLTEtMzE2OTI_02cf0c64-8d8f-4438-aef2-500cdfc02df7">1,273,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTgtMy0xLTEtMzE2OTI_ff70c092-ed75-452e-a04a-8529b1ffaffb">1,425,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTktMS0xLTEtMzE2OTI_2748f4cc-ed23-46eb-87e4-b96f108137ed">445,511,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTktMy0xLTEtMzE2OTI_c625b524-1a28-4e9e-820c-75fb2df75da9">495,941,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjItMS0xLTEtMzE2OTI_c4f72835-cfd1-4c08-aba1-35c28244c1ee">38,115,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjItMy0xLTEtMzE2OTI_1a23507b-a217-4e18-ae89-ae062701d8e1">47,644,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses due to affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjMtMS0xLTEtMzE2OTI_8a9a0785-4007-46b3-affe-2ecce83f95d7">1,407,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjMtMy0xLTEtMzE2OTI_f7512254-5894-4eee-87fb-e342c6502458">548,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="ino:AccruedClinicalTrialExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjQtMS0xLTEtMzE2OTI_3dd9cca5-329a-4f6f-bb0a-884acb7142d5">11,827,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="ino:AccruedClinicalTrialExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjQtMy0xLTEtMzE2OTI_43b5ae4f-7421-4748-9a5f-3df412e22d14">10,326,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjUtMS0xLTEtMzE2OTI_f33e7dde-7f77-4ba7-b02d-2417672bffd3">15,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjUtMy0xLTEtMzE2OTI_1e5bd6f5-3110-4bc1-bdc5-31f6b95552db">21,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjctMS0xLTEtMzE2OTI_ab1c731e-da96-4054-a2d5-67e1d6b5f866">2,672,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjctMy0xLTEtMzE2OTI_ffd42096-a766-4d80-9582-4652aeb6b01a">2,603,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="ino:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjgtMS0xLTEtMzE2OTI_cbb69522-ecd3-43ef-a682-434b3eb62ce3">5,283,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="ino:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjgtMy0xLTEtMzE2OTI_e8ff8db2-25eb-44d0-88c8-7be356d4160d">4,559,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability from affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="ino:DeferredGrantFundingFromAffiliateCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjktMS0xLTEtMzE2OTI_4358b33e-26ba-4faf-b828-aab30376fe72">37,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="ino:DeferredGrantFundingFromAffiliateCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjktMy0xLTEtMzE2OTI_0392b9dd-0cf5-4a9f-80f6-28274addc7a3">37,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzEtMS0xLTEtMzE2OTI_4a453139-5c5b-4df6-b1b8-124bfbf12963">59,359,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzEtMy0xLTEtMzE2OTI_1cf27318-153f-4987-945b-f217dfbc5b0b">65,741,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzItMS0xLTEtMzE2OTI_b1f6dc9e-b950-485b-92af-0c4f3dfb4fa5">60,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzItMy0xLTEtMzE2OTI_509401c6-141f-4a1f-83ae-ac3d2510a8d9">64,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzQtMS0xLTEtMzE2OTI_12981ebe-2272-4c99-a569-a0a19db11132">16,207,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzQtMy0xLTEtMzE2OTI_b5d588a8-996b-42df-ab75-d23a012c5b10">14,959,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzYtMS0xLTEtMzE2OTI_48470018-9aae-40be-be4f-a229126cca67">14,765,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzYtMy0xLTEtMzE2OTI_b33a9647-ece4-4669-acbd-59525fd8393d">15,459,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzctMS0xLTEtMzE2OTI_0fd1c72e-dc37-401f-b588-1b581ac74abc">32,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzctMy0xLTEtMzE2OTI_73766910-4af9-4298-8997-ff9ab6f344de">32,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzktMS0xLTEtMzE2OTI_47302764-2f9f-40d4-b4b0-4602c6f2c403">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzktMy0xLTEtMzE2OTI_be20b177-bf59-4d18-9452-4f22fec20145">14,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDAtMS0xLTEtMzE2OTI_06edd6a6-1f8f-4591-acee-61d67f2345d2">90,426,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDAtMy0xLTEtMzE2OTI_dbda98d3-4779-4d3f-a30e-386d220b7a82">96,272,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDItMS0xLTEtMzE2OTI_d2cb4928-8911-48fc-85fd-8b1a304e38e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDItMy0xLTEtMzE2OTI_aa54b408-5fef-486d-8767-609b70abcc2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDMtMS0xLTEtMzE2OTI_00bbc0fa-1e40-41bb-ad65-f9e476a36a05">226,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDMtMy0xLTEtMzE2OTI_dfabcb4d-2445-4ed1-aaeb-ad4dfdfa557f">217,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDQtMS0xLTEtMzE2OTI_d2a962af-e415-43fc-afe3-2a665c4eee79">1,642,419,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDQtMy0xLTEtMzE2OTI_80542ac7-d0db-47ce-be19-32e50b71c027">1,609,589,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDUtMS0xLTEtMzE2OTI_eedf7bc2-c9d8-456c-9744-95113dd99639">1,287,103,438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDUtMy0xLTEtMzE2OTI_9ac40e64-6bfa-4d80-9aeb-b55985b7cb7d">1,209,855,522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDYtMS0xLTEtMzE2OTI_5cac9c82-4aa7-4973-9397-d5d00cc98e49">457,888</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDYtMy0xLTEtMzE2OTI_5830f866-1b2d-46f2-aebd-041ed804642b">282,236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDctMS0xLTEtMzE2OTI_9916ac8f-df79-4344-9ff3-9b871ae53e5c">355,085,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDctMy0xLTEtMzE2OTI_cfb513e9-fd72-4c32-b9b2-a872f9ad6472">399,669,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNTAtMS0xLTEtMzE2OTI_e5645bcc-f15d-49be-9660-7049f5862e9e">445,511,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNTAtMy0xLTEtMzE2OTI_5d8d44e5-c314-4fd5-b7a0-76019a27412f">495,941,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i5cd930e6c7ce444abb7f72171f50164c_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.568%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21d5e20142404b77b5d380c961472ef1_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMy0xLTEtMS0zMTY5Mg_326bc894-ec56-495f-8499-640afa9f077f">65,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8b8138e63644098dfe464495c5f147_D20210101-20210331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMy0zLTEtMS0zMTY5Mg_7f56f6f8-0a60-4e2b-856e-628d78716b83">39,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue under collaborative research and development arrangements with affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d50bf6cf7f4ad2a522a955df7010fd_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfNC0xLTEtMS0zMTY5Mg_8473ad7b-aa6f-4269-ba6b-1d3d5a81b82e">8,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i998a91031a25433790f82a700988c0b4_D20210101-20210331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfNC0zLTEtMS0zMTY5Mg_b4a247a3-ffc5-4fb2-b7f2-a90f0b6cef48">49,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5b13173d5de4d16982a5e2c1dfbfd2e_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfNS0xLTEtMS0zMTY5Mg_ef1fb5e1-1f26-4f75-8748-765fde2ae696">124,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9fd62a63dd428f8b7307aa6489cfd8_D20210101-20210331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfNS0zLTEtMS0zMTY5Mg_9f2de166-53ac-4d70-99cc-b7b9bd71e4ef">281,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfOC0xLTEtMS0zMTY5Mg_bf790fa5-31ed-466b-ba90-04313c5f13d1">199,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfOC0zLTEtMS0zMTY5Mg_25b79a7c-1c2a-4bf3-9156-aeb8b640392f">371,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTAtMS0xLTEtMzE2OTI_6ba49846-46b5-4a80-9c41-f63e43c55ff0">55,978,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTAtMy0xLTEtMzE2OTI_5bd79373-ab8a-4b1b-a282-8940b91beb68">39,044,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTEtMS0xLTEtMzE2OTI_100e79b4-3148-46ad-8fa9-a484dabce48f">15,953,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTEtMy0xLTEtMzE2OTI_464d5428-c3a2-4a54-9884-ca4593d1cdeb">13,881,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTMtMS0xLTEtMzE2OTI_6bc775cc-d3ee-471f-ad17-23ec1db8b13b">71,932,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTMtMy0xLTEtMzE2OTI_d7859fa9-2cf8-4a96-abc1-68e04aa26c69">52,925,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTQtMS0xLTEtMzE2OTI_a9cce04f-c9ad-4c77-b1e3-e9b9c1ecfe1b">71,732,995</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTQtMy0xLTEtMzE2OTI_cf46f297-94cf-494b-a1c1-6118c91605ac">52,554,492</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTYtMS0xLTEtMzE2OTI_71021b12-3b25-4c79-b133-0864373184a7">669,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTYtMy0xLTEtMzE2OTI_b15ed74a-c0f8-4a2a-8bcb-4f10b8747ec4">769,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTctMS0xLTEtMzE2OTI_98bc3d15-faaa-44a4-874d-ee2f708b0fef">313,488</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTctMy0xLTEtMzE2OTI_18f7ce76-469b-4b98-93fb-63e4a4393c47">513,034</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on investment in affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMjAtMS0xLTEtMzE2OTI_ecb1a1a5-5b39-41ee-8abc-1d5b20d32337">537,728</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMjAtMy0xLTEtMzE2OTI_dcc3f8bf-e18e-4362-954b-1f6f9c75405f">830,475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMjEtMS0xLTEtMzE2OTI_08e8cb6b-4f27-41ab-b22c-384bec572ecb">4,840,641</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMjEtMy0xLTEtMzE2OTI_b6dd713f-41e1-477a-b330-63d7ac41060f">847,958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMjItMS0xLTEtMzE2OTI_24677325-463a-4107-b496-f39fa273b0a6">153,468</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMjItMy0xLTEtMzE2OTI_c11703d5-52bd-4eb8-81bd-04b29f43f5ca">8,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss before share in net loss of Geneos</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMjctMS0xLTEtMzE2OTI_3e8dee16-6ccd-4a70-9142-b9b2ac16b5be">76,908,506</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMjctMy0xLTEtMzE2OTI_db757ca7-7a65-4d7d-ab02-13500b6fb232">53,967,744</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMjktMS0xLTEtMzE2OTI_89e273fc-9caf-4ddd-bc12-676dae124baa">2,165,213</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMjktMy0xLTEtMzE2OTI_08fc516a-61dd-4990-ab3d-e3fba93edff0">434,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMzAtMS0xLTEtMzE2OTI_3eea9081-cbfd-4af6-9f0b-c4553fd245ef">79,073,719</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMzAtMy0xLTEtMzE2OTI_ff479c8d-ee27-4701-8be6-56e396699335">54,402,131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMzQtMS0xLTEtMzE2OTI_8e04dc4f-3a52-4033-bd3f-608c044e5d93"><ix:nonFraction unitRef="usdPerShare" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMzQtMS0xLTEtMzE2OTI_b3837ecf-3b13-4b76-98e6-3126dc8e52ed">0.36</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMzQtMy0xLTEtMzE2OTI_08957aea-d680-4957-9b57-9a78d9bab202"><ix:nonFraction unitRef="usdPerShare" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMzQtMy0xLTEtMzE2OTI_948ee088-d6a4-4fb2-8947-3bebcd779459">0.27</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of common shares outstanding </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMzctMS0xLTEtMzE2OTI_60f3e8c6-feae-4529-8773-8e98a853ff5c"><ix:nonFraction unitRef="shares" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMzctMS0xLTEtMzE2OTI_c955cf61-9003-445a-9774-971d1f6b564c">218,940,693</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMzctMy0xLTEtMzE2OTI_2d220722-7942-49bb-a30d-ce82d37c9713"><ix:nonFraction unitRef="shares" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMzctMy0xLTEtMzE2OTI_79cd82aa-6be7-4f81-bfd6-2e314da4d68a">202,414,445</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i5cd930e6c7ce444abb7f72171f50164c_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yMi9mcmFnOjRiMjNkNTAwMTNmMzQ1OTE5ODNmNzIzMDllZjIyODdkL3RhYmxlOmE0MWNlMzQwMTE5NjQ0ZGU5OGE2OGU4MDEyYTU3MTA5L3RhYmxlcmFuZ2U6YTQxY2UzNDAxMTk2NDRkZTk4YTY4ZTgwMTJhNTcxMDlfMi0xLTEtMS0zMTY5Mg_3c565199-6619-42e0-a6cb-69fe67fe9075">79,073,719</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yMi9mcmFnOjRiMjNkNTAwMTNmMzQ1OTE5ODNmNzIzMDllZjIyODdkL3RhYmxlOmE0MWNlMzQwMTE5NjQ0ZGU5OGE2OGU4MDEyYTU3MTA5L3RhYmxlcmFuZ2U6YTQxY2UzNDAxMTk2NDRkZTk4YTY4ZTgwMTJhNTcxMDlfMi0zLTEtMS0zMTY5Mg_8beb7afa-fc4f-4994-b007-d981f752526a">54,402,131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign currency translation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yMi9mcmFnOjRiMjNkNTAwMTNmMzQ1OTE5ODNmNzIzMDllZjIyODdkL3RhYmxlOmE0MWNlMzQwMTE5NjQ0ZGU5OGE2OGU4MDEyYTU3MTA5L3RhYmxlcmFuZ2U6YTQxY2UzNDAxMTk2NDRkZTk4YTY4ZTgwMTJhNTcxMDlfNS0xLTEtMS0zMTY5Mg_c1da97c2-770f-46b7-9bfe-b07b896390d3">6,555</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yMi9mcmFnOjRiMjNkNTAwMTNmMzQ1OTE5ODNmNzIzMDllZjIyODdkL3RhYmxlOmE0MWNlMzQwMTE5NjQ0ZGU5OGE2OGU4MDEyYTU3MTA5L3RhYmxlcmFuZ2U6YTQxY2UzNDAxMTk2NDRkZTk4YTY4ZTgwMTJhNTcxMDlfNS0zLTEtMS0zMTY5Mg_8da4e668-ff14-4086-ae55-bcfd7df95a74">14,419</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Unrealized gain (loss) on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yMi9mcmFnOjRiMjNkNTAwMTNmMzQ1OTE5ODNmNzIzMDllZjIyODdkL3RhYmxlOmE0MWNlMzQwMTE5NjQ0ZGU5OGE2OGU4MDEyYTU3MTA5L3RhYmxlcmFuZ2U6YTQxY2UzNDAxMTk2NDRkZTk4YTY4ZTgwMTJhNTcxMDlfNi0xLTEtMS0zMTY5Mg_273ada0f-0b23-4d9d-b099-b1f2ad3d2ddd">169,097</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yMi9mcmFnOjRiMjNkNTAwMTNmMzQ1OTE5ODNmNzIzMDllZjIyODdkL3RhYmxlOmE0MWNlMzQwMTE5NjQ0ZGU5OGE2OGU4MDEyYTU3MTA5L3RhYmxlcmFuZ2U6YTQxY2UzNDAxMTk2NDRkZTk4YTY4ZTgwMTJhNTcxMDlfNi0zLTEtMS0zMTY5Mg_5873a34c-01b7-40c3-b603-4009269b5ed8">4,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yMi9mcmFnOjRiMjNkNTAwMTNmMzQ1OTE5ODNmNzIzMDllZjIyODdkL3RhYmxlOmE0MWNlMzQwMTE5NjQ0ZGU5OGE2OGU4MDEyYTU3MTA5L3RhYmxlcmFuZ2U6YTQxY2UzNDAxMTk2NDRkZTk4YTY4ZTgwMTJhNTcxMDlfOS0xLTEtMS0zMTY5Mg_377a935d-468f-48cb-8c40-1777eaa8ac80">79,249,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yMi9mcmFnOjRiMjNkNTAwMTNmMzQ1OTE5ODNmNzIzMDllZjIyODdkL3RhYmxlOmE0MWNlMzQwMTE5NjQ0ZGU5OGE2OGU4MDEyYTU3MTA5L3RhYmxlcmFuZ2U6YTQxY2UzNDAxMTk2NDRkZTk4YTY4ZTgwMTJhNTcxMDlfOS0zLTEtMS0zMTY5Mg_d1c4f159-10c8-4f9c-85ef-72c6c917f5ef">54,411,689</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i5cd930e6c7ce444abb7f72171f50164c_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.804%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.125%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.125%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.588%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i804e05de6cd241ee8b38b4028e3fa675_I20211231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMy0xLTEtMS0zMzIwOA_9ac214a4-110a-480f-a9f6-117eb929a06e">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i804e05de6cd241ee8b38b4028e3fa675_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMy0zLTEtMS0zMzIwOA_1446e530-76d3-43e3-bfed-517c0d9ff2de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i48c5a28f11784bc08ca5f019b88b0a82_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMy01LTEtMS0zMzIwOA_edf2f9a8-7e21-43db-878c-a255733b3235">217,382,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48c5a28f11784bc08ca5f019b88b0a82_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMy03LTEtMS0zMzIwOA_713d1ea2-6eef-4c53-9528-0cb2fed464c0">217,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic94dcc9ceaba4c73bf5498290cc2a8f1_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMy05LTEtMS0zMzIwOA_ae996441-10be-46d0-9095-9ad5d11b41b6">1,609,589,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c094866746944c190a5cb5e6ec38207_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMy0xMS0xLTEtMzMyMDg_bb3ac70e-d45b-4ca0-ac30-e0a79efe4426">1,209,855,522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a5ff34a96be4b01892682db87c0bb82_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMy0xMy0xLTEtMzMyMDg_fbca0f39-f850-441c-95bc-52117e6c8021">282,236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMy0xNy0xLTEtMzY3OTE_0e28eb9c-ccbf-4032-9a6d-d0757edc1186">399,669,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNC0wLTEtMS0zODcxMw_3e7c1e5d-af94-4a9d-8491-3f37d7a30ea0">Cumulative adjustment from adoption of ASU 2020-06</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a5dd7608edd4c9b81f794075e1bf7c3_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNC05LTEtMS0zNzA2Nw_787ca225-03e9-4cc4-b2b2-a7ef89b58c55">3,294,019</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia20aee050b564621b0904ff547d1603d_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNC0xMS0xLTEtMzcwNjc_fa7c1b81-95ce-4949-a733-f5e44dfc5229">1,825,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8a58b7a2eeb4d1b8fa8e40ba25ea392_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNC0xNy0xLTEtMzcwNjc_08922a79-4276-4b04-8289-43c0161a4cde">1,468,216</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash, net of financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8289efe5fbaf48509196fa46a48e5ffc_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNC01LTEtMS0zMzIwOA_54731f3b-4446-47f4-ab9c-4d321b6c1084">8,480,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8289efe5fbaf48509196fa46a48e5ffc_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNC03LTEtMS0zMzIwOA_04387c71-f5e4-4f5a-875a-50dc4dec2eb4">8,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a41317c5a64ca1abb762b294f27a77_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNC05LTEtMS0zMzIwOA_b553cd7d-2246-40da-a154-c096ca4acd53">29,356,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNC0xNy0xLTEtMzY3OTE_21fb567b-6186-42c3-9cb6-7c578c62e837">29,364,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8289efe5fbaf48509196fa46a48e5ffc_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNS01LTEtMS0zMzIwOA_59238f51-d065-430b-9fa0-9a6394095df6">647,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8289efe5fbaf48509196fa46a48e5ffc_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNS03LTEtMS0zMzIwOA_9e2a2434-72c5-4f37-9048-bc1b4bfe1fcc">646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4a41317c5a64ca1abb762b294f27a77_D20220101-20220331" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNS05LTEtMS0zMzIwOA_aa9ddea4-2365-464d-bbc9-8008c1f33fce">943,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNS0xNy0xLTEtMzY3OTM_dfb80fa5-1d11-47a0-9214-3b3ff309b329">942,521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a41317c5a64ca1abb762b294f27a77_D20220101-20220331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNi05LTEtMS0zMzIwOA_114f422c-4802-4603-8b0b-50b2ab3a600e">7,711,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNi0xNy0xLTEtMzY3OTM_70e79bc0-c3e6-4595-9911-a5920598858f">7,711,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie499a30eb95c4720b752a618011da9de_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNy0xMS0xLTEtMzMyMDg_2b296a80-d66c-459e-906b-d822a2b51bc2">79,073,719</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNy0xNy0xLTEtMzY3OTM_1c585800-3b74-48b9-aca5-9d8b9b6c2579">79,073,719</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie50284eae13a4b7db5e6261db6e0f911_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfOC0xMy0xLTEtMzMyMDg_597857cb-923e-49ed-a105-7378bf35d369">169,097</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfOC0xNy0xLTEtMzY3OTM_93da5f9b-feff-4ce2-ab43-ba4dd07a9ec3">169,097</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie50284eae13a4b7db5e6261db6e0f911_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfOS0xMy0xLTEtMzMyMDg_0f8cfb0a-155f-4b2b-afab-0ee5c340ecd2">6,555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfOS0xNy0xLTEtMzY3OTM_cc2c93e6-f3f3-45d2-9b9b-641af8cd23df">6,555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic282ad05383d4cf390606ef8b610a75a_I20220331" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMTAtMS0xLTEtMzMyMDg_ae042e51-4f74-4f48-b2a2-216fb58474f7">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic282ad05383d4cf390606ef8b610a75a_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMTAtMy0xLTEtMzMyMDg_852888d6-5a6a-47c9-8290-676976b5fb8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33a11834f7f947429f551d48915db764_I20220331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMTAtNS0xLTEtMzMyMDg_39ae7211-b025-4671-804b-263aa5d525ce">226,510,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33a11834f7f947429f551d48915db764_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMTAtNy0xLTEtMzMyMDg_911824dd-99fb-45a2-b19b-b7ef45e0d7b1">226,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id541689a86584fd08a1e5666a6539c27_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMTAtOS0xLTEtMzMyMDg_ec947236-3cc8-4001-9668-d555a081b5d1">1,642,419,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09c58eec38c84e9ba577bfb58d9de2c6_I20220331" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMTAtMTEtMS0xLTMzMjA4_e0d88f3a-6650-4ee4-a417-f16156e71bcc">1,287,103,438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib931e527febe494c96c6bff98a6bc8c8_I20220331" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMTAtMTMtMS0xLTMzMjA4_93577bc6-631a-4cae-9668-fc302e6647ca">457,888</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMTAtMTctMS0xLTM2Nzkz_95a72bdc-b0e8-4970-bd53-bdbb1fa26664">355,085,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.480%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.586%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March  31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i197e743baebd4a54a1f59b2ead228a4b_I20201231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMy0xLTEtMS0zMTY5Mg_65f21174-88a5-4c8b-bf57-63fb8e550882">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i197e743baebd4a54a1f59b2ead228a4b_I20201231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMy0zLTEtMS0zMTY5Mg_cff89bc1-b5cd-479f-989b-57f8cf89e8f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a964ed0569a4e2687266fee8d3eb2cb_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMy01LTEtMS0zMTY5Mg_fb609d67-7b84-4a51-b966-d8224d6d911a">186,851,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a964ed0569a4e2687266fee8d3eb2cb_I20201231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMy03LTEtMS0zMTY5Mg_b70c2467-94b2-4e6f-b8fe-acb7d881d620">186,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic378134c645a455f8c29cf425649d9b4_I20201231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMy05LTEtMS0zMTY5Mg_1f1658bd-f8a1-49a9-8ae9-4fe070dd3c0d">1,367,406,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7fbf9be64024e8389236deb05644f9a_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMy0xMS0xLTEtMzE2OTI_8bf4bca2-d792-44a0-9e59-4026a4197569">906,196,812</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37a14c64016b44eeb0df3bd03a9c7261_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMy0xMy0xLTEtMzE2OTI_401e529c-e7ca-4b34-964c-13d198d13995">256,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01903000ca0941ae93dc226d9b97e700_I20201231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMy0xNy0xLTEtMzE2OTI_2e3aa51c-eee9-4dc9-9329-1ea82dd5ea5c">461,140,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash, net of financing costs of $<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNC0wLTEtMS0zMTY5Mi90ZXh0cmVnaW9uOmNiOTcxNzVlMjc0YzRiZjRhZWQ4NzFmNjUxM2EzMjEzXzY1_fa3612e7-2251-4c16-810d-114a05c3d82f">531,000</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c88a6a27b9e44eeba42ab6a651cc57c_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNC01LTEtMS0zMTY5Mg_253b7f9d-9f0e-4b6e-ac72-a9d054a95915">20,355,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c88a6a27b9e44eeba42ab6a651cc57c_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNC03LTEtMS0zMTY5Mg_8de5bcb1-c61a-4ee3-96e6-9649d38f4ea2">20,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i495f9f8bba37406aa957bb1fa1bb6b82_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNC05LTEtMS0zMTY5Mg_0af24370-041d-4521-8798-2fab9cbc55bf">162,084,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNC0xNy0xLTEtMzE2OTI_df6243d0-829e-41d2-8090-c9603898ba7c">162,105,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of December 2019 Bonds to common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c88a6a27b9e44eeba42ab6a651cc57c_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNS01LTEtMS0zMTY5Mg_10d88820-66a5-4c8f-acb1-81f3afd7ed88">1,009,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c88a6a27b9e44eeba42ab6a651cc57c_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNS03LTEtMS0zMTY5Mg_827503fd-968b-4512-885d-e10d1e075b31">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i495f9f8bba37406aa957bb1fa1bb6b82_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNS05LTEtMS0zMTY5Mg_7af0667d-b7a3-480d-a5c6-47346a235ec9">4,376,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNS0xNy0xLTEtMzE2OTI_2ad12492-ba24-44bd-aa2a-279ffe17b218">4,377,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c88a6a27b9e44eeba42ab6a651cc57c_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNi01LTEtMS0zMTY5Mg_79cc957d-58bc-49be-9ce4-a6d6fc1625bd">1,118,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c88a6a27b9e44eeba42ab6a651cc57c_D20210101-20210331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNi03LTEtMS0zMTY5Mg_7be43536-4702-4d24-a668-93f92a51799d">1,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i495f9f8bba37406aa957bb1fa1bb6b82_D20210101-20210331" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNi05LTEtMS0zMTY5Mg_2d32f3a1-90cd-48bc-b50a-388747164dec">1,202,907</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNi0xNy0xLTEtMzE2OTI_5599ba97-43fe-4b39-943a-dc90c8b268d5">1,201,789</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i495f9f8bba37406aa957bb1fa1bb6b82_D20210101-20210331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNy05LTEtMS0zMTY5Mg_b39682e7-e375-4506-970b-ad011ee8075e">9,595,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNy0xNy0xLTEtMzE2OTI_bf1b7514-c48b-4f69-8da2-fffcde82ba44">9,595,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i706e11fcf7b840a68346dcb076a72fe7_D20210101-20210331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfOC0xMS0xLTEtMzE2OTI_2c45c9df-36fa-40b8-8e23-00c8a1a8e7e4">54,402,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfOC0xNy0xLTEtMzE2OTI_e4f6753d-19c3-4c06-85f3-69c3cfd0fb8b">54,402,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b4db7184a6e4d539bd893221daa7b6b_D20210101-20210331" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfOS0xMy0xLTEtMzE2OTI_d19e8ca8-1a6f-43ea-89af-e0046fa9c9e9">4,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfOS0xNy0xLTEtMzE2OTI_d6198659-4c9a-4d60-bf17-88e361f7142e">4,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b4db7184a6e4d539bd893221daa7b6b_D20210101-20210331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMTAtMTMtMS0xLTMxNjky_b4c01727-ef37-4f2f-b3a8-ff0cfa965061">14,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMTAtMTctMS0xLTMxNjky_165d06a5-e09c-4fd7-a391-0b28e9a4ed70">14,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib17ceb956c2f426eb2b764885c99a7e2_I20210331" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMTEtMS0xLTEtMzE2OTI_628df666-524f-4bf0-a836-c1ff901d0107">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib17ceb956c2f426eb2b764885c99a7e2_I20210331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMTEtMy0xLTEtMzE2OTI_2ce2f870-43c2-433b-8ce4-57f81315f2ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f8d19094f794192baacd56f29fcdae7_I20210331" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMTEtNS0xLTEtMzE2OTI_ac00c91e-c16e-418c-a232-d3f1460021e8">209,334,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f8d19094f794192baacd56f29fcdae7_I20210331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMTEtNy0xLTEtMzE2OTI_8ad1ac8f-0287-4308-b2f5-08da6628fdc0">209,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a7141f817b64eedaa3b9d245abc6c8f_I20210331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMTEtOS0xLTEtMzE2OTI_efde530f-410d-4b72-8822-09b188489560">1,542,261,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iafaea1518ae5419386ac2efc6b2ba187_I20210331" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMTEtMTEtMS0xLTMxNjky_41f2eebe-227b-459a-96fd-c2548412c274">960,598,943</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd921433e3a44903b67d69cd507b789c_I20210331" decimals="0" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMTEtMTMtMS0xLTMxNjky_59aec09b-9b5e-48fb-8979-076658fda481">265,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2676a854bc50429cba33013cd2fd88be_I20210331" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMTEtMTctMS0xLTMxNjky_8e19c3de-9996-4676-ac0d-b200eb2d2f6f">581,606,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i5cd930e6c7ce444abb7f72171f50164c_28"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:71.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.124%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMy0xLTEtMS0zMTY5Mg_bc4f97ef-41d1-4b00-8992-62ff1e9178fc">79,073,719</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMy0zLTEtMS0zMTY5Mg_cc945208-e38a-42bd-8816-58b492f8a054">54,402,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNS0xLTEtMS0zMTY5Mg_b30f12ef-091d-41db-a747-d3e72336e7a6">929,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNS0zLTEtMS0zMTY5Mg_d8958138-1893-4ae0-b776-492c82844cc5">660,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNi0xLTEtMS0zMTY5Mg_2755fc59-0b9a-488e-be32-589910ea269f">126,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNi0zLTEtMS0zMTY5Mg_e2dfe149-a39c-4410-a547-990f49014c2e">136,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNy0xLTEtMS0zMTY5Mg_c39967c0-d5c2-46a8-abc7-e6c86bbdd3fc">319,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNy0zLTEtMS0zMTY5Mg_a1a128b1-4c78-486c-9b07-ebce9cef419a">278,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfOS0xLTEtMS0zMTY5Mg_4f60169a-72a1-485b-a73d-12c0ef1d85f4">7,711,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfOS0zLTEtMS0zMTY5Mg_dbeaffbd-1a06-4988-bbbd-7ab9f38f4043">9,595,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="ino:NonCashInterestIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTItMS0xLTEtMzE2OTI_fe7382b4-e831-44d1-9d76-de24c7801b8a">219,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="ino:NonCashInterestIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTItMy0xLTEtMzE2OTI_121c6675-2ddf-4277-ac67-684936780dd5">31,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:InvestmentIncomeAmortizationOfPremium" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTMtMS0xLTEtMzE2OTI_5b9e59f7-42e1-4b5f-ba07-45d279fd4003">125,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:InvestmentIncomeAmortizationOfPremium" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTMtMy0xLTEtMzE2OTI_a41af41b-326f-4763-bfa8-9ccc6a566f17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTQtMS0xLTEtMzE2OTI_066dec56-6cfb-4075-b292-74f75e296e6e">318,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTQtMy0xLTEtMzE2OTI_4f4f0c0e-5061-4795-a9a0-37ac9caf7035">10,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTUtMS0xLTEtMzE2OTI_f0f235c1-b7a6-48a7-a96d-c959c212d232">157,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTUtMy0xLTEtMzE2OTI_f62296c8-b3c3-4675-b55b-2430f23e3069">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on remeasurement of investment in Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="ino:GainLossOnRemeasurementOfEquityMethodInvestment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTYtMS0xLTEtMzE2OTI_2aa5b575-b9fe-4468-853c-94f179b1478c">165,215</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="ino:GainLossOnRemeasurementOfEquityMethodInvestment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTYtMy0xLTEtMzE2OTI_753226a5-eb91-49b8-9563-795e09393fb9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on equity investment in affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTgtMS0xLTEtMzE2OTI_2816e4dc-71bf-4646-90aa-c735398cc162">537,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTgtMy0xLTEtMzE2OTI_2f9f065c-1546-4a34-bc2f-b694fb55bedc">830,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share of net loss in Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTktMS0xLTEtMzE2OTI_35de1b14-b2e2-4305-bb76-1f7eeee6cc07">2,165,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTktMy0xLTEtMzE2OTI_1af6871b-59b7-4cdf-a0d4-410afc1442ef">434,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized loss on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMjItMS0xLTEtMzE2OTI_6bf6927b-1ddb-4822-9999-26494c475a44">4,840,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMjItMy0xLTEtMzE2OTI_af50048f-9d76-4e76-b91e-0d30e451fa5e">847,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized transaction loss on foreign-currency denominated debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMjYtMS0xLTEtMzE2OTI_9dfac862-6b58-403e-a4ca-126c42f60b1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMjYtMy0xLTEtMzE2OTI_420e9148-ff54-4d51-8cf3-7672bea842d3">176,927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, including from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMjktMS0xLTEtMzE2OTI_36f63754-ac5c-4f06-805e-0b4eb7788926">541,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMjktMy0xLTEtMzE2OTI_9d2ff146-6bf5-4703-ab6e-b54cb143a35b">8,804,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets, including from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzEtMS0xLTEtMzE2OTI_bf5f22b0-d0aa-4e04-a2a2-debff7115e0a">7,075,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzEtMy0xLTEtMzE2OTI_fb33deb0-89a6-4af4-b569-3757b940485f">19,108,348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzQtMS0xLTEtMzE2OTI_47e739f3-5138-46c6-bb13-d4723377a936">151,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzQtMy0xLTEtMzE2OTI_c9101a01-00b1-4f63-a233-dfb2b95ea718">75,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzUtMS0xLTEtMzE2OTI_6d316c75-a87f-47de-b3d6-c0e9e5e71e9e">9,859,913</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzUtMy0xLTEtMzE2OTI_dc9c9d4d-a9e8-4f84-8476-0488d568b340">4,735,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzYtMS0xLTEtMzE2OTI_e586fdba-6715-4ebd-acc1-0588d8b4e10e">1,501,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzYtMy0xLTEtMzE2OTI_7712ebf2-ed37-4cd7-a189-4e2172a4ec81">2,579,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses due to affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzctMS0xLTEtMzE2OTI_5ed906f2-69fe-429d-96e2-f351bc1294f1">859,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzctMy0xLTEtMzE2OTI_11d88447-771b-461a-8223-448184866269">125,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, including from affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzgtMS0xLTEtMzE2OTI_288f95ac-1ee2-47bb-8523-dc552b858a29">9,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzgtMy0xLTEtMzE2OTI_f9189d84-74d5-44e7-b116-4f32a6f0b228">72,463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDEtMS0xLTEtMzE2OTI_f9f48eb1-90c2-4623-a0bd-50b77ad06794">624,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDEtMy0xLTEtMzE2OTI_5d88603a-7840-4adf-b797-b5918afa4b7b">558,140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant funding liability, including from affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDItMS0xLTEtMzE2OTI_b9112111-faa7-4d84-ad3e-cc48f9642ac6">723,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDItMy0xLTEtMzE2OTI_53d30ab4-869f-42c0-a11b-67e27ebd2f33">2,480,826</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDUtMS0xLTEtMzE2OTI_104337c7-2950-4d75-bff1-f4cbd48151c3">14,826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDUtMy0xLTEtMzE2OTI_7a338da2-64ab-45a1-ac00-c665fbfe7b06">6,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDYtMS0xLTEtMzE2OTI_3e0dbdc4-b78f-478c-a837-1fb0df6b2c90">61,882,102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDYtMy0xLTEtMzE2OTI_e8fd920d-de05-4d57-a688-647172a5a498">52,867,428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDgtMS0xLTEtMzE2OTI_f8d204c5-d7fc-475b-9d02-15113a7c29fb">99,722,697</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDgtMy0xLTEtMzE2OTI_1fba48fb-a28f-47c1-9638-fc03cf44e234">275,408,976</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale or maturity of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDktMS0xLTEtMzE2OTI_6f5c1314-f397-4d13-9b60-876c8699bb1d">123,055,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDktMy0xLTEtMzE2OTI_8cd2045d-b319-48a6-90a6-4f7b4cfcdd35">504,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of capital assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNTAtMS0xLTEtMzE2OTI_f8b4324a-c0c4-4b14-9279-edfe44d11b24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNTAtMy0xLTEtMzE2OTI_5cc2a95c-35d0-4cf7-a353-765225916daa">210,824</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNTItMS0xLTEtMzE2OTI_252650df-1b20-4410-a932-6ff6d350d1b4">1,999,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNTItMy0xLTEtMzE2OTI_73b4028e-2c7c-4a91-9de3-d92fd53ce2dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNTYtMS0xLTEtMzE2OTI_913c40f6-f36d-417a-a149-2973bca7faf0">21,332,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNTYtMy0xLTEtMzE2OTI_53ae83a8-675f-41da-b821-1dd51b3ba864">275,115,336</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjAtMS0xLTEtMzE2OTI_0e0a03ce-0c5e-48b2-ae74-517ca161afab">29,364,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjAtMy0xLTEtMzE2OTI_130a60bb-33b1-4e31-bf66-507477e0a555">162,105,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjEtMS0xLTEtMzE2OTI_f2c82a0d-8259-40a7-ac5f-d9670b68c0f5">83,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjEtMy0xLTEtMzE2OTI_108cf06d-28a6-4185-a545-ea2c6e9d40d6">2,632,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjItMS0xLTEtMzE2OTI_484fd2f0-32a4-4a51-aac7-a20bc67976be">1,026,333</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjItMy0xLTEtMzE2OTI_2dce568c-9b43-4234-aaed-39c2ee3e304b">3,834,785</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjUtMS0xLTEtMzE2OTI_1f48b629-f19d-41f2-96f3-094663863b8d">28,422,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjUtMy0xLTEtMzE2OTI_c5a6e30d-3118-4652-b659-1b4c63b78bd9">160,903,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjYtMS0xLTEtMzE2OTI_ca3de3af-2b7e-4cf1-b5a4-a892c2ef6a4d">6,555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjYtMy0xLTEtMzE2OTI_260400d9-8171-45c0-93df-1577671244be">14,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjctMS0xLTEtMzE2OTI_b7d4267a-0cfd-43e6-9965-25f1b6d2632a">12,134,287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjctMy0xLTEtMzE2OTI_4f3ae497-3449-41df-b3de-d30544c59950">167,093,942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjgtMS0xLTEtMzE2OTI_0ed33ac2-401e-4a82-a8a9-982701d212db">71,143,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01903000ca0941ae93dc226d9b97e700_I20201231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjgtMy0xLTEtMzE2OTI_07699113-3e66-4b39-9d2b-5f3253b4587a">250,728,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjktMS0xLTEtMzE2OTI_0cee065a-0e66-4aa7-8a30-70ae86cc5b27">59,009,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2676a854bc50429cba33013cd2fd88be_I20210331" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjktMy0xLTEtMzE2OTI_b1ce785d-7379-43e7-80be-1f47438c9ab0">83,634,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts accrued for purchases of fixed assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNzItMS0xLTEtMzE2OTI_031ef378-80f3-4dec-976c-8a3505653154">330,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNzItMy0xLTEtMzE2OTI_b1630367-44d8-4e4a-b4e0-d5070c9f009b">35,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNzMtMS0xLTEtMzE2OTI_897dc688-96be-4b02-9c7b-01b4a4bc59a6">533,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNzMtMy0xLTEtMzE2OTI_fe33d174-47ca-4def-aae4-f3c80fb0c280">544,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to unaudited condensed consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i5cd930e6c7ce444abb7f72171f50164c_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_34"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">1. <ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNC9mcmFnOmE5Mzk2MDcxMWQ1YjRiM2RhZGRlZDQ5MDM2NzdmNDc4L3RleHRyZWdpb246YTkzOTYwNzExZDViNGIzZGFkZGVkNDkwMzY3N2Y0NzhfMzUwNg_dea64b5e-c9e7-47f7-9046-8b77bf3aba9e" continuedAt="i07b069bfed2e43bfa13c9d833a2bfc65" escape="true">Organization and Operations</ix:nonNumeric></span></div><ix:continuation id="i07b069bfed2e43bfa13c9d833a2bfc65"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;), is a biotechnology company focused on bringing to market precisely designed DNA medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer and conditions associated with human papillomavirus ("HPV"). INOVIO has shown in clinical trials that its DNA vaccine candidates can be delivered into cells in the body via a proprietary smart device allowing the nucleic-acid delivered gene products to activate functional T cell and antibody responses against targeted pathogens and cancers.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's DNA medicines pipeline is comprised of three types of product candidates: prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies ("dMAbs" and &#8220;dBTAs&#8221;), all of which utilize the two components of INOVIO's integrated platform, SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's proprietary SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce proteins or antigens to help the person&#8217;s immune system respond with antibodies and immune cells which recognize and then help block viruses and destroy cancerous or pre-cancerous cells. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's patented CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">smart delivery devices facilitate uptake of its DNA medicines into the cell, which has been a key limitation of historical DNA-based technology approaches. Human clinical trial data from more than 15,000 CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart device administrations across more than 5,000 participants to date have shown a tolerable safety profile.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's corporate strategy is to develop, seek regulatory approval for and commercialize its novel DNA medicines to address unmet global health needs. The Company continues to advance and clinically validate an array of DNA medicine candidates that target infectious diseases, such as COVID-19, as well as HPV-associated diseases and cancer. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's partners and collaborators include ApolloBio Corporation, AstraZeneca, Advaccine Biopharmaceuticals Suzhou Co., The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations ("CEPI"), The U.S. Department of Defense ("DoD"), Defense Advanced Research Projects Agency ("DARPA"), HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium ("MCDC"), International Vaccine Institute ("IVI"), Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its collaborators are currently evaluating the feasibility of, or conducting or planning clinical studies of, DNA medicines for COVID-19, including both homologous and heterologous booster vaccines; Middle East Respiratory Syndrome, or MERS; Lassa fever; Ebola; as well as HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis, or RRP; glioblastoma multiforme, or GBM; and prostate cancer. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_37"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNy9mcmFnOmVmNzQ4ZjQ0Mzc3YTQxMjlhOGEwM2E2MTMxN2Q4YmY2L3RleHRyZWdpb246ZWY3NDhmNDQzNzdhNDEyOWE4YTAzYTYxMzE3ZDhiZjZfNzQ4Mg_2fd6164a-570e-4b7c-a6ff-7cefaadd05f5" continuedAt="iae18d93f3a594652bb0b5f6ea4d9c4fe" escape="true">Basis of Presentation, Liquidity and Risks and Uncertainties</ix:nonNumeric></span></div><ix:continuation id="iae18d93f3a594652bb0b5f6ea4d9c4fe" continuedAt="iacc89370e8114638bd7c43c48a4688c0"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNy9mcmFnOmVmNzQ4ZjQ0Mzc3YTQxMjlhOGEwM2E2MTMxN2Q4YmY2L3RleHRyZWdpb246ZWY3NDhmNDQzNzdhNDEyOWE4YTAzYTYxMzE3ZDhiZjZfNzQ3MQ_26c54de1-e92d-4aa9-962c-fe1e83084e4d" continuedAt="ic62b12c6b7ef466da3d1e1e6bf441f84" escape="true"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of March&#160;31, 2022, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, the condensed consolidated statements of stockholders' equity and the condensed consolidated statements of cash flows for the three months ended March 31, 2022 and 2021 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three months ended March 31, 2022 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_7">Table of Contents</a></span></div></div><ix:continuation id="iacc89370e8114638bd7c43c48a4688c0"><ix:continuation id="ic62b12c6b7ef466da3d1e1e6bf441f84" continuedAt="i9805dec2e27541edad915808dde1a282"><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended December&#160;31, 2021, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;1, 2022. The balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of March&#160;31, 2022 and December 31, 2021, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC.  All intercompany accounts and transactions were eliminated upon consolidation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss attributable to common stockholders of $<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNy9mcmFnOmVmNzQ4ZjQ0Mzc3YTQxMjlhOGEwM2E2MTMxN2Q4YmY2L3RleHRyZWdpb246ZWY3NDhmNDQzNzdhNDEyOWE4YTAzYTYxMzE3ZDhiZjZfMjk3Mw_7a21bc19-35c7-4649-9c4e-f9fec1db0f8a">79.1</ix:nonFraction> million for the three months ended March 31, 2022. The Company had working capital of $<ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-5" name="us-gaap:Capital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNy9mcmFnOmVmNzQ4ZjQ0Mzc3YTQxMjlhOGEwM2E2MTMxN2Q4YmY2L3RleHRyZWdpb246ZWY3NDhmNDQzNzdhNDEyOWE4YTAzYTYxMzE3ZDhiZjZfMzA0NA_8ed54484-18d0-4d35-9eb1-eb789dd5b227">340.5</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-8" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNy9mcmFnOmVmNzQ4ZjQ0Mzc3YTQxMjlhOGEwM2E2MTMxN2Q4YmY2L3RleHRyZWdpb246ZWY3NDhmNDQzNzdhNDEyOWE4YTAzYTYxMzE3ZDhiZjZfMzA3OA_46508cf1-a783-4e41-aae3-d409ff353652">1.3</ix:nonFraction> billion as of March&#160;31, 2022. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNy9mcmFnOmVmNzQ4ZjQ0Mzc3YTQxMjlhOGEwM2E2MTMxN2Q4YmY2L3RleHRyZWdpb246ZWY3NDhmNDQzNzdhNDEyOWE4YTAzYTYxMzE3ZDhiZjZfMzQyNQ_adcd63b6-4323-4f01-bce3-5c820015b37d">360.4</ix:nonFraction> million as of March&#160;31, 2022 are sufficient to support the Company's planned operations for a period of at least 12 months from the date of issuance of these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has a history of conducting debt and equity financings, including the receipt of net proceeds of $<ix:nonFraction unitRef="usd" contextRef="if2af437e174542f6a96a9dd371a8e151_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNy9mcmFnOmVmNzQ4ZjQ0Mzc3YTQxMjlhOGEwM2E2MTMxN2Q4YmY2L3RleHRyZWdpb246ZWY3NDhmNDQzNzdhNDEyOWE4YTAzYTYxMzE3ZDhiZjZfMTA5OTUxMTYzODUxNA_29dc814c-5765-47d1-875b-50edffe3117b">29.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i13070eb515fa45c694edb66f1cadcb21_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNy9mcmFnOmVmNzQ4ZjQ0Mzc3YTQxMjlhOGEwM2E2MTMxN2Q4YmY2L3RleHRyZWdpb246ZWY3NDhmNDQzNzdhNDEyOWE4YTAzYTYxMzE3ZDhiZjZfODc5NjA5MzAzMzEzNw_99b72db1-e4a4-42f5-ae99-a8055b0d7ebb">47.7</ix:nonFraction>&#160;million under a Sales Agreement during the three months ended March 31, 2022 and year ended December 31, 2021, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i5188e2afa230429fab7f59ddf2c594b3_D20220101-20220331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNy9mcmFnOmVmNzQ4ZjQ0Mzc3YTQxMjlhOGEwM2E2MTMxN2Q4YmY2L3RleHRyZWdpb246ZWY3NDhmNDQzNzdhNDEyOWE4YTAzYTYxMzE3ZDhiZjZfNDA2MQ_f6c7de32-cc0a-4780-83b7-e9508304289c">162.1</ix:nonFraction>&#160;million from a January 2021 underwritten public offering of common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three months ended March 31, 2022 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9805dec2e27541edad915808dde1a282">The Company is, and from time to time&#160;may in the future be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition.</ix:continuation> </span></div><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="ino:RisksAndUncertaintiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNy9mcmFnOmVmNzQ4ZjQ0Mzc3YTQxMjlhOGEwM2E2MTMxN2Q4YmY2L3RleHRyZWdpb246ZWY3NDhmNDQzNzdhNDEyOWE4YTAzYTYxMzE3ZDhiZjZfNDk0NzgwMjMzNjA0Ng_463df0ed-833c-457c-a872-c5e912274168" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARs-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company continues to closely monitor the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will continue to impact the Company's business and operations will depend on future developments, including travel restrictions to, from and within the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, which remain uncertain.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_40"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180MC9mcmFnOjhkMzQ5MGIzYjZmNDQ0OTliNzFkMGJmMTQyNGIzNzFhL3RleHRyZWdpb246OGQzNDkwYjNiNmY0NDQ5OWI3MWQwYmYxNDI0YjM3MWFfMTY3Mjc_74b04da8-a4b0-4cee-a23c-7232c60de9fc" continuedAt="i3c3550c4b80f487da561743307bdd004" escape="true">Critical Accounting Policies</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i3c3550c4b80f487da561743307bdd004" continuedAt="i42403ea3f38b4d9e8b9e77162c68fc15"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180MC9mcmFnOjhkMzQ5MGIzYjZmNDQ0OTliNzFkMGJmMTQyNGIzNzFhL3RleHRyZWdpb246OGQzNDkwYjNiNmY0NDQ5OWI3MWQwYmYxNDI0YjM3MWFfNzE0NjgyNTY0MzQ3OA_e60f82b5-1e20-4350-8d63-3f73a5db5ecb" continuedAt="i290c3c4d75a44fcfa7774b7f98e0f41b" escape="true">Collaboration Agreements and Revenue Recognition</ix:nonNumeric></ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_7">Table of Contents</a></span></div></div><ix:continuation id="i42403ea3f38b4d9e8b9e77162c68fc15"><ix:continuation id="i290c3c4d75a44fcfa7774b7f98e0f41b"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. Differences in the allocation of the transaction price between delivered and undelivered performance obligations can impact the timing of revenue recognition but do not change the total revenue recognized under any agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For collaboration arrangements that include license fees, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For collaboration arrangements that include milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. This assessment is based on the Company&#8217;s past experience with its collaboration partner, market insight and partner communication. Milestone payments that are not within the Company&#8217;s or the collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment and could be material.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For collaboration arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue in the period the underlying sales occur. To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div></ix:continuation><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180MC9mcmFnOjhkMzQ5MGIzYjZmNDQ0OTliNzFkMGJmMTQyNGIzNzFhL3RleHRyZWdpb246OGQzNDkwYjNiNmY0NDQ5OWI3MWQwYmYxNDI0YjM3MWFfNzE0NjgyNTY0MzQ4MA_4558bcc4-b257-4039-b8e7-67ce75ae80c4" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMAbs. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt"><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_43"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180My9mcmFnOmVlYzA5MTBlMmM4ZjRkOGFiMWY4MDQ3MzE2NmQ0OGNiL3RleHRyZWdpb246ZWVjMDkxMGUyYzhmNGQ4YWIxZjgwNDczMTY2ZDQ4Y2JfMTE0MQ_5bce0517-6d2c-4994-9621-381241dd7184" continuedAt="i94a7eb079f0c4d6aa50b7f1d3f2d78fe" escape="true">Impact of Recently Issued Accounting Standards </ix:nonNumeric></span></div><ix:continuation id="i94a7eb079f0c4d6aa50b7f1d3f2d78fe" continuedAt="i8ce2bb7716e847bfb43a425c7603e752"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180My9mcmFnOmVlYzA5MTBlMmM4ZjRkOGFiMWY4MDQ3MzE2NmQ0OGNiL3RleHRyZWdpb246ZWVjMDkxMGUyYzhmNGQ4YWIxZjgwNDczMTY2ZDQ4Y2JfMTE0Mw_28fb9777-f0d2-4649-ba32-ea0274fbf536" continuedAt="ia1b66cb0fac54a0ab4d3ae0eeef0c84a" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Recently Adopted</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><ix:continuation id="i8ce2bb7716e847bfb43a425c7603e752"><ix:continuation id="ia1b66cb0fac54a0ab4d3ae0eeef0c84a"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2020-06.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;), which simplifies the guidance on an issuer&#8217;s accounting for convertible instruments and contracts in its own equity. ASU 2020-06 is effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2020-06 as of January 1, 2022 on a modified retrospective basis and recorded a net reduction in accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ifdd8f1364df749e5b75e252f613f37c5_I20220101" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180My9mcmFnOmVlYzA5MTBlMmM4ZjRkOGFiMWY4MDQ3MzE2NmQ0OGNiL3RleHRyZWdpb246ZWVjMDkxMGUyYzhmNGQ4YWIxZjgwNDczMTY2ZDQ4Y2JfMTA5OTUxMTYzNTY5Mw_2d940275-3e2b-45d9-a8ab-e90b55b68c0a">1.8</ix:nonFraction>&#160;million, a decrease in additional paid-in capital of $<ix:nonFraction unitRef="usd" contextRef="ifdd8f1364df749e5b75e252f613f37c5_I20220101" decimals="-5" sign="-" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180My9mcmFnOmVlYzA5MTBlMmM4ZjRkOGFiMWY4MDQ3MzE2NmQ0OGNiL3RleHRyZWdpb246ZWVjMDkxMGUyYzhmNGQ4YWIxZjgwNDczMTY2ZDQ4Y2JfMTA5OTUxMTYzMzczMA_9476901e-a5ee-4905-9a09-d5690fb6c782">3.3</ix:nonFraction>&#160;million, and an increase in convertible senior notes of $<ix:nonFraction unitRef="usd" contextRef="ifdd8f1364df749e5b75e252f613f37c5_I20220101" decimals="-5" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180My9mcmFnOmVlYzA5MTBlMmM4ZjRkOGFiMWY4MDQ3MzE2NmQ0OGNiL3RleHRyZWdpb246ZWVjMDkxMGUyYzhmNGQ4YWIxZjgwNDczMTY2ZDQ4Y2JfMTA5OTUxMTYzMzc0NA_e27b2d15-dcf5-4c67-9566-1d442bd960ee">1.5</ix:nonFraction>&#160;million to reflect the impact of the accounting change. The Company derecognized the related deferred tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="i5998790341a8497ba20d32d62e49492c_I20220331" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180My9mcmFnOmVlYzA5MTBlMmM4ZjRkOGFiMWY4MDQ3MzE2NmQ0OGNiL3RleHRyZWdpb246ZWVjMDkxMGUyYzhmNGQ4YWIxZjgwNDczMTY2ZDQ4Y2JfNDk0NzgwMjMzMTE2MQ_7b5fc575-9ad1-4ba4-bb35-2e97c5991d4e">1.5</ix:nonFraction>&#160;million with a corresponding adjustment to the valuation allowance, resulting in no net impact to the cumulative adjustment to retained earnings (see Note 8, "Convertible Debt").</span></ix:continuation></ix:continuation></div><div id="i5cd930e6c7ce444abb7f72171f50164c_46"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180Ni9mcmFnOjVmZDg1YTgyYzEwYTQ5Yjk5OTY0M2RjODY0MWJhM2NlL3RleHRyZWdpb246NWZkODVhODJjMTBhNDliOTk5NjQzZGM4NjQxYmEzY2VfNDY5_cb9af968-2d7c-4675-9f66-ea389fa01bfc" continuedAt="i762e17c5033049de95665d556833b8db" escape="true">Revenue Recognition  </ix:nonNumeric></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i762e17c5033049de95665d556833b8db">During the three months ended March 31, 2022 and 2021, the Company recognized total revenue under collaborative research and development arrangements of $<ix:nonFraction unitRef="usd" contextRef="i00d50bf6cf7f4ad2a522a955df7010fd_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180Ni9mcmFnOjVmZDg1YTgyYzEwYTQ5Yjk5OTY0M2RjODY0MWJhM2NlL3RleHRyZWdpb246NWZkODVhODJjMTBhNDliOTk5NjQzZGM4NjQxYmEzY2VfMTQz_4aef39c0-6a9e-40d9-a16e-440b72d76f15">9,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i998a91031a25433790f82a700988c0b4_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180Ni9mcmFnOjVmZDg1YTgyYzEwYTQ5Yjk5OTY0M2RjODY0MWJhM2NlL3RleHRyZWdpb246NWZkODVhODJjMTBhNDliOTk5NjQzZGM4NjQxYmEzY2VfMTA5OTUxMTYyODk2MQ_42584ede-3c07-4385-a469-0fa31eba7844">50,000</ix:nonFraction>, respectively, from its affiliated entity Plumbline Life Sciences, Inc. ("PLS") and $<ix:nonFraction unitRef="usd" contextRef="i9acea0aaff494ae8956e27ef9faf34c6_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180Ni9mcmFnOjVmZDg1YTgyYzEwYTQ5Yjk5OTY0M2RjODY0MWJhM2NlL3RleHRyZWdpb246NWZkODVhODJjMTBhNDliOTk5NjQzZGM4NjQxYmEzY2VfMjM3_8247d34e-0394-4a0c-9c1c-58c321140503">190,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib186138d47d74be9a37ef0b9377767e2_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180Ni9mcmFnOjVmZDg1YTgyYzEwYTQ5Yjk5OTY0M2RjODY0MWJhM2NlL3RleHRyZWdpb246NWZkODVhODJjMTBhNDliOTk5NjQzZGM4NjQxYmEzY2VfMTA5OTUxMTYyODk3MA_483f6d81-04d5-4f27-8d32-d65c52ce1b43">321,000</ix:nonFraction>, respectively, from various other contracts as a result of performance obligations being satisfied. Of the total revenue recognized during the three months ended March 31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180Ni9mcmFnOjVmZDg1YTgyYzEwYTQ5Yjk5OTY0M2RjODY0MWJhM2NlL3RleHRyZWdpb246NWZkODVhODJjMTBhNDliOTk5NjQzZGM4NjQxYmEzY2VfMzk0_fc59ff34-5532-40e3-a56c-c042b29af182">10,000</ix:nonFraction> was in deferred revenue as of December 31, 2021.</ix:continuation> </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_49"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfMzQxOQ_06294ae4-e0a1-4d8e-b087-82d893d6b9c1" continuedAt="i6dd2e9d53e2242e9ad651eedea7c8a1b" escape="true"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfMzQxOQ_d7e99c76-9868-441a-b937-48a0b140317e" continuedAt="i08d5b02521b843cdb0b8056581fee1ce" escape="true">Short-term Investments and Fair Value Measurements</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i6dd2e9d53e2242e9ad651eedea7c8a1b" continuedAt="ic6d59540179547c5a59a22861e2fdc80"><ix:continuation id="i08d5b02521b843cdb0b8056581fee1ce" continuedAt="ib9fa47360a62457fbe89a53cc99d3eba"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfNDk0NzgwMjMzMjE4MQ_99353627-c642-4f0d-876c-ad9e79eb7f4f" escape="true"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of March&#160;31, 2022 and December&#160;31, 2021:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dd96d739d1d4c6ba7fd44457e650877_I20220331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfMi0zLTEtMS0zMzc0MA_e501eed1-9055-4d53-a686-83cee61ba9fc">178,648,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dd96d739d1d4c6ba7fd44457e650877_I20220331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfMi01LTEtMS0zMzc0MA_0d90d9fb-ddd1-45ac-8275-8a072e4dd50d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dd96d739d1d4c6ba7fd44457e650877_I20220331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfMi03LTEtMS0zMzc0MA_8b813a3d-822e-4708-af6e-58ef7c00b591">6,367,983</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dd96d739d1d4c6ba7fd44457e650877_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfMi05LTEtMS0zMzc0MA_a4d6dca4-2a62-43d2-8c7e-f9bca25f8727">172,280,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="i200d0433fb874ceca8d01b4202a59cf7_D20220101-20220331" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfMy0xLTEtMS0zMzYyNi90ZXh0cmVnaW9uOjlkMzAwOTVmNDMxOTQ1ZDI5OGJkZGI0ODc5ZGVjZDc1XzE0_7680567d-2921-468f-9c48-205ef50d3ed4">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5059c8d38048299da6be38015206d8_I20220331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfMy0zLTEtMS0zMzc0MA_d5439cf6-fc54-4b4e-a188-d4dc19105f25">84,772,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5059c8d38048299da6be38015206d8_I20220331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfMy01LTEtMS0zMzc0MA_28c65b49-64ed-4e20-abb2-61c815148d3f">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d5059c8d38048299da6be38015206d8_I20220331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfMy03LTEtMS0zMzc0MA_df41fdf0-ea75-4c74-9821-93bad77b3dd1">108,139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5059c8d38048299da6be38015206d8_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfMy05LTEtMS0zMzc0MA_5c8c2bf6-c22e-43d7-b28f-04a1796f59a7">84,664,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="i96212faeb6564d55b7a90168c62339d7_D20210101-20211231" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNC0xLTEtMS0zMzczNi90ZXh0cmVnaW9uOmE2MzRkYTVlZGY0MDQxNTY5M2YwN2YzZTY2OTM5ZTNmXzQzOTgwNDY1MTExMjM_5f8d0286-9377-41f4-a82e-688cb9b65378">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea821ceda2b46c5ba64c5b0a9ebf7eb_I20220331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNC0zLTEtMS0zMzc0MA_03aaadeb-fd1b-41c7-a9b6-181b05dc84ac">39,986,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea821ceda2b46c5ba64c5b0a9ebf7eb_I20220331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNC01LTEtMS0zMzc0MA_7b0553ce-6661-4cfb-83db-672c05c3600d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea821ceda2b46c5ba64c5b0a9ebf7eb_I20220331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNC03LTEtMS0zMzc0MA_da996336-2937-4d65-899a-d282e1bc15f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea821ceda2b46c5ba64c5b0a9ebf7eb_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNC05LTEtMS0zMzc0MA_86201106-6fa1-4861-ace9-5088c4bc92ae">39,986,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="ib3b77e32e0d54bbe98f98ad16cfdcced_D20220101-20220331" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNS0xLTEtMS0zMzYyNi90ZXh0cmVnaW9uOmZjN2UyOWE0MWM3NzRhNGZiM2ZjYzAzNjBmZDlhZThhXzE0_a46a95a0-bbc1-4a8f-baef-9d9f967601df">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d2dabcc2e274335be3e08c2ede5ec0e_I20220331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNS0zLTEtMS0zMzc0MA_a9050fe2-bd30-45ee-93a2-ef2cacd3b955">2,976,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d2dabcc2e274335be3e08c2ede5ec0e_I20220331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNS01LTEtMS0zMzc0MA_e009af7a-2701-4634-ab2d-ab37237d77bc">15,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d2dabcc2e274335be3e08c2ede5ec0e_I20220331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNS03LTEtMS0zMzc0MA_e45afca0-f203-4c9a-8a54-9f653cffec37">333</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d2dabcc2e274335be3e08c2ede5ec0e_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNS05LTEtMS0zMzc0MA_cf12f469-6e7d-47d7-a3a3-a33c4dd0c519">2,991,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f4645750d14b1d8727f373d9bfec66_I20220331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNi0zLTEtMS0zMzc0MA_ccc8f824-2b97-4c60-99f1-532304b7e8e4">1,551,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f4645750d14b1d8727f373d9bfec66_I20220331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNi01LTEtMS0zMzc0MA_c2fe6ed3-140a-413c-a1b7-891c85fd6252">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15f4645750d14b1d8727f373d9bfec66_I20220331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNi03LTEtMS0zMzc0MA_422e1688-1664-4c1c-a8ae-e3cf4bdafa3f">90,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15f4645750d14b1d8727f373d9bfec66_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNi05LTEtMS0zMzc0MA_49319eda-9596-4395-a8cd-1aea74a5f896">1,461,623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNy0zLTEtMS0zNjg1Mw_302af4c0-bfa3-43cd-ae51-a76219e18095">307,935,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNy01LTEtMS0zNjg1Mw_53a80a44-dba7-4167-b2ad-863cff80e5d4">15,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNy03LTEtMS0zNjg1Mw_33723065-7999-4958-994c-f10b93129727">6,566,548</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNy05LTEtMS0zNjg1Mw_a7374ee7-d7cc-43fc-8f42-7bf40426a8e3">301,384,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35afa32f29f843dabd62652947f0eeb1_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfMi0zLTEtMS0zMzcyMg_ae7a480a-8b19-4e63-b760-076522bd06bc">192,966,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35afa32f29f843dabd62652947f0eeb1_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfMi01LTEtMS0zMzcyMg_4e1a1b3f-a0cf-4aec-b340-f3c44529b213">87,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35afa32f29f843dabd62652947f0eeb1_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfMi03LTEtMS0zMzcyMg_23225f31-ed90-424b-a7f3-0cbcd63d1e77">1,614,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35afa32f29f843dabd62652947f0eeb1_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfMi05LTEtMS0zMzcyMg_eeabc69a-e09a-4a7b-b81e-3855f0dd6316">191,439,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;<ix:nonNumeric contextRef="i3dd02c8047614f899869c90b0070ab8d_D20210101-20211231" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfMy0xLTEtMS0zMzYzMS90ZXh0cmVnaW9uOmE0NDcwNGIyYjAzOTQ1MzhiMGUxNjQwMjM3NTU2N2JmXzQzOTgwNDY1MTExMjM_0b419a77-852e-4b1c-ba07-a17f90dcf08f">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ad7b0c63c34318904c5962edc5336c_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfMy0zLTEtMS0zMzcyMg_dc36dee6-40eb-45a9-bf02-4e808539946b">94,193,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ad7b0c63c34318904c5962edc5336c_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfMy01LTEtMS0zMzcyMg_1bb7e42a-6a83-48dd-a4e6-72d7e493dc92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11ad7b0c63c34318904c5962edc5336c_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfMy03LTEtMS0zMzcyMg_633e34db-6e29-4d14-87b3-acf56e584dbb">9,921</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ad7b0c63c34318904c5962edc5336c_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfMy05LTEtMS0zMzcyMg_676b9252-ea42-40f2-a4ec-a3367fbbf116">94,183,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;<ix:nonNumeric contextRef="i96212faeb6564d55b7a90168c62339d7_D20210101-20211231" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNC0xLTEtMS0zMzcxOC90ZXh0cmVnaW9uOmQ5YzdhMTc4ZDhjMTQ2NjY4MTIzYTY2ODZmYTQzN2QyXzQzOTgwNDY1MTExMjM_eeb56cc7-7e23-432e-9869-8744d9d76619">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1de2f49204499c821a49656c3c3db0_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNC0zLTEtMS0zMzcyMg_336f9a35-6166-4ec6-b9ba-5dd27f045377">39,967,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1de2f49204499c821a49656c3c3db0_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNC01LTEtMS0zMzcyMg_92c1a0f3-5fb9-4c02-8ace-bdfa9b2ec6fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1de2f49204499c821a49656c3c3db0_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNC03LTEtMS0zMzcyMg_92933c3c-47dc-4ae4-a30d-e275fda14c5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c1de2f49204499c821a49656c3c3db0_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNC05LTEtMS0zMzcyMg_681c1e68-f3ec-4f47-857a-43842f921d2b">39,967,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="i256e22e1c0a840458b2307e674601335_D20210101-20211231" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNS0xLTEtMS0zNjg1NS90ZXh0cmVnaW9uOmEyNGNlZjBlOWY5MDQ3OWVhYTY4MThiZjFjOWNkMTgyXzQzOTgwNDY1MTExMjA_daa9446b-c97d-4d35-b946-71ccfbb90dbb">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c26ca99f7cb4cacbac0e8bc0ed494ed_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNS0zLTEtMS0zMzcyMg_03218fcd-1f83-47fa-8bae-f9f4cea90f50">2,976,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c26ca99f7cb4cacbac0e8bc0ed494ed_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNS01LTEtMS0zMzcyMg_63ffc9ec-60c0-4e84-9ed5-4135d8df15fa">15,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c26ca99f7cb4cacbac0e8bc0ed494ed_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNS03LTEtMS0zMzcyMg_9c472f0e-0ccb-4588-bfbf-192c7c93e817">338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c26ca99f7cb4cacbac0e8bc0ed494ed_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNS05LTEtMS0zMzcyMg_19bf8679-a058-492a-ac01-1fbde91460e8">2,991,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a46ac477e0c44908926cbfd89796968_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNi0zLTEtMS0zMzcyMg_e5750343-4b43-4e33-8877-40500f75e584">1,608,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a46ac477e0c44908926cbfd89796968_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNi01LTEtMS0zMzcyMg_80c06d68-48c7-4771-9480-44c50fcc6e84">4,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a46ac477e0c44908926cbfd89796968_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNi03LTEtMS0zMzcyMg_8fa79eb7-564f-45a8-be11-5468a61a8967">23,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a46ac477e0c44908926cbfd89796968_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNi05LTEtMS0zMzcyMg_dd97d989-63b4-4c79-a596-1dc060d8f6cc">1,588,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNy0zLTEtMS0zNjg0NA_f56e928f-0a14-4608-b549-1657f0def6dd">331,712,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNy01LTEtMS0zNjg0NA_8d193c5b-d99b-4274-8189-e39aedf9ed4b">107,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNy03LTEtMS0zNjg0NA_5dc2822e-d198-4341-a419-5bc0df766b0e">1,648,668</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNy05LTEtMS0zNjg0NA_3b065106-3190-4d9e-b86b-add0e7f3e4e1">330,170,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended March 31, 2022 and 2021, the Company recorded gross realized gain on investments of $<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfOTYw_1c59a375-e1b6-4bea-8757-c85c9cbd79cc">20,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfOTY3_922acaea-45d6-48cd-9c54-52d55d6b93e0">0</ix:nonFraction>, respectively, and gross realized loss on investments of $<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfMTAyNw_767cb7cc-af59-41da-ab79-6d5152a9738a">339,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfMTAzNA_511a25ea-66e7-46eb-8fea-98cc5d9b7be6">10,000</ix:nonFraction>, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded net unrealized loss on available-for-sale equity securities of $<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfMTMxNw_3f93485a-0b5a-4afe-af1e-8664180897c0">4.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfMTMyNA_5f6a908a-fe88-44fd-b629-c173e476ffd5">848,000</ix:nonFraction>, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the three months ended March 31, 2022 and 2021. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of March&#160;31, 2022, the Company had <ix:nonFraction unitRef="position" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfMTc2Mg_b47f5de8-634d-4528-b974-f4e85c62196c">29</ix:nonFraction> available-for-sale securities in an unrealized loss position, of which <ix:nonFraction unitRef="position" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfMTgzNg_6a3ae7d0-a66d-4865-8174-9d9c518ff8fd">13</ix:nonFraction> with an aggregate total unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfMTg4Mg_be682654-9b3c-4d28-bfe8-45ca17b66dbd">2.9</ix:nonFraction> million were in such position for longer than 12 months.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;March&#160;31, 2022&#160;were </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic6d59540179547c5a59a22861e2fdc80" continuedAt="i830c7f2c4ce74b6bb0688483e3b4da73"><ix:continuation id="ib9fa47360a62457fbe89a53cc99d3eba" continuedAt="i924c312d7cb54ca1ac2144b35d9dfe90"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">primarily due to changes in interest rates</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at March&#160;31, 2022, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfNDk0NzgwMjMzMjE4Mg_c7e369e3-6be8-4556-97f6-04dd8b27b990" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie327610064114130b6724b61e0aa0b11_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNC0xLTEtMS0zMzk0NQ_8b14693b-51e0-43ee-951b-569387065805">172,280,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a7a4020c94941b4b6acc78d93b58453_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNC0zLTEtMS0zMzk0NQ_203188ca-0147-4b3b-88ff-996c672e4804">172,280,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i471805632a1c4b1497d106f7f6d32bc1_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNC01LTEtMS0zMzk0NQ_4bdf38c7-8c0e-48b3-b066-c79988a43022">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3922f5859d40ef8c8a2487c7e981b6_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNC03LTEtMS0zMzk0NQ_fb228013-900c-4bc3-85fb-684eda6c62e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bad7403c49c468b8ceafcdd73d058f4_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNS0xLTEtMS0zMzk0NQ_26ec11b0-c531-41dc-bfa4-a414de649f92">84,664,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i910199c871b24e7281edfe262f9e595c_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNS0zLTEtMS0zMzk0NQ_b0c4598a-7f14-44f0-acb0-998bbd5ae206">84,664,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcdd3d9daef249babdd7610c465d9861_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNS01LTEtMS0zMzk0NQ_47d6715f-5867-4938-b2e3-4939132fe9d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fd176d27ac94f388085f5b57e2f24cd_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNS03LTEtMS0zMzk0NQ_e8910c3b-112b-4d31-989e-902423a2b45d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e6180b331b4e71ba67ae40963d4a03_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNi0xLTEtMS0zMzk0NQ_39f99b3f-43ce-4402-9b26-e5555fbb1a37">39,986,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc7f88e09b444751aad08e36afbd151d_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNi0zLTEtMS0zMzk0NQ_db7a3cec-8ccd-4ef1-b03d-b228d17e30a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7763d94f5b7e483eb2aa063bff3f4fc5_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNi01LTEtMS0zMzk0NQ_2ace0fb6-dbd5-4bd4-9cd1-7c53ca100b84">39,986,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37fe9e79f04d4894a64245d5e39a5f1e_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNi03LTEtMS0zMzk0NQ_bea2c840-7350-47a9-b916-5c5bd06f84c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05223ae01d645f69bb34279da86b5c0_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNy0xLTEtMS0zMzk0NQ_2cf9c9e0-0acf-4c08-baa7-5f5d6e666e21">2,991,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib091b9b6d4f644349ae9a24d2bdc827b_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNy0zLTEtMS0zMzk0NQ_2b2f7ae1-a1da-4d4c-854d-6e85075d0187">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf2144065280473599c7afda89ad1694_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNy01LTEtMS0zMzk0NQ_58bc8155-9171-4e4c-a3b8-70f9bb843fc5">2,991,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6412688827466ca20d0eb89182015c_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNy03LTEtMS0zMzk0NQ_d26c2c02-2491-4fdb-ad16-7204197283d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20a3ba1b8f6c4fdbbc57d85e7c759c66_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfOC0xLTEtMS0zMzk0NQ_f699acd7-6c7c-4c85-8f0f-284439cc84cf">1,461,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d964321f9c49ba80f2d28a540dfb8e_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfOC0zLTEtMS0zMzk0NQ_b453a512-114f-4f6e-b6c5-80212ac6fed0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05e130a7d4404dcf9c53ef79a503f2d8_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfOC01LTEtMS0zMzk0NQ_53650604-6ebb-4a05-9267-9c503420e6fd">1,461,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aee826afc7f4bb584c9baec2cacd2ff_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfOC03LTEtMS0zMzk0NQ_ca60a19c-f5ea-4d60-be08-b3c7f532e9bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b127be22eb4b9a9750afaa61f1ec0f_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfOS0xLTEtMS0zNjgwOQ_ff2e530a-abfb-49f5-923b-8bc37f4482e5">301,384,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae1ff7cfb12549c794647cdbfea00698_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfOS0zLTEtMS0zNjgwOQ_3648038a-7066-4308-ab35-62bc6d4b446f">256,945,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d2be785b7e4c0eb3075ccc1b52f222_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfOS01LTEtMS0zNjgwOQ_8a67d054-8e63-4a8a-854c-00ed7cbc70ea">44,439,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ab217ecf956405d9cf37acb90fb804c_I20220331" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfOS03LTEtMS0zNjgwOQ_18df8f07-a8ce-473e-a9b0-db954b0cc0a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b127be22eb4b9a9750afaa61f1ec0f_I20220331" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfMTEtMS0xLTEtMzM5NTI_e1e08fd3-c45b-4327-9edd-f40b09b69a8d">3,369,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae1ff7cfb12549c794647cdbfea00698_I20220331" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfMTEtMy0xLTEtMzM5NTI_d30958b6-92c9-401b-8e65-9152e367f392">3,369,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d2be785b7e4c0eb3075ccc1b52f222_I20220331" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfMTEtNS0xLTEtMzM5NTI_ea4ecf7c-3d42-4364-afba-718827db4ebf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ab217ecf956405d9cf37acb90fb804c_I20220331" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfMTEtNy0xLTEtMzM5NTI_dafe1f21-c855-4bcb-ba33-998d4a4ed174">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b127be22eb4b9a9750afaa61f1ec0f_I20220331" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfMTItMS0xLTEtMzY4MTM_a0e701da-7c82-4ccd-bb12-ab2539bdbcff">304,753,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae1ff7cfb12549c794647cdbfea00698_I20220331" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfMTItMy0xLTEtMzY4MTM_e6006363-5079-42a4-a7d9-74cb3152720d">260,314,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d2be785b7e4c0eb3075ccc1b52f222_I20220331" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfMTItNS0xLTEtMzY4MTM_b50c6866-9e8b-4424-9d21-f59fdb7ad212">44,439,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ab217ecf956405d9cf37acb90fb804c_I20220331" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfMTItNy0xLTEtMzY4MTM_29937bb3-a9e5-409d-9bac-e0581aabdae4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.689%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i735216c789474c09b2396fda353fb55e_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNC0xLTEtMS0zMzg2Nw_a1a26e5f-fcff-4d07-bd6c-d13759fb3ac6">191,439,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib92f6424c666449486766a5d1d0e1832_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNC0zLTEtMS0zMzg2Nw_e1074606-479e-485d-bef3-61c5f32b3b95">191,439,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a4147a900d44007bcbaff1d2000a812_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNC01LTEtMS0zMzg2Nw_b9d8b33c-b35e-4b9e-93d8-bb4c98895755">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i922d453abb054b1c959336166486250e_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNC03LTEtMS0zMzg2Nw_666c93b6-73cd-435f-9ba1-cd8fc104873c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a00852361e24abdb75f61f00ba8440e_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNS0xLTEtMS0zMzg2Nw_7f5e5b64-fa12-450e-a039-d22fd91b1fac">94,183,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0927a0eab1d4d2ea57f80d09385ab14_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNS0zLTEtMS0zMzg2Nw_cd4f9a4e-cfa3-46ee-bb73-c52338c9acdb">94,183,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2346a1c5f64c47f39444b2604e34bec9_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNS01LTEtMS0zMzg2Nw_7078890c-28ce-4d83-9c81-8a4208e4e277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff609476032e4fd5850ace07b081d978_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNS03LTEtMS0zMzg2Nw_5b82ac16-6dc1-415d-b2ab-f01a974b0234">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4df03a74cdb1441981e64076b32bf6cb_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNi0xLTEtMS0zMzg2Nw_0954cf49-3c92-4bb0-9997-b4eb5469d02c">39,967,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf4907bded604daa8b4f90733b4960a5_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNi0zLTEtMS0zMzg2Nw_aa4b5754-d024-4ff5-b468-9261ef9dc890">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic01a2bc151f341de9e5bc9ca12685bd1_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNi01LTEtMS0zMzg2Nw_baf25404-1f20-4ab4-ab7f-7ca01371ee93">39,967,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acf182b26a44980bccfb7dc1c75de40_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNi03LTEtMS0zMzg2Nw_e2e2813b-2f32-4de9-8b52-ef598d16960d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10431da7c03644c9875fb73a741719db_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNy0xLTEtMS0zMzg2Nw_ae643a2c-f8bc-451e-b490-34c65ea6a7f1">2,991,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cee4483f4e345c08e931ecf9ad3260d_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNy0zLTEtMS0zMzg2Nw_c15185e8-d762-460e-82f3-aa25bebb0930">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaca2ffe0ede4c7292c889e48dba76a7_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNy01LTEtMS0zMzg2Nw_a54d1908-cdf8-478b-852a-7e929f8536c2">2,991,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0768b2ff10a94d04af660988ce14766c_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNy03LTEtMS0zMzg2Nw_8f2ede96-fb8c-4575-8787-fbb4426f4455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia45b882b6c5449a098b1e8921b30765f_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfOC0xLTEtMS0zMzg2Nw_54519b59-ede3-4472-a0ec-102289f126ec">1,588,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fc8c9fb3dda470585109a269277aa90_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfOC0zLTEtMS0zMzg2Nw_b2771bc3-e71a-4916-8b69-af568e8e50bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddcca9c2136e4da798d1e5a739c72a2b_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfOC01LTEtMS0zMzg2Nw_0d4dfb6b-4bc9-4c07-b17a-d03b5c71cf8a">1,588,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id97388b64a184cbab4a4fa6e23803d1c_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfOC03LTEtMS0zMzg2Nw_08070171-f987-4dca-8345-93ceadd3e917">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4284e75eeec74588b5ab75d6c01392cc_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfOS0xLTEtMS0zNjgxNw_dd9ee312-21af-4575-a44e-cb52697b1654">330,170,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11026ef96064c518d5053ab32d38a62_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfOS0zLTEtMS0zNjgxNw_c0132655-4d61-4579-8865-e20ac36ccd1c">285,622,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5133a9aa6b974cd6be58671085bc9222_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfOS01LTEtMS0zNjgxNw_a8e6d0d3-9879-4ad0-b692-9a893a307595">44,547,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ffc37c7b05544bb97a430265cc2bef9_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfOS03LTEtMS0zNjgxNw_e76b5c58-4819-4de8-ae10-f1e8d3520328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4284e75eeec74588b5ab75d6c01392cc_I20211231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfMTEtMS0xLTEtMzM4NzA_2fa377eb-c3a6-4c32-902a-1d321089700d">3,906,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11026ef96064c518d5053ab32d38a62_I20211231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfMTEtMy0xLTEtMzM4NzA_e2df35b4-cd13-43a9-b624-fdde7dcd4aa9">3,906,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5133a9aa6b974cd6be58671085bc9222_I20211231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfMTEtNS0xLTEtMzM4NzA_e00e3d8b-316a-4600-aca5-39e01100c4b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ffc37c7b05544bb97a430265cc2bef9_I20211231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfMTEtNy0xLTEtMzM4NzA_de7bab64-13f5-43e6-8370-db41c779cda0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4284e75eeec74588b5ab75d6c01392cc_I20211231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfMTItMS0xLTEtMzY4MTk_8afd1a81-0f9a-4025-8b9a-4a0e9bb99411">334,077,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11026ef96064c518d5053ab32d38a62_I20211231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfMTItMy0xLTEtMzY4MTk_528f429a-2411-4e2d-b24e-a63cce4c7627">289,529,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5133a9aa6b974cd6be58671085bc9222_I20211231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfMTItNS0xLTEtMzY4MTk_ca1ddb84-8d5d-48cc-8b17-2a54e56932cd">44,547,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ffc37c7b05544bb97a430265cc2bef9_I20211231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfMTItNy0xLTEtMzY4MTk_c53b64b0-d436-4d7d-8d4a-042dff864224">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 assets at March&#160;31, 2022 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in <ix:nonFraction unitRef="shares" contextRef="ibd3476330236483c98b0ec3070d9e333_I20220331" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfMjE5OTAyMzI2MDk3NA_68223bbe-ec35-4052-9b24-2bdae8094251">597,808</ix:nonFraction> common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">rations as unrealized gain (loss) on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or as a gain (loss) on investment in affiliated entity. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at March&#160;31, 2022 consisted of commercial paper, certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i830c7f2c4ce74b6bb0688483e3b4da73"><ix:continuation id="i924c312d7cb54ca1ac2144b35d9dfe90"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets held as of March&#160;31, 2022.</span></div></ix:continuation></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_58"></div><div style="margin-bottom:3pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RleHRyZWdpb246MTI4Yzc4ZDIzZDZlNDUxMjhmMjJlNzc0ODMyMDU4ZmVfNzQz_2689ee0b-8a74-47ed-a1d7-051d6963340e" continuedAt="iea5e93376b2c4b8d9d93ea437c297e88" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="iea5e93376b2c4b8d9d93ea437c297e88" continuedAt="icbbb7e83c90e47f8929908f3aa67817a"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RleHRyZWdpb246MTI4Yzc4ZDIzZDZlNDUxMjhmMjJlNzc0ODMyMDU4ZmVfNzQ3_ded4e469-c0ea-469d-8a13-4c1c2fc2828c" continuedAt="i60b564ac6877476483b9339f36c23a42" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth the goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:18.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.918%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMy0zLTEtMS0zMTY5Mg_c2787b5c-5599-4e4a-a78c-fb79c314a644">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMy03LTEtMS0zMTY5Mg_a8a609a6-5fed-4649-a570-811217f7f67c">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMy05LTEtMS0zMTY5Mg_95221fe5-355a-48a3-a8aa-7637b087b259">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMy0xMy0xLTEtMzE2OTI_6ac362f7-4013-484f-a553-f57496982d4d">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i937bf2eba10942f6be46a1071b4f10d7_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfNi0xLTEtMS0zMTY5Mg_2af5a30b-8668-4979-95fa-c2dce4adf085">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac1da597f7b4340893eba51de04ad26_I20220331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfNi0zLTEtMS0zMTY5Mg_d268a7d4-0c73-4a4f-bb5c-17ef1dc275c6">1,323,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ac1da597f7b4340893eba51de04ad26_I20220331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfNi01LTEtMS0zMTY5Mg_119a9756-5227-4986-b162-20b95c313edf">1,312,787</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac1da597f7b4340893eba51de04ad26_I20220331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfNi03LTEtMS0zMTY5Mg_4681545f-7409-488f-884c-44960c1b06a6">10,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851991d1186f468b82660c9a9ba18e50_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfNi05LTEtMS0zMTY5Mg_12c5147b-07d5-4e62-9cf8-844968b763fe">1,323,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i851991d1186f468b82660c9a9ba18e50_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfNi0xMS0xLTEtMzE2OTI_177f8474-f26a-4acb-98a9-3f3b045925db">1,305,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i851991d1186f468b82660c9a9ba18e50_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfNi0xMy0xLTEtMzE2OTI_e85fdda3-07c3-434b-8786-b5cd132558de">18,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3175c5ab2f0d46d7883309efb700f354_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfOS0xLTEtMS0zMTY5Mg_d900c6e9-ef7e-48fe-8705-3fd98424fbb2">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72f5235c51804466877805e8fd527626_I20220331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfOS0zLTEtMS0zMTY5Mg_498cfec5-8547-46db-a3fb-2dd745c3a41e">5,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72f5235c51804466877805e8fd527626_I20220331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfOS01LTEtMS0zMTY5Mg_598a5f42-8960-4a27-9ada-15a1a556b5e5">2,798,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72f5235c51804466877805e8fd527626_I20220331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfOS03LTEtMS0zMTY5Mg_3c72c4cd-3cb3-4280-b315-2e4d4b3c8ad9">2,301,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee1c54551f24453a3c895ffdc0bfe2e_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfOS05LTEtMS0zMTY5Mg_6f767e53-7a44-45af-ad80-bc57f139396f">5,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4ee1c54551f24453a3c895ffdc0bfe2e_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfOS0xMS0xLTEtMzE2OTI_11da7a8d-3ee9-45cf-a151-e182186b4daf">2,735,556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee1c54551f24453a3c895ffdc0bfe2e_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfOS0xMy0xLTEtMzE2OTI_4553ded5-4924-4a8f-ba90-33ddacafc83a">2,364,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4f93349007644f839f68fbed0c369c0d_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTAtMS0xLTEtMzE2OTI_1f96328a-a9f5-4eaf-a4ee-65d9fa5ace63">18</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2a0788492e40989bb27421d1bd2073_I20220331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTAtMy0xLTEtMzE2OTI_18a3906c-f162-4b0d-b116-547179432057">4,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b2a0788492e40989bb27421d1bd2073_I20220331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTAtNS0xLTEtMzE2OTI_9f001e57-6fdb-4c54-88db-f59f6f5d4dc4">3,862,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b2a0788492e40989bb27421d1bd2073_I20220331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTAtNy0xLTEtMzE2OTI_bd8f0f91-ff14-4327-9ed8-9983525edbfe">187,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic060851ec89c42658d3355959c413ec0_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTAtOS0xLTEtMzE2OTI_09774e94-3090-453a-b8ce-bf957ffc69b9">4,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic060851ec89c42658d3355959c413ec0_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTAtMTEtMS0xLTMxNjky_42f85e36-8af5-4117-ba3a-3c8fa1bef3cf">3,806,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic060851ec89c42658d3355959c413ec0_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTAtMTMtMS0xLTMxNjky_7578075f-88f1-414d-b0fa-0c1915ceb5df">243,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib6fece0d322b434c8593f46a8150a928_D20220101-20220331" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTEtMS0xLTEtMzE2OTI_8ad620aa-9a32-4dfe-8b07-ce6a3f80915c">11</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTEtMy0xLTEtMzE2OTI_4b2633ac-118e-46d1-8924-692b128ca914">10,473,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTEtNS0xLTEtMzE2OTI_75cce7ec-6267-4231-87b1-d844d785b5e0">7,974,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTEtNy0xLTEtMzE2OTI_b9cd9d8d-3ac3-43fc-ba5a-b8cd4c91506f">2,499,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTEtOS0xLTEtMzE2OTI_cc863a10-bbf4-438e-85f0-532d6c2bab96">10,473,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTEtMTEtMS0xLTMxNjky_bc35f031-e1d0-47ca-bd88-0bc7420bb49d">7,847,406</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTEtMTMtMS0xLTMxNjky_f50c751e-9980-405e-8af5-31b749cb9b47">2,626,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="ino:GoodwillAndIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTItMy0xLTEtMzE2OTI_896927ea-eca7-4c8e-931b-3f57a55c9de6">20,987,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTItNS0xLTEtMzE2OTI_b5a52a84-6cbd-4552-98ef-327c16166cbb">7,974,176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="0" name="ino:GoodwillAndIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTItNy0xLTEtMzE2OTI_e328a328-bd53-4324-9240-b8731e26c88f">13,012,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="ino:GoodwillAndIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTItOS0xLTEtMzE2OTI_82c25188-849d-405d-8067-3619bbd5790c">20,987,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTItMTEtMS0xLTMxNjky_7b595f04-24e8-42ab-8b9e-260de0fdf0f0">7,847,406</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="0" name="ino:GoodwillAndIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTItMTMtMS0xLTMxNjky_e6cc26f0-7924-44fd-a5bc-e7f726b9b675">13,139,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div></ix:nonNumeric><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i60b564ac6877476483b9339f36c23a42" continuedAt="i790da80f9d474ca3b676710fecb27c94">(b)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"><ix:continuation id="i790da80f9d474ca3b676710fecb27c94">Other intangible assets represent the estimated fair value of acquired intellectual property.</ix:continuation> </span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icbbb7e83c90e47f8929908f3aa67817a">Aggregate amortization expense on intangible assets for the three months ended March 31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RleHRyZWdpb246MTI4Yzc4ZDIzZDZlNDUxMjhmMjJlNzc0ODMyMDU4ZmVfNDQ3_22f3e7ad-a7c3-4347-a15f-325b479d64f4">127,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RleHRyZWdpb246MTI4Yzc4ZDIzZDZlNDUxMjhmMjJlNzc0ODMyMDU4ZmVfNTM5_0c8c29b4-998c-4a94-9553-0a5bf3507daa">137,000</ix:nonFraction>, respectively. Estimated aggregate amortization expense is $<ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RleHRyZWdpb246MTI4Yzc4ZDIzZDZlNDUxMjhmMjJlNzc0ODMyMDU4ZmVfNjA5_8fa60e51-414e-4373-928e-8b313024a3a9">366,000</ix:nonFraction> for the remainder of fiscal year 2022, $<ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RleHRyZWdpb246MTI4Yzc4ZDIzZDZlNDUxMjhmMjJlNzc0ODMyMDU4ZmVfNjQ5_0a8ba264-5821-4ae4-ad6a-648e7aa70243">276,000</ix:nonFraction> for 2023, $<ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RleHRyZWdpb246MTI4Yzc4ZDIzZDZlNDUxMjhmMjJlNzc0ODMyMDU4ZmVfNjYx_a5151dc9-4105-4afe-bb14-56209d638a6c">253,000</ix:nonFraction> for 2024, $<ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RleHRyZWdpb246MTI4Yzc4ZDIzZDZlNDUxMjhmMjJlNzc0ODMyMDU4ZmVfNjcz_e8583ce1-2e51-450e-b990-5abd4eca8a98">253,000</ix:nonFraction> for 2025, $<ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RleHRyZWdpb246MTI4Yzc4ZDIzZDZlNDUxMjhmMjJlNzc0ODMyMDU4ZmVfNjg1_6b450b23-5fa1-4c17-8776-1d73cec49ef9">253,000</ix:nonFraction> for 2026 and $<ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-5" name="ino:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RleHRyZWdpb246MTI4Yzc4ZDIzZDZlNDUxMjhmMjJlNzc0ODMyMDU4ZmVfNzAw_506b50aa-3410-41a3-9f7c-5a763a073cf4">1.1</ix:nonFraction> million for 2027 and subsequent years combined.</ix:continuation> </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_61"></div><div style="margin-bottom:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTMzMDc_25220d92-f0f8-4cf9-9e3d-7b81af221466" continuedAt="i241d1cdb386341839a88575164a7476a" escape="true">Convertible Debt</ix:nonNumeric></span></div><ix:continuation id="i241d1cdb386341839a88575164a7476a" continuedAt="i55ec8d83dc23461cb6675ce57dfa136d"><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 19, 2019 and March 1, 2019, the Company completed a private placement of $<ix:nonFraction unitRef="usd" contextRef="ia23c27fd3cb34cb7ac69f9e4e67b758a_I20190301" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTM2_d9230176-de4f-4898-9112-8ce159a07e98">78.5</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="ia23c27fd3cb34cb7ac69f9e4e67b758a_I20190301" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTcz_49ee558f-706d-4b31-aa04-cbda8191881e">6.50</ix:nonFraction>% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $<ix:nonFraction unitRef="usd" contextRef="if641e7664fea4b26986aea56c1df79ee_D20190219-20190301" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfNDA1_5dfdcbf5-7f4b-47cf-a231-a07fcd7a1070">75.7</ix:nonFraction> million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of <ix:nonFraction unitRef="number" contextRef="ia23c27fd3cb34cb7ac69f9e4e67b758a_I20190301" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfNjE0_6b61af79-ac07-4987-b88c-5a39e4aa2516">6.50</ix:nonFraction>% per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate was 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ia23c27fd3cb34cb7ac69f9e4e67b758a_I20190301" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTQyNg_052b6279-a0e8-440a-9399-6c9c17282413">5.38</ix:nonFraction> per share), subject to adjustment upon the occurrence of specified events.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds <ix:nonFraction unitRef="number" contextRef="if641e7664fea4b26986aea56c1df79ee_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTc0MA_09fd97e2-2737-46f1-b6ad-1558df2e3a9c">130</ix:nonFraction>% of the conversion price on (i) each of at least <ix:nonFraction unitRef="day" contextRef="if641e7664fea4b26986aea56c1df79ee_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTc5MQ_62d5b352-90fb-4302-9a87-a8eab5cc401c">20</ix:nonFraction> trading days (whether or not </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i55ec8d83dc23461cb6675ce57dfa136d"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consecutive) during the <ix:nonFraction unitRef="day" contextRef="if641e7664fea4b26986aea56c1df79ee_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTg0Nw_9c582af3-ee2a-4387-8a4b-7a2a07d09c60">30</ix:nonFraction> consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to <ix:nonFraction unitRef="number" contextRef="if641e7664fea4b26986aea56c1df79ee_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMjExOA_457d86ef-377f-4957-94ae-dc2ad5c8bc56">100</ix:nonFraction>% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initially, in accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments, which do not have an associated convertible feature. The carrying amount of the equity component representing the conversion option for the Notes was $<ix:nonFraction unitRef="usd" contextRef="ia23c27fd3cb34cb7ac69f9e4e67b758a_I20190301" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTA5OTUxMTY1OTIzOA_72c1929e-4c14-4e62-93f7-89f6516d5098">16.3</ix:nonFraction>&#160;million and was recorded as a debt discount, which was being amortized to interest expense at an effective interest rate of <ix:nonFraction unitRef="number" contextRef="i89c242d635e34cc2882b5b395b26a546_I20220331" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMjE5OTAyMzI4ODYzOA_e3a22e68-514d-4963-936b-d50a0b67ad06">13.1</ix:nonFraction>%. In addition, the Company allocated $<ix:nonFraction unitRef="usd" contextRef="i89c242d635e34cc2882b5b395b26a546_I20220331" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTA5OTUxMTY1OTI2MQ_92b6427f-6f3f-4542-b766-01970dcfc3cf">592,000</ix:nonFraction> of debt issuance costs to the equity component and the remaining debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i11fba970b3414270a4d7e4804a06e0e9_I20220331" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTA5OTUxMTY1OTI3MQ_fe5e16e3-5551-4b1e-956f-7300c2708a28">2.2</ix:nonFraction>&#160;million were allocated to the liability component, which were being amortized to interest expense under the effective interest rate method.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, the Company adopted ASU No. 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;), which is intended to simplify the accounting for convertible instruments. The ASU eliminates the cash conversion feature models in ASC 470-20, Debt with Conversion and Other Options, which required an issuer of certain convertible debt to separately account for embedded conversion features as a component of equity. Instead, an issuer will account for these securities as a single unit of account, unless the conversion feature meets certain criteria. The Company adopted the new standard using the modified retrospective method, and recorded a net reduction to accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ifdd8f1364df749e5b75e252f613f37c5_I20220101" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTA5OTUxMTY1NTE2MQ_48cbc980-fe0f-45b4-86bf-5c2f0e9fe38e">1.8</ix:nonFraction>&#160;million, a decrease to additional paid-in capital of $<ix:nonFraction unitRef="usd" contextRef="ifdd8f1364df749e5b75e252f613f37c5_I20220101" decimals="-5" sign="-" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTA5OTUxMTY1NTE3NQ_1a274f06-7525-4587-8e0c-90ea6ec34735">3.3</ix:nonFraction>&#160;million, and an increase to convertible senior notes of $<ix:nonFraction unitRef="usd" contextRef="ifdd8f1364df749e5b75e252f613f37c5_I20220101" decimals="-5" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTA5OTUxMTY1NTE0NQ_2a5d5b34-310c-4e42-a524-2838ab37b63e">1.5</ix:nonFraction>&#160;million to reflect the impact of the accounting change. The Notes are now accounted for as a single liability measured at amortized cost, as no other embedded features require bifurcation and recognition as derivatives.</span></div><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTMzMTA_55ecba2d-618d-4973-b57b-cfab70791f72" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at March&#160;31, 2022 was as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if239e019c41f41df87d6fabeb16a8209_I20220331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RhYmxlOjJiYzA2Y2JjMjY0ODRhNjg4ZTE5MThjOTZiNGFmYTcwL3RhYmxlcmFuZ2U6MmJjMDZjYmMyNjQ4NGE2ODhlMTkxOGM5NmI0YWZhNzBfMC0xLTEtMS0zMTY5Mg_16ff3913-2442-4a69-b6d6-0738f50479a8">78,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if239e019c41f41df87d6fabeb16a8209_I20220331" decimals="0" name="ino:DebtInstrumentConvertibleDebtConvertedAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RhYmxlOjJiYzA2Y2JjMjY0ODRhNjg4ZTE5MThjOTZiNGFmYTcwL3RhYmxlcmFuZ2U6MmJjMDZjYmMyNjQ4NGE2ODhlMTkxOGM5NmI0YWZhNzBfMS0xLTEtMS0zMTY5Mg_38d4c224-e49c-4b51-be4e-44d28acf08da">62,085,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if239e019c41f41df87d6fabeb16a8209_I20220331" decimals="0" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RhYmxlOjJiYzA2Y2JjMjY0ODRhNjg4ZTE5MThjOTZiNGFmYTcwL3RhYmxlcmFuZ2U6MmJjMDZjYmMyNjQ4NGE2ODhlMTkxOGM5NmI0YWZhNzBfMy0xLTEtMS0zMTY5Mg_ddbd989e-4dc0-4a66-bc9e-b15a66c796a3">296,051</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if239e019c41f41df87d6fabeb16a8209_I20220331" decimals="0" name="ino:DebtInstrumentAccruedInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RhYmxlOjJiYzA2Y2JjMjY0ODRhNjg4ZTE5MThjOTZiNGFmYTcwL3RhYmxlcmFuZ2U6MmJjMDZjYmMyNjQ4NGE2ODhlMTkxOGM5NmI0YWZhNzBfNC0xLTEtMS0zMTY5Mg_d93028d6-8cb6-4dd0-b7d7-2deb4705c91e">88,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if239e019c41f41df87d6fabeb16a8209_I20220331" decimals="0" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RhYmxlOjJiYzA2Y2JjMjY0ODRhNjg4ZTE5MThjOTZiNGFmYTcwL3RhYmxlcmFuZ2U6MmJjMDZjYmMyNjQ4NGE2ODhlMTkxOGM5NmI0YWZhNzBfNS0xLTEtMS0zMTY5Mg_e8a125f7-3e51-4991-b69b-8f3bdbfce69b">16,207,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022 and 2021,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i93f4fe9cdb954509a29e6972a23d8717_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfNDc3MQ_b011eac6-65e9-420a-a6b7-6e594f4562f9">313,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie10fbf5fad8743a6b390d426979d8a2f_D20210101-20210331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfNDc3OA_c2b54d39-513e-436d-a8de-8cdda6e5ad0b">463,000</ix:nonFraction>, respectively, of interest expense related to the Notes, of which $<ix:nonFraction unitRef="usd" contextRef="i93f4fe9cdb954509a29e6972a23d8717_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfNDg0Nw_c17a439e-057c-466d-b1e7-ff156711be4d">267,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie10fbf5fad8743a6b390d426979d8a2f_D20210101-20210331" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfNDg1NA_262f7d12-3b6d-4eea-a571-28a8b1ec6fc6">267,000</ix:nonFraction>, respectively, related to the contractual interest coupon.</span></div><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTMzMTE_389ee9f7-7209-43f7-b53c-fe95775f31ae" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of <ix:nonFraction unitRef="number" contextRef="i89c242d635e34cc2882b5b395b26a546_I20220331" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfNTIzNA_a2a76a79-bd51-4290-af25-62886bc64d8e">6.5</ix:nonFraction>% per annum, were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89c242d635e34cc2882b5b395b26a546_I20220331" decimals="0" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RhYmxlOjc1MTQ4ZmNiNmFmZTRhNTdiYzYxMzE5YzU4MTkyODc0L3RhYmxlcmFuZ2U6NzUxNDhmY2I2YWZlNGE1N2JjNjEzMTljNTgxOTI4NzRfMi0yLTEtMS0zMTY5Mg_6c09a17e-4d34-4791-bd59-30e1a4b31486">534,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89c242d635e34cc2882b5b395b26a546_I20220331" decimals="0" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RhYmxlOjc1MTQ4ZmNiNmFmZTRhNTdiYzYxMzE5YzU4MTkyODc0L3RhYmxlcmFuZ2U6NzUxNDhmY2I2YWZlNGE1N2JjNjEzMTljNTgxOTI4NzRfMy0yLTEtMS0zMTY5Mg_c7f365c9-cbed-4715-b37f-1cfa19888c63">1,067,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89c242d635e34cc2882b5b395b26a546_I20220331" decimals="0" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RhYmxlOjc1MTQ4ZmNiNmFmZTRhNTdiYzYxMzE5YzU4MTkyODc0L3RhYmxlcmFuZ2U6NzUxNDhmY2I2YWZlNGE1N2JjNjEzMTljNTgxOTI4NzRfNC0yLTEtMS0zMTY5Mg_361b14ae-a2bb-4806-b29b-4c0a5f22d7d8">16,948,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89c242d635e34cc2882b5b395b26a546_I20220331" decimals="0" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RhYmxlOjc1MTQ4ZmNiNmFmZTRhNTdiYzYxMzE5YzU4MTkyODc0L3RhYmxlcmFuZ2U6NzUxNDhmY2I2YWZlNGE1N2JjNjEzMTljNTgxOTI4NzRfNi0yLTEtMS0zMTY5Mg_338314ae-be45-43b9-a1a8-c9d02b8a8a6c">18,549,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="padding-left:22.5pt"><span><br/></span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2019 Convertible Bonds </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#8220;December 2019 Bonds&#8221;) with an aggregate principal amount of <ix:nonFraction unitRef="krw" contextRef="ib3c3bc6efec5497d8d3e271600131a3b_I20191226" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfOTc5NA_0962f4d1-4e6a-4c1e-ba40-7425d0e058d4">4.7</ix:nonFraction> billion KRW (USD $<ix:nonFraction unitRef="usd" contextRef="ib3c3bc6efec5497d8d3e271600131a3b_I20191226" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfOTgyMA_18c25ee9-f6c6-40de-a976-cc49440b2bf0">4.1</ix:nonFraction> million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were $<ix:nonFraction unitRef="usd" contextRef="i257d1ac432f142b299c0fe356311ee8a_D20191226-20191226" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfOTk1OQ_6b029faa-3f7f-417d-9b37-f0206a7e3df7">4.0</ix:nonFraction> million.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2019 Bonds, which were unsecured obligations of the Company, were issued on December&#160;31, 2019 and accrued interest at a coupon rate of <ix:nonFraction unitRef="number" contextRef="ib3c3bc6efec5497d8d3e271600131a3b_I20191226" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTAxMTM_e17dc9a4-7a14-4579-bc05-ff52d075e17b">1.00</ix:nonFraction>% per annum, payable quarterly. The December 2019 Bonds were scheduled to mature on December&#160;31, 2024, unless earlier converted or repurchased. On March 17, 2021, the December 2019 Bonds were converted in full into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i257d1ac432f142b299c0fe356311ee8a_D20191226-20191226" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTAzNDU_effa7199-f4e2-488a-b517-1e000ce1e8ae">1,009,450</ix:nonFraction> shares of the Company's common stock, leaving no further December 2019 Bonds outstanding. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Upon conversion, the $<ix:nonFraction unitRef="usd" contextRef="ib7987401764743bca11a6fcb90ae347c_D20220101-20220331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTA5OTUxMTY2MzQxNw_37700e93-0adc-4b4b-81bf-1391259712f2">4.4</ix:nonFraction>&#160;million carrying value of the December 2019 Bonds was reclassified to stockholders' equity.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rate of the December 2019 Bonds was <ix:nonFraction unitRef="number" contextRef="ide3610d56f684b5fbb8f7fff6ee33eee_I20210331" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTI2OTE_ddd28c7a-ed59-438a-8727-40c4ee6d6832">6.2</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i6cd8ee10514043399860125bd7812d5e_D20210101-20210331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTI5MTQ_9d3887d4-75dd-4a26-b612-34164c7ec69f">59,000</ix:nonFraction> of interest expense related to the December 2019 Bonds, of which $<ix:nonFraction unitRef="usd" contextRef="i6cd8ee10514043399860125bd7812d5e_D20210101-20210331" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTMwMDQ_c9d860e8-c730-4a8a-be7b-bb20af3f1d9b">9,000</ix:nonFraction> related to the contractual interest coupon.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_67"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfNDIxNQ_9d0d836b-9f29-41b4-831f-f3f5fe584362" continuedAt="i757c80862d78409eb90ade3db66cd301" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i757c80862d78409eb90ade3db66cd301" continuedAt="i5f71e40b317a4ec2bd5920ec8454f87d"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfNDIxNw_14bdf4c9-534b-4168-a006-2c421163e52f" escape="true"><div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's authorized and issued common and preferred stock as of March&#160;31, 2022 and December&#160;31, 2021: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:42.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfMi0wLTEtMS0zMTY5Mi90ZXh0cmVnaW9uOjdmNDZlYTYwNDc5ODQ3YjY4MWFjNjljYThjZTg5MjY2XzI4_42509f08-a79c-4162-a370-0d39adc1b6a9"><ix:nonFraction unitRef="usdPerShare" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfMi0wLTEtMS0zMTY5Mi90ZXh0cmVnaW9uOjdmNDZlYTYwNDc5ODQ3YjY4MWFjNjljYThjZTg5MjY2XzI4_9e63a56d-556f-4164-bc62-dece1b154f41">0.001</ix:nonFraction></ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfMi0xLTEtMS0zMTY5Mg_6c47a2ad-d427-4fbf-bdd2-ab0c6535cb20">600,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfMi0zLTEtMS0zMTY5Mg_990c9a63-95e0-46bc-b85e-34f4c23f85fd">226,510,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfMi01LTEtMS0zMTY5Mg_6e8872cb-4fcf-4ab1-8901-ac694f042137">226,510,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfMi03LTEtMS0zMTY5Mg_c67c7797-e5c5-4951-aec9-b937ca8e6443">217,382,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="iee0415add3154b6c8fca72404d201bb7_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfNS0wLTEtMS0zMTY5Mi90ZXh0cmVnaW9uOjBjZjU0NWZlMWE1YTQzN2Y5ZjJkYjE2NjBkYWIzN2I5XzQw_55055fc1-e1c4-42a2-b494-74b71dc2bca0"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e2be23d00d345b6bed7ade8e6494fc7_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfNS0wLTEtMS0zMTY5Mi90ZXh0cmVnaW9uOjBjZjU0NWZlMWE1YTQzN2Y5ZjJkYjE2NjBkYWIzN2I5XzQw_cd91b93e-b091-47d7-9fd5-967e94eeebe6">0.001</ix:nonFraction></ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e2be23d00d345b6bed7ade8e6494fc7_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfNS0xLTEtMS0zMTY5Mg_1dc64823-b880-4aed-ac4f-d1351794881b">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e2be23d00d345b6bed7ade8e6494fc7_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfNS0zLTEtMS0zMTY5Mg_040f1ff6-de96-411e-9ff5-369a3d811636">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e2be23d00d345b6bed7ade8e6494fc7_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfNS01LTEtMS0zMTY5Mg_0a421073-a8b6-4235-9af7-ea53aeaddbe6">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee0415add3154b6c8fca72404d201bb7_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfNS03LTEtMS0zMTY5Mg_d31e7a47-1e1d-4768-ab66-cf185b779533">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, the Company entered into an ATM Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;2021 Sales Agreement&#8221;) with outside sales agents (collectively, the &#8220;Sales Agents&#8221;) for the offer and sale of its common stock for an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i9a881011504441e1a9c61a374bf1ccf4_D20211109-20211109" decimals="INF" name="ino:StockSalesAgreementMaximumAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMjE5OTAyMzI2MDgxOA_69fe655e-a171-4c99-b8d6-03a23e68e28a">300.0</ix:nonFraction>&#160;million. The 2021 Sales Agreement provides that the Sales Agents will be entitled to compensation in an amount equal to up to <ix:nonFraction unitRef="number" contextRef="i9a881011504441e1a9c61a374bf1ccf4_D20211109-20211109" decimals="INF" name="ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMjE5OTAyMzI2MDgzMw_9472ed17-189b-418b-957b-c763e7ab2d9a">3.0</ix:nonFraction>% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. For the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company sold <ix:nonFraction unitRef="shares" contextRef="i5e2f4f4898364123a256c32ca33facc9_D20220101-20220331" decimals="INF" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMjE5OTAyMzI2MDg5Mg_deb9d07d-2747-4587-a375-9526797eaad0">8,480,483</ix:nonFraction> shares of its common stock under the 2021 Sales Agreement. The sales were made at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i5e2f4f4898364123a256c32ca33facc9_D20220101-20220331" decimals="2" name="ino:StockSaleAgreementWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMjE5OTAyMzI2MDkwMA_666846c1-b8e2-4f5e-8669-297c63b17ea9">3.52</ix:nonFraction> per share, resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i5e2f4f4898364123a256c32ca33facc9_D20220101-20220331" decimals="-5" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMjE5OTAyMzI2MDkxNw_6c30f90a-25e5-414b-b953-c276787121b9">29.4</ix:nonFraction> million. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> there was $<ix:nonFraction unitRef="usd" contextRef="ief33ee4c2f9d472ca203587fdd030959_I20220331" decimals="INF" name="ino:StockSalesAgreementRemainingAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMjE5OTAyMzI2MDk2MA_231de15b-9a96-4799-a604-39d105a51d07">221.8</ix:nonFraction> million of remaining capacity under the 2021 Sales Agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company closed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i49690b96047544fa998f0502891752a4_D20210125-20210125" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMzkx_b26126b2-e599-435d-8ab4-c9edd686984b">20,355,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2d07fc0fc7734f8d9a8aaf0c1d8877ec_I20210125" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfNDQ3_e6b1a08f-5531-44db-b259-d34a4cde7b9c">8.50</ix:nonFraction> per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other offering expenses, were $<ix:nonFraction unitRef="usd" contextRef="i49690b96047544fa998f0502891752a4_D20210125-20210125" decimals="-5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfNTk4_8ef2cd41-30db-4797-b319-ec81490c3e48">162.1</ix:nonFraction>&#160;million. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the maximum number of shares of the Company&#8217;s common stock available for issuance over the term of the 2016 Incentive Plan was <ix:nonFraction unitRef="shares" contextRef="i506a7271caec452a979fcd2973d994a3_I20160513" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMjkzOA_c12def94-c9de-4b23-b666-ca455785339d">22,000,000</ix:nonFraction> shares. On the first business day of each calendar year, such maximum number of shares shall be increased by&#160;<ix:nonFraction unitRef="shares" contextRef="i506a7271caec452a979fcd2973d994a3_I20160513" decimals="INF" name="ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMzA1Mg_59d7bea3-8e93-4ce8-8334-9ec7a32c3141">2,000,000</ix:nonFraction> shares of common stock unless the Board determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2022, the maximum number of shares increased by <ix:nonFraction unitRef="shares" contextRef="i74e4addc1ab747f6b371d1e28eef2596_I20210101" decimals="INF" name="ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMzMzNg_e367abad-4051-4a93-ad18-39d018f4f338">2,000,000</ix:nonFraction>. At March&#160;31, 2022, the Company had <ix:nonFraction unitRef="shares" contextRef="i7c114109f3fb4d2e9bd8f37900a7cf35_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMzM2Mw_f57e3756-7738-4e96-9eaf-e01d1b8a16f6">838,641</ix:nonFraction> shares of common stock available for future grant under the 2016 Incentive Plan, <ix:nonFraction unitRef="shares" contextRef="i7c114109f3fb4d2e9bd8f37900a7cf35_I20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMzQ0Nw_8e76928a-d5d2-4a00-adef-d34d44fffbf3">3,491,330</ix:nonFraction> shares underlying outstanding but unvested restricted stock units and options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="i7c114109f3fb4d2e9bd8f37900a7cf35_I20220331" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMzU1Mg_62aa6957-e650-4e65-b878-77a353bbcddb">11,701,340</ix:nonFraction> shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over <ix:nonNumeric contextRef="ia7964dc3a17e4cfb80c440f5e98914ba_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMzcwOQ_dadcb4b7-8611-4b1a-95e3-06a6f4f42f60">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="ia7964dc3a17e4cfb80c440f5e98914ba_D20220101-20220331" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMzc1MQ_cbd82e6b-2412-40fb-8d73-cee0e42a91f5">ten years</ix:nonNumeric>. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5f71e40b317a4ec2bd5920ec8454f87d">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At March&#160;31, 2022, the Company had options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="i53998403d9a644378e830ed35dde9174_I20220331" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfNDAzNA_702fe1fe-8c47-4297-9b7c-4c0741915891">2,395,723</ix:nonFraction> shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over <ix:nonNumeric contextRef="i74c8f3b2f8074de68c07442296de5eda_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfNDE2MA_c107c7a9-c629-476d-885e-dcc5276357ae">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="i74c8f3b2f8074de68c07442296de5eda_D20220101-20220331" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfNDIwMg_54e886d2-1fa2-433e-a11b-b8e22592158b">ten years</ix:nonNumeric>.</ix:continuation> </span></div><div><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_70"></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.  <ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RleHRyZWdpb246Y2I3NzkzNThmMjRhNGZjNWIzNGU5OGQ1ODIxYmFhMTZfMjE3NA_e46ce02d-9000-4ed1-a085-b95ff7468cad" continuedAt="i7f5c48c98b5847cf990b3a14ea631db3" escape="true">Net Loss Per Share </ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><ix:continuation id="i7f5c48c98b5847cf990b3a14ea631db3" continuedAt="ib9e3e1f1f2e04a02b137f2bf65921fad"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and refle</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cts the potential dilution that would occur if securities or other con</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes issued by the Company (discussed in Note 8) has been considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three months ended March 31, 2022 and 2021, basic and diluted net </span></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib9e3e1f1f2e04a02b137f2bf65921fad"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss per share were the same, as the assumed exercise or settlement of stock options and restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes would have been anti-dilutive.</span></div><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RleHRyZWdpb246Y2I3NzkzNThmMjRhNGZjNWIzNGU5OGQ1ODIxYmFhMTZfMjE5MA_438a83eb-bc0d-456e-9c50-71c21690ccf9" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e593faba088418ca3470ba0e2ef170a_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfMi0xLTEtMS0zMTY5Mg_50908e25-811a-42c3-8899-d89ff9711a3a">14,097,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1f7c31d501f484e8655d8e19138ea45_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfMi0zLTEtMS0zMTY5Mg_6f405125-c9c3-4e08-9119-85c5d8096617">10,826,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8eeb39a62cfd45a19b16ff2f77b29ea0_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfMy0xLTEtMS0zMTY5Mg_08dca492-bf0b-4459-a1f3-449c7e3024ba">3,491,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d5160a767ac4bafba1dc028690dde9c_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfMy0zLTEtMS0zMTY5Mg_fa9f3cd5-6de7-4f24-a42d-3e9995cbf66a">2,610,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64c8814591c9419e86db1db17a0446e7_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfNC0xLTEtMS0zMTY5Mg_b078ae4b-997b-43db-acc0-986aa9696719">663,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i450d92211f544cdc985d06e7fed62e63_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfNC0zLTEtMS0zMTY5Mg_8e037620-aae5-4a4c-acf9-1d9316f550d5">663,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6079656cc273434d86458c6aebd9dc67_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfNS0xLTEtMS0zMTY5Mg_dfa6e162-b93c-4bf3-9732-43090901e24c">3,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i404ce3ef99524755b77883e75ca4a739_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfNS0zLTEtMS0zMTY5Mg_d06da410-31b1-414c-bc60-25bd518df26c">3,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f5a82e0fe634a5cb2409168cbd8cd88_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfNi0xLTEtMS0zMTY5Mg_f0d6e8a5-58a4-4af9-8104-4f5b691aaa23">3,049,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5454fcab37d841f7875d94376e14df0d_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfNi0zLTEtMS0zMTY5Mg_a322b4af-2785-4821-987e-f6cba6612d08">3,049,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfOS0xLTEtMS0zMTY5Mg_d225e15d-c920-48ff-aef5-a54a356e45cb">21,305,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfOS0zLTEtMS0zMTY5Mg_c08d224c-3bad-4cf3-94e9-f9978aa8c4db">17,153,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.263%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="i5cd930e6c7ce444abb7f72171f50164c_76"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.  <ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfNDA1OQ_56faed4a-06ae-4365-8870-d3007dfcb12b" continuedAt="i9ab08821fb374e1db4b46a39f8a5aa98" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i9ab08821fb374e1db4b46a39f8a5aa98" continuedAt="ie3e0c100ffdb4c4eb459e93d6fee2a20"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to restricted stock units ("RSUs") and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.</span></div><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfNDA3Mw_d09fff7b-5c4c-4c34-832b-ca4f9e401e1d" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5244cd2065d44efa8be7f4b42dc1fef1_D20220101-20220331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RhYmxlOjEwNGJkYWFjZjFlMTQwNWFiYjUxNjlkM2IyYTNjZTE5L3RhYmxlcmFuZ2U6MTA0YmRhYWNmMWUxNDA1YWJiNTE2OWQzYjJhM2NlMTlfMi0xLTEtMS0zMTY5Mg_a9d30af8-5634-433d-b663-cda88c4ff783">1.88</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i131de56e723d441a8b4d29a66a9f0297_D20210101-20210331" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RhYmxlOjEwNGJkYWFjZjFlMTQwNWFiYjUxNjlkM2IyYTNjZTE5L3RhYmxlcmFuZ2U6MTA0YmRhYWNmMWUxNDA1YWJiNTE2OWQzYjJhM2NlMTlfMi0zLTEtMS0zMTY5Mg_757013d2-b812-4ffd-8a11-88df84c9e638">0.88</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5244cd2065d44efa8be7f4b42dc1fef1_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RhYmxlOjEwNGJkYWFjZjFlMTQwNWFiYjUxNjlkM2IyYTNjZTE5L3RhYmxlcmFuZ2U6MTA0YmRhYWNmMWUxNDA1YWJiNTE2OWQzYjJhM2NlMTlfMy0xLTEtMS0zMTY5Mg_95d599f0-1528-4478-9c01-ffc0effbaa99">93</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i131de56e723d441a8b4d29a66a9f0297_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RhYmxlOjEwNGJkYWFjZjFlMTQwNWFiYjUxNjlkM2IyYTNjZTE5L3RhYmxlcmFuZ2U6MTA0YmRhYWNmMWUxNDA1YWJiNTE2OWQzYjJhM2NlMTlfMy0zLTEtMS0zMTY5Mg_6c03cc02-5610-4bd3-9720-cd4e4b7d7336">92</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5244cd2065d44efa8be7f4b42dc1fef1_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RhYmxlOjEwNGJkYWFjZjFlMTQwNWFiYjUxNjlkM2IyYTNjZTE5L3RhYmxlcmFuZ2U6MTA0YmRhYWNmMWUxNDA1YWJiNTE2OWQzYjJhM2NlMTlfNC0xLTEtMS0zMTY5Mg_04a59441-ce9b-433f-b7e8-f9e02b667dac">5.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i131de56e723d441a8b4d29a66a9f0297_D20210101-20210331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RhYmxlOjEwNGJkYWFjZjFlMTQwNWFiYjUxNjlkM2IyYTNjZTE5L3RhYmxlcmFuZ2U6MTA0YmRhYWNmMWUxNDA1YWJiNTE2OWQzYjJhM2NlMTlfNC0zLTEtMS0zMTY5Mg_72db336a-18a6-4bcb-8a07-1d37d4ef4d4f">5.8</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5244cd2065d44efa8be7f4b42dc1fef1_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RhYmxlOjEwNGJkYWFjZjFlMTQwNWFiYjUxNjlkM2IyYTNjZTE5L3RhYmxlcmFuZ2U6MTA0YmRhYWNmMWUxNDA1YWJiNTE2OWQzYjJhM2NlMTlfNS0xLTEtMS0zMTY5Mg_6f483219-af62-4bb6-a097-6dc7ddf9d522">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i131de56e723d441a8b4d29a66a9f0297_D20210101-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RhYmxlOjEwNGJkYWFjZjFlMTQwNWFiYjUxNjlkM2IyYTNjZTE5L3RhYmxlcmFuZ2U6MTA0YmRhYWNmMWUxNDA1YWJiNTE2OWQzYjJhM2NlMTlfNS0zLTEtMS0zMTY5Mg_27a30693-9ed4-4068-a91b-df0d74a7ab14">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three months ended March 31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="ieccf6f95500841c6a3689f60a52eee48_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMTU4NQ_f37e23b5-5526-49a6-93f0-4d18ff1030ca">7.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib1c041808f3c4fcdad3091644d6b6568_D20210101-20210331" decimals="-5" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjE5OTAyMzI1OTYzOQ_2a5e44da-012c-4667-bf9f-c9d43d57056f">9.2</ix:nonFraction> million, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="i12c8e38f5a5d4faf8e21cca6e3048613_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMTYyMA_e7858b2f-c22e-47a2-afd7-4e0f84c42ccd">3.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i466990d2769740b4be6de242e03e8e59_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjE5OTAyMzI1OTY0Ng_3e323835-6c09-4de4-aaa6-380a5d21e93d">5.2</ix:nonFraction> million, respectively, was included in research and development expenses, and $<ix:nonFraction unitRef="usd" contextRef="i82e293c63e7b45f497259112c8856cf3_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMTcwMQ_dcde26ec-e080-4dc4-81c3-2429ce014010">3.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ieaec0500407e4460af3ae9824374aa5f_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjE5OTAyMzI1OTY1NA_3861ab82-3758-4f2e-be17-7b41e61e4699">4.0</ix:nonFraction> million, respectively, was included in general and administrative expenses.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjEzMA_1dcb69e5-9e9b-41a7-b739-2f8eb889d941">19.8</ix:nonFraction> million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjI4MA_ff3558fb-2a24-4cc9-90bd-e315969f92a6">2.2</ix:nonNumeric> years.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was $<ix:nonFraction unitRef="usdPerShare" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjM5OQ_20ee04f5-0afb-473b-b5e9-14961b7b6f7f">2.48</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjE5OTAyMzI2MDAwMQ_408bbda5-06f6-4ab3-b10a-7657e483726d">8.34</ix:nonFraction> for employee and director stock options granted during the three months ended March 31, 2022 and 2021, respectively. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i91452942e5e5451087ce0e121faae465_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjU0NA_5f606af6-9c60-42f5-9876-2b0c72ff15c9">17.1</ix:nonFraction> million of total unrecognized compensation expense related to unvested service-based RSUs, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i7c416618392046e181d9a033a06b4af3_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjY5OQ_58baebef-db9c-4a5d-9780-cdfbd6b97e34">2.1</ix:nonNumeric> years.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $<ix:nonFraction unitRef="usdPerShare" contextRef="i7c416618392046e181d9a033a06b4af3_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjc2OA_35a985fd-4952-49e0-8327-9cc0b2693785">3.33</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="if2ec2de8f8e64ef6b6eb20c42e3919e2_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjE5OTAyMzI2MDE4Mg_075d48a1-92ba-4451-8f02-9bc035769286">11.42</ix:nonFraction> for service-based RSUs granted during the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three months ended March 31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="i7fdb61060a19450e8b33f7efaa1f435d_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMzE4NA_48a64fe6-6ba4-4738-b584-c551d351c76b">550,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i76d9cb0a9e604a1d89a1ce39c1ba9ed3_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMzMxNQ_14aef346-04a1-4011-acdf-594b49ef59b4">429,000</ix:nonFraction>, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;text-indent:27pt"><ix:continuation id="ie3e0c100ffdb4c4eb459e93d6fee2a20"><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 28, 2020, the Company granted <ix:nonFraction unitRef="shares" contextRef="i1fb6f216bfa54b49a624c469d5203ec1_D20200828-20200828" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMzM4MA_5af21d32-b9c7-4058-a811-197010123da7">663,353</ix:nonFraction> performance-based RSUs to key employees under the 2016 Incentive Plan. The RSUs will vest in two tranches as follows: <ix:nonFraction unitRef="number" contextRef="i491165f321fa4e9eba5d2778f326ed0d_D20200828-20200828" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMzQ5OA_5dcbfa53-4982-46fd-be58-890799acd38b">50</ix:nonFraction>% of the shares in each tranche will vest upon achievement of the predetermined performance milestones and the remaining <ix:nonFraction unitRef="number" contextRef="ie37803101927413c9caf0a2b10452612_D20200828-20200828" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMzYyMA_c27c8dce-aada-49ec-8722-b33d87077666">50</ix:nonFraction>% of the shares in each tranche will vest upon subsequent completion of a <ix:nonNumeric contextRef="ie37803101927413c9caf0a2b10452612_D20200828-20200828" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfNDA3MQ_e2326fce-f69c-4ae8-834c-ab94c89fa129">one-year</ix:nonNumeric> service period. The grant date fair value of the performance-based RSUs was $<ix:nonFraction unitRef="usd" contextRef="i1fb6f216bfa54b49a624c469d5203ec1_D20200828-20200828" decimals="-5" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMzc4NQ_01d42eca-9d01-43d6-8731-f16d51b0fd4c">8.0</ix:nonFraction>&#160;million based on the grant date closing price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i1fb6f216bfa54b49a624c469d5203ec1_D20200828-20200828" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMzgzOQ_90b355e0-8167-4dce-9a5a-ee5a233e6ad4">12.06</ix:nonFraction>. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;31, 2022</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, the underlying performance milestones of the RSUs were not probable of achievement, and no stock-based compensation expense was recognized for the performance-based RSUs for the three months then ended.</span></ix:continuation></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_79"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.  <ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzU2NA_b8218d96-ebdc-4b51-9352-230131a60423" continuedAt="i42cddae468444f658916642e5c1febcb" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i42cddae468444f658916642e5c1febcb"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owned <ix:nonFraction unitRef="shares" contextRef="i0505907c69774e2f9b14cd272f6e78ab_I20220331" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfODU_11be6962-3164-4b8d-baca-c82bad257dcf">597,808</ix:nonFraction> shares of common stock in PLS as of March&#160;31, 2022, representing a <ix:nonFraction unitRef="number" contextRef="i0505907c69774e2f9b14cd272f6e78ab_I20220331" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMTQz_15c92e7c-ea5d-4fb4-8d65-63079cc268e9">18.7</ix:nonFraction>% ownership interest, and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from PLS consists of milestone, license and patent fees. For the three months ended March 31, 2022 and 2021, the Company recognized revenue from PLS of $<ix:nonFraction unitRef="usd" contextRef="i00d50bf6cf7f4ad2a522a955df7010fd_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzgz_4aef39c0-6a9e-40d9-a16e-440b72d76f15">9,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i998a91031a25433790f82a700988c0b4_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfNDEy_02a4a584-9950-434b-af08-2c8d4b7a1fed">50,000</ix:nonFraction>, respectively. At March&#160;31, 2022 and December&#160;31, 2021, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="i113857f5676c45c8985e00527eadd700_I20220331" decimals="-3" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfNTEz_65560175-a84b-4549-9a0c-eb6760aa7fe2">34,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i54c2b2722e924db1b3ff26d952a3e88e_I20211231" decimals="-3" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfNTIw_137605dc-812b-4742-b74c-b203bed999cf">25,000</ix:nonFraction>, respectively, related to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $<ix:nonFraction unitRef="usd" contextRef="i8a14a4908e804611b1eb9dc197afef27_D20160301-20160331" decimals="-5" name="ino:CollaborativeAgreementExpensesToReimburse" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMTE3Mg_f619b526-728b-49a2-b4b0-c025f6cc9e07">3.1</ix:nonFraction> million during the <ix:nonNumeric contextRef="i8a14a4908e804611b1eb9dc197afef27_D20160301-20160331" name="ino:CollaborativeArrangementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzU2MQ_f1562519-155c-45c5-bd4a-7829af4a4588">five-year</ix:nonNumeric> term of the agreements. In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. The Company will have the exclusive right to in-license new intellectual property developed under this agreement.  </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company entered into collaborative research agreements with Wistar in support of the clinical development of INO-4800. Under the terms of these collaborative research agreements, the Company will reimburse Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $<ix:nonFraction unitRef="usd" contextRef="ic38879a67ed2417892b510c2282934e9_D20210101-20210331" decimals="-5" name="ino:CollaborativeAgreementExpensesToReimburse" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMTgxNA_8f453743-bb55-41a4-b83b-66354809db37">1.9</ix:nonFraction>&#160;million during the <ix:nonNumeric contextRef="ic38879a67ed2417892b510c2282934e9_D20210101-20210331" name="ino:CollaborativeArrangementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzU2Mg_4931e6c9-9ac4-400f-b148-910e58826f47">two-year</ix:nonNumeric> term of the agreements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Novem</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ber 2016, the Company received a&#160;$<ix:nonFraction unitRef="usd" contextRef="i154ff5c5f70146429ef3ca2399396227_D20161101-20161130" decimals="-5" name="ino:CollaborativeAgreementAwardedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMTkwMg_7ddfe1b5-8de4-4115-8925-be46ff81fa61">6.1</ix:nonFraction> million&#160;sub-grant through Wistar to develop a dMAb against the Zika infection, which was fully funded through December 2021. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2023.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $<ix:nonFraction unitRef="usd" contextRef="i1c89ed0e5b044d7e82c20c40f333fc2a_D20200101-20201231" decimals="-5" name="ino:CollaborativeAgreementAwardedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMjIyMg_120c6348-4d26-4d72-afd3-ca13ff5501d2">10.7</ix:nonFraction>&#160;million sub-grant through Wistar, which was amended in 2021 to $<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="-5" name="ino:CollaborativeAgreementAmendedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMjE5OTAyMzI1OTI5OQ_771703ab-5c08-4056-babd-08ba15180040">13.5</ix:nonFraction>&#160;million, for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding through November 2022. The sub-grant also includes an option for an additional $<ix:nonFraction unitRef="usd" contextRef="i0034e9c906a24164ba01742d7b986684_D20220101-20220331" decimals="-5" name="ino:CollaborativeAgreementAwardedOptionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMjQ0Mw_0afbef95-2efe-4695-ba8b-52291a4ad037">6.0</ix:nonFraction>&#160;million in funding through March 2024, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of which $<ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-5" name="ino:CollaborativeAgreementAwardedExercisedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMjE5OTAyMzI1OTM4Nw_a87004d5-9725-42df-8635-6ed3a52dd61b">3.3</ix:nonFraction>&#160;million has been exercised as of March&#160;31, 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three months ended March 31, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="if9fe7623f5234877ba048ec3fbd39a69_D20220101-20220331" decimals="-5" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMjcwMQ_e32dfbbc-2704-411e-ab9d-163e491f511a">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic38879a67ed2417892b510c2282934e9_D20210101-20210331" decimals="-3" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMjc2Mg_215346d9-9be1-4ebc-983b-6f1fde59a828">230,000</ix:nonFraction>, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 14). Research and development expenses recorded from Wistar for the three months ended March 31, 2022 and 2021 were $<ix:nonFraction unitRef="usd" contextRef="if9fe7623f5234877ba048ec3fbd39a69_D20220101-20220331" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzEyNw_8055efbb-0495-4d69-9e45-dafdd83ebc23">181,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic38879a67ed2417892b510c2282934e9_D20210101-20210331" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzIyMw_365c9a42-7ead-4bf5-ab31-da185a69a552">318,000</ix:nonFraction>, respectively. At March&#160;31, 2022 and December&#160;31, 2021, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="ic40026348a73461d8f5be933afc8a40e_I20220331" decimals="-5" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzMxMg_49c30c49-b0a5-4460-b344-99e809864c29">3.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i598d38fe89f5401ebb28138691b4da4e_I20211231" decimals="-5" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzMxOQ_388f8f06-a1fe-437b-98ea-b4d72bbde4e6">2.6</ix:nonFraction> million, respectively, and an accounts payable and accrued liability balance of $<ix:nonFraction unitRef="usd" contextRef="ic40026348a73461d8f5be933afc8a40e_I20220331" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzM5NA_3f5c4105-59b3-46ba-bc30-5820f58f913a">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i598d38fe89f5401ebb28138691b4da4e_I20211231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzQwMQ_e7837b60-ccef-4aa1-ae4e-43042235956e">548,000</ix:nonFraction>, respectively, related to Wistar. As of March&#160;31, 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ic40026348a73461d8f5be933afc8a40e_I20220331" decimals="-3" name="ino:DeferredGrantFundingFromAffiliate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzQ2OQ_36eb77a9-bb0f-4a62-b1a2-4855d4fbbb40">38,000</ix:nonFraction> as deferred grant funding and $<ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMjE5OTAyMzI1OTc5NA_1d52c12e-5b19-4418-b844-833a12496d1b">76,000</ix:nonFraction> as prepaid expenses on the condensed consolidated balance sheet related to Wistar.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_82"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.  <ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RleHRyZWdpb246YmIwMjI3YjI1OGY5NGJlZDkyYWNjZDFkNDc5Mzg0ZDFfMzIwMQ_8266586d-f4bf-4dd0-98c6-9bd07f8bd66e" continuedAt="i5b69eb860d444b6eb3f1e6975ec259ec" escape="true">Commitments and Contingencies                                                  </ix:nonNumeric></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="i5b69eb860d444b6eb3f1e6975ec259ec" continuedAt="if32ae4c606fa4055a92151d1049dd4ff">Leases</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if32ae4c606fa4055a92151d1049dd4ff" continuedAt="ie31492ef9ad44365a04da6e1d4ad183b"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="i93b7902a9abb40beb532a03c0df4ed2d_D20220101-20220331" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RleHRyZWdpb246YmIwMjI3YjI1OGY5NGJlZDkyYWNjZDFkNDc5Mzg0ZDFfMTAw_e571e419-546f-4269-bc93-9b36dc5a4dac">82,200</ix:nonFraction> square feet of office, laboratory, and manufacturing space in San Diego, California and <ix:nonFraction unitRef="sqft" contextRef="ic80593d7532d4f61b66a6152e7a7552b_D20220101-20220331" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RleHRyZWdpb246YmIwMjI3YjI1OGY5NGJlZDkyYWNjZDFkNDc5Mzg0ZDFfMTkx_6b3de1c5-7d76-47d9-9d14-0e4a01b83f2e">57,360</ix:nonFraction> square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of March&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of <ix:nonNumeric contextRef="i8bf07160649541bca2512ad124da7853_I20220331" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RleHRyZWdpb246YmIwMjI3YjI1OGY5NGJlZDkyYWNjZDFkNDc5Mzg0ZDFfMzUy_e8191aac-d137-4b8b-9744-25484bc44e2b">1.7</ix:nonNumeric> to <ix:nonNumeric contextRef="if296892e17fa4a3996048fd9a773bb41_I20220331" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RleHRyZWdpb246YmIwMjI3YjI1OGY5NGJlZDkyYWNjZDFkNDc5Mzg0ZDFfMzU4_ba21879a-aad5-483f-b17e-4eb5a5a2b3da">7.8</ix:nonNumeric> ye</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ars, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RleHRyZWdpb246YmIwMjI3YjI1OGY5NGJlZDkyYWNjZDFkNDc5Mzg0ZDFfMzIwNQ_e93dd233-8c98-48ed-807f-8bdbc6930e8a" escape="true"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of March&#160;31, 2022, the maturities of the Company's operating lease liabilities were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfMC0xLTEtMS0zMTY5Mg_deacc4ed-c791-4d90-ad2b-09785d3ab063">3,074,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfMS0xLTEtMS0zMTY5Mg_e31e2433-bf66-45ee-947a-985afa43a3e5">4,089,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfMi0xLTEtMS0zMTY5Mg_772778db-ff08-4ea0-bee7-8582cb29e8ed">3,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfMy0xLTEtMS0zMTY5Mg_6627acaf-75a6-4c44-94c4-35d119c4239a">3,063,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfNC0xLTEtMS0zMTY5Mg_ade494bc-d177-425e-9060-ed1356716df3">3,139,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-3" name="ino:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfNS0xLTEtMS0zMTY5Mg_34e0353e-aa38-4b8e-b629-828efd5ebe83">6,749,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfNi0xLTEtMS0zMTY5Mg_516ba003-4102-458e-89c7-fd8cd5f69e30">23,164,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfNy0xLTEtMS0zMTY5Mg_c27b85e8-b293-4741-a601-6afde3d2f43a">5,725,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfOC0xLTEtMS0zMTY5Mg_74b8f567-153a-458d-b111-6a081d8bdf83">17,439,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfOS0xLTEtMS0zMTY5Mg_2f1e46d3-05c0-4276-8930-98a8d3b95d27">2,673,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfMTAtMS0xLTEtMzE2OTI_0830d970-d0f8-48ed-8a51-ab40fb076140">14,766,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfMTItMS0xLTEtMzE2OTI_ce71c21f-fea7-448a-aabd-ac859709c3fc">6.4</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfMTMtMS0xLTEtMzE2OTI_939f3601-e78c-44a6-80e5-bb8bc2822ab7">8.5</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the condensed consolidated statements of operations for the three months ended March 31, 2022 and 2021 were $<ix:nonFraction unitRef="usd" contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RleHRyZWdpb246YmIwMjI3YjI1OGY5NGJlZDkyYWNjZDFkNDc5Mzg0ZDFfMjAyNQ_3bcf132f-aafb-44be-957b-d20ca04cf06d">830,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RleHRyZWdpb246YmIwMjI3YjI1OGY5NGJlZDkyYWNjZDFkNDc5Mzg0ZDFfMjAzMg_abf1926d-5666-4051-8cb0-da97ee49f6c0">850,000</ix:nonFraction>, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, the Company entered into <ix:nonFraction unitRef="agreement" contextRef="i9d671d2113a6459188a02276cfc2a5f6_D20190101-20191231" decimals="INF" name="ino:LesseeOperatingLeaseNumberOfAgreementsToSublease" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RleHRyZWdpb246YmIwMjI3YjI1OGY5NGJlZDkyYWNjZDFkNDc5Mzg0ZDFfMjQ1Mw_ab849f02-a27d-4af0-8a68-8d4e7d5b797a">two</ix:nonFraction> agreements to sublease a total of approximately <ix:nonFraction unitRef="sqft" contextRef="ia01bf7e261dd4db5917be920fa366418_D20190101-20191231" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RleHRyZWdpb246YmIwMjI3YjI1OGY5NGJlZDkyYWNjZDFkNDc5Mzg0ZDFfMjUwNA_1e17370a-da75-4b26-8d37-1fdd595e8024">13,500</ix:nonFraction> square feet in its Plymouth Meeting headquarters through periods between December 31, 2022 and March 31, 2025.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and J. Joseph Kim, the Company&#8217;s Chief Executive Officer, as defendants. The lawsuit alleges that the Company made materially false and misleading statements regarding its development of a vaccine for COVID-19 in its public disclosures in violation of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie31492ef9ad44365a04da6e1d4ad183b" continuedAt="i3e69bc6455b14d27bbeccde7c0fe7a03"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. On August 3, 2020, the lead plaintiff filed a consolidated complaint, naming the Company and three of its officers as defendants. On September 21, 2020, the lead plaintiff and another purported stockholder filed a first amended complaint, naming the Company and three of its officers as defendants. Defendants filed a motion to dismiss plaintiff&#8217;s first amended complaint on November 5, 2020. On February 16, 2021, the court issued an order granting in part, and denying in part, the defendants&#8217; motion to dismiss. The court granted the defendants&#8217; motion to dismiss, and dismissed with prejudice, the claims premised on certain of the Company&#8217;s statements. The court denied defendants&#8217; motion to dismiss as to the remaining statements. On March 9, 2021, the defendants filed their answer to the complaint. The case is currently in discovery. On July 29, 2021, the plaintiffs moved to certify the class action. That motion is fully briefed and remains pending. On February 17, 2022, the court granted Plaintiffs&#8217; motion for leave to amend their complaint, and further ordered that the amended complaint is deemed filed as of February 17. On March 21, 2022, Defendants moved to dismiss the new allegations in the amended complaint. The Company expects that motion to be fully briefed on May 10, 2022. No hearing date has been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class action complaint. The lawsuit accuses the Company&#8217;s board of directors of failing to exercise reasonable and prudent supervision over the Company&#8217;s management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of the Company as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12, 2020 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et al. and Devarakonda et al. v Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name the Company&#8217;s current directors as defendants. The Devarakonda complaint also names one of the Company&#8217;s former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 28, 2022, a fifth shareholder derivative complaint, Schumacher v. Benito et al., was filed in the Delaware Court of Chancery, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2022, the Delaware Court of Chancery entered a stay of the litigation.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to defend these actions vigorously.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#8217;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. On June 3, 2020, the Company filed a petition for preliminary injunction, which was denied on June 25, 2020. On June 26, 2020, the Company filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, VGXI filed an answer, new matter and counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from the Company. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, the Company filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. On October 1, 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Device License Agreement, or the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3e69bc6455b14d27bbeccde7c0fe7a03"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement, between the Company and GeneOne. The Company terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from the Company. On January 29, 2021, the Company filed preliminary objections to the complaint. On August 23, 2021, the court overruled the Company&#8217;s preliminary objections to the complaint. On September 13, 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#8217;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 18, 2021, GeneOne filed its answer to the Company&#8217;s counterclaims and new matter. On November 8, 2021, we filed our answer to GeneOne&#8217;s new matter. A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#8217;s consolidated results of operations or financial position.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_85"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjIwNTY_2bf2dd10-2dbb-4705-a94e-ef5e9e74f722" continuedAt="ifff5efd977ae4a819b1ad3796ac1bef7" escape="true">Collaborative Agreements</ix:nonNumeric></span></div><ix:continuation id="ifff5efd977ae4a819b1ad3796ac1bef7" continuedAt="i6fa089adc56348b88f3142385a290f0a"><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#8220;Advaccine&#8221;), which was amended and restated on June 7, 2021 (as amended and restated, the &#8220;Advaccine Agreement&#8221;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;) and 33 additional countries in Asia. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without the Company&#8217;s express prior written consent. As part of the collaboration, Advaccine also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2021 amendment relates to the collaboration between the Company and Advaccine to jointly conduct the global Phase 3 segment of the Company&#8217;s ongoing Phase 2/3 trial of INO-4800 and expand the existing collaboration to include the planned global Phase 3 trial. The parties will jointly participate in the trial and will equally share the global development costs for the trial, including the Company&#8217;s manufacturing costs to supply INO-4800. In certain instances, the Company will have the right to convert the exclusive license to a non-exclusive license in the licensed territories, other than Greater China, unless Advaccine agrees to pay the Company its full share of development costs in excess of a specified maximum. Notwithstanding the foregoing, Advaccine will be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. The Company will be fully responsible for its costs and expenses, if any, incurred solely as a result of its activities in connection with the performance of the trial in the United States. The parties may continue to conduct clinical trials of INO-4800 outside of the territories covered by the Advaccine Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that a global purchasing entity desires to enter into a purchase agreement for INO-4800 in both parties&#8217; territories, the parties will enter into good faith negotiations for an arrangement to supply INO-4800 to such entity. In addition, the Company is permitted to enter into an agreement with a global purchasing entity to authorize the entity to conduct a portion of the global Phase 3 trial in the licensed territory outside of Greater China.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, Advaccine made an upfront payment to the Company of $<ix:nonFraction unitRef="usd" contextRef="i2db1017a46a040d6861a567a358dcdd1_D20210101-20210131" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjcyOA_8c9fa8f6-b02b-4a40-abfe-498201c0dae8">3.0</ix:nonFraction>&#160;million in January 2021. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i2db1017a46a040d6861a567a358dcdd1_D20210101-20210131" decimals="-5" name="ino:CollaborationAgreementAdditionalRevenueToBeAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjg0MQ_902a5754-dbf2-4bb4-aa31-b40f1071e5c1">206.0</ix:nonFraction>&#160;million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China and the additional covered territories, if approved. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#8217;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for <ix:nonNumeric contextRef="if8516f2c2e834670831af151ddee24ed_D20220101-20220331" name="ino:CollaborationAgreementRoyaltyPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMzczNQ_53405238-fc16-4ca1-8cee-e763b3f9ba39">ten years</ix:nonNumeric> after the first commercial sale in a particular region </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6fa089adc56348b88f3142385a290f0a" continuedAt="i9fef30bed71e4c18a6d297f7f8ec4a51"><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the first calendar year following the first commercial sale of INO-4800 in the licensed territory outside of Greater China, Advaccine will pay the Company an annual maintenance fee of $<ix:nonFraction unitRef="usd" contextRef="if8516f2c2e834670831af151ddee24ed_D20220101-20220331" decimals="-5" name="us-gaap:CostMaintenance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfNDEyOA_91e5e4a6-aa5f-4429-8da8-e341b1cc4453">1.5</ix:nonFraction>&#160;million for a period of <ix:nonNumeric contextRef="if8516f2c2e834670831af151ddee24ed_D20220101-20220331" name="ino:AnnualMaintenancePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfNDE0Nw_64aa01f7-357c-41f3-9e77-e3933759e136">five years</ix:nonNumeric>, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, the Company will supply Advaccine&#8217;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#8217;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months&#8217; written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in the licensed territory, or 18 months&#8217; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808 at inception and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606. The license to INO-4800 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the Advaccine Agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the Advaccine Agreement consisted of the $<ix:nonFraction unitRef="usd" contextRef="i2db1017a46a040d6861a567a358dcdd1_D20210101-20210131" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfNjU0MA_bc1628ca-cf85-425d-a8e2-3c422f5f9571">3.0</ix:nonFraction>&#160;million upfront payment received in January 2021 plus a $<ix:nonFraction unitRef="usd" contextRef="i2db1017a46a040d6861a567a358dcdd1_D20210101-20210131" decimals="-5" name="ino:CollaborationAgreementPaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfNjU3Ng_92ff6486-cb75-4344-806f-58f157863174">2.0</ix:nonFraction>&#160;million milestone payment which was achieved upon contract signing. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $<ix:nonFraction unitRef="usd" contextRef="i7bcc9760314f413bba4b5e3b026f2e41_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfNzQ0OA_81261d29-d709-4d04-9b74-ac18694f04be">5.0</ix:nonFraction>&#160;million was allocated to the license performance obligation. The Company determined that as of December 31, 2020, the transfer of technology had occurred for the use and benefit of the license and accordingly, the performance obligation was fully satisfied. The Company accordingly recognized $<ix:nonFraction unitRef="usd" contextRef="i9818436ba9fe436cb6d8b574154f1b3b_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfNzczNg_bca8a8d0-ab04-461d-857f-4cc82e683406">5.0</ix:nonFraction>&#160;million in revenue under collaborative research and development arrangements on the consolidated statement of operations during the year ended December 31, 2020. For the three months ended March 31, 2022, <ix:nonFraction unitRef="usd" contextRef="i3e370c4fb7ad47f09d71f49dcf34f2f7_D20220101-20220331" decimals="INF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfNzk3Nw_cb7f0fa9-333b-4e4e-8c39-62695e2af265">no</ix:nonFraction> revenue was recognized from Advaccine. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the June 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement is a collaboration and not a contract with a customer and therefore concluded to account for the June 2021 amendment under ASC Topic 808. Reimbursements from Advaccine will be recognized as contra-research development expense on the condensed consolidated statement of operations once earned and collectibility is assured.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company has granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to an upfront payment received in 2018, the Company is entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i071ee78b7166461a9fbde479b660be3e_D20220101-20220331" decimals="-5" name="ino:CollaborationAgreementAdditionalRevenueToBeAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTA0NDk_7c11a390-4c8d-4903-b7da-40baf96be7f7">20.0</ix:nonFraction> million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for <ix:nonNumeric contextRef="i071ee78b7166461a9fbde479b660be3e_D20220101-20220331" name="ino:CollaborationAgreementRoyaltyPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTA5OTA_41d7e970-e636-4ebd-afce-52a74f8c2992">10</ix:nonNumeric> years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9fef30bed71e4c18a6d297f7f8ec4a51" continuedAt="i798225a0945a4bc095886739a116716a"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning <ix:nonNumeric contextRef="i071ee78b7166461a9fbde479b660be3e_D20220101-20220331" name="ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTE2MTI_46364715-2eb5-4f9d-9ce1-013d1d7882c8">one year</ix:nonNumeric> after the effective date for any reason upon <ix:nonNumeric contextRef="i071ee78b7166461a9fbde479b660be3e_D20220101-20220331" name="ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTE2NjA_a8687671-c77d-4082-94c6-41b92427dea6">90</ix:nonNumeric> days written notice to the Company.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of March&#160;31, 2022 there have been no significant reimbursable program costs under the ApolloBio Agreement.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplate preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i506a148e81644d5482e7e9eebdf0b1d5_D20180401-20180430" decimals="-6" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTU5NjQ_d273eb7f-f56a-4f69-85c8-1e8ca37db423">56</ix:nonFraction> million of costs over a <ix:nonNumeric contextRef="i506a148e81644d5482e7e9eebdf0b1d5_D20180401-20180430" name="ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjIwNjU_bea8e95b-5f93-4de9-a1e4-bf9cf18beb9f">five-year</ix:nonNumeric> period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the three months ended March 31, 2022 and 2021, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="id2be74ba561d442db493dddcc92ebd3e_D20220101-20220331" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTYyNTA_0a3d817a-4a98-416a-8f97-83873cb8cdb1">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8b96bf9a8fc445eaba5ecb1d140390f6_D20210101-20210331" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTY0MTg_85aa489f-5571-484e-9fe4-82ea5b40ed06">2.4</ix:nonFraction> million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of March&#160;31, 2022, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="i5e1c9fb9467945ab9163eda017d1f2da_I20220331" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTY1OTk_42d5140c-1cc8-4cd4-819b-a9a4d45fa7b2">3.8</ix:nonFraction> million on the condensed consolidated balance sheet related to these CEPI grants. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded the Company a grant of up to $<ix:nonFraction unitRef="usd" contextRef="i8f8f17f12161403fafe2948a7f9f402f_D20200101-20200131" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTY3MzY_313b37a8-918a-4f4d-8a07-ddae79ef41a2">9.0</ix:nonFraction> million to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="i152a732fccdd4dbdb5a4fc5c6458a1ec_D20200401-20200430" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTY5MDI_006879bb-98aa-4241-a1a3-ba54ebb0fcfd">6.9</ix:nonFraction> million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of $<ix:nonFraction unitRef="usd" contextRef="if9442dd1633e455b91a66f5a6ab2ce25_D20200401-20200430" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTcwODA_3d458e38-0689-42cc-9b07-86fb26abc37b">5.0</ix:nonFraction> million to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP, for the intradermal delivery of INO-4800, and a grant of $<ix:nonFraction unitRef="usd" contextRef="i32bf53bd03c54fc1a9176c9e8bd73481_D20200401-20200430" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTcyNjI_62b4dfa0-f0ef-4487-b3e1-f7afdd5e821b">1.3</ix:nonFraction> million to support large-scale manufacturing of INO-4800. During the three months ended March 31, 2022 and 2021, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="i2b14e2287928438d88d281f85c7278a8_D20220101-20220331" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTczNjI_fd94fabd-2bb6-4b5b-b571-f93f7ab9e37d">510,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5bfa9631ac274759b1b56aef9adc496f_D20210101-20210331" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTc1NTE_0641d8fd-48b1-48f7-a527-60d1151dd628">2.4</ix:nonFraction> million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of March&#160;31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="if5ba8467f8d240158db11dd9beaae7e2_I20220331" decimals="-5" name="ino:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTc3MTk_d0ee1eeb-8a72-4db1-8781-252f4d7d211f">2.7</ix:nonFraction> million recorded as deferred grant funding on the condensed consolidated balance sheet from the CEPI grants related to INO-4800.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Gates awarded and funded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="if5e81165a16440ebb8326d8a24d15995_D20181001-20181031" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTc5ODA_e7e4b2a8-41a9-4780-9142-0d5e03b2ed03">2.2</ix:nonFraction> million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $<ix:nonFraction unitRef="usd" contextRef="ic2b5bc317c764378a3de78871886838c_D20190801-20190830" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTgzNDM_4eacc471-a188-49f6-bfc5-5247f093ed3e">1.1</ix:nonFraction> million for the project. During the three months ended March 31, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i92f8729b1391467aa54b6475bbefade5_D20220101-20220331" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTg0NDc_9dd7d9c2-5261-4968-b05d-2ad4b542123e">80,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6295923acaed47d1956bd75c6c4c0edd_D20210101-20210331" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjE5OTAyMzI3OTkwNA_53705991-629a-4e4e-bf61-ca1dafadd3e1">0</ix:nonFraction>, respectively, as contra-research and development expense related to the Gates dMAb grant. As of March&#160;31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="i4b11763ebe53429599cade53585833b6_I20220331" decimals="-3" name="ino:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTg2ODk_49c86c66-a462-4a4b-85b0-8d930c352470">304,000</ix:nonFraction> recorded as deferred grant funding on the condensed consolidated balance sheet related to the grant.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Gates awarded and funded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="ie62aeb4d7cf747aeb6d6d6c6296bfe0a_D20200301-20200331" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTg4NTY_8afc24a8-11d8-415e-acb7-13f38f5f3eaa">5.0</ix:nonFraction> million to accelerate the development of the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device for the intradermal delivery of INO-4800. During the three months ended March 31, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i3e16f9f97cb444ca9d3dba5ea73d1d90_D20220101-20220331" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTg5OTc_c4427a70-339a-48be-9476-acef911d8464">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4518574f497f4fa2a453bf07d6721aa2_D20210101-20210331" decimals="-3" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTkwMDQ_2889b5d7-b3c9-4bf6-9e66-e16d0bd1acfc">893,000</ix:nonFraction>, respectively, as contra-research and development expense related to this Gates grant. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Defense (DoD) </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#8220;OTA Agreement&#8221;)&#160;with the DoD to fund the Company&#8217;s efforts in developing the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. Under the OTA Agreement, the Company intends to develop the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the device by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device, as well as large-scale DNA plasmid production for manufacture and supply of a specified number of doses of&#160;INO-4800&#160;in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is $<ix:nonFraction unitRef="usd" contextRef="i1204bafe5467488693dda8b9e96a2774_D20200601-20200630" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjAwNzY_e5857baf-187a-4365-a406-99691e1f3c89">54.5</ix:nonFraction> million. The Company has determined that the OTA Agreement should be considered under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is outside the scope of Topic 606, as the government agency granting the Company funds is not receiving reciprocal value for their contributions. The Company will record contra-research development expense on the condensed consolidated statement of operations in the same period that the underlying expenses are incurred. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#8220;Procurement Contract&#8221;) from the DoD for the purchase of the Company&#8217;s intradermal CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 device and accessories. The CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2000 devices will be used to inject&#160;INO-4800&#160;in the Company&#8217;s planned later-stage clinical trials. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The total purchase price under the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i798225a0945a4bc095886739a116716a"><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Procurement Contract is expected to be approximately $<ix:nonFraction unitRef="usd" contextRef="i17c519d2d2f7427e8cf34e5097504c60_D20200601-20200630" decimals="-5" name="ino:CollaborativeArrangementFixedPriceContractAmountAwarded" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjE5OTAyMzI4MTUyNQ_f7c52bd0-d4a1-42ad-a879-018ca2bb284c">10.7</ix:nonFraction>&#160;million. The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Company determined that the Procurement Contract falls under the scope of ASC Topic 606 as the contract is with a customer and the Company is able to satisfy its obligations under the arrangement as the Phase 3 clinical trials of INO-4800 are underway. Performance obligations under the Procurement Contract consist of the delivery of a specified number of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 devices and accessories. The total transaction price was allocated to the individual performance obligations based on the determined standalone selling price for the devices and accessories. The Company will recognize revenue on the condensed consolidated statement of operations upon shipment of the purchased devices and accessories. During the three months ended March 31, 2022 and 2021, the Company recorded <ix:nonFraction unitRef="usd" contextRef="i6c0779eaba8941deac45ec2a70e681f7_I20220331" decimals="INF" name="ino:CollaborativeArrangementRevenueFromTheProcurementContract" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjE5OTAyMzI4MTU0OQ_71780749-b9c5-4a07-8a18-7ac60e363373">no</ix:nonFraction> revenue from the Procurement Contract. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i8ee8e99d45ce4685bcbfe7aa1f6ef9ac_D20220101-20220331" decimals="-5" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjEyMjU_d490314a-1884-4f8d-bc3e-085bf3a5e988">3.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i74796e39acc84dc198e9df9ff90b38c2_D20210101-20210331" decimals="-5" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjEyMzI_e70d7955-7031-456f-81f4-dbd48ba756e0">7.8</ix:nonFraction>&#160;million, respectively, as contra-research and development expense related to the OTA Agreement. As of March&#160;31, 2022 and December 31, 2021, the Company had an accounts r</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eceivable balance of $<ix:nonFraction unitRef="usd" contextRef="i2125ae0ebb6c4ac58e7f4bb7948cf2ee_I20220331" decimals="-5" name="us-gaap:AccountsReceivableRelatedParties" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjE1NTk_d3267210-5740-4c0f-973e-7573c1682861">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i76c6ab34cb86461fbeae30681dd72330_I20211231" decimals="-5" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjE1NjY_7c125d1b-e4f3-4077-8b5d-b9cc01fa7d6a">3.6</ix:nonFraction>&#160;million, respectively, on the condensed consolidated balance sheet from the DoD. As of March&#160;31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="i2125ae0ebb6c4ac58e7f4bb7948cf2ee_I20220331" decimals="-5" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjE2Njg_43dcdb74-f75d-4d92-9473-4b2582dcc2f0">2.3</ix:nonFraction>&#160;million recorded as deferred grant funding on the condensed consolidated balance sheet related to the Procurement Contract.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company announced that the DoD had notified the Company that it will discontinue funding f</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the Phase 3 segment of the Company's clinical trial of INO-4800 in the United States, while continuing to fund the completion of the ongoing Phase 2 segment.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_88"></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184OC9mcmFnOjY0OWUwM2I5ZWI5YzRhYmI5MGIxMDA5NzBlMTg3MTQ3L3RleHRyZWdpb246NjQ5ZTAzYjllYjljNGFiYjkwYjEwMDk3MGUxODcxNDdfMTcwMg_930e9e2b-7e1b-4825-8e77-ea6f248dd51f" continuedAt="i432bdf24b2214efd8733d45d2aeb0c7a" escape="true">Income Taxes </ix:nonNumeric></span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i432bdf24b2214efd8733d45d2aeb0c7a" continuedAt="ie33b4208aca548bb9469024627e62aab">The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.</ix:continuation></span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie33b4208aca548bb9469024627e62aab">&#160;For the three months ended March&#160;31, 2022 and 2021, the Company has not recorded any income tax provision/(benefit) due to the Company&#8217;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.</ix:continuation> </span></div><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_91"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfOTkwNw_0e98a05b-6de6-4a2c-a4b1-d2af6f269162" continuedAt="ib114ff76c2034cc7a35e2ad75b12aaa5" escape="true">Geneos Therapeutics, Inc. </ix:nonNumeric></span></div><ix:continuation id="ib114ff76c2034cc7a35e2ad75b12aaa5" continuedAt="i000f799b913c4f72817a8533166ea847"><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In 2019, Geneos completed the initial closing of a&#160;Series A preferred stock financing. The Company invested&#160;$<ix:nonFraction unitRef="usd" contextRef="i5a59d1c482204129ace354f666e93b3c_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfMzc4_a11be6f0-cb6d-411c-b4cc-d3bb87e4a37b">1.2</ix:nonFraction> million&#160;in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;<ix:nonFraction unitRef="number" contextRef="i9287e5231b0c44c2a4df39c192522f21_I20191231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfNTA3_ebb5bca5-188d-44c5-afe5-85545f77e01f">61</ix:nonFraction>%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Geneos completed the second closing of the&#160;Series A preferred stock financing, in which the Company invested $<ix:nonFraction unitRef="usd" contextRef="i7ef6b938867e49d4b6bea20f92003696_I20200131" decimals="-3" name="ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfODAw_938383c0-e118-425e-b827-78dcf349b470">800,000</ix:nonFraction>. Following this transaction, the Company held&#160;<ix:nonFraction unitRef="number" contextRef="ief31b251d6394afd8f91a7cc96c6f6f0_I20200101" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfODcx_c914126b-dd95-4c51-aa9f-6a787001a6f9">52</ix:nonFraction>%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Geneos closed an additional&#160;Series A preferred stock financing round, in which the Company invested $<ix:nonFraction unitRef="usd" contextRef="i358168d3fb3e4081afe3f8f55ae73934_I20200630" decimals="-3" name="ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfMTEyMg_f72e78c0-40e7-4212-ba28-ef9d7d11b488">800,000</ix:nonFraction>.  Following this transaction, the Company owned <ix:nonFraction unitRef="number" contextRef="i2998f9f06ab149b7a5203f1dd82fad31_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfMTE3Mw_0cdfdad9-a420-45b6-9b30-1a4e28e463b7">47</ix:nonFraction>% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217; economic performance.  Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $<ix:nonFraction unitRef="usd" contextRef="i072b718ce60743018ae014282340909c_D20200601-20200601" decimals="-5" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfMTg0Mg_5d1d697c-ff63-42a1-9586-631a80cc75e9">4.1</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="i072b718ce60743018ae014282340909c_D20200601-20200601" decimals="-5" name="us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfMTg1NQ_07564bb0-c290-43ff-a1c6-5c247d13c855">2.4</ix:nonFraction> million related to the remeasurement of the retained noncontrolling interest investment to fair value.  </span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. Since the Company&#8217;s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#8217;s common stock investment and will therefore be recorded as an equity security under ASC 321.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the deconsolidation, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i000f799b913c4f72817a8533166ea847" continuedAt="idc0d6720b93d4dd4bbbaff03a9ac3a97"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's condensed consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217; net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020. The Company has determined that its Series A preferred stock investment in Geneos does not have a readily determinable fair value and has therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $<ix:nonFraction unitRef="usd" contextRef="i35c4e31704a040e18096a49a219271b0_D20201101-20201130" decimals="-5" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfNjg4Mg_ca24c351-2979-48a5-b966-4e34548178bd">1.4</ix:nonFraction>&#160;million in the Series A-1 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="icdd6b2404d2348d6be3af54fee60364d_I20201130" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfNzUxNw_ae93bc25-a0c7-443e-aed6-e401e7c21dc2">36</ix:nonFraction>% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continued to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share of net losses of Geneos for the three months ended March 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i7b0adeeead5e4699a63cb480fc0a0ac3_D20210101-20210331" decimals="-5" name="ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfODU1OQ_b4807b04-699b-4c50-93ff-6cf715ed2280">1.5</ix:nonFraction>&#160;million; however, only $<ix:nonFraction unitRef="usd" contextRef="i7af4410be8f148b5b8314f57ad7a668d_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfODU3Nw_8cdc0f1c-2e81-4fe5-aa4a-a28b8adb3b7f">434,000</ix:nonFraction> was recorded, reducing the Company's total investment in Geneos to $<ix:nonFraction unitRef="usd" contextRef="iade08220a0f74869bcb1f820413ac244_I20210331" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfODY0Nw_096121b5-ef54-43e8-a525-641a39493234">0</ix:nonFraction>. Of the total amount, $<ix:nonFraction unitRef="usd" contextRef="ie1f4de57b99d45e7878e83e0a961478f_D20200601-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfODY3Mg_90059821-6b37-42ed-b7d5-4830b5c649bd">819,000</ix:nonFraction> has been allocated to the equity method investment, thereby reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="i39108879adec43dd9ce939da4a9133c8_I20210331" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfODc1OQ_c663d86a-b50d-44c8-a080-072bbe7b40da">0</ix:nonFraction> as of March 31, 2021. The remaining $<ix:nonFraction unitRef="usd" contextRef="i240a06710e7f499c92f922af74aa1d72_D20200601-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfODc5OA_e8da989d-293e-41e0-ba4d-46d040ad74a3">4.2</ix:nonFraction> million loss has been allocated to the Company&#8217;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, thereby reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="i94cd371c1e2a482189fbcd1fa606ce5b_I20210331" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfODk2NA_a5c9ba74-b406-45fa-8a70-c689010078ad">0</ix:nonFraction> as of March 31, 2021.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will not reduce its investment below $<ix:nonFraction unitRef="usd" contextRef="i99ae48f06acb4be0999de4734437d7de_I20220331" decimals="INF" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfOTA2OQ_8479fc97-b9e0-4361-9655-c4245620d663">0</ix:nonFraction> and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Geneos completed a second closing of the Series A-1 preferred stock financing, in which the Company did not participate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="i37c604731df5488385ee8ef0f5eaa642_I20210228" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfOTM4MQ_4580ce71-58cc-42bd-9873-14b8bbfb2192">35</ix:nonFraction>% of the outstanding equity, on an as-converted to common stock basis.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Geneos completed the closing of a Series A-2 preferred stock financing. The Company invested $<ix:nonFraction unitRef="usd" contextRef="ic757f5e350bb42269e2c1e8b10f57ef6_I20220331" decimals="-5" sign="-" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfMTA5OTUxMTYzNzk2Ng_3d8f9667-9244-4191-9913-a44b2505475b">2.0</ix:nonFraction>&#160;million in the Series A-2 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continues to be a VIE as it does not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continues to not be the primary beneficiary of Geneos, as it does not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="idc03d9886d82421ebbc554d6ea904cd3_I20220331" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfMTA5OTUxMTYzOTMwMQ_4f360e19-1ab6-45ad-be47-c5995322e71a">24</ix:nonFraction>% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos&#8217;s Series A-2 preferred stock was based on the per share price paid by third-party investors in connection with the closing on March 21, 2022. The Company has concluded that its Series A-2 preferred stock investment is a similar financial instrument as its Series A-1 preferred stock, and therefore remeasured the carrying value of the Series A-1 preferred stock investment at the Series A-2 preferred stock price, resulting in a gain on remeasurement of $<ix:nonFraction unitRef="usd" contextRef="if6bb6660938e47b0a2d5df1338384e35_D20220101-20220331" decimals="-3" name="us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfMTA5OTUxMTY0MjAzNw_31352e66-cc5d-4b27-a839-9f0d2cc03827">165,000</ix:nonFraction>.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfNDk0NzgwMjM0MTcwNw_7fa91eea-87ee-4d9b-856a-4d7810796e05" continuedAt="i2665b58978df4661a1e6c1f87e0538b1" escape="true">The Company recorded its current and accumulated share of net losses of Geneos of $<ix:nonFraction unitRef="usd" contextRef="if6bb6660938e47b0a2d5df1338384e35_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfMTA5OTUxMTY0MzY5OA_61be27fa-32c5-4765-9679-8442b879f4f1">2.2</ix:nonFraction>&#160;million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="i6c48be9a581248328538c7ec76130395_I20220331" decimals="INF" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfMTA5OTUxMTY0MjcwMQ_8e9fd7e3-0076-49aa-b1ef-aef7cb91cc34">0</ix:nonFraction> as of March 31, 2022 as shown in the table below:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><ix:continuation id="idc0d6720b93d4dd4bbbaff03a9ac3a97" continuedAt="i7117f52b41084392b6a6f91aba0fdf85"><ix:continuation id="i2665b58978df4661a1e6c1f87e0538b1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-2 preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c076c415b0c4d348c148ffabebaa199_I20211231" decimals="0" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RhYmxlOjNiYzFkYjhiZWUxYTQ2MWU5ZDEzZTQzNzRiNDE2NGIyL3RhYmxlcmFuZ2U6M2JjMWRiOGJlZTFhNDYxZTlkMTNlNDM3NGI0MTY0YjJfMS0yLTEtMS0zODA0Ng_394203ac-f5bb-4828-aaf2-6a127c4df598">1,999,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remeasurement of  Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6bb6660938e47b0a2d5df1338384e35_D20220101-20220331" decimals="0" name="us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RhYmxlOjNiYzFkYjhiZWUxYTQ2MWU5ZDEzZTQzNzRiNDE2NGIyL3RhYmxlcmFuZ2U6M2JjMWRiOGJlZTFhNDYxZTlkMTNlNDM3NGI0MTY0YjJfMi0yLTEtMS0zODA1MA_a7a57260-3b46-4936-a8df-77a31a5aced6">165,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6bb6660938e47b0a2d5df1338384e35_D20220101-20220331" decimals="0" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RhYmxlOjNiYzFkYjhiZWUxYTQ2MWU5ZDEzZTQzNzRiNDE2NGIyL3RhYmxlcmFuZ2U6M2JjMWRiOGJlZTFhNDYxZTlkMTNlNDM3NGI0MTY0YjJfMy0yLTEtMS0zODA1MA_48921ca6-39b8-4018-8280-53966c1bf020">2,165,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c48be9a581248328538c7ec76130395_I20220331" decimals="0" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RhYmxlOjNiYzFkYjhiZWUxYTQ2MWU5ZDEzZTQzNzRiNDE2NGIyL3RhYmxlcmFuZ2U6M2JjMWRiOGJlZTFhNDYxZTlkMTNlNDM3NGI0MTY0YjJfNC0yLTEtMS0zODA0OA_12bc1413-a24d-4701-8fc0-ae611b6ef01f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><ix:continuation id="i7117f52b41084392b6a6f91aba0fdf85" continuedAt="i715fb3a4a03a40c29167a762d6d68628"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to exclusively license its SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapy and CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i715fb3a4a03a40c29167a762d6d68628">&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</ix:continuation>  </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_94"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185NC9mcmFnOmQ0NDc5M2NiNTA2ZjQ4Yzk4M2E2YjkyMTY4NDZiNmIxL3RleHRyZWdpb246ZDQ0NzkzY2I1MDZmNDhjOTgzYTZiOTIxNjg0NmI2YjFfMzc_9a5a64db-3185-4b2b-80b0-5b599f7c0210" continuedAt="i1b3161ee0fa64a42bebffee45bda7e77" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1b3161ee0fa64a42bebffee45bda7e77">From April 1, 2022 through April 21, 2022, the Company sold <ix:nonFraction unitRef="shares" contextRef="ic58ffceb77ce4063a7894330d50f5c66_D20220401-20220421" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185NC9mcmFnOmQ0NDc5M2NiNTA2ZjQ4Yzk4M2E2YjkyMTY4NDZiNmIxL3RleHRyZWdpb246ZDQ0NzkzY2I1MDZmNDhjOTgzYTZiOTIxNjg0NmI2YjFfMTA5OTUxMTYyODA2OA_b7aae710-251a-4c43-a575-2c36d7b273f5">2,502,269</ix:nonFraction> shares of common stock under the 2021 Sales Agreement for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ic58ffceb77ce4063a7894330d50f5c66_D20220401-20220421" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185NC9mcmFnOmQ0NDc5M2NiNTA2ZjQ4Yzk4M2E2YjkyMTY4NDZiNmIxL3RleHRyZWdpb246ZDQ0NzkzY2I1MDZmNDhjOTgzYTZiOTIxNjg0NmI2YjFfMTA5OTUxMTYyODA3OQ_6bd79cef-8aa6-4d21-b98d-e08c109309c8">8.7</ix:nonFraction>&#160;million.  The sales were made at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib3ee9fcf6611452784c45ad678fced93_I20220421" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185NC9mcmFnOmQ0NDc5M2NiNTA2ZjQ4Yzk4M2E2YjkyMTY4NDZiNmIxL3RleHRyZWdpb246ZDQ0NzkzY2I1MDZmNDhjOTgzYTZiOTIxNjg0NmI2YjFfMTA5OTUxMTYyODA5OQ_6bf1aced-c716-4e4c-b36c-4d9ae659ba4f">3.52</ix:nonFraction> per share.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i5cd930e6c7ce444abb7f72171f50164c_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report contains forward-looking statements, as defined in Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; the negative of such terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Although we believe that the expectations reflected in the forward-looking statements are reasonable based on our current expectations and projections, we cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. We are under no obligation to update any of the forward-looking statements after the filing of this Quarterly Report to conform such statements to actual results or to changes in our expectations.</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes and other financial information appearing elsewhere in this Quarterly Report and our audited consolidated financial statements and related notes for the year ended December 31, 2021 included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission, or SEC, on March 1, 2022 (our 2021 Annual Report). Readers are also urged to carefully review and consider the various disclosures made by us that attempt to advise interested parties of the factors that affect our business, including without limitation the disclosures made in Item&#160;1A of Part&#160;II of this Quarterly Report under the captions &#8220;Risk Factors&#8221; and &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and the disclosures made in our 2021 Annual Report under the caption &#8220;Risk Factors&#8221; and in our audited consolidated financial statements and related notes. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk factors that could cause actual results to differ from those contained in the forward-looking statements include but are not limited to: our history of losses; our lack of products that have received regulatory approval; uncertainties inherent in clinical trials and product development programs, including but not limited to the fact that preclinical and clinical results may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve desired results, that preclinical studies and clinical trials may not commence, have sufficient enrollment or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies, that results from an animal study may not be indicative of results achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is uncertain and failure can occur at any time during the clinical trial process, and that our electroporation technology and product candidates may fail to show the desired safety and efficacy traits in clinical trials; the availability of funding; the ability to manufacture our product candidates; the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; our ability to receive development, regulatory and commercialization event-based payments under our collaborative agreements; whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity; the impact of government healthcare laws and proposals; and the impact of COVID-19 on us and our third-party contractors and suppliers.</span></div><div style="margin-top:9pt;text-indent:27pt"><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_106"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biotechnology company focused on bringing to market precisely designed DNA medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer and conditions associated with human papillomavirus ("HPV"). We have shown in clinical trials that our DNA vaccine candidates can be delivered into cells in the body via a proprietary smart device allowing the nucleic-acid delivered gene products to activate functional T cell and antibody responses against targeted pathogens and cancers.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our DNA medicines pipeline is comprised of three types of product candidates: prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies ("dMAbs" and &#8220;dBTAs&#8221;), all of which utilize the two components of our integrated platform, SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce proteins or antigens to help the person&#8217;s immune system respond with antibodies and immune cells which recognize and then help block viruses and destroy cancerous or pre-cancerous cells. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patented CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> nucleic-acid delivered gene products smart delivery devices facilitate uptake of our DNA medicines into the cell, which has been a key limitation of historical DNA-based technology approaches. Human clinical trial </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">data from more than 15,000 CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart device administrations across more than 5,000 participants to date have shown a tolerable safety profile.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate strategy is to develop, seek regulatory approval for and commercialize our novel DNA medicines to address unmet global health needs. We continue to advance and clinically validate an array of DNA medicine candidates that target infectious diseases, such as COVID-19, as well as HPV-associated diseases and cancer. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners and collaborators include ApolloBio Corporation, AstraZeneca, Advaccine Biopharmaceuticals Suzhou Co, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations ("CEPI"), Defense Advanced Research Projects Agency ("DARPA"), The U.S. Department of Defense ("DoD"), HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium ("MCDC"), International Vaccine Institute ("IVI"), Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators are currently evaluating the feasibility of, or conducting or planning clinical studies of, our DNA medicines for COVID-19, including both homologous and heterologous booster vaccines; Middle East Respiratory Syndrome, or MERS; Lassa fever; Ebola; as well as HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis, or RRP; glioblastoma multiforme, or GBM; and prostate cancer. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are in the research and development phase. We have not generated any revenues from the sale of any products, and we do not expect to generate any such revenues for at least the next several years. We earn revenue from license fees and milestone revenue and collaborative research and development agreements. Our product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that we advance to clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had an accumulated deficit of $1.3 billion. We expect to continue to incur substantial operating losses in the future due to our commitment to our research and development programs, the funding of preclinical studies, clinical trials and regulatory activities and the costs of general and administrative activities.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impacts of COVID-19 On Our Business</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operationally, we have experienced some disruptions as a result of the COVID-19 pandemic. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, as a result of supply chain disruptions and global supply shortages, we have experienced delays in obtaining some clinical supplies, manufacturing supplies and components, and we have had to secure new vendors for certain supplies and components at higher prices. Some manufacturing supplies and components remain in limited supply with uncertain delivery dates.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the pandemic we implemented a work from home policy allowing employees who can work from home to do so, while those needing to work in laboratory facilities work in shifts to reduce the number of people gathered together at one time. Starting in April 2022, employees have begun to return to the office on a modified schedule. We have also im</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plemented a mask-wearing mandate for all on-site activities. We have taken measures to secure our research and development project activities, while work in laboratories has been organized to reduce risk of COVID-19 transmission.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our liquidity has not been negatively impacted to date by the pandemic. During the three months ended March 31, 2022, and year ending December 31, 2021, we raised $29.4 million and $47.7 million, respectively, in net proceeds from the sale of shares of our common stock through "at the market" equity sale programs, and in January 2021 we closed an underwritten public offering of our common stock, with net proceeds to us of $162.1&#160;million. As of March&#160;31, 2022, our cash and cash equivalents and short-term investments were $360.4 million in the aggregate. Subsequent to March 31, 2022, we raised an additional $8.7 million under our &#8220;at the market&#8221; equity sale program.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the pandemic will continue to impact our business and operations will depend on future developments, including travel restrictions to, from and within the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, which remain uncertain.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">INO-4800</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have decided to discontinue INNOVATE, the Phase 3 clinical trial of our COVID-19 vaccine candidate, INO-4800. The original primary endpoint of the INNOVATE trial was incidence of virologically confirmed COVID-19. As was the case with other COVID-19 vaccines, INO-4800 exhibited significantly decreased levels of both neutralizing and binding antibodies against the Omicron variant of the SARs-CoV-2 virus that causes COVID-19. Since the diminished neutralizing activity of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INO-4800 suggests it is unlikely to prevent symptomatic COVID-19, the primary endpoint was revised to be incidence of virologically confirmed severe COVID-19. The maintenance of T cell responses observed suggests that the INO-4800 is likely to protect against severe disease. However, based on emerging epidemiological data, we believe that INNOVATE will not be able to achieve the required number of cases of severe disease, as the projected attack rate in the key countries in which INNOVATE is currently being conducted is now significantly less than the attack rate previously assumed when the trial was designed.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are evaluating the reallocation of the resources previously committed to INNOVATE to pursuing a strategy for the development of INO-4800 as a potential heterologous booster vaccine, meaning that it could be a booster for a different primary vaccine. Our plans may include the conduct of non-inferiority clinical trials in countries whose populations have been vaccinated against COVID-19 using inactivated viral vaccines. We are also considering the initiation of a dose-finding clinical trial of INO-4800 combined with our DNA medicine INO-9112, which encodes the IL-12 plasmid, in the European Union to evaluate the non-inferiority of this combination against an mRNA vaccine regimen.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGX-3100</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our proposal to the FDA to amend the protocol for our REVEAL 2 (HPV-303) Phase 3 clinical trial of VGX-3100 in women with HPV-16/18 cervical high-grade dysplasia (HSIL), to reflect a biomarker-selected population as primary, the FDA has preliminarily advised us that while we may proceed with such an amendment, the revised trial would be viewed as an exploratory study to evaluate the biomarker-selected population, and unlikely be reviewable as the basis for a BLA.  Given that the results observed in the intent-to-treat (ITT) population in our REVEAL 1 (HPV-301) Phase 3 clinical trial of VGX-3100 were not statistically significant, the REVEAL 1 and REVEAL 2 studies alone would unlikely be supportive of a marketing authorization for VGX-3100. The FDA indicated that the subsequent conduct of one or two adequate and well-controlled trials in this selected population would be more likely to provide sufficient evidence to support approval of a marketing application for VGX-3100. The FDA also noted that there was a higher incidence of cervical carcinoma reported in the treatment group of REVEAL 1 that while low, and likely due to the trial design and not the vaccine candidate, warranted further consideration with respect to the benefit-risk profile of VGX-3100 versus standard of care, and as such, FDA recommended additional modifications to the REVEAL 2 protocol to address the potential for progression during the trial. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of this guidance from the FDA, we plan to modify and continue the REVEAL 2 trial to completion and will assess the path forward for the VGX-3100 program following analysis of the REVEAL 2 results. Top-line efficacy and safety data are expected to be available in the fourth quarter of 2022 or the first quarter of 2023. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_109"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to our critical accounting estimates since December 31, 2021. For a description of our critical accounting estimates and significant judgments used in the preparation of our condensed consolidated financial statements, refer to Note 3 to our Condensed Consolidated Financial Statements included in this Quarterly Report, as well as Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our 2021 Annual Report and Note 2 to our audited Consolidated Financial Statements contained in our 2021 Annual Report. </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_112"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of Recent Accounting Pronouncements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding recent accounting pronouncements is contained in Note&#160;4 to the Condensed Consolidated Financial Statements, included in this Quarterly Report.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_115"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue was $199,000 and $371,000 for the three months ended March 31, 2022 and 2021, respectively. Revenue primarily consisted of revenues under collaborative research and development arrangements, including arrangements with affiliated entities. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses for the three months ended March 31, 2022 and 2021 were $56.0 million and $39.0 million, respectively. Increases for the three-month period year over year included:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$10.8 million in drug manufacturing and clinical study expenses related to INO-4800;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$2.4 million in employee compensation;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$1.7 million in drug manufacturing expenses related to our COVID-19 variant studies; and</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$1.2 million in clinical study and drug manufacturing related to our RRP study.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The increase </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the three-month period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">was also due to a decrease of $6.3 million in contra-research and development expense recorded from grant agreements. These increases were offset by lower engineering services and expensed equipment of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$3.9 million related to our CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> 3PSP device array automation project and lower employee stock-based compensation of $1.5 million, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">among other variances. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions received from current grant agreements and recorded as contra-research and development expense were $7.5 million and $13.8 million for the three months ended March 31, 2022 and 2021, respectively. The decrease for the three-month period year over year was primarily due to a decrease of $4.6 million earned under the DoD 3PSP device development grant, and decreases of $1.8 million and $893,000 earned under the grants from CEPI and Gates related to INO-4800 and device development activities, respectively.  These decreases were offset by an increase of $1.3 million earned under sub-grants through Wistar, among other variances. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses, which include business development expenses, the amortization of intangible assets and patent expenses, were $16.0 million and $13.9 million for the three months ended March 31, 2022 and 2021, respectively.  Increases for the three-month period year over year included:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$1.5 million in employee compensation; and</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$869,000 in insurance expenses.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases were offset by a decrease of $490,000 in employee and consultant stock-based compensation, among other variances.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite vesting period. Total employee and director stock-based compensation expense for the three months ended March 31, 2022 and 2021 was $7.2 million and $9.2 million, respectively. Of these amounts, $3.7 million and $5.2 million, respectively, was included in research and development expenses, and $3.5 million and $4.0 million, respectively, was included in general and administrative expenses. The year over year decrease was primarily related to a lower weighted average grant date fair value for the awards granted in the first quarter of 2022. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest income. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the three months ended March 31, 2022 was $670,000, as compared to $769,000 for the three months ended March 31, 2021. The decrease was due to lower average cash balances.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest expense. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three months ended March 31, 2022 was $313,000, as compared to $513,000 for the three months ended March 31, 2021. The decrease for the three-month period year over year was due to lower non-cash  interest expense related to the Notes as a result of the adoption of ASU-2020-06, and no interest expense recorded on the December 2019 Bonds due to their full conversion into shares of our common stock in March 2021. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on investment in affiliated entities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss results from the change in the fair market value of our investment in PLS of $538,000 and $830,000 for the three months ended March 31, 2022 and 2021, respectively. We record our investment in PLS at its market value based on the closing price of the shares on the Korea New Exchange Market at each balance sheet date, with changes in fair value reflected in the condensed consolidated statements of operations.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net unrealized loss on available-for-sale equity securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized loss on available-for-sale equity securities for the three months ended March 31, 2022 and 2021 of $4.8 million and $848,000, respectively, resulted from a change in the fair market value of the investments.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share in net loss of Geneos.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The share in net loss of Geneos represents our share of Geneos' losses during the period after deconsolidation in June 2020. </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_118"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our primary uses of cash have been to finance research and development activities including clinical trial activities in the oncology, DNA vaccines and other immunotherapy areas of our business. Since inception, we have satisfied our cash requirements principally from proceeds from the sale of equity securities, indebtedness and grants and government contracts.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Working Capital and Liquidity</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had cash and short-term investments of $360.4 million and working capital of $340.5 million, as compared to $401.3 million and $382.7 million, respectively, as of December&#160;31, 2021. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $61.9 million and $52.9 million for the three months ended March 31, 2022 and 2021, respectively. The variance was primarily due to increased research and development expenses offset by the timing and changes in working capital balances.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) investing activities was $21.3 million and $(275.1) million for the three months ended March 31, 2022 and 2021, respectively. The variance was primarily the result of timing differences in short-term investment purchases, sales and maturities.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $28.4 million and $160.9 million for the three months ended March 31, 2022 and 2021, respectively. The variance was primarily due to the proceeds from the January 2021 underwritten public offering, with no such offering in 2022, partially offset by an increase in the proceeds from the sale of common stock under the Sales Agreement (defined below) in 2022 compared to 2021.  </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Issuances of Common Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, we entered into an ATM Equity Offering</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;Sales Agreement&#8221;) with outside sales agents (collectively, the &#8220;Sales Agents&#8221;) under which we may offer and sell, from time to time at our sole discretion, shares of our common stock with aggregate gross proceeds of up to $300.0 million, through the Sales Agents.</span></div><div style="text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the common stock by any method permitted by law deemed to be an &#8220;at the market offering&#8221;. The Sales Agents will use commercially reasonable efforts to sell the common stock from time to time, based upon instructions from us, including any price, time or size limits or other customary parameters or conditions we may impose. We will pay the Sales Agents a commission of up to three percent (3.0%) of the gross sales proceeds of any common stock sold through the Sales Agents under the Sales Agreement, and we have provided the Sales Agents with certain indemnification rights. During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we sold 8,480,483 shares of common stock under the Sales Agreement for aggregate net proceeds of $29.4 million. Subsequent to March 31, 2022, we raised an additional $8.7 million under the Sales Agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, we closed an underwritten public offering of 20,355,000 shares of our common stock at a public offering price of $8.50 per share. The net proceeds, after deducting the underwriters' discounts and commissions and other offering expenses payable by us, were $162.1&#160;million. </span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, stock options to purchase 26,069 shares of common stock were exercised for aggregate net proceeds to us of $84,000, which proceeds were offset by tax payments made related to net sh</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are settlement of RSU awards of $1.0 million. During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, stock options to purchase 572,857 shares of common stock were exercised for aggregate net proceeds to us of $2.6 million, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $3.8 million.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Funding Requirements</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had an accumulated deficit of $1.3 billion and we expect to continue to operate at a loss for some time. The amount of the accumulated deficit will continue to increase, as it will be expensive to continue research and development efforts. These activities will require additional financing. If these activities are successful and if we receive approval from the FDA to market our product candidates, then we will need to raise additional funding to market and sell the approved products and equipment. We cannot predict the outcome of the above matters at this time. We are evaluating potential collaborations as an additional way to fund operations. We believe that our current cash and short-term investments are sufficient to meet our planned working capital requirements for at least the next twelve months from the date of this report. </span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have existing supply agreements with contract manufacturers to manufacture INO-4800 drug substance. At March&#160;31, 2022, we had a $44.6&#160;million minimum purchase obligation in connection with these agreements. We expect to satisfy these obligations from existing cash.</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our decision to terminate the INNOVATE trial of INO-4800, we expect our research and development expenses to decrease in future periods.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">here have been no other significant changes to our contractual obligations and commitments described under Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2021. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_121"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:5pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are exposed to market risk related to changes in interest rates. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to increase the safety and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in short-term investment-grade securities. During the three months ended March 31, 2022, there was a pronounced increase in prevailing interest rates in the United States, which contributed to a loss of $4.8 million in the market value of our investment portfolio during the period. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on our indebtedness is fixed and not subject to fluctuations in interest rates.</span></div><div style="margin-top:5pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operated primarily in the United States and most transactions during the three months ended March 31, 2022 were made in United States dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations, with the exception of certain cash and cash equivalents held in South Korea that are denominated in South Korean Won and the valuation of our equity investment in PLS, which is denominated in South Korean Won and then translated into United States dollars. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain transactions are denominated primarily in foreign currencies, including South Korean Won, Euros, British Pounds and Canadian Dollars. These transactions give rise to monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. The value of these monetary assets and liabilities are subject to changes in currency exchange rates from the time the transactions are originated until settlement in cash. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets where we conduct business.</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use derivative financial instruments for speculative purposes and do not engage in exchange rate hedging or hold or issue foreign exchange contracts for trading purposes. </span></div><div style="margin-top:5pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation Risk</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor. Although inflation has increased generally in the United States in recent months, we do not believe that inflation has had a material effect on our business, financial condition or results of operations during the three months ended March 31, 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_124"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures, which are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules&#160;and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, or CEO, and Chief Financial Officer, or CFO, as appropriate to allow timely decisions regarding required disclosures. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an evaluation carried out as of the end of the period covered by this Quarterly Report, under the supervision and with the participation of our management, including our CEO and CFO, our CEO and CFO have concluded that, as of the end of such period, our disclosure controls and procedures (as defined in Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934) were effective as of March&#160;31, 2022 at the reasonable assurance level. </span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have not been any changes in our internal control over financial reporting that occurred during the quarter ended March&#160;31, 2022 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="i5cd930e6c7ce444abb7f72171f50164c_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II. Other Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_130"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming us and J. Joseph Kim, our Chief Executive Officer, as defendants. The lawsuit alleges that we made materially false and misleading statements regarding our development of a vaccine for COVID-19 in our public disclosures in violation of certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. On June 18, 2020, the court appointed Manuel Williams to serve as lead plaintiff. On August 3, 2020, Mr. Williams filed a consolidated complaint, naming us and three of our officers as defendants. On September 21, 2020, Mr. Williams and another purported stockholder, Andrew Zenoff filed a first amended complaint, naming us and three of our officers as defendants. Defendants filed a motion to dismiss plaintiff&#8217;s first amended complaint on November 5, 2020. On February 16, 2021, the court issued an order granting in part, and denying in part, Defendants&#8217; motion to dismiss. The court granted Defendants&#8217; motion to dismiss, and dismissed with prejudice, the claims premised on the April 30 and June 30, 2020 statements. The court denied Defendants&#8217; motion to dismiss as to the remaining statements. On March 9, 2021, Defendants filed their answer to the complaint. The case is currently in discovery. On July 29, 2021, Plaintiffs moved to certify the class action. That motion is fully briefed and remains pending. On February 17, 2022, the court granted Plaintiffs&#8217; motion for leave to amend their complaint, and further ordered that the amended complaint is deemed filed as of February 17. On March 21, 2022, Defendants moved to dismiss the new allegations in the amended complaint. We expect that motion to be fully briefed on May 10, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No hearing date has been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class action complaint. The lawsuit accuses our board of directors of failing to exercise reasonable and prudent supervision over our management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of us as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et al. and Devarakonda et al. v Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name our current directors as defendants. The Devarakonda complaint also names one of our former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 28, 2022, a fifth shareholder derivative complaint, Schumacher v. Benito et al., was filed in the Delaware Court of Chancery, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On May 4, 2022, the Delaware Court of Chancery entered a stay of the litigation.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to defend these actions vigorously.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2020, we filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached our supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. On June 3, 2020, we filed a petition for preliminary injunction, which was denied on June 25, 2020. On June 26, 2020, we filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, VGXI filed an answer, new matter and counterclaims against us, alleging that we had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from us. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that we had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, we filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. On October 1, 2020, we filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5cd930e6c7ce444abb7f72171f50164c_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to aggressively prosecute the claims set forth in our complaint against VGXI and to vigorously defend ourselves against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against us, alleging that we had breached the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Device License Agreement, or the Agreement, between us and GeneOne. We terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from us. On January 29, 2021, we filed preliminary objections to the complaint. On August 23, 2021, the Court overruled our preliminary objections to the complaint. On September 13, 2021, we filed an answer to the complaint, new matter, and counterclaims. The Company&#8217;s counterclaims allege that GeneOne breached the Agreement, and assert claims for breach of contract and declaratory judgment. The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs. On October 18, 2021, GeneOne filed its answer to our counterclaims and new matter. On November 8, 2021, we filed our answer to GeneOne&#8217;s new matter. A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to aggressively prosecute the claims set forth in our counterclaims against GeneOne and to vigorously defend ourselves against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt"><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_133"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;  RISK FACTORS</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business is subject to numerous risks. You should carefully consider and evaluate each of the following factors as well as the other information in this Quarterly Report on Form&#160;10-Q, including our financial statements and the related notes, the risk factors discussed in our 2021 Annual Report, which we filed with the SEC on March 1, 2022, in evaluating our business and prospects. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently consider immaterial may also impair our business operations. If any of the following risks actually occur, our business and financial results could be harmed. In that case, the trading price of our common stock could decline. You should also consider the more detailed description of our business contained in our 2021 Annual Report. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since inception, expect to incur significant net losses in the foreseeable future and may never become profitable.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant operating losses over the last several years. As of March&#160;31, 2022, our accumulated deficit was $1.3 billion. We have generated limited revenues, primarily consisting of license revenue, grant funding and interest income. We expect to continue to incur substantial additional operating losses for at least the next several years as we advance our clinical trials and research and development activities. We may never successfully commercialize our DNA vaccine, DNA immunotherapy and dMAb product candidates or electroporation-based synthetic vaccine delivery technology and thus may never have any significant future revenues or achieve and sustain profitability.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited sources of revenue and our success is dependent on our ability to develop our DNA vaccines, DNA immunotherapies, dMAbs and electroporation equipment. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not sell any products and may not have any other products commercially available for several years, if at all. Our ability to generate future revenues depends heavily on our success in: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and securing United States and/or foreign regulatory approvals for our product candidates, including securing regulatory approval for conducting clinical trials with product candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing our electroporation-based DNA delivery technology; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercializing any products for which we receive approval from the FDA and foreign regulatory authorities. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our electroporation equipment and product candidates will require extensive additional clinical study and evaluation, regulatory approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote our electroporation equipment and product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities. If we do not receive regulatory approval for and successfully commercialize any products, we will not generate any revenues from sales of electroporation equipment and products, and we may not be able to continue our operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A small number of licensing partners and government contracts currently account for a substantial portion of our revenue. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently derive, and in the past we have derived, a significant portion of our revenue from a limited number of licensing partners and government grants and contracts. Revenue can fluctuate significantly depending on the timing of upfront and event-based payments and work performed. If we fail to sign additional future contracts with major licensing partners and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the government, if a contract is delayed or deferred, or if an existing contract expires or is canceled and we fail to replace the contract with new business, our revenue would be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional capital to develop our DNA vaccines, DNA immunotherapies and dMAb programs and electroporation delivery technology.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting the costly and time-consuming research, pre-clinical studies and clinical testing necessary to obtain regulatory approvals and bring our product candidates and delivery technology to market will require a commitment of substantial funds in excess of our current capital. Our future capital requirements will depend on many factors, including, among others:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress of our current and new product development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, scope and results of our pre-clinical and clinical testing; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost involved in obtaining regulatory approvals; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our products and product candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of prosecuting, enforcing and defending against patent infringement claims and other intellectual property rights; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%;padding-left:14.5pt">debt service obligations</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and the related costs to establish and maintain collaborative and other arrangements with third parties to assist in potentially bringing our products to market. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional financing may not be available on acceptable terms, or at all. Domestic and international capital markets have from time to time experienced heightened volatility, particularly in light of the COVID-19 pandemic and geopolitical turmoil, making it more difficult in many cases to raise capital through the issuance of equity securities. Volatility in the capital markets can also negatively impact the cost and availability of credit, creating illiquid credit markets and wider credit spreads. Concern about the stability of the markets generally and the strength of counterparties specifically has led many lenders and institutional investors to reduce, and in some cases cease to provide, funding to borrowers. To the extent we are able to raise additional capital through the sale of equity securities, or we issue securities in connection with another transaction in the future, the ownership position of existing stockholders could be substantially diluted. If additional funds are raised through the issuance of preferred stock or debt securities, these securities are likely to have rights, preferences and privileges senior to our common stock and may involve significant fees, interest expense, restrictive covenants and the granting of security interests in our assets. Fluctuating interest rates could also increase the costs of any debt financing we may obtain. Raising capital through a licensing or other transaction involving our intellectual property could require us to relinquish valuable intellectual property rights and thereby sacrifice long-term value for short-term liquidity.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to successfully address ongoing liquidity requirements would have a substantially negative impact on our business. If we are unable to obtain additional capital on acceptable terms when needed, we may need to take actions that adversely affect our business, our stock price and our ability to achieve cash flow in the future, including possibly surrendering our rights to some technologies or product opportunities, delaying our clinical trials or curtailing or ceasing operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Product Development, Manufacturing and Regulatory Approval</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain FDA approval of our products, we will not be able to commercialize them in the United States.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need FDA approval prior to marketing our electroporation equipment and product candidates in the United States. If we fail to obtain FDA approval to market our electroporation equipment and product candidates, we will be unable to sell our products in the United States, which will significantly impair our ability to generate any revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This regulatory review and approval process, which includes evaluation of preclinical studies and clinical trials of our products as well as the evaluation of our manufacturing processes and our third-party contract manufacturers' facilities, is lengthy, expensive and uncertain. To receive approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials that our electroporation equipment and product candidates are both safe and effective for each indication for which approval is sought. To the extent that our product candidates are manufactured at multiple sites or using different processes, we will also need to demonstrate comparability across the manufacturing batches in order to obtain regulatory approval. Satisfaction of the approval requirements typically takes several years and the time needed to satisfy them may vary substantially, based on the type, complexity and novelty of the product. We do not know if or when we might receive regulatory approvals for our electroporation equipment and any of our product candidates currently under development. Moreover, any approvals that we obtain may not cover all of the clinical indications for which we are seeking approval, or could contain significant limitations in the form of narrow indications, warnings, precautions or contra-indications with respect to conditions of use. In such event, our ability to generate revenues from such products would be greatly reduced and our business would be harmed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has substantial discretion in the approval process and may either refuse to consider our application for substantive review or may form the opinion after review of our data that our application is insufficient to allow approval of our electroporation equipment and product candidates. If the FDA does not consider or approve our application, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our application. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for approval or even to make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our applications for approval, which might significantly harm our business and prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that none of our products or any product we may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us or our collaborators to commence product sales. Any delay in obtaining, or an inability to obtain, applicable regulatory approvals would prevent us from commercializing our products, generating revenues and achieving and sustaining profitability. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and can take many years to complete, and its outcome is uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our products may not be predictive of the results of later-stage clinical trials. Results from one study may not be reflected or supported by the results of similar studies. Results of an animal study may not be indicative of results achievable in human studies. Human-use equipment and product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical testing. The time required to obtain approval by the FDA and similar foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials, depending upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change. We have not obtained regulatory approval for any human-use products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products could fail to complete the clinical trial process for many reasons, including the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our electroporation equipment or product candidate is safe and effective for any indication; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of clinical or statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be successful in enrolling a sufficient number of participants in clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our electroporation equipment or product candidates' clinical and other benefits outweigh their safety risks; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our electroporation equipment or product candidate presents an advantage over existing therapies, or over placebo in any indications for which the FDA requires a placebo-controlled trial; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a new drug application or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of us or third-party manufacturers with which we or our collaborators contract for clinical and commercial supplies; and </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our proposal to the FDA to amend the protocol for our REVEAL 2 (HPV-303) Phase 3 clinical trial of VGX-3100 in women with HPV-16/18 cervical high-grade dysplasia (HSIL), to reflect a biomarker-selected population as primary, the FDA has preliminarily advised us that while we may proceed with such an amendment, the revised trial would be viewed as an exploratory study to evaluate the biomarker-selected population, and unlikely be reviewable as the basis for a BLA.  Given that the results observed in the intent-to-treat (ITT) population in our REVEAL 1 (HPV-301) Phase 3 clinical trial of VGX-3100 were not statistically significant, the REVEAL 1 and REVEAL 2 studies alone would unlikely be supportive of a marketing authorization for VGX-3100. The FDA indicated that the subsequent conduct of one or two adequate and well-controlled trials in this selected population would be more likely to provide sufficient evidence to support approval of a marketing application for VGX-3100. The FDA also noted that there was a higher incidence of cervical carcinoma reported in the treatment group of REVEAL 1 that while low, and likely due to the trial design and not the vaccine candidate, warranted </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">further consideration with respect to the benefit-risk profile of VGX-3100 versus standard of care, and as such, FDA recommended additional modifications to the REVEAL 2 protocol to address the potential for progression during the trial. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of this guidance from the FDA, we plan to modify and continue the REVEAL 2 trial to completion and will assess the path forward for the VGX-3100 program following analysis of the REVEAL 2 results. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are combination products regulated under both the biologic and device regulations of the Public Health Service Act and Federal Food, Drug, and Cosmetic Act. Third-party manufacturers may not be able to comply with cGMP regulations, regulations applicable to biologic/device combination products, including applicable provisions of the FDA&#8217;s drug cGMP regulations, device cGMP requirements embodied in the QSR or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could significantly affect supplies of our product candidates. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or other regulatory authorities due to a number of factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen safety issues; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our electroporation equipment and our product candidates may be harmed and our ability to generate product revenues will be delayed or eliminated altogether. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement, conduct or completion of clinical trials may adversely affect the trading price of our common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Delays in the commencement, conduct or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delays in the commencement, conduct or completion of clinical testing could significantly affect our product development costs. We do not know whether planned clinical trials will begin on time or be completed on schedule, if at all. In addition, ongoing clinical trials may not be completed on schedule, or at all, and could be placed on a hold by the regulators for various reasons. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining regulatory approval to commence a clinical trial;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">adverse results from third party clinical trials involving gene-based therapies and the regulatory response thereto;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reaching agreement on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">future bans or stricter standards imposed on clinical trials of gene-based therapy;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">manufacturing sufficient quantities of our electroporation equipment and product candidates for use in clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining institutional review board, or IRB, approval to conduct a clinical trial at a prospective site;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">slower than expected recruitment and enrollment of patients to participate in clinical trials for a variety of reasons, including competition from other clinical trial programs for similar indications;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conducting clinical trials with sites internationally due to regulatory approvals and meeting international standards;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">retaining patients who have initiated a clinical trial but may be prone to withdraw due to side effects from the therapy, lack of efficacy or personal issues, or who are lost to further follow-up;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">collecting, reviewing and analyzing our clinical trial data; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">global unrest, including geopolitical risks emanating from countries such as Russia and China, global pathogen outbreaks or pandemics, terrorist activities, and economic and other external factors beyond our control.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or other regulatory authorities due to a number of factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">unforeseen safety issues; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial.</span></div><div style="margin-top:5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our electroporation equipment and our product candidates may be harmed and our ability to generate product revenues will be delayed or eliminated altogether. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement, conduct or completion of clinical trials may adversely affect the trading price of our common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">None of our human vaccine candidates or our immunotherapy and DNA encoded monoclonal antibody product candidates have been approved for sale, and we may never develop commercially successful vaccine, immunotherapy or DNA encoded monoclonal antibody products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our human vaccine programs, our immunotherapy programs and our DNA encoded monoclonal antibodies program are in various stages of research and development, and currently include product candidates in discovery, preclinical studies and Phase 1, 2 and 3 clinical trials. There are limited data regarding the efficacy of synthetic vaccine candidates and immunotherapy candidates compared with conventional vaccines, and we must conduct a substantial amount of additional research and development before the FDA or any comparable foreign regulatory authority will approve any of our vaccine product candidates. The success of our efforts to develop and commercialize our product candidates could be delayed or fail for a number of reasons. For example, we could experience delays in product development and clinical trials. Our product candidates could be found to be ineffective or unsafe, or otherwise fail to receive necessary regulatory clearances to proceed with further clinical development or to be approved for marketing. Our products, even if they are deemed to be safe and effective by regulatory authorities, could be difficult to manufacture on a large scale or uneconomical to market, or our competitors could develop superior products more quickly and efficiently or more effectively market their competing products. The ability to manufacture sufficient quantities of our COVID-19 vaccine candidate on a large scale is particularly challenging and will require substantial resources and the engagement of third parties, which we may not be able to obtain on a timely basis, or at all.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, adverse events, or the perception of adverse events, relating to vaccine and immunotherapy candidates and delivery technologies may negatively impact our ability to develop commercially successful products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism. These and other claims may influence public perception of the use of vaccine and immunotherapy products and could result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approval of our potential products.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have modified our COVID-19 vaccine strategy to develop our vaccine candidate as a potential heterologous booster for other available vaccines, which will result in new and added risks and may not be successful.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As described in this report, we have decided to discontinue our INNOVATE trial of INO-4800 and instead will pursue a strategy to develop our COVID-19 vaccine as a potential booster following administration of other primary vaccines. However, there can be no guarantee that this revised strategy will be successful. We have not yet completed clinical trials of our COVID-19 vaccine candidate as a heterologous booster, and the results of our planned trials may not indicate efficacy or may indicate adverse events that could preclude its clinical viability. In addition, we have not yet identified a clear regulatory pathway for the approval of our COVID-19 vaccine candidate as a heterologous booster and we may not be successful in doing so.  Further, the prevalence and spread of new variants of the SARs-CoV-2 virus could reduce the efficacy of our vaccine candidate as a potential booster.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">There can be no assurance that our COVID-19 vaccine candidate will ever be granted an Emergency Use Authorization by the FDA or similar authorization by regulatory authorities outside of the United States if we were to decide to apply for such an authorization. The option of seeking an Emergency Use Authorization may no longer exist for our primary COVID-19 vaccine candidates, and if we cannot obtain such authorization or, if granted, it is terminated, we will be unable to sell vaccine candidate and instead will be required to pursue the biologic licensure process, which is lengthy and expensive. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek an Emergency Use Authorization, or EUA, from the FDA or similar authorization from regulatory authorities outside of the United States, for the use of our COVID-19 vaccine as a heterologous booster. If we apply for an EUA and it is granted, an EUA would authorize us to market and sell our COVID-19 vaccine under certain conditions of authorization as long as a public health emergency exists. The FDA expects that companies which receive an EUA for COVID-19 vaccines will proceed to licensure of their vaccine products under a full Biologics License Application. The FDA may issue an EUA during a Public Health Emergency if the agency determines that the potential benefits of a product outweigh the potential risks and if other regulatory criteria are met. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no guarantee that we will apply for an EUA or other similar authorization or, if we do apply, that we will be able to obtain such authorization. For example, we will only be able to seek an EUA for INO-4800 as a heterologous booster vaccine candidate, which strategy may not be successful. Even if an EUA or other authorization is ultimately granted, we will rely on the FDA or other applicable regulatory authority policies and guidance governing vaccines authorized in this manner in connection with the marketing and sale of our product. If these policies and guidance change unexpectedly and/or materially or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if we misinterpret them, potential sales of our product could be adversely impacted. Regulatory authorities may also terminate an EUA if safety issues or other concerns about our product arise or if we fail to comply with the conditions of authorization. If we apply for an EUA or similar authorization from regulatory authorities outside of the United States, the failure to obtain such authorization or the termination of such an authorization, if obtained, would adversely impact our ability to market and sell our COVID-19 vaccine, which could adversely impact our business, financial condition and results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DNA medicines are a novel approach, and negative perception of the efficacy, safety, or tolerability of any investigational medicines that we develop could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No DNA medicines have been granted EUA or have been approved to date by the FDA. Adverse events in clinical trials of our investigational medicines or in clinical trials of others developing similar products and the resulting publicity, as well as any other adverse events in the field of DNA medicine, or other products that are perceived to be similar to DNA medicines, such as those related to gene therapy or gene editing, could result in a decrease in the perceived benefit of one or more of our programs, increased regulatory scrutiny, decreased confidence by patients and clinical trial collaborators in our investigational medicines, and less demand for any product that we may develop. Our large pipeline of development candidates and investigational medicines could result in a greater quantity of reportable adverse events, including suspected unexpected serious adverse reactions, other reportable negative clinical outcomes, manufacturing reportable events or material clinical events that could lead to clinical delay or hold by the FDA or applicable regulatory authority or other clinical delays, any of which could negatively impact the perception of one or more of our programs, as well as our business as a whole. In addition, responses by U.S., state, or foreign governments to negative public perception may result in new legislation or regulations that could limit our ability to develop any investigational medicines or commercialize any approved products, obtain or maintain regulatory approval, or otherwise achieve profitability. More restrictive statutory regimes, government regulations, or negative public opinion would have an adverse effect on our business, financial condition, results of operations, and prospects and may delay or impair the development of our investigational medicines and commercialization of any approved products or demand for any products we may develop.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we and the contract manufacturers upon whom we rely fail to produce our electroporation devices and product candidates in the volumes that we require on a timely basis, or at all, or fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our electroporation equipment and product candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture some components of our electroporation devices and utilize the services of contract manufacturers to manufacture the remaining components of these devices. We also rely on third party contract manufacturers to produce our product candidates for use in our clinical trials and potentially for commercial distribution, if any product candidate is approved by regulatory authorities. The manufacture of these devices and our product candidates requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers often encounter difficulties in production, particularly in scaling up for commercial production. These problems include difficulties with production costs and yields, quality control, including stability of the equipment and product candidates and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our manufacturers were to encounter any of these difficulties or our manufacturers otherwise fail to comply with their obligations to us, our ability to provide our electroporation equipment to our partners and to supply product candidates for clinical trials or to commercially launch a product would be jeopardized. For example, we previously relied on VGXI to manufacture DNA plasmids for our product candidates, including INO-4800. In 2020, VGXI notified us that they would be unable to produce the necessary plasmids to meet this timeline due to a lack of manufacturing capacity. As a result, we have engaged several additional third-party contract manufacturers to support the planned large-scale manufacturing of INO-4800. However, there can be no assurance that we will be able to secure adequate additional manufacturing capacity on commercially reasonable terms. Our inability to secured sufficient manufacturing capacity, or our inability to transfer necessary manufacturing know-how to third parties, would adversely affect our commercialization plans and could also harm our reputation.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, any delay or interruption in the supply of clinical trial supplies for our product candidates could delay the completion of our clinical trials, increase the costs associated with maintaining our clinical trial program and, depending upon the period of delay, require us to commence new trials at significant additional expense or terminate the trials completely. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all manufacturers of our products must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the generation and maintenance of records and documentation. Manufacturers of our products may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. We have little control over our manufacturers' compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of product approval. If the safety of any product is compromised due to our or our manufacturers' failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products, and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of our products, entail higher costs or result in our being unable to effectively commercialize our products. Furthermore, if our manufacturers fail to deliver the required commercial quantities on a timely basis, pursuant to provided specifications and at commercially reasonable prices, we may be unable to meet demand for our products and would lose potential revenues.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are dependent on single-source suppliers for some of the components and materials used in, and the processes required to develop, our products, development candidates and investigational medicines.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently depend on single-source suppliers for some of the components and materials used in, and manufacturing processes required to develop and commercialize, our products, development candidates and investigational medicines. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs, or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes, and finished goods exposes us to several risks, including disruptions in supply, price increases, or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials, and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have to switch to a replacement supplier, the manufacture and delivery of our products, development candidates or investigational medicines could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers for any of the components or processes used in our products or investigational medicines, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single-source components and materials used in our products, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to supply our investigational medicines.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our reliance on these suppliers, service providers, and manufacturers subjects us to a number of risks that could harm our reputation, business, and financial condition, including, among other things:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">delays to the development timelines for our development candidates or investigational medicines;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">interruption of supply resulting from modifications to or discontinuation of a supplier&#8217;s operations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#8217;s variation in a component;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">a lack of long-term supply arrangements for key components with our suppliers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">production delays related to the evaluation and testing of components from alternative suppliers, and corresponding regulatory qualifications;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">delay in delivery due to our suppliers&#8217; prioritizing other customer orders over ours;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">damage to our reputation caused by defective components produced by our suppliers; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:13.8pt">fluctuation in delivery by our suppliers due to changes in demand from us or their other customers.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any of these risks materialize, costs could significantly increase and our ability to meet demand for our products could be impacted.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval, they may still face future development and regulatory difficulties.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if United States regulatory approval is obtained, the FDA may still impose significant restrictions on a product's indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies. This governmental oversight may be particularly strict with respect to gene-based therapies. Our products will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, advertising, promotion, record keeping and submission of safety and other post-market information. For example, the FDA strictly regulates the promotional claims that may be made about medical products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may in certain circumstances share truthful and not misleading information that is otherwise consistent with the product&#8217;s FDA approved labeling. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, regulations. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturer or us, including requiring withdrawal of the product from the market or suspension of manufacturing. If we, our product candidates, or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue Warning Letters or untitled letters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose civil or criminal penalties; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend regulatory approvals; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve pending applications or supplements to applications filed by us; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose restrictions on operations, including costly new manufacturing requirements; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products or require us to initiate a product recall. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval in the United States, we may never receive approval or commercialize our products outside of the United States (and the same risk applies for products approved outside the United States, with respect to regulatory approval in the United States).</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any electroporation equipment and product candidates outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Likewise, the same is the case for any regulatory approvals procured outside the United States, with respect to the approval by the FDA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval, and the regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the United States as well as other risks. Furthermore, regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval could have the same adverse effects detailed above regarding FDA approval in the United States. Such effects include the risks that our product candidates may not be approved for all indications requested, which could limit the uses of our product candidates and have an adverse effect on their commercial potential or require costly, post-marketing follow-up studies. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we are developing some of our development candidates or investigational medicines for the treatment of diseases in which there is little clinical experience and, in some cases, using new endpoints or methodologies, the FDA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no pharmacologic therapies approved to treat the underlying causes of many diseases that we currently attempt to address or may address in the future. There has been limited clinical trial experience for the development of pharmaceuticals to treat these rare diseases in general, and we are not aware of a registrational trial that led to approval of a drug to treat these diseases. There have been some historical trials with other agents which may have utilized clinical endpoints that are less applicable to our efforts that address the underlying defect. As a result, the design and conduct of clinical trials of investigational medicines for the treatment of these disorders and other disorders may take longer, be more costly, or be less effective as part of the novelty of development in these diseases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we or our strategic collaborators may conduct for our programs. Further, even if we do achieve the pre-specified criteria, our trials may produce results that are unpredictable or inconsistent with the results of the more traditional efficacy endpoints in the trial. The FDA also could give overriding weight to other efficacy endpoints over a primary endpoint, even if we achieve statistically significant results on that endpoint, if we do not do so on our secondary efficacy endpoints. The FDA also weighs the benefits of a product against its risks and the FDA may view the efficacy results in the context of safety as not being supportive of licensure. Other regulatory authorities in Europe and other countries may make similar findings with respect to these endpoints.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have obtained Orphan Drug Designation for one of our product candidates. As part of our business strategy, we may continue to seek Orphan Drug Designation for additional product candidates, and we may be unsuccessful in obtaining new designations or may be unable to obtain or maintain the benefits associated with Orphan Drug Designation, including the potential for orphan drug exclusivity.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained Orphan Drug Designation from the FDA for INO-3107 for the treatment of recurrent respiratory papillomatosis. We have sought and may continue to seek Orphan Drug Designation for one or more of our other product candidates, although we may be unsuccessful in doing so. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as tax advantages and user fee waivers. Opportunities for grant funding toward clinical trial costs may also be available for clinical trials of drugs for rare diseases, regardless of whether the drugs are designated for the orphan use. In addition, if a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years, except in limited circumstances. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have obtained Orphan Drug Designation for INO-3107 for the treatment of recurrent respiratory papillomatosis, and even if we obtain Orphan Drug Designation for our other product candidates in specific indications, we may not be the first to obtain marketing approval of these product candidates for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. If a competitor with a product that is determined by the FDA to be the same as one of our product candidates obtains marketing approval before us for the same indication we are pursuing and obtains orphan drug exclusivity, our product candidate may not be approved until the period of exclusivity ends unless we are able to demonstrate that our product candidate is clinically superior. Even after obtaining approval, we may be limited in our ability to market our product. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different principal molecular structural features can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug with the same principal molecular structural features for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek Orphan Drug Designation for some of our product candidates, we may never receive such designations. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax reform legislation enacted in 2017 reduced the amount of the qualified clinical research costs for a designated orphan product that a sponsor may claim as a credit from 50% to 25%. This reduction could further limit the advantage of, and may impact our future business strategy with respect to, seeking the Orphan Drug Designation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">A breakthrough therapy designation or fast track designation by the FDA for a drug may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that the drug will receive marketing approval.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may seek a breakthrough therapy designation for one or more of our investigational medicines. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the regulatory submission.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designation as a breakthrough therapy is at the discretion of the FDA. Accordingly, even if we believe that one of our investigational medicines meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a drug may not result in a faster development process, review, or approval compared to drugs considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. Even if we are successful in obtaining accelerated approval in the United States or under comparable pathways in other jurisdictions, we may face requirements and limitations that will adversely affect our prospects. For example, we may be approved only for a very limited indication, we may not successfully complete required post-approval trials, such trials may not confirm the clinical benefit of our drug, or approval of the drug may be withdrawn. In addition, even if one or more of our investigational medicines qualify as breakthrough therapies, the FDA may later decide that the investigational medicine no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reliance on Third Parties</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into, and may continue to enter into, distribution, co-promotion, partnership, sponsored research and other arrangements for development, manufacturing, sales, marketing and other commercialization activities relating to our products. For example, in the past we have entered into license and collaboration agreements to develop, obtain regulatory approval for and commercialize our product candidates for specified indications, including in jurisdictions outside of the United States. The amount and timing of resources applied by our collaborators are largely outside of our control. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our current or future collaborators breaches or terminates our agreements, or fails to conduct our collaborative activities in a timely manner, our commercialization of products could be diminished or blocked completely. We may not receive any event-based payments, milestone payments or royalty payments under our collaborative agreements if our collaborative partners fail to develop products in a timely manner or at all. It is possible that collaborators will change their strategic focus, pursue alternative technologies or develop alternative products, either on their own or in collaboration with others. Further, we may be forced to fund programs that were previously funded by our collaborators, and we may not have, or be able to access, the necessary funding. The effectiveness of our partners, if any, in marketing our products will also affect our revenues and earnings.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We desire to enter into new collaborative agreements. However, we may not be able to successfully negotiate any additional collaborative arrangements and, if established, these relationships may not be scientifically or commercially successful. Our success in the future depends in part on our ability to strategically enter into agreements with other organizations. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can extend the time it takes to develop, negotiate, implement and execute a collaboration. Once news of discussions regarding possible collaborations are known in the medical community, regardless of whether the news is accurate, failure to announce a collaborative agreement or the entity's announcement of a collaboration with another entity may result in adverse speculation about us, resulting in harm to our reputation and our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes could also arise between us and our existing or future collaborators, as to a variety of matters, including financial and intellectual property matters or other obligations under our agreements. These disputes could be both expensive and time-consuming and may result in delays in the development and commercialization of our products or could damage our relationship with a collaborator. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have agreements with government agencies, which are subject to termination and uncertain future funding. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with government agencies, such as the NIAID, DARPA and the DoD, and we intend to continue entering into these types of agreements in the future. Our business is partially dependent on the continued performance by these government agencies of their responsibilities under these agreements, including adequate continued funding of the agencies and their programs. We have no control over the resources and funding that government agencies may devote to these agreements, which may be subject to annual renewal and which generally may be terminated by the government agencies at any time. For example, in April 2021 we were notified by the DoD that they discontinued funding for the Phase 3 segment of our INNOVATE trial, which resulted in increased expenditures by us.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government agencies may fail to perform their responsibilities under these agreements, which may cause them to be terminated by the government agencies. In addition, we may fail to perform our responsibilities under these agreements. Many of our government agreements are subject to audits, which may occur several years after the period to which the audit relates. If an audit identifies significant unallowable costs, we could incur a material charge to our earnings or reduction in our cash position. As a result, we may be unsuccessful entering, or ineligible to enter, into future government agreements. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we and our collaborators may not be able to obtain regulatory approval for or commercialize our product candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators have entered into agreements with CROs to provide monitors for and to manage data for our on-going clinical programs. We and the CROs conducting clinical trials for our electroporation equipment and product candidates are required to comply with current good clinical practices, or GCPs, regulations and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or the CROs conducting clinical trials of our product candidates fail to comply with applicable GCPs, the clinical data generated in the clinical trials may be deemed unreliable and the FDA may require additional clinical trials before approving any marketing applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any relationships with CROs terminate, we or our collaborators may not be able to enter into arrangements with alternative CROs. In addition, these third-party CROs are not our employees, and we cannot control whether or not they devote sufficient time and resources to our on-going clinical programs or perform trials efficiently. These CROs may also have </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could harm our competitive position. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. Cost overruns by or disputes with our CROs may significantly increase our expenses.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We enter into various contracts in the normal course of our business in which we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">agree to indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we periodically enter into academic, commercial, service, collaboration, licensing, consulting and other agreements that contain indemnification provisions. With respect to our academic and other research agreements, we typically agree to indemnify the institution and related parties from losses arising from claims relating to the products, processes or services made, used, sold or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our sub licensees&#8217; exercise of rights under the agreement. With respect to our commercial agreements, we have agreed to indemnify our vendors from any third-party product liability claims that could result from the production, use or consumption of the product, as well as for alleged infringements of any patent or other intellectual property right by a third party. With respect to consultants, we typically agree to indemnify them from claims arising from the good faith performance of their services.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should our obligation under an indemnification provision exceed applicable insurance coverage or if we were denied insurance coverage or not covered by insurance, our business, financial condition and results of operations could be adversely affected. Similarly, if we are relying on a collaborator or other third party to indemnify us and the collaborator or other third party is denied insurance coverage or otherwise does not have assets available to indemnify us, our business, financial condition and results of operations could be adversely affected.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have a small marketing organization and no sales organization. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have a small sales organization for the marketing, sales and distribution of our electroporation equipment and product candidates. In order to commercialize any products, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. We contemplate establishing our own sales force or seeking third-party partners to sell our products. The establishment and development of our own sales force to market any products we may develop will be expensive and time consuming and could delay any product launch, and we may not be able to successfully develop this capability. We will also have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. To the extent we rely on third parties to commercialize our approved products, if any, we will receive lower revenues than if we commercialized these products ourselves. In addition, we may have little or no control over the sales efforts of third parties involved in our commercialization efforts. In the event we are unable to develop our own marketing and sales force or collaborate with a third-party marketing and sales organization, we would not be able to commercialize our product candidates which would negatively impact our ability to generate product revenues. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If products for which we receive regulatory approval do not achieve broad market acceptance, the revenues that we generate from their sales will be limited.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our electroporation equipment and product candidates for which we obtain marketing approval from the FDA or other regulatory authorities will depend upon the acceptance of these products by both the medical community and patient population. Coverage and reimbursement of our product candidates by third-party payors, including government payors, generally is also necessary for optimal commercial success. The degree of market acceptance of any of our approved products will depend on a number of factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to provide acceptable evidence of safety and efficacy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the relative convenience and ease of administration, including the acceptance and usage of our electroporation equipment by the medical community; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any actual or perceived adverse side effects; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in a product's FDA-approved labeling, including, for example, potential &#8220;black box&#8221; warnings; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of alternative treatments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and cost effectiveness; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our or any future collaborators' sales and marketing strategies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the public perception of new therapies and the reputational challenges that the vaccine industry is facing related to the growing momentum of the anti-vaccine movement, including with respect to COVID-19 vaccines;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain sufficient third-party coverage and adequate reimbursement; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to pay out of pocket in the absence of third-party coverage. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our electroporation equipment and product candidates are approved but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to uncertainty relating to coverage and reimbursement policies which, if not favorable to our product candidates, could hinder or prevent our products' commercial success. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs and medical treatments. Accordingly, our ability to commercialize our electroporation equipment and product candidates successfully will depend in part on the extent to which governmental authorities, including Medicare and Medicaid, private health insurers and other third-party payors establish appropriate coverage and reimbursement levels for our product candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors in the United States generally require that drug products and vaccines have been approved for marketing by the FDA. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are already available. Even if we obtain coverage for a given product, the associated reimbursement rate may not be adequate to cover our costs, including research, development, intellectual property, manufacture, sale and distribution expenses, or may require co-payments that patients find unacceptably high. Patients are unlikely to use our products unless reimbursement is adequate to cover all or a significant portion of the cost of our drug products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some of our products, if approved, will be provided under the supervision of a physician. When used in connection with medical procedures, our product candidates may not be reimbursed separately but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our product candidates or procedures using our product candidates, could reduce physician utilization of our products once approved.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement policies for products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs. We may not be able to obtain third-party payor coverage or reimbursement for our products in whole or in part.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Managing Our Growth and Employee and Operational Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have actions brought against us by stockholders relating to past transactions, changes in our stock price or other matters. For example, numerous purported shareholder class action complaints have been filed against us, naming us and our directors and executive officers as defendants, and alleging that we made materially false and misleading statements regarding the development of INO-4800 in violation of certain federal securities laws. We may also become party to litigation with third parties as a result of our business activities. In 2020, we filed a lawsuit against one of our contract manufacturers, who then filed a counterclaim against us alleging that we had breached our contract with them, among other claims. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These litigation </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">matters, described in this report, are ongoing, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">even though we intend to vigorously defend ourselves in these actions, there can be no assurance that we will ultimately prevail. These and any potential future actions against us could give rise to substantial damages, which could have a material adverse effect on our financial position, liquidity or results of operations. Even if an action is not resolved against us, the uncertainty and expense associated with litigation could harm our business, financial condition and reputation, as litigation is often costly, time-consuming and disruptive to business operations. The defense of our existing and potential future lawsuits could also result in diversion of our management's time and attention away from business operations, which could harm our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have experienced recent changes to our leadership team, which creates uncertainty and could harm our business.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recently experienced changes to our leadership team. Our President and Chief Executive Officer, Dr. Joseph Kim, who served in those roles since 2009, announced his resignation effective upon the filing of this report. Our Board of Directors has appointed Dr. Jacqueline Shea, previously our Chief Operating Officer, as our new Chief Executive Officer following the filing of this report.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although Dr. Shea has served with our company since 2019, the management transition could create uncertainty and potentially disrupt our operations and relationships with employees, suppliers and partners and result in operational inefficiencies, decreased employee morale and productivity and increased turnover.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any departure at a senior level could be particularly disruptive given that we are already experiencing leadership transitions and, to the extent we experience additional turnover, competition for top management is high such that it may take some time to find a candidate that meets our requirements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our competitors may seek to use this management transition and the related potential disruptions to gain a competitive advantage over us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully navigate the transition of our chief executive officer, our business could suffer.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend upon key personnel who may terminate their employment with us at any time and we may need to hire additional qualified personnel in order to obtain financing, pursue collaborations or develop or market our product candidates. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business strategy will depend to a significant degree upon the continued services of key management, technical and scientific personnel and our ability to attract and retain additional qualified personnel and managers, including personnel with expertise in clinical trials, government regulation, manufacturing, marketing and other areas. Competition for qualified personnel is intense among companies, academic institutions and other organizations. If we are unable to attract and retain key personnel and advisors, it may negatively affect our ability to successfully develop, test, commercialize and market our products and product candidates. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the global COVID-19 pandemic.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, in 2020 a number of governmental orders and other public health guidance measures were implemented across much of the United States, including in the locations of our offices, laboratories, clinical trial sites and third parties on whom we rely. As a result, our expected clinical development timelines were negatively impacted. During the pandemic, we implemented and have continued a work from home policy allowing employees who can work from home to do so, while those needing to work in laboratory facilities work in shifts to reduce the number of people gathered together at one time. Starting in April 2022, employees have begun to return to the office on a modified schedule. We have also implemented a mask-wearing mandate for all on-site activities. We have taken measures to secure our research and development project activities, while work in laboratories has been organized to reduce risk of COVID-19 transmission. Our increased reliance on personnel working from home may negatively impact our productivity, or could disrupt, delay or otherwise adversely impact our business. For example, with our personnel working from home, some of our research activities that require our personnel to be in our laboratories could be delayed.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as local jurisdictions continue to put restrictions in place or reinstitute restrictions they had previously lifted, our ability to continue to conduct and enroll patients in our clinical trials, manufacture our product candidates and pursue collaborations may also be limited. Such events may result in business and manufacturing disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations. The COVID-19 pandemic has also caused supply chain disruptions and supply shortages globally. As a result, we have experienced delays and disruptions in obtaining clinical supplies, manufacturing supplies and components, and have had to secure new vendors for certain supplies and components at higher prices. Some manufacturing supplies and components remain in limited supply with uncertain delivery dates.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19, which has caused a broad impact globally, could also affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, it has resulted in significant disruption of global financial markets, which could reduce our ability to access capital. Although we have raised significant funds from the sale of our common stock in the public markets during the pandemic, there can be no guarantee that we will be able to continue to so, which could negatively affect our future liquidity.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continued spread of COVID-19, including newly emerging SARs-CoV-2 variants globally, has affected and could continue to adversely affect our clinical trial operations, including our ability to initiate and conduct our planned trials on their </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expected timelines and to recruit and retain participants and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. Trial participants may not be able to or may not feel safe going into healthcare facilities, which is necessary for the collection and completion of data samples for our clinical trials. With respect to our VGX-3100 program, it has taken longer than anticipated to complete the data collection process, and we may continue to face delays in this and other trials. Further, the COVID-19 outbreak could also result in delays in our clinical trials due to prioritization of hospital resources toward the outbreak, restrictions in travel, potential unwillingness of participants to enroll in trials, participants withdrawing from trials following enrollment as a result of contracting COVID-19 or other health conditions, or the inability of participants to comply with clinical trial protocols as quarantines and travel restrictions impede participant movement or interrupt healthcare services. In addition, we rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the outbreak may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, COVID-19 may also result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with local and foreign regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furloughs of government employees, and refusals to accept data from clinical trials conducted in these affected geographies.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 may impact our business, operations and clinical trials will depend on future developments, including travel restrictions to, from and within the United States and other countries, the effectiveness of actions taken in the United States and other countries to contain and treat the disease, including mass vaccination efforts, and whether the United States and additional countries are required to move to complete lock-down status. The ultimate long-term impact of COVID-19 on our business is highly uncertain.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense and increasing competition and steps taken by our competitors such as the introduction of a new, disruptive technology may impede our ability to successfully commercialize our DNA medicines. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our competitors develop products with efficacy or safety profiles significantly better than our products and introduce new, disruptive technology, we may not be able to commercialize our products, and sales of any of our commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or products obsolete or noncompetitive, or result in treatments or cures superior to ours.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Many other companies are pursuing other forms of treatment or prevention for diseases that we target. For example, many of our competitors are working on developing and testing COVID-19 vaccines, cancer vaccines and immunotherapies, and several products such as the CAR-Ts developed by our competitors have been approved for human use. Some of our competitors have already received regulatory approval for their COVID-19 vaccines and have mass vaccination efforts underway in our target markets. For example, multiple COVID-19 vaccines and boosters have been approved by regulators in the United States and Europe and in August 2021 the world's first DNA vaccine against COVID-19 was approved for emergency use by India's regulators. In addition to widely distributed vaccines designed to stop the spread of COVID-19, several antiviral therapies are currently approved by the FDA for the treatment of COVID-19, and several antibody treatments have received EUA from the FDA. The earlier market entry of these other vaccines and drugs, and their actual or perceived efficacious or success relative to our own, has led to and may continue to lead to diversion of funding away from us, a declining market for COVID-19 vaccines, decreased demand for INO-4800, and difficulty in finding participants for our clinical trials. All of these factors could substantially impact our ability to complete the development of, commercialize and generate revenues from our COVID-19 vaccine candidate. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our competitors and potential competitors include large pharmaceutical and more established biotechnology companies. These companies have significantly greater financial and other resources and greater expertise than us in research and development, securing government contracts and grants to support research and development efforts, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing. This may make it easier for them to respond more quickly than us to new or changing opportunities, technologies or market needs. Many of these competitors operate large, well-funded research and development programs and have significant products approved or in development. Small companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical companies or through acquisition or development of intellectual property rights. Our potential competitors also include academic institutions, governmental agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for product and clinical development and marketing. Research and development by others may seek to render our technologies or products obsolete or noncompetitive.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to successfully acquire, develop and market additional product candidates or approved products would impair our ability to grow.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire, in-license, develop and/or market additional products and product candidates. The success of these actions depends partly upon our ability to identify, select and acquire promising product candidates and products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, future acquisitions may entail numerous operational and financial risks, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposure to unknown liabilities; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption of our business and diversion of our management's time and attention to develop acquired products or technologies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher than expected acquisition and integration costs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased amortization expenses; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to retain key employees of any acquired businesses. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, any product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical of product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the FDA and other government agencies could prevent new products from being developed or commercialized in a timely manner, which could negatively impact our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days from December 2018 to January 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on information technology and our systems and infrastructure face certain risks, including from cybersecurity breaches and data leakage.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely to a large extent upon sophisticated information technology systems to operate our businesses, some of which are managed, hosted provided and/or used for third-parties or their vendors. We collect, store and transmit large amounts of confidential information (including personal information and pseudonymized information), and we deploy and operate an array of technical and procedural controls to maintain the confidentiality and integrity of such confidential information. A significant breakdown, invasion, corruption, destruction, interruption, or unavailability of critical information technology systems or infrastructure, by our workforce, others with authorized access to our systems or unauthorized persons could negatively impact operations. Hardware, software, or applications we develop or obtain from third parties may contain defects in design or manufacture or other supply chain problems that could unexpectedly compromise our information and network security. The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our or our third-party providers' systems, portable media or storage devices. We could also experience a business interruption, theft of confidential information or reputational damage from industrial espionage attacks, malware or other cyber-attacks (including ransomware), which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers. While we have invested in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches. Any such interruption or breach of our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us. In addition, as the regulatory environment related to information security, data collection and use, and privacy becomes increasingly rigorous, with new and constantly changing requirements applicable to our business, compliance with those requirements could also result in additional costs.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure and, if successful claims are brought against us, we may incur substantial liability.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of our electroporation equipment and DNA vaccine, DNA immunotherapy and dMAb candidates in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism, and these companies have incurred material costs to defend these claims. If we cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our product candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our business reputation; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of related litigation; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distraction of management's attention from our primary business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenues; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to commercialize our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained product liability insurance coverage for our clinical trials, but our insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform measures could hinder or prevent our products' commercial success. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both the United States and certain foreign jurisdictions there have been, and we anticipate there will continue to be, a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell any of our products profitably. In the United States, the federal government enacted healthcare reform legislation, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA. Among the ACA&#8217;s provisions of importance to the pharmaceutical industry are that it:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposed an annual excise tax of 2.3% on any entity that manufactures or imports medical devices offered for sale in the United States, with limited exceptions, although the effective rate paid may be lower. However, the 2020 federal spending package permanently eliminated, effective January 1, 2020, this ACA-mandated medical device tax;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded the entities eligible for discounts under the Public Health program;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">established a Center for Medicare &amp; Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; and</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">created a licensure framework for follow on biologic products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been executive, judicial, and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties for not complying with the ACA&#8217;s individual mandate to carry qualifying health insurance coverage for all or part of a year. In addition, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage was eliminated, along with the health insurer tax. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges, and the healthcare reform measures of the Biden administration will impact the ACA and our business. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. Further, Congress is considering additional health reform measures as part of the budget reconciliation process.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. The Budget Control Act of 2011 included reductions to Medicare payments to providers of 2% per fiscal year, which, due to subsequent legislative amendments to the statute will remain in effect through 2030. The American Taxpayer Relief Act of 2012 reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has also been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. In 2020, the FDA released a final rule and guidance providing pathways for states to build and submit importation plans for drugs from Canada, and the Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January 1, 2023. In 2020, CMS issued an interim final rule implementing the Trump administration&#8217;s Most Favored Nation (MFN) executive order, which would have tied Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries. As a result of litigation challenging the MFN model, on December 27, 2021, CMS published a final rule that rescinded the MFN model interim final rule. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. Further, at the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. It is also possible that additional governmental action is taken in response to the COVID-19 pandemic. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to make and implement healthcare reforms may adversely affect: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price we believe is fair for our products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenues and achieve or maintain profitability; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain timely approval of our products. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with applicable healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to our business. The laws that may affect our ability to operate include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare program such as Medicare or Medicaid. The intent standard under the federal healthcare program Anti-Kickback Statute was amended by the ACA to a stricter standard such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, the ACA codified case law that a claim including items or services resulting from a violation of the federal healthcare program Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal healthcare program Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and related regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Physician Payments Sunshine Act, created under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with certain exceptions, to report annually to CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDCA, which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shifting regulatory environment, along with the requirement to comply with multiple jurisdictions with different compliance and/or reporting requirements, increases the possibility that a company may run afoul of one or more laws.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm, and the curtailment or restructuring of our operations. Any such penalties could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials and we and our third-party manufacturers must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and our third-party manufacturers' activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In the event of an accident, state or federal authorities may curtail the use of these materials and interrupt our business operations. If we are subject to any liability as a result of our or our third-party manufacturers' activities involving hazardous materials, our business and financial condition may be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have entered into collaborations with Chinese companies and conduct certain research and development activities in China. Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war, political unrest or unstable economic conditions in China could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct research and development activities in China through our collaboration with Advaccine, which is conducting and funding a clinical trial of INO-4800 in China. In addition, we are party to a license and collaboration agreement with China-based company ApolloBio, pursuant to which ApolloBio has the exclusive right to develop and commercialize VGX-3100 in China, Hong Kong, Macao and Taiwan. The Chinese legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions may be cited for reference but have limited precedential value. In addition, the Chinese legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or at all, and which may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules until after the occurrence of the violation. Any administrative and court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management attention. Because Chinese administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems. Furthermore, we are exposed to the possibility of disruption of our research and development activities in the event of changes in the policies of the United States or Chinese governments, political unrest or unstable economic conditions in China. For example, a trade war could lead to increased costs for clinical materials that are manufactured in China. These interruptions or failures could also impede commercialization of our product candidates and impair our competitive position. Further, we may be exposed to fluctuations in the value of the local currency in China. These uncertainties may impede our ability to enforce the contracts we have entered into and our ability to continue our research and development activities and could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, principal investigators, and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, and consultants. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the EU and other jurisdictions; provide accurate information to the FDA, the EMA, and other regulatory authorities; comply with healthcare fraud and abuse laws and regulations in the United States and abroad; or report financial information or data accurately or disclose unauthorized activities to us. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. Sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations, and prospects, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee litigation and unfavorable publicity could negatively affect our future business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees may, from time to time, bring lawsuits against us regarding injury, creating a hostile work place, discrimination, wage and hour disputes, sexual harassment, or other employment issues. In recent years there has been an increase in the number of discrimination and harassment claims generally. Coupled with the expansion of social media platforms and similar devices that allow individuals access to a broad audience, these claims have had a significant negative impact on some businesses. Certain companies that have faced employment- or harassment-related lawsuits have had to terminate management or other key personnel, and have suffered reputational harm that has negatively impacted their business. If we were to face any employment-related claims, our business could be negatively affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in part on obtaining and maintaining patent, trademark, trade secret, and other intellectual property protection relating to our electroporation equipment and product candidates, as well as successfully defending these intellectual property rights against third-party challenges. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. The laws and regulations regarding the breadth of claims allowed in biotechnology patents have evolved over recent years and continues to undergo review and revision, both in the United States and abroad. The biotechnology patent situation outside the United States can be even more uncertain depending on the country. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our licensed patents, our patents or in third-party patents, nor can we predict the likelihood of our patents surviving a patent validity challenge. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our intellectual property rights is uncertain, because legal decision-making can be unpredictable, thereby often times resulting in limited protection, which may not adequately protect our rights or permit us to gain or keep our competitive advantage, or resulting in an invalid or unenforceable patent. For example: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or the parties from whom we have acquired or licensed patent rights, may not have been the first to file the underlying patent applications or the first to make the inventions covered by such patents; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the named inventors or co-inventors of patents or patent applications that we have licensed or acquired may be incorrect, which may give rise to inventorship and ownership challenges; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may develop similar or alternative technologies, or duplicate any of our products or technologies that may not be covered by our patents, including design-arounds; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pending patent applications may not result in issued patents; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents covering our products and technologies may not provide us with any competitive advantages or have any commercial value; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be challenged and invalidated, or rendered unenforceable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">given the nature of the COVID-19 pandemic, governments in the United States or abroad may prevent us from enforcing patents on our vaccines, which could prevent us from excluding competitors from those markets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be subject to reexamination, which could result in a narrowing of the scope of claims or cancellation of claims found unpatentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop or acquire additional proprietary technologies that are patentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our trademarks may be invalid or subject to a third party's prior use; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enforce our patent rights will depend on our ability to detect infringement, and litigation to enforce patent rights may not be pursued due to significant financial costs, diversion of resources, and unpredictability of a favorable result or ruling. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend, in part, on our licensors and collaborators to protect a portion of our intellectual property rights. In such cases, our licensors and collaborators may be primarily or wholly responsible for the maintenance of patents and prosecution of patent applications relating to important areas of our business. If any of these parties fail to adequately protect these products with issued patents, our business and prospects would be harmed significantly. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our trade secrets to competitors. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our licensors fail to obtain or maintain patent protection or trade secret protection for our product candidates or our technologies, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and attain profitability. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, U.S. and other policymakers have proposed reforming the patent laws and regulations of their countries. In September 2011 the America Invents Act (the Act) was signed into law. The Act changed the current &#8220;first-to-invent&#8221; system to a system that awards a patent to the &#8220;first-inventor-to-file&#8221; for an application for a patentable invention. The </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Act also created a procedure to challenge newly issued patents in the patent office via post-grant proceedings and new inter parties reexamination proceedings. These changes may make it easier for competitors to challenge our patents, which could result in increased competition and have a material adverse effect on our product sales, business and results of operations. The changes may also make it harder to challenge third-party patents and place greater importance on being the first inventor to file a patent application on an invention. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other companies may have or may acquire intellectual property rights that could be enforced against us. If they do so, we may be required to alter our technologies, pay licensing fees or cease activities. If our products or technologies infringe the intellectual property rights of others, they could bring legal action against us or our licensors or collaborators claiming damages and seeking to enjoin any activities that they believe infringe their intellectual property rights. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications can take many years to issue, and there is a period when the application remains undisclosed to the public, there may be currently pending applications unknown to us or reissue applications that may later result in issued patents upon which our products or technologies may infringe. There could also be existing patents of which we are unaware that our products or technologies may infringe. In addition, if third parties file patent applications or obtain patents claiming products or technologies also claimed by us in pending applications or issued patents, we may have to participate in interference or derivation proceedings in the United States Patent and Trademark Office to determine priority or derivation of the invention. If third parties file oppositions in foreign countries, we may also have to participate in opposition proceedings in foreign tribunals to defend the patentability of our filed foreign patent applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a third party claims that we infringe its intellectual property rights, it could cause our business to suffer in a number of ways, including: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become involved in time-consuming and expensive litigation, even if the claim is without merit, the third party's patent is invalid or we have not infringed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become liable for substantial damages for past infringement if a court decides that our technologies infringe upon a third party's patent; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be enjoined by a court to stop making, selling or licensing our products or technologies without a license from a patent holder, which may not be available on commercially acceptable terms, if at all, or which may require us to pay substantial royalties or grant cross-licenses to our patents; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to redesign our products so that they do not infringe upon others' patent rights, which may not be possible or could require substantial investment or time. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, our business could suffer and the market price of our common stock may decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not yet registered our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to an Investment in Our Common Stock</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may not be sustained.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our common stock is listed on the Nasdaq Global Select Market, we cannot assure you that an active trading market for our shares will continue to be sustained. If an active market for our common stock is not sustained, it may be difficult for investors in our common stock to sell shares without depressing the market price for the shares or to sell the shares at all.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has been and may continue to be volatile, and an investment in our common stock could decline substantially in value. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of our small size and limited resources, as well as the uncertainties and risks that can affect our business and industry, our stock price has been and may continue to be highly volatile and has been and may in the future be subject to substantial drops, with or even in the absence of news affecting our business. Period to period comparisons are not indicative of future performance. The following factors, which are not exhaustive, in addition to the other risk factors described in this </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">report, and the potentially low volume of trades in our common stock, may have a significant impact on the market price of our common stock, some of which are beyond our control: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning any research and development, clinical trials, manufacturing, and marketing efforts or collaborations, particularly developments concerning the prospects of our COVID-19 vaccine candidate;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuating public or scientific interest in the potential for our vaccines or other product candidates to address COVID-19 or other diseases; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our announcement of significant acquisitions, strategic collaborations, joint ventures or capital commitments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our operating results; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new products or services that we or our competitors offer; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, conduct and/or outcome of intellectual property and/or litigation matters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial or other estimates by securities analysts or other reviewers or evaluators of our business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditions or trends in bio-pharmaceutical or other healthcare industries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States and other countries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceptions of gene-based therapy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the economic performance and/or market valuations of other biotechnology and medical device companies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions involving our common stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our capital structure;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions by executive officers or directors involving our common stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting principles; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">global unrest including geopolitical risks emanating from countries such as Russia and China, terrorist activities, and economic and other external factors; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">catastrophic weather and/or global disease pandemics, including COVID-19. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock market in general has recently experienced relatively large price and volume fluctuations, particularly in response to the COVID-19 pandemic. In particular, the market prices of securities of smaller biotechnology and medical device companies have experienced dramatic fluctuations that often have been unrelated or disproportionate to the operating results of these companies. Continued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. In addition, price volatility may increase if the trading volume of our common stock remains limited or declines.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have broad discretion in the use of our cash, cash equivalents, and investments, and may not use them effectively.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our management has broad discretion in the application of our cash, cash equivalents, and investments, and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. Furthermore, our operating expenses have significantly increased due to development and manufacturing activities for our COVID-19 vaccine program, and we may not deploy our expanded capital base effectively. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse impact on our business, cause the price of our common stock to decline, and delay the development of our investigational medicines. Pending their use, we may invest our cash, cash equivalents, and investments in a manner that does not produce income or that loses value.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation contains provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authority of our board of directors to issue shares of undesignated preferred stock and to determine the rights, preferences and privileges of these shares, without stockholder approval; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all stockholder actions must be effected at a duly called meeting of stockholders and not by written consent; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the elimination of cumulative voting. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors, including to delay or impede a merger, tender offer or proxy contest involving our company. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid cash dividends on our common stock and we do not anticipate paying dividends in the foreseeable future. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid no cash dividends on our common stock to date, and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any future debt or credit facility may preclude or limit our ability to pay any dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of potential gain for the foreseeable future. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Sections 382 and 383 of the revised Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage point change (by value) in the ownership of its equity by certain significant shareholders over a rolling three year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income and taxes may be limited. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our share ownership, some of which would be outside our control. If our ability to use our net operating losses and other tax attributes is limited by ownership changes, we may be unable to utilize a material portion of our net operating losses and other tax attributes to offset our future taxable income. In addition, there is also a risk that due to changes in laws and regulations, including changes proposed or implemented by the current U.S. presidential administration, such as alternative minimum taxes or suspensions on the use of net operating losses, or other unforeseen reasons, our existing net operating losses could expire or otherwise become unavailable to offset future income tax liabilities.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expenses related to our electroporation equipment, product candidates or future development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses related to corporate transactions, including ones not fully completed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addition or termination of clinical trials or funding support; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement lawsuit in which we may become involved; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any legal claims that may be asserted against us or any of our officers; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our electroporation equipment and product candidates or those of our competitors; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt service obligations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the fair value of our investments, including investments in affiliated entities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if any of our products receives regulatory approval, the levels of underlying demand for our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and liquidity needs could be materially affected by market fluctuations and general economic conditions. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be materially affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, energy costs, geopolitical issues, global pathogen outbreaks or pandemics, including COVID-19, and the availability and cost of credit have in the past and may continue to contribute to increased volatility and diminished expectations for the economy and the markets going forward. Market upheavals may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected. Our future cost of equity or debt capital and access to the capital markets could be adversely affected, and our stock price could decline. There may be disruption or delay in the performance of our third-party contractors and suppliers. If our contractors, suppliers and partners are unable to satisfy their contractual commitments, our business could suffer. In addition, we maintain significant amounts of cash </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and cash equivalents at one or more financial institutions that are in excess of federally insured limits, and we may experience losses on these deposits. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business, and we have limited research coverage by equity research analysts. Equity research analysts may elect not to initiate or continue to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. Even if we have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The issuance of additional stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation authorizes us to issue up to 600,000,000 shares of common stock and up to 10,000,000 shares of preferred stock with such rights and preferences as may be determined by our board of directors. Subject to compliance with applicable rules and regulations, we may issue our shares of common stock or securities convertible into our common stock from time to time in connection with a financing, acquisition, investment, our stock incentive plans or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs and demands upon management as a result of being a public company.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company listed in the United States, we incur significant legal, accounting and other costs that could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and stock exchanges, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management's time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws could adversely affect our business and financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax regimes to which we are subject or under which we operate are unsettled and may be subject to significant change. In December 2017, tax legislation commonly known as the Tax Cuts and Jobs Act was enacted, which significantly revised the Internal Revenue Code of 1986, as amended, or the Code. The Tax Cuts and Jobs Act, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35 percent to a flat rate of 21 percent, limitation of the tax deduction for interest expense to 30 percent of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80 percent of current-year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions). Notwithstanding the reduction in the corporate income tax rate, the overall impact of the federal tax law is uncertain and our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent various states will conform to the federal tax law. The issuance of additional regulatory or accounting guidance related to the Tax Act, or changes proposed or implemented by the current U.S. presidential administration or otherwise, could materially affect our tax obligations and effective tax rate.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate about our research, development candidates, investigational medicines, and the diseases our development candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, participants may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our development candidates and investigational medicines. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business.</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span><br/></span></div><div id="i5cd930e6c7ce444abb7f72171f50164c_148"></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Exhibits</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">Certificate of Incorporation with all amendments (incorporated by reference to Exhibit 3.1 of the registrant&#8217;s Form S-3 registration statement, filed on July 23, 2014).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">Amended and Restated Bylaws of Inovio Pharmaceuticals, Inc. dated August 10, 2011 (incorporated by reference to Exhibit 3.2 to the registrant&#8217;s Form 8-K current report filed on August 12, 2011).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-33122x10qex311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-33122x10qex311.htm">Certification of Chief Executive Officer Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-3312210qex312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-3312210qex312.htm">Certification of Chief Financial Officer Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-33122x10qex321.htm">32.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> *</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-33122x10qex321.htm">Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C.&#160;Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).*</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.906%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This exhibit shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any filings. </span></div><div style="margin-top:7.5pt;padding-left:11.25pt;text-indent:-11.25pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i5cd930e6c7ce444abb7f72171f50164c_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.927%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inovio Pharmaceuticals, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;J. JOSEPH KIM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">J. Joseph Kim</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director                                                                                         (On Behalf of the Registrant)</span></div></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;PETER KIES&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peter Kies </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer (Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ino-33122x10qex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i600ce2dae7984611865ed10c8d796ac0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CEO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, J. Joseph Kim, certify that&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Inovio Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-bottom:5pt;margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;J. J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OSEPH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">J. Joseph Kim</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director                       (Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ino-3312210qex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2599f9059b9d4c6db4943f7f2d8ccbf7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CFO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Peter Kies, certify that&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form&#160;10-Q of Inovio Pharmaceuticals, Inc.&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div style="margin-top:4.5pt;padding-left:24.75pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:4.5pt;padding-left:47.25pt;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></div><div style="margin-top:9pt;padding-left:72pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.193%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer                                                                    (Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ino-33122x10qex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9e7240cb02e34ac9b912d73afc12a56b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. Section&#160;1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report of Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form&#160;10-Q for the quarter ending March&#160;31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to his knowledge&#58; </font></div><div style="margin-top:4.5pt;padding-left:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-top:4.5pt;padding-left:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;J. J</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">OSEPH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">J. Joseph Kim</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Executive Officer)</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 10, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The foregoing certification is being furnished solely pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and is not filed with the Securities and Exchange Commission as part of the Form&#160;10-Q or as a separate disclosure document and is not incorporated by reference into any filing of Inovio Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>ino-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:500251c5-f1ff-4b5f-bcb3-245f4230a461,g:c147bae2-ade6-4d52-bd96-82e99e7a58d2-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://www.inovio.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.inovio.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.inovio.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsUnaudited" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLossUnaudited" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityUnaudited" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandOperations" roleURI="http://www.inovio.com/role/OrganizationandOperations">
        <link:definition>2101101 - Disclosure - Organization and Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationLiquidityandRisksandUncertainties" roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties">
        <link:definition>2102102 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies">
        <link:definition>2203201 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationLiquidityandRisksandUncertaintiesDetails" roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails">
        <link:definition>2404401 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CriticalAccountingPolicies" roleURI="http://www.inovio.com/role/CriticalAccountingPolicies">
        <link:definition>2105103 - Disclosure - Critical Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpactofRecentlyIssuedAccountingStandards" roleURI="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards">
        <link:definition>2106104 - Disclosure - Impact of Recently Issued Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ImpactofRecentlyIssuedAccountingStandardsDetails" roleURI="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandardsDetails">
        <link:definition>2407402 - Disclosure - Impact of Recently Issued Accounting Standards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.inovio.com/role/RevenueRecognition">
        <link:definition>2108105 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDetails" roleURI="http://www.inovio.com/role/RevenueRecognitionDetails">
        <link:definition>2409403 - Disclosure - Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurements" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements">
        <link:definition>2110106 - Disclosure - Short-term Investments and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsTables" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables">
        <link:definition>2311301 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails">
        <link:definition>2412404 - Disclosure - Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails">
        <link:definition>2413405 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>2414406 - Disclosure - Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets">
        <link:definition>2115107 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>2316302 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails">
        <link:definition>2417407 - Disclosure - Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>2418408 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebt" roleURI="http://www.inovio.com/role/ConvertibleDebt">
        <link:definition>2119108 - Disclosure - Convertible Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtTables" roleURI="http://www.inovio.com/role/ConvertibleDebtTables">
        <link:definition>2320303 - Disclosure - Convertible Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtNarrativeDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails">
        <link:definition>2421409 - Disclosure - Convertible Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails">
        <link:definition>2422410 - Disclosure - Convertible Debt - Balance of Convertible Bonds and Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtScheduleofMaturitiesDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails">
        <link:definition>2423411 - Disclosure - Convertible Debt - Schedule of Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.inovio.com/role/StockholdersEquity">
        <link:definition>2124109 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.inovio.com/role/StockholdersEquityTables">
        <link:definition>2325304 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails">
        <link:definition>2426412 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2427413 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.inovio.com/role/NetLossPerShare">
        <link:definition>2128110 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.inovio.com/role/NetLossPerShareTables">
        <link:definition>2329305 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" roleURI="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails">
        <link:definition>2430414 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.inovio.com/role/StockBasedCompensation">
        <link:definition>2131111 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.inovio.com/role/StockBasedCompensationTables">
        <link:definition>2332306 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationDetails" roleURI="http://www.inovio.com/role/StockBasedCompensationDetails">
        <link:definition>2433415 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.inovio.com/role/RelatedPartyTransactions">
        <link:definition>2134112 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2435416 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.inovio.com/role/CommitmentsandContingencies">
        <link:definition>2136113 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesTables">
        <link:definition>2337307 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2438417 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails">
        <link:definition>2439418 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.inovio.com/role/CollaborativeAgreements">
        <link:definition>2140114 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreementsDetails" roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails">
        <link:definition>2441419 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.inovio.com/role/IncomeTaxes">
        <link:definition>2142115 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsInc" roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc">
        <link:definition>2143116 - Disclosure - Geneos Therapeutics, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncTables" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables">
        <link:definition>2344308 - Disclosure - Geneos Therapeutics, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncNarrativeDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails">
        <link:definition>2445420 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncPreferredstockInvestmentDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails">
        <link:definition>2446421 - Disclosure - Geneos Therapeutics, Inc. - Preferred stock Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.inovio.com/role/SubsequentEvents">
        <link:definition>2147117 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.inovio.com/role/SubsequentEventsDetails">
        <link:definition>2448422 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ino_GeneosTherapeuticsInc.Member" abstract="true" name="GeneosTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_NonEmployeeMember" abstract="true" name="NonEmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_SalesAgreementMember" abstract="true" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_RelatedPartyTransactionsTextualAbstract" abstract="true" name="RelatedPartyTransactionsTextualAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_GoodwillAndIntangibleAssetsNet" abstract="false" name="GoodwillAndIntangibleAssetsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseinDeferredGrantFundingCurrent" abstract="false" name="IncreaseDecreaseinDeferredGrantFundingCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SanDiegoOfficeMember" abstract="true" name="SanDiegoOfficeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementExpensesToReimburse" abstract="false" name="CollaborativeAgreementExpensesToReimburse" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LassaFeverAndMERSVaccineMember" abstract="true" name="LassaFeverAndMERSVaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_SeriesA2OnePreferredStockMember" abstract="true" name="SeriesA2OnePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateNumberofSharesIssued" abstract="false" name="StockSaleAgreementAggregateNumberofSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_OtherCounterpartyMember" abstract="true" name="OtherCounterpartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_GrantProceedsReceived" abstract="false" name="GrantProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ApolloBioMember" abstract="true" name="ApolloBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_DebtSecuritiesAvailableforSaleContractualMaturity" abstract="false" name="DebtSecuritiesAvailableforSaleContractualMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CollaborationAgreementPaymentEarned" abstract="false" name="CollaborationAgreementPaymentEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_UnderwrittenPublicOfferingMember" abstract="true" name="UnderwrittenPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingToBeReceived" abstract="false" name="CollaborativeAgreementFundingToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" abstract="false" name="SaleOfStockSalesProceedsOfAnyCommonStockPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ino_RisksAndUncertaintiesPolicyTextBlock" abstract="false" name="RisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ino_DeferredGrantFundingCurrent" abstract="false" name="DeferredGrantFundingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DebtInstrumentConvertibleDebtConvertedAmount" abstract="false" name="DebtInstrumentConvertibleDebtConvertedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSalesAgreementMaximumAuthorizedAmount" abstract="false" name="StockSalesAgreementMaximumAuthorizedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GainLossOnRemeasurementOfEquityMethodInvestment" abstract="false" name="GainLossOnRemeasurementOfEquityMethodInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PlumblineLifeSciencesMember" abstract="true" name="PlumblineLifeSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementsUpfrontPaymentReceived" abstract="false" name="CollaborativeAgreementsUpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" abstract="false" name="StockSaleAgreementAggregateProceedsFromIssuanceOfStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInAccruedClinicalTrialExpense" abstract="false" name="IncreaseDecreaseInAccruedClinicalTrialExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_A2007IncentivePlanMember" abstract="true" name="A2007IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_EmployeesAndDirectorsMember" abstract="true" name="EmployeesAndDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_BiojectMember" abstract="true" name="BiojectMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" abstract="false" name="IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_INO4800Member" abstract="true" name="INO4800Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" abstract="false" name="CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedAmount" abstract="false" name="CollaborativeAgreementAwardedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliate" abstract="false" name="DeferredGrantFundingFromAffiliate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GoodwillAndIntangibleAssetsGross" abstract="false" name="GoodwillAndIntangibleAssetsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedExercisedAmount" abstract="false" name="CollaborativeAgreementAwardedExercisedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SeriesAOnePreferredStockMember" abstract="true" name="SeriesAOnePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CoalitionforEpidemicPreparednessInnovationsMember" abstract="true" name="CoalitionforEpidemicPreparednessInnovationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAmendedAmount" abstract="false" name="CollaborativeAgreementAmendedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborationAgreementAdditionalRevenueToBeAchieved" abstract="false" name="CollaborationAgreementAdditionalRevenueToBeAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AdvaccineMember" abstract="true" name="AdvaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_A6.50ConvertibleSeniorNotesDue2024Member" abstract="true" name="A6.50ConvertibleSeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedOptionAmount" abstract="false" name="CollaborativeAgreementAwardedOptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PlymouthMeetingPennsylvaniaMember" abstract="true" name="PlymouthMeetingPennsylvaniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseAreaofLandUnderLease" abstract="false" name="LesseeOperatingLeaseAreaofLandUnderLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="ino_NonCashInterestIncomeExpense" abstract="false" name="NonCashInterestIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_A2016IncentivePlanMember" abstract="true" name="A2016IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ServiceBasedRestrictedStockUnitsMember" abstract="true" name="ServiceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_LicensewithAffiliatedEntitiesMember" abstract="true" name="LicensewithAffiliatedEntitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborationAgreementRoyaltyPeriod" abstract="false" name="CollaborationAgreementRoyaltyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_DNAEncodedMonoclonalAntibodyTechnologyMember" abstract="true" name="DNAEncodedMonoclonalAntibodyTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliateCurrent" abstract="false" name="DeferredGrantFundingFromAffiliateCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CELLECTRA2000DeviceMember" abstract="true" name="CELLECTRA2000DeviceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" abstract="false" name="StockPurchaseAgreementCommitmentOfAdditionalInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ChangeInValueOfInvestmentsInAffiliatedCompany" abstract="false" name="ChangeInValueOfInvestmentsInAffiliatedCompany" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingReceived" abstract="false" name="CollaborativeAgreementFundingReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSaleAgreementWeightedAveragePricePerShare" abstract="false" name="StockSaleAgreementWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ino_AnnualMaintenancePeriod" abstract="false" name="AnnualMaintenancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_SARSCoV2COVID19VaccineMember" abstract="true" name="SARSCoV2COVID19VaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeArrangementFixedPriceContractAmountAwarded" abstract="false" name="CollaborativeArrangementFixedPriceContractAmountAwarded" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" abstract="false" name="CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_DebtInstrumentAccruedInterest" abstract="false" name="DebtInstrumentAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSalesAgreementRemainingAuthorizedAmount" abstract="false" name="StockSalesAgreementRemainingAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeArrangementRevenueFromTheProcurementContract" abstract="false" name="CollaborativeArrangementRevenueFromTheProcurementContract" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" abstract="false" name="CollaborativeAgreementPeriodFromEffectiveDateForTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_BillAndMelindaGatesFoundationMember" abstract="true" name="BillAndMelindaGatesFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_TheWistarInstituteMember" abstract="true" name="TheWistarInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_AccruedClinicalTrialExpenseCurrent" abstract="false" name="AccruedClinicalTrialExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_MutualFundsMember" abstract="true" name="MutualFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_SalesAgreementsMember" abstract="true" name="SalesAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" abstract="false" name="NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_December2019ConvertibleBondsMember" abstract="true" name="December2019ConvertibleBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CELLECTRA3PSPProprietarySmartDeviceMember" abstract="true" name="CELLECTRA3PSPProprietarySmartDeviceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_InitialConversionPriceMember" abstract="true" name="InitialConversionPriceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" abstract="false" name="LesseeOperatingLeaseNumberOfAgreementsToSublease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ino_DepartmentOfDefenceMember" abstract="true" name="DepartmentOfDefenceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>ino-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:500251c5-f1ff-4b5f-bcb3-245f4230a461,g:c147bae2-ade6-4d52-bd96-82e99e7a58d2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_68a4e682-535a-4983-97f5-d4cab35cf56b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_359f2393-7566-4554-9838-c844673b8b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_68a4e682-535a-4983-97f5-d4cab35cf56b" xlink:to="loc_us-gaap_Liabilities_359f2393-7566-4554-9838-c844673b8b26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_657202bb-20ee-4a30-bf5b-de6660418221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_68a4e682-535a-4983-97f5-d4cab35cf56b" xlink:to="loc_us-gaap_StockholdersEquity_657202bb-20ee-4a30-bf5b-de6660418221" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6152b281-2c62-4761-a9a9-bd6e68da6025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_52fc7f69-56f4-4587-895d-97af49089e03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6152b281-2c62-4761-a9a9-bd6e68da6025" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_52fc7f69-56f4-4587-895d-97af49089e03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7f939f01-b5e8-49a7-ae96-f3ea248e1ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6152b281-2c62-4761-a9a9-bd6e68da6025" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7f939f01-b5e8-49a7-ae96-f3ea248e1ebb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_2e4d3ae0-ec1c-4531-8f23-fe7458aa7d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6152b281-2c62-4761-a9a9-bd6e68da6025" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_2e4d3ae0-ec1c-4531-8f23-fe7458aa7d6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_854e378c-cc84-430c-a656-a7da1169990b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6152b281-2c62-4761-a9a9-bd6e68da6025" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_854e378c-cc84-430c-a656-a7da1169990b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_217619b4-c54a-406f-809d-380170678e82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6152b281-2c62-4761-a9a9-bd6e68da6025" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_217619b4-c54a-406f-809d-380170678e82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_86ded223-431b-45d5-8431-2b0830eb14c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6152b281-2c62-4761-a9a9-bd6e68da6025" xlink:to="loc_us-gaap_AssetsCurrent_86ded223-431b-45d5-8431-2b0830eb14c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5cb8a83e-3f5c-4990-8d90-70dbcc783491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6152b281-2c62-4761-a9a9-bd6e68da6025" xlink:to="loc_us-gaap_Goodwill_5cb8a83e-3f5c-4990-8d90-70dbcc783491" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_07fc7c58-3372-4fae-ad9c-a34140dcd7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9c3c6770-faf8-45b8-8bff-ffb0a69c5312" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_07fc7c58-3372-4fae-ad9c-a34140dcd7e8" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9c3c6770-faf8-45b8-8bff-ffb0a69c5312" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_8da3f0fb-e1dc-4fb6-81d2-448ee45f8cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_07fc7c58-3372-4fae-ad9c-a34140dcd7e8" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_8da3f0fb-e1dc-4fb6-81d2-448ee45f8cd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_00ab15a9-cdce-4176-ac79-361a4936cd5c" xlink:href="ino-20220331.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_07fc7c58-3372-4fae-ad9c-a34140dcd7e8" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_00ab15a9-cdce-4176-ac79-361a4936cd5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8a6b8683-510b-48ca-9fdc-95e5a9f30286" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_07fc7c58-3372-4fae-ad9c-a34140dcd7e8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8a6b8683-510b-48ca-9fdc-95e5a9f30286" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_fd42e90b-93a1-472b-82f9-ae5443207ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_07fc7c58-3372-4fae-ad9c-a34140dcd7e8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_fd42e90b-93a1-472b-82f9-ae5443207ea4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_6870ca98-aff2-4c2b-bba2-875a442c6efa" xlink:href="ino-20220331.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_07fc7c58-3372-4fae-ad9c-a34140dcd7e8" xlink:to="loc_ino_DeferredGrantFundingCurrent_6870ca98-aff2-4c2b-bba2-875a442c6efa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_dbcb14fd-b6ba-46f8-b9f5-f212e4da6f59" xlink:href="ino-20220331.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_07fc7c58-3372-4fae-ad9c-a34140dcd7e8" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_dbcb14fd-b6ba-46f8-b9f5-f212e4da6f59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a8338cdf-05f3-4311-9426-59d73fb9584f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8305b1f2-67d5-47b9-a677-b87690be1884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8338cdf-05f3-4311-9426-59d73fb9584f" xlink:to="loc_us-gaap_LiabilitiesCurrent_8305b1f2-67d5-47b9-a677-b87690be1884" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_837cd0fe-f9ac-44fd-8188-07756057d39b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8338cdf-05f3-4311-9426-59d73fb9584f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_837cd0fe-f9ac-44fd-8188-07756057d39b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_5327b119-c1bb-4231-b2e4-e907107565f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8338cdf-05f3-4311-9426-59d73fb9584f" xlink:to="loc_us-gaap_ConvertibleDebt_5327b119-c1bb-4231-b2e4-e907107565f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0933d2e4-c93c-44f9-a5c9-1872c66e98ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8338cdf-05f3-4311-9426-59d73fb9584f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0933d2e4-c93c-44f9-a5c9-1872c66e98ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c83e5a04-4dd3-4e82-af54-ddc3d7dd5f35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8338cdf-05f3-4311-9426-59d73fb9584f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c83e5a04-4dd3-4e82-af54-ddc3d7dd5f35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ef1d1ba6-bde9-4a7c-8303-53cafe4a7733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a8338cdf-05f3-4311-9426-59d73fb9584f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ef1d1ba6-bde9-4a7c-8303-53cafe4a7733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f470632d-d50a-4cd4-aa36-1af1629d548e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_29fabd62-df5d-4ef9-aeb7-6a2198a0efc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f470632d-d50a-4cd4-aa36-1af1629d548e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_29fabd62-df5d-4ef9-aeb7-6a2198a0efc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_9c60a72c-8911-493c-bb4b-f6e2dadbde65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f470632d-d50a-4cd4-aa36-1af1629d548e" xlink:to="loc_us-gaap_ShortTermInvestments_9c60a72c-8911-493c-bb4b-f6e2dadbde65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_68396b68-b0a1-490d-a62f-e12a475bfece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f470632d-d50a-4cd4-aa36-1af1629d548e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_68396b68-b0a1-490d-a62f-e12a475bfece" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_dc940457-a7b3-4aec-8351-c4d9c6056812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f470632d-d50a-4cd4-aa36-1af1629d548e" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_dc940457-a7b3-4aec-8351-c4d9c6056812" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_84778f75-e04e-418e-94f0-7379bc29371a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f470632d-d50a-4cd4-aa36-1af1629d548e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_84778f75-e04e-418e-94f0-7379bc29371a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_1d91a5d6-f200-4b2b-87b0-3e7e53b36ef7" xlink:href="ino-20220331.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f470632d-d50a-4cd4-aa36-1af1629d548e" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_1d91a5d6-f200-4b2b-87b0-3e7e53b36ef7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ea54eb8b-2dd8-4956-8945-27350804f197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_32d32f80-09ce-4b70-a4e4-d36cb6e27c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ea54eb8b-2dd8-4956-8945-27350804f197" xlink:to="loc_us-gaap_PreferredStockValue_32d32f80-09ce-4b70-a4e4-d36cb6e27c8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d2d033ff-67b7-4c57-9d8a-db996381bedf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ea54eb8b-2dd8-4956-8945-27350804f197" xlink:to="loc_us-gaap_CommonStockValue_d2d033ff-67b7-4c57-9d8a-db996381bedf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_dc3f0cb7-d266-4e4e-9ed9-99eb846e6852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ea54eb8b-2dd8-4956-8945-27350804f197" xlink:to="loc_us-gaap_AdditionalPaidInCapital_dc3f0cb7-d266-4e4e-9ed9-99eb846e6852" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_73cb5270-87ef-40c6-9f36-6b1e11d9bb86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ea54eb8b-2dd8-4956-8945-27350804f197" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_73cb5270-87ef-40c6-9f36-6b1e11d9bb86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_84552db7-c0ac-4def-ad19-11d9bbd8b25f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ea54eb8b-2dd8-4956-8945-27350804f197" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_84552db7-c0ac-4def-ad19-11d9bbd8b25f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="ino-20220331.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_60920eae-62ac-410f-a547-5a09d3ef4698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f761633a-b057-4c2f-aefb-40c3e65be494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_60920eae-62ac-410f-a547-5a09d3ef4698" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_f761633a-b057-4c2f-aefb-40c3e65be494" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9a085469-c033-494b-9a08-3e241e3a688b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_60920eae-62ac-410f-a547-5a09d3ef4698" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9a085469-c033-494b-9a08-3e241e3a688b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c335013a-f548-4a62-88cb-5104bed586d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f5d69b87-07d2-4428-8b0c-6226e8d28644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c335013a-f548-4a62-88cb-5104bed586d0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f5d69b87-07d2-4428-8b0c-6226e8d28644" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_88272b1b-4631-4fc5-aeb3-1a376fdd06ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c335013a-f548-4a62-88cb-5104bed586d0" xlink:to="loc_us-gaap_OperatingExpenses_88272b1b-4631-4fc5-aeb3-1a376fdd06ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1cd09572-81b8-4bda-8385-726537c7f7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_06a02bcc-fb61-4165-ae1e-90833aae4d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_1cd09572-81b8-4bda-8385-726537c7f7d8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_06a02bcc-fb61-4165-ae1e-90833aae4d9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0ff325bc-0f07-4a09-93bb-5345a18243b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_1cd09572-81b8-4bda-8385-726537c7f7d8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0ff325bc-0f07-4a09-93bb-5345a18243b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_25838dd4-067d-4c3c-b95f-fe1535d78c09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_2e5145e1-59d9-4b33-9f14-59494038a7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_25838dd4-067d-4c3c-b95f-fe1535d78c09" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_2e5145e1-59d9-4b33-9f14-59494038a7a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_783dbad8-e6cc-4776-9f16-e45861d50056" xlink:href="ino-20220331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_25838dd4-067d-4c3c-b95f-fe1535d78c09" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_783dbad8-e6cc-4776-9f16-e45861d50056" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_36b36ac9-d3e9-4bf1-9621-08b4aadc9c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_25838dd4-067d-4c3c-b95f-fe1535d78c09" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_36b36ac9-d3e9-4bf1-9621-08b4aadc9c20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_aa220e29-3766-4537-8ebf-76e969d630eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_25838dd4-067d-4c3c-b95f-fe1535d78c09" xlink:to="loc_us-gaap_InterestExpense_aa220e29-3766-4537-8ebf-76e969d630eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_931f8a75-23df-4e02-be3e-af1f159f675e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_25838dd4-067d-4c3c-b95f-fe1535d78c09" xlink:to="loc_us-gaap_OperatingIncomeLoss_931f8a75-23df-4e02-be3e-af1f159f675e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_d31ab984-3f1f-4540-bcb4-c8056a4ca6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_25838dd4-067d-4c3c-b95f-fe1535d78c09" xlink:to="loc_us-gaap_InterestIncomeOperating_d31ab984-3f1f-4540-bcb4-c8056a4ca6a6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="ino-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4e3117d3-2e64-4ae5-bcf3-1b297543a20b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_062695fb-ee45-4723-ac5d-8f8f7fc634e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4e3117d3-2e64-4ae5-bcf3-1b297543a20b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_062695fb-ee45-4723-ac5d-8f8f7fc634e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9886f744-aaa5-4935-9fc3-9744ef398688" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4e3117d3-2e64-4ae5-bcf3-1b297543a20b" xlink:to="loc_us-gaap_NetIncomeLoss_9886f744-aaa5-4935-9fc3-9744ef398688" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f9627cba-a1ce-46af-ae6d-157dff70eef8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4e3117d3-2e64-4ae5-bcf3-1b297543a20b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f9627cba-a1ce-46af-ae6d-157dff70eef8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="ino-20220331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_6c71d62c-47cf-4e1b-89ac-093bb754e8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_6c71d62c-47cf-4e1b-89ac-093bb754e8b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_065c7844-d290-4083-bde4-f15a857e608e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_065c7844-d290-4083-bde4-f15a857e608e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_475f5e84-d579-4056-8f6f-03e77c77d70f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_475f5e84-d579-4056-8f6f-03e77c77d70f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_e58b6590-cd1e-43c9-95b3-2c4215799eb8" xlink:href="ino-20220331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_e58b6590-cd1e-43c9-95b3-2c4215799eb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_e91bf6de-bffa-44cc-bf86-09971bce4968" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_e91bf6de-bffa-44cc-bf86-09971bce4968" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_e01f0c02-d02a-4386-906a-50d4f725111c" xlink:href="ino-20220331.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_e01f0c02-d02a-4386-906a-50d4f725111c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_6566adbd-a7b4-442a-bce3-f3e54fa92dd1" xlink:href="ino-20220331.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_6566adbd-a7b4-442a-bce3-f3e54fa92dd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense_90a380e3-e5c4-44f3-bb59-68f3c5a41ae3" xlink:href="ino-20220331.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_ino_NonCashInterestIncomeExpense_90a380e3-e5c4-44f3-bb59-68f3c5a41ae3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4d1de113-cb47-4ea4-887b-4b8085873e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4d1de113-cb47-4ea4-887b-4b8085873e87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_7d690c45-4374-420b-846d-ec2ed45cad89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_7d690c45-4374-420b-846d-ec2ed45cad89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_019101d0-75f3-4278-9647-6c9c1eb5c7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_019101d0-75f3-4278-9647-6c9c1eb5c7d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_acadc0f8-1264-4e2d-8ce7-a92ffef24c72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_acadc0f8-1264-4e2d-8ce7-a92ffef24c72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_daa19508-6cfe-4f9a-93de-4a6dcfad312d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_daa19508-6cfe-4f9a-93de-4a6dcfad312d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3c1432eb-5d03-444c-8c10-f9db44ecaf0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_3c1432eb-5d03-444c-8c10-f9db44ecaf0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_52f24d09-daf1-43ee-8a97-9969538fd446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_us-gaap_ShareBasedCompensation_52f24d09-daf1-43ee-8a97-9969538fd446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1ca5a5a4-0483-4c68-a5b8-4a061a651687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1ca5a5a4-0483-4c68-a5b8-4a061a651687" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_2d39bc8c-9ea8-4b6e-a576-b2ba36959564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_2d39bc8c-9ea8-4b6e-a576-b2ba36959564" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_da1e7c8b-b530-4ec4-9744-cde01c1685f6" xlink:href="ino-20220331.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_da1e7c8b-b530-4ec4-9744-cde01c1685f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1bc576a6-4c17-4986-9cc6-30af37e31dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1bc576a6-4c17-4986-9cc6-30af37e31dc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7f2bee90-9f80-41e3-a62c-00cbd2baa214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_7f2bee90-9f80-41e3-a62c-00cbd2baa214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_8dfba613-ba15-49f5-b72d-d5f6d2823a89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_us-gaap_Depreciation_8dfba613-ba15-49f5-b72d-d5f6d2823a89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cf580088-cc4a-4af4-b32e-4301d471a328" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_us-gaap_NetIncomeLoss_cf580088-cc4a-4af4-b32e-4301d471a328" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_7706e8be-f61c-4a14-92eb-eb5930b4ff98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="23" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_7706e8be-f61c-4a14-92eb-eb5930b4ff98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment_6286a518-0d90-4d97-b5cc-1b24227835b0" xlink:href="ino-20220331.xsd#ino_GainLossOnRemeasurementOfEquityMethodInvestment"/>
    <link:calculationArc order="24" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8da211a9-0a08-4092-a276-2dc864fb7d12" xlink:to="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment_6286a518-0d90-4d97-b5cc-1b24227835b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_030dff2d-abb2-4821-b0a9-2b032ff8e89f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_52efc14f-a635-4be7-a720-b8558f1ef5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_030dff2d-abb2-4821-b0a9-2b032ff8e89f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_52efc14f-a635-4be7-a720-b8558f1ef5bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_79e8bdad-f40e-4a79-b171-dcde985f56a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_030dff2d-abb2-4821-b0a9-2b032ff8e89f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_79e8bdad-f40e-4a79-b171-dcde985f56a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5fd783d7-57fa-4224-a5f9-8ec9e131efe3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_030dff2d-abb2-4821-b0a9-2b032ff8e89f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5fd783d7-57fa-4224-a5f9-8ec9e131efe3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7f9f4c77-5cb5-4e15-9b36-fe77dc4ee492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_030dff2d-abb2-4821-b0a9-2b032ff8e89f" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7f9f4c77-5cb5-4e15-9b36-fe77dc4ee492" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a9ca017-efd4-4d5c-9143-62025c304425" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2274e455-c966-4819-8267-2fceed8f3352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a9ca017-efd4-4d5c-9143-62025c304425" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2274e455-c966-4819-8267-2fceed8f3352" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_7b04ae9b-4884-429f-a88e-dc03dbb17a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a9ca017-efd4-4d5c-9143-62025c304425" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_7b04ae9b-4884-429f-a88e-dc03dbb17a0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_bd7f54b6-e669-4acc-87ec-32a1e69f15e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a9ca017-efd4-4d5c-9143-62025c304425" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_bd7f54b6-e669-4acc-87ec-32a1e69f15e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_6daac357-7cad-4cbe-80ae-3d467e087609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4a9ca017-efd4-4d5c-9143-62025c304425" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_6daac357-7cad-4cbe-80ae-3d467e087609" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a6c1df3-8ecc-4034-868e-252dc1bb6d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_95b0fa1d-1012-4b8c-b019-1398cef32084" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a6c1df3-8ecc-4034-868e-252dc1bb6d67" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_95b0fa1d-1012-4b8c-b019-1398cef32084" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b8ac6baa-b0ef-42fa-b1d2-6fab18df6d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a6c1df3-8ecc-4034-868e-252dc1bb6d67" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b8ac6baa-b0ef-42fa-b1d2-6fab18df6d40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0bfe5033-cd6b-4754-bfe2-d1c647b2bf30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a6c1df3-8ecc-4034-868e-252dc1bb6d67" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0bfe5033-cd6b-4754-bfe2-d1c647b2bf30" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_afd8552e-7ad5-4153-9836-9dbe9c428f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_38fb3bd3-0713-4f6f-9c4b-91bced15bf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_afd8552e-7ad5-4153-9836-9dbe9c428f32" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_38fb3bd3-0713-4f6f-9c4b-91bced15bf2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_896c4a64-8979-4bc8-a58d-e8c29115c5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_afd8552e-7ad5-4153-9836-9dbe9c428f32" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_896c4a64-8979-4bc8-a58d-e8c29115c5ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cc476308-f9ec-496c-b1bf-5302cc37afc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_afd8552e-7ad5-4153-9836-9dbe9c428f32" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cc476308-f9ec-496c-b1bf-5302cc37afc8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_504b7591-11e4-4690-8bea-d64348c92f74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9b142bc2-926a-4bad-8f43-dc4b26486873" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_504b7591-11e4-4690-8bea-d64348c92f74" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9b142bc2-926a-4bad-8f43-dc4b26486873" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_3c0862ad-351b-45d7-a14b-2cf2d1443461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_504b7591-11e4-4690-8bea-d64348c92f74" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_3c0862ad-351b-45d7-a14b-2cf2d1443461" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_94924730-7f21-4f85-b694-e6399da6375b" xlink:href="ino-20220331.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_06a4ca26-1da6-433e-9773-10e54d27b792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_94924730-7f21-4f85-b694-e6399da6375b" xlink:to="loc_us-gaap_GoodwillGross_06a4ca26-1da6-433e-9773-10e54d27b792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6cc06c67-6ce0-4c42-b8e4-11397e71be80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_94924730-7f21-4f85-b694-e6399da6375b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6cc06c67-6ce0-4c42-b8e4-11397e71be80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_dde8ceb0-027b-4d11-bca9-ecbe4ab50d31" xlink:href="ino-20220331.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3a2167ce-a93d-43ee-97e8-9a91e041ed9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_dde8ceb0-027b-4d11-bca9-ecbe4ab50d31" xlink:to="loc_us-gaap_Goodwill_3a2167ce-a93d-43ee-97e8-9a91e041ed9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_01aab6ac-f9c5-4c50-9e2f-b42050c53bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_dde8ceb0-027b-4d11-bca9-ecbe4ab50d31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_01aab6ac-f9c5-4c50-9e2f-b42050c53bec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_66a7af62-0c31-4a9c-b445-bd1f5d89af85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_38b3791e-d50d-4fb2-8a63-6fc9ae9f0c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Goodwill_66a7af62-0c31-4a9c-b445-bd1f5d89af85" xlink:to="loc_us-gaap_GoodwillGross_38b3791e-d50d-4fb2-8a63-6fc9ae9f0c3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ad838ed9-ee83-485f-bf49-0850c935af73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6d40d046-5fff-406d-b7b8-7f5111d6b05c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ad838ed9-ee83-485f-bf49-0850c935af73" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6d40d046-5fff-406d-b7b8-7f5111d6b05c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4d74b04c-2b3d-4dd2-98da-f02c31488341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ad838ed9-ee83-485f-bf49-0850c935af73" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4d74b04c-2b3d-4dd2-98da-f02c31488341" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0832153b-8036-433a-a58f-953d57007d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_13c23af2-7155-4802-b967-13bd1cf53cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_0832153b-8036-433a-a58f-953d57007d8a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_13c23af2-7155-4802-b967-13bd1cf53cbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_aabf9e39-8792-416d-9411-90beaddb3876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_0832153b-8036-433a-a58f-953d57007d8a" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_aabf9e39-8792-416d-9411-90beaddb3876" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccruedInterest_11fb2f2c-d03c-4a51-8942-53a03466d1e6" xlink:href="ino-20220331.xsd#ino_DebtInstrumentAccruedInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_0832153b-8036-433a-a58f-953d57007d8a" xlink:to="loc_ino_DebtInstrumentAccruedInterest_11fb2f2c-d03c-4a51-8942-53a03466d1e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_89d10cf1-dcbe-415a-9e9b-151612f51fa0" xlink:href="ino-20220331.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_0832153b-8036-433a-a58f-953d57007d8a" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_89d10cf1-dcbe-415a-9e9b-151612f51fa0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0af5ed98-7752-4750-b0d3-23dc0a4bb984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e15506db-9d56-4151-921d-c8c475d15ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_0af5ed98-7752-4750-b0d3-23dc0a4bb984" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e15506db-9d56-4151-921d-c8c475d15ae2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ba3b35e4-3375-44d2-9804-7c98ace3a720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_0af5ed98-7752-4750-b0d3-23dc0a4bb984" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ba3b35e4-3375-44d2-9804-7c98ace3a720" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c943620b-ab3a-4b09-a967-afd8d40d02ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_0af5ed98-7752-4750-b0d3-23dc0a4bb984" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c943620b-ab3a-4b09-a967-afd8d40d02ad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2612d49e-4b2c-4e16-a34e-58b2383af385" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ebbea3b1-3392-4bce-8d95-fed56da788d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2612d49e-4b2c-4e16-a34e-58b2383af385" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ebbea3b1-3392-4bce-8d95-fed56da788d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8e1a9da3-1bc0-45b2-ac0e-0f85dc92abdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2612d49e-4b2c-4e16-a34e-58b2383af385" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8e1a9da3-1bc0-45b2-ac0e-0f85dc92abdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c7bdefa0-b4ac-47de-b28b-8e320bb2167c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2612d49e-4b2c-4e16-a34e-58b2383af385" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c7bdefa0-b4ac-47de-b28b-8e320bb2167c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_acc372a3-9869-4362-9b44-a0008e5a4929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2612d49e-4b2c-4e16-a34e-58b2383af385" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_acc372a3-9869-4362-9b44-a0008e5a4929" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0f9ff556-19cc-4cba-a1d9-d1d1130792e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2612d49e-4b2c-4e16-a34e-58b2383af385" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0f9ff556-19cc-4cba-a1d9-d1d1130792e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_8a2c54c0-edf0-4568-96ee-da70bd2e2ed1" xlink:href="ino-20220331.xsd#ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2612d49e-4b2c-4e16-a34e-58b2383af385" xlink:to="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_8a2c54c0-edf0-4568-96ee-da70bd2e2ed1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f9623c67-0604-406d-867a-e74d9e51afe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d42b34a2-3884-4ad6-8f1c-9e8b8662e79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_f9623c67-0604-406d-867a-e74d9e51afe2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d42b34a2-3884-4ad6-8f1c-9e8b8662e79f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_082d4491-f28e-48db-aa14-ed08e1c553d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_f9623c67-0604-406d-867a-e74d9e51afe2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_082d4491-f28e-48db-aa14-ed08e1c553d4" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>ino-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:500251c5-f1ff-4b5f-bcb3-245f4230a461,g:c147bae2-ade6-4d52-bd96-82e99e7a58d2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="ino-20220331.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended" id="i67d880470b0e413180ad780e5f5a2fb9_CondensedConsolidatedStatementsofOperationsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9f97eab7-b448-4976-a31f-039ef106d3db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_a1824333-5ceb-40ce-b6eb-fabd2e5e6658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9f97eab7-b448-4976-a31f-039ef106d3db" xlink:to="loc_us-gaap_RevenuesAbstract_a1824333-5ceb-40ce-b6eb-fabd2e5e6658" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_551bc336-db1a-4016-89bb-d8e47d93eeed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_a1824333-5ceb-40ce-b6eb-fabd2e5e6658" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_551bc336-db1a-4016-89bb-d8e47d93eeed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_8ee4fbd3-aa02-463c-a094-1fd7343baf33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9f97eab7-b448-4976-a31f-039ef106d3db" xlink:to="loc_us-gaap_OperatingExpensesAbstract_8ee4fbd3-aa02-463c-a094-1fd7343baf33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_162b93c7-8d50-40dc-b97b-6c38a2e3c76e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8ee4fbd3-aa02-463c-a094-1fd7343baf33" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_162b93c7-8d50-40dc-b97b-6c38a2e3c76e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7ee22a00-5f91-4b11-8c1b-462c250c5ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8ee4fbd3-aa02-463c-a094-1fd7343baf33" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7ee22a00-5f91-4b11-8c1b-462c250c5ac6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_bfc92283-edca-4292-b0aa-7c47f8a814bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8ee4fbd3-aa02-463c-a094-1fd7343baf33" xlink:to="loc_us-gaap_OperatingExpenses_bfc92283-edca-4292-b0aa-7c47f8a814bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2784859a-993f-47b2-8465-13e4982d2c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9f97eab7-b448-4976-a31f-039ef106d3db" xlink:to="loc_us-gaap_OperatingIncomeLoss_2784859a-993f-47b2-8465-13e4982d2c7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_45a8cd93-4f80-4255-b5fc-2a91c525c62c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9f97eab7-b448-4976-a31f-039ef106d3db" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_45a8cd93-4f80-4255-b5fc-2a91c525c62c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_ce685579-296e-437d-b2df-38f534d22f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_45a8cd93-4f80-4255-b5fc-2a91c525c62c" xlink:to="loc_us-gaap_InterestIncomeOperating_ce685579-296e-437d-b2df-38f534d22f9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d2bf3cdb-b12c-465c-bff0-b60619408db9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_45a8cd93-4f80-4255-b5fc-2a91c525c62c" xlink:to="loc_us-gaap_InterestExpense_d2bf3cdb-b12c-465c-bff0-b60619408db9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_0acce8d5-067b-4537-9340-a2ae73a8ff4f" xlink:href="ino-20220331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_45a8cd93-4f80-4255-b5fc-2a91c525c62c" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_0acce8d5-067b-4537-9340-a2ae73a8ff4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cc3a54b1-6567-4ae0-a72f-0a1d6e5232b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_45a8cd93-4f80-4255-b5fc-2a91c525c62c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cc3a54b1-6567-4ae0-a72f-0a1d6e5232b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_18f1b56f-d959-470e-b410-2409e1b59371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_45a8cd93-4f80-4255-b5fc-2a91c525c62c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_18f1b56f-d959-470e-b410-2409e1b59371" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1e25a8cd-8204-4390-8fad-4f480c2daae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_45a8cd93-4f80-4255-b5fc-2a91c525c62c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1e25a8cd-8204-4390-8fad-4f480c2daae3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_625ea1d9-b4c0-4eb8-a566-58ee026017d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_45a8cd93-4f80-4255-b5fc-2a91c525c62c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_625ea1d9-b4c0-4eb8-a566-58ee026017d1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_099cd891-377a-43eb-8560-a3ede0307fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_45a8cd93-4f80-4255-b5fc-2a91c525c62c" xlink:to="loc_us-gaap_NetIncomeLoss_099cd891-377a-43eb-8560-a3ede0307fb9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a9219a72-1a25-483b-b37f-5cbad4fbcd62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9f97eab7-b448-4976-a31f-039ef106d3db" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a9219a72-1a25-483b-b37f-5cbad4fbcd62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_839039a6-b07c-442f-877e-1e17b21cab2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a9219a72-1a25-483b-b37f-5cbad4fbcd62" xlink:to="loc_us-gaap_EarningsPerShareBasic_839039a6-b07c-442f-877e-1e17b21cab2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3de58f50-ed61-4a54-9444-f943a2c1c649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a9219a72-1a25-483b-b37f-5cbad4fbcd62" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3de58f50-ed61-4a54-9444-f943a2c1c649" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_9a023578-cc7b-4d67-bcb7-6e5cbfc10503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9f97eab7-b448-4976-a31f-039ef106d3db" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_9a023578-cc7b-4d67-bcb7-6e5cbfc10503" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4c5fdfec-e158-47e2-85c8-5493d7d8c3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_9a023578-cc7b-4d67-bcb7-6e5cbfc10503" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4c5fdfec-e158-47e2-85c8-5493d7d8c3bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ddc41ecc-58cf-48a3-953c-c85bd5830a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_9a023578-cc7b-4d67-bcb7-6e5cbfc10503" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ddc41ecc-58cf-48a3-953c-c85bd5830a3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ddd0e557-f9e4-4ce2-98d2-47403d97e639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9f97eab7-b448-4976-a31f-039ef106d3db" xlink:to="loc_us-gaap_StatementTable_ddd0e557-f9e4-4ce2-98d2-47403d97e639" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e5b3e82e-aa25-43ad-ab5a-c4e1bbef0602" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ddd0e557-f9e4-4ce2-98d2-47403d97e639" xlink:to="loc_srt_ProductOrServiceAxis_e5b3e82e-aa25-43ad-ab5a-c4e1bbef0602" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e5b3e82e-aa25-43ad-ab5a-c4e1bbef0602_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_e5b3e82e-aa25-43ad-ab5a-c4e1bbef0602" xlink:to="loc_srt_ProductsAndServicesDomain_e5b3e82e-aa25-43ad-ab5a-c4e1bbef0602_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_65ee47ee-c461-47fd-aab2-dd749abf664a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_e5b3e82e-aa25-43ad-ab5a-c4e1bbef0602" xlink:to="loc_srt_ProductsAndServicesDomain_65ee47ee-c461-47fd-aab2-dd749abf664a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_c70b23a5-9c23-44ad-b9ae-9712ddba8938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_65ee47ee-c461-47fd-aab2-dd749abf664a" xlink:to="loc_us-gaap_LicenseMember_c70b23a5-9c23-44ad-b9ae-9712ddba8938" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_dcbe1d19-5e7a-43e1-9550-66588147900b" xlink:href="ino-20220331.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_65ee47ee-c461-47fd-aab2-dd749abf664a" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_dcbe1d19-5e7a-43e1-9550-66588147900b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_2ccdfa60-4513-456a-869e-d55f8c8cd482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_65ee47ee-c461-47fd-aab2-dd749abf664a" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_2ccdfa60-4513-456a-869e-d55f8c8cd482" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="ino-20220331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended" id="ie3a4d2832eef4fb3afbacc32696e898c_CondensedConsolidatedStatementsofStockholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_355f0ceb-da88-45d9-866c-9912625cb17e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_355f0ceb-da88-45d9-866c-9912625cb17e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_0b28c7dc-232f-4cf0-ae91-bd5c5a6b171d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_SharesIssued_0b28c7dc-232f-4cf0-ae91-bd5c5a6b171d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d5d31e9e-2d71-49cf-8022-1186319c2456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_StockholdersEquity_d5d31e9e-2d71-49cf-8022-1186319c2456" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6ee58967-894b-48e8-959f-f95a5b294403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6ee58967-894b-48e8-959f-f95a5b294403" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4b8fa87a-26d8-4cfc-9e88-1277fced14bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4b8fa87a-26d8-4cfc-9e88-1277fced14bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b46daaff-b10b-40ff-a855-10283b55ee61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b46daaff-b10b-40ff-a855-10283b55ee61" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_a74c8ade-462c-41d4-8d08-82c411f02de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_a74c8ade-462c-41d4-8d08-82c411f02de9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0838363e-b0c3-4e5b-9b44-50c773f4cd41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0838363e-b0c3-4e5b-9b44-50c773f4cd41" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_541a92b8-08a2-42dc-bef5-dd4925137f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_541a92b8-08a2-42dc-bef5-dd4925137f24" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f99d7d6e-1511-4662-b6b5-35106eb8178d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f99d7d6e-1511-4662-b6b5-35106eb8178d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b8d84cdd-9d07-4ad2-bd88-9fb7c6f2cc86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_NetIncomeLoss_b8d84cdd-9d07-4ad2-bd88-9fb7c6f2cc86" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ea9fc72d-e61f-45de-bd06-18e1b69b760b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ea9fc72d-e61f-45de-bd06-18e1b69b760b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_59708296-f83d-478c-8b04-ef8fbd3ee495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_59708296-f83d-478c-8b04-ef8fbd3ee495" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_058d3167-8bf2-45fe-9610-3dbd7a9a9309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_e731d304-9637-4f49-99da-5168c1ee73cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_8865c8b8-853b-4811-bf50-25f8e8e2b747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_355f0ceb-da88-45d9-866c-9912625cb17e" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_8865c8b8-853b-4811-bf50-25f8e8e2b747" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f7853339-c9eb-43e1-a367-b8e170c86248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_355f0ceb-da88-45d9-866c-9912625cb17e" xlink:to="loc_us-gaap_StatementTable_f7853339-c9eb-43e1-a367-b8e170c86248" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_edc82e7f-451c-40f1-8f9a-7232148d2e12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f7853339-c9eb-43e1-a367-b8e170c86248" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_edc82e7f-451c-40f1-8f9a-7232148d2e12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_edc82e7f-451c-40f1-8f9a-7232148d2e12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_edc82e7f-451c-40f1-8f9a-7232148d2e12" xlink:to="loc_us-gaap_EquityComponentDomain_edc82e7f-451c-40f1-8f9a-7232148d2e12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d3cb2bd2-503a-4dc1-9726-0a63dbd8b1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_edc82e7f-451c-40f1-8f9a-7232148d2e12" xlink:to="loc_us-gaap_EquityComponentDomain_d3cb2bd2-503a-4dc1-9726-0a63dbd8b1a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_d7ee7beb-bcdc-493d-8e50-91c8204b24f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d3cb2bd2-503a-4dc1-9726-0a63dbd8b1a9" xlink:to="loc_us-gaap_PreferredStockMember_d7ee7beb-bcdc-493d-8e50-91c8204b24f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f52ca698-6004-4c82-ac9a-df2b38c7bced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d3cb2bd2-503a-4dc1-9726-0a63dbd8b1a9" xlink:to="loc_us-gaap_CommonStockMember_f52ca698-6004-4c82-ac9a-df2b38c7bced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5a1d69f3-d8b3-4e6f-8fdc-788d72f4f247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d3cb2bd2-503a-4dc1-9726-0a63dbd8b1a9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5a1d69f3-d8b3-4e6f-8fdc-788d72f4f247" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3054d8ac-3de5-4736-8c44-5a0fae440c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d3cb2bd2-503a-4dc1-9726-0a63dbd8b1a9" xlink:to="loc_us-gaap_RetainedEarningsMember_3054d8ac-3de5-4736-8c44-5a0fae440c35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b0d3abd7-aad1-425a-be53-509e9ad9989f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d3cb2bd2-503a-4dc1-9726-0a63dbd8b1a9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b0d3abd7-aad1-425a-be53-509e9ad9989f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3bc9782b-f869-4bce-a54b-3b05ebcf32cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f7853339-c9eb-43e1-a367-b8e170c86248" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3bc9782b-f869-4bce-a54b-3b05ebcf32cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3bc9782b-f869-4bce-a54b-3b05ebcf32cd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3bc9782b-f869-4bce-a54b-3b05ebcf32cd" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_3bc9782b-f869-4bce-a54b-3b05ebcf32cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_82d12a2d-9ed6-48ef-a34f-73c095ab769e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3bc9782b-f869-4bce-a54b-3b05ebcf32cd" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_82d12a2d-9ed6-48ef-a34f-73c095ab769e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_83086125-4774-460a-b2ef-189ccf20e27a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_82d12a2d-9ed6-48ef-a34f-73c095ab769e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_83086125-4774-460a-b2ef-189ccf20e27a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="extended" id="iebfbd76c18c645f69c39e798c8e71aa1_BasisofPresentationLiquidityandRisksandUncertaintiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f8c4aa8e-e0c4-4b74-90b9-e530d3d8866c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1991d259-b234-49bd-aaaa-d6c1743854fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f8c4aa8e-e0c4-4b74-90b9-e530d3d8866c" xlink:to="loc_us-gaap_NetIncomeLoss_1991d259-b234-49bd-aaaa-d6c1743854fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Capital_714fb7c8-4e6f-4c3a-881f-a531b1398771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Capital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f8c4aa8e-e0c4-4b74-90b9-e530d3d8866c" xlink:to="loc_us-gaap_Capital_714fb7c8-4e6f-4c3a-881f-a531b1398771" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d3964aa9-c7d5-45b3-9c2e-43397a5380dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f8c4aa8e-e0c4-4b74-90b9-e530d3d8866c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d3964aa9-c7d5-45b3-9c2e-43397a5380dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_fa732548-996f-41f6-9922-54ecce1b8f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f8c4aa8e-e0c4-4b74-90b9-e530d3d8866c" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_fa732548-996f-41f6-9922-54ecce1b8f21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_18387747-48a9-46db-bed8-e82c8e783861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f8c4aa8e-e0c4-4b74-90b9-e530d3d8866c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_18387747-48a9-46db-bed8-e82c8e783861" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ae52873f-a97d-4a34-a163-b7869851e09e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f8c4aa8e-e0c4-4b74-90b9-e530d3d8866c" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ae52873f-a97d-4a34-a163-b7869851e09e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bae7a259-9490-43a1-aff7-028a7a59ff75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ae52873f-a97d-4a34-a163-b7869851e09e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bae7a259-9490-43a1-aff7-028a7a59ff75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_bae7a259-9490-43a1-aff7-028a7a59ff75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bae7a259-9490-43a1-aff7-028a7a59ff75" xlink:to="loc_us-gaap_ClassOfStockDomain_bae7a259-9490-43a1-aff7-028a7a59ff75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_43a64741-7123-41b5-99a9-5dd4f221ba69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bae7a259-9490-43a1-aff7-028a7a59ff75" xlink:to="loc_us-gaap_ClassOfStockDomain_43a64741-7123-41b5-99a9-5dd4f221ba69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a9d678a9-a968-4d15-afc8-ec7453d44a20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_43a64741-7123-41b5-99a9-5dd4f221ba69" xlink:to="loc_us-gaap_CommonStockMember_a9d678a9-a968-4d15-afc8-ec7453d44a20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fe2a1d8e-39c8-4107-b2c5-8411fa5e1a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ae52873f-a97d-4a34-a163-b7869851e09e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fe2a1d8e-39c8-4107-b2c5-8411fa5e1a05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe2a1d8e-39c8-4107-b2c5-8411fa5e1a05_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fe2a1d8e-39c8-4107-b2c5-8411fa5e1a05" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fe2a1d8e-39c8-4107-b2c5-8411fa5e1a05_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_037fba5a-9b04-46b4-be4a-72d0f6fe0395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fe2a1d8e-39c8-4107-b2c5-8411fa5e1a05" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_037fba5a-9b04-46b4-be4a-72d0f6fe0395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementsMember_5c32b1d4-2a2e-417a-a89b-760ee174f254" xlink:href="ino-20220331.xsd#ino_SalesAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_037fba5a-9b04-46b4-be4a-72d0f6fe0395" xlink:to="loc_ino_SalesAgreementsMember_5c32b1d4-2a2e-417a-a89b-760ee174f254" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember_c4602bf2-b14c-4a5e-a49d-df16a58263b6" xlink:href="ino-20220331.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_037fba5a-9b04-46b4-be4a-72d0f6fe0395" xlink:to="loc_ino_UnderwrittenPublicOfferingMember_c4602bf2-b14c-4a5e-a49d-df16a58263b6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandardsDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#ImpactofRecentlyIssuedAccountingStandardsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandardsDetails" xlink:type="extended" id="i1803ff5367c74315b61544535845665c_ImpactofRecentlyIssuedAccountingStandardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e0112c3b-9987-444f-8bd0-ad73acd08c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4b6c03c7-660a-4849-9786-7e485dbbc234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e0112c3b-9987-444f-8bd0-ad73acd08c87" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4b6c03c7-660a-4849-9786-7e485dbbc234" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3bbdd195-1271-4eab-99fc-550094506e22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e0112c3b-9987-444f-8bd0-ad73acd08c87" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3bbdd195-1271-4eab-99fc-550094506e22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_f3cf7c6f-3985-4532-9fdc-9a81038ae2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e0112c3b-9987-444f-8bd0-ad73acd08c87" xlink:to="loc_us-gaap_ConvertibleDebt_f3cf7c6f-3985-4532-9fdc-9a81038ae2dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e89b38eb-65aa-417e-aeb1-f208c722e7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e0112c3b-9987-444f-8bd0-ad73acd08c87" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e89b38eb-65aa-417e-aeb1-f208c722e7b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fa8c4c6c-7d88-4741-ae94-a56efcb784e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e0112c3b-9987-444f-8bd0-ad73acd08c87" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fa8c4c6c-7d88-4741-ae94-a56efcb784e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a2b8b098-ba00-4013-9a21-5f52406a1d59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fa8c4c6c-7d88-4741-ae94-a56efcb784e0" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a2b8b098-ba00-4013-9a21-5f52406a1d59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a2b8b098-ba00-4013-9a21-5f52406a1d59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a2b8b098-ba00-4013-9a21-5f52406a1d59" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a2b8b098-ba00-4013-9a21-5f52406a1d59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_fe7a8737-2c0b-4ea1-affa-85120d376b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a2b8b098-ba00-4013-9a21-5f52406a1d59" xlink:to="loc_us-gaap_TypeOfAdoptionMember_fe7a8737-2c0b-4ea1-affa-85120d376b9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_e215dc13-a371-4ba5-b155-64bf63b395bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_fe7a8737-2c0b-4ea1-affa-85120d376b9c" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_e215dc13-a371-4ba5-b155-64bf63b395bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#RevenueRecognitionDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="extended" id="i19db8cc8a1e34f1ea217050596eb44f1_RevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_357c7193-f8c0-4de5-b59d-09c9322564c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9c1becc1-ba76-49b0-a59f-5e6958bdfad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_357c7193-f8c0-4de5-b59d-09c9322564c4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9c1becc1-ba76-49b0-a59f-5e6958bdfad5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5bedc256-30e6-46e8-93cd-7cc4371a2869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_357c7193-f8c0-4de5-b59d-09c9322564c4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5bedc256-30e6-46e8-93cd-7cc4371a2869" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_182cb3cd-0845-4cb4-9095-72376b6b6e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_357c7193-f8c0-4de5-b59d-09c9322564c4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_182cb3cd-0845-4cb4-9095-72376b6b6e1e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_87f5990c-9861-493a-8c46-db91261078f3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_182cb3cd-0845-4cb4-9095-72376b6b6e1e" xlink:to="loc_srt_ProductOrServiceAxis_87f5990c-9861-493a-8c46-db91261078f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_87f5990c-9861-493a-8c46-db91261078f3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_87f5990c-9861-493a-8c46-db91261078f3" xlink:to="loc_srt_ProductsAndServicesDomain_87f5990c-9861-493a-8c46-db91261078f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_59c3debe-4155-4c1f-a3e9-66ac69e8934a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_87f5990c-9861-493a-8c46-db91261078f3" xlink:to="loc_srt_ProductsAndServicesDomain_59c3debe-4155-4c1f-a3e9-66ac69e8934a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_300dd7b1-7cbf-4dbe-989d-53883c4c4fcb" xlink:href="ino-20220331.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_59c3debe-4155-4c1f-a3e9-66ac69e8934a" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_300dd7b1-7cbf-4dbe-989d-53883c4c4fcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_157c9390-5de1-43b0-8862-b7428348ebca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_182cb3cd-0845-4cb4-9095-72376b6b6e1e" xlink:to="loc_srt_CounterpartyNameAxis_157c9390-5de1-43b0-8862-b7428348ebca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_157c9390-5de1-43b0-8862-b7428348ebca_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_157c9390-5de1-43b0-8862-b7428348ebca" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_157c9390-5de1-43b0-8862-b7428348ebca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e298e5cd-cf7e-432c-9539-84220ad38c39" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_157c9390-5de1-43b0-8862-b7428348ebca" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e298e5cd-cf7e-432c-9539-84220ad38c39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherCounterpartyMember_96cd698c-706a-4c10-bdb0-848b5d170849" xlink:href="ino-20220331.xsd#ino_OtherCounterpartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e298e5cd-cf7e-432c-9539-84220ad38c39" xlink:to="loc_ino_OtherCounterpartyMember_96cd698c-706a-4c10-bdb0-848b5d170849" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended" id="i38123e9b26f04c279213ddf01505fa0f_ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25d737c7-9326-4586-b0c9-990436335e09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_e94c0ae6-a366-4615-8842-0b437d46410d" xlink:href="ino-20220331.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25d737c7-9326-4586-b0c9-990436335e09" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_e94c0ae6-a366-4615-8842-0b437d46410d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a84d3cd6-adce-49c9-a0fb-8e6b8bb632a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25d737c7-9326-4586-b0c9-990436335e09" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a84d3cd6-adce-49c9-a0fb-8e6b8bb632a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e84f7166-9ef2-4048-ac5e-eb1cccc84e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a84d3cd6-adce-49c9-a0fb-8e6b8bb632a1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e84f7166-9ef2-4048-ac5e-eb1cccc84e0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_29b75b8f-41f7-46ec-9b65-2ed4dc8d51d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a84d3cd6-adce-49c9-a0fb-8e6b8bb632a1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_29b75b8f-41f7-46ec-9b65-2ed4dc8d51d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2f05b07e-6e81-4748-93a3-3d9847841cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a84d3cd6-adce-49c9-a0fb-8e6b8bb632a1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2f05b07e-6e81-4748-93a3-3d9847841cc9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_af8c9e37-8cba-41f2-9f00-ca2a54f1f801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a84d3cd6-adce-49c9-a0fb-8e6b8bb632a1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_af8c9e37-8cba-41f2-9f00-ca2a54f1f801" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_de546a33-ddf9-4036-b81e-79fd6e785533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25d737c7-9326-4586-b0c9-990436335e09" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_de546a33-ddf9-4036-b81e-79fd6e785533" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_30d47367-48c1-4929-9977-81e622c1d740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_de546a33-ddf9-4036-b81e-79fd6e785533" xlink:to="loc_us-gaap_FinancialInstrumentAxis_30d47367-48c1-4929-9977-81e622c1d740" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_30d47367-48c1-4929-9977-81e622c1d740_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_30d47367-48c1-4929-9977-81e622c1d740" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_30d47367-48c1-4929-9977-81e622c1d740_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_505ad22c-46f6-43db-a3db-2cb3f748b3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_30d47367-48c1-4929-9977-81e622c1d740" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_505ad22c-46f6-43db-a3db-2cb3f748b3fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_6878b170-d8ab-49f4-8bf8-36c1e0738791" xlink:href="ino-20220331.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_505ad22c-46f6-43db-a3db-2cb3f748b3fc" xlink:to="loc_ino_MutualFundsMember_6878b170-d8ab-49f4-8bf8-36c1e0738791" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_474b7ea7-8d30-4b47-8c2a-f084a6a1f2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_505ad22c-46f6-43db-a3db-2cb3f748b3fc" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_474b7ea7-8d30-4b47-8c2a-f084a6a1f2ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_bf3ff68a-69ed-454e-8ce0-247159b579f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_505ad22c-46f6-43db-a3db-2cb3f748b3fc" xlink:to="loc_us-gaap_CommercialPaperMember_bf3ff68a-69ed-454e-8ce0-247159b579f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_0bad7b63-fc6a-4a01-87d9-e9011b14b629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_505ad22c-46f6-43db-a3db-2cb3f748b3fc" xlink:to="loc_us-gaap_CertificatesOfDepositMember_0bad7b63-fc6a-4a01-87d9-e9011b14b629" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_0531fe52-a3ec-4eb1-b257-342a961bc100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_505ad22c-46f6-43db-a3db-2cb3f748b3fc" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_0531fe52-a3ec-4eb1-b257-342a961bc100" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i40f92d3a30f845159ad5e86f632dfdd7_ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_51310a4d-bed0-470a-8b73-cc139160b1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_e7973077-9337-419e-942b-fa00fb129b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_51310a4d-bed0-470a-8b73-cc139160b1b6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_e7973077-9337-419e-942b-fa00fb129b5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_4ee1675b-c82c-4f29-be61-209078b8e826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_51310a4d-bed0-470a-8b73-cc139160b1b6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_4ee1675b-c82c-4f29-be61-209078b8e826" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_8317b676-0f0b-45da-b2ab-32fe2795f58d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_51310a4d-bed0-470a-8b73-cc139160b1b6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_8317b676-0f0b-45da-b2ab-32fe2795f58d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0289daf3-2b9a-42ee-8c8d-43e1f752e5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_51310a4d-bed0-470a-8b73-cc139160b1b6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0289daf3-2b9a-42ee-8c8d-43e1f752e5ff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_0fab745f-c46c-4122-a350-dcce3a2602b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_51310a4d-bed0-470a-8b73-cc139160b1b6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_0fab745f-c46c-4122-a350-dcce3a2602b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_2ac50102-c7d2-4f24-a2f0-0c517809013b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_51310a4d-bed0-470a-8b73-cc139160b1b6" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_2ac50102-c7d2-4f24-a2f0-0c517809013b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_8aa70601-d743-441a-b4e3-33acf425d647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_51310a4d-bed0-470a-8b73-cc139160b1b6" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_8aa70601-d743-441a-b4e3-33acf425d647" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_be616cde-75ed-44a9-b35e-3c40d00fe6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_51310a4d-bed0-470a-8b73-cc139160b1b6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_be616cde-75ed-44a9-b35e-3c40d00fe6a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_18d112d1-71ae-43e5-b1af-1a2ac770b57a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_be616cde-75ed-44a9-b35e-3c40d00fe6a1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_18d112d1-71ae-43e5-b1af-1a2ac770b57a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18d112d1-71ae-43e5-b1af-1a2ac770b57a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_18d112d1-71ae-43e5-b1af-1a2ac770b57a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_18d112d1-71ae-43e5-b1af-1a2ac770b57a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2c0d2e7c-0c70-4e95-aded-e10a8d846d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_18d112d1-71ae-43e5-b1af-1a2ac770b57a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2c0d2e7c-0c70-4e95-aded-e10a8d846d45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a0289283-8f5d-4d80-9fe0-e63497ca7b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2c0d2e7c-0c70-4e95-aded-e10a8d846d45" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a0289283-8f5d-4d80-9fe0-e63497ca7b10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_172975ea-cc4b-4c44-b714-a518d13e04fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_be616cde-75ed-44a9-b35e-3c40d00fe6a1" xlink:to="loc_us-gaap_InvestmentTypeAxis_172975ea-cc4b-4c44-b714-a518d13e04fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_172975ea-cc4b-4c44-b714-a518d13e04fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_172975ea-cc4b-4c44-b714-a518d13e04fb" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_172975ea-cc4b-4c44-b714-a518d13e04fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6d67733d-651c-43b8-96ea-f9bee74b994a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_172975ea-cc4b-4c44-b714-a518d13e04fb" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6d67733d-651c-43b8-96ea-f9bee74b994a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6ccfcd5a-83f7-4489-95b0-e71e5a55c1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6d67733d-651c-43b8-96ea-f9bee74b994a" xlink:to="loc_us-gaap_CommonStockMember_6ccfcd5a-83f7-4489-95b0-e71e5a55c1b4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i723c27347a2d4fecae991c24aa73e989_ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3bcab706-90ba-42f9-8a37-6b5e18584c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_fe80704a-2a07-4b15-bb09-8c496e1cb3db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3bcab706-90ba-42f9-8a37-6b5e18584c9e" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_fe80704a-2a07-4b15-bb09-8c496e1cb3db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_66c48e8b-0e7a-4b98-8d9b-4bc10d626936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_fe80704a-2a07-4b15-bb09-8c496e1cb3db" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_66c48e8b-0e7a-4b98-8d9b-4bc10d626936" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_56bb705d-745f-4651-b965-e696facac0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_fe80704a-2a07-4b15-bb09-8c496e1cb3db" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_56bb705d-745f-4651-b965-e696facac0ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_90cdd11f-1f0e-4865-bd1f-2377fd08f80e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_fe80704a-2a07-4b15-bb09-8c496e1cb3db" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_90cdd11f-1f0e-4865-bd1f-2377fd08f80e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ad98ca20-803f-4ad9-8643-39432cb980b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3bcab706-90ba-42f9-8a37-6b5e18584c9e" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ad98ca20-803f-4ad9-8643-39432cb980b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_48f459ad-6bb6-4a69-a947-e41735021b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ad98ca20-803f-4ad9-8643-39432cb980b0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_48f459ad-6bb6-4a69-a947-e41735021b3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_48f459ad-6bb6-4a69-a947-e41735021b3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_48f459ad-6bb6-4a69-a947-e41735021b3a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_48f459ad-6bb6-4a69-a947-e41735021b3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7b43a47a-da76-433e-9edb-299df53703ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_48f459ad-6bb6-4a69-a947-e41735021b3a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7b43a47a-da76-433e-9edb-299df53703ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c4eab15e-66ae-472e-aaba-88933f6fc975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7b43a47a-da76-433e-9edb-299df53703ee" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c4eab15e-66ae-472e-aaba-88933f6fc975" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6d68000f-5d87-44f1-a0f0-0742783e3f27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ad98ca20-803f-4ad9-8643-39432cb980b0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6d68000f-5d87-44f1-a0f0-0742783e3f27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6d68000f-5d87-44f1-a0f0-0742783e3f27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6d68000f-5d87-44f1-a0f0-0742783e3f27" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6d68000f-5d87-44f1-a0f0-0742783e3f27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37931fab-ca1e-47a6-ab20-92e77b38e7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6d68000f-5d87-44f1-a0f0-0742783e3f27" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37931fab-ca1e-47a6-ab20-92e77b38e7cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_7daa090f-d5b8-4c16-a874-d840a668b267" xlink:href="ino-20220331.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37931fab-ca1e-47a6-ab20-92e77b38e7cd" xlink:to="loc_ino_MutualFundsMember_7daa090f-d5b8-4c16-a874-d840a668b267" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7dd3ca60-a667-4e47-8cec-50f31482f57a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37931fab-ca1e-47a6-ab20-92e77b38e7cd" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_7dd3ca60-a667-4e47-8cec-50f31482f57a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_5c929cfd-c88a-4a5d-9d2b-192d080cede5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37931fab-ca1e-47a6-ab20-92e77b38e7cd" xlink:to="loc_us-gaap_CommercialPaperMember_5c929cfd-c88a-4a5d-9d2b-192d080cede5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f77934ff-cdca-4522-b2a7-e8a86faa1a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37931fab-ca1e-47a6-ab20-92e77b38e7cd" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f77934ff-cdca-4522-b2a7-e8a86faa1a76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_f85f9bdb-88da-4d9d-8282-b2b1a4b45423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37931fab-ca1e-47a6-ab20-92e77b38e7cd" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_f85f9bdb-88da-4d9d-8282-b2b1a4b45423" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d1515ef-7c5a-4564-bd8c-8991e12b5479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ad98ca20-803f-4ad9-8643-39432cb980b0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d1515ef-7c5a-4564-bd8c-8991e12b5479" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0d1515ef-7c5a-4564-bd8c-8991e12b5479_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d1515ef-7c5a-4564-bd8c-8991e12b5479" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0d1515ef-7c5a-4564-bd8c-8991e12b5479_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2a06972-ad7c-462d-8be9-3c472b6bf700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d1515ef-7c5a-4564-bd8c-8991e12b5479" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2a06972-ad7c-462d-8be9-3c472b6bf700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_64830976-19b4-4995-b3ba-f0adb5d6c9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2a06972-ad7c-462d-8be9-3c472b6bf700" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_64830976-19b4-4995-b3ba-f0adb5d6c9ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e18c8efa-2db5-4a1b-8176-49d1a5ec440a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2a06972-ad7c-462d-8be9-3c472b6bf700" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e18c8efa-2db5-4a1b-8176-49d1a5ec440a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_111c1fe1-7b8f-488d-84c4-3617fe4efff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2a06972-ad7c-462d-8be9-3c472b6bf700" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_111c1fe1-7b8f-488d-84c4-3617fe4efff3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="extended" id="i16d4d1da456442cd9feb45c497d8b33b_GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_8d6fc778-d823-4566-9155-d5839a9831cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_24cb57b8-f3f9-4013-9849-048dd7e2a37e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_8d6fc778-d823-4566-9155-d5839a9831cc" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_24cb57b8-f3f9-4013-9849-048dd7e2a37e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_be34ed9f-5fb3-46db-aefd-6b2cabb22627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_24cb57b8-f3f9-4013-9849-048dd7e2a37e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_be34ed9f-5fb3-46db-aefd-6b2cabb22627" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_0d665d3e-dfc7-4f98-83ba-2b3acbcf6ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_be34ed9f-5fb3-46db-aefd-6b2cabb22627" xlink:to="loc_us-gaap_GoodwillGross_0d665d3e-dfc7-4f98-83ba-2b3acbcf6ad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3cadf4f0-b26f-48e0-865d-194bf228fc11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_be34ed9f-5fb3-46db-aefd-6b2cabb22627" xlink:to="loc_us-gaap_Goodwill_3cadf4f0-b26f-48e0-865d-194bf228fc11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_85693b69-d1d3-4f5b-8fe9-3153ffda975e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_24cb57b8-f3f9-4013-9849-048dd7e2a37e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_85693b69-d1d3-4f5b-8fe9-3153ffda975e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3016fd07-207d-4a89-8ff2-c43b2977b198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_85693b69-d1d3-4f5b-8fe9-3153ffda975e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3016fd07-207d-4a89-8ff2-c43b2977b198" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d476da31-98c4-484f-a6f0-016a039a9c73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_85693b69-d1d3-4f5b-8fe9-3153ffda975e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d476da31-98c4-484f-a6f0-016a039a9c73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_474e06f9-f6ec-4e48-9723-9753b337f3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_85693b69-d1d3-4f5b-8fe9-3153ffda975e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_474e06f9-f6ec-4e48-9723-9753b337f3fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d35440e9-867d-44d7-b0b6-c332fded1600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_85693b69-d1d3-4f5b-8fe9-3153ffda975e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d35440e9-867d-44d7-b0b6-c332fded1600" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_19569c69-e78a-4716-897c-c1721d936db3" xlink:href="ino-20220331.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_24cb57b8-f3f9-4013-9849-048dd7e2a37e" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_19569c69-e78a-4716-897c-c1721d936db3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_d58e69ad-1f6e-4f40-98f9-f0e2582dab89" xlink:href="ino-20220331.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_24cb57b8-f3f9-4013-9849-048dd7e2a37e" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_d58e69ad-1f6e-4f40-98f9-f0e2582dab89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_896a06f5-6db1-4802-bf46-4fc94d30c839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_8d6fc778-d823-4566-9155-d5839a9831cc" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_896a06f5-6db1-4802-bf46-4fc94d30c839" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3be5a89a-17cb-470f-ac1e-773a98468d8f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_896a06f5-6db1-4802-bf46-4fc94d30c839" xlink:to="loc_srt_RangeAxis_3be5a89a-17cb-470f-ac1e-773a98468d8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3be5a89a-17cb-470f-ac1e-773a98468d8f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3be5a89a-17cb-470f-ac1e-773a98468d8f" xlink:to="loc_srt_RangeMember_3be5a89a-17cb-470f-ac1e-773a98468d8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d1af7339-a0c8-46d3-931b-08dbf9736ede" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3be5a89a-17cb-470f-ac1e-773a98468d8f" xlink:to="loc_srt_RangeMember_d1af7339-a0c8-46d3-931b-08dbf9736ede" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_cfab31f2-ffe4-4d95-9c50-37a5bf34df0b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d1af7339-a0c8-46d3-931b-08dbf9736ede" xlink:to="loc_srt_WeightedAverageMember_cfab31f2-ffe4-4d95-9c50-37a5bf34df0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_94043dca-65ae-4f2b-99b8-986ec3146a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_896a06f5-6db1-4802-bf46-4fc94d30c839" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_94043dca-65ae-4f2b-99b8-986ec3146a3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_94043dca-65ae-4f2b-99b8-986ec3146a3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_94043dca-65ae-4f2b-99b8-986ec3146a3f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_94043dca-65ae-4f2b-99b8-986ec3146a3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2dd66e0b-7fe9-4497-a506-4a33a1577a21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_94043dca-65ae-4f2b-99b8-986ec3146a3f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2dd66e0b-7fe9-4497-a506-4a33a1577a21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_5bd2c1f4-cf4c-4f39-b157-e4c8d32e3f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2dd66e0b-7fe9-4497-a506-4a33a1577a21" xlink:to="loc_us-gaap_LicensingAgreementsMember_5bd2c1f4-cf4c-4f39-b157-e4c8d32e3f06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_2c9b4f01-fc69-4a2c-a4dd-fea010327b8c" xlink:href="ino-20220331.xsd#ino_BiojectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2dd66e0b-7fe9-4497-a506-4a33a1577a21" xlink:to="loc_ino_BiojectMember_2c9b4f01-fc69-4a2c-a4dd-fea010327b8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_c67935b8-3a6a-4796-8bf1-9b344c6a7adf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2dd66e0b-7fe9-4497-a506-4a33a1577a21" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_c67935b8-3a6a-4796-8bf1-9b344c6a7adf" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended" id="i8f97854faa6c4212b25529b29cbc78e2_ConvertibleDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_37d0589b-c277-4332-bc57-cc007ff3fd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_37d0589b-c277-4332-bc57-cc007ff3fd1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_55b33d88-1e1b-4f97-ab8c-f4bf35f800e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_55b33d88-1e1b-4f97-ab8c-f4bf35f800e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_eb4ba8ce-eb83-41fb-971f-d45557269378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_eb4ba8ce-eb83-41fb-971f-d45557269378" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0c429bea-7470-4c4a-a444-6b8906672591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0c429bea-7470-4c4a-a444-6b8906672591" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_cd42ac8e-40bc-4848-958b-6deaf3017207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_cd42ac8e-40bc-4848-958b-6deaf3017207" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_396339c1-02c7-4b20-a017-67637040a3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_396339c1-02c7-4b20-a017-67637040a3a6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2fe9eb46-251e-4f84-ba0b-95fdc556b5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2fe9eb46-251e-4f84-ba0b-95fdc556b5d3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_20b7c31d-c885-4ced-814a-600af25b2008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_20b7c31d-c885-4ced-814a-600af25b2008" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_0292eae3-6e2d-4a94-9240-11de1a3f41db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_0292eae3-6e2d-4a94-9240-11de1a3f41db" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_88ec4a51-ba08-4078-bd93-96ab4be23797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_88ec4a51-ba08-4078-bd93-96ab4be23797" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d2945998-2a92-4d48-9c14-58231be9b409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d2945998-2a92-4d48-9c14-58231be9b409" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_35a1a939-eaac-4bbe-927b-c10e9f418b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_35a1a939-eaac-4bbe-927b-c10e9f418b87" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aabaeaeb-01ff-414e-a742-4f76207852af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aabaeaeb-01ff-414e-a742-4f76207852af" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_7fa90e9b-1736-4788-8fb8-ae6253ef529c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_ConvertibleDebt_7fa90e9b-1736-4788-8fb8-ae6253ef529c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_999c442a-7af4-452c-ad51-bf5141461f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_InterestExpense_999c442a-7af4-452c-ad51-bf5141461f2d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_0bf967da-8b47-4d91-807a-d550ed287159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_InterestExpenseDebt_0bf967da-8b47-4d91-807a-d550ed287159" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_db6115ff-7bc4-4054-a0e3-4ec4502cc41d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_db6115ff-7bc4-4054-a0e3-4ec4502cc41d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_586b4574-bd63-4416-ac77-fc7a9903759f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_AdditionalPaidInCapital_586b4574-bd63-4416-ac77-fc7a9903759f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_ec56ba5f-8187-465d-865e-1367cdddca89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_ec56ba5f-8187-465d-865e-1367cdddca89" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3f05c2f1-28d2-4d41-a3a3-ba0b951d62a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtInstrumentTable_3f05c2f1-28d2-4d41-a3a3-ba0b951d62a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3fe696bf-260a-4437-8625-e81aab70acf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3f05c2f1-28d2-4d41-a3a3-ba0b951d62a8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3fe696bf-260a-4437-8625-e81aab70acf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3fe696bf-260a-4437-8625-e81aab70acf7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3fe696bf-260a-4437-8625-e81aab70acf7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3fe696bf-260a-4437-8625-e81aab70acf7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_77bf42c6-dd39-4234-b8ee-c40b01c9b923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3fe696bf-260a-4437-8625-e81aab70acf7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_77bf42c6-dd39-4234-b8ee-c40b01c9b923" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_2609e8f6-8815-4910-8b6e-fcec76d2f0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_77bf42c6-dd39-4234-b8ee-c40b01c9b923" xlink:to="loc_us-gaap_ConvertibleDebtMember_2609e8f6-8815-4910-8b6e-fcec76d2f0b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b3af5e08-a0a2-4efe-90e1-4947d75ee0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3f05c2f1-28d2-4d41-a3a3-ba0b951d62a8" xlink:to="loc_us-gaap_DebtInstrumentAxis_b3af5e08-a0a2-4efe-90e1-4947d75ee0fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b3af5e08-a0a2-4efe-90e1-4947d75ee0fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b3af5e08-a0a2-4efe-90e1-4947d75ee0fe" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b3af5e08-a0a2-4efe-90e1-4947d75ee0fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_787d5e71-e0fa-4ec3-a523-dd9278c7e5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b3af5e08-a0a2-4efe-90e1-4947d75ee0fe" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_787d5e71-e0fa-4ec3-a523-dd9278c7e5b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_bb0f2317-192a-4ae4-aeac-27c7c505563b" xlink:href="ino-20220331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_787d5e71-e0fa-4ec3-a523-dd9278c7e5b8" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_bb0f2317-192a-4ae4-aeac-27c7c505563b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_b31abe05-1af0-4cee-a4f8-3e2b7a841794" xlink:href="ino-20220331.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_787d5e71-e0fa-4ec3-a523-dd9278c7e5b8" xlink:to="loc_ino_December2019ConvertibleBondsMember_b31abe05-1af0-4cee-a4f8-3e2b7a841794" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b0a0911f-6559-4b84-a560-52792abae510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3f05c2f1-28d2-4d41-a3a3-ba0b951d62a8" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b0a0911f-6559-4b84-a560-52792abae510" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_b0a0911f-6559-4b84-a560-52792abae510_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b0a0911f-6559-4b84-a560-52792abae510" xlink:to="loc_us-gaap_DebtConversionNameDomain_b0a0911f-6559-4b84-a560-52792abae510_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_103a417b-fc50-4d9e-aef8-694f803baf77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b0a0911f-6559-4b84-a560-52792abae510" xlink:to="loc_us-gaap_DebtConversionNameDomain_103a417b-fc50-4d9e-aef8-694f803baf77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InitialConversionPriceMember_6cc3a431-3eed-493c-8da5-bc8547cf316a" xlink:href="ino-20220331.xsd#ino_InitialConversionPriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_103a417b-fc50-4d9e-aef8-694f803baf77" xlink:to="loc_ino_InitialConversionPriceMember_6cc3a431-3eed-493c-8da5-bc8547cf316a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1428795a-71f5-4596-af23-4dfee5a91977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3f05c2f1-28d2-4d41-a3a3-ba0b951d62a8" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1428795a-71f5-4596-af23-4dfee5a91977" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1428795a-71f5-4596-af23-4dfee5a91977_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1428795a-71f5-4596-af23-4dfee5a91977" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1428795a-71f5-4596-af23-4dfee5a91977_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_6ef3c12b-74a6-418a-bf73-9aafe12d3ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1428795a-71f5-4596-af23-4dfee5a91977" xlink:to="loc_us-gaap_TypeOfAdoptionMember_6ef3c12b-74a6-418a-bf73-9aafe12d3ad1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_1f2211d2-b7a6-4347-ae2c-c74a57f331f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_6ef3c12b-74a6-418a-bf73-9aafe12d3ad1" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_1f2211d2-b7a6-4347-ae2c-c74a57f331f1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="extended" id="i48c879c627a54f69b3bc22b36b467503_ConvertibleDebtBalanceofConvertibleBondsandNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fd86e3ad-9d43-4efa-bb94-926443feec91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_b2d90149-9be3-4e1f-b703-f907d6d9bd55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd86e3ad-9d43-4efa-bb94-926443feec91" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_b2d90149-9be3-4e1f-b703-f907d6d9bd55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_9029c95c-7922-4bde-a929-77490daa0894" xlink:href="ino-20220331.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd86e3ad-9d43-4efa-bb94-926443feec91" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_9029c95c-7922-4bde-a929-77490daa0894" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_e785aed9-8258-4bdb-84fb-ff250c9bae10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd86e3ad-9d43-4efa-bb94-926443feec91" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_e785aed9-8258-4bdb-84fb-ff250c9bae10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccruedInterest_b607e73e-369a-40b6-b87b-d3b6f93c49aa" xlink:href="ino-20220331.xsd#ino_DebtInstrumentAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd86e3ad-9d43-4efa-bb94-926443feec91" xlink:to="loc_ino_DebtInstrumentAccruedInterest_b607e73e-369a-40b6-b87b-d3b6f93c49aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_74647cec-724e-4cf7-9024-0daea7e27a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd86e3ad-9d43-4efa-bb94-926443feec91" xlink:to="loc_us-gaap_LongTermDebt_74647cec-724e-4cf7-9024-0daea7e27a44" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0ff18f9d-dc46-4f8c-a33e-0f882156d924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd86e3ad-9d43-4efa-bb94-926443feec91" xlink:to="loc_us-gaap_DebtInstrumentTable_0ff18f9d-dc46-4f8c-a33e-0f882156d924" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9d9bb5bb-ecfa-4986-a0c4-7d11f365bfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0ff18f9d-dc46-4f8c-a33e-0f882156d924" xlink:to="loc_us-gaap_DebtInstrumentAxis_9d9bb5bb-ecfa-4986-a0c4-7d11f365bfe9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9d9bb5bb-ecfa-4986-a0c4-7d11f365bfe9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9d9bb5bb-ecfa-4986-a0c4-7d11f365bfe9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9d9bb5bb-ecfa-4986-a0c4-7d11f365bfe9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_440ee378-2721-4948-a25c-ba9e57523168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9d9bb5bb-ecfa-4986-a0c4-7d11f365bfe9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_440ee378-2721-4948-a25c-ba9e57523168" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_b2a24d7e-7ac4-4c1a-801a-e9f85948d573" xlink:href="ino-20220331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_440ee378-2721-4948-a25c-ba9e57523168" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_b2a24d7e-7ac4-4c1a-801a-e9f85948d573" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended" id="i934b9eb0f71348659e46b4a525fd59bd_ConvertibleDebtScheduleofMaturitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5ce3bb0b-60d7-4e40-925f-81babe93bd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6bf85021-76d6-4ab5-852f-23621754a4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ce3bb0b-60d7-4e40-925f-81babe93bd9a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6bf85021-76d6-4ab5-852f-23621754a4a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_dce402ea-4d39-469d-b677-b723d39b7bed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ce3bb0b-60d7-4e40-925f-81babe93bd9a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_dce402ea-4d39-469d-b677-b723d39b7bed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8c755d9d-a90b-45d6-8b9a-27b15176a22f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ce3bb0b-60d7-4e40-925f-81babe93bd9a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8c755d9d-a90b-45d6-8b9a-27b15176a22f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_eed8bebe-e1d0-45a9-8ecb-67be3bc7ea4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ce3bb0b-60d7-4e40-925f-81babe93bd9a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_eed8bebe-e1d0-45a9-8ecb-67be3bc7ea4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_81b8bf0c-b7bb-4f8d-a642-f8d2447ddaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ce3bb0b-60d7-4e40-925f-81babe93bd9a" xlink:to="loc_us-gaap_LongTermDebt_81b8bf0c-b7bb-4f8d-a642-f8d2447ddaa7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6a31a05e-50d3-4b90-950e-7ac6067d9b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ce3bb0b-60d7-4e40-925f-81babe93bd9a" xlink:to="loc_us-gaap_DebtInstrumentTable_6a31a05e-50d3-4b90-950e-7ac6067d9b73" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_14132ff3-35a2-42f0-a43f-a4a84393f044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6a31a05e-50d3-4b90-950e-7ac6067d9b73" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_14132ff3-35a2-42f0-a43f-a4a84393f044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_14132ff3-35a2-42f0-a43f-a4a84393f044_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_14132ff3-35a2-42f0-a43f-a4a84393f044" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_14132ff3-35a2-42f0-a43f-a4a84393f044_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_063c4b27-fb5f-440a-a4f8-3864f9e97fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_14132ff3-35a2-42f0-a43f-a4a84393f044" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_063c4b27-fb5f-440a-a4f8-3864f9e97fe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_67e4847b-6a33-4304-b237-c9b7629f4a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_063c4b27-fb5f-440a-a4f8-3864f9e97fe0" xlink:to="loc_us-gaap_ConvertibleDebtMember_67e4847b-6a33-4304-b237-c9b7629f4a5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4a444aee-c880-4b80-bed1-47ebf0ca7bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6a31a05e-50d3-4b90-950e-7ac6067d9b73" xlink:to="loc_us-gaap_DebtInstrumentAxis_4a444aee-c880-4b80-bed1-47ebf0ca7bf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4a444aee-c880-4b80-bed1-47ebf0ca7bf0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_4a444aee-c880-4b80-bed1-47ebf0ca7bf0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4a444aee-c880-4b80-bed1-47ebf0ca7bf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a2d298a3-084c-434e-9038-4482d432284d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_4a444aee-c880-4b80-bed1-47ebf0ca7bf0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a2d298a3-084c-434e-9038-4482d432284d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_9d249d51-f93c-4977-b17e-22ecbf5b5473" xlink:href="ino-20220331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a2d298a3-084c-434e-9038-4482d432284d" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_9d249d51-f93c-4977-b17e-22ecbf5b5473" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="extended" id="i4b1efc843f2a4aa8ae48aef119f8e901_StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_079f1097-d315-494a-b2ef-a9003babbb49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ea8d340a-5caa-466c-b0fe-22378696c63f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_079f1097-d315-494a-b2ef-a9003babbb49" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ea8d340a-5caa-466c-b0fe-22378696c63f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a239e858-d3a3-4200-9e0f-ef90d67c8f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ea8d340a-5caa-466c-b0fe-22378696c63f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a239e858-d3a3-4200-9e0f-ef90d67c8f57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e648363d-f8d9-4a3e-8696-43888c400d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ea8d340a-5caa-466c-b0fe-22378696c63f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e648363d-f8d9-4a3e-8696-43888c400d4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2abdcec0-34ce-4d76-be9e-dae2f9b3f5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ea8d340a-5caa-466c-b0fe-22378696c63f" xlink:to="loc_us-gaap_CommonStockSharesIssued_2abdcec0-34ce-4d76-be9e-dae2f9b3f5f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4b077f9b-7ff4-4ad3-a998-0eaafd72f130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ea8d340a-5caa-466c-b0fe-22378696c63f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4b077f9b-7ff4-4ad3-a998-0eaafd72f130" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f07ef8f2-1a63-4172-b68b-cf21bd15c9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ea8d340a-5caa-466c-b0fe-22378696c63f" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f07ef8f2-1a63-4172-b68b-cf21bd15c9c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e34100bf-2d1c-49b0-a1ba-397960c65f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ea8d340a-5caa-466c-b0fe-22378696c63f" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e34100bf-2d1c-49b0-a1ba-397960c65f57" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_c8f8e5b1-c782-4a98-a507-db7c08740aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ea8d340a-5caa-466c-b0fe-22378696c63f" xlink:to="loc_us-gaap_PreferredStockSharesIssued_c8f8e5b1-c782-4a98-a507-db7c08740aa7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_bf2c21aa-a3bd-4e03-ad4f-0c6d74b74ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ea8d340a-5caa-466c-b0fe-22378696c63f" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_bf2c21aa-a3bd-4e03-ad4f-0c6d74b74ea0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_07add59b-b0f3-4efa-a8d8-15e423db5989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_079f1097-d315-494a-b2ef-a9003babbb49" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_07add59b-b0f3-4efa-a8d8-15e423db5989" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_35d07fff-6388-4464-8f46-9bb17c00ff7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_07add59b-b0f3-4efa-a8d8-15e423db5989" xlink:to="loc_us-gaap_StatementClassOfStockAxis_35d07fff-6388-4464-8f46-9bb17c00ff7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_35d07fff-6388-4464-8f46-9bb17c00ff7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_35d07fff-6388-4464-8f46-9bb17c00ff7e" xlink:to="loc_us-gaap_ClassOfStockDomain_35d07fff-6388-4464-8f46-9bb17c00ff7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f5e49105-7b86-46ec-baa0-d1c7928ed0af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_35d07fff-6388-4464-8f46-9bb17c00ff7e" xlink:to="loc_us-gaap_ClassOfStockDomain_f5e49105-7b86-46ec-baa0-d1c7928ed0af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_04c1bf31-0c22-442a-9191-a254c6739381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f5e49105-7b86-46ec-baa0-d1c7928ed0af" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_04c1bf31-0c22-442a-9191-a254c6739381" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i623a68b4ea7543b286abec2b4f77d651_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_f6a77ab7-bdc4-48ef-9696-e78a6f056041" xlink:href="ino-20220331.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_f6a77ab7-bdc4-48ef-9696-e78a6f056041" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_b1cb0045-71c0-4f5d-a025-c527ea2de4fb" xlink:href="ino-20220331.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_b1cb0045-71c0-4f5d-a025-c527ea2de4fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_bc834db2-bdd5-4f69-9c83-ee06b19bca15" xlink:href="ino-20220331.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_bc834db2-bdd5-4f69-9c83-ee06b19bca15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_6343a73b-1d1a-4dc6-b8c8-ecebd1f31ed9" xlink:href="ino-20220331.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_6343a73b-1d1a-4dc6-b8c8-ecebd1f31ed9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_6318b17b-e4d3-4cba-9ac4-d1c78f887560" xlink:href="ino-20220331.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_6318b17b-e4d3-4cba-9ac4-d1c78f887560" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_29f66328-a58f-43e1-8d5d-b31672b43c5b" xlink:href="ino-20220331.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_29f66328-a58f-43e1-8d5d-b31672b43c5b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_85cf24c5-3bd1-47cb-813b-05b9c738ab13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_85cf24c5-3bd1-47cb-813b-05b9c738ab13" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_17c7bd3c-ef93-416d-9ed4-4cd3babb9eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_17c7bd3c-ef93-416d-9ed4-4cd3babb9eca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2156d3d5-631e-4824-a62a-03c129b20433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2156d3d5-631e-4824-a62a-03c129b20433" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_db015ba8-45be-4bd8-8523-5a6c34d6972b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_db015ba8-45be-4bd8-8523-5a6c34d6972b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_fed41532-1fc5-4337-8a22-19bdabc6aef8" xlink:href="ino-20220331.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_fed41532-1fc5-4337-8a22-19bdabc6aef8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_731245b8-e883-4d43-90ed-0835aefcba58" xlink:href="ino-20220331.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_731245b8-e883-4d43-90ed-0835aefcba58" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4ef658b9-bfe5-4501-b4fc-a552912c4204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4ef658b9-bfe5-4501-b4fc-a552912c4204" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3ddc0f2f-d253-4373-8798-a060c4a80948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3ddc0f2f-d253-4373-8798-a060c4a80948" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_cb39a30b-cd41-4f0c-a411-9001bdcfab5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_cb39a30b-cd41-4f0c-a411-9001bdcfab5f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6e70bcc7-a0ed-4411-aaff-982c30fd058f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6e70bcc7-a0ed-4411-aaff-982c30fd058f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_876a30a2-4f86-459e-8da3-883fc59885a8" xlink:href="ino-20220331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_876a30a2-4f86-459e-8da3-883fc59885a8" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d43944b5-1d15-481a-aa33-2b0ec7bb0ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d43944b5-1d15-481a-aa33-2b0ec7bb0ed2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b0e6a947-a816-407d-943b-6d83b944d488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d43944b5-1d15-481a-aa33-2b0ec7bb0ed2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b0e6a947-a816-407d-943b-6d83b944d488" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b0e6a947-a816-407d-943b-6d83b944d488_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b0e6a947-a816-407d-943b-6d83b944d488" xlink:to="loc_us-gaap_ClassOfStockDomain_b0e6a947-a816-407d-943b-6d83b944d488_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a474e2a0-c113-434a-89dd-5256e2562edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b0e6a947-a816-407d-943b-6d83b944d488" xlink:to="loc_us-gaap_ClassOfStockDomain_a474e2a0-c113-434a-89dd-5256e2562edd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f0956795-b9eb-4dc1-9d73-78d165c9fb81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a474e2a0-c113-434a-89dd-5256e2562edd" xlink:to="loc_us-gaap_CommonStockMember_f0956795-b9eb-4dc1-9d73-78d165c9fb81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_62e126f1-0919-4c30-85e5-7fd121fafed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d43944b5-1d15-481a-aa33-2b0ec7bb0ed2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_62e126f1-0919-4c30-85e5-7fd121fafed4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_62e126f1-0919-4c30-85e5-7fd121fafed4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_62e126f1-0919-4c30-85e5-7fd121fafed4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_62e126f1-0919-4c30-85e5-7fd121fafed4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_239c4eb1-4eca-4e00-8675-5c995cc80839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_62e126f1-0919-4c30-85e5-7fd121fafed4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_239c4eb1-4eca-4e00-8675-5c995cc80839" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember_a0ae1a61-50f4-464f-8e16-85ed4281c57f" xlink:href="ino-20220331.xsd#ino_SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_239c4eb1-4eca-4e00-8675-5c995cc80839" xlink:to="loc_ino_SalesAgreementMember_a0ae1a61-50f4-464f-8e16-85ed4281c57f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember_23604822-78aa-44c3-93f5-a0e23510819a" xlink:href="ino-20220331.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_239c4eb1-4eca-4e00-8675-5c995cc80839" xlink:to="loc_ino_UnderwrittenPublicOfferingMember_23604822-78aa-44c3-93f5-a0e23510819a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_27d8d327-f66e-49f6-972b-aa060a239a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d43944b5-1d15-481a-aa33-2b0ec7bb0ed2" xlink:to="loc_us-gaap_PlanNameAxis_27d8d327-f66e-49f6-972b-aa060a239a16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_27d8d327-f66e-49f6-972b-aa060a239a16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_27d8d327-f66e-49f6-972b-aa060a239a16" xlink:to="loc_us-gaap_PlanNameDomain_27d8d327-f66e-49f6-972b-aa060a239a16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_85a4d0b8-4317-4e10-9c8e-294f1c890063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_27d8d327-f66e-49f6-972b-aa060a239a16" xlink:to="loc_us-gaap_PlanNameDomain_85a4d0b8-4317-4e10-9c8e-294f1c890063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_5f3c8d19-27e2-4756-9abc-738243d2beeb" xlink:href="ino-20220331.xsd#ino_A2016IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_85a4d0b8-4317-4e10-9c8e-294f1c890063" xlink:to="loc_ino_A2016IncentivePlanMember_5f3c8d19-27e2-4756-9abc-738243d2beeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_2fec2a01-c516-472e-87f9-171e12a6bf6f" xlink:href="ino-20220331.xsd#ino_A2007IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_85a4d0b8-4317-4e10-9c8e-294f1c890063" xlink:to="loc_ino_A2007IncentivePlanMember_2fec2a01-c516-472e-87f9-171e12a6bf6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8100e558-6cee-467c-97d6-fbc4bef32629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d43944b5-1d15-481a-aa33-2b0ec7bb0ed2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8100e558-6cee-467c-97d6-fbc4bef32629" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8100e558-6cee-467c-97d6-fbc4bef32629_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8100e558-6cee-467c-97d6-fbc4bef32629" xlink:to="loc_us-gaap_EquityComponentDomain_8100e558-6cee-467c-97d6-fbc4bef32629_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_04f601ab-9c1d-4e2d-ac89-a7ed2e7224a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8100e558-6cee-467c-97d6-fbc4bef32629" xlink:to="loc_us-gaap_EquityComponentDomain_04f601ab-9c1d-4e2d-ac89-a7ed2e7224a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9a782b94-e6d3-4d6a-8682-afbab0f89360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_04f601ab-9c1d-4e2d-ac89-a7ed2e7224a3" xlink:to="loc_us-gaap_CommonStockMember_9a782b94-e6d3-4d6a-8682-afbab0f89360" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="extended" id="i9f68a2c8611c49c18af66e441a404752_NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_23ac80c5-ebd6-4616-ae59-104ee5bfec89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5ddd65b9-0378-4463-8862-440799ff07f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_23ac80c5-ebd6-4616-ae59-104ee5bfec89" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5ddd65b9-0378-4463-8862-440799ff07f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c93839e1-ff43-4c01-a82e-4fc0d8653b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_23ac80c5-ebd6-4616-ae59-104ee5bfec89" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c93839e1-ff43-4c01-a82e-4fc0d8653b2e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2827ff95-8667-4eeb-8f52-d754eda6e830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c93839e1-ff43-4c01-a82e-4fc0d8653b2e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2827ff95-8667-4eeb-8f52-d754eda6e830" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2827ff95-8667-4eeb-8f52-d754eda6e830_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2827ff95-8667-4eeb-8f52-d754eda6e830" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2827ff95-8667-4eeb-8f52-d754eda6e830_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a5b06191-70ba-45fa-a5cd-a0592078d7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2827ff95-8667-4eeb-8f52-d754eda6e830" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a5b06191-70ba-45fa-a5cd-a0592078d7eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bcd83191-5894-45b7-bd0f-9a982dafdfab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a5b06191-70ba-45fa-a5cd-a0592078d7eb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bcd83191-5894-45b7-bd0f-9a982dafdfab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_f6d6b5b9-2cc6-4bea-aa26-0f6879c0e371" xlink:href="ino-20220331.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a5b06191-70ba-45fa-a5cd-a0592078d7eb" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_f6d6b5b9-2cc6-4bea-aa26-0f6879c0e371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cb94424a-d732-4a64-b03f-9293c2073822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a5b06191-70ba-45fa-a5cd-a0592078d7eb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cb94424a-d732-4a64-b03f-9293c2073822" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_bc342cd4-2b78-4f91-a924-9513a391731f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a5b06191-70ba-45fa-a5cd-a0592078d7eb" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_bc342cd4-2b78-4f91-a924-9513a391731f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_9c2e8bd1-5273-4847-af4c-21fbfd2fd6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a5b06191-70ba-45fa-a5cd-a0592078d7eb" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_9c2e8bd1-5273-4847-af4c-21fbfd2fd6b0" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#StockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="extended" id="i6bb101b3ad87486f8240b5d87d40652e_StockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c61f2adc-5123-4ace-8c92-6778aaf05588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c61f2adc-5123-4ace-8c92-6778aaf05588" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b3468235-09d4-45d8-ad19-caf984ba5584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b3468235-09d4-45d8-ad19-caf984ba5584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3fd02026-13fd-4830-8bcd-2c635ca16e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3fd02026-13fd-4830-8bcd-2c635ca16e6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2d0ec1c6-fcb4-4238-9169-25ef6b94a481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2d0ec1c6-fcb4-4238-9169-25ef6b94a481" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d2683d49-7b3f-489d-94cd-0ce4974838ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_ShareBasedCompensation_d2683d49-7b3f-489d-94cd-0ce4974838ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5e8d3d93-f910-475c-a48c-ffa5cb7f58a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5e8d3d93-f910-475c-a48c-ffa5cb7f58a5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f3f486d4-65c2-4ccf-94ab-3d3e16246d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f3f486d4-65c2-4ccf-94ab-3d3e16246d34" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_347d955c-8468-4878-af46-0b55c99cd100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_347d955c-8468-4878-af46-0b55c99cd100" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c1f4e922-b108-40a1-9575-1ce3f8ebcbed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c1f4e922-b108-40a1-9575-1ce3f8ebcbed" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8c5410ef-a234-4471-bb8d-200b77e2a8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8c5410ef-a234-4471-bb8d-200b77e2a8b5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6f96fb62-e9d4-4582-b4b9-85a87506ba17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6f96fb62-e9d4-4582-b4b9-85a87506ba17" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_095770b0-f2d0-4024-a8db-c5301300aec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_095770b0-f2d0-4024-a8db-c5301300aec4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6339dbb0-2b1d-4d40-891f-d13af5102625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6339dbb0-2b1d-4d40-891f-d13af5102625" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_831e303f-36b9-499d-aee6-7ed99cf6c927" xlink:href="ino-20220331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_831e303f-36b9-499d-aee6-7ed99cf6c927" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc85a6c0-701e-4f0e-bc7d-4508f178c748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc85a6c0-701e-4f0e-bc7d-4508f178c748" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ef411478-bb20-40c7-82d6-2b3f623454ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc85a6c0-701e-4f0e-bc7d-4508f178c748" xlink:to="loc_us-gaap_AwardTypeAxis_ef411478-bb20-40c7-82d6-2b3f623454ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef411478-bb20-40c7-82d6-2b3f623454ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ef411478-bb20-40c7-82d6-2b3f623454ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ef411478-bb20-40c7-82d6-2b3f623454ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5453427b-50cc-4b7c-ae55-b2e2ab848399" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ef411478-bb20-40c7-82d6-2b3f623454ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5453427b-50cc-4b7c-ae55-b2e2ab848399" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e64dfeb0-eed3-475c-ac35-e039042fd26b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5453427b-50cc-4b7c-ae55-b2e2ab848399" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e64dfeb0-eed3-475c-ac35-e039042fd26b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_80088144-33ca-4582-93d4-0f446acf2343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5453427b-50cc-4b7c-ae55-b2e2ab848399" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_80088144-33ca-4582-93d4-0f446acf2343" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2d3902c1-cceb-4c18-b05f-5e0a97f6e267" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc85a6c0-701e-4f0e-bc7d-4508f178c748" xlink:to="loc_srt_TitleOfIndividualAxis_2d3902c1-cceb-4c18-b05f-5e0a97f6e267" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2d3902c1-cceb-4c18-b05f-5e0a97f6e267_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_2d3902c1-cceb-4c18-b05f-5e0a97f6e267" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2d3902c1-cceb-4c18-b05f-5e0a97f6e267_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_28ec8605-a04f-4144-90c6-96ec210a4897" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_2d3902c1-cceb-4c18-b05f-5e0a97f6e267" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_28ec8605-a04f-4144-90c6-96ec210a4897" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_241f5669-8e48-4f0d-8248-1e115c49e168" xlink:href="ino-20220331.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_28ec8605-a04f-4144-90c6-96ec210a4897" xlink:to="loc_ino_EmployeesAndDirectorsMember_241f5669-8e48-4f0d-8248-1e115c49e168" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_bf655695-e4f6-4f9d-8584-3cfc534b7501" xlink:href="ino-20220331.xsd#ino_NonEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_28ec8605-a04f-4144-90c6-96ec210a4897" xlink:to="loc_ino_NonEmployeeMember_bf655695-e4f6-4f9d-8584-3cfc534b7501" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a0c7ea65-c502-490b-8984-cf9705d2883c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc85a6c0-701e-4f0e-bc7d-4508f178c748" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a0c7ea65-c502-490b-8984-cf9705d2883c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a0c7ea65-c502-490b-8984-cf9705d2883c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a0c7ea65-c502-490b-8984-cf9705d2883c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a0c7ea65-c502-490b-8984-cf9705d2883c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1e11f9e3-505d-465e-889c-66177ff2e3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a0c7ea65-c502-490b-8984-cf9705d2883c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1e11f9e3-505d-465e-889c-66177ff2e3f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9d74bf63-a87f-4af4-8dd3-a2d976fdcadd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1e11f9e3-505d-465e-889c-66177ff2e3f7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9d74bf63-a87f-4af4-8dd3-a2d976fdcadd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a2bf007d-285c-4d1f-9be0-a313309f7e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1e11f9e3-505d-465e-889c-66177ff2e3f7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a2bf007d-285c-4d1f-9be0-a313309f7e95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e084be37-a010-44e1-8288-25663bcaccfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc85a6c0-701e-4f0e-bc7d-4508f178c748" xlink:to="loc_us-gaap_PlanNameAxis_e084be37-a010-44e1-8288-25663bcaccfb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e084be37-a010-44e1-8288-25663bcaccfb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e084be37-a010-44e1-8288-25663bcaccfb" xlink:to="loc_us-gaap_PlanNameDomain_e084be37-a010-44e1-8288-25663bcaccfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c78138e3-d0bf-42ed-b610-0cee6dd0c899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e084be37-a010-44e1-8288-25663bcaccfb" xlink:to="loc_us-gaap_PlanNameDomain_c78138e3-d0bf-42ed-b610-0cee6dd0c899" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_b7cd3c8a-3a99-4e71-991d-f966a014e824" xlink:href="ino-20220331.xsd#ino_A2016IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c78138e3-d0bf-42ed-b610-0cee6dd0c899" xlink:to="loc_ino_A2016IncentivePlanMember_b7cd3c8a-3a99-4e71-991d-f966a014e824" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_3f76b085-3ae5-4f4e-8a6b-242ed6c306ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc85a6c0-701e-4f0e-bc7d-4508f178c748" xlink:to="loc_us-gaap_VestingAxis_3f76b085-3ae5-4f4e-8a6b-242ed6c306ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_3f76b085-3ae5-4f4e-8a6b-242ed6c306ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_3f76b085-3ae5-4f4e-8a6b-242ed6c306ae" xlink:to="loc_us-gaap_VestingDomain_3f76b085-3ae5-4f4e-8a6b-242ed6c306ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_d4e07df8-1b82-4f92-97f0-91adeccd3759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_3f76b085-3ae5-4f4e-8a6b-242ed6c306ae" xlink:to="loc_us-gaap_VestingDomain_d4e07df8-1b82-4f92-97f0-91adeccd3759" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4d4cd93d-16b2-4d8d-a899-0ccc01a8ab08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_d4e07df8-1b82-4f92-97f0-91adeccd3759" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4d4cd93d-16b2-4d8d-a899-0ccc01a8ab08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1a9dc610-d350-4e88-b0b2-95cd1107df47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_d4e07df8-1b82-4f92-97f0-91adeccd3759" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1a9dc610-d350-4e88-b0b2-95cd1107df47" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i2ab1d33dc9a14024ae8d579035faec36_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_595d11be-7e26-4d01-9b70-4d4d836b4d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:href="ino-20220331.xsd#ino_RelatedPartyTransactionsTextualAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_595d11be-7e26-4d01-9b70-4d4d836b4d5c" xlink:to="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_4de46485-5274-44ff-b32a-91417a91e655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_4de46485-5274-44ff-b32a-91417a91e655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9ca56994-c6b7-4790-8d0f-eb883674182b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9ca56994-c6b7-4790-8d0f-eb883674182b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ec401b7a-9206-47ff-8eac-1e272b1ad090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ec401b7a-9206-47ff-8eac-1e272b1ad090" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_a7e47416-cda2-4fa3-b5b6-441d9f59b70c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_a7e47416-cda2-4fa3-b5b6-441d9f59b70c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_bb3960e3-48fb-430c-bc25-b070646aa842" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_bb3960e3-48fb-430c-bc25-b070646aa842" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_c1bd3f64-46f2-4341-b41d-fabd00406674" xlink:href="ino-20220331.xsd#ino_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_ino_CollaborativeArrangementTerm_c1bd3f64-46f2-4341-b41d-fabd00406674" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_d14d2872-9f4e-4c12-a200-b0c5724307f8" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_d14d2872-9f4e-4c12-a200-b0c5724307f8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount_844489e2-0bbe-45ed-b4fa-ddf100075918" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_ino_CollaborativeAgreementAmendedAmount_844489e2-0bbe-45ed-b4fa-ddf100075918" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_0af64486-3d18-4c06-a1c2-de5b28942b89" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_0af64486-3d18-4c06-a1c2-de5b28942b89" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedExercisedAmount_6c97e836-88f0-4d90-800b-637672a262b0" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementAwardedExercisedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_ino_CollaborativeAgreementAwardedExercisedAmount_6c97e836-88f0-4d90-800b-637672a262b0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_7ea9d0b2-5912-4a22-833e-b958dbefcd08" xlink:href="ino-20220331.xsd#ino_GrantProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_ino_GrantProceedsReceived_7ea9d0b2-5912-4a22-833e-b958dbefcd08" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_01972f83-6c0e-40b9-9194-b5f1bfcd26ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_01972f83-6c0e-40b9-9194-b5f1bfcd26ea" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_11912951-0879-4458-92b5-0fd7db84e613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_11912951-0879-4458-92b5-0fd7db84e613" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_20771f52-d9dc-4f8a-ace4-48f7a36193c7" xlink:href="ino-20220331.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_20771f52-d9dc-4f8a-ace4-48f7a36193c7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_69fffae2-73c8-43f3-a8b3-d9a7a7cc0f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_69fffae2-73c8-43f3-a8b3-d9a7a7cc0f24" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c072406e-930b-49eb-a810-8e07d985c061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_595d11be-7e26-4d01-9b70-4d4d836b4d5c" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c072406e-930b-49eb-a810-8e07d985c061" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2fbc8c8c-4fc7-4ca5-b80d-58a370bf9c4e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c072406e-930b-49eb-a810-8e07d985c061" xlink:to="loc_srt_CounterpartyNameAxis_2fbc8c8c-4fc7-4ca5-b80d-58a370bf9c4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2fbc8c8c-4fc7-4ca5-b80d-58a370bf9c4e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2fbc8c8c-4fc7-4ca5-b80d-58a370bf9c4e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2fbc8c8c-4fc7-4ca5-b80d-58a370bf9c4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1a4a1c53-ed92-4e78-9333-da5fc2ea96cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2fbc8c8c-4fc7-4ca5-b80d-58a370bf9c4e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1a4a1c53-ed92-4e78-9333-da5fc2ea96cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_53d4ed22-4bca-4f46-bff0-9e8ea9ad5be7" xlink:href="ino-20220331.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1a4a1c53-ed92-4e78-9333-da5fc2ea96cc" xlink:to="loc_ino_PlumblineLifeSciencesMember_53d4ed22-4bca-4f46-bff0-9e8ea9ad5be7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_25c81d0f-9dce-4d15-ad98-9f8dce485175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c072406e-930b-49eb-a810-8e07d985c061" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_25c81d0f-9dce-4d15-ad98-9f8dce485175" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_25c81d0f-9dce-4d15-ad98-9f8dce485175_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_25c81d0f-9dce-4d15-ad98-9f8dce485175" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_25c81d0f-9dce-4d15-ad98-9f8dce485175_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_5168ff31-c943-4491-92ab-1c2dc294ce8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_25c81d0f-9dce-4d15-ad98-9f8dce485175" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_5168ff31-c943-4491-92ab-1c2dc294ce8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_a23485f7-c5fe-4646-94b9-90d0b932a099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_5168ff31-c943-4491-92ab-1c2dc294ce8d" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_a23485f7-c5fe-4646-94b9-90d0b932a099" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9eb50156-00fc-4f74-90fb-717b3b257c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c072406e-930b-49eb-a810-8e07d985c061" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9eb50156-00fc-4f74-90fb-717b3b257c7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9eb50156-00fc-4f74-90fb-717b3b257c7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9eb50156-00fc-4f74-90fb-717b3b257c7f" xlink:to="loc_us-gaap_RelatedPartyDomain_9eb50156-00fc-4f74-90fb-717b3b257c7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_40e07cdf-a247-41b4-86fc-b0e7355f1d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9eb50156-00fc-4f74-90fb-717b3b257c7f" xlink:to="loc_us-gaap_RelatedPartyDomain_40e07cdf-a247-41b4-86fc-b0e7355f1d68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_c18bc278-3dca-448d-af77-3ab04f7a0ffe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_40e07cdf-a247-41b4-86fc-b0e7355f1d68" xlink:to="loc_srt_DirectorMember_c18bc278-3dca-448d-af77-3ab04f7a0ffe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_455fc1b3-f718-4481-994b-8da0514a855c" xlink:href="ino-20220331.xsd#ino_TheWistarInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_40e07cdf-a247-41b4-86fc-b0e7355f1d68" xlink:to="loc_ino_TheWistarInstituteMember_455fc1b3-f718-4481-994b-8da0514a855c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_12792158-5e9f-4b6e-89e1-4bf2d6add845" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c072406e-930b-49eb-a810-8e07d985c061" xlink:to="loc_srt_ProductOrServiceAxis_12792158-5e9f-4b6e-89e1-4bf2d6add845" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_12792158-5e9f-4b6e-89e1-4bf2d6add845_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_12792158-5e9f-4b6e-89e1-4bf2d6add845" xlink:to="loc_srt_ProductsAndServicesDomain_12792158-5e9f-4b6e-89e1-4bf2d6add845_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_11cc939d-c44b-4946-a359-2b2416a0a954" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_12792158-5e9f-4b6e-89e1-4bf2d6add845" xlink:to="loc_srt_ProductsAndServicesDomain_11cc939d-c44b-4946-a359-2b2416a0a954" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_ec2f4b22-b0b3-46d3-8e2a-efb89f142e80" xlink:href="ino-20220331.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_11cc939d-c44b-4946-a359-2b2416a0a954" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_ec2f4b22-b0b3-46d3-8e2a-efb89f142e80" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="i7192aa153611466baf2ed93165e18f06_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6248323-e371-45da-b8eb-bba2cc256d70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_f3b5eb2f-d8bd-4efe-abde-8f06509dc8dd" xlink:href="ino-20220331.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6248323-e371-45da-b8eb-bba2cc256d70" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_f3b5eb2f-d8bd-4efe-abde-8f06509dc8dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_439b4474-e5c6-47b2-aaee-3256e4f0e8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6248323-e371-45da-b8eb-bba2cc256d70" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_439b4474-e5c6-47b2-aaee-3256e4f0e8ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_d8eef449-9b55-42ef-aa6a-a70c272ab9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6248323-e371-45da-b8eb-bba2cc256d70" xlink:to="loc_us-gaap_LeaseCost_d8eef449-9b55-42ef-aa6a-a70c272ab9a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_d91ee6a8-de0d-43b1-ac61-9af0886fd9f9" xlink:href="ino-20220331.xsd#ino_LesseeOperatingLeaseNumberOfAgreementsToSublease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6248323-e371-45da-b8eb-bba2cc256d70" xlink:to="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_d91ee6a8-de0d-43b1-ac61-9af0886fd9f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_d1daeba8-b000-490b-9524-811d1d85bda0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6248323-e371-45da-b8eb-bba2cc256d70" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_d1daeba8-b000-490b-9524-811d1d85bda0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ab64b84d-ec18-48fc-b604-3cb7d38321cb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d1daeba8-b000-490b-9524-811d1d85bda0" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ab64b84d-ec18-48fc-b604-3cb7d38321cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ab64b84d-ec18-48fc-b604-3cb7d38321cb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ab64b84d-ec18-48fc-b604-3cb7d38321cb" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_ab64b84d-ec18-48fc-b604-3cb7d38321cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_39c7aef8-3928-4c08-930a-05d119cbae0d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ab64b84d-ec18-48fc-b604-3cb7d38321cb" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_39c7aef8-3928-4c08-930a-05d119cbae0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoOfficeMember_0dd679a1-ceb3-4069-a4b6-79c28617b447" xlink:href="ino-20220331.xsd#ino_SanDiegoOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_39c7aef8-3928-4c08-930a-05d119cbae0d" xlink:to="loc_ino_SanDiegoOfficeMember_0dd679a1-ceb3-4069-a4b6-79c28617b447" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_7c497d3e-67fe-4d7e-aba7-823a2490c8a3" xlink:href="ino-20220331.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_39c7aef8-3928-4c08-930a-05d119cbae0d" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_7c497d3e-67fe-4d7e-aba7-823a2490c8a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_29e61c2a-8f08-4427-9b36-efce8c6afed2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d1daeba8-b000-490b-9524-811d1d85bda0" xlink:to="loc_srt_RangeAxis_29e61c2a-8f08-4427-9b36-efce8c6afed2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_29e61c2a-8f08-4427-9b36-efce8c6afed2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_29e61c2a-8f08-4427-9b36-efce8c6afed2" xlink:to="loc_srt_RangeMember_29e61c2a-8f08-4427-9b36-efce8c6afed2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5df10529-5f2f-4cfe-be98-777ae9bc6111" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_29e61c2a-8f08-4427-9b36-efce8c6afed2" xlink:to="loc_srt_RangeMember_5df10529-5f2f-4cfe-be98-777ae9bc6111" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c4255f5d-3dc2-489b-a90f-c51092825833" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5df10529-5f2f-4cfe-be98-777ae9bc6111" xlink:to="loc_srt_MinimumMember_c4255f5d-3dc2-489b-a90f-c51092825833" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a03e1fe0-315d-4b24-a1b7-bc948c8818d8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5df10529-5f2f-4cfe-be98-777ae9bc6111" xlink:to="loc_srt_MaximumMember_a03e1fe0-315d-4b24-a1b7-bc948c8818d8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#CollaborativeAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended" id="i44389bed825a479d863368c066fe0c6e_CollaborativeAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_1110ceb5-4982-421e-b5df-736bbe8c179f" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_1110ceb5-4982-421e-b5df-736bbe8c179f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_7543aec0-3eb7-438a-8687-59c5f1d2a13b" xlink:href="ino-20220331.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_7543aec0-3eb7-438a-8687-59c5f1d2a13b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementPaymentEarned_cb818525-b418-47a7-818a-062bf24f1112" xlink:href="ino-20220331.xsd#ino_CollaborationAgreementPaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborationAgreementPaymentEarned_cb818525-b418-47a7-818a-062bf24f1112" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_48d21d69-55f2-4095-ae43-f3daacfcc9bb" xlink:href="ino-20220331.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_48d21d69-55f2-4095-ae43-f3daacfcc9bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostMaintenance_0d999809-d946-4a5f-be6d-e339e228588c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostMaintenance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_us-gaap_CostMaintenance_0d999809-d946-4a5f-be6d-e339e228588c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AnnualMaintenancePeriod_c5927239-56f9-485a-acf9-80b39c6d3a3e" xlink:href="ino-20220331.xsd#ino_AnnualMaintenancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_AnnualMaintenancePeriod_c5927239-56f9-485a-acf9-80b39c6d3a3e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5fc7b144-7253-4958-8ad1-7b6ee6af7cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5fc7b144-7253-4958-8ad1-7b6ee6af7cd6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_81f850fb-b8e8-41f9-82a6-1bd316afaa56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_us-gaap_AccountsReceivableNet_81f850fb-b8e8-41f9-82a6-1bd316afaa56" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_86df0382-01b4-47de-bab5-b7cde05211bb" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_86df0382-01b4-47de-bab5-b7cde05211bb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_4158dd58-fa26-4059-91eb-681cb70e7213" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_4158dd58-fa26-4059-91eb-681cb70e7213" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_4180c2e0-56a6-4cef-aa75-671eed053718" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_4180c2e0-56a6-4cef-aa75-671eed053718" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_22d88cb5-11ab-4d67-b276-7202c4b9ecd8" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_22d88cb5-11ab-4d67-b276-7202c4b9ecd8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_52da29d4-00f2-4b33-a22b-cb6239a97015" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_52da29d4-00f2-4b33-a22b-cb6239a97015" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_76e64171-c633-450d-9c23-2ea7ed5cd058" xlink:href="ino-20220331.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_DeferredGrantFundingCurrent_76e64171-c633-450d-9c23-2ea7ed5cd058" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_0375c89d-ab92-4032-8734-eaf196aea164" xlink:href="ino-20220331.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_0375c89d-ab92-4032-8734-eaf196aea164" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract_281ea593-8b37-46d6-a23a-8a73053d2bdf" xlink:href="ino-20220331.xsd#ino_CollaborativeArrangementRevenueFromTheProcurementContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract_281ea593-8b37-46d6-a23a-8a73053d2bdf" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_f07e4501-6cff-415d-ac31-609f9095afc0" xlink:href="ino-20220331.xsd#ino_GrantProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_GrantProceedsReceived_f07e4501-6cff-415d-ac31-609f9095afc0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_d6491618-17ed-4eba-8290-cbc6b10d7d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_d6491618-17ed-4eba-8290-cbc6b10d7d6c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_2f79424c-b50b-43ee-b4a1-54668b68a396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_us-gaap_GrantsReceivable_2f79424c-b50b-43ee-b4a1-54668b68a396" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1832ef24-8af0-4a00-9e29-f5ad76b097b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1832ef24-8af0-4a00-9e29-f5ad76b097b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a2db91e4-54ed-4200-88a8-dcddaa73e267" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1832ef24-8af0-4a00-9e29-f5ad76b097b6" xlink:to="loc_srt_CounterpartyNameAxis_a2db91e4-54ed-4200-88a8-dcddaa73e267" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2db91e4-54ed-4200-88a8-dcddaa73e267_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a2db91e4-54ed-4200-88a8-dcddaa73e267" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2db91e4-54ed-4200-88a8-dcddaa73e267_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2593754-ff17-4ff0-91dd-8ec327a81d6e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a2db91e4-54ed-4200-88a8-dcddaa73e267" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2593754-ff17-4ff0-91dd-8ec327a81d6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_bd499c94-c5a4-4752-93e4-6b3faf131d2a" xlink:href="ino-20220331.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2593754-ff17-4ff0-91dd-8ec327a81d6e" xlink:to="loc_ino_AdvaccineMember_bd499c94-c5a4-4752-93e4-6b3faf131d2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_5a1504d2-d97c-4ce2-a2f0-9c0ae3787233" xlink:href="ino-20220331.xsd#ino_ApolloBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2593754-ff17-4ff0-91dd-8ec327a81d6e" xlink:to="loc_ino_ApolloBioMember_5a1504d2-d97c-4ce2-a2f0-9c0ae3787233" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_c58920c1-897a-4b93-8254-661edc7d1c61" xlink:href="ino-20220331.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2593754-ff17-4ff0-91dd-8ec327a81d6e" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_c58920c1-897a-4b93-8254-661edc7d1c61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_915258d9-22f4-4153-99e0-57764ac96d6f" xlink:href="ino-20220331.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2593754-ff17-4ff0-91dd-8ec327a81d6e" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_915258d9-22f4-4153-99e0-57764ac96d6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember_af75c182-9a26-4eee-9dff-7653b1641933" xlink:href="ino-20220331.xsd#ino_DepartmentOfDefenceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2593754-ff17-4ff0-91dd-8ec327a81d6e" xlink:to="loc_ino_DepartmentOfDefenceMember_af75c182-9a26-4eee-9dff-7653b1641933" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_14c3993d-0371-47b7-b195-98d8ca50a2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1832ef24-8af0-4a00-9e29-f5ad76b097b6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_14c3993d-0371-47b7-b195-98d8ca50a2c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14c3993d-0371-47b7-b195-98d8ca50a2c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_14c3993d-0371-47b7-b195-98d8ca50a2c7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14c3993d-0371-47b7-b195-98d8ca50a2c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9597f322-65dc-4147-8064-4e7e8720eda8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_14c3993d-0371-47b7-b195-98d8ca50a2c7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9597f322-65dc-4147-8064-4e7e8720eda8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_b9dc4f2b-de16-497c-8add-6a73ab65ea20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9597f322-65dc-4147-8064-4e7e8720eda8" xlink:to="loc_us-gaap_CollaborativeArrangementMember_b9dc4f2b-de16-497c-8add-6a73ab65ea20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3a536ca7-3f70-4f1d-91ab-6d44f9e11a7f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1832ef24-8af0-4a00-9e29-f5ad76b097b6" xlink:to="loc_srt_MajorCustomersAxis_3a536ca7-3f70-4f1d-91ab-6d44f9e11a7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3a536ca7-3f70-4f1d-91ab-6d44f9e11a7f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_3a536ca7-3f70-4f1d-91ab-6d44f9e11a7f" xlink:to="loc_srt_NameOfMajorCustomerDomain_3a536ca7-3f70-4f1d-91ab-6d44f9e11a7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_29707956-1b5d-4b05-94f0-25fe07bf349e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_3a536ca7-3f70-4f1d-91ab-6d44f9e11a7f" xlink:to="loc_srt_NameOfMajorCustomerDomain_29707956-1b5d-4b05-94f0-25fe07bf349e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_21009d32-f6ce-49cd-a87c-c628d6cd7951" xlink:href="ino-20220331.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_29707956-1b5d-4b05-94f0-25fe07bf349e" xlink:to="loc_ino_AdvaccineMember_21009d32-f6ce-49cd-a87c-c628d6cd7951" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_889456bf-68b2-419f-95dc-d9364da7a281" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1832ef24-8af0-4a00-9e29-f5ad76b097b6" xlink:to="loc_srt_ProductOrServiceAxis_889456bf-68b2-419f-95dc-d9364da7a281" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_889456bf-68b2-419f-95dc-d9364da7a281_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_889456bf-68b2-419f-95dc-d9364da7a281" xlink:to="loc_srt_ProductsAndServicesDomain_889456bf-68b2-419f-95dc-d9364da7a281_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c0bd709e-95b0-4e69-a0e2-2bdd59ca3dca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_889456bf-68b2-419f-95dc-d9364da7a281" xlink:to="loc_srt_ProductsAndServicesDomain_c0bd709e-95b0-4e69-a0e2-2bdd59ca3dca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_6f12c02e-7fd9-4439-9864-44876d1f5ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0bd709e-95b0-4e69-a0e2-2bdd59ca3dca" xlink:to="loc_us-gaap_LicenseMember_6f12c02e-7fd9-4439-9864-44876d1f5ef4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_3eadea35-da3c-433e-8e01-f538cc98aaea" xlink:href="ino-20220331.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0bd709e-95b0-4e69-a0e2-2bdd59ca3dca" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_3eadea35-da3c-433e-8e01-f538cc98aaea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember_cb4ddd7e-8a64-422f-b4e1-f98920ff777f" xlink:href="ino-20220331.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0bd709e-95b0-4e69-a0e2-2bdd59ca3dca" xlink:to="loc_ino_SARSCoV2COVID19VaccineMember_cb4ddd7e-8a64-422f-b4e1-f98920ff777f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_dd624db0-aa38-43aa-8d34-b373130459d6" xlink:href="ino-20220331.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0bd709e-95b0-4e69-a0e2-2bdd59ca3dca" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_dd624db0-aa38-43aa-8d34-b373130459d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member_5f1186e8-692b-4c81-8e3b-7d49995564cf" xlink:href="ino-20220331.xsd#ino_INO4800Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0bd709e-95b0-4e69-a0e2-2bdd59ca3dca" xlink:to="loc_ino_INO4800Member_5f1186e8-692b-4c81-8e3b-7d49995564cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_f7a8d093-d765-49c0-beb2-706e06425be2" xlink:href="ino-20220331.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0bd709e-95b0-4e69-a0e2-2bdd59ca3dca" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_f7a8d093-d765-49c0-beb2-706e06425be2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA2000DeviceMember_2fdfbc42-6dad-4b5c-be28-d7505dd5c954" xlink:href="ino-20220331.xsd#ino_CELLECTRA2000DeviceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c0bd709e-95b0-4e69-a0e2-2bdd59ca3dca" xlink:to="loc_ino_CELLECTRA2000DeviceMember_2fdfbc42-6dad-4b5c-be28-d7505dd5c954" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended" id="i2ad8110a1c91405a885a2b0d2c2b6997_GeneosTherapeuticsIncNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_f3a47571-b2d6-4bdf-83a2-40c823a2f492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_f3a47571-b2d6-4bdf-83a2-40c823a2f492" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_17843f61-3328-40b0-a4ad-0779c23f8177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_17843f61-3328-40b0-a4ad-0779c23f8177" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_0c9721c1-5466-4f3a-95bc-26ecc19ad83b" xlink:href="ino-20220331.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:to="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_0c9721c1-5466-4f3a-95bc-26ecc19ad83b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a4f929b8-d9e7-4275-aa27-7416a08c475a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a4f929b8-d9e7-4275-aa27-7416a08c475a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_4980223e-c6ac-4ff5-898e-5fee6d42dc85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_4980223e-c6ac-4ff5-898e-5fee6d42dc85" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_5dd1c57a-9377-4116-b878-24dd5efeae15" xlink:href="ino-20220331.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:to="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_5dd1c57a-9377-4116-b878-24dd5efeae15" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_6697a0f9-3ef0-44f6-b247-9a9956c29e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_6697a0f9-3ef0-44f6-b247-9a9956c29e07" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5f05499d-62a9-4f66-9d37-8f1a932c8993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5f05499d-62a9-4f66-9d37-8f1a932c8993" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_d733b7f6-bbe2-4e4d-aaeb-a8ba4e325ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:to="loc_us-gaap_EquityMethodInvestments_d733b7f6-bbe2-4e4d-aaeb-a8ba4e325ed4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_60fa2cfb-bdff-4b08-9a07-610c61a0109a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:to="loc_us-gaap_MinorityInterestTable_60fa2cfb-bdff-4b08-9a07-610c61a0109a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7efcc8cf-cf45-4da0-8e2d-98ead2134e5c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_60fa2cfb-bdff-4b08-9a07-610c61a0109a" xlink:to="loc_srt_CounterpartyNameAxis_7efcc8cf-cf45-4da0-8e2d-98ead2134e5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7efcc8cf-cf45-4da0-8e2d-98ead2134e5c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7efcc8cf-cf45-4da0-8e2d-98ead2134e5c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7efcc8cf-cf45-4da0-8e2d-98ead2134e5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f272db30-3350-46e8-9584-7bf0528c4ab9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7efcc8cf-cf45-4da0-8e2d-98ead2134e5c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f272db30-3350-46e8-9584-7bf0528c4ab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_d35b3c1d-1b3e-4f50-ba35-b25480837d7f" xlink:href="ino-20220331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f272db30-3350-46e8-9584-7bf0528c4ab9" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_d35b3c1d-1b3e-4f50-ba35-b25480837d7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_6fea4547-0bb4-4a44-982b-28f9a37c1445" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_60fa2cfb-bdff-4b08-9a07-610c61a0109a" xlink:to="loc_srt_OwnershipAxis_6fea4547-0bb4-4a44-982b-28f9a37c1445" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6fea4547-0bb4-4a44-982b-28f9a37c1445_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_6fea4547-0bb4-4a44-982b-28f9a37c1445" xlink:to="loc_srt_OwnershipDomain_6fea4547-0bb4-4a44-982b-28f9a37c1445_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_bee2eee9-96df-48c2-93d3-ca52a6224952" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_6fea4547-0bb4-4a44-982b-28f9a37c1445" xlink:to="loc_srt_OwnershipDomain_bee2eee9-96df-48c2-93d3-ca52a6224952" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_d77ba609-f1e9-43c6-a987-0292626ab9e5" xlink:href="ino-20220331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_bee2eee9-96df-48c2-93d3-ca52a6224952" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_d77ba609-f1e9-43c6-a987-0292626ab9e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_129c3b12-279f-4358-8d12-a95cf7cbe10e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_60fa2cfb-bdff-4b08-9a07-610c61a0109a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_129c3b12-279f-4358-8d12-a95cf7cbe10e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_129c3b12-279f-4358-8d12-a95cf7cbe10e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_129c3b12-279f-4358-8d12-a95cf7cbe10e" xlink:to="loc_us-gaap_ClassOfStockDomain_129c3b12-279f-4358-8d12-a95cf7cbe10e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9e0ffaa0-7e3f-4f85-826e-63a658cd60f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_129c3b12-279f-4358-8d12-a95cf7cbe10e" xlink:to="loc_us-gaap_ClassOfStockDomain_9e0ffaa0-7e3f-4f85-826e-63a658cd60f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_541dbeb1-dca5-4643-8da1-33ed498200cb" xlink:href="ino-20220331.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9e0ffaa0-7e3f-4f85-826e-63a658cd60f6" xlink:to="loc_ino_SeriesAOnePreferredStockMember_541dbeb1-dca5-4643-8da1-33ed498200cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_024ee0ad-178d-4173-b532-4744686fdc06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9e0ffaa0-7e3f-4f85-826e-63a658cd60f6" xlink:to="loc_us-gaap_CommonStockMember_024ee0ad-178d-4173-b532-4744686fdc06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_39682205-5bfe-43ab-b110-163766d34581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9e0ffaa0-7e3f-4f85-826e-63a658cd60f6" xlink:to="loc_us-gaap_PreferredStockMember_39682205-5bfe-43ab-b110-163766d34581" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#GeneosTherapeuticsIncPreferredstockInvestmentDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="extended" id="i8f46e6e8607244108abc40012a7fdb19_GeneosTherapeuticsIncPreferredstockInvestmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_cde31b94-d949-4677-8b32-999f196a8248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_98dbf7d2-2792-422d-9a57-c51efb735b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_cde31b94-d949-4677-8b32-999f196a8248" xlink:to="loc_us-gaap_EquityMethodInvestments_98dbf7d2-2792-422d-9a57-c51efb735b3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_a4a18bb0-0eb6-415d-b163-0ea3e7fcbddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_cde31b94-d949-4677-8b32-999f196a8248" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_a4a18bb0-0eb6-415d-b163-0ea3e7fcbddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_dea63e3b-bc9a-4942-bf2c-25292efb09bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_cde31b94-d949-4677-8b32-999f196a8248" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_dea63e3b-bc9a-4942-bf2c-25292efb09bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_79a104de-d498-4914-97dd-b04811d9c1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_dcdb39e5-7871-459c-95a6-5c08dc5ddc97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_cde31b94-d949-4677-8b32-999f196a8248" xlink:to="loc_us-gaap_MinorityInterestTable_dcdb39e5-7871-459c-95a6-5c08dc5ddc97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3167d811-01da-484b-9355-9915f035eff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_dcdb39e5-7871-459c-95a6-5c08dc5ddc97" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3167d811-01da-484b-9355-9915f035eff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3167d811-01da-484b-9355-9915f035eff1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3167d811-01da-484b-9355-9915f035eff1" xlink:to="loc_us-gaap_ClassOfStockDomain_3167d811-01da-484b-9355-9915f035eff1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f38db73a-13f1-45e1-a6d6-d6a30ed8b86d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3167d811-01da-484b-9355-9915f035eff1" xlink:to="loc_us-gaap_ClassOfStockDomain_f38db73a-13f1-45e1-a6d6-d6a30ed8b86d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesA2OnePreferredStockMember_b110976f-781f-4444-bf9e-690d0a9bee48" xlink:href="ino-20220331.xsd#ino_SeriesA2OnePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_f38db73a-13f1-45e1-a6d6-d6a30ed8b86d" xlink:to="loc_ino_SeriesA2OnePreferredStockMember_b110976f-781f-4444-bf9e-690d0a9bee48" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="extended" id="i47881934e4fb4850bf119a67062c2968_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_5fa2d278-41eb-4cb1-a902-0a67338d3efe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ce3e39d8-a586-41c2-a07f-c351e2928762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5fa2d278-41eb-4cb1-a902-0a67338d3efe" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ce3e39d8-a586-41c2-a07f-c351e2928762" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ecd6a79c-f1b6-4e94-b62a-0cd4aa8f8155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5fa2d278-41eb-4cb1-a902-0a67338d3efe" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ecd6a79c-f1b6-4e94-b62a-0cd4aa8f8155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c9bee677-c8ef-4d8b-af56-707bf9884543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5fa2d278-41eb-4cb1-a902-0a67338d3efe" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c9bee677-c8ef-4d8b-af56-707bf9884543" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_d30d3b2a-aa98-49f9-a7d5-52f1576af0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_5fa2d278-41eb-4cb1-a902-0a67338d3efe" xlink:to="loc_us-gaap_SubsequentEventTable_d30d3b2a-aa98-49f9-a7d5-52f1576af0c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2ed290cb-350b-4a24-b3ea-6eb8ba9adfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_d30d3b2a-aa98-49f9-a7d5-52f1576af0c1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2ed290cb-350b-4a24-b3ea-6eb8ba9adfa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2ed290cb-350b-4a24-b3ea-6eb8ba9adfa1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2ed290cb-350b-4a24-b3ea-6eb8ba9adfa1" xlink:to="loc_us-gaap_ClassOfStockDomain_2ed290cb-350b-4a24-b3ea-6eb8ba9adfa1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7797da9d-3e70-49a1-9a8e-77f53d6fbf89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2ed290cb-350b-4a24-b3ea-6eb8ba9adfa1" xlink:to="loc_us-gaap_ClassOfStockDomain_7797da9d-3e70-49a1-9a8e-77f53d6fbf89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b5930f78-71c1-4d7a-8bd9-8e47b4b5a8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7797da9d-3e70-49a1-9a8e-77f53d6fbf89" xlink:to="loc_us-gaap_CommonStockMember_b5930f78-71c1-4d7a-8bd9-8e47b4b5a8f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cf233ed9-f4c6-4756-8891-445772a86ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_d30d3b2a-aa98-49f9-a7d5-52f1576af0c1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cf233ed9-f4c6-4756-8891-445772a86ab1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cf233ed9-f4c6-4756-8891-445772a86ab1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cf233ed9-f4c6-4756-8891-445772a86ab1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cf233ed9-f4c6-4756-8891-445772a86ab1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_aa44d1aa-f12c-4822-85a3-d197b9c2ae5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cf233ed9-f4c6-4756-8891-445772a86ab1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_aa44d1aa-f12c-4822-85a3-d197b9c2ae5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_50bd9590-1c72-4819-9b98-83859792a699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_aa44d1aa-f12c-4822-85a3-d197b9c2ae5f" xlink:to="loc_us-gaap_SubsequentEventMember_50bd9590-1c72-4819-9b98-83859792a699" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>ino-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:500251c5-f1ff-4b5f-bcb3-245f4230a461,g:c147bae2-ade6-4d52-bd96-82e99e7a58d2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_f73a9922-d95f-450a-b63f-1eb628bfff62_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities that are measured at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_861b4ee8-013f-40fe-8218-4c112b43c903_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_96fa9188-8bc1-4a2d-aeca-dff6524c623d_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_bb00be1c-f57f-465a-9dc0-241d9600e72d_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_0f98de78-7aac-481b-9b99-dce86fceb7c5_negatedTerseLabel_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_label_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Income (Expense)</link:label>
    <link:label id="lab_ino_NonCashInterestIncomeExpense_documentation_en-US" xlink:label="lab_ino_NonCashInterestIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense" xlink:href="ino-20220331.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonCashInterestIncomeExpense" xlink:to="lab_ino_NonCashInterestIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b8400432-497f-40fc-a148-b711c5dfec68_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_b3d4f288-d523-4878-b6ea-7aad56a6445d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_67f5ba71-f4d0-463a-a85a-ce626099a44b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d6b765a3-10bd-41e5-880b-ad5708dc8adb_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4d92a9b2-8522-47b4-8a19-37d4e3a7c708_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_78170842-a5a6-43fc-90b3-1dadb4c2b7d3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_085b28e7-a88b-4fdb-b1d6-1e68981e38c3_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_UnderwrittenPublicOfferingMember_410a18a7-5f4d-4835-a954-fe90efb6eef6_terseLabel_en-US" xlink:label="lab_ino_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Public Offering</link:label>
    <link:label id="lab_ino_UnderwrittenPublicOfferingMember_label_en-US" xlink:label="lab_ino_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Public Offering [Member]</link:label>
    <link:label id="lab_ino_UnderwrittenPublicOfferingMember_documentation_en-US" xlink:label="lab_ino_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Public Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember" xlink:href="ino-20220331.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_UnderwrittenPublicOfferingMember" xlink:to="lab_ino_UnderwrittenPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_fbd22a1b-4c13-4d4a-91c8-cd7bd1566cb3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1b9a7911-8e13-4eb0-bf4e-77ae715b9dba_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_7ac33879-ba7b-45ed-8336-1973adea8d7d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_f9924885-aaaf-40d5-b2f1-5817ac91493a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostMaintenance_4da5e739-cef2-4010-838b-0d3b196b4f7d_terseLabel_en-US" xlink:label="lab_us-gaap_CostMaintenance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual maintenance fee</link:label>
    <link:label id="lab_us-gaap_CostMaintenance_label_en-US" xlink:label="lab_us-gaap_CostMaintenance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Maintenance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostMaintenance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostMaintenance" xlink:to="lab_us-gaap_CostMaintenance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_9bbdc842-c3d3-4a97-b998-4b69fbc385b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_48adc80f-6d64-4095-9145-f3e67f1999e6_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_628bf591-9bd9-4001-8573-b38bd2456d2c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in affiliated entity</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ef54eaec-876a-4b4b-b8bc-907804baa590_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_70220916-bbf1-4d8e-a676-4f1a2f32aed2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_5aada19b-4fba-4ff8-9ed2-6c06690582ce_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f35ae5a9-7378-42fa-a639-5628aee7b3a5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_ad516f7c-db36-4e75-8ad8-0178771d4c1c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5bf8ae02-e7d2-4c1f-babd-052fb47bd62e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_49f8f21d-1273-4e49-a495-91c8c8eb9d4a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_66630c4a-caf7-4636-8419-36012a657b1b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_00dfd1f3-e66e-4940-a993-3eb831583ee4_terseLabel_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of potential shares authorized for issuance under share based compensation plan (in shares)</link:label>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_label_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Potential Shares Authorized For Issuance Under Share Based Compensation Plan</link:label>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_documentation_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of potential shares authorized for issuance under a share-based compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:href="ino-20220331.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:to="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2007IncentivePlanMember_74df61a3-2b10-4960-980e-9f49aca80d49_terseLabel_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember" xlink:href="ino-20220331.xsd#ino_A2007IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2007IncentivePlanMember" xlink:to="lab_ino_A2007IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_02e75119-da2b-4505-9bfc-596f292fd453_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_a9ea1545-d41e-4e51-8812-e974d3836426_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_467ed330-a78d-4ad8-8dda-a5127bfccd7b_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementPaymentEarned_db350f32-8a89-4006-89e2-7cabeb1a6c0a_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementPaymentEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, payment earned</link:label>
    <link:label id="lab_ino_CollaborationAgreementPaymentEarned_label_en-US" xlink:label="lab_ino_CollaborationAgreementPaymentEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Payment Earned</link:label>
    <link:label id="lab_ino_CollaborationAgreementPaymentEarned_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementPaymentEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Payment Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementPaymentEarned" xlink:href="ino-20220331.xsd#ino_CollaborationAgreementPaymentEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementPaymentEarned" xlink:to="lab_ino_CollaborationAgreementPaymentEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_41c258c9-b8bc-4bca-acb0-ee99e3336082_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_fde27baf-c227-47c9-9725-c64539f22874_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, redemption price percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1acf0c69-0edc-4d2f-8c23-6702edc558d9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_db2d025d-26f9-4ceb-b7d7-ed9649ad068f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of common and preferred stock authorized, issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_7f6f6d12-9292-4833-a992-62026e234bb7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_ec4df0cb-0290-4406-a970-780516e3cb96_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_adf9bf34-2a5a-4f76-b247-f9b06607f9f9_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses related to affiliated entity</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantProceedsReceived_49a377ff-4892-40c1-8097-e59cac21e462_terseLabel_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contra-research and development expense</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_label_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_documentation_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived" xlink:href="ino-20220331.xsd#ino_GrantProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantProceedsReceived" xlink:to="lab_ino_GrantProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_bb90b584-ed87-4c3d-84c2-62c0dd9e649a_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_3ab1bad2-901a-4a91-8db0-4f7660f3db68_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_645b601e-0987-49e8-aeeb-2fd8f3fecd38_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionNameDomain_b64d314a-f7fa-499c-a164-349ed710325e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtConversionNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionNameDomain" xlink:to="lab_us-gaap_DebtConversionNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_7ee61239-c66e-43c6-b35e-15d7a6990593_totalLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total goodwill and intangible assets, Net Book Value</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Net</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet" xlink:href="ino-20220331.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet" xlink:to="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b9ab4a72-f241-4531-a0bf-4bb0d0612471_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_83a6ecc9-30c1-45ae-a480-212f33fc98bd_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_5d2e9b64-c349-4fdf-92a6-d48a8f648c69_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amortization expense on intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_8d321fc5-7aae-46c3-8a6f-d1141b22ce2f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_fd7326a1-4da8-4e22-8ae7-2ccb7cd688b5_terseLabel_en-US" xlink:label="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2027</link:label>
    <link:label id="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="ino-20220331.xsd#ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ca099627-3730-4d8f-a561-4a0b04d3079c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5cc4589d-e231-4a51-b128-e8cbe6cda488_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_12b45045-9874-4577-8d7d-03c470e193ae_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_163faac8-238c-4a53-b6ad-35073ac87e30_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_8013d7e6-4ca0-44f8-acb9-1c274281c66d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_4d8ada04-52eb-4b0a-a16c-fa1eeb6ccc57_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_dfb8ee53-064e-45f5-bf94-d817c304b8e4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedParties" xlink:to="lab_us-gaap_AccountsReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_27c24323-654a-4cd0-9749-f7319c4234e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, restricted stock units (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_8ef2db36-5365-411e-81fa-0d3902350bf1_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_93efe688-32ad-45be-b1b2-23c2523a02aa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on short-term investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DepartmentOfDefenceMember_88b9a53f-908c-4c2c-ae87-ad1961cdce90_terseLabel_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department of Defence</link:label>
    <link:label id="lab_ino_DepartmentOfDefenceMember_label_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Of Defence [Member]</link:label>
    <link:label id="lab_ino_DepartmentOfDefenceMember_documentation_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Of Defence [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember" xlink:href="ino-20220331.xsd#ino_DepartmentOfDefenceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DepartmentOfDefenceMember" xlink:to="lab_ino_DepartmentOfDefenceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_bdc538ef-3f39-4858-8426-0c4a8c68c970_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_811ead38-fa84-47d0-96aa-ba32f3e361b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_3e63fde5-e3e8-4f76-bf7c-d99d51bcd26b_terseLabel_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Bonds</link:label>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_label_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_documentation_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Convertible Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember" xlink:href="ino-20220331.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_December2019ConvertibleBondsMember" xlink:to="lab_ino_December2019ConvertibleBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_733a1b8d-55ca-47ce-a321-66240f06dba1_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_65a2a960-dfea-4839-9aa2-6c9d397c38ba_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_4280be91-bda6-427a-974e-cbe1a4feffb2_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_b24cff01-fe84-4e28-b21b-3fde7a221f09_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Summary of Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3b2c6ae6-ab24-40c5-9bd6-d0f6edde22b7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fe9e7a93-ea53-480a-99ad-de74e9811d7b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_3a050331-d7c6-4766-9a81-e6fe29963870_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_b6f7d257-fb95-4295-a479-87c759cb52f9_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_84ba9e2a-fa4d-4fba-853a-a3c2f72594f6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_MutualFundsMember_b46dec59-7f4b-42d6-8f92-f909ce0f04d1_verboseLabel_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_label_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Funds [Member]</link:label>
    <link:label id="lab_ino_MutualFundsMember_documentation_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember" xlink:href="ino-20220331.xsd#ino_MutualFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MutualFundsMember" xlink:to="lab_ino_MutualFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_1c560ff1-d92a-4408-98f7-80d3fd7ee926_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_INO4800Member_b82c0870-233b-48aa-8f36-67650ccb908d_terseLabel_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INO-4800</link:label>
    <link:label id="lab_ino_INO4800Member_label_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INO-4800 [Member]</link:label>
    <link:label id="lab_ino_INO4800Member_documentation_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INO-4800 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member" xlink:href="ino-20220331.xsd#ino_INO4800Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_INO4800Member" xlink:to="lab_ino_INO4800Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c576c054-69cc-4e72-bf41-945bd790b85a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a7563da5-6a4d-46ae-a755-04d95a6b73d3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_3eaad2ba-f52c-4bed-9f31-63df99cbfe08_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1e3bfe54-d487-4a42-90fc-3a03ad77808e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets, including from affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_3e979abb-0d34-42f1-9c99-c11995b00124_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_e2167723-cdf3-49c7-829d-814c79abedcd_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_bdffc7ea-ca84-492e-bfa5-64cdc2d4c6f3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_05fce36b-e326-464b-ab33-435e021f8249_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of December 2019 Bonds to common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_874fe126-a3ce-45d9-af98-5cc8b46760e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BiojectMember_dec2d9a6-4d60-4eae-8d48-6461c061f6ae_terseLabel_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject</link:label>
    <link:label id="lab_ino_BiojectMember_label_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject [Member]</link:label>
    <link:label id="lab_ino_BiojectMember_documentation_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember" xlink:href="ino-20220331.xsd#ino_BiojectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BiojectMember" xlink:to="lab_ino_BiojectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7a1a4fdc-3b7e-4cac-8ebc-557b2b74e791_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2eef07f1-aa15-4488-8168-21a230105781_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, including from affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_ca9183e1-eefc-47b4-a2c6-04e393103d17_verboseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on deconsolidation of investment</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0c56ae00-e565-4558-b088-101663d73241_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts accrued for purchases of fixed assets</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_e4b62470-526e-4de0-804a-99c9239f7042_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:to="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_6bb837b7-9291-4045-9afc-190aede4ac6d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0604517f-052f-452a-b24d-4063ab847da6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1cf4fc57-6647-4e83-9a03-94981b457022_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_14e9476d-a106-4c24-8d09-ccd9472b2f86_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable/accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_ecf5aef4-045d-4328-8091-2613fb8f0401_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in affiliated entity</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_20a9aa87-8e53-451a-8428-97a1ff9de00c_terseLabel_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase agreement, commitment of additional investment</link:label>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_label_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Commitment Of Additional Investment</link:label>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_documentation_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Commitment Of Additional Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:href="ino-20220331.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:to="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_4be2ef5b-6bf2-4344-946e-3c8f2b27f3fd_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_label_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:href="ino-20220331.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:to="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_70af9d3d-8fb8-46c7-a7cc-9385722c69ae_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_212acea3-681d-4053-ad0c-91299c8f89e8_verboseLabel_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-based restricted stock units</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:href="ino-20220331.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:to="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ca4e60a4-c199-404b-94dd-7425151317cf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_3218c7ea-7731-419f-9568-a3a7abd511af_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_99b4bf18-4d98-4cba-8bce-4d0a02ece05e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of unvested restricted stock units and options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f06f50ac-a382-4d4f-bbd6-186afb2a9dad_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_b17c3c3c-4de1-46c2-8289-f3e59bba48b3_terseLabel_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill and Melinda Gates Foundation</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_label_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_documentation_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember" xlink:href="ino-20220331.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BillAndMelindaGatesFoundationMember" xlink:to="lab_ino_BillAndMelindaGatesFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_eb73ddbc-bca8-4103-981c-e13b0c822946_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, contractual interest</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_0b859b79-0bed-4837-8d4c-f87ba8c610d8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, other shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Other Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:to="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_dd673e44-a505-41ba-afd1-8bc89ed01f53_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum authorized amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_label_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:href="ino-20220331.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:to="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_c6caec83-cb2d-4860-bbe6-b27e89642386_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_ebaf0f02-2dce-41f2-befa-63486c87d799_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a6a9c3be-ca19-4164-87ea-bdae819580eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_20a61e14-5f14-4c92-8331-e8f74c666f13_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses - Clinical Trial Accruals</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_4edfd74e-2ef3-47c7-aebf-336a309817fb_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_fec3dcc1-220a-4d83-90b7-d209befaa1b9_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_63b2342e-2230-44d6-9d3c-d8753d687107_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid balance</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_04b1d92d-487d-4b7a-8ad5-91102bdb7614_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_bb3da9f7-8d1c-4f0d-a6bb-d424a6ab2d02_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_963b5e69-298b-4e36-bb58-76bde16af4f3_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2cdc452b-7e2a-4ddd-bd1b-28c8cc02d030_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SalesAgreementMember_f1abcc19-c64b-43fe-8a47-7f1543226908_terseLabel_en-US" xlink:label="lab_ino_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement</link:label>
    <link:label id="lab_ino_SalesAgreementMember_label_en-US" xlink:label="lab_ino_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_SalesAgreementMember_documentation_en-US" xlink:label="lab_ino_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember" xlink:href="ino-20220331.xsd#ino_SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SalesAgreementMember" xlink:to="lab_ino_SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_226217af-c6e5-4ef0-a223-9203d90ffb90_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_5779242a-329b-4012-acda-652cd31f76e9_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SalesAgreementsMember_013d6ba8-f079-4301-ade6-930c7842dff9_terseLabel_en-US" xlink:label="lab_ino_SalesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreements</link:label>
    <link:label id="lab_ino_SalesAgreementsMember_label_en-US" xlink:label="lab_ino_SalesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreements [Member]</link:label>
    <link:label id="lab_ino_SalesAgreementsMember_documentation_en-US" xlink:label="lab_ino_SalesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementsMember" xlink:href="ino-20220331.xsd#ino_SalesAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SalesAgreementsMember" xlink:to="lab_ino_SalesAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_68cfd7c5-bec0-4d3f-b9b5-d89137b7ce21_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_0633d526-0b66-49ca-a001-bd9af75b930f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1c832588-ccfc-4911-a8a6-b91d8fe14f40_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1c186b50-39eb-4409-9317-44bd78e9dacd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_01f5f6d8-a9b5-49d0-bf92-05515d1c5c94_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_83a815fb-716c-4312-bcb6-bd5817743cc3_totalLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total goodwill and intangible assets, Gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross" xlink:href="ino-20220331.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross" xlink:to="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_09d94710-28b5-429e-9c4a-f13fef4db96e_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_86c609e9-f236-4bc1-93c8-24c4287af804_negatedLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_292790d6-fe00-46b3-92c8-7cc2da6c0f7a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_cce9cc29-538f-48b2-ba4e-5d966e7e4b0b_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_cc4ff168-2af6-4193-bd98-e65c0d1ab49a_terseLabel_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_label_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_documentation_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember" xlink:href="ino-20220331.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EmployeesAndDirectorsMember" xlink:to="lab_ino_EmployeesAndDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_ba97e259-7c5d-4f51-827d-e472dac1ce65_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation, Liquidity and Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a9c579ea-02f3-400f-a79c-8638d3d453b2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_1c3243b1-e9fb-4ff8-be2b-fba9f8051f91_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_560af6dd-a2c6-455e-933d-c726340f4d19_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_a1b09b56-b768-4875-b9cd-8de151866f49_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_628ad9e2-35f3-44f1-8db7-4bb8400a94bb_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_22831241-26f2-4d16-ae6e-4eb2bf58e17b_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_53b985cf-4a8b-4ae1-baa1-64c62134253c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2484e462-ab50-4957-8492-239fd53762f9_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_3a883ff9-8526-4bc0-9874-0102cbdfc6f0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gain on investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_7145e048-0de3-4c59-8a95-f990f2e89434_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_223951a8-6e6d-4c1f-a307-ddf3550c51e9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bc3afb5e-d1d9-4693-9690-79d39a665d2d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_0ed1be72-16a0-4f6d-9c40-1cf9142321f5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_3a9a49e9-ba7c-4348-a1f6-94d4a73be5f9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_489ebcfd-e560-47e1-b6d4-1153ec931e0c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_dea36e3e-a38a-4047-9948-6f9c86fafcb5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_dbfb676a-7b0d-4409-99c6-0ce7967a8355_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_7ca8df7b-fbc1-4a3c-8831-7c708b26146f_verboseLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on investment in affiliated entities</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_6e6fbec3-a465-4a50-9bf4-869f45c35ad0_negatedLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on equity investment in affiliated entities</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_label_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Value of Investments in Affiliated Company</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_documentation_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:href="ino-20220331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:to="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_2505dae8-9945-42c5-9e79-355567d5c68b_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_a4a0a462-290c-4309-910f-45f36e12d3aa_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_061f94cc-25db-44f2-81ae-cc37ce50218e_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160;Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a148ae52-9cef-4eed-9d1b-f2ca9bd7fe9f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_f5ef048d-69d5-47fc-b8a7-b460ffe437b7_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_73f886e8-1374-4cff-9f78-c47285a605c8_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate number of shares issued (in shares)</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:href="ino-20220331.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:to="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_17a37480-e16f-4eb1-b938-ffb2c3bc3aa5_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AdvaccineMember_433646b6-ded8-4af9-8cb6-1159c28d2d02_terseLabel_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advaccine</link:label>
    <link:label id="lab_ino_AdvaccineMember_label_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advaccine [Member]</link:label>
    <link:label id="lab_ino_AdvaccineMember_documentation_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advaccine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember" xlink:href="ino-20220331.xsd#ino_AdvaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AdvaccineMember" xlink:to="lab_ino_AdvaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_269f679f-61cd-48f7-9477-e11f10ef42ae_terseLabel_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, sales proceeds of any common stock, percentage</link:label>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_label_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</link:label>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_documentation_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:href="ino-20220331.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:to="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_a0087960-aa74-470c-8209-fcba4964da52_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded option amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1984209f-0579-4063-b551-a1736282054f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for cash, net of financing costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_3d5978e8-65fc-4874-8610-d62be20b28cd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_dee06c15-ff33-476b-9873-8292dccc3529_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_5fc6cb6b-f8ac-482b-b830-8da4f3f25e56_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_8fe8bf8e-b56b-4e7a-aa20-3d83e255c1f6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_1bb41156-f2e3-423c-9397-fd9df94ef878_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_0d12b4da-70c9-4cd8-9a5a-8ff725e3476c_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant funding, from affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate" xlink:href="ino-20220331.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliate" xlink:to="lab_ino_DeferredGrantFundingFromAffiliate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_8af5017b-4cc6-4b6c-999d-27a185d295f9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_816f78e3-c397-46fb-a1b1-d326b86195db_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_67269450-0f8d-4b94-a138-856f2997e5bf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for cash, net of financing costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TheWistarInstituteMember_eb517e85-0327-43ed-98c5-064fecbb3606_terseLabel_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Wistar Institute</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_label_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_documentation_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember" xlink:href="ino-20220331.xsd#ino_TheWistarInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TheWistarInstituteMember" xlink:to="lab_ino_TheWistarInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6c05b884-bc1f-49e1-bb13-f33076e524dd_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_91d7612c-739f-45c4-98e9-7f8c85d6c627_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b9d5423c-f6a9-4f0e-ac4c-f3deb0805476_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized transaction loss on foreign-currency denominated debt</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_4e0a68e3-1ecf-4abc-a0b3-f4a2a717c8dd_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_d48c0d59-7195-4c39-8520-a1d4083da1f8_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeAmortizationOfPremium_a45d5202-3359-401d-a402-98b3e4787b22_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums on investments</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeAmortizationOfPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Amortization of Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:to="lab_us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_41dfb873-1f7a-4e3a-98d8-75f8ffc94363_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9e52302f-1f8b-4fa0-907c-1e441c137e99_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_01a5ddae-6f66-424a-9090-123d61fd68a5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_ce064439-7c8c-4ade-a379-a8d81f646e54_terseLabel_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_label_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:href="ino-20220331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:to="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_17c18c9c-20e9-4f39-af03-50bea8e96242_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_87b170a5-ae61-42cc-8bf3-65a8582c57da_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0133fee7-3a99-4247-b48d-1789637ec259_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_235ffa62-9d8e-4141-88d4-b98652bbec15_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="ino-20220331.xsd#ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_83500262-b1e4-458e-b74b-5aa241cd56d1_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_d7433b86-2316-478d-bc43-c31224ee235b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_2b9eb836-5862-4200-9eb0-e616e862671a_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_b0ae21d8-3a55-4a56-bcde-29b8c2c855f6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_457c16f6-3a59-4035-a01e-eade9267bd0a_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_d399e806-47bc-4788-9271-a0bd705b6a72_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_b21da8eb-40fc-461e-9fee-6f4414198325_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_6c9c07a0-509f-44d1-bde6-b4d1ed22f0bb_terseLabel_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_label_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_documentation_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:href="ino-20220331.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:to="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_10a0e40e-b1b9-457a-b75e-6aa561c4dbf6_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a895823a-1c73-4d66-8eae-c97fec1660e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_9b59fc76-4397-48ef-99b2-f32012ea6777_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability from affiliated entity</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:href="ino-20220331.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:to="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_03f2e037-796a-47c5-b9f6-6fe4711d415c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_0ee8b26b-30cb-4a13-8cc2-79358798d22e_terseLabel_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SARS-CoV-2/COVID-19 Vaccine</link:label>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_label_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SARS-CoV-2/COVID-19 Vaccine [Member]</link:label>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_documentation_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SARS-CoV-2/COVID-19 Vaccine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember" xlink:href="ino-20220331.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SARSCoV2COVID19VaccineMember" xlink:to="lab_ino_SARSCoV2COVID19VaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_a2c9f8a8-93f5-4ad1-a3b2-e76ddf729ffa_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from affiliated entities</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_a8c073c1-de46-44c1-a626-95a4a82b0f8f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of carrying value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_00984209-3585-4a50-8ccf-96ed58177873_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_151bce4a-88bd-4ec8-aa77-f5a980eb8adf_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtInstrumentAccruedInterest_a8d196b2-831e-4121-9394-15d0198ca524_terseLabel_en-US" xlink:label="lab_ino_DebtInstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_ino_DebtInstrumentAccruedInterest_label_en-US" xlink:label="lab_ino_DebtInstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Accrued Interest</link:label>
    <link:label id="lab_ino_DebtInstrumentAccruedInterest_documentation_en-US" xlink:label="lab_ino_DebtInstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccruedInterest" xlink:href="ino-20220331.xsd#ino_DebtInstrumentAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentAccruedInterest" xlink:to="lab_ino_DebtInstrumentAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_1aa76ed2-eda1-4727-89b4-d976eac4cc2e_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_5fe123c1-fbeb-4072-b650-809488ba7dc2_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9817e375-7091-46bc-9fe8-36a0dd15758e_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7bebfc2-8938-4362-ab4f-4e794963add1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3ca09ceb-683b-4916-8b6d-80e410e25992_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_464686a8-c41b-48d0-bfe1-6fe06d36b749_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonEmployeeMember_5f0b54dd-3bba-4204-b787-77a14267dbae_terseLabel_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee</link:label>
    <link:label id="lab_ino_NonEmployeeMember_label_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee [Member]</link:label>
    <link:label id="lab_ino_NonEmployeeMember_documentation_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non employee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember" xlink:href="ino-20220331.xsd#ino_NonEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonEmployeeMember" xlink:to="lab_ino_NonEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b4547a50-2bec-4e61-aa7d-06b7d91f2597_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_dd43e66f-670b-4a21-8bb0-214d22e2f1aa_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_af226711-7b56-4fda-b4fd-a0d7dffa7efb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_b75685d5-3b56-4614-ae39-f18ade9574d0_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_d30cda1e-a320-4168-af9e-512cad5ffaa8_terseLabel_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Maturity&#160;(in&#160;years)</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_label_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale Contractual Maturity</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_documentation_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale contractual maturity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:href="ino-20220331.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:to="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_93737093-a75c-4e4f-a845-d3d49c3dc684_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale or maturity of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_f6952b7d-587b-46a6-9096-16418c4e8d86_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ccf8f913-1444-4b86-83ef-82ed4e71e807_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_1108f92f-5a12-495e-bccf-7af817054e8d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_fb75452e-33ac-4233-8f7f-c9e40d7dcb12_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_832df17c-3689-4162-b037-f264892b77cc_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_74f1e49c-ff86-4ab9-9468-0471d0bb5ce0_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160;Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_64fa4afb-5333-4593-aaf7-aa2d67b61e36_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5aca880b-a182-43dd-9c9a-2f9990957089_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4f0cfee1-e5e2-4922-9115-1ad8eb881d5f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_caa433f9-e16f-4070-8b00-7acd0a421d0b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_337d00e2-5c98-4409-8acb-fdefe21200a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_8b5ba487-ed87-42c2-98e6-b7ef129ff7b0_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f125cc61-159d-4734-8d60-440a566cd0a4_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_2abbbc09-c7ee-45ce-9921-200ae8f3a783_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_0110aa6a-548f-49f9-86d0-5bfb775ea62a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_9833761c-36ff-42be-ba76-b1e8d159e654_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b66b2c7-f065-48cb-81bd-ae2d218cc54a_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_2eafe517-6e98-4143-9103-8893e02fec5e_terseLabel_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_label_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_5ef831aa-0a5c-4afe-8170-e9b4d87bf095_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a4f5178b-8212-44e2-9f65-347e68901bbf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_56730d74-9872-492a-9aa9-f6d21917b5df_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of capital assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d34c0248-f8f0-475b-a341-fa2ade4e0fc0_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aaadace7-3d39-4e5a-9829-43d33b272ae1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_2d07ccbe-31e4-41bd-88c2-af28afdc7353_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses to reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_label_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:to="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_dd0ad45e-4301-4706-a35c-4c11e3113c25_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_86e0fe41-bc40-4010-9b11-81a46a346581_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_f022c3a0-ac65-47ef-afb2-9003b5b1b454_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets by major asset class</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_1eeec1b2-c9a8-425c-96bb-0f72e5528cc4_terseLabel_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_label_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member" xlink:href="ino-20220331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GeneosTherapeuticsInc.Member" xlink:to="lab_ino_GeneosTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantsReceivable_24edf5db-5a8e-411e-a235-17ab3efe1b30_terseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant funding, from affiliate</link:label>
    <link:label id="lab_us-gaap_GrantsReceivable_label_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivable" xlink:to="lab_us-gaap_GrantsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_9a64cf09-a092-43ea-b007-f3943cc70c45_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_96752524-4834-49d0-929a-c7444a42e8f4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_af35ffe9-dd35-4753-bedc-ec5aed79db6d_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6b63dba8-5043-4b37-87e2-f334d507f91d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_0176e601-0906-4c3d-952f-5189505e9a59_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_6eb92fb8-0020-4e87-9c63-1bc07be62697_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_5fe063ca-508a-4484-968d-423bae83d73a_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_88b66f96-9806-4f25-ba93-17610ea15398_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_f50cd45c-30ba-4e06-81bb-c7d5bd188f24_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b9e16cb9-0cef-4061-8566-49e55261f98b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_a3d34519-dc8d-42b2-a796-a4fb0679d11a_terseLabel_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A One Preferred Stock</link:label>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_label_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_documentation_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember" xlink:href="ino-20220331.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SeriesAOnePreferredStockMember" xlink:to="lab_ino_SeriesAOnePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_209dd104-c261-4470-8ff0-38f4425841e0_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, funding to be received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding To Be Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding Received for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:to="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8d9ab513-0970-4b3e-bbb7-b947d13de96e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b89ca1fa-b3b5-4593-974d-6c1f1a76bcba_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_32be992d-e804-4d6a-ae93-5f38f10e3b9a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_ae4813fc-2261-424b-b704-f1b7b61aecc6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized loss on investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RisksAndUncertaintiesPolicyTextBlock_4c1056f4-fa01-4a2e-baf4-838283902825_terseLabel_en-US" xlink:label="lab_ino_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties</link:label>
    <link:label id="lab_ino_RisksAndUncertaintiesPolicyTextBlock_label_en-US" xlink:label="lab_ino_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties [Policy Text Block]</link:label>
    <link:label id="lab_ino_RisksAndUncertaintiesPolicyTextBlock_documentation_en-US" xlink:label="lab_ino_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RisksAndUncertaintiesPolicyTextBlock" xlink:href="ino-20220331.xsd#ino_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RisksAndUncertaintiesPolicyTextBlock" xlink:to="lab_ino_RisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_205a82cc-af63-4199-9d79-7c7e8d2c6a4b_verboseLabel_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_label_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_documentation_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:href="ino-20220331.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:to="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_aa1fb385-afc2-4140-9835-3d3272270d57_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_596f4e7a-07e6-481d-afe1-142af9af1b82_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_d67bec3c-895e-4c46-8984-1d02abffbd81_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_f83d2d31-11a9-45f4-b217-0f33445d6af9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_c7ef9e62-f0f6-4944-a6a3-60f16b600538_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Original principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_f0250ec7-a26c-452c-98fc-0c125b7ff4ff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_7f8e5b4c-4a18-49b7-8ad2-30a4c0f7133b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_7fee6dc2-9c92-4027-aef2-05f4bcdc5f8e_verboseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d832732a-0b31-4c3c-b73d-95f4f1697733_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_6ba6f79c-b4fc-4e32-bab8-f61d0ff7e929_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_36c19105-9bc2-4921-83a6-4bd52040ab35_netLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e2c68dfb-0639-4e8e-b0b3-dfb020aff19e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_d39b8cc9-c9eb-4f6d-a292-e17da7d27fe5_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_fe4fd9b0-b01f-42bf-b0a4-9a9fdd937e68_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability, including from affiliated entity</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:href="ino-20220331.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:to="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_90cd18db-83ec-4d00-8598-e53c6ac97497_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_be32cc4c-49f4-4aaf-9130-170554c862d6_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_3dd68e26-a2a0-46c2-a260-2248891b3c4b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_0a0e6271-b343-4d76-8b47-1097aeba6ef6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c5e8d5df-3327-4fc7-ab47-5af666872b3c_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_256a06f6-faa0-4f96-8e0c-91f2df772a1d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7dd11f9f-8290-43ba-9f97-7c30d3e82404_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_6b688c79-a7fa-4e0d-ba1f-0a8d38f2366a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedExercisedAmount_10aff7eb-6a97-4396-8d4f-bb5faa02d26f_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, awarded exercised amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedExercisedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Exercised Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedExercisedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Exercised Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementAwardedExercisedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_d3eecb22-0be8-4a81-8ac3-a97c8cf44140_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_ec7c1ee2-fbd5-4512-8112-2656e7a2e425_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_16090059-e343-4bfb-bcd5-8d0e406fbb37_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_ba7db348-28ec-4e9e-bb7c-4d493e6daa1e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="lab_us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_f3279d57-f8c0-4e72-b84b-7d3f30c8d84c_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_3e14aed4-32d5-40e3-9455-e00692f6a8a6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_fa363418-acae-4194-92b3-a8dae339f1c2_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_0f868ca1-058b-4385-adff-9e211142879b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SanDiegoOfficeMember_907a4a65-db65-4568-94c0-2e9247a680cc_terseLabel_en-US" xlink:label="lab_ino_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego, California</link:label>
    <link:label id="lab_ino_SanDiegoOfficeMember_label_en-US" xlink:label="lab_ino_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego Office [Member]</link:label>
    <link:label id="lab_ino_SanDiegoOfficeMember_documentation_en-US" xlink:label="lab_ino_SanDiegoOfficeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego Office [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoOfficeMember" xlink:href="ino-20220331.xsd#ino_SanDiegoOfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SanDiegoOfficeMember" xlink:to="lab_ino_SanDiegoOfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_0730f001-2b17-476d-a4ae-86c957c4a546_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_b67b90b9-893e-44f4-a3e4-0b2c669ebf50_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_855ed42a-d911-4bc1-856c-9b22edffd1e8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_25ee628b-8e79-4aa8-a587-7db2c032da08_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_6caa3e58-a499-4011-b6e7-dad57152bbd2_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area leased (in square feet)</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:href="ino-20220331.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:to="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e3c79df5-1565-487a-97e6-3495e039eb49_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_84d848a8-42bd-4009-b55a-27eb8a0b9b03_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RelatedPartyTransactionsTextualAbstract_05f5abcb-ef82-46d7-b588-606f01fbf77f_verboseLabel_en-US" xlink:label="lab_ino_RelatedPartyTransactionsTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Transactions (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_RelatedPartyTransactionsTextualAbstract_label_en-US" xlink:label="lab_ino_RelatedPartyTransactionsTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_RelatedPartyTransactionsTextualAbstract_documentation_en-US" xlink:label="lab_ino_RelatedPartyTransactionsTextualAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related party transactions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RelatedPartyTransactionsTextualAbstract" xlink:href="ino-20220331.xsd#ino_RelatedPartyTransactionsTextualAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract" xlink:to="lab_ino_RelatedPartyTransactionsTextualAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9ec951ea-c2fa-433b-b011-d1d80edae96a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_59feb74c-3084-469a-b1a7-a939b7760bdf_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_38cbc975-6fb0-4759-afeb-f58675b80476_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_4f9c8fb4-b272-45ed-ae68-ad8064d037db_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6a5ba2a6-0891-4e60-9860-b4d15d848555_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c30b1a18-c2c6-4046-8d71-9cad9802ffe8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_07840a1f-358b-4aad-8a24-4727f8b8a4d7_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total remaining lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_bf2b0cbe-1396-4cbe-8e8b-dc8d4a097f82_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_a3729bd2-57c4-415e-989f-10b3d1c98249_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_24bc69a0-883e-44e1-a752-b14c1fc423ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_ee313749-37a9-4a61-9252-561a4734bafd_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:href="ino-20220331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract_7d3f2a94-c9fc-4213-8008-d4f2f8eb53fe_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement , revenue from the procurement contract</link:label>
    <link:label id="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract_label_en-US" xlink:label="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement , Revenue from the Procurement Contract</link:label>
    <link:label id="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement , Revenue from the Procurement Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:href="ino-20220331.xsd#ino_CollaborativeArrangementRevenueFromTheProcurementContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:to="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_0885aebf-2b65-453d-bada-c3657f237127_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_2af98e69-2faf-4eb3-a2d4-9cebede679b8_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_0e5bda7c-5927-4305-926d-a62e261ddd7a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OtherCounterpartyMember_2ca8e875-90f5-4ded-a6ab-e67390120be3_terseLabel_en-US" xlink:label="lab_ino_OtherCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Counterparty</link:label>
    <link:label id="lab_ino_OtherCounterpartyMember_label_en-US" xlink:label="lab_ino_OtherCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Counterparty [Member]</link:label>
    <link:label id="lab_ino_OtherCounterpartyMember_documentation_en-US" xlink:label="lab_ino_OtherCounterpartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Counterparty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherCounterpartyMember" xlink:href="ino-20220331.xsd#ino_OtherCounterpartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OtherCounterpartyMember" xlink:to="lab_ino_OtherCounterpartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_98f3807b-ae27-417e-9b3b-a711809e6059_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_8d9c7376-c65c-4262-954b-9c08c8ed5ec9_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:href="ino-20220331.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:to="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_3e8848de-3b1a-41da-be7f-79ba78df9463_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price, procurement contract</link:label>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_label_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</link:label>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:href="ino-20220331.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:to="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fb721e06-a935-4938-9fe0-aa0a433f2aed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_c5a3a2c9-7333-48aa-a3c9-213fa29df751_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5b62c35c-3b33-45c0-988a-22bb04618d4c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_991bbb5d-967b-4a43-8ddf-187b3443bb16_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_a80e8b21-b37a-43da-b598-5faccf2411f0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_3e5aa3c2-3faa-4357-890f-c8d09bf35862_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period from effective date for termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period From Effective Date For Termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period From Effective Date For Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:to="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_3a0cf219-9032-4107-9ae1-d8f2ca4644db_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3dcbffeb-3229-4676-9b6c-34910c7ee3b8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3a571ef3-c21a-4eab-ab3b-a3df56740a47_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, including from affiliated entity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_0eb1c4d7-efe4-40b3-ba4d-bb70c2b11a4c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options for cash and vesting of RSUs, net of tax payments</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_810a2ce6-1be3-4388-af2a-9401fde1e1e5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair&#160;Market&#160;Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ff902bfe-24a2-4e45-9987-037a872c960d_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available for sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_d59c1b1e-c94c-4986-9571-b3139175e434_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate proceeds</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:href="ino-20220331.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:to="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_15ccf288-3102-4615-b33f-a6fc941f9f89_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9a04d510-0b4c-47d8-b055-4c1ed062a80c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_014d71a5-2145-4418-88ed-16531a8148bc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_bfca1fa2-3762-4d7e-aa05-650c2bcaf259_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Useful Life (Yrs)</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_0fd6a03d-10fb-4234-8131-c2ecfa381a8d_terseLabel_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_label_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device [Member]</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_documentation_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:href="ino-20220331.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:to="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_11de8c1a-f306-4b0c-82c5-5fbc905eef6a_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Unobservable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_7b72e5a1-dcda-4bc0-a98b-58ba20b3c4f9_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_4bd20da6-394e-4c4c-b526-a1616e27f2f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Summary of Intangible Assets by Major Asset Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_d5f644a4-a93a-4a96-bdd0-95df13656151_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5383183a-6e5c-4d08-aa0e-b825ae9c7e8d_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2edf8b1b-1b58-4928-846b-8dac000d8bc4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_eddffc44-e054-4118-a60d-fb0d73d652d4_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_20a57442-5759-4ce7-a461-74d4509c96d5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_6d2ab797-8db7-4e2d-a842-f447853febb6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_4c11619d-b1d7-4dd9-b9fa-a9799467daab_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_fe8693fd-0068-453f-85fd-f78563b769e9_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_b03af9f4-3809-4d4c-b88f-f159df504e1d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_cd42edfe-3429-4ebf-9cc2-7bef136a765d_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_84aa540f-3072-490d-867b-6c318a72ab4e_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_4fd676b7-4d0f-4341-ad26-ba1c9e620d39_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_37eda7bb-5ff5-418e-868b-ca8729c4dc2a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_61094819-bc8e-41f3-bd38-bb0c6da914c8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_1568d74c-eff7-4946-b588-b60b98939cf5_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares authorized (in shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:href="ino-20220331.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_678bbc93-402e-4eee-8644-4162a8d6e31d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_ab2eae77-5954-4ab4-a390-6be483061c0d_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_71c8350c-510e-4106-bc40-1b71831f3e93_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_8122bbcf-5693-4a81-bdb9-0f5df3580529_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_6402e82b-a3a7-41ae-b6fb-f060760ee1ca_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_d7c811b6-0b31-4caa-9cd8-7f3a39cece0d_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_46d009b5-a698-4a58-9a27-c4b62df025c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_ce41510a-feb1-45b5-bb55-81255795784e_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. agency mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed Securities, Issued by US Government Sponsored Enterprises [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_84066b23-5aac-4780-9048-0b0b3aa65e3f_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Critical Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_f05a9a77-de84-4c3b-bf37-13e0664a975b_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_837ea1af-de69-4210-bf88-c20847f12f1f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f4749d03-7c82-41f0-8c96-7d46c7affc11_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_460de76a-d515-49ce-994d-745a5a7efbb8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_2d850889-bfcf-418e-8a48-f86b003450ad_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_04e4cbfe-4573-4c67-91c6-171bef5e1529_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets and liabilities, net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:href="ino-20220331.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:to="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2e974bc3-4588-4d33-9818-a6b71bf125f4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_a8b9d6dd-38a8-4fdd-b91d-d5645e1099de_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_56b5877f-e8a9-4d23-addb-66e7f6b4aaed_verboseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_11e1b624-7771-4196-bb0f-84c25dff156a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_52595de0-6470-4dbc-8d4e-4dd93a04fc15_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_a5c6e58a-b1d6-47b2-bd11-bc65d8ed85d9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_10482a9e-e338-48e9-98d1-37a61d23f44d_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_99b7a0c7-df9b-41fe-a6d9-ec52dacafa39_terseLabel_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_label_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology [Member]</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_documentation_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DNA-Encoded Monoclonal Antibody Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:href="ino-20220331.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:to="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_ba9d34f3-2b7b-46b2-b50f-347f3d702538_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_0a85c07c-fa2a-454a-ab56-dc66a3d06010_verboseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_7f24aad9-22cb-4c46-8e78-4e26b0ecbff4_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_e4d4728b-a6cb-4161-b0f8-21d9ca66846c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_75985f60-1b38-4d2c-8db3-6d4361604167_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_e79c0dde-4d80-4d82-8481-6bc9447a39a7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment_1cf8a11e-79a0-4c5a-9618-e8e406fc7b17_negatedTerseLabel_en-US" xlink:label="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on remeasurement of investment in Geneos</link:label>
    <link:label id="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment_label_en-US" xlink:label="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Remeasurement Of Equity Method Investment</link:label>
    <link:label id="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment_documentation_en-US" xlink:label="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Remeasurement Of Equity Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:href="ino-20220331.xsd#ino_GainLossOnRemeasurementOfEquityMethodInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:to="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_90732da5-f6ca-41cc-b8f5-c2693e875600_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Definite lived:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_a03d07d7-6783-431f-aa20-746567a948d1_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_0c0f7882-5432-4f6d-bd07-f9e903846ac0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9544240e-f667-4321-af29-bf75d445e1bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_88248140-2e12-4897-8a9d-fee09706e372_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_1c382941-2e8a-4587-9ac8-d8a757f6ea48_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of net loss in Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_65d0da3e-948a-4589-91d0-02c2c8541d2f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c6ede258-99bc-4f5e-8771-eb236a5bb8e4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of December 2019 Bonds to common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_8d3ca838-2716-40c9-8555-83aadb8d2c50_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bdf7ac19-1c0b-47a4-9272-b5a92ae72b3d_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d5ef4108-54ec-4d0e-9f77-625742bc23c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_42e92aa8-2dc1-487f-b459-8a5e61b689bf_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4bac08cc-f42f-4c4a-b660-91ab716b07bc_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_594fc50d-d583-49ee-aceb-90ae4e398f6a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense for remainder of 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_1abf0e95-c5f1-4c29-ad84-31e0dc19dc83_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_aeeba269-ad71-4dad-9886-4baa00466429_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0267e309-e24f-4fba-ab35-e7794c0c3222_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19684da7-f8fd-45fa-9813-72415c708496_verboseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_70087cf8-da44-457b-ac35-bdfdc3751237_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_11b74821-dddc-4486-910f-8ca546527ee7_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_0b8452c2-b3f0-4566-8624-7981fe9409ef_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Geneos</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_0e7c330c-1184-4667-8097-8ec8d536d783_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire additional interest in subsidiaries</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4fdb2f81-e939-463e-b767-82dd566708a7_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a94923aa-bc07-4d7c-97ee-2905c71c9b47_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_70e485ff-b07d-44bd-b199-73b7260b02aa_verboseLabel_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets from affiliated entities</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_label_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets from Affiliated Entity</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_documentation_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:href="ino-20220331.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:to="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_91bdb053-4de0-4dcc-9295-d015a16aaa2b_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_ad91eed2-59c3-4075-bc8d-08a46c43fb1b_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, amended amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Amended Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Amended Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAmendedAmount" xlink:to="lab_ino_CollaborativeAgreementAmendedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Capital_b7720358-7e6c-43f3-8d6b-dc6ffd55e21b_terseLabel_en-US" xlink:label="lab_us-gaap_Capital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_us-gaap_Capital_label_en-US" xlink:label="lab_us-gaap_Capital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Banking Regulation, Total Capital, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Capital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Capital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Capital" xlink:to="lab_us-gaap_Capital" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_c1b8b7f1-cde9-4fff-84a3-54b74cb348c0_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent" xlink:href="ino-20220331.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingCurrent" xlink:to="lab_ino_DeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_38bf401a-266b-4e53-b6d5-420b3b9d9692_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_e74d0420-88be-4420-9916-7fec85d54e8c_verboseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding received for research and development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingReceived" xlink:to="lab_ino_CollaborativeAgreementFundingReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_11a61b85-ab40-4e3c-a833-560a7ad8207c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4f4af325-1283-49c8-8788-fb15f21ca40f_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_b41cfa77-c77a-46c8-ac93-5343ba2a6b62_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_e7a0fa6e-086d-463d-bbcd-e538fba26fba_negatedTerseLabel_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount converted into common shares</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_label_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Converted Amount</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_documentation_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Converted Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:href="ino-20220331.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:to="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3dc17945-810a-46b7-b1a7-18c18074bd9c_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SeriesA2OnePreferredStockMember_329b1b41-d718-47ea-8b73-46f1f0459644_terseLabel_en-US" xlink:label="lab_ino_SeriesA2OnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-2 One Preferred Stock</link:label>
    <link:label id="lab_ino_SeriesA2OnePreferredStockMember_label_en-US" xlink:label="lab_ino_SeriesA2OnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-2 One Preferred Stock [Member]</link:label>
    <link:label id="lab_ino_SeriesA2OnePreferredStockMember_documentation_en-US" xlink:label="lab_ino_SeriesA2OnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-2 One Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesA2OnePreferredStockMember" xlink:href="ino-20220331.xsd#ino_SeriesA2OnePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SeriesA2OnePreferredStockMember" xlink:to="lab_ino_SeriesA2OnePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_f335e7bb-bf45-45b3-9b44-7aee1131b9a6_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4c1fef2c-6a5f-41a1-8819-81bd433c7397_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_a1c77212-a59c-42e2-92ef-6b7cd272bef2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements and Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementTerm_a70faf8e-4580-45f2-b6cb-89c5b606b374_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm" xlink:href="ino-20220331.xsd#ino_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementTerm" xlink:to="lab_ino_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_058865bb-aacc-4a3d-aabf-3befd920e2ec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4c52656c-1040-4e6a-bf45-538e40410611_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_a11e644d-8be0-42de-9bc2-58e3b3783e8d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_01696996-a5db-4738-9ee0-4d001e9e5894_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Product</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_ee42a242-079e-4caa-805e-61b09a6884e5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on short-term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_a9017352-3975-49a3-a1e1-5a4f03d1084b_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_d6f83d7a-afec-4069-bf15-daf8879e5fc7_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of Geneos Series A-1 preferred stock</link:label>
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_9bb2d649-cfb6-4ffe-8430-a957df54d018_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_ea2f829d-2d1d-4a0e-9f32-e9dda526c6b9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a0295085-d2b5-4612-b13a-9f114e41e6a7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_92cee7eb-b701-47ed-93be-da46d65a56ba_negatedLabel_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from equity method investment, recorded and allocated to investment</link:label>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_label_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</link:label>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_documentation_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:href="ino-20220331.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:to="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_1abe632e-3d2e-4acf-b305-5801baf621d9_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillGross_8f9f82d1-3894-4dad-8f5d-42a1d529ead2_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, gross</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_label_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross" xlink:to="lab_us-gaap_GoodwillGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_ec96d66f-6bbf-4e9f-a517-4379cd049b28_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities in a gross unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CELLECTRA2000DeviceMember_653f7576-63d8-449b-a458-031ab81d8384_terseLabel_en-US" xlink:label="lab_ino_CELLECTRA2000DeviceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 2000 Device</link:label>
    <link:label id="lab_ino_CELLECTRA2000DeviceMember_label_en-US" xlink:label="lab_ino_CELLECTRA2000DeviceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 2000 Device [Member]</link:label>
    <link:label id="lab_ino_CELLECTRA2000DeviceMember_documentation_en-US" xlink:label="lab_ino_CELLECTRA2000DeviceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 2000 Device [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA2000DeviceMember" xlink:href="ino-20220331.xsd#ino_CELLECTRA2000DeviceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CELLECTRA2000DeviceMember" xlink:to="lab_ino_CELLECTRA2000DeviceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8bb381c9-5a6d-4c88-ba07-2883db3fc003_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_fae696df-d330-4aeb-87f3-c29b9faccdb0_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_ea36fa51-c895-4f79-b012-d7237f5c3a30_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_0997a2a4-5a32-4001-bee5-90204e83abe4_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_8b072394-918a-4f7e-8921-7321948c6a12_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_87cee61a-3722-4f3f-8c02-ff8016c5817e_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contractual term (in years)</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award maximum contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:href="ino-20220331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_33950ca0-df76-4b12-a4c3-a7b390047f89_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_256a4a9c-cfc3-4036-98f1-8c73bf1fa908_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, period to receive funding for research and development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:to="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_d07a8a2d-c418-4fc9-b32d-4ae259103a78_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6bd94a51-3e71-4c4a-a0f5-67ba1ee71b4e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5d3c0716-b65e-4924-9ab4-46e1b00a4a8d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d8d8ede9-e486-4444-985b-7ba3a48a5eff_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_a40b400e-83bc-4d03-bf76-fc7a3f44ff8b_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_c48c02e7-7afe-4344-9da6-ddc80c9beabc_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_b9a852f2-9462-4870-864b-0d0c3f06957e_terseLabel_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_label_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_documentation_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:href="ino-20220331.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:to="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_103cdfe4-169e-4a36-95c1-99bdc0e6b13b_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_aeb10ab1-2874-47b1-a882-06aac18a56bc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_349d68f9-84b8-49e4-9615-cdf2fc501fd5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment owned (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6c1873e6-4c32-49bc-b9b6-1e8b9fffea4c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_c65afbc6-5101-4ad4-bdd7-e46cf3d6fe99_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_7b0d5dd9-6919-429c-bbba-f5d5ad74a3a7_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_6ec8ce5a-aae3-4c63-8ae8-33d8867eec9c_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_d3d64612-6861-4b47-b784-3fc62d2f4232_terseLabel_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue under collaborative research and development arrangements with affiliated entities</link:label>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_label_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License with Affiliated Entities [Member]</link:label>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_documentation_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License with Affiliated Entities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember" xlink:href="ino-20220331.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LicensewithAffiliatedEntitiesMember" xlink:to="lab_ino_LicensewithAffiliatedEntitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b807f9bb-a63f-40e7-ba8c-fa6836011362_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AnnualMaintenancePeriod_9c4cfa5f-f309-44f6-a442-29792571a505_terseLabel_en-US" xlink:label="lab_ino_AnnualMaintenancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual maintenance period</link:label>
    <link:label id="lab_ino_AnnualMaintenancePeriod_label_en-US" xlink:label="lab_ino_AnnualMaintenancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Maintenance Period</link:label>
    <link:label id="lab_ino_AnnualMaintenancePeriod_documentation_en-US" xlink:label="lab_ino_AnnualMaintenancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Maintenance Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AnnualMaintenancePeriod" xlink:href="ino-20220331.xsd#ino_AnnualMaintenancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AnnualMaintenancePeriod" xlink:to="lab_ino_AnnualMaintenancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_01ce1dac-9e0b-4f39-93bd-9ecae4f66d33_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_5c445e0e-479f-4064-91e7-f7f2b6f25da6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_35ef3fc8-7c2b-4a46-b7a3-b0a9f56109ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_a2c8a633-bbcf-4c5d-be78-f6ff7eb1b048_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_26f39e08-1664-4b69-b9fc-55646dd55164_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_91daa752-36a2-4bbb-8fea-effbd20388f8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_eaaa6493-1975-4390-b257-be2ba78533cb_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d1073510-43a0-476c-bc17-c4f755cde54a_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_4a241b7a-5d78-4c96-847a-61e7031e3a8f_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional revenue to be achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_label_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:href="ino-20220331.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:to="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_4e401dd2-9ea8-4ef5-bded-ea98385032fa_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of days written notice before termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_label_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number of Days Written Notice Before Termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number of Days Written Notice Before Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:to="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_92e8e198-6fd0-42e5-bc7e-697502064c6f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_a6ef3265-d69a-4510-92e2-749010d84ca4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_f830825b-f1b3-409b-9de5-5c3df278c9eb_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_d293c156-7fa8-4bf5-a69f-4edb60023fb1_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3184ac75-8b29-4641-82af-1f9c8289421f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3679f25b-def2-4145-b567-079e0d51ca1c_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e499b7f2-ca75-46a2-bf17-4294879d07d8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ca19cea1-44aa-4a05-81bd-78ae7fba01a5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1343325f-0698-4445-b3a0-014fae29cd16_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4ada9d34-baa5-435b-8e53-4d70136c334a_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ab161a25-7a6f-46f0-996f-2cbac2473611_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_8562fada-68df-4a4b-9ca7-46c527d5a905_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4c906b44-29d0-4efa-a3bf-0cd7d7235390_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_422f1c5a-8d1e-4e73-9bfa-11e4b0195279_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d492aac0-42aa-4b4f-aaf8-2c63a9794855_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2016IncentivePlanMember_ab28ceba-690b-4783-99d0-0cf2af9ae79c_terseLabel_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember" xlink:href="ino-20220331.xsd#ino_A2016IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2016IncentivePlanMember" xlink:to="lab_ino_A2016IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_32875558-56bc-4d57-b31e-7a2ad8f6bb1f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_be3a2094-5192-407b-a1b6-a604c79a8b7e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_70ecadc2-a5d5-44bd-93dd-a0d26f0bcd55_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty period</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_label_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:href="ino-20220331.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:to="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_1d815a4f-4e0e-4e6d-811d-fb4a575de1a2_terseLabel_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_label_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_documentation_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember" xlink:href="ino-20220331.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlumblineLifeSciencesMember" xlink:to="lab_ino_PlumblineLifeSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_78b5974f-d530-468b-8f55-437eed011755_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e9f530a9-b128-42e4-ba4f-0055f12da1fe_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_0525d802-566c-40ca-8797-265fdc57c5ce_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock sale agreement weighted average price (in dollars per share)</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_label_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Weighted Average Price Per Share</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement Weighted Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:href="ino-20220331.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:to="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ApolloBioMember_498dfd97-9299-49d0-96fb-2b3fcb246d31_terseLabel_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio</link:label>
    <link:label id="lab_ino_ApolloBioMember_label_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:label id="lab_ino_ApolloBioMember_documentation_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember" xlink:href="ino-20220331.xsd#ino_ApolloBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ApolloBioMember" xlink:to="lab_ino_ApolloBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_InitialConversionPriceMember_99bbde0d-f253-4f20-ac59-6bbc51eac2a8_terseLabel_en-US" xlink:label="lab_ino_InitialConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Conversion Price</link:label>
    <link:label id="lab_ino_InitialConversionPriceMember_label_en-US" xlink:label="lab_ino_InitialConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Conversion Price [Member]</link:label>
    <link:label id="lab_ino_InitialConversionPriceMember_documentation_en-US" xlink:label="lab_ino_InitialConversionPriceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Conversion Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InitialConversionPriceMember" xlink:href="ino-20220331.xsd#ino_InitialConversionPriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_InitialConversionPriceMember" xlink:to="lab_ino_InitialConversionPriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_d37750d7-4250-41e0-9ef1-f4e5ce7bacbd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_af1a5055-dfa9-4a6d-95dc-5d8e7f4deebc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3c1d0d30-d1aa-4137-9f71-34792f0b4fb9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a83b451e-5122-42c2-919a-a2a23599f9e3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_aa66d7ca-a373-4345-a705-bd11012d71fa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities in a gross unrealized loss position for more than twelve months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_52b88a31-931e-4b52-9a61-66b16678b2e8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost related to unvested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_253353bd-840c-46b7-9521-2283ed4cf91b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_5da1ea1b-4a41-44db-9dd0-6f8d4575bf96_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_ca1c3690-9239-4694-907d-8cebcaf8efa5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_76f5f625-c715-42c4-acf0-bb1e84ff423f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_a725ca4b-35f6-4c60-a134-fc5bbfe962e5_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, Net Book Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_d55a6de6-1e37-4c2e-95ff-640004b7bc93_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_59962c07-a3d1-4be1-8be9-ad87947e7c7b_totalLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, net book value</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_239baacd-98e3-41ee-8a98-c7eb5e2b561c_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue under collaborative research and development arrangements</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_6d5cb7c5-bd73-4b43-96fc-21e9c7fe387c_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_4fc3cfa7-a35b-4db3-a436-f69071cf15a6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_00b99db8-5419-46fd-a0f1-8fe98216b5e9_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Operations</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d27b1f83-0483-4d77-9aba-d1518ce1402b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_ff85b2be-b6f9-4df7-84e7-8bf0e946f457_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_ef93fd32-61db-4f12-b878-73a1226eb425_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of agreements</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Agreements To Sublease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Agreements To Sublease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:href="ino-20220331.xsd#ino_LesseeOperatingLeaseNumberOfAgreementsToSublease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:to="lab_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_55525f70-324d-45de-8234-d7507f6a34e0_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_4680ea37-95d6-427d-ab00-d4fee13ed90b_terseLabel_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lassa Fever and MERS Vaccine</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_label_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_documentation_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember" xlink:href="ino-20220331.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LassaFeverAndMERSVaccineMember" xlink:to="lab_ino_LassaFeverAndMERSVaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_a2e6e870-f074-4986-a51e-811411307dfa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, unamortized discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b48cf9e1-16e3-410d-a145-f787573be888_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ino-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:500251c5-f1ff-4b5f-bcb3-245f4230a461,g:c147bae2-ade6-4d52-bd96-82e99e7a58d2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/CoverPage" xlink:type="simple" xlink:href="ino-20220331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8b17df00-284c-4fcc-918f-71d78e706db9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_DocumentType_8b17df00-284c-4fcc-918f-71d78e706db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_2f9a3f3a-a7b9-4ad1-b997-1be284918917" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_DocumentQuarterlyReport_2f9a3f3a-a7b9-4ad1-b997-1be284918917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b2769945-a8f0-40ac-9c69-e8e6cc8cd6c2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_DocumentPeriodEndDate_b2769945-a8f0-40ac-9c69-e8e6cc8cd6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_d337f8c1-aa11-4150-b83e-52e9a1b6ca9e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_DocumentTransitionReport_d337f8c1-aa11-4150-b83e-52e9a1b6ca9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7819f986-299c-4d91-99d0-df5ab56b359c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_EntityFileNumber_7819f986-299c-4d91-99d0-df5ab56b359c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b617567e-ad32-4b4c-9bfc-f97966ff5eed" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_EntityRegistrantName_b617567e-ad32-4b4c-9bfc-f97966ff5eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_90cacbde-250c-448a-865c-13a3ea0ea6f4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_90cacbde-250c-448a-865c-13a3ea0ea6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_4eda4d24-33a7-4afc-980d-7e0cebbf5453" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_EntityTaxIdentificationNumber_4eda4d24-33a7-4afc-980d-7e0cebbf5453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_07b11ce1-c587-417e-a169-eca31ade7911" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_EntityAddressAddressLine1_07b11ce1-c587-417e-a169-eca31ade7911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_243639c1-2994-476e-96d5-086dce90ca8d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_EntityAddressCityOrTown_243639c1-2994-476e-96d5-086dce90ca8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e980b9b1-d6d5-40e9-a8f6-a0f43a8f0c3b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_EntityAddressStateOrProvince_e980b9b1-d6d5-40e9-a8f6-a0f43a8f0c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c744abd6-afd7-425e-93ba-82a8d994a84d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_EntityAddressPostalZipCode_c744abd6-afd7-425e-93ba-82a8d994a84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4e3d7f98-fb48-4048-90ba-769e341e4559" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_CityAreaCode_4e3d7f98-fb48-4048-90ba-769e341e4559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_245686aa-d671-455b-ac76-bf7f2889de46" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_LocalPhoneNumber_245686aa-d671-455b-ac76-bf7f2889de46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2bf81868-9974-4032-a418-ed7b8416606a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_Security12bTitle_2bf81868-9974-4032-a418-ed7b8416606a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4514fd19-35be-44c8-bb9e-50d16b2c81da" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_TradingSymbol_4514fd19-35be-44c8-bb9e-50d16b2c81da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9163c7cf-5326-4f7c-a49e-b11cc5c83948" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_SecurityExchangeName_9163c7cf-5326-4f7c-a49e-b11cc5c83948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3bd86962-c7fb-43dd-bee5-d11f3703c903" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_EntityCurrentReportingStatus_3bd86962-c7fb-43dd-bee5-d11f3703c903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fce77a86-6d17-4656-a28e-3a702f581d71" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_EntityInteractiveDataCurrent_fce77a86-6d17-4656-a28e-3a702f581d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_992c4fc1-fed6-496f-9e97-7b9137e5d3ce" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_EntityFilerCategory_992c4fc1-fed6-496f-9e97-7b9137e5d3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_272322b6-aebd-4039-a7af-dea31e21b201" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_EntitySmallBusiness_272322b6-aebd-4039-a7af-dea31e21b201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_52a60e4f-3f8a-40c4-9322-53033a96796e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_EntityEmergingGrowthCompany_52a60e4f-3f8a-40c4-9322-53033a96796e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_91cc79b3-a238-4ea9-b4d7-1872b187563c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_EntityShellCompany_91cc79b3-a238-4ea9-b4d7-1872b187563c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_18ca9320-1443-44b3-bda3-98b49f9f9832" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_18ca9320-1443-44b3-bda3-98b49f9f9832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d3214bed-0476-4209-9485-7af1ba65a207" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_AmendmentFlag_d3214bed-0476-4209-9485-7af1ba65a207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c9e9c015-0ba8-43e1-8e5d-ccfdd66f559e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_DocumentFiscalYearFocus_c9e9c015-0ba8-43e1-8e5d-ccfdd66f559e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0a4be26b-2ace-4517-9130-3a4910d08cd6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0a4be26b-2ace-4517-9130-3a4910d08cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d7afbdce-036c-4868-805f-99bb83768edd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_EntityCentralIndexKey_d7afbdce-036c-4868-805f-99bb83768edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9f2f5e7a-6cb9-4d4b-872f-e653580b5e76" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2db561e9-fa42-42b1-b2bf-97a5c1565bd4" xlink:to="loc_dei_CurrentFiscalYearEndDate_9f2f5e7a-6cb9-4d4b-872f-e653580b5e76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20220331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_945a6946-58c8-4b21-baba-77aad1aac744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7b005bec-118c-4a49-938e-b88ceea499bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_945a6946-58c8-4b21-baba-77aad1aac744" xlink:to="loc_us-gaap_AssetsAbstract_7b005bec-118c-4a49-938e-b88ceea499bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f7425706-18c0-4680-95a0-eda20414ef92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7b005bec-118c-4a49-938e-b88ceea499bf" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f7425706-18c0-4680-95a0-eda20414ef92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0015cc92-1c36-4caf-afa5-8ed76f065f31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f7425706-18c0-4680-95a0-eda20414ef92" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0015cc92-1c36-4caf-afa5-8ed76f065f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_8e547f05-46ec-4534-ae25-02c38e4aa583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f7425706-18c0-4680-95a0-eda20414ef92" xlink:to="loc_us-gaap_ShortTermInvestments_8e547f05-46ec-4534-ae25-02c38e4aa583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8dc9917a-08fb-4255-aee6-b055dc0b96b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f7425706-18c0-4680-95a0-eda20414ef92" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8dc9917a-08fb-4255-aee6-b055dc0b96b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_5acf12b0-68c6-44f7-80a8-eff6bb297a80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f7425706-18c0-4680-95a0-eda20414ef92" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_5acf12b0-68c6-44f7-80a8-eff6bb297a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3641601e-9913-45f1-af74-ca15db3bbd78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f7425706-18c0-4680-95a0-eda20414ef92" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3641601e-9913-45f1-af74-ca15db3bbd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_f7701b79-a06c-41a6-b0e8-b0afa523e77b" xlink:href="ino-20220331.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f7425706-18c0-4680-95a0-eda20414ef92" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_f7701b79-a06c-41a6-b0e8-b0afa523e77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_511c4178-cf69-44fd-aab8-3b9a1d0f7540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f7425706-18c0-4680-95a0-eda20414ef92" xlink:to="loc_us-gaap_AssetsCurrent_511c4178-cf69-44fd-aab8-3b9a1d0f7540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fe318957-8bf0-431e-a34b-1eb632556950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7b005bec-118c-4a49-938e-b88ceea499bf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fe318957-8bf0-431e-a34b-1eb632556950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_23478ad7-70d5-49b6-8514-e93c5337964c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7b005bec-118c-4a49-938e-b88ceea499bf" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_23478ad7-70d5-49b6-8514-e93c5337964c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_26fe9611-6831-4a58-b9ef-d52d1f3f11c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7b005bec-118c-4a49-938e-b88ceea499bf" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_26fe9611-6831-4a58-b9ef-d52d1f3f11c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_aed73932-601d-4533-8858-585c00f582c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7b005bec-118c-4a49-938e-b88ceea499bf" xlink:to="loc_us-gaap_Goodwill_aed73932-601d-4533-8858-585c00f582c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9e19e592-5c29-4a75-923f-f35d2cb29289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7b005bec-118c-4a49-938e-b88ceea499bf" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9e19e592-5c29-4a75-923f-f35d2cb29289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_85264513-d0da-417f-bb3e-800de49fecc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7b005bec-118c-4a49-938e-b88ceea499bf" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_85264513-d0da-417f-bb3e-800de49fecc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_db7494f2-16af-4e56-9186-20c589300f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7b005bec-118c-4a49-938e-b88ceea499bf" xlink:to="loc_us-gaap_Assets_db7494f2-16af-4e56-9186-20c589300f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ff6a188-e1ea-468e-a67c-ea3eac617a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_945a6946-58c8-4b21-baba-77aad1aac744" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ff6a188-e1ea-468e-a67c-ea3eac617a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ba23121b-dfab-49e6-92c9-35cab7a5a248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ff6a188-e1ea-468e-a67c-ea3eac617a6b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_ba23121b-dfab-49e6-92c9-35cab7a5a248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_47bf8921-e7eb-4796-bdcd-c6e0dac7fb24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ba23121b-dfab-49e6-92c9-35cab7a5a248" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_47bf8921-e7eb-4796-bdcd-c6e0dac7fb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_91604ade-a146-4a26-a54d-9d3342fb5367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ba23121b-dfab-49e6-92c9-35cab7a5a248" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_91604ade-a146-4a26-a54d-9d3342fb5367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_dfbc458d-9a74-4710-bd88-25a82e048c68" xlink:href="ino-20220331.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ba23121b-dfab-49e6-92c9-35cab7a5a248" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_dfbc458d-9a74-4710-bd88-25a82e048c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ef4b14f1-a006-48c3-a67d-3d2372a446dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ba23121b-dfab-49e6-92c9-35cab7a5a248" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ef4b14f1-a006-48c3-a67d-3d2372a446dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6ef11874-2b85-41d7-8fe4-aa3de0d7f252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ba23121b-dfab-49e6-92c9-35cab7a5a248" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6ef11874-2b85-41d7-8fe4-aa3de0d7f252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_13e74cc0-5571-4bc4-9fd3-4079f7409ca5" xlink:href="ino-20220331.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ba23121b-dfab-49e6-92c9-35cab7a5a248" xlink:to="loc_ino_DeferredGrantFundingCurrent_13e74cc0-5571-4bc4-9fd3-4079f7409ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_abed7718-a233-43f9-913d-717464fd671f" xlink:href="ino-20220331.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ba23121b-dfab-49e6-92c9-35cab7a5a248" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_abed7718-a233-43f9-913d-717464fd671f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_869181ea-c759-49e6-867f-c4f8aca06982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ba23121b-dfab-49e6-92c9-35cab7a5a248" xlink:to="loc_us-gaap_LiabilitiesCurrent_869181ea-c759-49e6-867f-c4f8aca06982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_4cd0991b-1f3b-42ea-8283-17f14b24964e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ff6a188-e1ea-468e-a67c-ea3eac617a6b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_4cd0991b-1f3b-42ea-8283-17f14b24964e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_dbcec210-cc8c-4930-8b25-c1e4126c46ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ff6a188-e1ea-468e-a67c-ea3eac617a6b" xlink:to="loc_us-gaap_ConvertibleDebt_dbcec210-cc8c-4930-8b25-c1e4126c46ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_16049bb1-3d2e-41bf-8e48-cbf0e8097377" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ff6a188-e1ea-468e-a67c-ea3eac617a6b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_16049bb1-3d2e-41bf-8e48-cbf0e8097377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b8867928-f793-4cbd-b1ed-f46ec03be183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ff6a188-e1ea-468e-a67c-ea3eac617a6b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b8867928-f793-4cbd-b1ed-f46ec03be183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_620faad8-85b8-40ca-9785-b93a4ca69294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ff6a188-e1ea-468e-a67c-ea3eac617a6b" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_620faad8-85b8-40ca-9785-b93a4ca69294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_79735a43-f445-42f0-8a18-2497be0d7237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ff6a188-e1ea-468e-a67c-ea3eac617a6b" xlink:to="loc_us-gaap_Liabilities_79735a43-f445-42f0-8a18-2497be0d7237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4105ce22-dffe-4a0c-99fc-7869846469ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ff6a188-e1ea-468e-a67c-ea3eac617a6b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4105ce22-dffe-4a0c-99fc-7869846469ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8dedb5e6-235d-4e4d-9e65-44eb054e524d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4105ce22-dffe-4a0c-99fc-7869846469ff" xlink:to="loc_us-gaap_PreferredStockValue_8dedb5e6-235d-4e4d-9e65-44eb054e524d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_70286769-0856-4195-b4bc-da88e5b66856" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4105ce22-dffe-4a0c-99fc-7869846469ff" xlink:to="loc_us-gaap_CommonStockValue_70286769-0856-4195-b4bc-da88e5b66856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0d8ce690-5298-4cb1-a08b-b734a892ff3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4105ce22-dffe-4a0c-99fc-7869846469ff" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0d8ce690-5298-4cb1-a08b-b734a892ff3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b343e526-af9d-4bd2-986e-cc6ad02bcdc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4105ce22-dffe-4a0c-99fc-7869846469ff" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b343e526-af9d-4bd2-986e-cc6ad02bcdc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5888d669-2b6c-4f54-ba06-e4b7e774df00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4105ce22-dffe-4a0c-99fc-7869846469ff" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5888d669-2b6c-4f54-ba06-e4b7e774df00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f89e3354-0b1c-431e-8f60-5196ca8271d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4105ce22-dffe-4a0c-99fc-7869846469ff" xlink:to="loc_us-gaap_StockholdersEquity_f89e3354-0b1c-431e-8f60-5196ca8271d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2958730b-5a20-41a8-a833-544273d2bf1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5ff6a188-e1ea-468e-a67c-ea3eac617a6b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2958730b-5a20-41a8-a833-544273d2bf1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="simple" xlink:href="ino-20220331.xsd#CondensedConsolidatedStatementsofOperationsUnaudited"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_1f71b4c3-7431-4848-b607-364da4cb472c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ddd0e557-f9e4-4ce2-98d2-47403d97e639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1f71b4c3-7431-4848-b607-364da4cb472c" xlink:to="loc_us-gaap_StatementTable_ddd0e557-f9e4-4ce2-98d2-47403d97e639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_e5b3e82e-aa25-43ad-ab5a-c4e1bbef0602" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ddd0e557-f9e4-4ce2-98d2-47403d97e639" xlink:to="loc_srt_ProductOrServiceAxis_e5b3e82e-aa25-43ad-ab5a-c4e1bbef0602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_65ee47ee-c461-47fd-aab2-dd749abf664a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_e5b3e82e-aa25-43ad-ab5a-c4e1bbef0602" xlink:to="loc_srt_ProductsAndServicesDomain_65ee47ee-c461-47fd-aab2-dd749abf664a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_c70b23a5-9c23-44ad-b9ae-9712ddba8938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_65ee47ee-c461-47fd-aab2-dd749abf664a" xlink:to="loc_us-gaap_LicenseMember_c70b23a5-9c23-44ad-b9ae-9712ddba8938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_dcbe1d19-5e7a-43e1-9550-66588147900b" xlink:href="ino-20220331.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_65ee47ee-c461-47fd-aab2-dd749abf664a" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_dcbe1d19-5e7a-43e1-9550-66588147900b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_2ccdfa60-4513-456a-869e-d55f8c8cd482" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_65ee47ee-c461-47fd-aab2-dd749abf664a" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_2ccdfa60-4513-456a-869e-d55f8c8cd482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9f97eab7-b448-4976-a31f-039ef106d3db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ddd0e557-f9e4-4ce2-98d2-47403d97e639" xlink:to="loc_us-gaap_StatementLineItems_9f97eab7-b448-4976-a31f-039ef106d3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_a1824333-5ceb-40ce-b6eb-fabd2e5e6658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9f97eab7-b448-4976-a31f-039ef106d3db" xlink:to="loc_us-gaap_RevenuesAbstract_a1824333-5ceb-40ce-b6eb-fabd2e5e6658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_551bc336-db1a-4016-89bb-d8e47d93eeed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_a1824333-5ceb-40ce-b6eb-fabd2e5e6658" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_551bc336-db1a-4016-89bb-d8e47d93eeed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_8ee4fbd3-aa02-463c-a094-1fd7343baf33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9f97eab7-b448-4976-a31f-039ef106d3db" xlink:to="loc_us-gaap_OperatingExpensesAbstract_8ee4fbd3-aa02-463c-a094-1fd7343baf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_162b93c7-8d50-40dc-b97b-6c38a2e3c76e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8ee4fbd3-aa02-463c-a094-1fd7343baf33" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_162b93c7-8d50-40dc-b97b-6c38a2e3c76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7ee22a00-5f91-4b11-8c1b-462c250c5ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8ee4fbd3-aa02-463c-a094-1fd7343baf33" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7ee22a00-5f91-4b11-8c1b-462c250c5ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_bfc92283-edca-4292-b0aa-7c47f8a814bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8ee4fbd3-aa02-463c-a094-1fd7343baf33" xlink:to="loc_us-gaap_OperatingExpenses_bfc92283-edca-4292-b0aa-7c47f8a814bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2784859a-993f-47b2-8465-13e4982d2c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9f97eab7-b448-4976-a31f-039ef106d3db" xlink:to="loc_us-gaap_OperatingIncomeLoss_2784859a-993f-47b2-8465-13e4982d2c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_45a8cd93-4f80-4255-b5fc-2a91c525c62c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9f97eab7-b448-4976-a31f-039ef106d3db" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_45a8cd93-4f80-4255-b5fc-2a91c525c62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_ce685579-296e-437d-b2df-38f534d22f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_45a8cd93-4f80-4255-b5fc-2a91c525c62c" xlink:to="loc_us-gaap_InterestIncomeOperating_ce685579-296e-437d-b2df-38f534d22f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_d2bf3cdb-b12c-465c-bff0-b60619408db9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_45a8cd93-4f80-4255-b5fc-2a91c525c62c" xlink:to="loc_us-gaap_InterestExpense_d2bf3cdb-b12c-465c-bff0-b60619408db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_0acce8d5-067b-4537-9340-a2ae73a8ff4f" xlink:href="ino-20220331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_45a8cd93-4f80-4255-b5fc-2a91c525c62c" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_0acce8d5-067b-4537-9340-a2ae73a8ff4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cc3a54b1-6567-4ae0-a72f-0a1d6e5232b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_45a8cd93-4f80-4255-b5fc-2a91c525c62c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cc3a54b1-6567-4ae0-a72f-0a1d6e5232b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_18f1b56f-d959-470e-b410-2409e1b59371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_45a8cd93-4f80-4255-b5fc-2a91c525c62c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_18f1b56f-d959-470e-b410-2409e1b59371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1e25a8cd-8204-4390-8fad-4f480c2daae3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_45a8cd93-4f80-4255-b5fc-2a91c525c62c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1e25a8cd-8204-4390-8fad-4f480c2daae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_625ea1d9-b4c0-4eb8-a566-58ee026017d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_45a8cd93-4f80-4255-b5fc-2a91c525c62c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_625ea1d9-b4c0-4eb8-a566-58ee026017d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_099cd891-377a-43eb-8560-a3ede0307fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_45a8cd93-4f80-4255-b5fc-2a91c525c62c" xlink:to="loc_us-gaap_NetIncomeLoss_099cd891-377a-43eb-8560-a3ede0307fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a9219a72-1a25-483b-b37f-5cbad4fbcd62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9f97eab7-b448-4976-a31f-039ef106d3db" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a9219a72-1a25-483b-b37f-5cbad4fbcd62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_839039a6-b07c-442f-877e-1e17b21cab2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a9219a72-1a25-483b-b37f-5cbad4fbcd62" xlink:to="loc_us-gaap_EarningsPerShareBasic_839039a6-b07c-442f-877e-1e17b21cab2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3de58f50-ed61-4a54-9444-f943a2c1c649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_a9219a72-1a25-483b-b37f-5cbad4fbcd62" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3de58f50-ed61-4a54-9444-f943a2c1c649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_9a023578-cc7b-4d67-bcb7-6e5cbfc10503" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9f97eab7-b448-4976-a31f-039ef106d3db" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_9a023578-cc7b-4d67-bcb7-6e5cbfc10503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4c5fdfec-e158-47e2-85c8-5493d7d8c3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_9a023578-cc7b-4d67-bcb7-6e5cbfc10503" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4c5fdfec-e158-47e2-85c8-5493d7d8c3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ddc41ecc-58cf-48a3-953c-c85bd5830a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_9a023578-cc7b-4d67-bcb7-6e5cbfc10503" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ddc41ecc-58cf-48a3-953c-c85bd5830a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="ino-20220331.xsd#CondensedConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cf1b0bfa-5e12-467a-b42f-731b3a3f9e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_cc178288-1615-40a8-9318-4ea0b8380706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cf1b0bfa-5e12-467a-b42f-731b3a3f9e3f" xlink:to="loc_us-gaap_NetIncomeLoss_cc178288-1615-40a8-9318-4ea0b8380706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8480067c-2103-4b0d-9759-fb5e3a55452d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cf1b0bfa-5e12-467a-b42f-731b3a3f9e3f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8480067c-2103-4b0d-9759-fb5e3a55452d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f482e158-20d8-45a9-b368-9164c18e6c32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8480067c-2103-4b0d-9759-fb5e3a55452d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f482e158-20d8-45a9-b368-9164c18e6c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0ee3a16f-1e7c-4b89-8c40-0fb2b28a964c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8480067c-2103-4b0d-9759-fb5e3a55452d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0ee3a16f-1e7c-4b89-8c40-0fb2b28a964c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_626d791f-1bc4-4990-92d4-bd5939409ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cf1b0bfa-5e12-467a-b42f-731b3a3f9e3f" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_626d791f-1bc4-4990-92d4-bd5939409ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="simple" xlink:href="ino-20220331.xsd#CondensedConsolidatedStatementsofStockholdersEquityUnaudited"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_da0db09d-fe37-42b9-b4e5-5c556a84bef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f7853339-c9eb-43e1-a367-b8e170c86248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_da0db09d-fe37-42b9-b4e5-5c556a84bef4" xlink:to="loc_us-gaap_StatementTable_f7853339-c9eb-43e1-a367-b8e170c86248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_edc82e7f-451c-40f1-8f9a-7232148d2e12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f7853339-c9eb-43e1-a367-b8e170c86248" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_edc82e7f-451c-40f1-8f9a-7232148d2e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d3cb2bd2-503a-4dc1-9726-0a63dbd8b1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_edc82e7f-451c-40f1-8f9a-7232148d2e12" xlink:to="loc_us-gaap_EquityComponentDomain_d3cb2bd2-503a-4dc1-9726-0a63dbd8b1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_d7ee7beb-bcdc-493d-8e50-91c8204b24f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d3cb2bd2-503a-4dc1-9726-0a63dbd8b1a9" xlink:to="loc_us-gaap_PreferredStockMember_d7ee7beb-bcdc-493d-8e50-91c8204b24f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f52ca698-6004-4c82-ac9a-df2b38c7bced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d3cb2bd2-503a-4dc1-9726-0a63dbd8b1a9" xlink:to="loc_us-gaap_CommonStockMember_f52ca698-6004-4c82-ac9a-df2b38c7bced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5a1d69f3-d8b3-4e6f-8fdc-788d72f4f247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d3cb2bd2-503a-4dc1-9726-0a63dbd8b1a9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5a1d69f3-d8b3-4e6f-8fdc-788d72f4f247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_3054d8ac-3de5-4736-8c44-5a0fae440c35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d3cb2bd2-503a-4dc1-9726-0a63dbd8b1a9" xlink:to="loc_us-gaap_RetainedEarningsMember_3054d8ac-3de5-4736-8c44-5a0fae440c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b0d3abd7-aad1-425a-be53-509e9ad9989f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d3cb2bd2-503a-4dc1-9726-0a63dbd8b1a9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b0d3abd7-aad1-425a-be53-509e9ad9989f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3bc9782b-f869-4bce-a54b-3b05ebcf32cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f7853339-c9eb-43e1-a367-b8e170c86248" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3bc9782b-f869-4bce-a54b-3b05ebcf32cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_82d12a2d-9ed6-48ef-a34f-73c095ab769e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_3bc9782b-f869-4bce-a54b-3b05ebcf32cd" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_82d12a2d-9ed6-48ef-a34f-73c095ab769e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_83086125-4774-460a-b2ef-189ccf20e27a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_82d12a2d-9ed6-48ef-a34f-73c095ab769e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_83086125-4774-460a-b2ef-189ccf20e27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_355f0ceb-da88-45d9-866c-9912625cb17e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f7853339-c9eb-43e1-a367-b8e170c86248" xlink:to="loc_us-gaap_StatementLineItems_355f0ceb-da88-45d9-866c-9912625cb17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_355f0ceb-da88-45d9-866c-9912625cb17e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_0b28c7dc-232f-4cf0-ae91-bd5c5a6b171d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_SharesIssued_0b28c7dc-232f-4cf0-ae91-bd5c5a6b171d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d5d31e9e-2d71-49cf-8022-1186319c2456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_StockholdersEquity_d5d31e9e-2d71-49cf-8022-1186319c2456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6ee58967-894b-48e8-959f-f95a5b294403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6ee58967-894b-48e8-959f-f95a5b294403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4b8fa87a-26d8-4cfc-9e88-1277fced14bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4b8fa87a-26d8-4cfc-9e88-1277fced14bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b46daaff-b10b-40ff-a855-10283b55ee61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_b46daaff-b10b-40ff-a855-10283b55ee61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_a74c8ade-462c-41d4-8d08-82c411f02de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_a74c8ade-462c-41d4-8d08-82c411f02de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0838363e-b0c3-4e5b-9b44-50c773f4cd41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0838363e-b0c3-4e5b-9b44-50c773f4cd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_541a92b8-08a2-42dc-bef5-dd4925137f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_541a92b8-08a2-42dc-bef5-dd4925137f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f99d7d6e-1511-4662-b6b5-35106eb8178d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f99d7d6e-1511-4662-b6b5-35106eb8178d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b8d84cdd-9d07-4ad2-bd88-9fb7c6f2cc86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_NetIncomeLoss_b8d84cdd-9d07-4ad2-bd88-9fb7c6f2cc86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ea9fc72d-e61f-45de-bd06-18e1b69b760b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ea9fc72d-e61f-45de-bd06-18e1b69b760b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_59708296-f83d-478c-8b04-ef8fbd3ee495" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_59708296-f83d-478c-8b04-ef8fbd3ee495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_058d3167-8bf2-45fe-9610-3dbd7a9a9309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_StockholdersEquity_058d3167-8bf2-45fe-9610-3dbd7a9a9309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_e731d304-9637-4f49-99da-5168c1ee73cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9445e127-8f3a-4b1a-aafd-68b06b774e8d" xlink:to="loc_us-gaap_SharesIssued_e731d304-9637-4f49-99da-5168c1ee73cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_8865c8b8-853b-4811-bf50-25f8e8e2b747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_355f0ceb-da88-45d9-866c-9912625cb17e" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_8865c8b8-853b-4811-bf50-25f8e8e2b747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="ino-20220331.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f709f6ff-2683-4dd4-9438-4b10eb37e671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_d0318ff3-31f5-4973-80be-8e717c07c1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f709f6ff-2683-4dd4-9438-4b10eb37e671" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_d0318ff3-31f5-4973-80be-8e717c07c1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="ino-20220331.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_aa441af1-7435-4cbe-a0b0-130b80bdc330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b064baea-7025-4bae-a223-9f5b68966bed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa441af1-7435-4cbe-a0b0-130b80bdc330" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b064baea-7025-4bae-a223-9f5b68966bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1ede4974-f1a4-48d1-aac7-447d4d880e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b064baea-7025-4bae-a223-9f5b68966bed" xlink:to="loc_us-gaap_NetIncomeLoss_1ede4974-f1a4-48d1-aac7-447d4d880e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dee557b-511c-4acf-9958-88448b00cc38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b064baea-7025-4bae-a223-9f5b68966bed" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dee557b-511c-4acf-9958-88448b00cc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_4ba1cef9-2fb8-409d-8054-60aba48fcafe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dee557b-511c-4acf-9958-88448b00cc38" xlink:to="loc_us-gaap_Depreciation_4ba1cef9-2fb8-409d-8054-60aba48fcafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_9fc56bf2-ccf7-44f7-bbab-95d56e42b836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dee557b-511c-4acf-9958-88448b00cc38" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_9fc56bf2-ccf7-44f7-bbab-95d56e42b836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_fb156de3-a92c-496c-9029-bf01d92ad773" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dee557b-511c-4acf-9958-88448b00cc38" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_fb156de3-a92c-496c-9029-bf01d92ad773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_01e358d9-f053-4bfc-9528-f75fcc55487d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dee557b-511c-4acf-9958-88448b00cc38" xlink:to="loc_us-gaap_ShareBasedCompensation_01e358d9-f053-4bfc-9528-f75fcc55487d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestIncomeExpense_819b3dc9-2e02-4072-955b-c3ba49fa8ef4" xlink:href="ino-20220331.xsd#ino_NonCashInterestIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dee557b-511c-4acf-9958-88448b00cc38" xlink:to="loc_ino_NonCashInterestIncomeExpense_819b3dc9-2e02-4072-955b-c3ba49fa8ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_64d81f23-deb4-43f6-8cae-dc18fd9cf1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dee557b-511c-4acf-9958-88448b00cc38" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_64d81f23-deb4-43f6-8cae-dc18fd9cf1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_ae571af8-a5d1-440f-a772-69683436a367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dee557b-511c-4acf-9958-88448b00cc38" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_ae571af8-a5d1-440f-a772-69683436a367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4aa704b3-b392-4770-b56a-49ec4a817602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dee557b-511c-4acf-9958-88448b00cc38" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_4aa704b3-b392-4770-b56a-49ec4a817602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment_a0c77b2e-16d2-474c-ae48-9cc33616ad9b" xlink:href="ino-20220331.xsd#ino_GainLossOnRemeasurementOfEquityMethodInvestment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dee557b-511c-4acf-9958-88448b00cc38" xlink:to="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment_a0c77b2e-16d2-474c-ae48-9cc33616ad9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_546fa6af-998c-4c0a-9af4-4772eaa94ce6" xlink:href="ino-20220331.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dee557b-511c-4acf-9958-88448b00cc38" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_546fa6af-998c-4c0a-9af4-4772eaa94ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_40acd8e0-c382-4650-a3d9-e5d6f1648df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dee557b-511c-4acf-9958-88448b00cc38" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_40acd8e0-c382-4650-a3d9-e5d6f1648df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_aa50ef13-1320-4738-93f7-ed1b5f088a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dee557b-511c-4acf-9958-88448b00cc38" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_aa50ef13-1320-4738-93f7-ed1b5f088a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_cd03855d-8bb1-4ee4-ab90-63636e2a7c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dee557b-511c-4acf-9958-88448b00cc38" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_cd03855d-8bb1-4ee4-ab90-63636e2a7c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5a3c7dd-72c5-4cf3-a345-5eb28fd8894d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dee557b-511c-4acf-9958-88448b00cc38" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5a3c7dd-72c5-4cf3-a345-5eb28fd8894d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_97d1e041-c88d-4dae-964d-29a732b794f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5a3c7dd-72c5-4cf3-a345-5eb28fd8894d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_97d1e041-c88d-4dae-964d-29a732b794f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3d2aa2ee-b696-4b49-9843-0700836f5a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5a3c7dd-72c5-4cf3-a345-5eb28fd8894d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3d2aa2ee-b696-4b49-9843-0700836f5a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_425ff075-bf9d-4105-b78e-965066653823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5a3c7dd-72c5-4cf3-a345-5eb28fd8894d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_425ff075-bf9d-4105-b78e-965066653823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bb22f2c4-6d12-483b-ad14-1f90f7827489" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5a3c7dd-72c5-4cf3-a345-5eb28fd8894d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bb22f2c4-6d12-483b-ad14-1f90f7827489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_720120eb-8f3c-4f80-8656-88a713c68249" xlink:href="ino-20220331.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5a3c7dd-72c5-4cf3-a345-5eb28fd8894d" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_720120eb-8f3c-4f80-8656-88a713c68249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_f780e583-20f6-4bb4-b727-b616d28437b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5a3c7dd-72c5-4cf3-a345-5eb28fd8894d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_f780e583-20f6-4bb4-b727-b616d28437b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b168f905-f7c8-4673-85f2-2cba06835e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5a3c7dd-72c5-4cf3-a345-5eb28fd8894d" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b168f905-f7c8-4673-85f2-2cba06835e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_f4cca671-7339-4c26-9460-8374747aa6f0" xlink:href="ino-20220331.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5a3c7dd-72c5-4cf3-a345-5eb28fd8894d" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_f4cca671-7339-4c26-9460-8374747aa6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_bcf0b918-6182-45fb-a8a5-5d81e2e73c36" xlink:href="ino-20220331.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5a3c7dd-72c5-4cf3-a345-5eb28fd8894d" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_bcf0b918-6182-45fb-a8a5-5d81e2e73c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7ec69677-de0e-425d-90ec-89a52f7090c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c5a3c7dd-72c5-4cf3-a345-5eb28fd8894d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7ec69677-de0e-425d-90ec-89a52f7090c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2baab862-0d05-4595-9ba2-58d791df5a27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b064baea-7025-4bae-a223-9f5b68966bed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2baab862-0d05-4595-9ba2-58d791df5a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8847e243-3aae-484b-9a86-70de64aea49c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa441af1-7435-4cbe-a0b0-130b80bdc330" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8847e243-3aae-484b-9a86-70de64aea49c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_a75d85f3-8734-41e7-add7-dda3a33d2ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8847e243-3aae-484b-9a86-70de64aea49c" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_a75d85f3-8734-41e7-add7-dda3a33d2ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_ac5d0d54-c297-4bda-b728-d2db7813e393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8847e243-3aae-484b-9a86-70de64aea49c" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_ac5d0d54-c297-4bda-b728-d2db7813e393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4847a77b-8989-4edf-a366-c031c3c8c80b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8847e243-3aae-484b-9a86-70de64aea49c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4847a77b-8989-4edf-a366-c031c3c8c80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_c3794d40-95b8-4c49-8933-e99b62610dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8847e243-3aae-484b-9a86-70de64aea49c" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_c3794d40-95b8-4c49-8933-e99b62610dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1f183394-b1fe-4ba1-bb6a-022e421acec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8847e243-3aae-484b-9a86-70de64aea49c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1f183394-b1fe-4ba1-bb6a-022e421acec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c61faf8d-a18e-4f7b-a408-44deb47d067a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa441af1-7435-4cbe-a0b0-130b80bdc330" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c61faf8d-a18e-4f7b-a408-44deb47d067a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_187a86c7-c528-4f8a-b3f8-2c7365af3612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c61faf8d-a18e-4f7b-a408-44deb47d067a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_187a86c7-c528-4f8a-b3f8-2c7365af3612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_51c5bd98-67c1-4379-a987-306c07884387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c61faf8d-a18e-4f7b-a408-44deb47d067a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_51c5bd98-67c1-4379-a987-306c07884387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e3abf174-f17a-48be-9015-c4aad7cdfc15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c61faf8d-a18e-4f7b-a408-44deb47d067a" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e3abf174-f17a-48be-9015-c4aad7cdfc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1b4f61c4-5088-45ed-9c39-5376660e5842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c61faf8d-a18e-4f7b-a408-44deb47d067a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1b4f61c4-5088-45ed-9c39-5376660e5842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_13329bd1-bfe1-48e0-a2be-49ad6523c601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa441af1-7435-4cbe-a0b0-130b80bdc330" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_13329bd1-bfe1-48e0-a2be-49ad6523c601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1044efb-a24a-41fe-a35f-3c260276b5de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa441af1-7435-4cbe-a0b0-130b80bdc330" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e1044efb-a24a-41fe-a35f-3c260276b5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_262b69bf-f6fc-4027-92dc-879f3f76ef86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa441af1-7435-4cbe-a0b0-130b80bdc330" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_262b69bf-f6fc-4027-92dc-879f3f76ef86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9da22b08-f773-4444-a8fd-14a720d45e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa441af1-7435-4cbe-a0b0-130b80bdc330" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9da22b08-f773-4444-a8fd-14a720d45e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_82931815-30cf-44be-835a-f731da44af99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_aa441af1-7435-4cbe-a0b0-130b80bdc330" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_82931815-30cf-44be-835a-f731da44af99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c2a5b3ca-301b-4d93-8764-c833146a0205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_82931815-30cf-44be-835a-f731da44af99" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_c2a5b3ca-301b-4d93-8764-c833146a0205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_ad90cbe3-77bb-47af-8a95-ca49e892c1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_82931815-30cf-44be-835a-f731da44af99" xlink:to="loc_us-gaap_InterestPaidNet_ad90cbe3-77bb-47af-8a95-ca49e892c1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/OrganizationandOperations" xlink:type="simple" xlink:href="ino-20220331.xsd#OrganizationandOperations"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/OrganizationandOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be863468-b661-41e4-9624-994ca72060ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_6accd4e7-fb93-40ba-a745-010b09d15e54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_be863468-b661-41e4-9624-994ca72060ea" xlink:to="loc_us-gaap_NatureOfOperations_6accd4e7-fb93-40ba-a745-010b09d15e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="simple" xlink:href="ino-20220331.xsd#BasisofPresentationLiquidityandRisksandUncertainties"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_285dd39f-103e-48c5-b80d-c8b017716640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_16e1b588-a5b9-4653-a793-c21861fb67b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_285dd39f-103e-48c5-b80d-c8b017716640" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_16e1b588-a5b9-4653-a793-c21861fb67b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="simple" xlink:href="ino-20220331.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e056853f-1eb5-48ad-96d1-6057c6ae3d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ee3818d3-449a-4358-b378-e1a3727bea07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e056853f-1eb5-48ad-96d1-6057c6ae3d8c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ee3818d3-449a-4358-b378-e1a3727bea07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RisksAndUncertaintiesPolicyTextBlock_c3705ec9-7a4e-475b-bfe8-86dacf166e7e" xlink:href="ino-20220331.xsd#ino_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e056853f-1eb5-48ad-96d1-6057c6ae3d8c" xlink:to="loc_ino_RisksAndUncertaintiesPolicyTextBlock_c3705ec9-7a4e-475b-bfe8-86dacf166e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_8ade2849-d2c8-4d4e-8567-1a079dbfe043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e056853f-1eb5-48ad-96d1-6057c6ae3d8c" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_8ade2849-d2c8-4d4e-8567-1a079dbfe043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_ce8b7323-79f7-41f7-aa94-a14225cddee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e056853f-1eb5-48ad-96d1-6057c6ae3d8c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_ce8b7323-79f7-41f7-aa94-a14225cddee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9067d731-a1de-4e04-8de9-f59cc751ea76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e056853f-1eb5-48ad-96d1-6057c6ae3d8c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9067d731-a1de-4e04-8de9-f59cc751ea76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#BasisofPresentationLiquidityandRisksandUncertaintiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_05184afc-26e0-4c20-a695-6ca33bc87a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ae52873f-a97d-4a34-a163-b7869851e09e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_05184afc-26e0-4c20-a695-6ca33bc87a03" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ae52873f-a97d-4a34-a163-b7869851e09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_bae7a259-9490-43a1-aff7-028a7a59ff75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ae52873f-a97d-4a34-a163-b7869851e09e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_bae7a259-9490-43a1-aff7-028a7a59ff75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_43a64741-7123-41b5-99a9-5dd4f221ba69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_bae7a259-9490-43a1-aff7-028a7a59ff75" xlink:to="loc_us-gaap_ClassOfStockDomain_43a64741-7123-41b5-99a9-5dd4f221ba69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a9d678a9-a968-4d15-afc8-ec7453d44a20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_43a64741-7123-41b5-99a9-5dd4f221ba69" xlink:to="loc_us-gaap_CommonStockMember_a9d678a9-a968-4d15-afc8-ec7453d44a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_fe2a1d8e-39c8-4107-b2c5-8411fa5e1a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ae52873f-a97d-4a34-a163-b7869851e09e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_fe2a1d8e-39c8-4107-b2c5-8411fa5e1a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_037fba5a-9b04-46b4-be4a-72d0f6fe0395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_fe2a1d8e-39c8-4107-b2c5-8411fa5e1a05" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_037fba5a-9b04-46b4-be4a-72d0f6fe0395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementsMember_5c32b1d4-2a2e-417a-a89b-760ee174f254" xlink:href="ino-20220331.xsd#ino_SalesAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_037fba5a-9b04-46b4-be4a-72d0f6fe0395" xlink:to="loc_ino_SalesAgreementsMember_5c32b1d4-2a2e-417a-a89b-760ee174f254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember_c4602bf2-b14c-4a5e-a49d-df16a58263b6" xlink:href="ino-20220331.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_037fba5a-9b04-46b4-be4a-72d0f6fe0395" xlink:to="loc_ino_UnderwrittenPublicOfferingMember_c4602bf2-b14c-4a5e-a49d-df16a58263b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f8c4aa8e-e0c4-4b74-90b9-e530d3d8866c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ae52873f-a97d-4a34-a163-b7869851e09e" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f8c4aa8e-e0c4-4b74-90b9-e530d3d8866c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1991d259-b234-49bd-aaaa-d6c1743854fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f8c4aa8e-e0c4-4b74-90b9-e530d3d8866c" xlink:to="loc_us-gaap_NetIncomeLoss_1991d259-b234-49bd-aaaa-d6c1743854fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Capital_714fb7c8-4e6f-4c3a-881f-a531b1398771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Capital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f8c4aa8e-e0c4-4b74-90b9-e530d3d8866c" xlink:to="loc_us-gaap_Capital_714fb7c8-4e6f-4c3a-881f-a531b1398771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d3964aa9-c7d5-45b3-9c2e-43397a5380dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f8c4aa8e-e0c4-4b74-90b9-e530d3d8866c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d3964aa9-c7d5-45b3-9c2e-43397a5380dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_fa732548-996f-41f6-9922-54ecce1b8f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f8c4aa8e-e0c4-4b74-90b9-e530d3d8866c" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_fa732548-996f-41f6-9922-54ecce1b8f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_18387747-48a9-46db-bed8-e82c8e783861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_f8c4aa8e-e0c4-4b74-90b9-e530d3d8866c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_18387747-48a9-46db-bed8-e82c8e783861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="simple" xlink:href="ino-20220331.xsd#CriticalAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CriticalAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dac7c982-e3f5-4137-a912-62114058eb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_18cf1e21-bb7b-4a66-a1f9-e3cd8cebf334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dac7c982-e3f5-4137-a912-62114058eb1b" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_18cf1e21-bb7b-4a66-a1f9-e3cd8cebf334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards" xlink:type="simple" xlink:href="ino-20220331.xsd#ImpactofRecentlyIssuedAccountingStandards"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ac27be19-23a6-492b-8e6d-5d173bcabfdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_f811fd85-0fa3-4942-978d-4c86eb95ff84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ac27be19-23a6-492b-8e6d-5d173bcabfdd" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_f811fd85-0fa3-4942-978d-4c86eb95ff84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandardsDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#ImpactofRecentlyIssuedAccountingStandardsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f54b7ba0-a877-4332-881e-f2d7c166bd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fa8c4c6c-7d88-4741-ae94-a56efcb784e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f54b7ba0-a877-4332-881e-f2d7c166bd6e" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fa8c4c6c-7d88-4741-ae94-a56efcb784e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a2b8b098-ba00-4013-9a21-5f52406a1d59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fa8c4c6c-7d88-4741-ae94-a56efcb784e0" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a2b8b098-ba00-4013-9a21-5f52406a1d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_fe7a8737-2c0b-4ea1-affa-85120d376b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_a2b8b098-ba00-4013-9a21-5f52406a1d59" xlink:to="loc_us-gaap_TypeOfAdoptionMember_fe7a8737-2c0b-4ea1-affa-85120d376b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_e215dc13-a371-4ba5-b155-64bf63b395bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_fe7a8737-2c0b-4ea1-affa-85120d376b9c" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_e215dc13-a371-4ba5-b155-64bf63b395bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e0112c3b-9987-444f-8bd0-ad73acd08c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_fa8c4c6c-7d88-4741-ae94-a56efcb784e0" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e0112c3b-9987-444f-8bd0-ad73acd08c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4b6c03c7-660a-4849-9786-7e485dbbc234" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e0112c3b-9987-444f-8bd0-ad73acd08c87" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_4b6c03c7-660a-4849-9786-7e485dbbc234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3bbdd195-1271-4eab-99fc-550094506e22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e0112c3b-9987-444f-8bd0-ad73acd08c87" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3bbdd195-1271-4eab-99fc-550094506e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_f3cf7c6f-3985-4532-9fdc-9a81038ae2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e0112c3b-9987-444f-8bd0-ad73acd08c87" xlink:to="loc_us-gaap_ConvertibleDebt_f3cf7c6f-3985-4532-9fdc-9a81038ae2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e89b38eb-65aa-417e-aeb1-f208c722e7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_e0112c3b-9987-444f-8bd0-ad73acd08c87" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e89b38eb-65aa-417e-aeb1-f208c722e7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognition" xlink:type="simple" xlink:href="ino-20220331.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7e9ddab7-7f37-4993-8dc1-c31e6fce0491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_ba1a245e-3165-468d-8eee-f3bcd44123d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7e9ddab7-7f37-4993-8dc1-c31e6fce0491" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_ba1a245e-3165-468d-8eee-f3bcd44123d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#RevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_289d2f07-c2f0-4344-9520-58a5aa2a3565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_182cb3cd-0845-4cb4-9095-72376b6b6e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_289d2f07-c2f0-4344-9520-58a5aa2a3565" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_182cb3cd-0845-4cb4-9095-72376b6b6e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_87f5990c-9861-493a-8c46-db91261078f3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_182cb3cd-0845-4cb4-9095-72376b6b6e1e" xlink:to="loc_srt_ProductOrServiceAxis_87f5990c-9861-493a-8c46-db91261078f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_59c3debe-4155-4c1f-a3e9-66ac69e8934a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_87f5990c-9861-493a-8c46-db91261078f3" xlink:to="loc_srt_ProductsAndServicesDomain_59c3debe-4155-4c1f-a3e9-66ac69e8934a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_300dd7b1-7cbf-4dbe-989d-53883c4c4fcb" xlink:href="ino-20220331.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_59c3debe-4155-4c1f-a3e9-66ac69e8934a" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_300dd7b1-7cbf-4dbe-989d-53883c4c4fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_157c9390-5de1-43b0-8862-b7428348ebca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_182cb3cd-0845-4cb4-9095-72376b6b6e1e" xlink:to="loc_srt_CounterpartyNameAxis_157c9390-5de1-43b0-8862-b7428348ebca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e298e5cd-cf7e-432c-9539-84220ad38c39" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_157c9390-5de1-43b0-8862-b7428348ebca" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e298e5cd-cf7e-432c-9539-84220ad38c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OtherCounterpartyMember_96cd698c-706a-4c10-bdb0-848b5d170849" xlink:href="ino-20220331.xsd#ino_OtherCounterpartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e298e5cd-cf7e-432c-9539-84220ad38c39" xlink:to="loc_ino_OtherCounterpartyMember_96cd698c-706a-4c10-bdb0-848b5d170849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_357c7193-f8c0-4de5-b59d-09c9322564c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_182cb3cd-0845-4cb4-9095-72376b6b6e1e" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_357c7193-f8c0-4de5-b59d-09c9322564c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9c1becc1-ba76-49b0-a59f-5e6958bdfad5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_357c7193-f8c0-4de5-b59d-09c9322564c4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9c1becc1-ba76-49b0-a59f-5e6958bdfad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5bedc256-30e6-46e8-93cd-7cc4371a2869" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_357c7193-f8c0-4de5-b59d-09c9322564c4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5bedc256-30e6-46e8-93cd-7cc4371a2869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements" xlink:type="simple" xlink:href="ino-20220331.xsd#ShorttermInvestmentsandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8e5e3d61-85ba-4e01-b4cc-fc0104128201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_f5ab5339-084d-4ca4-9546-0910c73a3eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8e5e3d61-85ba-4e01-b4cc-fc0104128201" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_f5ab5339-084d-4ca4-9546-0910c73a3eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ba0f9b92-a3b8-4b59-a895-0c1a488d30be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8e5e3d61-85ba-4e01-b4cc-fc0104128201" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ba0f9b92-a3b8-4b59-a895-0c1a488d30be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables" xlink:type="simple" xlink:href="ino-20220331.xsd#ShorttermInvestmentsandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1a18981c-9d34-4dc7-9758-b59c805e8758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_65ba2cde-63fa-4699-8650-0a30b81da6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1a18981c-9d34-4dc7-9758-b59c805e8758" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_65ba2cde-63fa-4699-8650-0a30b81da6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8b35324a-4091-456b-9787-84b99c910304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1a18981c-9d34-4dc7-9758-b59c805e8758" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_8b35324a-4091-456b-9787-84b99c910304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_176455f5-e30a-4cce-bc14-7cf53703149d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_de546a33-ddf9-4036-b81e-79fd6e785533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_176455f5-e30a-4cce-bc14-7cf53703149d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_de546a33-ddf9-4036-b81e-79fd6e785533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_30d47367-48c1-4929-9977-81e622c1d740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_de546a33-ddf9-4036-b81e-79fd6e785533" xlink:to="loc_us-gaap_FinancialInstrumentAxis_30d47367-48c1-4929-9977-81e622c1d740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_505ad22c-46f6-43db-a3db-2cb3f748b3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_30d47367-48c1-4929-9977-81e622c1d740" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_505ad22c-46f6-43db-a3db-2cb3f748b3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_6878b170-d8ab-49f4-8bf8-36c1e0738791" xlink:href="ino-20220331.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_505ad22c-46f6-43db-a3db-2cb3f748b3fc" xlink:to="loc_ino_MutualFundsMember_6878b170-d8ab-49f4-8bf8-36c1e0738791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_474b7ea7-8d30-4b47-8c2a-f084a6a1f2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_505ad22c-46f6-43db-a3db-2cb3f748b3fc" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_474b7ea7-8d30-4b47-8c2a-f084a6a1f2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_bf3ff68a-69ed-454e-8ce0-247159b579f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_505ad22c-46f6-43db-a3db-2cb3f748b3fc" xlink:to="loc_us-gaap_CommercialPaperMember_bf3ff68a-69ed-454e-8ce0-247159b579f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_0bad7b63-fc6a-4a01-87d9-e9011b14b629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_505ad22c-46f6-43db-a3db-2cb3f748b3fc" xlink:to="loc_us-gaap_CertificatesOfDepositMember_0bad7b63-fc6a-4a01-87d9-e9011b14b629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_0531fe52-a3ec-4eb1-b257-342a961bc100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_505ad22c-46f6-43db-a3db-2cb3f748b3fc" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_0531fe52-a3ec-4eb1-b257-342a961bc100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25d737c7-9326-4586-b0c9-990436335e09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_de546a33-ddf9-4036-b81e-79fd6e785533" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25d737c7-9326-4586-b0c9-990436335e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_e94c0ae6-a366-4615-8842-0b437d46410d" xlink:href="ino-20220331.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25d737c7-9326-4586-b0c9-990436335e09" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_e94c0ae6-a366-4615-8842-0b437d46410d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a84d3cd6-adce-49c9-a0fb-8e6b8bb632a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25d737c7-9326-4586-b0c9-990436335e09" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a84d3cd6-adce-49c9-a0fb-8e6b8bb632a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e84f7166-9ef2-4048-ac5e-eb1cccc84e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a84d3cd6-adce-49c9-a0fb-8e6b8bb632a1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e84f7166-9ef2-4048-ac5e-eb1cccc84e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_29b75b8f-41f7-46ec-9b65-2ed4dc8d51d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a84d3cd6-adce-49c9-a0fb-8e6b8bb632a1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_29b75b8f-41f7-46ec-9b65-2ed4dc8d51d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2f05b07e-6e81-4748-93a3-3d9847841cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a84d3cd6-adce-49c9-a0fb-8e6b8bb632a1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2f05b07e-6e81-4748-93a3-3d9847841cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_af8c9e37-8cba-41f2-9f00-ca2a54f1f801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a84d3cd6-adce-49c9-a0fb-8e6b8bb632a1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_af8c9e37-8cba-41f2-9f00-ca2a54f1f801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_448257b3-72aa-4195-943d-a19d9e252427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_be616cde-75ed-44a9-b35e-3c40d00fe6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_448257b3-72aa-4195-943d-a19d9e252427" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_be616cde-75ed-44a9-b35e-3c40d00fe6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_18d112d1-71ae-43e5-b1af-1a2ac770b57a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_be616cde-75ed-44a9-b35e-3c40d00fe6a1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_18d112d1-71ae-43e5-b1af-1a2ac770b57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2c0d2e7c-0c70-4e95-aded-e10a8d846d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_18d112d1-71ae-43e5-b1af-1a2ac770b57a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2c0d2e7c-0c70-4e95-aded-e10a8d846d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a0289283-8f5d-4d80-9fe0-e63497ca7b10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2c0d2e7c-0c70-4e95-aded-e10a8d846d45" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a0289283-8f5d-4d80-9fe0-e63497ca7b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_172975ea-cc4b-4c44-b714-a518d13e04fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_be616cde-75ed-44a9-b35e-3c40d00fe6a1" xlink:to="loc_us-gaap_InvestmentTypeAxis_172975ea-cc4b-4c44-b714-a518d13e04fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6d67733d-651c-43b8-96ea-f9bee74b994a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_172975ea-cc4b-4c44-b714-a518d13e04fb" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6d67733d-651c-43b8-96ea-f9bee74b994a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6ccfcd5a-83f7-4489-95b0-e71e5a55c1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6d67733d-651c-43b8-96ea-f9bee74b994a" xlink:to="loc_us-gaap_CommonStockMember_6ccfcd5a-83f7-4489-95b0-e71e5a55c1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_51310a4d-bed0-470a-8b73-cc139160b1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_be616cde-75ed-44a9-b35e-3c40d00fe6a1" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_51310a4d-bed0-470a-8b73-cc139160b1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_e7973077-9337-419e-942b-fa00fb129b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_51310a4d-bed0-470a-8b73-cc139160b1b6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_e7973077-9337-419e-942b-fa00fb129b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_4ee1675b-c82c-4f29-be61-209078b8e826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_51310a4d-bed0-470a-8b73-cc139160b1b6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_4ee1675b-c82c-4f29-be61-209078b8e826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_8317b676-0f0b-45da-b2ab-32fe2795f58d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_51310a4d-bed0-470a-8b73-cc139160b1b6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedLoss_8317b676-0f0b-45da-b2ab-32fe2795f58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0289daf3-2b9a-42ee-8c8d-43e1f752e5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_51310a4d-bed0-470a-8b73-cc139160b1b6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0289daf3-2b9a-42ee-8c8d-43e1f752e5ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_0fab745f-c46c-4122-a350-dcce3a2602b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_51310a4d-bed0-470a-8b73-cc139160b1b6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_0fab745f-c46c-4122-a350-dcce3a2602b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_2ac50102-c7d2-4f24-a2f0-0c517809013b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_51310a4d-bed0-470a-8b73-cc139160b1b6" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_2ac50102-c7d2-4f24-a2f0-0c517809013b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_8aa70601-d743-441a-b4e3-33acf425d647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_51310a4d-bed0-470a-8b73-cc139160b1b6" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_8aa70601-d743-441a-b4e3-33acf425d647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_81382b13-1a1c-4202-83b1-51c79166e6de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ad98ca20-803f-4ad9-8643-39432cb980b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_81382b13-1a1c-4202-83b1-51c79166e6de" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ad98ca20-803f-4ad9-8643-39432cb980b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_48f459ad-6bb6-4a69-a947-e41735021b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ad98ca20-803f-4ad9-8643-39432cb980b0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_48f459ad-6bb6-4a69-a947-e41735021b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7b43a47a-da76-433e-9edb-299df53703ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_48f459ad-6bb6-4a69-a947-e41735021b3a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7b43a47a-da76-433e-9edb-299df53703ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c4eab15e-66ae-472e-aaba-88933f6fc975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_7b43a47a-da76-433e-9edb-299df53703ee" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c4eab15e-66ae-472e-aaba-88933f6fc975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6d68000f-5d87-44f1-a0f0-0742783e3f27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ad98ca20-803f-4ad9-8643-39432cb980b0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6d68000f-5d87-44f1-a0f0-0742783e3f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37931fab-ca1e-47a6-ab20-92e77b38e7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6d68000f-5d87-44f1-a0f0-0742783e3f27" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37931fab-ca1e-47a6-ab20-92e77b38e7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_7daa090f-d5b8-4c16-a874-d840a668b267" xlink:href="ino-20220331.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37931fab-ca1e-47a6-ab20-92e77b38e7cd" xlink:to="loc_ino_MutualFundsMember_7daa090f-d5b8-4c16-a874-d840a668b267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7dd3ca60-a667-4e47-8cec-50f31482f57a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37931fab-ca1e-47a6-ab20-92e77b38e7cd" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_7dd3ca60-a667-4e47-8cec-50f31482f57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_5c929cfd-c88a-4a5d-9d2b-192d080cede5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37931fab-ca1e-47a6-ab20-92e77b38e7cd" xlink:to="loc_us-gaap_CommercialPaperMember_5c929cfd-c88a-4a5d-9d2b-192d080cede5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_f77934ff-cdca-4522-b2a7-e8a86faa1a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37931fab-ca1e-47a6-ab20-92e77b38e7cd" xlink:to="loc_us-gaap_CertificatesOfDepositMember_f77934ff-cdca-4522-b2a7-e8a86faa1a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_f85f9bdb-88da-4d9d-8282-b2b1a4b45423" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37931fab-ca1e-47a6-ab20-92e77b38e7cd" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_f85f9bdb-88da-4d9d-8282-b2b1a4b45423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d1515ef-7c5a-4564-bd8c-8991e12b5479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ad98ca20-803f-4ad9-8643-39432cb980b0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d1515ef-7c5a-4564-bd8c-8991e12b5479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2a06972-ad7c-462d-8be9-3c472b6bf700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d1515ef-7c5a-4564-bd8c-8991e12b5479" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2a06972-ad7c-462d-8be9-3c472b6bf700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_64830976-19b4-4995-b3ba-f0adb5d6c9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2a06972-ad7c-462d-8be9-3c472b6bf700" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_64830976-19b4-4995-b3ba-f0adb5d6c9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e18c8efa-2db5-4a1b-8176-49d1a5ec440a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2a06972-ad7c-462d-8be9-3c472b6bf700" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e18c8efa-2db5-4a1b-8176-49d1a5ec440a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_111c1fe1-7b8f-488d-84c4-3617fe4efff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a2a06972-ad7c-462d-8be9-3c472b6bf700" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_111c1fe1-7b8f-488d-84c4-3617fe4efff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3bcab706-90ba-42f9-8a37-6b5e18584c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_ad98ca20-803f-4ad9-8643-39432cb980b0" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3bcab706-90ba-42f9-8a37-6b5e18584c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_fe80704a-2a07-4b15-bb09-8c496e1cb3db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3bcab706-90ba-42f9-8a37-6b5e18584c9e" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_fe80704a-2a07-4b15-bb09-8c496e1cb3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_66c48e8b-0e7a-4b98-8d9b-4bc10d626936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_fe80704a-2a07-4b15-bb09-8c496e1cb3db" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_66c48e8b-0e7a-4b98-8d9b-4bc10d626936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_56bb705d-745f-4651-b965-e696facac0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_fe80704a-2a07-4b15-bb09-8c496e1cb3db" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_56bb705d-745f-4651-b965-e696facac0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_90cdd11f-1f0e-4865-bd1f-2377fd08f80e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_fe80704a-2a07-4b15-bb09-8c496e1cb3db" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_90cdd11f-1f0e-4865-bd1f-2377fd08f80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="ino-20220331.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1fd758d7-3fc4-436e-bf42-1e22d1ff3ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_ba9535de-a05f-4675-9e7e-50bf1981de3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1fd758d7-3fc4-436e-bf42-1e22d1ff3ab0" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_ba9535de-a05f-4675-9e7e-50bf1981de3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="ino-20220331.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bb136c41-a848-4093-89a4-3b29a9d99d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_ebc640a0-4245-44c6-801d-3de2c9299ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bb136c41-a848-4093-89a4-3b29a9d99d4f" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_ebc640a0-4245-44c6-801d-3de2c9299ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_faf38dfd-c3ae-48f4-bdd4-3a9b46de13bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_896a06f5-6db1-4802-bf46-4fc94d30c839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_faf38dfd-c3ae-48f4-bdd4-3a9b46de13bc" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_896a06f5-6db1-4802-bf46-4fc94d30c839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3be5a89a-17cb-470f-ac1e-773a98468d8f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_896a06f5-6db1-4802-bf46-4fc94d30c839" xlink:to="loc_srt_RangeAxis_3be5a89a-17cb-470f-ac1e-773a98468d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d1af7339-a0c8-46d3-931b-08dbf9736ede" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3be5a89a-17cb-470f-ac1e-773a98468d8f" xlink:to="loc_srt_RangeMember_d1af7339-a0c8-46d3-931b-08dbf9736ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_cfab31f2-ffe4-4d95-9c50-37a5bf34df0b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d1af7339-a0c8-46d3-931b-08dbf9736ede" xlink:to="loc_srt_WeightedAverageMember_cfab31f2-ffe4-4d95-9c50-37a5bf34df0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_94043dca-65ae-4f2b-99b8-986ec3146a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_896a06f5-6db1-4802-bf46-4fc94d30c839" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_94043dca-65ae-4f2b-99b8-986ec3146a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2dd66e0b-7fe9-4497-a506-4a33a1577a21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_94043dca-65ae-4f2b-99b8-986ec3146a3f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2dd66e0b-7fe9-4497-a506-4a33a1577a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_5bd2c1f4-cf4c-4f39-b157-e4c8d32e3f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2dd66e0b-7fe9-4497-a506-4a33a1577a21" xlink:to="loc_us-gaap_LicensingAgreementsMember_5bd2c1f4-cf4c-4f39-b157-e4c8d32e3f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_2c9b4f01-fc69-4a2c-a4dd-fea010327b8c" xlink:href="ino-20220331.xsd#ino_BiojectMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2dd66e0b-7fe9-4497-a506-4a33a1577a21" xlink:to="loc_ino_BiojectMember_2c9b4f01-fc69-4a2c-a4dd-fea010327b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_c67935b8-3a6a-4796-8bf1-9b344c6a7adf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2dd66e0b-7fe9-4497-a506-4a33a1577a21" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_c67935b8-3a6a-4796-8bf1-9b344c6a7adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_8d6fc778-d823-4566-9155-d5839a9831cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_896a06f5-6db1-4802-bf46-4fc94d30c839" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_8d6fc778-d823-4566-9155-d5839a9831cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_24cb57b8-f3f9-4013-9849-048dd7e2a37e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_8d6fc778-d823-4566-9155-d5839a9831cc" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_24cb57b8-f3f9-4013-9849-048dd7e2a37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_be34ed9f-5fb3-46db-aefd-6b2cabb22627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_24cb57b8-f3f9-4013-9849-048dd7e2a37e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_be34ed9f-5fb3-46db-aefd-6b2cabb22627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_0d665d3e-dfc7-4f98-83ba-2b3acbcf6ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_be34ed9f-5fb3-46db-aefd-6b2cabb22627" xlink:to="loc_us-gaap_GoodwillGross_0d665d3e-dfc7-4f98-83ba-2b3acbcf6ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_3cadf4f0-b26f-48e0-865d-194bf228fc11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_be34ed9f-5fb3-46db-aefd-6b2cabb22627" xlink:to="loc_us-gaap_Goodwill_3cadf4f0-b26f-48e0-865d-194bf228fc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_85693b69-d1d3-4f5b-8fe9-3153ffda975e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_24cb57b8-f3f9-4013-9849-048dd7e2a37e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_85693b69-d1d3-4f5b-8fe9-3153ffda975e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3016fd07-207d-4a89-8ff2-c43b2977b198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_85693b69-d1d3-4f5b-8fe9-3153ffda975e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3016fd07-207d-4a89-8ff2-c43b2977b198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d476da31-98c4-484f-a6f0-016a039a9c73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_85693b69-d1d3-4f5b-8fe9-3153ffda975e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d476da31-98c4-484f-a6f0-016a039a9c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_474e06f9-f6ec-4e48-9723-9753b337f3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_85693b69-d1d3-4f5b-8fe9-3153ffda975e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_474e06f9-f6ec-4e48-9723-9753b337f3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d35440e9-867d-44d7-b0b6-c332fded1600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_85693b69-d1d3-4f5b-8fe9-3153ffda975e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d35440e9-867d-44d7-b0b6-c332fded1600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_19569c69-e78a-4716-897c-c1721d936db3" xlink:href="ino-20220331.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_24cb57b8-f3f9-4013-9849-048dd7e2a37e" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_19569c69-e78a-4716-897c-c1721d936db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_d58e69ad-1f6e-4f40-98f9-f0e2582dab89" xlink:href="ino-20220331.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_24cb57b8-f3f9-4013-9849-048dd7e2a37e" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_d58e69ad-1f6e-4f40-98f9-f0e2582dab89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1f7148d6-4b58-400c-a6a6-85f8173259ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_6cb07edf-16b9-4833-af83-f5998a8d99eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1f7148d6-4b58-400c-a6a6-85f8173259ed" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_6cb07edf-16b9-4833-af83-f5998a8d99eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0dd92542-27e0-4b62-ae13-c4a8f44f5574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1f7148d6-4b58-400c-a6a6-85f8173259ed" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0dd92542-27e0-4b62-ae13-c4a8f44f5574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_71b6a014-ed0c-4550-a34a-ccee078a9a83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1f7148d6-4b58-400c-a6a6-85f8173259ed" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_71b6a014-ed0c-4550-a34a-ccee078a9a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a9400fe7-35d6-4347-9780-3bd0e023097e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1f7148d6-4b58-400c-a6a6-85f8173259ed" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a9400fe7-35d6-4347-9780-3bd0e023097e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4e59c226-c397-478c-b639-87dc61cdf849" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1f7148d6-4b58-400c-a6a6-85f8173259ed" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4e59c226-c397-478c-b639-87dc61cdf849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7c97dc9b-63c1-40e2-9540-6a4b15cc81cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1f7148d6-4b58-400c-a6a6-85f8173259ed" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_7c97dc9b-63c1-40e2-9540-6a4b15cc81cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_d4c873a1-091a-4ebe-a747-e0d91b4d2c7e" xlink:href="ino-20220331.xsd#ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1f7148d6-4b58-400c-a6a6-85f8173259ed" xlink:to="loc_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_d4c873a1-091a-4ebe-a747-e0d91b4d2c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebt" xlink:type="simple" xlink:href="ino-20220331.xsd#ConvertibleDebt"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d2768b57-4c92-45b5-b56c-5cb931818199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_9a6bd7ff-0abb-419c-adf5-f5aaee2424d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d2768b57-4c92-45b5-b56c-5cb931818199" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_9a6bd7ff-0abb-419c-adf5-f5aaee2424d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="simple" xlink:href="ino-20220331.xsd#ConvertibleDebtTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_77d1d57e-07ad-43ce-8d77-64f46039f96d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_054536d4-e1d1-4aae-9678-b39f2f26c903" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_77d1d57e-07ad-43ce-8d77-64f46039f96d" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_054536d4-e1d1-4aae-9678-b39f2f26c903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_daac63e6-c735-496f-b081-4833c193e6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_77d1d57e-07ad-43ce-8d77-64f46039f96d" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_daac63e6-c735-496f-b081-4833c193e6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_21759099-063e-4646-a580-3c085c7e7541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3f05c2f1-28d2-4d41-a3a3-ba0b951d62a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_21759099-063e-4646-a580-3c085c7e7541" xlink:to="loc_us-gaap_DebtInstrumentTable_3f05c2f1-28d2-4d41-a3a3-ba0b951d62a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3fe696bf-260a-4437-8625-e81aab70acf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3f05c2f1-28d2-4d41-a3a3-ba0b951d62a8" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3fe696bf-260a-4437-8625-e81aab70acf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_77bf42c6-dd39-4234-b8ee-c40b01c9b923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3fe696bf-260a-4437-8625-e81aab70acf7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_77bf42c6-dd39-4234-b8ee-c40b01c9b923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_2609e8f6-8815-4910-8b6e-fcec76d2f0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_77bf42c6-dd39-4234-b8ee-c40b01c9b923" xlink:to="loc_us-gaap_ConvertibleDebtMember_2609e8f6-8815-4910-8b6e-fcec76d2f0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b3af5e08-a0a2-4efe-90e1-4947d75ee0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3f05c2f1-28d2-4d41-a3a3-ba0b951d62a8" xlink:to="loc_us-gaap_DebtInstrumentAxis_b3af5e08-a0a2-4efe-90e1-4947d75ee0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_787d5e71-e0fa-4ec3-a523-dd9278c7e5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b3af5e08-a0a2-4efe-90e1-4947d75ee0fe" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_787d5e71-e0fa-4ec3-a523-dd9278c7e5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_bb0f2317-192a-4ae4-aeac-27c7c505563b" xlink:href="ino-20220331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_787d5e71-e0fa-4ec3-a523-dd9278c7e5b8" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_bb0f2317-192a-4ae4-aeac-27c7c505563b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_b31abe05-1af0-4cee-a4f8-3e2b7a841794" xlink:href="ino-20220331.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_787d5e71-e0fa-4ec3-a523-dd9278c7e5b8" xlink:to="loc_ino_December2019ConvertibleBondsMember_b31abe05-1af0-4cee-a4f8-3e2b7a841794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b0a0911f-6559-4b84-a560-52792abae510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3f05c2f1-28d2-4d41-a3a3-ba0b951d62a8" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b0a0911f-6559-4b84-a560-52792abae510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionNameDomain_103a417b-fc50-4d9e-aef8-694f803baf77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_b0a0911f-6559-4b84-a560-52792abae510" xlink:to="loc_us-gaap_DebtConversionNameDomain_103a417b-fc50-4d9e-aef8-694f803baf77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_InitialConversionPriceMember_6cc3a431-3eed-493c-8da5-bc8547cf316a" xlink:href="ino-20220331.xsd#ino_InitialConversionPriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_103a417b-fc50-4d9e-aef8-694f803baf77" xlink:to="loc_ino_InitialConversionPriceMember_6cc3a431-3eed-493c-8da5-bc8547cf316a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1428795a-71f5-4596-af23-4dfee5a91977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3f05c2f1-28d2-4d41-a3a3-ba0b951d62a8" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1428795a-71f5-4596-af23-4dfee5a91977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_6ef3c12b-74a6-418a-bf73-9aafe12d3ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1428795a-71f5-4596-af23-4dfee5a91977" xlink:to="loc_us-gaap_TypeOfAdoptionMember_6ef3c12b-74a6-418a-bf73-9aafe12d3ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_1f2211d2-b7a6-4347-ae2c-c74a57f331f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_6ef3c12b-74a6-418a-bf73-9aafe12d3ad1" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_1f2211d2-b7a6-4347-ae2c-c74a57f331f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3f05c2f1-28d2-4d41-a3a3-ba0b951d62a8" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_37d0589b-c277-4332-bc57-cc007ff3fd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_37d0589b-c277-4332-bc57-cc007ff3fd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_55b33d88-1e1b-4f97-ab8c-f4bf35f800e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_55b33d88-1e1b-4f97-ab8c-f4bf35f800e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_eb4ba8ce-eb83-41fb-971f-d45557269378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_eb4ba8ce-eb83-41fb-971f-d45557269378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0c429bea-7470-4c4a-a444-6b8906672591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_0c429bea-7470-4c4a-a444-6b8906672591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_cd42ac8e-40bc-4848-958b-6deaf3017207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_cd42ac8e-40bc-4848-958b-6deaf3017207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_396339c1-02c7-4b20-a017-67637040a3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_396339c1-02c7-4b20-a017-67637040a3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2fe9eb46-251e-4f84-ba0b-95fdc556b5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2fe9eb46-251e-4f84-ba0b-95fdc556b5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_20b7c31d-c885-4ced-814a-600af25b2008" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_20b7c31d-c885-4ced-814a-600af25b2008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_0292eae3-6e2d-4a94-9240-11de1a3f41db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_0292eae3-6e2d-4a94-9240-11de1a3f41db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_88ec4a51-ba08-4078-bd93-96ab4be23797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_88ec4a51-ba08-4078-bd93-96ab4be23797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d2945998-2a92-4d48-9c14-58231be9b409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d2945998-2a92-4d48-9c14-58231be9b409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_35a1a939-eaac-4bbe-927b-c10e9f418b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_35a1a939-eaac-4bbe-927b-c10e9f418b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aabaeaeb-01ff-414e-a742-4f76207852af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_aabaeaeb-01ff-414e-a742-4f76207852af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_7fa90e9b-1736-4788-8fb8-ae6253ef529c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_ConvertibleDebt_7fa90e9b-1736-4788-8fb8-ae6253ef529c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_999c442a-7af4-452c-ad51-bf5141461f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_InterestExpense_999c442a-7af4-452c-ad51-bf5141461f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_0bf967da-8b47-4d91-807a-d550ed287159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_InterestExpenseDebt_0bf967da-8b47-4d91-807a-d550ed287159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_db6115ff-7bc4-4054-a0e3-4ec4502cc41d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_db6115ff-7bc4-4054-a0e3-4ec4502cc41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_586b4574-bd63-4416-ac77-fc7a9903759f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_AdditionalPaidInCapital_586b4574-bd63-4416-ac77-fc7a9903759f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_ec56ba5f-8187-465d-865e-1367cdddca89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2710527f-7685-41ea-b376-352a8fcb4871" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_ec56ba5f-8187-465d-865e-1367cdddca89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_85bc7ef6-bb62-4046-b50d-76008bd1ee67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0ff18f9d-dc46-4f8c-a33e-0f882156d924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_85bc7ef6-bb62-4046-b50d-76008bd1ee67" xlink:to="loc_us-gaap_DebtInstrumentTable_0ff18f9d-dc46-4f8c-a33e-0f882156d924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9d9bb5bb-ecfa-4986-a0c4-7d11f365bfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0ff18f9d-dc46-4f8c-a33e-0f882156d924" xlink:to="loc_us-gaap_DebtInstrumentAxis_9d9bb5bb-ecfa-4986-a0c4-7d11f365bfe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_440ee378-2721-4948-a25c-ba9e57523168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9d9bb5bb-ecfa-4986-a0c4-7d11f365bfe9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_440ee378-2721-4948-a25c-ba9e57523168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_b2a24d7e-7ac4-4c1a-801a-e9f85948d573" xlink:href="ino-20220331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_440ee378-2721-4948-a25c-ba9e57523168" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_b2a24d7e-7ac4-4c1a-801a-e9f85948d573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_fd86e3ad-9d43-4efa-bb94-926443feec91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0ff18f9d-dc46-4f8c-a33e-0f882156d924" xlink:to="loc_us-gaap_DebtInstrumentLineItems_fd86e3ad-9d43-4efa-bb94-926443feec91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_b2d90149-9be3-4e1f-b703-f907d6d9bd55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd86e3ad-9d43-4efa-bb94-926443feec91" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_b2d90149-9be3-4e1f-b703-f907d6d9bd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_9029c95c-7922-4bde-a929-77490daa0894" xlink:href="ino-20220331.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd86e3ad-9d43-4efa-bb94-926443feec91" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_9029c95c-7922-4bde-a929-77490daa0894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_e785aed9-8258-4bdb-84fb-ff250c9bae10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd86e3ad-9d43-4efa-bb94-926443feec91" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_e785aed9-8258-4bdb-84fb-ff250c9bae10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentAccruedInterest_b607e73e-369a-40b6-b87b-d3b6f93c49aa" xlink:href="ino-20220331.xsd#ino_DebtInstrumentAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd86e3ad-9d43-4efa-bb94-926443feec91" xlink:to="loc_ino_DebtInstrumentAccruedInterest_b607e73e-369a-40b6-b87b-d3b6f93c49aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_74647cec-724e-4cf7-9024-0daea7e27a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_fd86e3ad-9d43-4efa-bb94-926443feec91" xlink:to="loc_us-gaap_LongTermDebt_74647cec-724e-4cf7-9024-0daea7e27a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_88c17b56-e692-4081-b77c-1a2dc368f8df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6a31a05e-50d3-4b90-950e-7ac6067d9b73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_88c17b56-e692-4081-b77c-1a2dc368f8df" xlink:to="loc_us-gaap_DebtInstrumentTable_6a31a05e-50d3-4b90-950e-7ac6067d9b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_14132ff3-35a2-42f0-a43f-a4a84393f044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6a31a05e-50d3-4b90-950e-7ac6067d9b73" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_14132ff3-35a2-42f0-a43f-a4a84393f044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_063c4b27-fb5f-440a-a4f8-3864f9e97fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_14132ff3-35a2-42f0-a43f-a4a84393f044" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_063c4b27-fb5f-440a-a4f8-3864f9e97fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_67e4847b-6a33-4304-b237-c9b7629f4a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_063c4b27-fb5f-440a-a4f8-3864f9e97fe0" xlink:to="loc_us-gaap_ConvertibleDebtMember_67e4847b-6a33-4304-b237-c9b7629f4a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_4a444aee-c880-4b80-bed1-47ebf0ca7bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6a31a05e-50d3-4b90-950e-7ac6067d9b73" xlink:to="loc_us-gaap_DebtInstrumentAxis_4a444aee-c880-4b80-bed1-47ebf0ca7bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a2d298a3-084c-434e-9038-4482d432284d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_4a444aee-c880-4b80-bed1-47ebf0ca7bf0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a2d298a3-084c-434e-9038-4482d432284d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_9d249d51-f93c-4977-b17e-22ecbf5b5473" xlink:href="ino-20220331.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a2d298a3-084c-434e-9038-4482d432284d" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_9d249d51-f93c-4977-b17e-22ecbf5b5473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5ce3bb0b-60d7-4e40-925f-81babe93bd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6a31a05e-50d3-4b90-950e-7ac6067d9b73" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5ce3bb0b-60d7-4e40-925f-81babe93bd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6bf85021-76d6-4ab5-852f-23621754a4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ce3bb0b-60d7-4e40-925f-81babe93bd9a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6bf85021-76d6-4ab5-852f-23621754a4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_dce402ea-4d39-469d-b677-b723d39b7bed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ce3bb0b-60d7-4e40-925f-81babe93bd9a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_dce402ea-4d39-469d-b677-b723d39b7bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8c755d9d-a90b-45d6-8b9a-27b15176a22f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ce3bb0b-60d7-4e40-925f-81babe93bd9a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8c755d9d-a90b-45d6-8b9a-27b15176a22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_eed8bebe-e1d0-45a9-8ecb-67be3bc7ea4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ce3bb0b-60d7-4e40-925f-81babe93bd9a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_eed8bebe-e1d0-45a9-8ecb-67be3bc7ea4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_81b8bf0c-b7bb-4f8d-a642-f8d2447ddaa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5ce3bb0b-60d7-4e40-925f-81babe93bd9a" xlink:to="loc_us-gaap_LongTermDebt_81b8bf0c-b7bb-4f8d-a642-f8d2447ddaa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ino-20220331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_fd8c6aba-29d2-4c22-9053-ad6bf17cecb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_92050dbf-ac46-4f26-9ba1-fac41753ee34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_fd8c6aba-29d2-4c22-9053-ad6bf17cecb9" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_92050dbf-ac46-4f26-9ba1-fac41753ee34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="ino-20220331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_e637ed9c-3278-4ed6-8389-31248810c071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_bd65b96d-bdc6-4c6a-ab79-ffb514125590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e637ed9c-3278-4ed6-8389-31248810c071" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_bd65b96d-bdc6-4c6a-ab79-ffb514125590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_df1967f1-2a94-4395-823d-5600d27de259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_07add59b-b0f3-4efa-a8d8-15e423db5989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_df1967f1-2a94-4395-823d-5600d27de259" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_07add59b-b0f3-4efa-a8d8-15e423db5989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_35d07fff-6388-4464-8f46-9bb17c00ff7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_07add59b-b0f3-4efa-a8d8-15e423db5989" xlink:to="loc_us-gaap_StatementClassOfStockAxis_35d07fff-6388-4464-8f46-9bb17c00ff7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f5e49105-7b86-46ec-baa0-d1c7928ed0af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_35d07fff-6388-4464-8f46-9bb17c00ff7e" xlink:to="loc_us-gaap_ClassOfStockDomain_f5e49105-7b86-46ec-baa0-d1c7928ed0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_04c1bf31-0c22-442a-9191-a254c6739381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f5e49105-7b86-46ec-baa0-d1c7928ed0af" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_04c1bf31-0c22-442a-9191-a254c6739381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_079f1097-d315-494a-b2ef-a9003babbb49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_07add59b-b0f3-4efa-a8d8-15e423db5989" xlink:to="loc_us-gaap_ClassOfStockLineItems_079f1097-d315-494a-b2ef-a9003babbb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ea8d340a-5caa-466c-b0fe-22378696c63f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_079f1097-d315-494a-b2ef-a9003babbb49" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ea8d340a-5caa-466c-b0fe-22378696c63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_a239e858-d3a3-4200-9e0f-ef90d67c8f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ea8d340a-5caa-466c-b0fe-22378696c63f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_a239e858-d3a3-4200-9e0f-ef90d67c8f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e648363d-f8d9-4a3e-8696-43888c400d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ea8d340a-5caa-466c-b0fe-22378696c63f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e648363d-f8d9-4a3e-8696-43888c400d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2abdcec0-34ce-4d76-be9e-dae2f9b3f5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ea8d340a-5caa-466c-b0fe-22378696c63f" xlink:to="loc_us-gaap_CommonStockSharesIssued_2abdcec0-34ce-4d76-be9e-dae2f9b3f5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4b077f9b-7ff4-4ad3-a998-0eaafd72f130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ea8d340a-5caa-466c-b0fe-22378696c63f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4b077f9b-7ff4-4ad3-a998-0eaafd72f130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f07ef8f2-1a63-4172-b68b-cf21bd15c9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ea8d340a-5caa-466c-b0fe-22378696c63f" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f07ef8f2-1a63-4172-b68b-cf21bd15c9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_e34100bf-2d1c-49b0-a1ba-397960c65f57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ea8d340a-5caa-466c-b0fe-22378696c63f" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_e34100bf-2d1c-49b0-a1ba-397960c65f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_c8f8e5b1-c782-4a98-a507-db7c08740aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ea8d340a-5caa-466c-b0fe-22378696c63f" xlink:to="loc_us-gaap_PreferredStockSharesIssued_c8f8e5b1-c782-4a98-a507-db7c08740aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_bf2c21aa-a3bd-4e03-ad4f-0c6d74b74ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ea8d340a-5caa-466c-b0fe-22378696c63f" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_bf2c21aa-a3bd-4e03-ad4f-0c6d74b74ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_a0d426bb-f199-4350-9027-a775bd675324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d43944b5-1d15-481a-aa33-2b0ec7bb0ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_a0d426bb-f199-4350-9027-a775bd675324" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d43944b5-1d15-481a-aa33-2b0ec7bb0ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b0e6a947-a816-407d-943b-6d83b944d488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d43944b5-1d15-481a-aa33-2b0ec7bb0ed2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b0e6a947-a816-407d-943b-6d83b944d488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a474e2a0-c113-434a-89dd-5256e2562edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b0e6a947-a816-407d-943b-6d83b944d488" xlink:to="loc_us-gaap_ClassOfStockDomain_a474e2a0-c113-434a-89dd-5256e2562edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f0956795-b9eb-4dc1-9d73-78d165c9fb81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a474e2a0-c113-434a-89dd-5256e2562edd" xlink:to="loc_us-gaap_CommonStockMember_f0956795-b9eb-4dc1-9d73-78d165c9fb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_62e126f1-0919-4c30-85e5-7fd121fafed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d43944b5-1d15-481a-aa33-2b0ec7bb0ed2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_62e126f1-0919-4c30-85e5-7fd121fafed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_239c4eb1-4eca-4e00-8675-5c995cc80839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_62e126f1-0919-4c30-85e5-7fd121fafed4" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_239c4eb1-4eca-4e00-8675-5c995cc80839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember_a0ae1a61-50f4-464f-8e16-85ed4281c57f" xlink:href="ino-20220331.xsd#ino_SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_239c4eb1-4eca-4e00-8675-5c995cc80839" xlink:to="loc_ino_SalesAgreementMember_a0ae1a61-50f4-464f-8e16-85ed4281c57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember_23604822-78aa-44c3-93f5-a0e23510819a" xlink:href="ino-20220331.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_239c4eb1-4eca-4e00-8675-5c995cc80839" xlink:to="loc_ino_UnderwrittenPublicOfferingMember_23604822-78aa-44c3-93f5-a0e23510819a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_27d8d327-f66e-49f6-972b-aa060a239a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d43944b5-1d15-481a-aa33-2b0ec7bb0ed2" xlink:to="loc_us-gaap_PlanNameAxis_27d8d327-f66e-49f6-972b-aa060a239a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_85a4d0b8-4317-4e10-9c8e-294f1c890063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_27d8d327-f66e-49f6-972b-aa060a239a16" xlink:to="loc_us-gaap_PlanNameDomain_85a4d0b8-4317-4e10-9c8e-294f1c890063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_5f3c8d19-27e2-4756-9abc-738243d2beeb" xlink:href="ino-20220331.xsd#ino_A2016IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_85a4d0b8-4317-4e10-9c8e-294f1c890063" xlink:to="loc_ino_A2016IncentivePlanMember_5f3c8d19-27e2-4756-9abc-738243d2beeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_2fec2a01-c516-472e-87f9-171e12a6bf6f" xlink:href="ino-20220331.xsd#ino_A2007IncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_85a4d0b8-4317-4e10-9c8e-294f1c890063" xlink:to="loc_ino_A2007IncentivePlanMember_2fec2a01-c516-472e-87f9-171e12a6bf6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8100e558-6cee-467c-97d6-fbc4bef32629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d43944b5-1d15-481a-aa33-2b0ec7bb0ed2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8100e558-6cee-467c-97d6-fbc4bef32629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_04f601ab-9c1d-4e2d-ac89-a7ed2e7224a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8100e558-6cee-467c-97d6-fbc4bef32629" xlink:to="loc_us-gaap_EquityComponentDomain_04f601ab-9c1d-4e2d-ac89-a7ed2e7224a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9a782b94-e6d3-4d6a-8682-afbab0f89360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_04f601ab-9c1d-4e2d-ac89-a7ed2e7224a3" xlink:to="loc_us-gaap_CommonStockMember_9a782b94-e6d3-4d6a-8682-afbab0f89360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d43944b5-1d15-481a-aa33-2b0ec7bb0ed2" xlink:to="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_f6a77ab7-bdc4-48ef-9696-e78a6f056041" xlink:href="ino-20220331.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_f6a77ab7-bdc4-48ef-9696-e78a6f056041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_b1cb0045-71c0-4f5d-a025-c527ea2de4fb" xlink:href="ino-20220331.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_b1cb0045-71c0-4f5d-a025-c527ea2de4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_bc834db2-bdd5-4f69-9c83-ee06b19bca15" xlink:href="ino-20220331.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_bc834db2-bdd5-4f69-9c83-ee06b19bca15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_6343a73b-1d1a-4dc6-b8c8-ecebd1f31ed9" xlink:href="ino-20220331.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_6343a73b-1d1a-4dc6-b8c8-ecebd1f31ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_6318b17b-e4d3-4cba-9ac4-d1c78f887560" xlink:href="ino-20220331.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_6318b17b-e4d3-4cba-9ac4-d1c78f887560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_29f66328-a58f-43e1-8d5d-b31672b43c5b" xlink:href="ino-20220331.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_29f66328-a58f-43e1-8d5d-b31672b43c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_85cf24c5-3bd1-47cb-813b-05b9c738ab13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_85cf24c5-3bd1-47cb-813b-05b9c738ab13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_17c7bd3c-ef93-416d-9ed4-4cd3babb9eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_17c7bd3c-ef93-416d-9ed4-4cd3babb9eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2156d3d5-631e-4824-a62a-03c129b20433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2156d3d5-631e-4824-a62a-03c129b20433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_db015ba8-45be-4bd8-8523-5a6c34d6972b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_db015ba8-45be-4bd8-8523-5a6c34d6972b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_fed41532-1fc5-4337-8a22-19bdabc6aef8" xlink:href="ino-20220331.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_fed41532-1fc5-4337-8a22-19bdabc6aef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_731245b8-e883-4d43-90ed-0835aefcba58" xlink:href="ino-20220331.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_731245b8-e883-4d43-90ed-0835aefcba58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4ef658b9-bfe5-4501-b4fc-a552912c4204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4ef658b9-bfe5-4501-b4fc-a552912c4204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3ddc0f2f-d253-4373-8798-a060c4a80948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3ddc0f2f-d253-4373-8798-a060c4a80948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_cb39a30b-cd41-4f0c-a411-9001bdcfab5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_cb39a30b-cd41-4f0c-a411-9001bdcfab5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6e70bcc7-a0ed-4411-aaff-982c30fd058f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6e70bcc7-a0ed-4411-aaff-982c30fd058f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_876a30a2-4f86-459e-8da3-883fc59885a8" xlink:href="ino-20220331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3d5afb1e-9740-4d30-a087-5242f2e3329c" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_876a30a2-4f86-459e-8da3-883fc59885a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="ino-20220331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0e20a2ad-8ffd-4bd2-8f1c-9ec697f86d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_3d2373c9-74f9-451f-9220-d3d8c57a246c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0e20a2ad-8ffd-4bd2-8f1c-9ec697f86d1e" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_3d2373c9-74f9-451f-9220-d3d8c57a246c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="ino-20220331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_745a5d6e-b3cb-4fdd-b6c5-6577e3392070" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6b356405-e8b6-4814-9813-5e70f2f85cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_745a5d6e-b3cb-4fdd-b6c5-6577e3392070" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_6b356405-e8b6-4814-9813-5e70f2f85cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_13936055-4105-4842-83b9-0c2ffa2d8521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c93839e1-ff43-4c01-a82e-4fc0d8653b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_13936055-4105-4842-83b9-0c2ffa2d8521" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c93839e1-ff43-4c01-a82e-4fc0d8653b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2827ff95-8667-4eeb-8f52-d754eda6e830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c93839e1-ff43-4c01-a82e-4fc0d8653b2e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2827ff95-8667-4eeb-8f52-d754eda6e830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a5b06191-70ba-45fa-a5cd-a0592078d7eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2827ff95-8667-4eeb-8f52-d754eda6e830" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a5b06191-70ba-45fa-a5cd-a0592078d7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bcd83191-5894-45b7-bd0f-9a982dafdfab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a5b06191-70ba-45fa-a5cd-a0592078d7eb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bcd83191-5894-45b7-bd0f-9a982dafdfab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_f6d6b5b9-2cc6-4bea-aa26-0f6879c0e371" xlink:href="ino-20220331.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a5b06191-70ba-45fa-a5cd-a0592078d7eb" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_f6d6b5b9-2cc6-4bea-aa26-0f6879c0e371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cb94424a-d732-4a64-b03f-9293c2073822" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a5b06191-70ba-45fa-a5cd-a0592078d7eb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cb94424a-d732-4a64-b03f-9293c2073822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_bc342cd4-2b78-4f91-a924-9513a391731f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a5b06191-70ba-45fa-a5cd-a0592078d7eb" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_bc342cd4-2b78-4f91-a924-9513a391731f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_9c2e8bd1-5273-4847-af4c-21fbfd2fd6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a5b06191-70ba-45fa-a5cd-a0592078d7eb" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_9c2e8bd1-5273-4847-af4c-21fbfd2fd6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_23ac80c5-ebd6-4616-ae59-104ee5bfec89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c93839e1-ff43-4c01-a82e-4fc0d8653b2e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_23ac80c5-ebd6-4616-ae59-104ee5bfec89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5ddd65b9-0378-4463-8862-440799ff07f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_23ac80c5-ebd6-4616-ae59-104ee5bfec89" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5ddd65b9-0378-4463-8862-440799ff07f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="ino-20220331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71899905-ef0b-42b8-b779-3448c15b0290" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_81462917-5cdd-451f-85b7-f5ee13d2089d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71899905-ef0b-42b8-b779-3448c15b0290" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_81462917-5cdd-451f-85b7-f5ee13d2089d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="ino-20220331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49b4089a-7126-4567-ad82-f7d4f7d1d58e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4b2a2c98-d60a-439f-b6e7-5d16b82f16be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_49b4089a-7126-4567-ad82-f7d4f7d1d58e" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4b2a2c98-d60a-439f-b6e7-5d16b82f16be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#StockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5ae729d-706b-4251-94f0-4569da2787bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc85a6c0-701e-4f0e-bc7d-4508f178c748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f5ae729d-706b-4251-94f0-4569da2787bc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc85a6c0-701e-4f0e-bc7d-4508f178c748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ef411478-bb20-40c7-82d6-2b3f623454ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc85a6c0-701e-4f0e-bc7d-4508f178c748" xlink:to="loc_us-gaap_AwardTypeAxis_ef411478-bb20-40c7-82d6-2b3f623454ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5453427b-50cc-4b7c-ae55-b2e2ab848399" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ef411478-bb20-40c7-82d6-2b3f623454ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5453427b-50cc-4b7c-ae55-b2e2ab848399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e64dfeb0-eed3-475c-ac35-e039042fd26b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5453427b-50cc-4b7c-ae55-b2e2ab848399" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e64dfeb0-eed3-475c-ac35-e039042fd26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_80088144-33ca-4582-93d4-0f446acf2343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5453427b-50cc-4b7c-ae55-b2e2ab848399" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_80088144-33ca-4582-93d4-0f446acf2343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2d3902c1-cceb-4c18-b05f-5e0a97f6e267" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc85a6c0-701e-4f0e-bc7d-4508f178c748" xlink:to="loc_srt_TitleOfIndividualAxis_2d3902c1-cceb-4c18-b05f-5e0a97f6e267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_28ec8605-a04f-4144-90c6-96ec210a4897" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_2d3902c1-cceb-4c18-b05f-5e0a97f6e267" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_28ec8605-a04f-4144-90c6-96ec210a4897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_241f5669-8e48-4f0d-8248-1e115c49e168" xlink:href="ino-20220331.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_28ec8605-a04f-4144-90c6-96ec210a4897" xlink:to="loc_ino_EmployeesAndDirectorsMember_241f5669-8e48-4f0d-8248-1e115c49e168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_bf655695-e4f6-4f9d-8584-3cfc534b7501" xlink:href="ino-20220331.xsd#ino_NonEmployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_28ec8605-a04f-4144-90c6-96ec210a4897" xlink:to="loc_ino_NonEmployeeMember_bf655695-e4f6-4f9d-8584-3cfc534b7501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a0c7ea65-c502-490b-8984-cf9705d2883c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc85a6c0-701e-4f0e-bc7d-4508f178c748" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a0c7ea65-c502-490b-8984-cf9705d2883c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1e11f9e3-505d-465e-889c-66177ff2e3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a0c7ea65-c502-490b-8984-cf9705d2883c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1e11f9e3-505d-465e-889c-66177ff2e3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9d74bf63-a87f-4af4-8dd3-a2d976fdcadd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1e11f9e3-505d-465e-889c-66177ff2e3f7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9d74bf63-a87f-4af4-8dd3-a2d976fdcadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a2bf007d-285c-4d1f-9be0-a313309f7e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1e11f9e3-505d-465e-889c-66177ff2e3f7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a2bf007d-285c-4d1f-9be0-a313309f7e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e084be37-a010-44e1-8288-25663bcaccfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc85a6c0-701e-4f0e-bc7d-4508f178c748" xlink:to="loc_us-gaap_PlanNameAxis_e084be37-a010-44e1-8288-25663bcaccfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c78138e3-d0bf-42ed-b610-0cee6dd0c899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e084be37-a010-44e1-8288-25663bcaccfb" xlink:to="loc_us-gaap_PlanNameDomain_c78138e3-d0bf-42ed-b610-0cee6dd0c899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_b7cd3c8a-3a99-4e71-991d-f966a014e824" xlink:href="ino-20220331.xsd#ino_A2016IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c78138e3-d0bf-42ed-b610-0cee6dd0c899" xlink:to="loc_ino_A2016IncentivePlanMember_b7cd3c8a-3a99-4e71-991d-f966a014e824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_3f76b085-3ae5-4f4e-8a6b-242ed6c306ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc85a6c0-701e-4f0e-bc7d-4508f178c748" xlink:to="loc_us-gaap_VestingAxis_3f76b085-3ae5-4f4e-8a6b-242ed6c306ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_d4e07df8-1b82-4f92-97f0-91adeccd3759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_3f76b085-3ae5-4f4e-8a6b-242ed6c306ae" xlink:to="loc_us-gaap_VestingDomain_d4e07df8-1b82-4f92-97f0-91adeccd3759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4d4cd93d-16b2-4d8d-a899-0ccc01a8ab08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_d4e07df8-1b82-4f92-97f0-91adeccd3759" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4d4cd93d-16b2-4d8d-a899-0ccc01a8ab08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1a9dc610-d350-4e88-b0b2-95cd1107df47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_d4e07df8-1b82-4f92-97f0-91adeccd3759" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1a9dc610-d350-4e88-b0b2-95cd1107df47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc85a6c0-701e-4f0e-bc7d-4508f178c748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c61f2adc-5123-4ace-8c92-6778aaf05588" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c61f2adc-5123-4ace-8c92-6778aaf05588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b3468235-09d4-45d8-ad19-caf984ba5584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b3468235-09d4-45d8-ad19-caf984ba5584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3fd02026-13fd-4830-8bcd-2c635ca16e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_3fd02026-13fd-4830-8bcd-2c635ca16e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2d0ec1c6-fcb4-4238-9169-25ef6b94a481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2d0ec1c6-fcb4-4238-9169-25ef6b94a481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d2683d49-7b3f-489d-94cd-0ce4974838ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_ShareBasedCompensation_d2683d49-7b3f-489d-94cd-0ce4974838ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5e8d3d93-f910-475c-a48c-ffa5cb7f58a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5e8d3d93-f910-475c-a48c-ffa5cb7f58a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f3f486d4-65c2-4ccf-94ab-3d3e16246d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f3f486d4-65c2-4ccf-94ab-3d3e16246d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_347d955c-8468-4878-af46-0b55c99cd100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_347d955c-8468-4878-af46-0b55c99cd100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c1f4e922-b108-40a1-9575-1ce3f8ebcbed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c1f4e922-b108-40a1-9575-1ce3f8ebcbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8c5410ef-a234-4471-bb8d-200b77e2a8b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8c5410ef-a234-4471-bb8d-200b77e2a8b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6f96fb62-e9d4-4582-b4b9-85a87506ba17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6f96fb62-e9d4-4582-b4b9-85a87506ba17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_095770b0-f2d0-4024-a8db-c5301300aec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_095770b0-f2d0-4024-a8db-c5301300aec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6339dbb0-2b1d-4d40-891f-d13af5102625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6339dbb0-2b1d-4d40-891f-d13af5102625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_831e303f-36b9-499d-aee6-7ed99cf6c927" xlink:href="ino-20220331.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0c27901f-25da-4b67-8d78-b9a0e78a2348" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue_831e303f-36b9-499d-aee6-7ed99cf6c927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ino-20220331.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_e2968544-bbea-4799-b578-dfd98befeeaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_db17e189-8446-4753-9c1c-98ce4df23124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_e2968544-bbea-4799-b578-dfd98befeeaf" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_db17e189-8446-4753-9c1c-98ce4df23124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_5e6a71c5-45aa-4094-9777-c1800b9e8204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c072406e-930b-49eb-a810-8e07d985c061" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_5e6a71c5-45aa-4094-9777-c1800b9e8204" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c072406e-930b-49eb-a810-8e07d985c061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2fbc8c8c-4fc7-4ca5-b80d-58a370bf9c4e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c072406e-930b-49eb-a810-8e07d985c061" xlink:to="loc_srt_CounterpartyNameAxis_2fbc8c8c-4fc7-4ca5-b80d-58a370bf9c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1a4a1c53-ed92-4e78-9333-da5fc2ea96cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2fbc8c8c-4fc7-4ca5-b80d-58a370bf9c4e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1a4a1c53-ed92-4e78-9333-da5fc2ea96cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_53d4ed22-4bca-4f46-bff0-9e8ea9ad5be7" xlink:href="ino-20220331.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1a4a1c53-ed92-4e78-9333-da5fc2ea96cc" xlink:to="loc_ino_PlumblineLifeSciencesMember_53d4ed22-4bca-4f46-bff0-9e8ea9ad5be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_25c81d0f-9dce-4d15-ad98-9f8dce485175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c072406e-930b-49eb-a810-8e07d985c061" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_25c81d0f-9dce-4d15-ad98-9f8dce485175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_5168ff31-c943-4491-92ab-1c2dc294ce8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_25c81d0f-9dce-4d15-ad98-9f8dce485175" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_5168ff31-c943-4491-92ab-1c2dc294ce8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_a23485f7-c5fe-4646-94b9-90d0b932a099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_5168ff31-c943-4491-92ab-1c2dc294ce8d" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_a23485f7-c5fe-4646-94b9-90d0b932a099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9eb50156-00fc-4f74-90fb-717b3b257c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c072406e-930b-49eb-a810-8e07d985c061" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9eb50156-00fc-4f74-90fb-717b3b257c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_40e07cdf-a247-41b4-86fc-b0e7355f1d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9eb50156-00fc-4f74-90fb-717b3b257c7f" xlink:to="loc_us-gaap_RelatedPartyDomain_40e07cdf-a247-41b4-86fc-b0e7355f1d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_c18bc278-3dca-448d-af77-3ab04f7a0ffe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_40e07cdf-a247-41b4-86fc-b0e7355f1d68" xlink:to="loc_srt_DirectorMember_c18bc278-3dca-448d-af77-3ab04f7a0ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_455fc1b3-f718-4481-994b-8da0514a855c" xlink:href="ino-20220331.xsd#ino_TheWistarInstituteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_40e07cdf-a247-41b4-86fc-b0e7355f1d68" xlink:to="loc_ino_TheWistarInstituteMember_455fc1b3-f718-4481-994b-8da0514a855c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_12792158-5e9f-4b6e-89e1-4bf2d6add845" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c072406e-930b-49eb-a810-8e07d985c061" xlink:to="loc_srt_ProductOrServiceAxis_12792158-5e9f-4b6e-89e1-4bf2d6add845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_11cc939d-c44b-4946-a359-2b2416a0a954" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_12792158-5e9f-4b6e-89e1-4bf2d6add845" xlink:to="loc_srt_ProductsAndServicesDomain_11cc939d-c44b-4946-a359-2b2416a0a954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_ec2f4b22-b0b3-46d3-8e2a-efb89f142e80" xlink:href="ino-20220331.xsd#ino_LicensewithAffiliatedEntitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_11cc939d-c44b-4946-a359-2b2416a0a954" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_ec2f4b22-b0b3-46d3-8e2a-efb89f142e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_595d11be-7e26-4d01-9b70-4d4d836b4d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_c072406e-930b-49eb-a810-8e07d985c061" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_595d11be-7e26-4d01-9b70-4d4d836b4d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:href="ino-20220331.xsd#ino_RelatedPartyTransactionsTextualAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_595d11be-7e26-4d01-9b70-4d4d836b4d5c" xlink:to="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_4de46485-5274-44ff-b32a-91417a91e655" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_4de46485-5274-44ff-b32a-91417a91e655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9ca56994-c6b7-4790-8d0f-eb883674182b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9ca56994-c6b7-4790-8d0f-eb883674182b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ec401b7a-9206-47ff-8eac-1e272b1ad090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ec401b7a-9206-47ff-8eac-1e272b1ad090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_a7e47416-cda2-4fa3-b5b6-441d9f59b70c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_a7e47416-cda2-4fa3-b5b6-441d9f59b70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_bb3960e3-48fb-430c-bc25-b070646aa842" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_bb3960e3-48fb-430c-bc25-b070646aa842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_c1bd3f64-46f2-4341-b41d-fabd00406674" xlink:href="ino-20220331.xsd#ino_CollaborativeArrangementTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_ino_CollaborativeArrangementTerm_c1bd3f64-46f2-4341-b41d-fabd00406674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_d14d2872-9f4e-4c12-a200-b0c5724307f8" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_d14d2872-9f4e-4c12-a200-b0c5724307f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount_844489e2-0bbe-45ed-b4fa-ddf100075918" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_ino_CollaborativeAgreementAmendedAmount_844489e2-0bbe-45ed-b4fa-ddf100075918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_0af64486-3d18-4c06-a1c2-de5b28942b89" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_0af64486-3d18-4c06-a1c2-de5b28942b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedExercisedAmount_6c97e836-88f0-4d90-800b-637672a262b0" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementAwardedExercisedAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_ino_CollaborativeAgreementAwardedExercisedAmount_6c97e836-88f0-4d90-800b-637672a262b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_7ea9d0b2-5912-4a22-833e-b958dbefcd08" xlink:href="ino-20220331.xsd#ino_GrantProceedsReceived"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_ino_GrantProceedsReceived_7ea9d0b2-5912-4a22-833e-b958dbefcd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_01972f83-6c0e-40b9-9194-b5f1bfcd26ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_01972f83-6c0e-40b9-9194-b5f1bfcd26ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_11912951-0879-4458-92b5-0fd7db84e613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_11912951-0879-4458-92b5-0fd7db84e613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_20771f52-d9dc-4f8a-ace4-48f7a36193c7" xlink:href="ino-20220331.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_20771f52-d9dc-4f8a-ace4-48f7a36193c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_69fffae2-73c8-43f3-a8b3-d9a7a7cc0f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_RelatedPartyTransactionsTextualAbstract_1d05d711-6592-4af8-a994-2351393a215d" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_69fffae2-73c8-43f3-a8b3-d9a7a7cc0f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ino-20220331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_be19050d-82d3-4c50-a7a4-d4da85cbb055" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0f36bb05-cda5-4982-a254-cad47c9b8ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_be19050d-82d3-4c50-a7a4-d4da85cbb055" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0f36bb05-cda5-4982-a254-cad47c9b8ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="ino-20220331.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_905bcea7-8dcb-4217-9c4e-2eff9d3290cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_663f6993-535c-43c8-a04e-b1e05095a9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_905bcea7-8dcb-4217-9c4e-2eff9d3290cc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_663f6993-535c-43c8-a04e-b1e05095a9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f12a5b4e-251f-4e07-8d0d-fc2a6f1cb577" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_d1daeba8-b000-490b-9524-811d1d85bda0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f12a5b4e-251f-4e07-8d0d-fc2a6f1cb577" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_d1daeba8-b000-490b-9524-811d1d85bda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ab64b84d-ec18-48fc-b604-3cb7d38321cb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d1daeba8-b000-490b-9524-811d1d85bda0" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ab64b84d-ec18-48fc-b604-3cb7d38321cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_39c7aef8-3928-4c08-930a-05d119cbae0d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ab64b84d-ec18-48fc-b604-3cb7d38321cb" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_39c7aef8-3928-4c08-930a-05d119cbae0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoOfficeMember_0dd679a1-ceb3-4069-a4b6-79c28617b447" xlink:href="ino-20220331.xsd#ino_SanDiegoOfficeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_39c7aef8-3928-4c08-930a-05d119cbae0d" xlink:to="loc_ino_SanDiegoOfficeMember_0dd679a1-ceb3-4069-a4b6-79c28617b447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_7c497d3e-67fe-4d7e-aba7-823a2490c8a3" xlink:href="ino-20220331.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_39c7aef8-3928-4c08-930a-05d119cbae0d" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_7c497d3e-67fe-4d7e-aba7-823a2490c8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_29e61c2a-8f08-4427-9b36-efce8c6afed2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d1daeba8-b000-490b-9524-811d1d85bda0" xlink:to="loc_srt_RangeAxis_29e61c2a-8f08-4427-9b36-efce8c6afed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5df10529-5f2f-4cfe-be98-777ae9bc6111" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_29e61c2a-8f08-4427-9b36-efce8c6afed2" xlink:to="loc_srt_RangeMember_5df10529-5f2f-4cfe-be98-777ae9bc6111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c4255f5d-3dc2-489b-a90f-c51092825833" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5df10529-5f2f-4cfe-be98-777ae9bc6111" xlink:to="loc_srt_MinimumMember_c4255f5d-3dc2-489b-a90f-c51092825833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a03e1fe0-315d-4b24-a1b7-bc948c8818d8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5df10529-5f2f-4cfe-be98-777ae9bc6111" xlink:to="loc_srt_MaximumMember_a03e1fe0-315d-4b24-a1b7-bc948c8818d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6248323-e371-45da-b8eb-bba2cc256d70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d1daeba8-b000-490b-9524-811d1d85bda0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6248323-e371-45da-b8eb-bba2cc256d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_f3b5eb2f-d8bd-4efe-abde-8f06509dc8dd" xlink:href="ino-20220331.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6248323-e371-45da-b8eb-bba2cc256d70" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_f3b5eb2f-d8bd-4efe-abde-8f06509dc8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_439b4474-e5c6-47b2-aaee-3256e4f0e8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6248323-e371-45da-b8eb-bba2cc256d70" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_439b4474-e5c6-47b2-aaee-3256e4f0e8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_d8eef449-9b55-42ef-aa6a-a70c272ab9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6248323-e371-45da-b8eb-bba2cc256d70" xlink:to="loc_us-gaap_LeaseCost_d8eef449-9b55-42ef-aa6a-a70c272ab9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_d91ee6a8-de0d-43b1-ac61-9af0886fd9f9" xlink:href="ino-20220331.xsd#ino_LesseeOperatingLeaseNumberOfAgreementsToSublease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_e6248323-e371-45da-b8eb-bba2cc256d70" xlink:to="loc_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease_d91ee6a8-de0d-43b1-ac61-9af0886fd9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_01b293e7-af61-4686-b46f-5b3ed191ecb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_48c10160-7680-4a86-8052-ec2e15e75905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_01b293e7-af61-4686-b46f-5b3ed191ecb3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_48c10160-7680-4a86-8052-ec2e15e75905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_825f7e3a-6280-4c71-a2fb-afa830401381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_01b293e7-af61-4686-b46f-5b3ed191ecb3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_825f7e3a-6280-4c71-a2fb-afa830401381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_75938a42-5955-4335-9f34-6fdbbbdbfecc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_01b293e7-af61-4686-b46f-5b3ed191ecb3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_75938a42-5955-4335-9f34-6fdbbbdbfecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_746c985d-0e78-40bd-ab99-b81ef676ed42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_01b293e7-af61-4686-b46f-5b3ed191ecb3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_746c985d-0e78-40bd-ab99-b81ef676ed42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_04500642-a2b1-4f61-ac7c-8e9f60a5c05f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_01b293e7-af61-4686-b46f-5b3ed191ecb3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_04500642-a2b1-4f61-ac7c-8e9f60a5c05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_d9cdd69c-f6d0-40ba-b18e-a33f84de714d" xlink:href="ino-20220331.xsd#ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_01b293e7-af61-4686-b46f-5b3ed191ecb3" xlink:to="loc_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_d9cdd69c-f6d0-40ba-b18e-a33f84de714d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6d89ff22-1cac-4397-89ca-954dea07955f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_01b293e7-af61-4686-b46f-5b3ed191ecb3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_6d89ff22-1cac-4397-89ca-954dea07955f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6240e4b1-6d92-41fc-83d5-4fa3260446b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_01b293e7-af61-4686-b46f-5b3ed191ecb3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6240e4b1-6d92-41fc-83d5-4fa3260446b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_55f44632-448d-4082-b929-9416ca7c834f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_01b293e7-af61-4686-b46f-5b3ed191ecb3" xlink:to="loc_us-gaap_OperatingLeaseLiability_55f44632-448d-4082-b929-9416ca7c834f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_169ef31e-3d36-46e5-91be-997e5af4a496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_01b293e7-af61-4686-b46f-5b3ed191ecb3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_169ef31e-3d36-46e5-91be-997e5af4a496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5e1680c8-43aa-4e22-92da-f1830a000f15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_01b293e7-af61-4686-b46f-5b3ed191ecb3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5e1680c8-43aa-4e22-92da-f1830a000f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_bc4c58e9-7773-4c83-ac51-0a32de944238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_01b293e7-af61-4686-b46f-5b3ed191ecb3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_bc4c58e9-7773-4c83-ac51-0a32de944238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ff3ceb04-1730-4f04-869c-37fce0d2ae59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_01b293e7-af61-4686-b46f-5b3ed191ecb3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ff3ceb04-1730-4f04-869c-37fce0d2ae59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="ino-20220331.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c885ca18-7341-4270-8226-7809099b25cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3b09daba-b58e-4c6e-a0fc-4408a6b2a40e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c885ca18-7341-4270-8226-7809099b25cd" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_3b09daba-b58e-4c6e-a0fc-4408a6b2a40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#CollaborativeAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_41a67e0e-d8b6-4be2-9ac0-c84ed17f08a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1832ef24-8af0-4a00-9e29-f5ad76b097b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_41a67e0e-d8b6-4be2-9ac0-c84ed17f08a5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1832ef24-8af0-4a00-9e29-f5ad76b097b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a2db91e4-54ed-4200-88a8-dcddaa73e267" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1832ef24-8af0-4a00-9e29-f5ad76b097b6" xlink:to="loc_srt_CounterpartyNameAxis_a2db91e4-54ed-4200-88a8-dcddaa73e267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2593754-ff17-4ff0-91dd-8ec327a81d6e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a2db91e4-54ed-4200-88a8-dcddaa73e267" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2593754-ff17-4ff0-91dd-8ec327a81d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_bd499c94-c5a4-4752-93e4-6b3faf131d2a" xlink:href="ino-20220331.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2593754-ff17-4ff0-91dd-8ec327a81d6e" xlink:to="loc_ino_AdvaccineMember_bd499c94-c5a4-4752-93e4-6b3faf131d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_5a1504d2-d97c-4ce2-a2f0-9c0ae3787233" xlink:href="ino-20220331.xsd#ino_ApolloBioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2593754-ff17-4ff0-91dd-8ec327a81d6e" xlink:to="loc_ino_ApolloBioMember_5a1504d2-d97c-4ce2-a2f0-9c0ae3787233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_c58920c1-897a-4b93-8254-661edc7d1c61" xlink:href="ino-20220331.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2593754-ff17-4ff0-91dd-8ec327a81d6e" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_c58920c1-897a-4b93-8254-661edc7d1c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_915258d9-22f4-4153-99e0-57764ac96d6f" xlink:href="ino-20220331.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2593754-ff17-4ff0-91dd-8ec327a81d6e" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_915258d9-22f4-4153-99e0-57764ac96d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember_af75c182-9a26-4eee-9dff-7653b1641933" xlink:href="ino-20220331.xsd#ino_DepartmentOfDefenceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a2593754-ff17-4ff0-91dd-8ec327a81d6e" xlink:to="loc_ino_DepartmentOfDefenceMember_af75c182-9a26-4eee-9dff-7653b1641933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_14c3993d-0371-47b7-b195-98d8ca50a2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1832ef24-8af0-4a00-9e29-f5ad76b097b6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_14c3993d-0371-47b7-b195-98d8ca50a2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9597f322-65dc-4147-8064-4e7e8720eda8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_14c3993d-0371-47b7-b195-98d8ca50a2c7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9597f322-65dc-4147-8064-4e7e8720eda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_b9dc4f2b-de16-497c-8add-6a73ab65ea20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9597f322-65dc-4147-8064-4e7e8720eda8" xlink:to="loc_us-gaap_CollaborativeArrangementMember_b9dc4f2b-de16-497c-8add-6a73ab65ea20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3a536ca7-3f70-4f1d-91ab-6d44f9e11a7f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1832ef24-8af0-4a00-9e29-f5ad76b097b6" xlink:to="loc_srt_MajorCustomersAxis_3a536ca7-3f70-4f1d-91ab-6d44f9e11a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_29707956-1b5d-4b05-94f0-25fe07bf349e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_3a536ca7-3f70-4f1d-91ab-6d44f9e11a7f" xlink:to="loc_srt_NameOfMajorCustomerDomain_29707956-1b5d-4b05-94f0-25fe07bf349e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_21009d32-f6ce-49cd-a87c-c628d6cd7951" xlink:href="ino-20220331.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_29707956-1b5d-4b05-94f0-25fe07bf349e" xlink:to="loc_ino_AdvaccineMember_21009d32-f6ce-49cd-a87c-c628d6cd7951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_889456bf-68b2-419f-95dc-d9364da7a281" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1832ef24-8af0-4a00-9e29-f5ad76b097b6" xlink:to="loc_srt_ProductOrServiceAxis_889456bf-68b2-419f-95dc-d9364da7a281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c0bd709e-95b0-4e69-a0e2-2bdd59ca3dca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_889456bf-68b2-419f-95dc-d9364da7a281" xlink:to="loc_srt_ProductsAndServicesDomain_c0bd709e-95b0-4e69-a0e2-2bdd59ca3dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_6f12c02e-7fd9-4439-9864-44876d1f5ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0bd709e-95b0-4e69-a0e2-2bdd59ca3dca" xlink:to="loc_us-gaap_LicenseMember_6f12c02e-7fd9-4439-9864-44876d1f5ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_3eadea35-da3c-433e-8e01-f538cc98aaea" xlink:href="ino-20220331.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0bd709e-95b0-4e69-a0e2-2bdd59ca3dca" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_3eadea35-da3c-433e-8e01-f538cc98aaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember_cb4ddd7e-8a64-422f-b4e1-f98920ff777f" xlink:href="ino-20220331.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0bd709e-95b0-4e69-a0e2-2bdd59ca3dca" xlink:to="loc_ino_SARSCoV2COVID19VaccineMember_cb4ddd7e-8a64-422f-b4e1-f98920ff777f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_dd624db0-aa38-43aa-8d34-b373130459d6" xlink:href="ino-20220331.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0bd709e-95b0-4e69-a0e2-2bdd59ca3dca" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_dd624db0-aa38-43aa-8d34-b373130459d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member_5f1186e8-692b-4c81-8e3b-7d49995564cf" xlink:href="ino-20220331.xsd#ino_INO4800Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0bd709e-95b0-4e69-a0e2-2bdd59ca3dca" xlink:to="loc_ino_INO4800Member_5f1186e8-692b-4c81-8e3b-7d49995564cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_f7a8d093-d765-49c0-beb2-706e06425be2" xlink:href="ino-20220331.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0bd709e-95b0-4e69-a0e2-2bdd59ca3dca" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_f7a8d093-d765-49c0-beb2-706e06425be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA2000DeviceMember_2fdfbc42-6dad-4b5c-be28-d7505dd5c954" xlink:href="ino-20220331.xsd#ino_CELLECTRA2000DeviceMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c0bd709e-95b0-4e69-a0e2-2bdd59ca3dca" xlink:to="loc_ino_CELLECTRA2000DeviceMember_2fdfbc42-6dad-4b5c-be28-d7505dd5c954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1832ef24-8af0-4a00-9e29-f5ad76b097b6" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_1110ceb5-4982-421e-b5df-736bbe8c179f" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_1110ceb5-4982-421e-b5df-736bbe8c179f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_7543aec0-3eb7-438a-8687-59c5f1d2a13b" xlink:href="ino-20220331.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_7543aec0-3eb7-438a-8687-59c5f1d2a13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementPaymentEarned_cb818525-b418-47a7-818a-062bf24f1112" xlink:href="ino-20220331.xsd#ino_CollaborationAgreementPaymentEarned"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborationAgreementPaymentEarned_cb818525-b418-47a7-818a-062bf24f1112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_48d21d69-55f2-4095-ae43-f3daacfcc9bb" xlink:href="ino-20220331.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_48d21d69-55f2-4095-ae43-f3daacfcc9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostMaintenance_0d999809-d946-4a5f-be6d-e339e228588c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostMaintenance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_us-gaap_CostMaintenance_0d999809-d946-4a5f-be6d-e339e228588c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AnnualMaintenancePeriod_c5927239-56f9-485a-acf9-80b39c6d3a3e" xlink:href="ino-20220331.xsd#ino_AnnualMaintenancePeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_AnnualMaintenancePeriod_c5927239-56f9-485a-acf9-80b39c6d3a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5fc7b144-7253-4958-8ad1-7b6ee6af7cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5fc7b144-7253-4958-8ad1-7b6ee6af7cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_81f850fb-b8e8-41f9-82a6-1bd316afaa56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_us-gaap_AccountsReceivableNet_81f850fb-b8e8-41f9-82a6-1bd316afaa56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_86df0382-01b4-47de-bab5-b7cde05211bb" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_86df0382-01b4-47de-bab5-b7cde05211bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_4158dd58-fa26-4059-91eb-681cb70e7213" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_4158dd58-fa26-4059-91eb-681cb70e7213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_4180c2e0-56a6-4cef-aa75-671eed053718" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_4180c2e0-56a6-4cef-aa75-671eed053718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_22d88cb5-11ab-4d67-b276-7202c4b9ecd8" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_22d88cb5-11ab-4d67-b276-7202c4b9ecd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_52da29d4-00f2-4b33-a22b-cb6239a97015" xlink:href="ino-20220331.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_52da29d4-00f2-4b33-a22b-cb6239a97015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_76e64171-c633-450d-9c23-2ea7ed5cd058" xlink:href="ino-20220331.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_DeferredGrantFundingCurrent_76e64171-c633-450d-9c23-2ea7ed5cd058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_0375c89d-ab92-4032-8734-eaf196aea164" xlink:href="ino-20220331.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_0375c89d-ab92-4032-8734-eaf196aea164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract_281ea593-8b37-46d6-a23a-8a73053d2bdf" xlink:href="ino-20220331.xsd#ino_CollaborativeArrangementRevenueFromTheProcurementContract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract_281ea593-8b37-46d6-a23a-8a73053d2bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_f07e4501-6cff-415d-ac31-609f9095afc0" xlink:href="ino-20220331.xsd#ino_GrantProceedsReceived"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_ino_GrantProceedsReceived_f07e4501-6cff-415d-ac31-609f9095afc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_d6491618-17ed-4eba-8290-cbc6b10d7d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_d6491618-17ed-4eba-8290-cbc6b10d7d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_2f79424c-b50b-43ee-b4a1-54668b68a396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b9a6c08f-e30b-4515-8001-b9089e267b4d" xlink:to="loc_us-gaap_GrantsReceivable_2f79424c-b50b-43ee-b4a1-54668b68a396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ino-20220331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_974e6aea-da9a-497b-abba-e90df097bafe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_b34f4fa1-0ed5-44bf-8a85-dcdba77271dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_974e6aea-da9a-497b-abba-e90df097bafe" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_b34f4fa1-0ed5-44bf-8a85-dcdba77271dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="simple" xlink:href="ino-20220331.xsd#GeneosTherapeuticsInc"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_c4fb7829-7b65-4c7c-92f1-24f44276b293" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8b95ced2-1572-4ef2-8cf9-afaf5ad22b58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_c4fb7829-7b65-4c7c-92f1-24f44276b293" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8b95ced2-1572-4ef2-8cf9-afaf5ad22b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="simple" xlink:href="ino-20220331.xsd#GeneosTherapeuticsIncTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_9409ef4e-a1e5-4c94-91c4-7ad077be63c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_3c1dd186-8340-4d6c-b2ad-6d11a86a810f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_9409ef4e-a1e5-4c94-91c4-7ad077be63c8" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_3c1dd186-8340-4d6c-b2ad-6d11a86a810f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_575a0a8e-7c90-46bd-8b4c-a6ea1b9e1211" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_60fa2cfb-bdff-4b08-9a07-610c61a0109a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_575a0a8e-7c90-46bd-8b4c-a6ea1b9e1211" xlink:to="loc_us-gaap_MinorityInterestTable_60fa2cfb-bdff-4b08-9a07-610c61a0109a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7efcc8cf-cf45-4da0-8e2d-98ead2134e5c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_60fa2cfb-bdff-4b08-9a07-610c61a0109a" xlink:to="loc_srt_CounterpartyNameAxis_7efcc8cf-cf45-4da0-8e2d-98ead2134e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f272db30-3350-46e8-9584-7bf0528c4ab9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7efcc8cf-cf45-4da0-8e2d-98ead2134e5c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f272db30-3350-46e8-9584-7bf0528c4ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_d35b3c1d-1b3e-4f50-ba35-b25480837d7f" xlink:href="ino-20220331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f272db30-3350-46e8-9584-7bf0528c4ab9" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_d35b3c1d-1b3e-4f50-ba35-b25480837d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_6fea4547-0bb4-4a44-982b-28f9a37c1445" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_60fa2cfb-bdff-4b08-9a07-610c61a0109a" xlink:to="loc_srt_OwnershipAxis_6fea4547-0bb4-4a44-982b-28f9a37c1445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_bee2eee9-96df-48c2-93d3-ca52a6224952" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_6fea4547-0bb4-4a44-982b-28f9a37c1445" xlink:to="loc_srt_OwnershipDomain_bee2eee9-96df-48c2-93d3-ca52a6224952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_d77ba609-f1e9-43c6-a987-0292626ab9e5" xlink:href="ino-20220331.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_bee2eee9-96df-48c2-93d3-ca52a6224952" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_d77ba609-f1e9-43c6-a987-0292626ab9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_129c3b12-279f-4358-8d12-a95cf7cbe10e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_60fa2cfb-bdff-4b08-9a07-610c61a0109a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_129c3b12-279f-4358-8d12-a95cf7cbe10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9e0ffaa0-7e3f-4f85-826e-63a658cd60f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_129c3b12-279f-4358-8d12-a95cf7cbe10e" xlink:to="loc_us-gaap_ClassOfStockDomain_9e0ffaa0-7e3f-4f85-826e-63a658cd60f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_541dbeb1-dca5-4643-8da1-33ed498200cb" xlink:href="ino-20220331.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9e0ffaa0-7e3f-4f85-826e-63a658cd60f6" xlink:to="loc_ino_SeriesAOnePreferredStockMember_541dbeb1-dca5-4643-8da1-33ed498200cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_024ee0ad-178d-4173-b532-4744686fdc06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9e0ffaa0-7e3f-4f85-826e-63a658cd60f6" xlink:to="loc_us-gaap_CommonStockMember_024ee0ad-178d-4173-b532-4744686fdc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_39682205-5bfe-43ab-b110-163766d34581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9e0ffaa0-7e3f-4f85-826e-63a658cd60f6" xlink:to="loc_us-gaap_PreferredStockMember_39682205-5bfe-43ab-b110-163766d34581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_60fa2cfb-bdff-4b08-9a07-610c61a0109a" xlink:to="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_f3a47571-b2d6-4bdf-83a2-40c823a2f492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_f3a47571-b2d6-4bdf-83a2-40c823a2f492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_17843f61-3328-40b0-a4ad-0779c23f8177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_17843f61-3328-40b0-a4ad-0779c23f8177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_0c9721c1-5466-4f3a-95bc-26ecc19ad83b" xlink:href="ino-20220331.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:to="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_0c9721c1-5466-4f3a-95bc-26ecc19ad83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a4f929b8-d9e7-4275-aa27-7416a08c475a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a4f929b8-d9e7-4275-aa27-7416a08c475a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_4980223e-c6ac-4ff5-898e-5fee6d42dc85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_4980223e-c6ac-4ff5-898e-5fee6d42dc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_5dd1c57a-9377-4116-b878-24dd5efeae15" xlink:href="ino-20220331.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:to="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_5dd1c57a-9377-4116-b878-24dd5efeae15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_6697a0f9-3ef0-44f6-b247-9a9956c29e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_6697a0f9-3ef0-44f6-b247-9a9956c29e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5f05499d-62a9-4f66-9d37-8f1a932c8993" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5f05499d-62a9-4f66-9d37-8f1a932c8993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_d733b7f6-bbe2-4e4d-aaeb-a8ba4e325ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_834ea60d-2705-4237-8d98-89f6d317b8ed" xlink:to="loc_us-gaap_EquityMethodInvestments_d733b7f6-bbe2-4e4d-aaeb-a8ba4e325ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#GeneosTherapeuticsIncPreferredstockInvestmentDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_61ff8170-1224-406a-b74b-4abb835f71b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_dcdb39e5-7871-459c-95a6-5c08dc5ddc97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_61ff8170-1224-406a-b74b-4abb835f71b3" xlink:to="loc_us-gaap_MinorityInterestTable_dcdb39e5-7871-459c-95a6-5c08dc5ddc97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3167d811-01da-484b-9355-9915f035eff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_dcdb39e5-7871-459c-95a6-5c08dc5ddc97" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3167d811-01da-484b-9355-9915f035eff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f38db73a-13f1-45e1-a6d6-d6a30ed8b86d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3167d811-01da-484b-9355-9915f035eff1" xlink:to="loc_us-gaap_ClassOfStockDomain_f38db73a-13f1-45e1-a6d6-d6a30ed8b86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesA2OnePreferredStockMember_b110976f-781f-4444-bf9e-690d0a9bee48" xlink:href="ino-20220331.xsd#ino_SeriesA2OnePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_f38db73a-13f1-45e1-a6d6-d6a30ed8b86d" xlink:to="loc_ino_SeriesA2OnePreferredStockMember_b110976f-781f-4444-bf9e-690d0a9bee48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_cde31b94-d949-4677-8b32-999f196a8248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_dcdb39e5-7871-459c-95a6-5c08dc5ddc97" xlink:to="loc_us-gaap_MinorityInterestLineItems_cde31b94-d949-4677-8b32-999f196a8248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_98dbf7d2-2792-422d-9a57-c51efb735b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_cde31b94-d949-4677-8b32-999f196a8248" xlink:to="loc_us-gaap_EquityMethodInvestments_98dbf7d2-2792-422d-9a57-c51efb735b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_a4a18bb0-0eb6-415d-b163-0ea3e7fcbddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_cde31b94-d949-4677-8b32-999f196a8248" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_a4a18bb0-0eb6-415d-b163-0ea3e7fcbddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_dea63e3b-bc9a-4942-bf2c-25292efb09bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_cde31b94-d949-4677-8b32-999f196a8248" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_dea63e3b-bc9a-4942-bf2c-25292efb09bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_79a104de-d498-4914-97dd-b04811d9c1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_cde31b94-d949-4677-8b32-999f196a8248" xlink:to="loc_us-gaap_EquityMethodInvestments_79a104de-d498-4914-97dd-b04811d9c1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ino-20220331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1de050ff-20bf-4470-9a1d-6e36cbb4dedb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_31ca7d15-2ebf-4a64-afc6-3733139295c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1de050ff-20bf-4470-9a1d-6e36cbb4dedb" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_31ca7d15-2ebf-4a64-afc6-3733139295c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ino-20220331.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_97d39066-d52c-498c-a7cb-84439757e395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_d30d3b2a-aa98-49f9-a7d5-52f1576af0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_97d39066-d52c-498c-a7cb-84439757e395" xlink:to="loc_us-gaap_SubsequentEventTable_d30d3b2a-aa98-49f9-a7d5-52f1576af0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2ed290cb-350b-4a24-b3ea-6eb8ba9adfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d30d3b2a-aa98-49f9-a7d5-52f1576af0c1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2ed290cb-350b-4a24-b3ea-6eb8ba9adfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7797da9d-3e70-49a1-9a8e-77f53d6fbf89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2ed290cb-350b-4a24-b3ea-6eb8ba9adfa1" xlink:to="loc_us-gaap_ClassOfStockDomain_7797da9d-3e70-49a1-9a8e-77f53d6fbf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b5930f78-71c1-4d7a-8bd9-8e47b4b5a8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7797da9d-3e70-49a1-9a8e-77f53d6fbf89" xlink:to="loc_us-gaap_CommonStockMember_b5930f78-71c1-4d7a-8bd9-8e47b4b5a8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_cf233ed9-f4c6-4756-8891-445772a86ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d30d3b2a-aa98-49f9-a7d5-52f1576af0c1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_cf233ed9-f4c6-4756-8891-445772a86ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_aa44d1aa-f12c-4822-85a3-d197b9c2ae5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_cf233ed9-f4c6-4756-8891-445772a86ab1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_aa44d1aa-f12c-4822-85a3-d197b9c2ae5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_50bd9590-1c72-4819-9b98-83859792a699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_aa44d1aa-f12c-4822-85a3-d197b9c2ae5f" xlink:to="loc_us-gaap_SubsequentEventMember_50bd9590-1c72-4819-9b98-83859792a699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_5fa2d278-41eb-4cb1-a902-0a67338d3efe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_d30d3b2a-aa98-49f9-a7d5-52f1576af0c1" xlink:to="loc_us-gaap_SubsequentEventLineItems_5fa2d278-41eb-4cb1-a902-0a67338d3efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ce3e39d8-a586-41c2-a07f-c351e2928762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5fa2d278-41eb-4cb1-a902-0a67338d3efe" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ce3e39d8-a586-41c2-a07f-c351e2928762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ecd6a79c-f1b6-4e94-b62a-0cd4aa8f8155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5fa2d278-41eb-4cb1-a902-0a67338d3efe" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ecd6a79c-f1b6-4e94-b62a-0cd4aa8f8155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c9bee677-c8ef-4d8b-af56-707bf9884543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5fa2d278-41eb-4cb1-a902-0a67338d3efe" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c9bee677-c8ef-4d8b-af56-707bf9884543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ino-20220331_g1.jpg
<TEXT>
begin 644 ino-20220331_g1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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MX5.2T_$F1&."E:+"18,H1F2EQ"='9H2C_\0 '@$!  (# 0 # 0
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (G*\,Z \
MHB\<H#RB\<KR@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(O'* \HB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M20"N8;*1@+W,5>$/)IZTA<#(S-'9@**U!S#-&ZR#0!$1 $1$ 1$0!$1 $1$
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M_AM'>QMH'<2*-I!Z@(2%PGKR-T2,SA(/RM#CNAM)D]*9.3'9*+D7<CIVP9_
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MG*OX#Q* P41$0!$1 %(KW2OTQ>V?]OU=_![JY1U*17NE?IB]L_[?J[^#W5R
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M#K/_ .(9/^\98W@C_ ^F?ZEC?[J(1%X6BFTE [M%9-KV\VZMEG%V_FA:O@Y
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MO$W#&>.MWL+9=N?,^9@R]<B9O-@&")BXX<AY<FVW1O;AX'R6ED6:IIN_=Y>
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M!+)XNU1LV:-ZO+4NTK$U2Y5F'IFJVZTA0V*\H_H9(9@.,Q^0A=O/WN!Z*(B
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MBO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_ +?J[^#W5R N]HB( B(@"(B (B(
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MFFLSJ;(NXB5;#T9K?@N3.XO:F 6KTXW82+Q;<T$3"+DYLS.[3;=G;T>+<S4
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M2]R(JV3B;R8J]Z$V$&+I8#,I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M2JXIJQ31'[<-N>U&7F+NI,$ 1$0!$1 $1$ 6!7>@?$'N9]@X?PKCUGJL"N]
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MB(B (B( I%>Z5^F+VS_M^KOX/=7*.I2*]TK],7MG_;]7?P>ZN0%WM$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.DOQDQRIC*YSWT7Q ZD^S.DOQDQ
MRIC( B(@"(B (B( B(@"(B +GFV.YN<T=G\7J;3E^;&YG$6H[=.U"1-[0/\
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M-F$;T?/W?R_S+^'I+F94_P"7\F7Y%2^L_P#+^\JUK*^9RDAJ_IN^WR,-MS<
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M'4R2 (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M4TDAU9"DZ:&0=H6C]7NE)4M1H#RB(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M[3W1WQ":*_NQ^&;R CD[X?N[G/U[=_1-%RE_H^N\16%N"C"-A?5%.$1Y>0&
M1S<4?]$#C*,#F%^22MBSK9%SP!*!QR ,D<@D$D9BQ 8&SB0&),XD)"[B0NSL
M[.[.SLJ>?>I=WH6UN;+5^E*9?S/L[99GKPQ_.]*Y>P9<XLNGD8\5;+@\1([
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M"(B (B( B(@(GN^J^(3.?9[2GX<JJF@KE_?5?$)G/L]I3\.55300!$1 $1$
M5X;NI_I?MN/L?E_QDS*H\J\-W4_TOVW'V/R_XR9E 2%(B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B\.@(/>_;[9TFVNU;:3PEOU?56Y$EC"P
MG&7$U#344;/J+(!P[$,L\4L&'K$W#B>1EL@7748#I-[>:6/*WH:PL[0#Q)9,
M?T$(^3LS_P!,;\ #?5?GAV%UFYWNG:BDW3WVU;?@M>-I_2TWS&Z<C&1S@"E@
MCDBR-J/R$'/(YLLC:*1AZG@*K7(Y JQFNO=J-.1XG&0-89X[>3%YI'?V3 &
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MTK$5FK,<-B NN.4/HA+W.W'T+B[<B0DSB0NXDSB_#Y[[-[Q4]11M4L=%7+Q
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B+^3-A9R)V869W=W?AF9O-W=W\F
M9F\W=_)F0$,/?9=I-])[;P:,QTXQYC7UHJ5EA?B6OIJBS3Y:4>'Y$KL[TL8/
M4'25>U>(3&6$.:AZSL[Q_M'EN;NUJ3+U[+S8+$RMIS38B?5".,Q3E%-:CZ>
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M-F5PDK9+5KA(_P ]O,1#)5PIL('6Q11Q3S,[RY3ERCI5(=T1 $1$ 1$0!$1
M%_)&PL[D[,S-R[N_#,S>]W=_)F7;6S&QVJ]PLY6T[I#"W,SD[!!UC7C=JU*
MBX*YDKA<5L?3C\W.Q9DC%W;PXFDF*.([5/8?[H326W?JFH=:^IZRUD'1-$$]
M=CT[@IV=C#X.I6&+U^["3,XY.\'(&S'3JU#%I" AG[%_=(:YW+]6S>I1GT5H
MV3ID&W<A9L]EHG\_^2<7,/,$),[<9')#%"[.SU:UUF/HM-]G/LHZ%VJQ0XO1
MF#@H=<<87LG-^:LSE3#AWFR61D;QIB,^9/!#P:<)/TU:L$0A&.1;,O* (B(
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MV[CK836A-+9O8=GAK874\SLYF3\L$>+S,Q>37>L*-HR_-\<9D5T*I>KM(Y7
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M%4>?6(8A9O$S6,AZBC\VDOT0>HWBV(*415/?Y?K?K_7^1V^1 $1$ 1$0!$1
M2^=U9WA,FUV<#1^J;<A: U#=#Y_/(Y1Z4RMAVC^%(^OGP\5;+PQR\(NP0NS9
M*,&,;?K%PVM9CFCCEB,)8I0&2*6,A..2,Q8@DC,7<3 Q=B$A=Q(79V=V=G6M
MV5DGN>>\1<O@_9_6MWS$6K:%S%F1N29G]C2UN4WY*06=_@.0N7>,"QCER-&,
M@+(Z(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B B>[
MZKXA,Y]GM*?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$ 1$0!7ANZG^E^VX^Q^7
M_&3,JCRKPW=3_2_;<?8_+_C)F4!(4B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( J-?I)VY)93>[3>G!)WBTOH:F3 Q,XM:SV2N6IBXZGZ92AJ5
M!)G87<(XGXX=B>\HM=UWM&:?5?:ZU[48WDKU]1Z8T]%STNX08_!X**^'LN3<
M16RR+LW5U<,W6P%U ,&>T+JBQN'K-WM&S(K4^J_DZH6Y$F]^NR=,>W7?;?IN
M8'B3)56+.<OLQWE+^;",IO\ =R[GV=KM,MC<'BJ3"S/#3B>3AN.9IF\:9W^N
M4LAD[?5?Y5W'2J_R_E_+ZZ].E4^MQ];_ .K^7R-Y+E]2KY/^LZX0ZUJDK;;;
M9O>5MD[)/?O*<G*7[VSGW;;*VRRZ?6=LYV2?QE.3G+^+;9<M[,>#"EMIH.@4
M8],&C-.021DPN)%\#U&FZVXZ2\0W-Y/)V)R=W]ZK#=ZMW><FUF8DW$T32Z=O
MLS;C;*XRI"31Z/R]J1Q;I .0AT_DIB :3LT<>/NR?![\13T65J#8YO\ ["](
M_:S@OP957,=6:5QV=QE_#9>E7R.+RE6>CD*-H&DKVZEF-XIH)0?WB8$[<L[$
M+\$#L3,[?TU^"7&N1PY3I5V/S3Q_T?@TY.,WM&^B%%:7IM&VO[55FWNRWB]X
M3G&5YM;X.Q=7TBG#NBDXXU7T>W;=U3548I_.#22G'LUU6TE%K7B92C#DJSRQ
M\=?'),WOY_IF^5O/ZGN?_-9@[H3O'3U-7J[3:]OF6JL76(-+9R].SGJ;&5_H
M<79FD=BDSN,@=AB(R*7*4(?&)Y+E>R<L/G;\[$F3V'U@#5/6;N@-16;!Z6RD
MO,IU"'Y[-IW)RLS-Z_1B+FK/(PODJ0/8'F:O=&+">Y'/%+5R^)LST;U*>&Y3
MN5)3@M4[<!M+!8KS1NQQ2Q2"QQF+MP[?*WD]_N(M"TWC#1H2KG&4;8>=A945
M[^/<DXOFCWZ23JR*6^NS72<83C4WA[6<_@[5Y8V1&7D.:KLK;?).MO=)/MV]
M^FQ?%=XN2>Q7Y117=V)WA=;>33IX?/R0U-Q=-UXASE41""/-TV8(HM1XV$'Z
M6CGD=HLE5C$6H7G]F..G9I]4J#.N?^O:%DZ9EW8676Z[Z)<LEWC)=XV0E]ZN
MR+4H27>+79[I7>TK5*,W'JR<>:LJMBI1DO3XQDO247O&2]&CROX,&)G$F8A)
MG8A=N6)G\G9V?R=G;EG9_)_<Z_M%AS(%./O4NQ')M%K)M7Z=JN&@-97Y"@A@
MC<:^F\_*!6+6&)Q;HCI7^BQ?Q#%TL(M;H@W33B\2,+*1S =;*XVQ-4NU)H;5
M2W5D*&S4MUY!F@GKR@[''-#*(21&+LXD+.WN6P WRV6P.X>E<SH[4M7UO$9N
MH=:9A?IGK2MP=:]3EX?P;M&R,=JK+P[#-$/6)QN<948]Y=B<]M=KG*;>:FX*
MU3FA>E>C!Q@R^(N2&.-S%47?GPK0QF,D?+^!<@M4R(C@-U>;P3\2XZI@SP,^
MQ?3,"G=SL>_TG#@ME;+?[4ZEM7?NFY;PL;DYSY:=>,W 4]-S(:QI\7&FVS>R
M$%MY=K]Z45MVC/9SJVV46I0Z)1WMF=V5VY:^\NB!')2PQZZTO%4Q^K*8NP%:
M,HSCIZAKP^734S/J\TA '4%6[':J]73'$Y24JC?L3=U;LWKK$ZYTM=K6AK3C
M7R^,E\6"'-Z?L2Q/D,;,XM*+221"TM.9^/5;\-:R_B!&<!W3]KMS,1K'3^*U
M-@K(VL5EZHV:TC-P8>91S5YPY?P[-2P$M6U$_G%8BDC?EQ5,>).(N%M0SIW\
M*ZSA:G@9"ED1IQY3A?AOF2LJLQKH57UU*<EY,I5I<DE7NY0;<^^''%\M1Q(T
MY2Y,_'@E=&3CS6PZ*-RV;W](VM=%/9]%.*.P5X=>46')(*_?>L]E\,)E8MU<
M#4&&IE;%6CK".O$PB&4(8ZN-SDO1PP>O1QU\9;D=F$[,=$B?Q[,A2149BJ&0
MJ-,#_/!%NIQ?@A)FY8V)N"9V=O)V=G9VY9^5<IW!T)C-483*:>S-<;6,R]*:
MC=@?R<H9QXZ@+CD)8RZ989&\XY0 V\Q95$MR=L,GMUK#-:+S/)OC[)-3M.W
M9+$SN9XW(Q^7D]FLX%-&W5X%H9Z[D;Q=3TQ]HK@JVC,AKN/SR5[C&]MN3C=7
M%1V;>^T;*H)UKM&5<DMH\J*[>)G#:Q<KZ77'^]LZ35B7:K*VW;^2N2YU^W&W
MLG%%A/NY>U ^X.BPQV5L-)JO2@PXW,=9-XU^IP8XO+]'T3O;KQ^!;/S8K]:P
M;=(R@ R"SV8X@.64QCCC$CDD,F$(P 7(S,R=A$1%G(B=V9F9W?AF50+8O>B]
MM9KG&ZNIC--3#JHYNE!QU9'!6Y(3NUP$G$"FC*&&W5ZR 6MUH6<P%R=36=ZQ
MVO*>B=@<SG<!DHI+^NJ=;3ND[D!\>*.H87>WD:[OTF)4L%Z_;A=P=X[85@F!
MF<^):\.?%2C*X>OS,NS>_2<5RRMWO.ZNNMNJQ>KG;R^4^[=JW>WF11OG!'&,
M;M.M63+?(TZO:W=^]=4HOR;5OWE-1\N7=NQ<S_E(E.?MV[_R;F;MZ[UAXI'2
MO9VS4PK.?4T6!Q+MC,.,?!$$?CTJD=V8(R*+URU9,'+K<B[?[,NY[W*8U9I.
M;=%QBDY+SD@?^@2^?N]GF,N>?:!W\F)A:-;Q69F9O)F;AOD9N/\ V7(-*:VO
M82XUZA((3,!1DQBQQ21GP[@8.[=3=3,3.SB3$+.Q-Y\T&>L3OS,K)R=Y_3K+
MK,GU;G=.5G,EVWC.6Z_9YETW(;U/'GDN=K?UTK)6\SW2YI2<II].TMW^'3X$
M@W;5SE6#&8VF#B]C)6?66C9VZ@KU!?KD)O>S%-* #SQU\'T\]!<9@]S9V=GS
MNLM/6;-=C K+:GNL8._3BL%()8\9/)V\.SD9*QLQMT2!8C%^6-0X:?'+Z_U1
M5COSG8.8A>U(S,,=3&UWZY0@ ?9B 0=XX1;S.>47,B(S-7:>Z.V/##:4R&KI
M8&CDS\@8S%,[</%A</))"3Q<BW 6+[2B;B_$C4H7=FZ!Y^.!^'WQ%QAH.AKZ
MW'Q[8ZUJFZWC'3=,M5M--L=]N7+S?(I:WZ;IM.,MC\M)TKZ;JNG:8DG'S5J.
M?MU2Q\62G&$EZQOR%57UVZ;/LR7AEY1%UN+;!=,[T;!:6U_C'QFI<9#<$&)Z
MET!&+(X^0O?+1N"+RP._EX@,[PS,S#-%(+,R[F18[5]'Q-0QKL/.QJ<O$R(.
MN_&R*X74VP?>,ZYIQDNS6ZZ-)K9I,Q^JZ3BYV/;B9N/3E8M\7"['R*XVTV0?
MI.N:<7U2:W71I-;-)E9OM*]WAK#0[V,CB EU7IR-SD];H5C?*4(/?_REC8O%
M(@A%^#N4O%A<!>Q-#3#JCCCR(_\ ZO=P_P!1V^K[_+W_ %5=Q6$^_?8'V_UX
M4MR:@6"S<G+OF,)T5I)C^K>I.+TKK\\<R20C:X9F&R(\B_.'QA]@B%LK<W@W
M*A0VW-Z-J%DW5OU;CA9[Y[(+LH4Y:FM]V\N$=HJF?&OL@XJLGD\.VJF+?,]-
MRIRE"/QCC94N::7I&O)Y^O?(4=HJJ^1_R9>A?JPV(CAL1!-#(+C)%(+$!L_R
M.S_WV=O-GX=G9V9VDGWC[L'<73QS6,)'5U=C1ZB \;(U?* #/Y-/C+1!UEQY
M-ZC8N=?#DX1<L*CIU5@\EAK1T,O0N8N[']%5R%::G.S<\,[16 C-Q+WB8LX$
MWFSNSLN>W%/A[Q/PMEUO4M-U+2,BBZ,L?+<+*H*^J7/79B9]+=,YPE%3A9C7
MR<9)24DTFHH?ASEZ5-+.Q;L649=)2BU%R3Z.NZ.]<NO9USDM^S,2-<;/RU'.
MUBNJQ6^B*KYE9@][EX?F[SQM\C-\];W<'PSKE'9V[66X&UE][FC-0W,;$<@E
M>P\SO;P>1\,G?IOXF=WKE)YF+6H6@O1,<@Q6H_$-B[>GN?*NM]3:2H9!RD,/
M"L>;^/#PQ$[_ /Q1^AD_7)NKZAMR[/UV]ES^ZHVT8M/#OBIBV:Q@\L:*^)<>
MB&1FPK6T8?IG :4<]07?.Q4LW:/-9C9M\Y7$AZ1Q;9CRBYSLC*'V+ZY-6QZ?
M>::<OFT]VNZEN2\:P[X_"[A;7:MTAJS3MG3^I\IA)*E.]BS^$<!?LO)$;,8'
MX=_%&8B[-'(-ZNSLY/=#J:(<!](Y6M9Q4CU[$,[,+<^%(!N+NWDQ"+]0O]8F
M9_K+!K)Z(NU7)P%K,3>XXOHN.?T43^TS_6'K;Z_/DWP:\IPR,0$<<@\MU"1!
M(/UN1=B;Z[*]/%_L]<">+.+1K'!G%V/%50CM]!G5JF+7O)VJO*PIW8^H8%SE
M)J5>1;"=:Z?1EML;EJ.OSU.==]E\+IU4^2I144W!RE).<8I;2WF_NQ>VV^[Z
MDY'9B[=^7VSTEE=.8/"4K5^[FK.1^%<C8ED@KM-5K0!''CH8XGED!X7D*22X
M(%U,'@^3D_16[_:.UMKJ8I-3ZBOY"!W=X\<$KU<1 W4Y"T.+K>%38AYZ?'DB
MELF(@TLTG0/$;&/UEE*[.T5V9F=_-B<9.?+WOX@EY^7O]ZY%'N7F.?.Q&?'E
M[5:!O>W_ & #_-PJ;^+']SB\8M6G+$Q.,N'<K0*4J\/3+<_5M,4:HQ24;\7&
MT6['R)<W,U/(R;IISV4E'=K4^((:OEXT<3Z;_>E<>2O'\R=57+NVE.%=:C8]
MWWLYVO1^ADB3?Z&X_:Y7SX0=\A#Y/PT?OX?CES;EN?=SY-Y+H.3<;*E_UT0^
M3MY5X_KMS[3%Y_YOK+U9=9Y.3Z*V;<^_I&,/]0!X_:6I^'']RP\1M.S8967J
M7!U=<:[:I1CJ6KVVI6PE6Y1C'056W%/?9VK?MNM]U'VD\$9^-F5Y6^))0YO<
M=ML6^:+CW6/-+9-_'?M\S+C7,T9B$;2 W2 ]?M"_2S>_JX\F\OD?_P 5TME-
M24HG=O&&1^.&&+B1_+ZX\C_?=F73-F]++YS3&;-Y_/)")F^NS$_#?M<+O39_
MLQZ_U]( Z1TIF,S"9"+7HJSU\4/43#U'E;95\>+"[MUOZS\[9^39A5HM(_N8
MFC_49/&/%N1DXN*I;8>EXU&D8\93:<U=J&;;G6VQGRI/RZ<.6T4XRB^;?8]2
MX!LUC*KLRK;+.2+C5B85332;3DY62\RRURY8IN-=:2222>[?6]S4IR\^&'0S
M^YR\R_O?0M^MR3?K\+WM"Z#SVJLI7P^GL5D<[EK1L,%''5IK<[\O[4AM&+C7
MK@W)S6)GBKPQB4LTL<8$33H]GKN/[DG@7MS=0QUH_(SP&F)'FFZ?)_"MYJS
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M;S$XS$3 F\Q)F=O-E?'[!G:-#=':[3&IY) ++-3'%:AC N7BSN,8:M\^GEW
M+I .1@!W=QKVXA(B(2=4,U.7W&_:2?3^N,KM[D+#MB]:UVN8H"=NB#4F*AD-
MQC]SC\)XII@E]_5+CJ;,P\F1 6Q41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MFL:!U!.9X&V[G*6*M.Q2S:>OR%R7BUQ8I<?.9%ZY2;S)[->RS1G( B(@"(B
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MMVY AP)LF4 P4*$,UJY9DCKP5JL1SV;5F8ACAK5H(1*6::60PCBAB$CDD(0
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M?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MTM!.3%)A")V<;!GC!<VFH11V9UK=:]B2&2.:&22&:(PEBEB,HY8I8R8XY8I
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M?\9,RJ/*O#=U/]+]MQ]C\O\ C)F4!(4B(@"(B (B( B(@"(B (B( B(@"(B
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MEM"S@]!I#YDL::R9R25' 2?J=L9>&U2D86Z(8),<W5U3=(@3?(B( B(@"(B
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M&B(@"(B +MG8W>G.[>:JP^L--V/5\IA[(S )]3U[E<O9MXZZ D+RT[T#G7L
MQ"3";21&$T<<@]3(@-@UV;.T'@=T-'8C66GI'>GDHB&Q5D?\TXS(UW\*_C+8
M\"[6*=AB#JZ6">)XK4/5!/$9=[*EUW6';?+:?6@XG-V^C0VK9H:F8>>4A@PN
M1?B*AJ .7\...-^FGE'?I%Z$C63/JH1@=T*.02%B$F(29B$A=B$A)N6)G;R=
MG;S9V\G;W(#^T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MPG%[QE%]FG_6NZ?1[-%?3O(^Q86F[=K<W1U3IPUF5IM5XFJ#\8RU*;L6<J1
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M;V2R-R4I9I781=R,S)V".(1CAB$8HHXX8P 9U-8T:&3C. @\2*>,HYP(&Z"
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MC",4DDDDD6WQ<6JBN%--<*JJHJ%==<5"$(16RC&*22279)!$1>X] 1$0!$1
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M.[.6G=S=.3:>U!"0^93XW)P,#7\1>Z'".Y3D)G;Y>FQ7/YS:AYBE;Z @J/\
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M"VEQ5:_9]8U!HTFTSEW(W*:>"H'.%O2=7).5G%/7BFD<B\6Y5M2\BQL R=H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M%FM/&[C)#/!*(2Q2 [.Q 8B3?473FJMO&-RLXX>#=^J2KRS"3^;N4+_H2_\
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MI8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MNP+.5I8X':)A<F;Z)V;RX^5F_P#-OD6(>Z/:BITRDKT'^$+;.X\1DWJL1?\
MW6=N>MV?]!"Q/[V(@X;G[;)=^K_@0Q/5]=XAO4<?S:JD^CAO6H+?OTVC#Y2D
M^9_-G0O:4V@QFGK,%["F88^Y(44E.0_$>K88>OF W?K>O*+$[ ;D41L[,9 8
MB&+\4QQR1RQD4<L1M)%+&11RQ2-[CBD!Q.,V?S8P<29_-G7+-8:[RF=F:;(V
M2E87?PH1;HKP,_R11MY<NWT4A.4A-QU'PS,W#E]2R'#^'DX^'13EWO)OKCM*
MYMN4ENW%2DTG.44U%S:WEMN]WU<U_8O[^S?C:$:N-R&5_FH:6K,P#@=<9"Y/
MDHH6Z6:#':P<+V9IL LX0_"$6:K5V(1CI/%&$*N/=A+OH=E=]GJXK&YGYD=;
M6&=FT3JR:M1R=J4(_$E'!VVE^#\^(#U'T8^9[K1 <LU&$ /IUF2_>O8.*2.:
M,Y(IH9(YH9HC*.6&:(F..6*0'$XY8S83CD!Q,"9B%V)F=1)QGX,:-JZE9"E8
M&9+=_2<2,8QG)^M^/TJM6_64HJNZ3;WM[(V[#U>VK9-\\.GNRZ[+Y/NOXI?
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M.<A=I(-,8UWBJ>;LSL^1R'KMTNEW ZHX]_(QD9 3<PPA& QQB(1@(@ "S"(
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M1R%'&4</B&T;.@.^41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 4$7?<=D=]1:7J;G86
MKXF9TB(U,_'$+>);TM-)(7K7DW5++A;LHS=+OPV/M7Y&?K@CCDG=7R\WAJF1
MIV\??KQ6Z-ZM/3N59P:2&S5LQ%#8@E!_(XY8C.,Q?R<2=D!K@T657;4[-%K:
M7<7.Z/E\23'Q2-DM/VI6+JN:?OR2EC9'-_*66NT<N/M2B_2=RE8?@/, Q50!
M$1 $1$!*WW/_ &GFT!NE7PF0L^#@-P?4M.W.OJ>*+--/(.FK1,Q,P.5VY-C'
ME<7$1R?5*XQ@\D=S5:W2"Q)#)'-"9130R!+#+&[C)%+&3''(!-YB0&S$+MYL
M[,[*^/V"^T?'NGM=IK5)F+Y5JY8G4,3%U'#G<4[5;KGSYLUUAAR<#._/JMZ!
MR]IW9@,Q$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %1:[S;X^
M]S?LY5_ >)5Z546N\V^/O<W[.5?P'B4!@HB(@"(B *17NE?IB]L_[?J[^#W5
MRCJ4BO=*_3%[9_V_5W\'NKD!=[1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 14=]%
M\0.I/LSI+\9,<J8RN<]]%\0.I/LSI+\9,<J8R (B( B(@"NT]T=\0FBO[L?A
MF\J2RNT]T=\0FBO[L?AF\@))T1$ 1$0!$1 $1$ 1$0!$1 $1$!Z.3QE>[6L4
M[<$5JI:AEKV:T\8RP6*\P/'-#-$;.$D4L9$!@3.)"3L[.S\*F%WF_8"L[/ZD
M^%\'!+-M_J*U.>(E;Q)?@&X3O*>GKLIN1, "3OB+$QD=NI&44DDEJK.<ETM=
M:;P[1X'7>F\MI34M(+V'S%62K9B+AI(W)N8K567ARKW*DO18JV X.&>,#'W<
M.!KND66';)[).>V<UE;TUEAELXZ7JMZ=SGA=%?-XHB9@F%QY".[5)_5LC5Y8
MX+ >((O5GJRRXGH B(@"(B +E6AM<Y;3.9QFH,#>FQN9P]R&_CKT#\206:YL
M8.XOR$L1\/'/!*)0V(#D@F XI#%^*H@+U/8([:V)WIT>&4C:*CJ;%>%3U3A1
M)_S)=<2\.[48B(Y,7D1 IJDCNY1$TU29WFKD1YSK7X]F'M(ZAVHUACM8Z<-B
ML5>JOD,?+(85,SBIR KF+N]'/SJ;PPEAEZ3>K;AKVXP(X6$KT/9YW^T]N9I/
M%ZOTU9\?'Y&/B6 W'UK'7HV%K>,O1B[^%;IR/T2#]"8N$T3G#+&9 =VHB( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4
M_#E54T$ 1$0!$1 %>&[J?Z7[;C['Y?\ &3,JCRKPW=3_ $OVW'V/R_XR9E 2
M%(B( B(@"(B (B( B(@"(B *O1WX7>(RZ*PW\R31N0*OJW4M,9M3Y"J0^/@-
M,6F,&IQ2,[O7RF?%BC$F;Q:N*:Q.#Q36J4X3 ]KSM+8C:/;W4>NLOT2#B*1M
MC:!2>$66S=@7BQ&*C/AW$KMUXXY)!$WAK^-8Z#:)V?7SYO,Z@W&U/FM6ZBME
M:RN=R,^2R^0)GZ'L3ORU>L!D3C#7B:.M3@ZB&O5BAC=^D!ZI^\"_#^&H94M4
MS()X6!->7"2WCD9:VE%-/I*NA.-DT^DIRJAM*+FB/>/^)?HE'T>J6UU\7S-/
MK"KJFU\)3>\8OT2D^CV9U[I?3DUHQBKQ.3MQSY<  MY<F[^0BWGQS]1V;GW+
M([ :+KU&$I>)YF;GEV^="_\ V1?CGC^F/Y/<++FFD-(22S5,1AJ-BW<MS15J
ME.I"=BY=M2NP1QQQQ,4DTTA<,PB+NWR,PMY6.>Q/W0%6F%/4V[$0W+SC'/4T
M7'(!T:9.[&!9ZQ$1-?L"W2SXZO(U*$NL;$U[EABLWQGX@86D4>;E6\CEOY./
M7M+(R&OU(=-H_K3DXUQZ*4N9QBX,T?AW+U2[DIKWBFN>R?2JI/UD^O7X02<G
MMT6R;*X>::3'5:5Z[6MUZ61>8,=;EJSQ5+YUR<+ TK4D85K)5R;IF&&4WB)G
M$V9_)?)DE"Y%TP6'C<F\V9^@GY^1C;S;R^N/O6P-U-MAIS-84M.9; X?(X H
M0K_ US'5)\8,,0],,<=*2$J\30#QZN\0 4#B+PN#BSM"?VE>XJTAF"L97;'-
M6M%Y,GEE^ [SR972\\CNYA'7ZG;*8ANIW%WCLWZ@QL 18^)V,SC#A3V@-)OL
M=>HXMF"W)JN_F^E4*+?N^9R5PLKEMLFU5;'?>3E!=%F>+O!S5/+4M.S8V.*3
ME5R1IG*2779RE)3COOM%V5]-EM)K<@4V'[8>[NTLL;:/U5;;%QEU%IW,L69T
M],+F\AQ^H63\2DTA<N4N*LX^SR1.,[>(?5/EV:N_:T/G3KXO<K$VM"924@B;
M+5VERVEI3?@>9K$0-D\4Q$_T5FE/1B!B.QD8A9N8$]^^RINGM--+'K?2MR+%
M1GTQ:BQ[?"NG+(NSD,@Y.JQ-3)V8N8,G'0M#TD_@>&X2'CFS8Z^/LN($_P"L
M[._O\OE_D[^7O4C:YX>\.<24_28PHE.Q-QS]/LKC:VUWG.M2KNDO57PLE'[/
MNO<C?2_$/B+AVSZ/F5W2K@]G5?"<H**>W2,MK*X_!U246NO5;&PST;K7#ZAQ
MU?+8+*8_,8RV#25[^,MPW:DPN+%[$]<SC<F8FZAZNL'?@A9_)<H6O=VFW.UU
MMKDGR^@M3933]@C$[$5&PY8V^P.SL&1QDGB8^\#MR+>LUY)(Q<O!.,GZE.1V
M:>_KDB>#%[O:8\-V=@?5>DXS.)QX\CR.G9S.:(F=OGD^,NV!D(O8QM8 ]JMO
M%OL]ZK@\UNGRCJ5"Z\L$JLJ*^'DRDXV[+I]39*<GU52[%@>%/&K2M148W2^A
MW/9>_+FI;[?RB2<.O^4C&,>SFRRTBZ:V7[0VB-Q,:.6T3J?$ZCI<-XCX^T)6
M:I.S/X5^A)X=_'SMRW57O5J\XOY%&R[DY4$9.-93.55U<ZK8/EG79"5<X27=
M2A)*46O@TF2_3="R,9URC.$EO&<)*49)]G&46TU\TSU[=.&Q%)!/%'-!,!1S
M0S ,D4L9MTG')&;$!@8NXD),XDSNSL[.H@NU'W,.V.MRMY7282;>:FG>68K.
M& IM/W;!\DQWM/22A5AYE?JDDP\F,.1SD.=K$KB03#(LKH/$N?I=WGX&5=C6
M=.;RY>Y8EVC;6]Z[8_LV1E'?KMN8_5M$Q,ZMU9>/5?![[*R*;COTWA+[4)?M
M0<7\RC-V@^PWNSLZ<EK56"')Z:@*1GU3I\I<KA&BZ3\.6\SP17L5SPW7\(TX
M(0/V0L2CT2'AV$V/R0<^R)GY\^\2=_-WYY=_-_/E;%F2,3%P(6(29Q(29B$A
M)N'$A?R)G;EG9_)V?S43O:H[GC:[<+Q\E@J[[?:F-B,,CIRM &(M2OR_.5T]
MQ#2G$G?DY:!XRXY<$]DQZXY+.\'>T?"7+3K>/Y;Z1^F8L7*O^=;C[N<?VITR
MGOVC3%(KKQ;[/D&Y7Z/>ZK$W)46-1;?PC:MHR^$8V1CMZV%/%\#?QIO-C;,M
M?J?J)HB8HC?R\SB)BB-^/+DA=^/+EE]^EN=+R$.3K^"3NPO9A\X>?-NHP-W.
M)O=R[/*S/[3N(_0Y9]J_L0;E;'RP3ZEJULMIB[<>ACM3X>3QZ%BR\,UD*ERG
M)Q>QMPZ]>>8([$15Y(X97@MS%'*,>(D5O'Y 6Y< ,OJ<.+\M]3Z_[:_;Q6]G
M/PY\4L6R[4,+!RLU5JNO7-+G7CZQB2<-ZHVY5*Y[/+B^>&'J5=],=]_HZ;;*
M?^(_A3A9UMN/Q#I4)Y="4/I^/%4ZC1S1WKE*V"<K8*+4ZZ[U?0T^:,-GN<JN
MW&=O)V=B^5G]_P!=G;ZWR_\ UJ:WN-]RRK:]U+IR27B#4.EVR,8D_D62P&0K
MQ^'&WGQ))4RM^4WY9G"HS%RX@R@JL1>K $74Q"PNP.S\MTB[LW'U&8>EOU^>
M5GMW8&M_@7>305EY& +F4MX>4G=F%H\M3N4F%^KR]J22(6X_1.+MY\<<G/9'
MX.R>%N/_ !%X&R[(W.C0M7QU.*<8Y65H6I861I^2JVWRJW%G??&&\I05JBI/
MWFXZ]CR$]"XYR=/=G-#DLH\Q+E5KIRZ:X6<K[*>-=?+E;WAS;;]&R[*B\,O*
MM(=HPB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M#<N#SU)2B>6%W87.O8%AL5I'9O%KRQ2<,Q+A*GT[]3LU/B=3X3<S'0,-#4L
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M16)A;\]Y&P9V\I==^D'=[F0GLV.7%G9I&'AN&9N^$ 1$0!$1 $1$ 1$0!$1
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M#JG?C6?P1I^QX9]-F^[4H7YX<!-G*S+_ /HZXFPNWND.-W\N5;%[LK8QMO\
M971.)EA:'(9+&AJ3+B[=,GPCJ!AR)1S<MU>)5K2UZ9"3OT>K] \" LU2K0VA
M7W1WNT/H$0\?''F:4&2BXY"2G7YR^><V;S\-L95.L?'F'3*3>3LKLN\>_P!H
MC;G%/E=9ZCQ6F\=$'SM[T[#/.P-TM%1HPM+>O2^3"$%*O/*3](B#N[,OZ)_9
M?\*I\*>%_#&G_1YO6>,+)<8:E7"N4LAT9=4:-!Q>2*=G+#34KG2UO7E7Y#V3
MG(Z0>Q9X;U:!PY9GWQA5?J#^EWVSVCRPNC&5,)3EMRQKQ8T3V>W)9==\6=SK
M@NXFYNGM(XN?-:HS6,P&)K-\^R&6N04JPOP[C&,DY@TLTG2[101=<TI>S'&1
M.S/70[3??TV[7K&*V<TYTL75$.KM65B9V'R;UC&:="4"ZW\S@DR\XL' %9Q4
MCN< P<;FZVUCN%E&SNO=1Y/45\>OP9,G8ZJ],3?DX\?1!HZ="(O)B"E7A8F$
M6/GI'BY/"'L]ZIF\ENHS6FX[ZNMI69<EWV\I-0IW[;VSYXOJZ7V<Z\6^-FE:
M<I0HE]+N6Z7(^6E/^?UE/\*XN,OUT6%.TWW\^"HG9Q&TNGYM3W1\2+YI\Z$N
M.T_&?#@,N/QXNV4RK ?M==AL57)A%X3M1R=8P*[S;\;D;JW2O[@:IR&:A<VD
MAQ9$-' T6%^0"CAZ8PT8'C;AFL%%+=EZ1*S9L2<R/U1);QV.%W'I)Q;S(N&9
MN&]__N_]Y9=]G?L)[O;MO7GTYIX\9IZ=^7U1J%SQ6%:)G9GDJ,<9W\HY,[O$
M..IV(C?I\2>",O%:R>C\%\.<+T?27''H<%M+.S;(2OE)+M"RS90E+_)X\:^=
MI;0DTBO^H<;\1\2VNC$KN54GNJJ82C!1?3=PCUE%?KW2:CZM(Q*>GC\:+<])
MNXL;-R/#,[>7+_+^OY-]9EWSL-V9MS-U['J^A=+W;E 9/"GSMD"QVG:KL[,;
M29>P UII8N6>2K2>U< 7$G@Z3%WLC]FCN4]M-('7RFL3L;@YV+H-H\F/JVFJ
MLHB/)5\'&9^MEXC$77EK5Z-O8>*M 8N1S$8O%5:->&I2K04ZE<!BKU:L,=>O
M!$/D,<,$0A'$ _H0 1%OD91=Q=[2&/4I4Z-CO(GU7TK)4JZ$_C72FKK5\YRI
MV?W9(WWA;V>Y3E&_6,AM[[^16U.?X2L_DZ_PA&S=?>B^T$'9G[BS2N'>#);I
M9D]:9)G:0L'C"M8O3,!,[.P22L<66RS#Y\G(6.AE;@3HLS$QS@Z)T#@]-8ZO
MB-.X?&8/%5 &*MCL11K8^E!&+<",=:K'%$+,WU!Y?S=W?EURU%6+B3C/4]7L
M\S4,RV_9[QK;Y**_]'1!1JATZ;J/,TO>DWU+&:'PS@:;6J\+&JH6VSE%;V3_
M )]DMYR_!RV7HD@B(M8,Z$1$ 7CA?,S.;IXZK-=R%NM1IUP>2Q;N3Q5JT$;>
M\YIYB"*,&_IB)F^NHENT+WU>SNC2L4<!<N;@YJ%B%ZVF8N<1%+Y<#8U#;:+'
M2-SRQ_!99,XB$HY@B/R6;T/AK/U*SRL#$ORIK;F\JMRA#?L[+.E=:^=DHKYF
M-U+6,7#AYF5D541]'9-1<OE&/VIOY13?R/0[W;NGM/\ :.TE+;QL-##[J8*G
MTZ5U--$X1W:\4WK,FF,\<3C)/B;[%8BJ3F\IX._9;(UXYHO7*5WU>Y*[6N7U
M_M=8T/K=KM7=/97(!MYKS'Y;ELQSC6GJ8/*WO$9I9CR%/'V*LM\V)K^1Q61G
M&:QR4QPK;\=[_O?KYYJ>%M4MO<)*W0-338%+F)(^7=WMZAO,=CK=GZ7?&5<2
M#![)#*_)OV7W5<.1TWK,]TH\A=NV;&=Q6@]WANV;-VQD--ZZF:+0&L;%B;QI
MY;FF];4K>(RL]B9H(-/9U[\DE>/%V/7+!ZCX;:MC<*Y%.KVTR6);5DZ95"3N
MMP[;)*NW'G;MR>3E\RJKIKE."S'3-22E/>-]+\4-*S-8IP<.4I6WQM4IO:$;
M/*@[=X0^VW&$)S<I*#Y(RW7;:WHB(JPDM!$1 $1$ 1$0!$1 $1$ 1$0&+O;-
M[/E?=#;;5&CY&!K=ZB5G#6";GU3.T':WB9V?AW$'M1!!8Z>"DJ3V(F=O$=U0
M=R.-L4[%BG;B."U4GFJVH)&XD@L5Y"BGA-OD..0" F^1V=ELA%3B[Y7LU-HG
M=.34E&#PL)N%'/FXF'^AQ9ZN\,>H(1\FX>Q--6RA-R7SW(R]+B+" @1&(B(
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MR$W/46-JO6QSNQ$#G5,XWZ39 9UHB( B(@"(B (B( B(@"(B (B( B(@"(B
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M>;Z:]:P7OZ6I95L?;,^ER]7BL1CQXKJ\N@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( J+7>;?'WN;]G*OX#Q*O2JBUWFWQ][F_9RK^ \2@,%$1$
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0'AU4_[P;,O:WGUR7+N,5O$519_+I:IIW#UR9N>>&*2*0_J.1.3,S$S*V
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M>@*,B(B (B( B(@+?W<8_$I8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1
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M;A8;&I,G\!X@R;VO@?"</;G'^E&UEY[%=Q?VO^2V-O8D%3]( B(@"(B (B(
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M3;RU*[GB[%75.(C)Q\Z>0?U#+A&+>UTUKL-"8R?EG+)"S.W#L@+$J(B (B(
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M>,V?GV"8?[W#^3J^GOAV/]L]QXW'66B\%F;'0X1Y0Z85<W7;EWXK9JGZOE(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MC'XE+'V[Z@_>F'4R2AM[C'XE+'V[Z@_>F'4R2 (B( B(@"(B (B( B(@"(B
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M^MT..!PM*C/)&W SW0B8[]EO)GXL73GF;JY)A-F=W=N7[J1$ 1$0!$1 $1$
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MMU/YL+.7[3-S^UY?*L"]O,]5JZOPV4O^=&MJG&9*][/B.].OF8+5OV'X8^8
ME]E_HOH7?S69H6?G4OG_ -5)_J%Q_G4=E6/Q&,?>Y]0\?5<O+_.[_P"=?;^X
MU:+#D\1<F7VK/_1O$36W-&&VN62Y7MTYG*._7JX1W70JSP!+;Z3/]7R=M_\
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MY<!HXCJTF?WE#/G;U4+U@'XZ3*KC\;)TD0Q2QD(RJQQ#"$8#'& A& L(  L
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M'6+,0B[M\\("9Q(1)K_^E]24LSC,=E\;.%K'96C4R5"S&_,=BE>KQVJLX/\
M*$T$H2"_RB3+7&*W%W(W:5;5.WEO0U^?JR^@9HH:HF7)SZ;R93RXTX^KAR&A
M9BN8^00<FKPQT6/H:Q"+@37(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MXG;G_E7-''A<5RWO<6R&0KN?'F,;&?+,+NU"-FX9FY=_KN_+O]=W^5W][O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MP.0 >2LUA'(,W+6_#FH6N3T=K#)Z?RN/SF%NSX[+8JW#>Q]ZL?1/5M0$QQR
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M+HO*AY-'X.ZY1E^#A39'Y]M\[I'@'J^8U/4LI8\'U<'/GGU^%=3Y7_M6Q?\
M93EVZ[->Z>M,?8R^"T=EH]/U:UF[9U%E8FP> AI5*YV;%ILEE'JP6:\<,9.\
ME/UD>INCEB9V:";<74TN8REW(2GU^-,30OSR(UXWZ*XB_#<MX;,[OPW)$1<-
MU*[OZ15VX(](: @V@P=Y@U)N'"-C/C"7YHQ^AX+3C8CD<7^<MJ2[6+%"QL_K
M6-@S40#Y%)'1>O\ RK=/#GBC/UG"EJ.7CU8E-]C6%1#GG-TU[QE=;;/93\RS
M>%?)56E&MSV:FFI"TO@#3]$N<,5RMOY%&ZZ:C%;MQER0C%-Q72,I;SFVVENM
MFGE;W;>EWS7:&V9QPCUO+N)I^PP\DW_-MGX4=^0<7]D:3E[^'Z7ZN1Y9;3I:
MW[N#=O?FA[4^@W<"*+3]+4^IYB'CYT..PT].O(7+/[+W\G2A?W.WC-P[/[]D
M"JV>TKF*6KX5*?\ ):?&37PE;D7_ /AKC_QL3)PW':F;^-C_ (1C_P"81$5<
MS8@B(@"(B (B( B(@"(B (B( B(@*KO?J]FQL/JG"[FX^NP4]6#'@\Z<8\!\
M/XRF[X^>5V'AI;^%J%"SN[]0X=_9Y9R.!%7[NV9V>8-T=M]3:.,8_7+M)[.&
MFD=A&MG*#^M8J;K?RC%[480S'[O5YIF=B%W%Z#-NG/7FFK689*UFO++7LUY@
M>.:O8@,HIX)HR]H)890.*4"\P,2%_-D!ZZ(B (B( LW^[O[2)[8;JZ;S<TIQ
MX3)V8].ZD%BX#X(R\\4!7)&=^''%6O5LF7#.;Q59HXFZY&980+P0L[.S^YV=
MG_6?WH#9'@;$S$+L0DS$)"[.Q,[<L[.WD[.WFSMY.R_I1J=U)VE2W&VDP[7[
M#3:ATF[Z8S?+N\DK41_Y(O'R[NY7<0]0IS?ABO17.@6C8%)6@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (BC\[S3M*MMCM-G,C5G\'.Y[C3.G>EV\4<ADX9O'MA\HMCL;%=
MN^)Y,,L4$;$,DL?(%7+O-.TFVYN[.=R%.QX^"T_SI?3Y 3%#)3Q<\[6KL/2[
M@09#)26[,<S.[S57J\OT!& 1_K^1'AF9O<S,S?K-Y+^D 1$0!$1 %.3W'79J
M^:'7.2W"R, GB]%5BJXMC'D9=292-P&86=G%VQF,>R;\^8V;M.8'8H7=0=0P
MG(81Q 4DDAC''&#<G)(9,  +?*1D["S?5=E?)[!G9R#:S:[36EC!ARGJY9;4
M$GZ*7.Y5VM7F)^!Y:FSPXR#EN6JT8!)R(7)P,PF7E$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 %@5WH'Q![F?8.'\*X]9ZK KO0/B#W,^P</X5QZ H
MR(B( B(@"(B M_=QC\2EC[=]0?O3#J9)0V]QC\2EC[=]0?O3#J9) $1$ 1$0
M!$1 $1$ 1$0!$1 5"._+W*++[P4<%'(Y5=)Z4Q]5XNIB ,GE[%K*7I1X^A>6
MB>&BD%^7YJL[_(S0S+)OMH;D_-=NQN#GPD\6"WJG*P4S9W<"HXV<L93./J]I
MHY:]..8&?AV:3S9GY9L9$ 1$0!$1 =N; ;>2:NUUHW2\8N7P_JC!8J5V;GPZ
MEO)5HKT[LS.[A6I//9DX9W:.(GX\EL*ZE2.O%%!"#1PPQA%%&/D,<48L  +?
M(PBS,WUF5.+N6-M/AW>VEDSCZX-)X/+9IR\N([-B(<-5)^?+S^$9N..7Y9G;
MCCEKDR (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B I6]\%M:V
MFM]-2688_#IZJIXG4U=F;@/&LTPQ^29G_1229/'6KDK>]GN#\G2HP590](!V
MX^<;=ZPCC?@;.6TQ;EXX%CG@#+XZ-W^4C&GE3%G]S1%Q[WXK7H B(@"(B RU
M[!VY?S([Q;>9UY'BBBU'4H6B;AOS)FPEP=H7Y=F9B@R)L[N_#,[N_NY5]M:W
M**Q+"0S02%%/$0RP2AY%%-&3'%(/_:"1A)G^JS>2V'>QVOX]5Z+TEJ>-A$=0
MZ;PF9Z =W&(LEC:ULX>7=R9X9)2B(2=R$@<2]IG0':2(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B *BUWFWQ][F_9RK^ \2KTJHM=YM\?>YOV<J_@/$H#!
M1$1 $1$ 4BO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B
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M(=FJ&<Q(R/QSX>0Q7-IX1;E_%M8NF[\.S1^;<UA-:T\QIBVV.U?I[*Z>ND1
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MNY.7#F%Y.-%M;3M]^7QV?V%_1Z[>CDT$1%#9G@B(@"(B (B( B(@"(B (B(
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M:G ?<-C,VQGR<H=7)^$5IX1,B((Q<G62J(H@S<^_)L=N1=;?;+[5EUD[9O\
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MFM-9G'UP?GA[5BA.%1WX9W]FUX1>3/[O<ZUYM:5CC V]Q@)-^L0L[(#]D1$
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MQ1P0011PP0Q ,<4,,0,$<48"S"$<8"(  LPB+,S,S,O91%S_ &R80B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( O3OT8;4$U:S#%8K6(
MI(+$$T8RPS0S \<L4L9L021R 1!(!,XF!.),[.Z]Q>'9 T4!>\7['LFSNYF8
MTU!!,VF,J/PUI&S(W(2X:X9,5)I&\GGPMQIL;(!\3^#%5M2#T6X3DQ#V[P=6
MRT\,YA'8K2.Y"3LSG$3^S(#>\FYY$N/,>1YXZF5Y?O.NQ3'O-M[/4QT<(:QT
MX<F8TI9-F9YIPCXNX64_)QK9BN+PL7N@NQTK+L00R1R41<_B[5*8S>.>G<IR
MR5;D,@'#8KS0R/#-%/$3"<<L,HE#/$;,0DS@;-TNRO\ ^$?'<=7TRMVR4LW#
M4,?+BW[T]H[59'X7QBW)_P"5A:DE'E*P^)7"EE,[*J9RHKO?FX]D5NH;/>=3
M7PCOR[=U&4);M]#OU@QE-OD-V_69N?\ /_X+V,#DKN8R5'":?Q\V1RV3L!3Q
MV.HQ/-;N6I7XC@KQC[1RGQY-[N.7?AFY6,,F7L2_1RO]?CR^I]1?K3LRQ21S
M122131&$L4T1E'+%+&3''+%(#B<<D9LQ@8$) 3,0NSLSJ3\K4VHR5<4I;/E<
MEO%2^ZW&+3DD]MTI1;71-=U#6-P14I*67;9?[R<ES;;KN]MTXI[=GR/;X,GO
MV:[EG>?5/A6=53X;0%"40/PK]N/-9I@/VO/'XB:2E"?0[.T<^4"8"=PGAB,7
M%I9MDNX[VBTV\-K4TN<U_D0X>1LU9CH83K]SO!AL4,!/&0^3Q9+(93A^2$A\
MF'%[NO.^#AS88[;O=O)!!G!\"EI[6MZ:,(,XY%X4&-S\A#''5RS?.HZV4DD>
M'+$3C;>"\+29"QRSJE7B/X@\64Y5F'F9#PH/?RUI\713=7V4ZLC>61*+7249
M7;Q;<)QC+H6GX&X*X<>/"_#QH7R6RF\K:RVN>W6-E72J,EWBXU[27O0DUU."
M;?;7:;TG1'&:8P6)T_CQX?U3$4*U"$R$>EI)1K1Q^-+QY/++UR%[R)W\USM>
M44%6W3LE*<Y2G.3WE.<G*4G\92;;;^;9+,(1BE&,5&*6RC%))+X)+HE^ 1%T
MGNWVD= Z#B\;6.L=.Z<9P*6.'*92I7N3QC]$5:@\CW;7'N=JU>5V^LOOC8MM
MTU7379;9+[-=<)3G+\(Q3D_R1\6W0KBY62C"*[RG)1BOQ;:2.[$4'>\??R[5
M81Y:^D<1J37=T'<0EK5X\#A'(??XF3RG-UQ?R<)*>&N@7+\D/'G%]NUWW&]6
MI6D@TM1P&A*LC.(S5:C9W+ SER)#;R\94!DZ?9)_@@A?WBP/YJ4="\$^(L[E
M?T+Z)7+;ZS-FJ-M_C3M/)_[$T/6/$_1<)/S,R%LH_<H7F?NGTJ_[0M[9'*5J
M<)V+=B"K7C;DY[,T<$(-YOR<LA" MPW/+DS*/O>7O6=B=$G+7N:YHYO(PNXE
MC-)QS:DLL;?11RV,:,N,JRCY=45V_6D;Y!?A^*=&X>O->:WE.QK766I-1D;D
M[QYC,6[%,>I^2"#'O*./K1<^Z"M5BA'EV",66/FN,G0PL/JU1XY<@8LS,(L\
M=4'_ .L/W>V[?T*/Z[&7L\,<RZ)[,]$-IZEJ-EG;>K#A&J._P\ZY62DOPIK>
MWJB+,OQ^^D7+&TK"\RR3V4[I.<8KUG-5\L81BNK;LE\$FVDYJN\&[]^UK'2^
M7T-MM@<KIF'-P24,KJC)7XH<P.,F;HM5,52Q_BM1EOP$4,E\\AZS6KG(,%<)
MY0L05A;HL(\,S,S#PS,W#,S-Y,S-Y,S?(S+FMZ1RZB)W(B=R(G?EW=WY=W=_
M-W=_-UPR_P"Y_P!93[PMPCI^C8[Q]/H5-<Y>99)RE.RV>R7-99-N3V2VC%;0
MCUY8K=[^F[5<G+G&S)L\R:7+TBH02[[0BNB6_P =Y/IS-G"+WR_KO_XK(OL+
M=ER[O+N[HC;^K$9TLKFJMK4<X,SM2TIC)H[NHK3N[.+2%C8IJ=/J$@+(6Z82
M#X9&XXZ7OE_7?_Q5T;T;[L0EI?1F7WDSM7IS&X 18_2P31\24='X^>4I+L+O
MYB6I,CQ.1>;'C\9C#B<1GF\3#^)G%T=%T?*RU)+(G'Z/AQ?>63<FH22]?)BI
MWR3Z-5./=I/:>'L)WWQAM[J?--_L1VW7YO:/Y[]DRR[B\;!2K5Z=6(8*M2"*
MM6@!N AKUXQBAB!O/@(XP$1;E_)F7OHBYO-[]7U;[LF$(B+X 1$0!$1 $1$
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MVMR\CK/5&H-69:0I,CJ++WLM9Y)R:%[<Y20U(N7=QKTJ[Q4ZL?+M%6KQ1,_
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MG49Q1<E\&W)I9</=L&+?T*KDI)*/47NDRE<6\G\@*R*(B (B( B(@+,_</\
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M$5JO7Y NJHOG8G+5;]6O>I6(+E.Y!%9J6JTH35[-><!DAG@FC(HY8I8R$XY
M)P,28A=V?E?10!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:" (B(
M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
M1$0!$1 $1$ 45W>@=W32WNTR-_"A4H;B8"$RP.1G?P8<I5;JDFT]DYA G&M9
M-WDI6B WH7>D_*M-; Y45X=9;0]<R=.RJ<S$L=5]$N:,N\6NTH3CVG7..\9Q
M?246T>//P:LFJ=%T>:N:V:]5\)1?I*+ZQ:[-&LGU1@<AA\A?Q.7I6,;EL7;F
MH9+&W(BKVZ5RN;A-#-"?#B0DWGQ[+L[&',1QF7$9I%>#[SONML9O-2/5.F/5
M\1N7BZ91U9Y&"'&ZIKP@[Q8C.DPN\<K?T/'95G\2FY>%.TM3AH:46Y.@<WI7
M,Y'3VHL5=P>:Q4[U\AB\A'X=FI*WR/YD$T$C>W6M0G)!9B<9899 )B>\_!/'
M6'KN-YM+5636E]+Q').=,GTYX=G91-_8L2]UODGRRVWK9Q1PE;IUSZ.=$VW7
M:EM%_LR](R77>._SC[O;@LLB^3-(OVFD7SV Y3:.,7,R?@1%N7=W^HW\N&_O
MK>DMC 5PZ=>WS[?-_@C+[L=]NW7VQV?^&-(9#Q,=:,/AS3%\CEP6<A9Q_/%=
MGYJW@$6&ME:?AW:X\QN<M62>M-:5R??R[3Y#;F//U\'E[VJ[GB4GT!?JQ\5L
MA%$!O8O9>0#Q\N <C%X<A5"Q<L,Q1-C(;4=F&M3NPVB1#B6YP<C>;0<\Q@_/
MZ-V^C+ZS/T<\\]?EQS0N&\F;CZC-[N&;AN%''%? 6DZKD57WT-7UR3G=1/R7
M?"/:NYQ6\UVVFG&V*2C"Q1Z&1Q/$'*P:YX^)9&<))I.Q>9"MOO*E/IOWZ/>M
MM[N$GU.UNT#O;D]Q-37=49>A@\;/:-V@QNG\/1P^-HUV(G"&..I#'+<EY(BF
MOY&6W>G,B8IQ@&&O#T9)[F_E]5>^?N7H2>YOY?56YXM,:X5UUQ4:ZXJ$(+M&
M$>BBE\-OWO=O=MLT^639=.5ELG.<Y<TI/NW)[M_!?@MDNR6QZ,OO_E]1?.D^
M7^7RKZ,OO_E]1?.D?W_R^596C_C^![J_3_CT/FS>[]K_ ,%]_0FW^;U7F\=I
MS3>,N9G.9BR%/'8VA$\UFS,9<>0M[,<,0\RV;,I1UZM<)+%F6*",Y!R?[(O8
M=U_O9FQQ>D,638VO.,>;U/>9X,#@H^CK)[5A^#MW2%P&OBZ V+TIRQ221UZ3
M3W8+L/8:[O/0VQ6&>O@8"RFI+\$09_5V1CB?*9(Q9B.O58!Z,9B FZBK8VL[
MLPM&=VQ>MB]HX]X^\5,+0X.J+CE:A*/U>+"72O==)Y4EOY45]I5_RMBVY5&$
MO,C(7"O"-^>U-IU8R?O727V_C&I/;G?HY?8CUW;DN5X==V)W0V&V@CJ:SUJ-
M//[ERP%X)1N5C#Z1"P+-)6Q(R,,=O*=#-':S<D R SS5L;X%:6Q)<FX9>45)
M>(>(\S5<J>7FW2NNGT6_2%<$VXU50[5UPW?+%>K<I-RE*3G_ $[3:<2J--$%
M"$?SE)^LIR[RD]NK?X+9))$1%@SW!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MLJPW)^5"QIV./H[''IWZJ"<N5;)RG)<QZ9_+^VO2/WKW3^7]M>D?O60K]/\
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MVL=>NUVEP&B(QU+DW,>8IKT4GAX*CY\LYRY#B\8NSB];'3@3B4D;O=.0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 42??94QDV'RDCN_-;4FEYAX]SD>
M3&L[%Y/Y=-@G;W>VP^?R/+8HN^^4C(NSUK)Q9W8,AHTC=FY81?6>!!G+ZC.9
M@+/_ $Q"WRH"EFB(@"(B (B("[SW2^3];[/>W4G49>'6U!4YD][>H:MS]'I;
MS?YV'J_1$WN:(09F9O)I%U&#W.,Y%V>M$B_NBNZQ /+W"6M-03.S_5]N4WY?
MY'9O<S*3Y $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %1:[S;X^]S?LY5_ >
M)5Z546N\V^/O<W[.5?P'B4!@HB(@"(B *17NE?IB]L_[?J[^#W5RCJ4BO=*_
M3%[9_P!OU=_![JY 7>T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$5'?1?$#J3[,Z
M2_&3'*F,KG/?1?$#J3[,Z2_&3'*F,@"(B (B( KM/='?$)HK^['X9O*DLKM/
M='?$)HK^['X9O("2=$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 ?A9K1SQR0S1A-#,!Q2Q2@,D<L<@N!QR1FSB8&+N)@3.)"
M[L[.S\*G1WIO=\2[5YY]5:8J2R;?ZBMRD 1MUAI?*S&\KXB;ANJ/&V>HSPTQ
M=0 ,<M"4P.*J]FX\N#[D[<875^!RNFM0T8<EALS3FHWZDS<C)#,/'5&;>W#8
MA+IFK68G&:M8CCGA,)8P)@-=.BS/[<O8VS6S&LI\);\6Y@,@\MS2V<<> R6-
MZA=X)W%NF/)XYY!KWX?)B)H[47->S'QA@@"(B (B( OO:6U/D,)D\?F<1<GQ
M^4Q5ROD,=>K&\<]2Y4E&:O/$;>XHY %^'Y$QY V*,B%_@H@+P?=V]NG';T:3
M$[1UJ>ML)''!J?#Q&S,3N[QU\U1B+@WQN286-V9G:C<>:B9FT<4T\AJUZ_9]
MW[U%MGJO&:OTQ9\#(X\W&6 W+U3)4)2![F+O@+\RT[@@+&WT44@0V(N)H(B&
M]'V7^TKIW=?1^/U?IR7YQ99X,ACY)(SN8;*P@!6\7>:-^&G@\0)(SX$;-66O
M;C%HYP0&0J(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B B>[ZKXA,Y]GM*?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$ 1$0!7AN
MZG^E^VX^Q^7_ !DS*H\J\-W4_P!+]MQ]C\O^,F90$A2(B (B( B(@"(B (B(
M B(@"<HL<>U)VEL'M7I2WJ7,EXLO/JN(Q<9L-K,9202>"G79_,09A>6W8=O#
MK5@DE/EV$#]FGX%V5?5C8]<K;[YQKJK@MY3G)[)+^UO916[;239X]0SZ<6BW
M)R+(U440E9;9-[1A"*W;?]B6[;V23;2.LNVYVSL1M'IXIOG&0U5DHI!T_@SD
M=O%)N0+)7FCYDBQE0W9Y29P.U(S5*YB9'+#36WFW'S6KLYDM1:BOS9++Y.=Y
M[5J9W^1NF.""/GHKU:T8C#6K1<100@( S,R[LWGW>SVNLUD=3ZCN%<R61D<W
M][5ZE87?U>A2B]T%*I&[1P1#YO[4LI23R2R'BWG?>_Z[_P#Y2O5P+X;T:!AK
MFY;=0O@GE9"ZI=GY%+>SC3!^O1VR7F3VVA"NA''/B;D<0Y[VYJ=.HFUB8SZ-
M]T\B]+=2OL3Z+K&F#\N&[=D[.K;_ ,GZ_P#YKX)_^7_BOO7_ )/U_P#S7P3_
M /+_ ,5FI?:E^)YL7LCTS^7]M>A,3"Q$3L(@+D9$["(B/FY$3\,+-[W=_)EW
MELCL1J3</4-+36E\;/DLG>)W&&%N&C@!Q:>W8F)O"JTZ[$/CW;!!7A<P%R*6
M2**2T_MKW&NU(;?6M+ZXK2:@U#E8X9;^I:%NWCY\3<B9R -/D)!TUH)'?K>_
M!,V0;@K-:./PZT.L\3<<Z?H_D_3)S<[7'EIIC&=WEM[2N<92@HUQZ[.4ESM.
M,%)QEM)'"/ ^9JF\JXJNB&_-=9NH-]U"'1N4WT]-HI[R?5)T<]7;INSE!C>E
MV;D7MDW/5]>N!?)SSQ(;>?O$?/E=#W;ARF4DAE)(3\F9DY$3_5=W=^?K?492
MO=XUW6&<V,RY/CM4Z?UGINU9**D5?)XZKJ['"1/X5?.Z9*UZTY WSM\EBQL4
MI7'Q)X<:\@UAC6I[5YFSQ\YC@9_EFDX=OE\QC:0OY?44F\/ZAB9F-7DX4U=3
M:MXV)23?Q4HS49PDO6,HQ:^&SW-V6!1IK=5G)3./VG.4>>6WKOOU3Z[<ON^B
M1U?-*ODSR_YUD[C>SQ/([/9MD_\ V8(NG]=F.1R=_K/T"NS,1V;\:+?/*TEA
MW^6:67_5C*,?VN';_,MAA6_@>#(XVTW'3YK^?;T@O_ZG$X;V4>VCK#:O4%3,
M:>SU[#6X7:)KM<R..2OQP]'+4CZJV5QAOQS7M13> ;#/#TRQQ21WB.[Z[X[2
MFZ08[3NLRH:4UM8""&I,,_3IS5%@V81/$697+U"Y8)V>/$W)Y",R\.E;N%[#
M4C-;]D@I:LEC!D\-J,7)J5@S."QT^;QQS&Y20S./E'UN<9$S 3QL;R!C)MQN
MM;TW:>G=&:2@,[A/6?EK%"8)'&22!G=G$XS9_%AZA9R!R#HDY=]!XZ\,]/UR
MI_2*_*RHQVJS*DE=#;[,9=E=6F^M4^FS?ERKF^8SO"W&%=ZLNTF]6JN2>3@S
M>R?-VDH]?+G))\MD'R3:VENXN)MNN453_NT>^5GP\&*TGN;DYLUI2< APNM3
M-[60PL9.PPULV;_/\CBHF<HFND\V2Q[",4HVJX\U+6>.R5>W7@MU)X;-6U#%
M8K6:\H35[%><&DAG@FC<HYHIHR&2.2,B P(2$G%V=45XSX(SM#R?(RX;PGS.
MC(ANZ;X1?5Q;ZQG'=>95+:<&UNG%QE*9M$UZC/K<ZFU./2VF?2RJ7PE'X;I[
M271[-=&FE[J(BT\S01$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 7RLYG:6,IV<ADK=:A0I0R6;EVY-'6JU:\0N4DT\\Q!
M%%%&+.1F9"(MYNZ^%K_<#"Z6P][/ZAR-7$X?&PO/<O7)&CAA!N&%OE(Y9#<8
MX88V.6:4@CB S(1>G/WB?>49[=^Y+@\,]O!;>U9>*^)<_#N9Z6(^0R.>*,N"
M!W8)*>*8B@J?T2=[%KI.#=>"^!\K6;FJTZ\:N25^3);PAZ\D%T\RUKM!/9+:
M4W&.S>D<:<=8NC4IV/S<JU/Z/C1>TY[=.>;_ ,75%]YM;M[Q@I2WVR:[Q'OB
M[^I"OZ,VFMV,7IQVL4\IK"/Q:V5S8OS$<6#?YW-BL88^(SWG8<E= P*%L=&!
M>LU^3][_ %_-W^J[^]W^J[^]W?SY7N2?^?\ I9>F?O5P>&^&\32Z%CXE:A'9
M.<WL[;IKISVSV7-+OLME&*Z0C&.R*I:UQ%EZG>\C+LYY/=0@NE=4?U*H;OEC
MT6[W<I=YRE+J>B?_ )?^*]$_<O>/_P O_%>B7N6TU^G_ !ZGEJ_L/3D^7]O_
M $,O0F]Z[9VKV?U+KG-U-.Z3PUW-YB\1#!4I1/([ +-XL\\GE'7JP#[<]F<H
MX(0\Y#'R9YS<CZ.WJ6_MM</YO*F-W.F ;=/'QP%+I:,&AZGP5[) #Y$;-B1W
M"7-4H9(*AB(Q4+T+%-/B-:XPTW2Y51SLNNB5THJ$6I3GRM[>9*%<92C5%[[V
M22AT:3W6QNG#_#.9GN3QZ92KAOS6OW:UT^RI/I*>W:$=WU6^RZE8'6NY%/%B
M48=-JXWN@ N!C?AN'GD;E@^3V!YD=OD'GE8<ZLU)<R=CQ[DKF3$[1@WLQ0C_
M $L4;.XBWU7\R+ANHBX;CO;M%; :RVQU1D='Z[P5[ 9_'DQ25KD;^%;KR-S#
MD<;<;FOD\=99^8;U.26$C:2"0H[,,\$>-MSWM_WE).G^5.N%M4XVPLBIUVPD
MI0G"23C*$H[IQDGNFFTUZDE:-HM>+O[K=JZ2G-;23[-)/["^*[^C;/GO_P"7
M^A2,]V_WENN.S=JWX9P!29G2N3, U9HBU<D@QF;@9A!KU0N)(\=J"E&WYBR8
M1.TH-ZE>":H0^#',_P#Y?Z%X34]+Q\W'MQ<NF%^/='DMJFFXRCW[IJ491:4H
M3BXSA)*4)*236R56RA)2BW&2>Z:]/^/7]QMK.RKVIM';R:)Q&O=#Y(<CA<K%
MP<9,P7<7?BX&[B<I6Y<JF1H2N\-B$O)^!EB*2"2*4LC%J^.Z^[RK5'9OUU'E
MZ)3Y/1&;GK0:YTGXA>#DJ0/X8Y;' [^'6U#BHB*2E98>+< GC+7,$L<E;9=[
M-[P:=U_I;!ZSTGDX,OIW46/AR6*R%=^0GKR\BXF/T45BO,,E:W6DXFJVH9J\
MPC+$8M0'Q2\-+N'\M.'-=IV1*3Q,A]7%]WCW-))75KJI)*-L%SQ2:G77O.FZ
MC&^/79617O1_\2^3_@^GP;[,1$46&3"(B (B( B(@"(B (B( B(@"(B (B(
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M8Z[?@>+4&M9&U-E&,>F6O5L1C'A,>_N=AKXT8[,@ORXW+UMF)P:/IE%7XUX
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MU1$0!$1 %9R]'W_YBW.^S.F_WADE6-5G+T?C_F+<W[,Z;_>&20%AY$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %&9WQ'TNFX']OT3_"%I
M129J,7OC; AV=]= _/,UO1<8<-Y=0Z[TS._5YMPW1"?FW/M<-QP_+ 4J41$
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M<>>\+O'7(GE/#UZ]60R;%Y&;*%52HMELE5<JH5UJB;^S9RKR9/WVZFW5O$^
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M_20]RS]\HMKY,(B+3#.!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M B(@"D5[I7Z8O;/^WZN_@]U<HZE(KW2OTQ>V?]OU=_![JY 7>T1$ 1$0!$1
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M9RED(M)Y.T8C'I_)VI'9\59GD(>C#Y&<Q>J9OTX^\9"Y#5M?F8"U:B(@"(B
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M=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B (B( B(@"(B
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M$[DZ_P =I73^9U+EYF@QF"QMS*792=AX@IPG,8L[^76?0T<;?HC(6^5 5O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M0G<=+Y:?I <M$Q/P&.LD(1Y>,'%HQZ<B E)!-'8B+3A ;(JO8CFC"6(PEBE
M9(Y(R$XY(S9B P,7<3 Q=B$A=Q)G9V=V\U^RK7=SOWB'AO0V?UM=]EWAIZ!R
ML[OY>3B&EK4K\LS>0M@C)V;WXOGJ]1 K** (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4_#E54T$ 1$0!$1
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MYV<W,>&KB-50XC-R]+%IW4\?P%E6D)OZ'7>T7P?DG9_)RQ5^\(NXB;@9,"D
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M=G;EG;S9V?W.WUG7E $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1%X=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M:PQV=>X>QT/@9#=G4TF<L=3')IS2\UJAAQ;_ .#8S<L=;+W6=_,SJ08AV9W
M7?I:4IRMH]B]'Z"QL>(T=IS$Z=H1B O%C:D<,D[@+#XERT[%;O6"X8I;-R>>
MQ-)U232G(1$^H<5^T5IF)S5:95/4;D]O-ZT8B?;?GE%VV[?"-<827V;38N'O
M '/S'&[6,KR8/KY,7SV?@XQ?EPW7ZTY279P164[/W<B[BZI:"_N)FH-"8V3@
MSQ5'P,SJ4XG]\9$$I8?&RDW/$ARY1X>1ZZAEU1AFSVK^SKM1V<MJ,I/I#3U-
M]::D'YF,1J7-.&5U)&>0@(,K?I7K4;OCY*^,&W(/P9'2".S+ 72X P*>=V51
M'OI>TRV<W FPM2P\F,T+4+$5X6)O"EU#><)\M8\OHBBZ:5(^7?PVH2]#"<LC
M/%O"G%^M\5:S35F9,H8%#>7D8N,G3C.NIQY*K%%N=\;+G7!QOLL]QSVVV9+&
MJ\*Z3P[IMCP\:"R;4L>J^W:RY2FFI3C)I*MPK4Y)U1@N91W]"#'=G/>L60HQ
M%S%3^CX?V7L./#\_)\Z#V&^HY2-]5=-R![U]RR9&1&3N1F3D1/[R(GY=_P!=
MW?EU\V0%;FI[=O0B;'DDDE_Q_P#O/BR!PK.'HVNTG7E]S-=RQ<^K4,1H^A-P
MW(O;G?-9>-G?S=C:G@WX%F9GC]KE^.*S4H?R_E\BO<=R/LJ>C^S]I>U:A:+(
MZRLY+6%ING@O5,G:*'!,YN(D328"IC;3B3<12VI8Q<A%I#B?QVUKZ-P]=4I;
M3SKZ,6*WZ\JD[['MWVY*'"3[?6)>J3D7@#%\W4(2V]VFNRU_#?95Q7X\T^9?
MS6_0EO1$5$B>@B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"JU^D
M#8$QU1H7(B+],^E\Y4<N&X\2M>AE$6?CS=QLN[L[OQPW''*M** ?O\]$/9TC
MH//"'/J>H\C@Y";GG_EC#V+L+/P_D+/A)FYX]YLW/+LSRAX-9:JXBP-^UGTB
MK\[,:Y1_?+E1IO']+GI63MWAY4_Z-U;?\-RGI&/^?W+WHP7YQ!Y-^LO>C!7G
MMF5CNL_X_P"/@2\=R/KJOBM\:F%OA#-C=:Z9S^F[-6V,<E2><(Z^<J>-#*Q1
MRD18>:G$!"3%Z\8</UNK"G:'[F[9S6[3V\5C)= YJ7K(+^DFAJ4/&(G/JLZ?
MD L5)$Y.S''5BH2O'R,,\!/UM37[/N[CZ$UYH_5XD0QZ<U%B\I9(&8B>C!:C
M^$! 7\B(J)V1$7\B)V9_)W6Q^J6HYXHYHC&2*:,)8C%V(3CD%C Q)G=G$A=G
M%V=V=O-G=N%5OQDSL_2M5Q-1P,F_$>3C>7*5,Y1C99C6/=60^Q8O+NJ7+9&4
M6EVV)E\-L;%S]/R,3+HJR(TW\ZC;%2<:[X+;E?VH/GKL>\6FGZE.K?ON<MY=
M#--<TV-3<;$0]1L>";U#.C$+.[E)@+DYE,;,W]!QE[(SF[B,,,A/PT9&1R5F
MA;EQF>QMS&9"%W&>AE*=C'WX'9^DAFJ6XH+$1,3.+M)&W!,XNW+<+8J<+H[>
MOLT:!W&HEC];:4P^H8'9F"2Y6Z+]9V]QTLI6*#)T)6;EFFI6Z\K"1"Q])DS_
M +\+^TEF4\M>JXL,N'1/(QN6G(2]92J?U%DO@H?1U\68?B?V?].RN:S!LEB6
M]XPGO.O?T2FOK8+XM^;\D4#K&G\=='F,@8N>68F;EB][<$WNX?W/Y.WO\EEG
ML1VX-YMJPAATUJZ[?PT!.(Z=U'))GL.$;]#^'3@MR/:Q<3<%P&,N58'.4Y"A
M>1^I3 ]H+N$<=+XU[:G5DN'GY(XM/ZMDL7L4_O<88<Y5@GRM,&)^EI+-/,2=
M#,)=1]4CPK[\=E?=C:IS/6ND;]3$Q%T_#M!ARVGG8N'$CRM-I(JW7U"P_"#5
M)'+B)@ZA\,9[TOC;AKB6I8[LQ;W9_P"Y9T(0NYFMMH57;J<UOTE1*>W=231#
M6;P;Q1PY-W8\KI50Z^;3.4X<JZ^].'6,>G56Q6_9K8G4[/G?U:4R;Q4-S=,7
MM'7>0C+,X8YL_@)7?ABFEKM!#E\:SN[N\(PY4 !N7NF7LJ:_:??#1VN\<&6T
M=J;"ZEQYLSO/B,A7N/"7ES%;AB-YZ=@.6:6M;BAL0E[,L8%Y+7YPY;'7A]L0
M;J;Z('9V_P!+MQ]7CA?8TQ\+:?R 9G2F;R6#RD3B\=_#7[..NCT/U SS598S
M,1)^6 W(.?-Q6A\4>SEIF3S6:9=9I]KZJJ3ED8S?P2G+SZ]WZ^;-1]*^R-OX
M>]H3)H<:M6QN==G:DJK/QWBO*ET].2#?K(V(_*\JH1L#WU^[.C_!I:XI4=Q,
M7$XB5N88,)J0(6\F%KM"JV.N$+,S"5O'#8DY(K%R8WZFG$[.7>U;-;B^!5'.
MGI#-RN /@]9#7Q$[S%RW35R(V;&&NBY"_A^!D/'<7#QJ\$AM$U<^*/"'7=*Y
MI6XCR*(_^\X>]]>WZTHJ*NK2]7;5"/S?0G[A[Q&TC4U'R,J$+)=J;FJY[_!-
MMUS?RA.3^1)FB_..1C82%V(2%B$A=B$F?AV<7;R=G9^6=O)V\V7Z*,C>0B(@
M/#NJUO?R][M2VNP-W:/0-NG>W)U'2*OG[@2A,.@\#?K'U6#C:*8"U+DX#"/%
M4I3KR8^I8?.2D[ACZU_DW?(]]_B=F:V0VXVVL5\UNQ;JS0W<A&T%O$[?#,#
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M=XL-N'%6PAL3LT4>?K'-)IZ5^2;I.Q+8MXH..IY)LC #@7 G'<90!$1 $1$
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MT>"I>YV>2?)]-SI+@2K8VWY]72)76$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MMG0.]&#^%]'949+=80',Z?NMZKG<'9(6ZH+U(^".'JY&#(57GQ]KA_ LF0R
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MSMT8UH[LH%[<=J_8B?D8QXE/7XUJT<,<<,,8111 $<448B$<<8"PA& "S"
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M?K M-:4EMXZM9KR<MX&5R'C/D<J)1^Q/%+-#0L<F[X\!<8PPTP^F*F.=I)7
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M?VOR5CJLX.<]0:=:0W<WP]\XX\G1C9W\XZ&3=K8<<NS960'Z8X8V5A! $1$
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MF/TYA<1I_%0#6QF$QM'$X^N#<##2Q]:.K6C;_NPQ SN_+N_+N[N[N@.5(B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB + KO0/B#W,^P</X5QZSU6!7>@?$'N9]@X?PKCT!1D1$0!$1 $1$!;^[C'X
ME+'V[Z@_>F'4R2AM[C'XE+'V[Z@_>F'4R2 (B( B(@"(B (B( B(@"(B (B(
M"!OOW=A7RVB<!N!3@Z[6DLDV-RD@CR8X3.F$,<I\>\*V7"C'QQ[+7CD=Q #=
M54UL1-Y=L*.M=*:ATGDA9Z6H,3=Q<Q$+'X7K4)!%8$7=N3K3>'/'P[.QQB[.
MS^:U\6MM'9#3N9R^G\M"5?)X/)WL1D(2]\=S'69*D[,[>1@\D1%'(/(21N,D
M;N!"[@<81$0!$1 %:][C'M&MG=#Y7;R]8ZLCHJRUO& ;MU2Z=S,\THM%R7)M
MC\HUJ*5F%F@BMT1ZG\41&J$LP^P;VCRVLW0TWJ>60AQ!V6P^HA;GA\%E#C@N
MS.+?1O0+P<D <.YE38!X(A)@+YJ+\:]B.:,)8C"6*4!DCDC(3CDC,6(# Q=Q
M,#%V(2%W$A=G9W9U^R (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"P6[QSM&_S,
MMIM2YJM/ZOFLG ^G=.D+LTHYC+PS0Q686=VYDQU4;63'R-F]39S @8F?.E5%
M.^T[2HZKW%JZ)Q]AI<3H"&6&WX9<Q2ZDR<<$N0ZG'V9#QU0*M'WD]>R5^#V)
M/'% 0L"/#,S>YF9O[W^?^^OZ1$ 1$0!$7\D3,SN_DS,[N_U&;WN@)QNXOV$;
M.[@Y?75N'KIZ)QSU\>9?0MG<]%8J,8^YG.MB1R O]$P>N1DXL3QDULQ1[=U_
MV>GVZV>TY1LP>!F-0"^J\VQ!T3-=S,-<J\$S<\M)3Q<./ID!,+@4!"0"?7S(
M2@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( J+7>;?'WN;]G*OX#Q
M*O2JBUWFWQ][F_9RK^ \2@,%$1$ 1$0!2*]TK],7MG_;]7?P>ZN4=2D5[I7Z
M8O;/^WZN_@]U<@+O:(B (B( B(@"(B (B( B(@"(B (B("*COHOB!U)]F=)?
MC)CE3&5SGOHOB!U)]F=)?C)CE3&0!$1 $1$ 5VGNCOB$T5_=C\,WE265VGNC
MOB$T5_=C\,WD!).B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/XDC$A(39B F<2
M$F9Q(7;AQ)G\G9VY9V?R=G=G51'O8>[Q_F<98]=Z/I,.A,Y:_-U&L!=&ELS9
MD=W@8&Y&/"Y&0NK'.+C'2L/)CO#BA]1\2WBN+ZUT7B]1XC(X'-TH,EB<M3GH
M9"C9!CALU; .$L9MY.SNS\@8N)QFPR1D)B),!KET6>?> ]B'*;+:N.D(SV](
M9F2>QI3,2>V4M<>DI<5>D86$<IC>MHY.69K=?PKL;-XDL4.!B (B( B(@"^G
MA<U<QMRID<?9GI7Z%F"Y2N5I'BL5;5:09H+$$H\$$L4H"8$WN)F7S$0%UONT
MNWM4WCTQZAEI(*^O=/5H@S],.F,<G69Q@AU!0AYY]7LD\87HA9QI7S\+RAGJ
MN<FJUX&R^\FH-O\ 4V*U;I>YZEF<1/XT!F+G6L1%[-BC>A$XWL4+L75!;@:2
M,CB)WCDBF&.4+SO9$[5FGMX-'4]58(VAF8FIYS$&?5:PF7CC [%&?D8WDCZ9
M!FIVA!HK=62.:/AW,  RB1$0!$1 $1$ 1$0!$1 $1$ 1$0$3W?5?$)G/L]I3
M\.55305R_OJOB$SGV>TI^'*JIH( B(@"(B *\-W4_P!+]MQ]C\O^,F95'E7A
MNZG^E^VX^Q^7_&3,H"0I$1 $1$ 1$0!$1 $1$ 1$0!$1 %_+CS[_ '?4_P W
M\F7](@(1NW7W.^ UR5S5&W/J.E=6RN5BWBB$H-.9^9W(I3*. 2^!LC-SSZU5
MA.G8E%FM5@.:6\%6G>38K/:3R]G3VL,+=P>:J._SJW$\921]72%FI.W,%ZE*
M[.\5BO)-7DX=F-C$A'8GKI??+L]:.W(PYX/66#J9FEQ)ZN<HE'=H2RBPE8QU
M^%PMT;'L@[R5Y0<GC#Q&-A85./ ?C7F:<H8NH*>=A1VC&7,OI5$>R4)R>UT(
MKHJ[6FELH6PC%0<=<3>'M&7S78SCCY#W;6WU-C_:BEO7)OO.":?5RA)O<UQ^
M4TU8I\D[>+"S_P!%!G=F;_MC[P?Z[\C\C$Z^2+>Y63^U/W)^J=/O8RFV5L]7
M8EG,WP5^6K5U+5BX<G:"8AJX[,"#-PXCZE</V1AJVI"=08:YVCM8N]8QN4Q]
MW!9>J739H7JLM6>,N7;Y]5G&.06=Q+ID!F ^.1<V\VM+H7%.GZK5YN!E5W;+
M>=>_+=5\K*9;60ZO9-QY9/[,I+J0;K&@Y6%-PR:95[]%+O7/^98MXRZ==D^9
M>J78ZWT_I$[HC)RY [^YO<SL_#L_'RM]?_Q7:=/3E.D+/,0L[?H6X=_V_J?R
M\EUG%7RV(<WB<O!/Z,H_GD)LS<=1"WM _'O=V!^/<3LN/9/4%F?ES/C_ +O/
M^;EW6ZT:A5""3BXR71I+HW\5^/S_ (]R,-4TG.R+G%Y$88_390W4]OA)=MUV
MWCONMFVNR[7S.OJ]42"!A#WM[/#D_P"W[_[RZ5SNNK5AR8"<6\_:?S?^][O[
M[O\ K+X%DG=W=_-_JKXLW_FO/=J<Y](^ZM_3O^_T_+]YG-(X8Q<?9J"G/UG/
MJW\^NY\FY.<C]1D1D_O<G=W_ /J^M[ES'05!_P T62;R?B /K^?7(_[7$;-_
M]]RN$6/=_?\ ]"[NT_CO5Z->/C@G!I#_ ._+P;_WN6']I8G-MVC\Y/;\N[_L
M7YF;U?(\NCE71V-1Z=/=75[?P7X,]@P7IFW]YU]20/K+TS%8V$MC7*Y_\?(^
M88?^RQ@W-S/K-XH0?F&H/A,WO9Y>>92_O\ WU&'GY799"ZMS+4*,T_EXG#A"
MS_+*3<!Y?*PO[3MY<LW'RK#RT3OU.[NY/R[N_F[N[^;O]5^>>7^59W3J]_??
MX+^U_EV_,WOA7$W<KY+I'W(?-O[3_)=-_F_@?#L-_+^^OBROQYM[+\^]G=O\
M[>:^W8]W\OKKG>W>VDN;F:29I H [LY@["<YL[?.XW=GX%O/KD;W<=(^T_(Y
MRM&^W9E=%<K;9*$(+=M_U+XM^B.H?ABY#YQ6K4;M[O#L3!^MQTFWU&_O,OJU
MMT]1U'^<9O("S>X9)WL W_Z.PTH?M=/G_>4EVE]BM-PU^NUB*4D;-YO/'XIG
MY>YR-W(G?ZO4L,.TOHG3V*L59,-&U*6R<K3T0D*2%HQ%G:Q&!N10^T[1N#$T
M9\LX@+@?/J\I)=4OW?\ T-7T'CW U+->%7BVR?O;6RKJG3O%.34O><H[I=-H
MR2Z;M>G$\3VH-45G9II*=X6XY\>J$<A?_?U7A%OVH_\ 0NX=/=L*L[B.4PT\
M3<MU38^P$S-]=H+'@%PWO?\ -#OQ[A=_?@H?O7CE?G+'@^\5^73_ .AO-_#^
M'9WHC%_&&]>WY1:7[TR7C2.]VF,PX!5RL$4Q^ZO<?U.9R?\ 0BT_0)ER_#-&
M9<O]#RLF-O\ <C4.EK89#36<RV!NB76UG$Y"S0,BXXY-Z\D8RLX^RXRL8N/L
MNSL_"K_XO%3WIXJM6%YYYBZ8XAXY)_-W\R=A$6;ER(B$19G<G9N765^E\%N=
MI>NUG'"=ZC"W7)0:8<E" ,WFSU#*.P(,S>;T29P9G+EFY=_#DZ7"R,H-1G&2
MVE79%2BU\))IIKY..QJ.JZ%CXTH.&=7CV2>]4<BV%4F^RY;$XM/?HO=ZOION
M6V>SGWV&ML$]>EN#CH=9XT7CCDR=*.MB=111,[L4I!#'#B<C*P.SC&<..*5X
MV:2TQF<RL'=G?M::#W1H/<TAG(+DT8==S$V6:IFL?YL+^N8V0O& &)V%K$7C
M5#)V\.P?++7*;:]JS#91XZF7#X&OD[1L<A$>/FEY87$;#LQ5G=_<-IA!N>CQ
MR)AZLT]':NR6$R%/,X/)6L9DJ9M/2R6.L'!9A)V\CAGA=GZ#%^"'EXI0)P,2
M G9X+XQ\$--S%*>+#]&Y3W:=,?[UL?PGCIJ,%Z<U#KVWW<)OH9?3N.-3TV:J
MS8RR*O\ .OZWE_6KOZ^9^$W/?MS0-A0SKRJW79*[ZJS3*##[OU_6:74$4>M,
M/1,K52)Q$>O/X:FTAW(P-G*3(86NU@8C%I,3*\,UV6PUH?7.&U+B:&=T_E*&
M:PV3KQVL?E,9:BN4;E>1N0E@L0$<9B_N=F+D"9P-A,79JH\4\%ZAH]OE9M#C
M&3:JOAO/'NVZ_5V;)<VW5UR4;(KK*"31,^B:_BZA5YN-9S;?;KELK*W\)PW>
MWR:WC+[LF<K1$6JF9"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(N$;B;DX#26)M9W4V7Q^#P],>JSD,E9CK5H^
M>>D>N1VZY3X=HX8V.60O9C G\E^E54[)1A",ISFU&$(1<I2DWLHQBDVVWT22
MW;['TLLC&+E)J,8IN4I-*,4NK;;Z))=6WT1S;E<6UEKG"Z=H2Y7/97'X;&P^
M4M[)W(*-42Z2)@\:P<8/(8@3QQ"[R2<.P"3^2KS=J+OTQ,K.(V@Q(RL[G$VK
MM1U)0CX\A:QB<!(\,Y._F<,N9\+H=A>?%2,Y1M!YN'NOJO7>3^%]7Y_)Z@R'
M+O'-D+!2QUF+ABCI518:M&)V$6>.K!")=(]3.[<J?.#_ &?-3S5&[49K3*'L
MU7*/F9DE\ZMXQIW[?6S\R+[TLA?B[QLT_ YJ\.#S[E]Y2\O&B_\ 2[2E;MW^
MKAR27:U%I?=_ODMK\"4E73<&6UM>!W%CQL0X[#,3.[.QY7(],IL[<.!T<=>
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M$OSW?4(B+0S(!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MW=+F;(72;@7ZKEZ6Q9?J;J;Q."=W9W?NQ $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MR[.SNQ,0DSNQ"0N)"[/PXD+\.),_DXOYL_+/[EX0!$1 %X=N?)>40%S'N?\
MM/OK_:ZMALE9\;4>A9 P-WK)GFM8E@Z\%D';ER+FFSXZ4W\RLX^60N&F#F5]
M48>[@[4;[4;HXC+V[/@:<S7_ -C^J1)W\$<9=D#P+YMSTB6)OC7N>*[.XU1N
MQ,X#8,FO-12B8B8$)@8L0&+L0D)-R)"[<LXDSL[.SNSL_+(#]$1$ 1$0!$1
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M!$1 $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:"
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MR(>T-&I;F=Q"(C'*14Z>^#[7_P#-!U^6D\18\32N@YYZ,1QD)09/49"T>6R
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M;7] ;B[$+D)"[$)"3B0D+\B0D+L0D+LSB0NSB[,[.SL@-D<BAG[J/O#FW*Q
M:(U=<9]>8*HWJURQ*WBZKQ%<!'U_DN"DR](68,J')G8#HR?412VAKS,( B(@
M"(B (B( B(@"(B B>[ZKXA,Y]GM*?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$
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MV?VM<%LSH?(:MS#C8M<^HZ?PS2,%C.9N>,RJT(/>0Q"P'8NV&%QJTX9IB\V
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MDW][]1_>^R]Y;;V8T1%5DWD(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M$$D4L9$$D9BXF!.),[.[+VT0%+OO.>[^GV@U$V9T_7EEV]U!8+X+EZCF+ Y
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M,DTTIG-/*1S32'(9$_".S[L%IO;/2N,T?I6FU3%XT'<C+H>WD+LO!6\GD9@
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M5VE;TN,SF%M1WL?=KEP<$X,XD!LW#25[$125[,$G,=FM+-!*)!(3/='C'A;
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M7*4;3 [^V 9/)C9EZ>!:6M4I6!<PDC=@)T:U>.&..*(!CBB 8XXP%A (P%A
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M'!93(X7+U):.4Q-VQC\A3F%QDK7*DI0SQ$SLW/28OTDWLF#B8\B3.@./HB(
MB(@"DL[L7MLR;0ZXCKY6<FT1JF6"CJ.-W)PQ]AN8\?GX@;R8J,AM%>X;F3&R
M3%[4E> 5&FB V1%2W%/%%/!($T,T82PS1$)Q2Q2"QQR1F+N)@8.Q 8NXD+L[
M.[/RO85?#N8>W@V6H1;0ZKNBV2Q%9OF)O69G<\CB8!+Q=/D4GOLX>(1/&BQD
M\V,ZJT81CC0\:P>@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B *KUWU7;@;,7WV@TU:ZL9BIZ]K6=J
M%_8N9: QL4L&)L_SR#%DT-R]Q[!9#U>!_GE"5FE6[S7MR0;/Z->MBIHCUSJ:
M*Q3T[6ZA(\="P]%O4-F/@F:&AUB-,)68;>0**-F.&&V\5*:W;FL2RV+$TMBQ
M/+)//8GD.:>>>8WDFFGED<I)9I9"*260R<S,B(G<G=T!ZZ(B (B( B([_P#N
M@,ENR)V;<CNQK[!Z,H/)#!;E>YFKT3#U8S 4RC?)WF<V(&E8)(ZM3K$@*]:J
M@0D)NSWVM*:5Q^#QF/PV)JQ4<9BZ=?'T*D+.T=>I4B&&"(.7=W8(P%NHG(S?
MDC(B=W>*SNANQP^W&A&U/FZ;P:OUQ#7O6XYH^+&*P8]4F)Q3\^U%+-'(V2OQ
M^P36)XJTPN=$7:7- $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 5%KO-OC[W-^SE7\!XE7I51:[S;X^]S?LY5_ >)0&"B(B (B( I%>Z5^
MF+VS_M^KOX/=7*.I2*]TK],7MG_;]7?P>ZN0%WM$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$!%1WT7Q ZD^S.DOQDQRIC*YSWT7Q ZD^S.DOQDQRIC( B(@"(B *[
M3W1WQ":*_NQ^&;RI+*[3W1WQ":*_NQ^&;R DG1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!8G]L?LE8#>+1UO3.8$:]V+KMZ?S(QL=C"Y<8R"&T
M'#B4E:7GP;]3K$;59R'D91BDBRP1 :[G>#://:#U+EM):FI^I9K"V?5[<3.1
MPR"0#+7MU)2"-YZ5RN<=FI/T#XL$@$XB74 ]:JZ;WFO8#K[PZ;'*X2.&#7^G
M:TCX6P3A$&8I,YS2Z?O2EPPQS&<DN.G,F&I=-^MVKV;+JF!D\99HV;-*[7FJ
M7*=B:K;J6(RBL5K->0H9Z\\1LQ1S0R@4<@$S.)B[.WD@/11$0!$1 $1$!(#W
M>O;ER>R^K1GG.Q<T9FI(X-48>-^MV!FZ(<S1C?Z')8[GJ<0<?7:?BU).3]6D
M@NV:1U=C<]B\?FL/=@R.*RE2"_C[U8VD@M5+,8RPS1FWZ$@)N6=F(7Y$V$Q(
M6UR2FQ[I?O#WT!E8=O-8WN-%9RX 8?(62,@TOF;<O0+')YM%A,G/( VR-F@Q
MMEQOG)!4*\; 6WT7\@;$S.SL[.S.SL[.SL_FSL[>]G;S9V\N%_2 (B( B(@"
M(B B>[ZKXA,Y]GM*?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$ 1$0!7ANZG^E^
MVX^Q^7_&3,JCRKPW=3_2_;<?8_+_ (R9E 2%(B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B J6]]O3]4WKQTK#TC?V^T_9Z_:Z3DCS>J:9MR3]/6
M$=6'J$/98"C)VZI"=XPL/D/=YO\ )]3^7R*9OO\ O2[P:CVVU (^S;P^>PT\
MG''M4;M&]3#JX\^6R%XF9W;IZ7=F?J+B"O#W_=Y_471CPBRU?PWI4UZ8[I?R
M=%ME#7R_D]U\FBA'B]H[AK6I;K[5_FI[=U=7"U?]_;\3M[(1-+$4C?1,+N_E
MY\LS_P";R;]OA?5[GQV#M*;6.Y,#>NZL%W=V%G<]OM7 (N_+,_6;B+#^B-Q9
MF=W9<:Q]YBC)G]S@3?YEZ'=F9@<=O]M39)^EBU9#2;EF?SRM*]B1;AR%O,KS
M"SL_(N[$(D3,#YKC2CFTG5H+O9I>H0_.6)<E_6?7P43KS)J7:&7ILEO\%=8_
MX;&P)1.5U=O/O)IS;_365U=JO(QXO!X>N\]NS(SF9$1#'!5K0@SR6KEN<HZ]
M2K")2SSR!& \OY<TJ*)VSA55"5EEDHPKKA%RG.<FHQC&*W<I2;222W;>R+[6
MVQA&4YR480BY2E)I1C&*W<I-]$DENV^B1U_VK.U#IK:'1N2UCJ:8GAJB\.-Q
ME<XVR&<RTD9E3Q./"4@ K%D@=RD,AAK0#+9L&,,)NJ/6^.]^J=X-99#6VK;#
MG9MEX6/H 9?!^"Q41/ZIBL;&["T=> .2FEZ1FNVCGNV2.Q.9+GG:_P"UCJ+?
MG6QZCRT94<'C3M4](X!C<H\/B9IA=Y+#]1!+E\B$%:;+6(^F,I(HZ\(M6K1.
M_4."TYE<QDL=I?2^-L9C/9:R%/'8VF(//<M&SN,8%(44,48BQ'+8L2PUZ\0G
M/8EBA S&^7A+X8TZ!B/-S?+_ $A;4Y7V3<5##IVYG1&;?*MDE+(MW47)<J;K
M@I2IOXJ^(]VK9,=+TWG=/.HQ4$W*V>_+YDHI<W=\M5??KNTI2:CRC:S:O/[@
MZGQ6A-&U&M9?+2.(D76-6E6B;JMY3(S )^KX^E%S)/*XNY.X00C)8GBB.Z]V
M-^R-IS9K1]736#C&>]-X=O46<./IN9[+O&PS7)_,GC@B;F"A3%_#IU1 &8I2
MFEEZI[O3L'8G9/2YPR'#D]9YP8;&J,Z+=0%* #X6(Q9%'')%AJ!=3PB8M+:L
MR37+'!21PUY"%7GQC\59:U>\+#G*.EX\^C6\7F6Q?\M-=&JH]J:VO\[/:4HQ
MJFSPI\,Z]$QE=?%3U"^.]DGLW3&75UQEUWF_\9-?*$6XQ;F1$4'$OCE0Q][M
MW@3[8Z=;0^D[O1N%JRF_1/ X'+IG 32'7L9@Q?GP[UUHK%/#,0NX3C/>X<:;
M!+GAVRNUA@=F]#9+5^;()IQ=J.!Q+&XV,YG9XY#I8V!A8B$7\*2Q<G87"K2@
ML6#X:/SHU:MUEG=<ZFR^LM57GR.:S5I[M^WTO'"). C'6JPD1^KTJ<0A4IUV
M,O"@AC#J,F<RGOP0\-/TKE+4,RO?3\2Q<D)1]W+R8[25?5;2IJZ2N3W4VXU;
M23LY8@\6O$&&D8<J:II9=\&ELUS4UOIS?%3GUC7\.LMTU#?C&G,2-2$K,[N1
M/R;D9.9R2/[1$9%R1$1/U&1.[N[\N[N[NID>Z4["3[D9\=S-6U!ET1IRZ8X2
MA8C=XM1ZCI2C\](2;HEQ&#E$O&;VQM94 JN[!2N1281=D+LK9C>[7-72N->:
MII_'/7NZMS,3-_R5A7E(7CA)V<'RF4>&:KC )B%I6FMF!UZDPO>$T!H+$Z6P
MF+T[@:4..P^&I08_'4H!88X*U<& !^J1EYG+(7)RRF<LCD9D3S#XZ>)BTW'>
MDX-FV;DU_P!\3@_>Q<::[;K[-UZZ0^]75O9T<ZI$1^"WA]//R'K>HPWJA/?&
MKFNEED7T?7O"I]9>DK-H[M0G$Y@B(J1ENPJW_?A]I["RW=+;4TH(+V8K6OFF
MS=UW8GP@'5GJ8JA%TO\ GS)C/8L61-F:"G%5?@RN"\,T?;![3F(VAT!G-;99
MPE*C$%;$8]W?Q<OG;K^#B\;"(NQDTUA_%M&#MZM0AMVY""&O(8T2[>HLMJG/
MYG5VHK1W,SG<C9S&4MF[^W:M2O*0QB_/AUX6Z*]2 7Z(*L4,$8C'&(M8CP!X
M#GFYDM6N4HXV"Y0H[I79<H;=UMO"B$U.:[.<JXO>/.B%_&3C:K3L+Z*FI79*
MBYKHW"A37I^M9)<L?@E)K9\K.IM]<>SQT+3,WLR2UB?_ +PM+&WU/^KD_P#=
M8X/']99A;JTVGPLI-Y^%+!8'Y?<3QD_Z_ARG[O\ 1RL3WB5PL6W:*7P;1%F!
M=O6OAOT^:?5?UGQ#@9V=G;EG;S_]V5Y7N+>U9+K_ &ABTSEK96=1;<V!P$\D
MI,\UK3\K%/IRT;O[9E7J-)ASD+J*1\6,\DA2SGQ1]>+]92O]RYVBCV^WSP56
MQ8:'":Z@ET=EA-V:+Q[9-9P-I^786FKYB""J$A._36R-P!%RE9VCKQAX;6J:
M'DJ,=\C#3S<=[>]O3%NV":ZOS*'9%1[2L5;:WBC>>#]8>-FU<SVKN:IL6_3W
MVE"7^S/E>[[1YMNY?01>&7E<^BP01$0!$7AW0'E%^-BQ'%&<LIC'%&)'))(0
MA'& ,Y&9F;L(@(LY$3NS,S.[NS,H]=]N]4V-V^EFIY36M7+9:%W$\/I:"?45
MT)&\WCGFQXGC*,C,[.T>0R-,B9V<&)EDM+T;+S;/*P\6_*L]8453M:7QER1?
M+%>LI;)>K/+E9M-$>>ZVNJ/ZUDXP3^2YFMW\EU)$$59W=#TB"L+RQ:)VXGL>
M1C%>U/EPJ S^?1*^/Q<-J24/<Y0O?K$_FS2M[UA%JGOU=^,D1>IGHO  [OT#
MBM-SSF _(Q'G,MF!,_<Y$T48D3<M&(^PI/T[P*XAO2E/'HQ4^WTG(@G^<:?.
MG'\)13^1JF5X@:;6]E99:UW\JJ6W[Y\B?XIM%S]%1@O][;V@K1$9:^FAZAZ.
MFKA\%7%N7=^H6#'<"3=7D3>?#"WR+@MOO'=^+0D,FZ6JF$V9G:&:E![GY]DH
M*0&/U^DFY;R?RY6PU>SIJS^WF:='\)Y,OQ_]V7]FYBY^)^$NU&4_]FI?_M2^
MRBU_5WMJ[QVS\27=/73&PL',>?M1-TL[NWL1],?5R[^UT\NW#._#,S>E_/@;
MR>\-UM=>?R'G[K_WW:1O]#+VQ]F_.VZZEA)^OU=[7[^7^Q'DGXJXR[8F0_\
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M8RUB_A&2S&%$(G*P4S]/@.#?/(Y1?S:0?-F9N>M^/"ZF,>J*77NHFR^8RN3
M2$;UVQ/$!-[;1&;M ),WEUM$P,3,_#%RS>2NH^O5>OH0[X2U:A1=G863&?D8
MZARRFFDK92:Y.OWN2,G+;TY&^Z+M'HX\Q0OEJG#L,NW.CIS8N6(9(2;V7'R;
MWW)&]INH.&%G\R5J=5<^X!Q_JFHM35/ZET)@ZWUOG%R"+ZK_ -)]5U:,7/CQ
MOV_](\Q[=Z\5_P#P]:_J2+#^'UG-IL)>CORFOP>18_[0B(HD-V"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MF\@))T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M7!?/E@HK=]V]MVVVV13J6M])WY-SZ)N=ELI2>WXO=OX)+\$CX99TF^AB%O\
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MW'V/R_XR9E4>5>&[J?Z7[;C['Y?\9,R@)"D1$ 1$0!$1 $1$ 1$0!$1 $1$
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M#5RH^'#GZ3.WL\G=XR@"SCTAD_! &C@9W BF1$0!$1 %X)N6=OJ_R\G;W/\
M7^1>40%X_NS.TG_-+VFT_?MV?6,]@8@TSJ(B/JGDR.*@BBBO3\^?B92B]6_(
M3\,4T\S W2+,T@*I[=RYVDFT=N<>E+]CPL/N%#7Q8,9<11:BI//+A)&9WZ0D
MN-/;QGEP\\UFI&3$\<3#<)0!$1 $1$ 6$'>']I)MKMJM29^O( 9NY V#TY&3
MOU%F<MS7BL"S>9!C:[V,K*W(,84GA:0))0=9OJH[WW?:3+4VX=/0M"QU8;0M
M;\V@!>Q8U/D@:6X9MSP_P=CWITX>68XYY\DS]0'&[ 0IF9$3F9$9D[D9F[D9
MF3]1&1/YD1$[D1/YN[NZ_E$0!$1 $1$ \_D9R?Y!%G(B?Y!$19W(G?R9F9W=
M_)O-7NN[Y[-C;6[6:=TY-!X.9M1/GM2<L/B/GLK'#):BE<69B.A!'5Q8OU&S
M148Q$R 1=5=>Z>[-G\T3=O%2W*WC8#1H!JG+E(+E <]2< PE GXZ7EM9-PM#
M&3BQU<==)G=XN@KL" (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B + KO0/B#W,^P</X5QZSU6!7>@
M?$'N9]@X?PKCT!1D1$0!$1 $1$!;^[C'XE+'V[Z@_>F'4R2AM[C'XE+'V[Z@
M_>F'4R2 (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( O4OT8;4$U:S#%8K
M6(I(+$$P#+#/!*!1RPRQ&Q!)%*!$$D9BXF!.),[.O;1 4K.\X[!MC:#57PGA
M:\LF@=1SR2X6?AS;#WB8Y;&GK1\>SX3,<^+D+E[%%GC<GFJ3.482V&V^6R>G
M]Q-+Y72.IJ8W,3EH/#D;R:>K8C=I*M^G*[.\%VE.(3UIA\QD!F)BC(P*B_VL
M>R[J#:+6-[2>>!Y0%RM87+!&05<WASE,*V0KL7+ ?L^%=K,9O3MA+ YR T<L
M@&-*(B (B( B(@)H^Z\[S*?;BY4T)KBZ4NW]V<QHY.P4LLND+4WF+B_MD6 G
MF_/4#-QC3D*Y!Q!ZQ$]N*A?@M00V:TT5BM9BCGKV()!EAG@F 9(IH90<@DBE
MC(3CD G Q)B%W9V=:WI3/=V?WH-S;:S5T5KJW;R&@;)Q08Z](1V;.CI"=Q9X
MA]J67 &Y,]BF'46.=GL4XWC>: @+>2+Y>$S=/)4ZN0Q]J"[1NP16J=RK*$]:
MS6G 9(9X)HW*.6*6,A,# G$A=G9U]1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 7CE>57?[SSO7&Q;Y';G:_(">4X.IJ+6%*83
MCQO4SC/BL%/$Y">19G\.YDHSZ<>75!6ZKC')5 ]SO4N]$CQ$63VQVXOC)F)H
MSI:IU/2F?C# ;N-C#8F>)V8LM)&SQ7KD9$&.BE."$OA'K.E6#_D[N_+N_P!=
M_EY?S=W\UY=W=W=W=W=W=W=W=R<GY)R=^7(G=W=W=W=W=W=^77A $1$ 1$0!
M$7+M Z"S&J,UC=/8"A/D\SE[4=+'TJX\R33ROY<O]#'#&+%+/.;M'!"$DTA"
M $[ =U]DGLNY[=W6F.TGA0DBAD)K.<R_A]=?!X>)V]9O3._L/*7E7HP/R]FY
M+%&S-&TTD=ZG9O:'!:#TSA])Z;J#2Q&%J1U:T;><LI,W,]NU)Y%/<N3.=FU.
M?M2SR&;\<LS8Y=A#L7X?9;1T6&KO!>U%DGBNZIS@1NQ9#(M$PC6K%(S3!B<<
MSE!CZY=#/U3W3ACM7;/.;: (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MZ%E\7(PC]1C+];RZ>?\ \;]I9VT/G>*-V?WB+?\ XK_RX6PZ?6DI/U_LV_\
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MRW1$5'B>@B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M2Q]N^H/WIAU,DH;>XQ^)2Q]N^H/WIAU,D@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( L->V_V.,)O/HZ? WW"GFJ+3W-,9OHZI,5E#B86:1F]N7'
M77CBAR5879YH0"0.+%> PS*1 :[+=?:K.Z(U%E=*ZEH28[-8>R5:Y6/@@?R8
MX;-:4?8LT[4)!/5LQ.\<T)B0OSRS=>*Z]WCO=\XW>; ->Q;5L=K["P&6%R9
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MCD=R#-VH96:K5DCBDP\764S/?GZ:$_C,@/*(B (B( B(@"(B (B( B(@"(B
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M5[>Q^YE[3@^(>F,N\V9T=;D<B\7"RV'$L=+*3,TMW"2F-"T_M$<7J=N3I]=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M+%7LZ=+R;AWKYJ<1+@2=G=F>0/1G;6V?U#$,V%W/T%D8RXZ7KZKPK]74XLW
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M;OWIHZU2K$ ,Y$<L\H1LW'DY=3\,W+7>^PAV2Z.SFWN+TO'X-C-6.K*:HR@
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M1'KXE\S,UC2[I;SCD^2HR?7=U0KIY7^W%*'-\=TWUW+^>.I!6KP5H_H*\,4
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MQCX9G/3SV2=@<.7MY"[9Y=G\W?B5O:_1<=3>3LL^53_C:[S-9U:?ZVI9K_\
MB;-BU/#5?)IV!']7#QE_V, H3._IY_F+XUF^77>!Y=WXX_,F5=OU^7X;]OS\
ME-FH3._J^)?&_;U@/WKE%E?"[_VAT?\ UVK^MGAXW_P1J/\ JMO_ '2JJ;/\
M$NWN?E_?\G ^?/U./KJ[[W:_Q#[6_:I1_P!>7S_;]ZI!RF[XCA_JNWUW\O+G
MZO''E_\ 5Q=\[M?XA]K?M3H_ZTJLI[3/^"]/_P!?_P#EKBN7LX_\MU3^8_\
M?0,X$1%2XML0S=^QAO6-BSM=/46.U?IFPWT7(M/9EI$7L^7##:\W-NGCGW%P
MJG0OUXIV]_'_ ).KC??(X3UWL^:U-AZO4)<!D/<;]+09['@Y>Q[N&E\W/D&;
MWM[E3BQ#]>,D;W\,S\?W_P#S_E\MY/9OOYM!OAW=>H9"_!2IQI)+\VW^93WV
MBJN74<*S;O51^]76QW_=LBZMW5&8]<[/^VQ>_P!6P\]%_+CSI9&[7^J_/'0S
M<MPS\>3-[E(4HGNY2RCV.S_IR,F=CI9K5E,VZ>EN!U!>GBZ?-^IO L1<EY<G
MU-QPW+RPJH_'E'E:WJ]?I'4\Y+\/I-FW\"TG"UWF:9I\_P!;"Q7^^F!\C4&'
MBR-"[CY_Z#>J6:<WES\ZM0G!)Y<MS[)OY<MS[N6]ZUV.GL7)C<CD\3./1-CK
M]_&3 [_02TK4U24'][>P<1#^U\JV,CJA+VPM(?,WOMNKBF#PXWUSFLK$/GTM
M#J&Q\T,;!S^@$,JP"S>R+#T#Y!PT[^S%G\N7JN+O_*48]Z7^ALG5)_\ Q$/X
M$,>T3I_F:9CW)?R=EL-_G.$9Q_W4B3?N$]8O3W(W#TVY/QF-)4,W&/+]#'IW
M,A1D=AYX8S'4T?4[-R81#R_3&*[(])L[20:>VET]MO7L,-_<34$5N[7&1AD/
M3^D)JF6F(X_)S@?.'@A?Y.L!Y\N5@[W3.JVPO:)TV)&X19S%:AP9LW_6//0]
M?@!_K/:QL!/]3I43'?I=K*+=/M$ZJEQ]I[."T-!#M[AN@V*N3X"W?FS=J)@9
MA([&H+V2B*<F>66"G5B<RAKP<;IJ7!GTKQ AE2B_)HPL?4[);='=3S8F-'?L
MI*VFNQ+UC3+\3W>%NK>;PO3!-<RMMQU\HRVNE^35C7^TB//2N\5R@T=:VY7*
M0.PBTC\V*\?/T,,CO[48>;C!([BWT,91LZR6Q&?JWX!L5)@FB+Y1XY$OE"0?
M>!M\HDS.W/+>3L[QUG8+]9?:TYJN]BI_'IS/&[\,<9-U12CS]#)&_D7U&)N#
M'WB3.I]MQ$^L>C_@S\]4X6KNWG7M7;W?3:$W^TDNC?ZR7QW3[J0DI5^3RKB&
MV&=M:J@NR8_&7YI<76>WDQJUIK4=6J '));,X0-PK11QR2S2RB(UX@DEE<8A
M*1ON>*SLSL_+/\OR.WU>?E7B4-FUTYEMNM^JW[;_  W]#0[<&=4Y0LCRRB]F
MGL_3?OV?1I[K=--'O/+_ "_ERO3G 3;S;ZS/_+W_ *WU/J+\7E_DR_(I?Y<^
M:_6$'W6Z?R/M"O;KV/OX35%[&2,=>9^EGYZ";JC?]<'?V?UQ=OUW7=6FM^;.
M/RN+SV/.7#Y["WJN2QN0JDYC#>IRC-!,S-T2 W6##)'R8G&Y@1=)N*QP>5?D
M\GRM_F7K:4HRA9%2A*+C*+2<91:V:::V::;33Z-/9GER-%QKK89$J_+R*VG"
M^INNU-/=-N+2EL]MN=2V]-F;&WL3]LS3&\>BL+J#%Y+%CG9<?!\T>G(<A7FR
M.#RT?SB[#/48AM#4DL@<F-M2UXAMTI()A$"(HQS*Y6K;PV?M8ZU#>H6[./O5
MRZJ]VE8FJ6X"_IH+58XYX2\F]J.07;C]921[-=[QO_HQH8:>O)\Y1BZ>,=JR
ME4U!7,0^A K<XQ9F.-OE&KEJ[E\KN[#Q4[B;V;KO-MMTK-I\J<Y3AC94;*W5
M%MM51O@KO,Y5[L7.%;Z+FDWO)S?IGB)!0A#*IL<HQC&5U?++G:23G*#Y.5ON
MU%M;]DET-@$JJG?:]C+YF,_#O'INHX8C4ER"CK.O6BXAH9\X^BGG#"-F&"#-
M!"U:],[,!9AH992*UE2*3UMJ_2.\K&,46M=MZ-MV86EN:7R\U-Y"_1&&.RL=
ML8F9^':-\E+U>;/(S^:S O=]7V;]R-.Y72FN*NK<%BL]CYL;DX,MIZ7(5BBL
MBX$]>SIJ?-6@D@)QF@LE3@."8 E!F(&=:QPEPEQ1PSJE.:M,R,BA/RLJO#E7
MD^?C3:YU&%,YSYH[*RO>":LA'FZ<R/VXER=)UK MQ+,FJ$I+FJE<G7Y5J3Y)
M-S2CL]W&6SZQD]NNS*R^1A'(U&EC=QFC9G8P)QD$A=B"0#!V(3$F9V(79Q=F
M(79V97#.ZA[:G\U?0(8K-VVEUUHJ*GBM1>*8^LY6KX918O4?2S#U/DHZ\D=\
M@%@')U[+\1QS0"].7)7</@L]E,3C-05-18:K=FBQ>=A">M%E<:[\U+9U[4-:
M>K8. @:U7EA!X+0S1CU (&7??9C[35S:'<+"ZZPM@+-.*4:FH<;#-&_PMIVW
M+%\)4NGEV]9CC$;= WX:._6KN3^$\HG9+Q2X*KXATEJJ/]^4Q^DX,I1<)\SB
MG*B:FE*"R()0E&2CR6JN4]O+:*U>&NO9'#FK2Q<B,_H5\G78TG*M+F>TXR6\
M7Y4O>BXM\U;E&._,MK]Z+JO1V]VDL]B<;F\7J'#V,=E:5;(4IOA&F+G7M1#+
M&Y \W5&;"3#)&7!QR,49LQ"[+[MG<O3D(]<V?PD0<LW7)E:$8<O[FZCL,W+_
M "-RN>\\.Z,G"55BE%N+BX234D]FFMMTT^C1=J-\&DU.+32::DMFGU33WZIK
ML<W6'7;B[(.'WGT)?TM?>*IE87?(:9S91,<V&S< OX$S.W!O2MCS3R=<"9IZ
M<INS-/'!)'V1J/M5[9X@'/):_P!'5!'GGQ=1XGEN.KGD0M$3<=)?)\CLL4]?
M][MV?L !]6OJV9F%N0KZ<QV5SA2OS]"%FC3/'@[-R[E8N0Q^7'7U.(OL/#^E
M:Q#)HR=.P\Z6119&RJRC&NGRSB^C]V#CR^DE+W7'=2WBVC&:IE8,J;*<N['5
M5D'"R%EL(J49+9KK)/?X;=4]FNNQ3BR6GLKIK,YC2>I:4N/S.$OV,7DZ5@2$
MX;58W!S#K$?%KS#T6*=D.8;=2:&S <D$T9EEUV"NV'>V+U\&1LG:L:(S[14-
M6XR'KE$(.L7JY^I6;GKR.(?K=F#@[5">W5=CE*J4/T^\U[7^VN\&I,1J71&G
M=0X?-TX),?F,ME@Q]6'/8Z-F*@\N/J6KT@VZ$GB!7MG8CDDI6'@LQ.4%0:\;
M-S/V+(B$I\QC]"(LS-^V_'47[;NS/SPS+H#1MK.C1IU;"G1/+H\O*Q)[;US3
MV<H23ER[3BKJ)?;A[G,E.+13A<.9&DZX\K2LJN6/"SF5F\MIQVWVY%'WGLW7
M8FXPFN;:336_;W>2=NW7G:KU+7KC5OZ'VDT_;F^ M/W)">_E[ 2''\T6;JAX
M<<^3E@X"C4=SHX6(YA@LW;$DUB3'C0VA,7I^KZMCJXQ]3,\]DN"LVB']'/+Q
MR_'GT@W$<;<L(MR_/:^V&VVH-9YRCIO2^*MYK.9 G:KCZ0,<K@) ,EB8R<8:
MM.!Y \>[9DBJP=8-+,#F'-F#L5]R)C,,534.[TU7.Y(/"LU](8^:0\'3E;ID
M <S<88BS,L;\--2A8,4YL44AY.L_5)K6K\3Z+PM@U8N\**ZH?WO@T^_D7;M[
MS<6^9N<MW.^Z48.6ZYM]HDLJ&IZY:^6+56_O2>\*(;?K2V?/)=-H1YFNC4(]
M61@]@+NTM2[P7*^:RK6M/;?03<VLS+"06\YX1<24-/1RL+2=3L\5C+.Q4Z;M
M(,;6K43UAN([8[88+1N"QVF]-8VOBL-BX!KU*=8.D1%OHY93\SGLSGS+9LS$
M<]B8SEF,C)W?F-#'5ZD$-6K!%6K5XPA@KP1A#!!#&+!'%#%&PA'& LP@ "PB
MS,S,S+W53GCSQ$S=>N4K?J<6MMX^)"3<*_3GLELG;<UT<VDDMU",$VG+_#7"
MV/IM;4/?NFOK;Y+:4OV8KKR5I]HIO?O)R>VQ$11^;.$1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 %7)[^'LV/+5TYNGC:[.=0FTSJ<HX^2>M.138*_*
M8^Z."SZUCY2/GDKM$1<6 NJQLNI=]MHL=KW1VH]'Y1OS'J#%6\>4G')59Y8W
M>I=B;R^?4K30VXN>1>2$6-B!R%P->2BY9KS1&2TSF\MIW,0^KY7"9"WB\A#Y
M\#:IS%#*X._OB-Q\2$O+KB(#X]I<30!$1 $1$!DSV.^T!8VPW(TMK*(S:IC[
MXU\U"!$PV\#D&>IEH)!;R/HK2/<KL3$(7:M6?H(HA97Z<7DX+M:O<JRA/5MP
M16:T\;L4<U>>,9890)O(@DC,3%V]XNSK6^JXGW,?:3^;/:V/3%ZP\V:V\D@P
MDG6[/+)@9QFDT[,_M<O'!6@GQ0%TB_3C!ZNH^J0P)=K5J."*2:8PBAAC.666
M0F"...,7,Y#(N!$ %G(B=V9A9W?R94+>W-VBYMT=SM3ZI8S?%O</%Z>B,G=H
ML!C))*V.-A]T9WA8\E. \]$UPX^N3H8WM!=[_P!I0M![47<5C['@Y_7$KZ=H
M$)<2U\<8M)GK@LSL3=..8Z,1L[/'9OPRMSX3L],9F9O)O)F]S?60!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M*..IQ5&C.'PVE>>/I<9S/VI)G(>6?J=WXX?@181;R9F;[>^>YM?!8R:;J%R
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M--B\"B6\7<]GESB^G1K>%&Z_5=DT]G&V.Q*NG\)2>T\^Y7/O]'I3KQE\IO\
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M:G,[,[^!:CBF9F?D&X797* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M=C\,WD!).B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M$]?6^E6ADY%B?H:UDJT[=+NX%XD$?M"71U!TF6Q,X7E;A1[1?$$%M*&G6O\
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M4D?1-%BGAZ-/TGY]KPXZ4AWQ9_=-D[#\-U*5Y $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M 1$0!$1 %@5WH'Q![F?8.'\*X]9ZK KO0/B#W,^P</X5QZ HR(B( B(@"(B
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M/4FDX9JV;&U@;///#MX>7KU.>'\G<2(?<[$XNSO1>7AV9_?YH#8YZ>U5B\O
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M_"N/0%&1$1 $1$ 1$0%O[N,?B4L?;OJ#]Z8=3)*&WN,?B4L?;OJ#]Z8=3)(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MB (B( B(@"(B (B( B(@"(B (B( B(@"(O#(#RB(@"(B (B( B(@"(B (B(
MB(@"+PO* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (O'*\H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MOT^]ERG">EP=D.V3#/;W,QC.Y,YWMOKT@BS-RSNV-N9 ^"?V1Z1)^?HF$?-
M6=44'^W'I'_8LU//'5J[X8G$V9./8U7IS6ND*X.3DS,62U+IO%XEWX'J)X[Y
MB#./6XN3,I/MH>UEM?N!7AM:'W$T5JV"P[#7DT[J;#Y9IW+Z%HFI7)BDZOT/
M0S]7R<H#()$1 $1$ 1$0!$1 $1$ 1%XY0'E$1 $1$ 1$0!$1 $1$ 1$0!$1
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MM*[0XZ7Q BN1?_9OJB.(G;H,<CF:%#"0V8V;EB;3LT/).)1R,S$]4B.,0%A
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M6TM<8MN=UN@ +1.>N5Y*N?D&+KFLZ+S(D$6:@$F-CQ]F&AG*[MR>.DK/#;F
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M 3"K1M3W].R122028N&3U2[1 VSZ+!_L!]X5MGVD]"5]>[9Y<[=-I IYS"9
M(JNHM*Y=X0GDP^H,='-8:K;&,QDAF@FLT+T+M8Q]RS#R:S@0!$1 %!#Z1IVM
M-Q-E>S7?UQM=J>QI'5<.MM&XJ+,5J&(R,H4,K?EKWJ_JN;Q^3H$TT?#=95"D
M!Q%XS'SYG>59?TM?Z4#)_=&V]_"TJ I.?EBCMK?V?,W]Y^V7\1UZE_TB_MKQ
M032#OYFW*.*0Q9]'[9<.X Y-SQHAGXY;SX=G^H[*&5?.S'YTM?L>?]R) ;WR
M G< =_-W$7=_JN[,OU7XU_Z''_W!_P!5E^R (B("F9Z4CWF6^VPFLMG\7M!N
M'>T11U+IG5]_.04\+I;*M?MXS*X*O2E(M18+,'"\,-VP'36*$3ZV>1B<1=JL
M_P"6*.VM_9\S?WG[9?Q'4UWIIGQA;!?:;K[\-Z85*Q 32_EBCMK?V?,W]Y^V
M7\1U9M]'?](:U'N1J:793M"ZC@R>KLY8GN[>:^NP8;"CFK'0#SZ'RM7%TL7B
MX\KP$EO3=JO6B+*AZUBYH_7X*)Y#7VKV:5V>K/!:J6+%2W5GAM5+=2:2M;J6
MZTHSUK=6S"035[5:>..:O8A,)89@"2,Q,1=@-[,SKRJUOH[O?30]H[1/S :]
MR CO7H+%U6S$T_@0_-[@(NFI#K&@$31 ^1"40@U11B@C"I=GK78!*ID0&O92
M0!$1 $1$ 1$0!$1 $1$ 1$0'2'::U%>P^VVX.6QEF2EDL7HC5F1QUR'I\6I>
MHX&_9J68NL3#Q(+$4<H=8$/4#=0NW++4P4._M[9$L$,A=H/6[%)%&;LU;2_#
M.8"3\<Z>=^.7\N7=_JNZVPO:^^*7='[G>MOQ:R:T@^'_ #I5_8\'[D* E^_)
MYNV/^J$UO_BVEOXNK8[]P)V@-9[H]DK:K76X.H+NJM7YJ;<(,MGLB-8;E]L3
MNCK;"8[QAIP5:S/6Q>-HTP\*"-O"KARSEU$^H;6V#]&)^D?V6_9&Z?\ #-N&
M@)[41$ 1$0!$1 $15R.]N](WVM[.4V0T3I6*+<S=RN'AS:<QMR./ :4G,.J-
M]99N(I/5;3,49C@<?%:RYQF)V@Q\!QSF!8%W W$T_I/#Y#46J<YA]-:?Q-<[
M>4SF?R5/$8C&U8F<I;-[)9":O3J01BSN<L\T8"WF[LJL';E]+CV3T$=O#;08
M/([SY^$BA^%8;9:8T'7/AF>;X?M4+V1S+ Y,<<6&PTU6T\<D,F6H.X3/1([;
M_>4;U=HK,EEMUM:W<U6CL%/C-+T!;$:-P;=;E#%B]/52]7(JPNP19#*29/,$
MS.4^2ED.0CP70$]7:R])2[6.Z;VJM370;78.R)!\$[80'@;PQ$?6POJV:2WJ
MB.4'YC"SBLEB)'B]F3K+DWA!U[K_ %!JNU)?U7J#/:IO2RE/+<U-FLIJ"U),
M?/7,5C+V[DSRGU%U2.?474[N[\NN)K^))1 7(R$1;S<B=A%F;WN[OPS(#^A9
MF9F9F9F\F9O)F;ZC-\B\KDV@M$YO5=UL9I3!YK5.2=A=L=IG$9'4%_@BZ1?U
M/$5KEAA(O9$GC9G+@6?EV99U:&[HSM2:D:,L/L!NC*$O2P/?TU/@GY-W%NN/
M/R8J6+S9^?%C!A;ARX9V= 1WIRI>:W<&=LB4>MM@-8 W+MTRWM+1GY<>?2^H
M'?CSX9WXYX?RX7P<YW%_; QT9RV>SYKQXP+I<JOP!>=W?EV<0IYN>4A=F^B8
M.&?@2X)V9P(I%^$M6(R$SC C!^0,A%R!V=G9P)VZA=G9G9Q=G9V9_D63VZ/8
MMWDT1!/:UAM+N7IJG6$CLY#+Z'U)6Q< 1B1R'+EO@XL6(1 )'*?KG3'&+F;L
M'M+%V"_!*_3'-%(7OX"0#?C]87=T!FIV>N\2WZVHLQ6=N]X=P],#%)XOP=#J
M;(Y/3TTG0\;%<TMG)<IIJ^X@_$;W<1.\7_5.#^:LH]D3TQ3=/3QT<=O-M[@=
MP<6+P0V]0:2M/I+5$,+$ 36VQ-J/(8#+V A9Y&I^M:>"Q.1/Z]6CZ0:G+RB
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M!]SS;[][91 85_D\W;'_ %0FM_\ %M+?Q=3\GF[8_P"J$UO_ (MI;^+JB21
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M(R>=RDT4NAIY8L=B*4^0NR10AIWKFD"M7E((@]J0F8!\W96;UB]VW_B6W?\
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M$0!$1 $1$ 1$0!$1 %I%^V!\;^[GW5=R/QTSBW="TB_; ^-_=S[JNY'XZ9Q
M8[JVMZ/_ -Q)L[VI]KM7:UW%S>X>,RV!UY9TS3ATAG,'C*!X^'!87)!)8ARF
MF,W-);>QD9Q*4+$4;Q#$+0B3&1U*5L>_0U_B W(^Z[>_%+2R YU^4[.RY^FS
M>_[[M(?\/D_*=G9<_39O?]]VD/\ A\K7:("J)^4[.RY^FS>_[[M(?\/D_*=G
M9<_39O?]]VD/^'RM=H@*HGY3L[+GZ;-[_ONTA_P^3\IV=ES]-F]_WW:0_P"'
MRM=H@*HGY3L[+GZ;-[_ONTA_P^3\IV=ES]-F]_WW:0_X?*UVB JB?E.OLN?I
MLWP^^[2'_#Y<*U1Z&CV>)XI?@?<O>[&62ZO">YEM Y6G%R#L+>KMM]C[<@L?
M29=61ZB%B!B'D2"W@B H ;\^A@:IIUII]LMZ\5F[ "YPXW7&FYL,\Y<^S ^6
MP5O(QP^7OL/BS\FY:N[\,]8+MJ]V'OKV>KCP[K;>Y; XP['J]'55(H,YH[)D
M\GAQ>J:BQ9V*<$EAW!X:.5;&91O&A":A#+(,:W/BX9N%MU@-6X3)Z;U3A<7J
M+3^9ISX_+83-4:V3Q>2I68RBGJW:-R.6O8@EC(A..6,A=G]R T82*S[Z0QW%
M$?9QR46Z.V%>U/LSJ;*M1N8GBQ:EVVSMSSIT);9E+)+I;+R]=?"V[9^)C;_A
M86::5K>,<JP2 M3^C6=]):V5UAC=D=PLG+)M+KK-15-/W[LY'%M[J[+2QUJI
M1G*?14TIG[I15\E"'16Q.3L#F.F.M8RDH[,AGY\V\V?W/\CM]9:(XQ8F<7Y9
MG_I7<7;ZXD+L0DWO8A=B%_-G9VY6V%]'*[P2YOWV<L&6H[WKVO-N;4F@]76)
M#ZK.1;&QA+IW-V&X9_'RNGI:!79.2&;)U[\H^&QM#$!/:B(@"(B *JQWZOI%
MF&V$'(;6[/S8G5&\QA'%E\A.SY#3FW$,_+F^4"O+&&2U6\#==+3_ *R XYYJ
MV0S;/!X..O\ Z>D6]^DVP>%DVBVMOQ2[R:IQLA9/+UYHC_F9Z>O5C"++&PN9
M#JO)M(!:<IRQ@-:L,^;G,6AQ\%[6=W;L]F>>U:GGMV[4\UJW;M326;5NU8D*
M:Q:M69B.:Q9L3&<T\\QG+-*922&1D[N!S+='='4FM]19G5^L<YDM3:IU#;._
MFL]F+)V\CD;1^3'-,?D$4(,,%2I ,5.C5CBJ4J]>K#%"'!$65/8V[%.Y6_NM
MJN@=K=.RY_.S1^M7IY".KA-/XUC8#R^H\LT4T.*QPF[1!)(!SV[!!5I5[%@O
M#8#%*640%R,A 6XY(G9F;EV9O-_+EW=F9OE=V9O-3H=@CT>#M)[\C3R\.F!V
MWT1::"8=8[@A/C/7*LS"0S8+3 ,VH,PW0_6TTU?%XTV9QCR12L\*NW=U1Z-U
ML_V?HL=JC6->CNONO"4=OYI<YCHST]INWT1NT6CM.VO'KU2J2L;P9_(C9SLA
MD\T,V.C<*<-C01869F9F9F9F9FX9F;R9F9O)F9O<S("J1V2/1%NSUHOU?([E
M9C5>[N9!@(Z>2M1Z:T=%(S];M%@<&T>1NCSS%(V9SV1JS1B)-1@-SZK#FPW8
MKVBVOABAV\VUT3H[P0>..Q@=.8NC=8";AP+(1U_7I =O+IDLFW'/EYNLG40!
M>%Y1 %XX_E_+^7^E>40'3^[G9\T)K^H]#7&C=+ZNJ>$<(PZCP6-S Q1R<]8P
M%?K3G7=^IW8H"C(2?J$F+S4"O:N]%<[*^X@6+6F<+F]HLX8?.;NW^0"+#M((
M\ UK2N9AR>$.!BY*5L=#B;DO/'KP"(,-DI$!J\^WAZ+%VA]J8[.9T#'6WLTK
M 9$9:8@'&ZSHUN3Z);6DKMN0LF(LT8ROIV]D[;'+U?!@U8IK,=:G*XJW0MVJ
M%^I;Q]^C.=6]0OUIZ5ZE:B?B6M<IV8XK-6Q&_E)#/%'(#^1"RWL2B([RGN4-
MCNTW0GL:LT]#@->!4DKXG<K35>"AJBF3\G!'DY(QC@U+CH)W\4<;G!M1Q==A
MJ4M([5B20#4#+]ZEJ6O/!9KS35K56>*U5M5Y9*]FK:KF,M>S5L0D$U>S!*(2
MP6(3"6&01DC,3%B:3CO/.Z4W6[*NI8<7KFF&7TIEK!0:5W%PU:R.FM0&PE(U
M";Q7E/":A"(2DFP5Z<Y9(XY9\;9R56*:>*,! 7KNXO\ 2;9RGPVSW:8S<1-,
M53%:.W=OD\3E*;A7K8?<.P1/",DIO''3U<XUZ[N_AY]HC'X4GO>P3A* 21F,
MD<@B<<@$Q@8&W4!@0NXD!"[.)"[L[.SMY+1)&#$SB3,0DSB0DS.+L[<.SL_D
M[.WD[/Y.RO#>C1=_!-C;6"[-F\V;DFQUN5L=M3K;,W3EEI6IC(JN@\]D+LY&
M56<R]5TA<D,W@,H-.FX0_!;,!?L1$0!1\=ZOV47WM[/.[.V]>*.7+YS1^6ET
MSXKB QZLQ5<LKIDGE-G: #S-.G!-.WM15Y9C'VF92#KPZ T2'1(+N$L4D$P$
M4<T$P%'-!-&[A+!-&3,4<T,@E'+&3,4<@D!,SL[(I=N_=[*1;.]JO=?3<%1Z
MF#SN6@U]ICI!PAFPFM(&RD[U^6Y>.GJ)M08HW]WCXZ9Q;PW!1$H"^WZ&;VLR
MLXG=C8_(3NYX:SC]R-+QD1._P=ER;"ZIJQAQX81TLI7PMYG9WDFEST_4S! "
MO*K4#=Q'VL6V<[5&U6HK=OU/ ZAS+;?:FD)P:$<3K4HL16L3E(8110T,\>&O
M6;$CNU>E7MR"S%P0[?E $1$ 1$0!$1 $1$ 48G?(]L,-B^S=NAKZ.<8<Q%@9
M,!I<'D*.6?5&IY P6%"!P..7Q*]JZUXSB=RKUZ<]LV:&O*0R=JAEZ9EVLVEL
M;3[&T+7/JYVMT=2UXY/H2\+(Z9TJ%F-N/(_'U)8@Y=V<H'+IY$#$"BI5KM%%
M'$/+M&  SO[W8!8>7X\N7XY=>PBR2['?9CS6]&Z>@]JM/SQT\IKG45/"!D)J
MY6H,32)I+67S4]49JQ6HL/B*U[)%4&S6*WZJU4;,!3#* &-J?R?]9<ZW0VXR
MVCM3ZCTAGH/5<WI7/9;3N7@;J< R&&OSX^T\1&($=>66!YJLK@/C5I(IA;ID
M9<%0&U*]%Z[6;[E]E'2>#O60L9[:>Y=VVR#-_1&Q.()K.CRD%@$ <-*6\51;
MI(_$>@4Y=#S>&%B9:T[T1'M<2Z-W_P!1;77K0QX'=C2DTU2&61Q"/6>CI&NX
MLZ[$?A#)D,!=U!5M" >/;.GBF<GCI,+;+% $1$ 1$0!$1 $1$ 5;+TJ3M9EM
MSV6,UI>A9:#.;O9G':!K,+NTK8$R?+ZOD#V" @GP>/FPLS$X$(9KQ8GZXV=K
M)JUI'I=G:T+6/:"P.V%&<CP^TNE:SWHQE=X9=7ZQ8,K?(@&0HC/'Z?CP-:*1
MQ::":YE*Y.+$[$!5&7Y3S#&!R%Y#&)&3MSY"+.3OY>?N;Y/-?JL\N[ [(Y;Z
M[_;7[8R0%/B<[J:I;U0+#(3#I#!O\,:E&3PB"2,+N-IRXH; DWJ\V0BG=B8'
M$@-G?W"/8V'9'LN[<:<LUA@U#J2B6X&K2Z &674&KP@OD$Y!_1"QF('$X. Y
M.)6IXJK'*S21DICU^<401B( (@ "P  ,PB "W2(B+,S"(LW#,S,S,W#,OT0!
M:5OO'OIC.T)]W?>/^$?4JW4BTK?>/?3&=H3[N^\?\(^I4!AFK4'H]7<D;2=J
M[1NY&H-R,SK[&7=(:NQN!QD>CLUA<76EIV\%7R<IW8\KIO.22V6L2D(20RUX
MVB81>(BY-ZKZV$WH6OQ8;X_=)P?XI4D!D?\ E.SLN?ILWO\ ONTA_P /D_*=
MG9<_39O?]]VD/^'RM=H@*HGY3L[+GZ;-[_ONTA_P^3\IV=ES]-F]_P!]VD/^
M'RM=H@*HGY3L[+GZ;-[_ +[M(?\ #Y/RG9V7/TV;W_?=I#_A\K7:("J)^4[.
MRY^FS>_[[M(?\/D_*=G9<_39O?\ ?=I#_A\K7:("J)^4[.RY^FS>_P"^[2'_
M  ^3\IV=ES]-F]_WW:0_X?*UVB JB?E.SLN?ILWO^^[2'_#Y/RG9V7/TV;W_
M 'W:0_X?*UVB JB?E.SLN?ILWO\ ONTA_P /D_*=G9<_39O?]]VD/^'RM=H@
M*L&E_1"^S%B<IB\M6U5O6=G$Y/'Y6L$^K-)' =G&7(;M<9@'0,9'"\T -*(2
M1F0.3#(!<$UI]$0!$1 4[/3.OB-VC^[&'XAZR6NB6Q=],Z^(W:/[L8?B'K):
MZ) =S]F_;NCJ_<70&DLI):BQFJ=;:5TYD9:,D<5V*AF\[1QMN2G+-#8ABM!!
M9D*O)+7GC"5A(X9!9P?8G?E.SLN?ILWO^^[2'_#Y:^WL-_';LW]U7;S\;<0M
MV:@*HGY3L[+GZ;-[_ONTA_P^3\IV=ES]-F]_WW:0_P"'RM=H@*HGY3L[+GZ;
M-[_ONTA_P^3\IV=ES]-F]_WW:0_X?*UVB JB?E.SLN?ILWO^^[2'_#Y/RG9V
M7/TV;W_?=I#_ (?*UVB JB?E.SLN?ILWO^^[2'_#Y/RG9V7/TV;W_?=I#_A\
MK7:("J)^4Z^RY^FS>_[[M(?\/UQC/^AK=F^<)'QNXF^>.F)A:/Q,]H&_5C=F
M9B<H9=N8K1]7'+MZ\#,_T+,/ JW$B H:;S>A:V(X9)=N]]RGG^>%'2UOI&(0
MX9G>*+X0P&0BY(O(2E?'"(/[31DS](UN.V_W)':3[/\ %8R>N-O[&1TK7]HM
M;:+LCJG3(1\\==\ZD<68PHCYN1YO#XZOTLY1V)1$B;<)+\+56*>.2&:,)H90
M*.6*4!DCDC-G$PDC-G$P(7<2$F=G9W9VX= :)0#8F8A=B$F9Q(79Q=G;EG9V
M\G9V\V=O)V]R_I7TO2#_ $<_#CA\YOQV>\%5PUG#ULEG-Q=M,15D&CEZ,;-<
MMZET90K=4.,R6.C&W8RNGJ54:>6K&]G&A3O4RK96A6!L3,0NQ"3,0D+L[.S^
M;.SMY.SMYL[>3MYH#.[NZ>\*U[V:-R\7N+H:W(<8G!2U9IF68AQ.LM-O-U6\
M-DH>IH_6(P*2QALCPUC%9)HYXI&@DMP6-OWV3NU!I+>?;O2FYNA[S7].:MQ4
M.2ID3=%FG,_,5_%9"%^"KY+$WH[&.R$#MQ';K2L!'&X2'I&%=8]#U[>5O%:O
MUIV><W?DDPVI:$VO-"PV)B(,;GL8\-;5>,J ;],<&:H3T,L->)Q$+N+R-AHS
MER$\@@;!A$1 %67]+7^E R?W1MO?PM*K-"K+^EK_ $H&3^Z-M[^%I4!J]U\[
M,?G2U^QY_P!R)?17SLQ^=+7['G_<B0&][K_T./\ [@_ZK+]E^-?^AQ_]P?\
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M;9F>"/$#-)U2WMO\]/;GPIP\@)$.!R,60P4T?7.]6H&'<CCCN5X([:: (B(
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M):[W4R7@3V\%B98-,XN>5H6SFKLBST]-8<2Z9"8+>4E@>W($<IUZ$=NUX9M
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M1 $1$ 7!-SMS=/:,T]F-5ZLS%#3^F]/T+&4S6:REB.I0QU"J#R3V;$\CL(B
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MV5LN4VK]/T:S&VD[]J<G.SJ?3]:&8\?++*4^:P40CTR7L5:GN70T 1$0!$1
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M=K7.TVI/$EOZ/S4E2K?.)X1S6"M1A>T]GH!X87ARV(L5+).#,$=I[-;@3KF
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M)W:4KV/!ADLX#,2@ !%J/ D?@V1<6')4/5<M [O/:@J7R/16OI-=$?;/K_\
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M_MP#\#T5/$L#^P-V)6V.T]FL"VIGU1\+YALMZV^&;"^K\4X*GJ_@-E<KXO\
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M-6"'X1TKJ6M&#WL7;!B+Q*\G4-S%7HR."_CIX)A,9FL002$H B(@"(B (B(
MH8O2&_I+NT!]I];\8L(IG5#%Z0W])=V@/M/K?C%A$!J+%X?W.O*\/[G0&YR[
MIWZ5CLT_< V;_@ZTXL_U@!W3OTK'9I^X!LW_  =:<6?Z (B( B(@"(B \.M6
MCZ4#V]I=WNT9?T7BK92Z+V7A/2>-".0"K9#5EH(;>L,PS1\B;P6'JZ=K$9&4
M0XB[)'X8WY0?8!=[SVYH.SOV?MPMR(YJX:BK8B;"Z'@L@4L5O6^=C/'::"2
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M]5JPW;,T76;POFJ4U#4$0NXB4&5B., C(1:7% $1$ 1$0!$1 $1$ 1$0!$1
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M4,OBK<-_&92G6R&/NUS:2O;I7(0L5;,)M]%%-#($@/Y<B3<LSH#[B(B (B(
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M- ;./T0OZ4J;[K&O?]7"*T:JN7HA?TI4WW6->_ZN$5HU $1$ 1$0!$1 $1$
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M;6Z8C%L5H_!U,9ZPT;1R9*^PO-E<O9'DG>UE<E):OSN9R%XEAQ>0^GE90(B
M(B( B(@"(B (B( B(@"(B (B("M[Z4KV/Z^Y?9<S^JZ],9M1;.W(=?XRP(.5
MF/#0]-'5]:-Q'EX)<%-+>LQF8P<XR"R;%-4KN.K16\FWFVXHZQT?JO2.4KC;
MQFJM-9W3>1JFPN%FCG,7:QENN;&Q!TS5[4D9,8D/!/U,[<LM2Q>]'][8U*>>
MG'L/J^_'4FEJQWX;NE1BNQUY"BCN1C+J1I1"R -.(R-UBQLQ<NSN@(>K$(R
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M\O>WD_N?S;Y?-?J@-JKZ+KOU3UKV0-#XZ*;Q,CMWEM1[?YB'@!>M-C,@^5Q
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MD+&[>\G#@0+FB(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MDJ]RO7N5)XK52U#%9JV:\@306*\\8RPSP2QN02PRQD,D<@$X&!,0NXNSKW4
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M,MD];S\OYNS-+J A$'\X@$8O+HX8"85$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 6H%[^_P"G'[0'VY5/Q8P"V_2U O?W_3C]H#[<JGXL8! 1$J\'
MZ%-_TC[2'V%VE_?VY*H^*\'Z%-_TC[2'V%VE_?VY* OVHB( N&[B_P#1[._8
M;*?O&=<R7#=Q?^CV=^PV4_>,Z T6&'_.E7]CP?N0KZ*^=A_SI5_8\'[D*^B@
M-J%Z*U])KHC[9]?_ (UY%6+E71]%:^DUT1]L^O\ \:\BK%R (B(#7P^DZ=Q\
M&D;F7[2NTN&&+2^2M-;W8TMBZO3%@,G<E=I=>XZM W3%B<G9DC^:F"*$8J%^
M0\^9#7M9.2"E;RMZUGL#2RE&YC,E4KW\=D*L]*]1MPA8JW*=J(H;%:S!*)1S
M03PF<4L4@D!@1"3.SNM5MW_?<O7>R_KIM3Z/J6+.R6N<A8/35GJ.P6C,U*16
M)]$Y.1PZXJ@ 7B:5NV9)"O4(Y:$L\E['F4X%>Y79O1@.^Y^9RWB^S/NSFY3P
MF2MO7VCU/E;3R1X2W, N&WMZU,[O#BK<P2R:3FGD*.I;G/3P'%5DPM:*DROT
MBE.,XY(SDBEBD":*:*0XIH9HC:2*:&6,ADBFBD$9(I8R&2*01D A,6)@-[8B
MJK>C=]]RV^FFHMG-S,FS[P:*Q,18[+6W",MQ=*TN*X9,3ZOGVIL)$U:'4D;A
M')?":OFH!G>7)^J6J4 1$0!$1 $1$!KT?32/C-V'^T76OX?P:I>JZ%Z:1\9N
MP_VBZU_#^#5+U 38^CD_3L["_977'\%6O%MOUJ0/1R?IV=A?LKKC^"K7BVWZ
M (B( M6AZ5U]./J#[GFWW[VRBVEZU:'I77TX^H/N>;??O;*("M\K7GH=_P!,
MYK'[C&?_ !OT4JH:M+>B-:UPV![2>K[N=R^+PM,]GL[7CM9;(5,;7DG+5FC3
M& )KDT,9S$$<AM$).;A&9L/2!.P&S:1=*?SRNW/Z?]%??5@O_7I_/*[<_I_T
M5]]6"_\ 7H#NM%TI_/*[<_I_T5]]6"_]>G\\KMS^G_17WU8+_P!>@.ZT72G\
M\KMS^G_17WU8+_UZ?SRNW/Z?]%??5@O_ %Z [K1=*?SRNW/Z?]%??5@O_7I_
M/*[<_I_T5]]6"_\ 7H#NM%TI_/*[<_I_T5]]6"_]>G\\KMS^G_17WU8+_P!>
M@.ZT72G\\KMS^G_17WU8+_UZ?SRNW/Z?]%??5@O_ %Z [K1=*?SRNW/Z?]%?
M?5@O_7I_/*[<_I_T5]]6"_\ 7H#NM%U_I'=C2VH)I:V!U+I_-V((O'G@Q&9Q
MV2FAA<VC::6*G9F..)S(0\0Q8',F'GEV9^P$ 7Y3P!+&<4H!)%(!1R1R"QA(
M!LXF!@3.) 0NXD),[$SNSL[.OU1 :A3OR.[DN=FS?S4FGZM2:/06L;-_6>W%
MQP/U?X"R5TY;VGAF?D9+.DLA8?%&#D4WP86'N3<%>\X>EN4N]#[M+1':CVSN
MZ#U8/J.4JG+D]&:JKQ#)D=*:B:$HX,A69^/'IV!XJY?'&319"B1Q$X3!!-%J
M;>W%V%-R.SQKN[M_N9A2QN3B\6;$9:NTDN U5B@-ACS&G<@0"%NJ;''ZU6?I
MNXR<_5;\$,O1X@&'SLSL[.W+/Y.S^;.S_([*QQW1?I'&Y?9NJ8[0VK:-K=#:
M2H4-:EA+&2:OJC1E#K$3CTCE+@S5[6.JQ.1T]+90ZU$79JE#*X:L3/%7(1 ;
MDKL1][EV?>T%7KCMQN-@[6?EK':GT3F+4.#UO2BB+HG.;3.1DAR,\%<G!IKN
M/CN40::N[V6:>+JDF6B3K320S0V8))8+-:8+%:S7DD@LUK$1,<5BM8B()J\\
M1LQQ30F$D9,Q 3.S*9'LM>D ]K/:5ZE;#;K7M4X2H(@VG-QJ5;66-EC'GIC+
M(W/5]5UV9W(G>EJ6H4A$[S/([#P!MVT5#?L^>FA2A'#!NOLF<D@@ 393;O/P
MF$A\MXL[874OJKP"[<N%8<U:=N/:LOSPIKMA?2C.Q[K=X(;NN<SM[?G/H:EN
M'I?)X>./Z%NJ?.8QLWI:$>2X;Q,\)%P1"+@+D@+#2+&;9_MH;1[@0P6-$;F:
M%U3':=AK-A-48>]-.[\<>%7AME.?5U"PN,;L3OPSNLF4 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!:1?M@?&_NY]U7<C\
M=,XMW0M(OVP/C?W<^ZKN1^.F<0&.ZV/GH:[?_J_[D/\ )_->O^?ZVDM*\_WE
MK@UV5HS>C6FFZTM/36L]7Z;ISS/9GIZ>U1G<'5FLN 1O8FKXN_4AEG>...-Y
MI *3PP .KI$68#>3(M(1_/6;K?V5=SO\H6L/]\I_/6;K?V5=SO\ *%K#_?*
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M*G]55_\ #Q?[2 \? U3^I:_^!C_V4^!JG]2U_P# Q_[*\_#%3^JJ_P#AXO\
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M?*Z?U-B,=GL)DZDL<U:_BLK4BO4;<$L1'')'/6GCD$@,A=G\G= <X1$0!$1
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M[?=:_C/E5U.@-DKZ&K]+1N-]W_4G\&>TRMMJI)Z&K]+1N-]W_4G\&>TRMMH
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MP-4_J6O_ (&/_97GX8J?U57_ ,/%_M)\,5/ZJK_X>+_:0'CX&J?U+7_P,?\
MLI\#5/ZEK_X&/_97GX8J?U57_P /%_M)\,5/ZJK_ .'B_P!I >/@:I_4M?\
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M=G;F/+$WEY^8EDW$F^JSL[/[G9V7:6CNY=[)>"D&6AV<]GRD NH"R>AL%G'
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M/&X'_P F"_WTMPLB T]/Y!=VP_U/&X'_ ,F"_P!])^07=L/]3QN!_P#)@O\
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MPNIL!?K97 ZBQ&-SN$RE*:.Q3R6(R].'(8V_4L0D<,]:Y3L0V()HC..6*0#
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MM3^=,VK_ +&>W_WF:<_W:L@40&/W\Z9M7_8SV_\ O,TY_NU/YTS:O^QGM_\
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MQQ&XXNO6D:1JD<A 0.+YV8_.EK]CS_N1+Z*^=F/SI:_8\_[D2 WP*(B (B(
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MV@/MRJ?BQ@$!$2KP?H4W_2/M(?87:7]_;DJCXKP?H4W_ $C[2'V%VE_?VY*
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M;!?:;K[\-Z85*Q 38>CH?3G[(?9/5'XCZE6W 6H_]'0^G/V0^R>J/Q'U*MN
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M<=D:L]'(XVY;QV1H60\.S1R%"Q+4O4[ /]!/5M0RP2CYLQQOP[MYK>P+6/\
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M5</N!IWUK*;=:ME$V^"LP<+C)B\H<,<LUC3>;88ZV7JC',<3A7R5./UZC6=
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MJ%OA^B0L3B;6=RM=G^A<X6SV(D)F\P:87=^#9FO&H B(@"(B (B( B(@"(B
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M6PF]"U^+#?'[I.#_ !2I+7LK83>A:_%AOC]TG!_BE20%TI$1 $1$ 1$0!$1
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M!2<*,>GLZ^4RDT0OE-4:BRF+EAR>H<P8ES/?OR-& 1^+X5.E#4QM1XZE.N
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MG5@$YK-NU.<<%:M"!S3S&$48$9,+@=X]ESLU:KWBW#TEMCHBGZ]J?6.5CQM
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M (B( B(@"(B JX>D;]R0&_NEY=V-M<7%_-GT;BQ";'UAAKEN'IFD12R82P?
MC+J#%P'//INU.3%.X_ <L\5:Q!)5UD<\$D4DD,T4L$T,DD$\$\9PSP3PF44T
M$\,HA+#/#*!Q30R ,D4H'&8B8NS;VM4&_2>^X]#%'F.TWM'A8X\?,=O)[SZ9
MQT9 U:>0@EEW%Q=.,'B:*4GL2:VCC*)VE>+4 12R2YF9@*.:LB>CS=]19[-V
MM0V_UW?<MD=<Y4"RDUF24PV^U%9!J\6JZ0,QM'B+YC6K:KKBP@$$<.;#Y[3M
MA<K=L_\ >7AVY\G]R N:^F:Y.O=W$V N4YX;52WM]J^S5M5Y FKV:\^;P4L$
M\$T;E'+#-$0212 1 8$)"[B[.J9:[[W5[36LM;Z6VYTAJ?)_"N)VJP^6T]HH
MYP(LAC\!EKU>^6'GME*3VJ6.EK108B,HP*A1$:8F<,<3#T(@)L?1R?IV=A?L
MKKC^"K7BVWZU('HY/T[.POV5UQ_!5KQ;;] $1$ 6K0]*Z^G'U!]SS;[][91;
M2]:M#TKKZ<?4'W/-OOWME$!6^5KST._Z9S6/W&,_^-^BE5#5KST._P"F<UC]
MQC/_ (WZ*0&RT1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %7$]*#[#=G=[LUY+4.
M"IR7-6;0Y$-?8RM!&<EF_A(8):&KL=!'&SG+-\!V)LK7A$2*>UB8*X,QSL36
M.UZ>0Q\%NO/5M0Q6:MF&6O9KSQC+!/!,!1S0S1&Q!)%+&1!)&8N)@3B3.SNR
M T3(&Q"Q"[$),SB0OR+L[<L[.WD[.WFS_*WN0Q8F<29B$F=B%VY9V?R=G9_>
MSMY.WU'=3-]^AW8=KLP;UY#"XZO(VV^N),GJC;2X[D<<&+*X)932AS.S=5O2
M5FY7J").\AX>UB+$A'++*;PS(#9">BU][C5W)T)7[/\ KO+!_-%V]HO'H^Q=
MG?UG6&@:<4?JP!),9'<S>E&ZZ%^,'*63#!C,@XD37I MU\K1C[:;F:AT9J'#
M:LTEFLAIW4VG<A!E,'G,5.];(8V_7=_#GKR,Q"3$!'#8KS!+6MU99ZEN&>K/
M-">RR[F3TD70F^M/$[?[KVL?H'>.*O2HQS7)J]'2>X5QV>#UK3-N69AQ^:M2
M1C-;TQ>\(QFM1QX.SE86E&J!:'1$0!$1 $1$ 1$0!$1 %3V]+:[QS':2VNK]
MGG 9$#UAN<6-R6K(:E@PLX/;_%Y2.^PVWA<2B^:S+8L,2%:20?7</!FXI89J
MDAL4D'?!]_3MKV7L58P6/DJ:[W@NQE%BM"8R]7<,$4M>26#,ZXM1R$6$Q,;M
M%X=( FS>3.: :=$:96<E2U;7: W_ -7[IZSU!N!KW-6,_JS4]TKV6R4[, N7
M#1P4Z5</G5'&T*XQU<?1@9H:M:,(QZCZY# Z=7\22" D9/P("Y$_U!%N7?\
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MWXI:66N$6Q[]#7^(#<C[KM[\4M+("WJB(@"(B (B( B(@"(B (B( B(@"(B
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M,3F)*[-7''Y.]&T]X"HLLS>QMWA>\W9_R,M_:37F7TI%:L!;R.$#P<AIC+V
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M,[,(LP&\X7P\SJ;&XX>O(9"C0#AGZKEN"J/#]7#]4\@-P_0?#\^?07]*_&D
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ML,3-&#%6*$V !%@8NCI#IZ6P@S'YTM?L>?\ <B0&^!1$0!$1 $1$ 1$0!$1
M$1$!C=VR?B@W5^YOKG\6,HM(?A_SI5_8\'[D*W>';)^*#=7[F^N?Q8RBTA^'
M_.E7]CP?N0H#Z*M;]VWZ4%=[/&RVB]GH=F*^JX]'QYN,<^>N3PY7_AG4>7U
M[OCFTQD6KO7?+/5X:Y+XC0-+['B= U2$0%YO\NJY']3M5_RER?Q+3\NJY']3
MM5_RER?Q+5&1$!>;_+JN1_4[5?\ *7)_$M/RZKD?U.U7_*7)_$M49$0%YO\
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MD\K%TSX31E2UTR6-/Z1:6&.8C?@(,OJ"9AM98HNBM#0Q_%4K&2(@"(B (B(
MM7)Z65].%DON9: _=-0+:-K5R>EE?3A9+[F6@/W34" K5*U9Z'U]-#J;[CNH
M_P 9]'JJFK5GH?7TT.ION.ZC_&?1Z V8B(B (B( B(@"(B (B( B(@"JL^DA
M]R'_ #=]-EO#MECN=XM%8J0,AB*K5XFW&TK49ISQDO7&QRZGP<<<TVF)6L1-
M;BFNX6P-@[&+DH6IEXX0&B3DC,#..0#BDB,XI8I0.*6&6(WCEAFBD$9(IHI!
M*.6*01DCD$@,1,79OX5WGTGSN0AP<^6[36TN&D?%W;$=C=S2F*J%(&.M3.,!
M;@XRI7%WAI3%X(:NKPQ>#7D?YHR\&-\S,](5G9V9V\V?S0'E>']SKRO#^YT!
MN<NZ=^E8[-/W -F_X.M.+/\ 6 '=._2L=FG[@&S?\'6G%G^@,8^V=VHL%LKM
M7KK=/4DC#BM%:>O9@XNERDOW0%H,3BJX,0==K+Y:>EC*HN<8O8MQ]<L0=4@:
M6_=[=7-:[U;JC7&HY_6=0:QU#E]3YJ?J<V/)9J]-?LB!%[3PPG-ZO79_H*\4
M0>3"S-=Q],2[?+<:*[-V"M\O,-7<7<+P96<6KQ3V*VC,%8%A?VY[E>]J&Q&\
M@20A1PLA1R0WA)J)2 *^=Z'5V#Y*]+7?:+SM)A?*.6WVWYR@WB/CZ,PVM8YB
M%W;J:"YDQQV$@=G'J/"Y%R$HRK2*CMM!M)G]?:LTUH?2M1[NI-7YO':>PE;I
MD(3R&3L!6BDF\())1JU6,K=R0(S>&G!/-TDT;LMTMV.NS%@MF-KM"[7:<%O@
MK1.F\7@H[#QC'+D;52L W\M:$.6];RMY[&0M.SNWCV38>!860&2J(B (B( B
M(@"(B (B( B(@"(B +6V^ES]AD=#[QZ<WFPU HL%N[0DH:AGACXJP:[TO4J0
M,4SMRT5G/:<]6L1]3BUH\'D91!Y([$DFR245??2=A<>T)V==P-"5*D-G5-;&
MR:HT(4H@Q1ZRT[%+?P]>.<N"K?"SA-A)YA,1&MDIO&:2#Q(9 -/&N4Z&UQEM
M,9S"ZFP-LJ.<TYE\9GL-=!R9ZN5P]V'(4)_8(2<8[5>)Y!$A<X^H.6ZEQ@XY
M (HYH9:\\1G%/7G HIZ\\1/'-7GB-F.*>"43BFB-F..4" V8A=F_E ;J#N\>
MV%B-^]F-O]UL1TQCJK 5I\K19^3Q.HZ;EC]28>5ND'YQN;JWJT4C@ V:P07(
M6>O8B(LT%K]?0]>WS)B]3:T[.N?NM\&Z@JRZ]T ,\ILU;-T'AJZNPU<"<HG'
M*T9<?FZT<?@N$^-S$A^LG=#P-@4@"(B (B( B(@"(B *OYZ4/]))NS]D]K_X
M6-$JP&J_GI0_TDF[/V3VO_A8T2@-4DOFYG\Z6OV/-^YDOI+YN9_.EK]CS?N9
M(#>-=F_XN]!?:7I;\!T5W0NE^S?\7>@OM+TM^ Z*[H0!$1 $1$ 1$0$=G>L]
MA/']H[8G7.UMEP@RF3HQY3262(8G+$ZQP<C9'3UUGE=@:"2["V/R(N<3SXF]
M?K--!XWC!IO-2Z:R.$R>3PF8IRX[,87)7\-E\?.SC-0RN*MS8_(T9F=FXEJ7
M:\]>3R^BC?CRX6]66M>]+/[O*/;G=S$;V:=QW@:7WB*Q7U(]6N\=/'[C8BK"
M<LDY!S%'9U=A@/)APT;V[V$SEN03LR333 5,$1$!YZ3=V&.,YI#<0BAB%SEF
ME-V&.&(&\SEE-QCC!O,S)A;S=EMV.XC[N<>S9V?]/::RE< UWJJ0M:;A3LS=
M0ZART$ P8<"<1D]6T[B8*&'C$O([5:[=8(CNR1C1;]&6[N<M[=_J>L<[CGL[
M?[,G0U9EBL1-)0R>KRF<]&X&039X[#Q6:]C45J#@ACCQ--K/$=V&.QM.T 1$
M0!$1 $1$ 1$0&CGW^^,#<#[?=:_C/E5U.NV-_OC W ^WW6OXSY5=3H#9*^AJ
M_2T;C?=_U)_!GM,K;:J2>AJ_2T;C?=_U)_!GM,K;: (B(#%_MO?$MN]]R_7_
M .*F66D>P_YTJ_L>#]R%;N'MO?$MN]]R_7_XJ99:1[#_ )TJ_L>#]R% ?15K
MONW_ $H:[V>ME=$;/1;+U]5QZ,AS<(Y\]<GB#R'PSJ7,ZB<GQS:8R#5O5WR[
MU.&N3>(T'C>QXGAA5$1 7F_RZKD?U.U7_*7)_$M/RZKD?U.U7_*7)_$M49$0
M%YO\NJY']3M5_P I<G\2T_+JN1_4[5?\I<G\2U1D1 7F_P NJY']3M5_RER?
MQ+3\NJY']3M5_P I<G\2U1D1 7F_RZKD?U.U7_*7)_$M/RZKD?U.U7_*7)_$
MM49$0%YO\NJY']3M5_RER?Q+3\NJY']3M5_RER?Q+5&1$!>;_+JN1_4[5?\
M*7)_$M/RZKD?U.U7_*7)_$M49$0%YO\ +JN1_4[5?\I<G\2T_+JN1_4[5?\
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MJ[4<1='E[/,>3%^GR;V?=Y-Y>2]RUOMKR<'BGU[KJ:,N'>.76>II =Q=G%W
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M_P"N>R_W[ZF_B GY4,[6?]<]E_OWU-_$!;.9$!K&?RH9VL_ZY[+_ '[ZF_B
MGY4,[6?]<]E_OWU-_$!;.9$!K&?RH9VL_P"N>R_W[ZF_B GY4,[6?]<]E_OW
MU-_$!;.9$!K&?RH9VL_ZY[+_ '[ZF_B K\/=6=F#4FR_9\VNVOU?+BIM2:-T
MY'B,K+A+4]W%G9CLV9>JG:LTZ$\T3A*#]4M2 F+D>GRY>05$ 1$0$!WI!/=;
M[A]JS;;0VD-N,MHO$973.OAU5>FUMD\YB\?-CVTUGL*\-2;!:;U-9.YZQE8)
M&CFIP0>#'*_K#2, '4Y_*<_:G_3GL!]^.XO_  D6RW1 :[#LW^B5=IC2&XN@
M-6Y35^Q<V,TKK;2NI,C#0U9K^:_-0P>=HY.Y%2AL;65*\MN2O5D"M'/:K0G,
MX#)8A BE'8GHB (B( B(@"(B (B( B(@"(B *-KO:NP-%VE=B=8[5QV:./SF
M0"EE](Y;)/.%'%:LP=D+V&M73K5KEF.A-($N.R1UJMBPV-O7&@A.5Q922H@-
M:1^4Y^U/^G/8#[\=Q?\ A(GY3G[4_P"G/L__ 'X[B_\ "1;+=$!%'W,O9:WC
MV2V.P&U&\N4T3G,EHJS<QFE<QHG-9[+P3:/.5[>*QV4?/Z6TO/7NX,IY\35]
M6AN0S8FMCRDE"R$S'*XB( H>N_*[O[6O:8V'N;7Z!R.E\5J&QJO2V=CMZOO9
M;'89JF#N26;,1V<+@]0W6L2B0C (XXHW=R>26-F;JF%1 :TC\IS]J?\ 3GV?
M_OQW%_X2+U[GH;_:GEAEB^;7L_CXL9Q]7S8;BOT]8N//'\R5N>.>>.6Y]W*V
M7Z(#\X1<0$7]["+/Q[N69F\O=_H9?HB( B(@*LOI"W<D[M]K#5.V.<VVSNW6
M(JZ+P&IL5E8M<9K4V*GGL9K(XBY6/'C@=':HCEACCQTHSO8DJ&QF#1A(/435
MXORG/VI_TY[ ??CN+_PD6RW1 46>Z=]&;[0.Q?:#VYW6UAJ?9R_IO2-W,V,I
M4TUJ;6M[.31Y'3>8Q$'J%7*;<86A,8VK\!2C8RE01KM-(!G( 0RWID1 $1$
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M  \C3HO=S]KPV-@DR&I<M)?U#DYV8S9[&0R=F<F)V*1V6:2( B(@"(B (B(
MB(@"IB=^+Z._OCVE-^;>Z.@-2;4XS3]C1^F=/#3UAJ#5^,S W,*63*S*5?"Z
M"U%2]6D]>!H";(O*70;R0Q^3/<[1 :TC\IS]J?\ 3GL!]^.XO_"138]PMW F
M]?9>WGS&X>X>H-K<K@LAH',:6AKZ,U!JS)Y8,E>S.G\A7EDK9S0FFJ;4F@Q=
MH9I1R!SA*5<0JRA)))#<&1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!Z&4Q=:]6L4K
ME>"W3MP2UK56S$$]:S6G HIZ]B&02CFAFB(HY8I!() (A(7%W94#>W%Z'[K_
M "6Y6?RNP.I=L\-MIEI&R.*TYKK4&K\?EM-6[4DTE[!T'P^B-40V]/TR>+X&
MGMY'X0BKR/2LA(U2.U8V *(#6D?E.?M3_ISV ^_'<7_A(O#^AS=J=_\ ]L]@
M/OQW%_X2+9<(@,8.Q%LIE=M=E]H=N<[8Q]O-Z VOT!HK,6L3+9GQ5G*Z5TIB
M<%D+&,GN5*%N;'S6Z$TE*6U1IV9*Q1G/4KRN4(9/HB U\?;.]&,[8N]FZFN-
MU-2ZUV!')ZRSMK)!2^;7<6:+#XH7:OA<%6D;:"$3KX;%15:(S-#"]N2*6[+$
M$]J5EC)^4Y^U/^G/8#[\=Q?^$BV6Z("FCW('HU6O=@=YX]V=X\YMUGWTU@\A
M!H?&Z)RVILN]?4N8#X.LYO*?#^D=+0QCC\'+D:F.BA:^Y6\F]UVJS8^K(=RY
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!0A[QOT3[=O7N]NX>NMHM1[1X?0NL
M<Y\TE##:KSVL,5F,9D\I4K6-1P'6PV@M14"JV-0ED[].0,B\CU[D<<T(2QD1
MX3?E.?M3_ISV ^_'<7_A(MENB UW/9F]%G[8VU&XFBMRM+:Z[/\ !G]$:BQV
M?Q_5K'<9HK+59>F]C;/&T;N]/+XV6YB;K,SEZI=F<.)&!VV']9Y'CC>8 "5P
M%Y0CD*6,)'%G,(Y2BA*0!+E@D*&(C%F)XP=^EOW1 $1$ 1$0!$1 $1$ 477?
M,=BC5G:'[.NN=I-$7]/8S4NI;>CK&/N:JN9*A@HAT[K;3VI;@W+>(Q&=OQ%-
M2Q%B&MX.+LL5HX0E\&(CFCE%1 :TC\IS]J?].>P'WX[B_P#"1>M<]#?[4\T,
ML7S:]G\?$C./J^;#<5^GK%QYX_F2MSQSSQRW/U5LP$0'7NT>E+.!TIIC!W3@
MDN8;3V%Q-N2J<DE8[..QM:G.=>26*"4X"EA-XCD@AD*-Q<XHR=P;L)$0!$1
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MGLO]^^IOX@+9S(@-8S^5#.UG_7/9?[]]3?Q 3\J&=K/^N>R_W[ZF_B MG,B
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MS'Z'J8<-#9C4F6.L>F;&K)KQ9+X?TAI<81F'/U6J>JO<<WBL>,T##&\MGM$
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M 681%F869F9E["( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
J (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749329701128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INOVIO PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0969592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">660 W. GERMANTOWN PIKE, SUITE 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">PLYMOUTH MEETING<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-4200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">COMMON STOCK, $0.001 PAR VALUE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,041,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749328656456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 59,009,491<span></span>
</td>
<td class="nump">$ 71,143,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">301,384,357<span></span>
</td>
<td class="nump">330,170,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">4,003,680<span></span>
</td>
<td class="nump">5,466,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable from affiliated entities</a></td>
<td class="nump">3,487,116<span></span>
</td>
<td class="nump">2,565,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">31,946,477<span></span>
</td>
<td class="nump">38,836,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity', window );">Prepaid expenses and other current assets from affiliated entities</a></td>
<td class="nump">75,772<span></span>
</td>
<td class="nump">261,192<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">399,906,893<span></span>
</td>
<td class="nump">448,444,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">16,696,936<span></span>
</td>
<td class="nump">17,453,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Investment in affiliated entity</a></td>
<td class="nump">3,369,068<span></span>
</td>
<td class="nump">3,906,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,499,585<span></span>
</td>
<td class="nump">2,626,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">10,513,371<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">11,251,440<span></span>
</td>
<td class="nump">11,571,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,273,795<span></span>
</td>
<td class="nump">1,425,794<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">445,511,088<span></span>
</td>
<td class="nump">495,941,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">38,115,396<span></span>
</td>
<td class="nump">47,644,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accounts payable and accrued expenses due to affiliated entities</a></td>
<td class="nump">1,407,386<span></span>
</td>
<td class="nump">548,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">11,827,755<span></span>
</td>
<td class="nump">10,326,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">15,378<span></span>
</td>
<td class="nump">21,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">2,672,974<span></span>
</td>
<td class="nump">2,603,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="nump">5,283,271<span></span>
</td>
<td class="nump">4,559,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliateCurrent', window );">Grant funding liability from affiliated entity</a></td>
<td class="nump">37,500<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">59,359,660<span></span>
</td>
<td class="nump">65,741,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">60,648<span></span>
</td>
<td class="nump">64,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible senior notes</a></td>
<td class="nump">16,207,864<span></span>
</td>
<td class="nump">14,959,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">14,765,868<span></span>
</td>
<td class="nump">15,459,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">32,046<span></span>
</td>
<td class="nump">32,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,826<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">90,426,086<span></span>
</td>
<td class="nump">96,272,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">226,509<span></span>
</td>
<td class="nump">217,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,642,419,819<span></span>
</td>
<td class="nump">1,609,589,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,287,103,438)<span></span>
</td>
<td class="num">(1,209,855,522)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(457,888)<span></span>
</td>
<td class="num">(282,236)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</a></td>
<td class="nump">355,085,002<span></span>
</td>
<td class="nump">399,669,421<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 445,511,088<span></span>
</td>
<td class="nump">$ 495,941,493<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Expense, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749329723736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 199,074<span></span>
</td>
<td class="nump">$ 371,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">55,978,611<span></span>
</td>
<td class="nump">39,044,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">15,953,458<span></span>
</td>
<td class="nump">13,881,194<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">71,932,069<span></span>
</td>
<td class="nump">52,925,612<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(71,732,995)<span></span>
</td>
<td class="num">(52,554,492)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">669,814<span></span>
</td>
<td class="nump">769,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(313,488)<span></span>
</td>
<td class="num">(513,034)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Loss on investment in affiliated entities</a></td>
<td class="num">(537,728)<span></span>
</td>
<td class="num">(830,475)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized loss on available-for-sale equity securities</a></td>
<td class="num">(4,840,641)<span></span>
</td>
<td class="num">(847,958)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(153,468)<span></span>
</td>
<td class="nump">8,978<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Net loss before share in net loss of Geneos</a></td>
<td class="num">(76,908,506)<span></span>
</td>
<td class="num">(53,967,744)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="num">(2,165,213)<span></span>
</td>
<td class="num">(434,387)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (79,073,719)<span></span>
</td>
<td class="num">$ (54,402,131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted average number of common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">218,940,693<span></span>
</td>
<td class="nump">202,414,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">218,940,693<span></span>
</td>
<td class="nump">202,414,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Revenue under collaborative research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 65,895<span></span>
</td>
<td class="nump">$ 39,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember', window );">Revenue under collaborative research and development arrangements with affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">8,842<span></span>
</td>
<td class="nump">49,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 124,337<span></span>
</td>
<td class="nump">$ 281,556<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749329543320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (79,073,719)<span></span>
</td>
<td class="num">$ (54,402,131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(6,555)<span></span>
</td>
<td class="num">(14,419)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="num">(169,097)<span></span>
</td>
<td class="nump">4,861<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">$ (79,249,371)<span></span>
</td>
<td class="num">$ (54,411,689)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749326433384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Adjustment</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th">
<div>Additional paid-in capital </div>
<div>Adjustment</div>
</th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th">
<div>Accumulated deficit </div>
<div>Adjustment</div>
</th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">186,851,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 461,140,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 186,851<span></span>
</td>
<td class="nump">$ 1,367,406,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (906,196,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (256,150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs</a></td>
<td class="nump">162,105,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,355<span></span>
</td>
<td class="nump">162,084,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of December 2019 Bonds to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,009,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of December 2019 Bonds to common stock</a></td>
<td class="nump">4,377,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,009<span></span>
</td>
<td class="nump">4,376,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,118,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="num">(1,201,789)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,118<span></span>
</td>
<td class="num">(1,202,907)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">9,595,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,595,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(54,402,131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,402,131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">4,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(14,419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,419)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">581,606,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 209,333<span></span>
</td>
<td class="nump">1,542,261,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(960,598,943)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(265,708)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">209,334,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">186,851,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">461,140,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 186,851<span></span>
</td>
<td class="nump">1,367,406,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(906,196,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(256,150)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 399,669,421<span></span>
</td>
<td class="num">$ (1,468,216)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 217,382<span></span>
</td>
<td class="nump">1,609,589,797<span></span>
</td>
<td class="num">$ (3,294,019)<span></span>
</td>
<td class="num">(1,209,855,522)<span></span>
</td>
<td class="nump">$ 1,825,803<span></span>
</td>
<td class="num">(282,236)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">217,382,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,480,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs</a></td>
<td class="nump">$ 29,364,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,481<span></span>
</td>
<td class="nump">29,356,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">647,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="num">(942,521)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 646<span></span>
</td>
<td class="num">(943,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,711,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,711,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(79,073,719)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(79,073,719)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="num">(169,097)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(169,097)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(6,555)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,555)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 355,085,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 226,509<span></span>
</td>
<td class="nump">$ 1,642,419,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,287,103,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (457,888)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">226,510,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(1)<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(2)<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(01)<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749330046392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 531<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749326605512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (79,073,719)<span></span>
</td>
<td class="num">$ (54,402,131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">929,383<span></span>
</td>
<td class="nump">660,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">126,770<span></span>
</td>
<td class="nump">136,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">319,586<span></span>
</td>
<td class="nump">278,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">7,711,151<span></span>
</td>
<td class="nump">9,595,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NonCashInterestIncomeExpense', window );">Non-cash interest expense</a></td>
<td class="num">(219,999)<span></span>
</td>
<td class="num">(31,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfPremium', window );">Amortization of premiums on investments</a></td>
<td class="nump">125,810<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherInvestments', window );">Loss on short-term investments</a></td>
<td class="nump">318,684<span></span>
</td>
<td class="nump">10,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">157,666<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GainLossOnRemeasurementOfEquityMethodInvestment', window );">Gain on remeasurement of investment in Geneos</a></td>
<td class="num">(165,215)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Loss on equity investment in affiliated entities</a></td>
<td class="nump">537,728<span></span>
</td>
<td class="nump">830,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="nump">2,165,213<span></span>
</td>
<td class="nump">434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized loss on available-for-sale equity securities</a></td>
<td class="nump">4,840,641<span></span>
</td>
<td class="nump">847,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Unrealized transaction loss on foreign-currency denominated debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(176,927)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, including from affiliated entities</a></td>
<td class="nump">541,248<span></span>
</td>
<td class="nump">8,804,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets, including from affiliated entities</a></td>
<td class="nump">7,075,934<span></span>
</td>
<td class="num">(19,108,348)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">151,999<span></span>
</td>
<td class="nump">75,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(9,859,913)<span></span>
</td>
<td class="nump">4,735,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense', window );">Accrued clinical trial expenses</a></td>
<td class="nump">1,501,489<span></span>
</td>
<td class="num">(2,579,476)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Accounts payable and accrued expenses due to affiliated entities</a></td>
<td class="nump">859,354<span></span>
</td>
<td class="nump">125,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue, including from affiliated entity</a></td>
<td class="num">(9,963)<span></span>
</td>
<td class="num">(72,463)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet', window );">Operating lease right-of-use assets and liabilities, net</a></td>
<td class="num">(624,673)<span></span>
</td>
<td class="num">(558,140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent', window );">Grant funding liability, including from affiliated entity</a></td>
<td class="nump">723,550<span></span>
</td>
<td class="num">(2,480,826)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(14,826)<span></span>
</td>
<td class="nump">6,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(61,882,102)<span></span>
</td>
<td class="num">(52,867,428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of investments</a></td>
<td class="num">(99,722,697)<span></span>
</td>
<td class="num">(275,408,976)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale or maturity of investments</a></td>
<td class="nump">123,055,048<span></span>
</td>
<td class="nump">504,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of capital assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(210,824)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Investment in Geneos</a></td>
<td class="num">(1,999,998)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">21,332,353<span></span>
</td>
<td class="num">(275,115,336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">29,364,538<span></span>
</td>
<td class="nump">162,105,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">83,812<span></span>
</td>
<td class="nump">2,632,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(1,026,333)<span></span>
</td>
<td class="num">(3,834,785)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">28,422,017<span></span>
</td>
<td class="nump">160,903,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(6,555)<span></span>
</td>
<td class="num">(14,419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Decrease in cash and cash equivalents</a></td>
<td class="num">(12,134,287)<span></span>
</td>
<td class="num">(167,093,942)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">71,143,778<span></span>
</td>
<td class="nump">250,728,118<span></span>
</td>
<td class="nump">$ 250,728,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">59,009,491<span></span>
</td>
<td class="nump">83,634,176<span></span>
</td>
<td class="nump">$ 71,143,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Amounts accrued for purchases of fixed assets</a></td>
<td class="nump">330,779<span></span>
</td>
<td class="nump">35,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 533,487<span></span>
</td>
<td class="nump">$ 544,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GainLossOnRemeasurementOfEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Remeasurement Of Equity Method Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GainLossOnRemeasurementOfEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Clinical Trial Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInAccruedClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseinDeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NonCashInterestIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NonCashInterestIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) included in earnings for investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of purchase premium on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749329939832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Organization and Operations</a></td>
<td class="text">Organization and Operations<div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;), is a biotechnology company focused on bringing to market precisely designed DNA medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer and conditions associated with human papillomavirus ("HPV"). INOVIO has shown in clinical trials that its DNA vaccine candidates can be delivered into cells in the body via a proprietary smart device allowing the nucleic-acid delivered gene products to activate functional T cell and antibody responses against targeted pathogens and cancers.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's DNA medicines pipeline is comprised of three types of product candidates: prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies ("dMAbs" and &#8220;dBTAs&#8221;), all of which utilize the two components of INOVIO's integrated platform, SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's proprietary SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce proteins or antigens to help the person&#8217;s immune system respond with antibodies and immune cells which recognize and then help block viruses and destroy cancerous or pre-cancerous cells. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's patented CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">smart delivery devices facilitate uptake of its DNA medicines into the cell, which has been a key limitation of historical DNA-based technology approaches. Human clinical trial data from more than 15,000 CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> smart device administrations across more than 5,000 participants to date have shown a tolerable safety profile.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's corporate strategy is to develop, seek regulatory approval for and commercialize its novel DNA medicines to address unmet global health needs. The Company continues to advance and clinically validate an array of DNA medicine candidates that target infectious diseases, such as COVID-19, as well as HPV-associated diseases and cancer. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's partners and collaborators include ApolloBio Corporation, AstraZeneca, Advaccine Biopharmaceuticals Suzhou Co., The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations ("CEPI"), The U.S. Department of Defense ("DoD"), Defense Advanced Research Projects Agency ("DARPA"), HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium ("MCDC"), International Vaccine Institute ("IVI"), Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its collaborators are currently evaluating the feasibility of, or conducting or planning clinical studies of, DNA medicines for COVID-19, including both homologous and heterologous booster vaccines; Middle East Respiratory Syndrome, or MERS; Lassa fever; Ebola; as well as HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis, or RRP; glioblastoma multiforme, or GBM; and prostate cancer. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749334347016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Liquidity and Risks and Uncertainties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation, Liquidity and Risks and Uncertainties</a></td>
<td class="text">Basis of Presentation, Liquidity and Risks and Uncertainties<div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of March&#160;31, 2022, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, the condensed consolidated statements of stockholders' equity and the condensed consolidated statements of cash flows for the three months ended March 31, 2022 and 2021 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three months ended March 31, 2022 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended December&#160;31, 2021, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;1, 2022. The balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of March&#160;31, 2022 and December 31, 2021, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC.  All intercompany accounts and transactions were eliminated upon consolidation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss attributable to common stockholders of $79.1 million for the three months ended March 31, 2022. The Company had working capital of $340.5 million and an accumulated deficit of $1.3 billion as of March&#160;31, 2022. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $360.4 million as of March&#160;31, 2022 are sufficient to support the Company's planned operations for a period of at least 12 months from the date of issuance of these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has a history of conducting debt and equity financings, including the receipt of net proceeds of $29.4 million and $47.7&#160;million under a Sales Agreement during the three months ended March 31, 2022 and year ended December 31, 2021, respectively, and $162.1&#160;million from a January 2021 underwritten public offering of common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three months ended March 31, 2022 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is, and from time to time&#160;may in the future be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARs-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company continues to closely monitor the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will continue to impact the Company's business and operations will depend on future developments, including travel restrictions to, from and within the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, which remain uncertain.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749334385272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Critical Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Critical Accounting Policies</a></td>
<td class="text">Critical Accounting PoliciesCollaboration Agreements and Revenue Recognition<div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. Differences in the allocation of the transaction price between delivered and undelivered performance obligations can impact the timing of revenue recognition but do not change the total revenue recognized under any agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For collaboration arrangements that include license fees, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For collaboration arrangements that include milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. This assessment is based on the Company&#8217;s past experience with its collaboration partner, market insight and partner communication. Milestone payments that are not within the Company&#8217;s or the collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment and could be material.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For collaboration arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue in the period the underlying sales occur. To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMAbs. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749330066088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Impact of Recently Issued Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Impact of Recently Issued Accounting Standards</a></td>
<td class="text">Impact of Recently Issued Accounting Standards <div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Recently Adopted</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2020-06.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;), which simplifies the guidance on an issuer&#8217;s accounting for convertible instruments and contracts in its own equity. ASU 2020-06 is effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2020-06 as of January 1, 2022 on a modified retrospective basis and recorded a net reduction in accumulated deficit of $1.8&#160;million, a decrease in additional paid-in capital of $3.3&#160;million, and an increase in convertible senior notes of $1.5&#160;million to reflect the impact of the accounting change. The Company derecognized the related deferred tax liabilities of $1.5&#160;million with a corresponding adjustment to the valuation allowance, resulting in no net impact to the cumulative adjustment to retained earnings (see Note 8, "Convertible Debt").</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749334378296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition  During the three months ended March 31, 2022 and 2021, the Company recognized total revenue under collaborative research and development arrangements of $9,000 and $50,000, respectively, from its affiliated entity Plumbline Life Sciences, Inc. ("PLS") and $190,000 and $321,000, respectively, from various other contracts as a result of performance obligations being satisfied. Of the total revenue recognized during the three months ended March 31, 2022, $10,000 was in deferred revenue as of December 31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749331048824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-term Investments and Fair Value Measurements</a></td>
<td class="text">Short-term Investments and Fair Value Measurements<div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of March&#160;31, 2022 and December&#160;31, 2021:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,648,717&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,367,983)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,280,734&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,772,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,139)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,664,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,986,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,986,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,093)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,935,569&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,336&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,566,548)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,384,357&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,966,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,614,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,193,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,608,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,712,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,195&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,648,668)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended March 31, 2022 and 2021, the Company recorded gross realized gain on investments of $20,000 and $0, respectively, and gross realized loss on investments of $339,000 and $10,000, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded net unrealized loss on available-for-sale equity securities of $4.8 million and $848,000, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the three months ended March 31, 2022 and 2021. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of March&#160;31, 2022, the Company had 29 available-for-sale securities in an unrealized loss position, of which 13 with an aggregate total unrealized loss of $2.9 million were in such position for longer than 12 months.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;March&#160;31, 2022&#160;were </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">primarily due to changes in interest rates</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at March&#160;31, 2022, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,280,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,280,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,664,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,664,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,986,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,986,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,384,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,945,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,439,073&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,369,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,369,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,753,425&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,314,352&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,439,073&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,622,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,077,736&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,529,746&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 assets at March&#160;31, 2022 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">rations as unrealized gain (loss) on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or as a gain (loss) on investment in affiliated entity. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at March&#160;31, 2022 consisted of commercial paper, certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets held as of March&#160;31, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Short-term Investments and Fair Value Measurements</a></td>
<td class="text">Short-term Investments and Fair Value Measurements<div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of March&#160;31, 2022 and December&#160;31, 2021:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,648,717&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,367,983)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,280,734&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,772,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,139)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,664,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,986,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,986,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,093)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,935,569&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,336&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,566,548)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,384,357&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,966,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,614,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,193,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,608,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,712,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,195&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,648,668)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the three months ended March 31, 2022 and 2021, the Company recorded gross realized gain on investments of $20,000 and $0, respectively, and gross realized loss on investments of $339,000 and $10,000, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded net unrealized loss on available-for-sale equity securities of $4.8 million and $848,000, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the three months ended March 31, 2022 and 2021. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of March&#160;31, 2022, the Company had 29 available-for-sale securities in an unrealized loss position, of which 13 with an aggregate total unrealized loss of $2.9 million were in such position for longer than 12 months.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;March&#160;31, 2022&#160;were </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">primarily due to changes in interest rates</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at March&#160;31, 2022, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,280,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,280,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,664,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,664,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,986,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,986,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,384,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,945,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,439,073&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,369,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,369,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,753,425&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,314,352&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,439,073&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,622,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,077,736&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,529,746&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Level 1 assets at March&#160;31, 2022 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">rations as unrealized gain (loss) on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or as a gain (loss) on investment in affiliated entity. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at March&#160;31, 2022 consisted of commercial paper, certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no Level 3 assets held as of March&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749329905880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth the goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:18.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.918%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,312,787)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,305,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,798,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,301,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,735,556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,862,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,806,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,974,176)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,499,585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,847,406)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,974,176)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,012,956&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,847,406)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,139,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Other intangible assets represent the estimated fair value of acquired intellectual property. </span></div>Aggregate amortization expense on intangible assets for the three months ended March 31, 2022 and 2021 was $127,000 and $137,000, respectively. Estimated aggregate amortization expense is $366,000 for the remainder of fiscal year 2022, $276,000 for 2023, $253,000 for 2024, $253,000 for 2025, $253,000 for 2026 and $1.1 million for 2027 and subsequent years combined.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749329934248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Debt</a></td>
<td class="text">Convertible Debt<div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5 million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $75.7 million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of 6.50% per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate was 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.38 per share), subject to adjustment upon the occurrence of specified events.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days (whether or not </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initially, in accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments, which do not have an associated convertible feature. The carrying amount of the equity component representing the conversion option for the Notes was $16.3&#160;million and was recorded as a debt discount, which was being amortized to interest expense at an effective interest rate of 13.1%. In addition, the Company allocated $592,000 of debt issuance costs to the equity component and the remaining debt issuance costs of $2.2&#160;million were allocated to the liability component, which were being amortized to interest expense under the effective interest rate method.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, the Company adopted ASU No. 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;), which is intended to simplify the accounting for convertible instruments. The ASU eliminates the cash conversion feature models in ASC 470-20, Debt with Conversion and Other Options, which required an issuer of certain convertible debt to separately account for embedded conversion features as a component of equity. Instead, an issuer will account for these securities as a single unit of account, unless the conversion feature meets certain criteria. The Company adopted the new standard using the modified retrospective method, and recorded a net reduction to accumulated deficit of $1.8&#160;million, a decrease to additional paid-in capital of $3.3&#160;million, and an increase to convertible senior notes of $1.5&#160;million to reflect the impact of the accounting change. The Notes are now accounted for as a single liability measured at amortized cost, as no other embedded features require bifurcation and recognition as derivatives.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at March&#160;31, 2022 was as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,085,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296,051)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,207,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022 and 2021,&#160;the Company recognized $313,000 and $463,000, respectively, of interest expense related to the Notes, of which $267,000 and $267,000, respectively, related to the contractual interest coupon.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.328%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,549,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:22.5pt"><span><br/></span></div><div style="margin-bottom:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2019 Convertible Bonds </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#8220;December 2019 Bonds&#8221;) with an aggregate principal amount of 4.7 billion KRW (USD $4.1 million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were $4.0 million.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2019 Bonds, which were unsecured obligations of the Company, were issued on December&#160;31, 2019 and accrued interest at a coupon rate of 1.00% per annum, payable quarterly. The December 2019 Bonds were scheduled to mature on December&#160;31, 2024, unless earlier converted or repurchased. On March 17, 2021, the December 2019 Bonds were converted in full into an aggregate of 1,009,450 shares of the Company's common stock, leaving no further December 2019 Bonds outstanding. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Upon conversion, the $4.4&#160;million carrying value of the December 2019 Bonds was reclassified to stockholders' equity.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rate of the December 2019 Bonds was 6.2%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized $59,000 of interest expense related to the December 2019 Bonds, of which $9,000 related to the contractual interest coupon.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749330059528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's authorized and issued common and preferred stock as of March&#160;31, 2022 and December&#160;31, 2021: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:42.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,510,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,510,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,382,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, the Company entered into an ATM Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;2021 Sales Agreement&#8221;) with outside sales agents (collectively, the &#8220;Sales Agents&#8221;) for the offer and sale of its common stock for an aggregate offering price of up to $300.0&#160;million. The 2021 Sales Agreement provides that the Sales Agents will be entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. For the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended March 31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company sold 8,480,483 shares of its common stock under the 2021 Sales Agreement. The sales were made at a weighted average price of $3.52 per share, resulting in aggregate net proceeds of $29.4 million. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> there was $221.8 million of remaining capacity under the 2021 Sales Agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company closed an underwritten public offering of 20,355,000 shares of common stock at a public offering price of $8.50 per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other offering expenses, were $162.1&#160;million. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the maximum number of shares of the Company&#8217;s common stock available for issuance over the term of the 2016 Incentive Plan was 22,000,000 shares. On the first business day of each calendar year, such maximum number of shares shall be increased by&#160;2,000,000 shares of common stock unless the Board determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2022, the maximum number of shares increased by 2,000,000. At March&#160;31, 2022, the Company had 838,641 shares of common stock available for future grant under the 2016 Incentive Plan, 3,491,330 shares underlying outstanding but unvested restricted stock units and options outstanding to purchase 11,701,340 shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.</span></div>The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At March&#160;31, 2022, the Company had options outstanding to purchase 2,395,723 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749329907528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and refle</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cts the potential dilution that would occur if securities or other con</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes issued by the Company (discussed in Note 8) has been considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three months ended March 31, 2022 and 2021, basic and diluted net </span><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss per share were the same, as the assumed exercise or settlement of stock options and restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes would have been anti-dilutive.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,097,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,826,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,491,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,610,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,305,035&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,153,244&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749334347016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to restricted stock units ("RSUs") and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.88%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.88%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three months ended March 31, 2022 and 2021 was $7.2 million and $9.2 million, respectively, of which $3.7 million and $5.2 million, respectively, was included in research and development expenses, and $3.5 million and $4.0 million, respectively, was included in general and administrative expenses.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, there was $19.8 million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 2.2 years.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was $2.48 and $8.34 for employee and director stock options granted during the three months ended March 31, 2022 and 2021, respectively. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2022, there was $17.1 million of total unrecognized compensation expense related to unvested service-based RSUs, which is expected to be recognized over a weighted-average period of 2.1 years.  </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $3.33 and $11.42 for service-based RSUs granted during the three months ended March 31, 2022 and 2021, respectively.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three months ended March 31, 2022 and 2021 was $550,000 and $429,000, respectively.</span></div><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 28, 2020, the Company granted 663,353 performance-based RSUs to key employees under the 2016 Incentive Plan. The RSUs will vest in two tranches as follows: 50% of the shares in each tranche will vest upon achievement of the predetermined performance milestones and the remaining 50% of the shares in each tranche will vest upon subsequent completion of a one-year service period. The grant date fair value of the performance-based RSUs was $8.0&#160;million based on the grant date closing price per share of $12.06. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;31, 2022</span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, the underlying performance milestones of the RSUs were not probable of achievement, and no stock-based compensation expense was recognized for the performance-based RSUs for the three months then ended.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749330119320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transaction, Due from (to) Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plumbline Life Sciences, Inc.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owned 597,808 shares of common stock in PLS as of March&#160;31, 2022, representing a 18.7% ownership interest, and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from PLS consists of milestone, license and patent fees. For the three months ended March 31, 2022 and 2021, the Company recognized revenue from PLS of $9,000 and $50,000, respectively. At March&#160;31, 2022 and December&#160;31, 2021, the Company had an accounts receivable balance of $34,000 and $25,000, respectively, related to PLS.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreements. In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. The Company will have the exclusive right to in-license new intellectual property developed under this agreement.  </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company entered into collaborative research agreements with Wistar in support of the clinical development of INO-4800. Under the terms of these collaborative research agreements, the Company will reimburse Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $1.9&#160;million during the two-year term of the agreements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Novem</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ber 2016, the Company received a&#160;$6.1 million&#160;sub-grant through Wistar to develop a dMAb against the Zika infection, which was fully funded through December 2021. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2023.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $10.7&#160;million sub-grant through Wistar, which was amended in 2021 to $13.5&#160;million, for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding through November 2022. The sub-grant also includes an option for an additional $6.0&#160;million in funding through March 2024, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of which $3.3&#160;million has been exercised as of March&#160;31, 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three months ended March 31, 2022 and 2021, the Company recorded $1.5 million and $230,000, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 14). Research and development expenses recorded from Wistar for the three months ended March 31, 2022 and 2021 were $181,000 and $318,000, respectively. At March&#160;31, 2022 and December&#160;31, 2021, the Company had an accounts receivable balance of $3.5 million and $2.6 million, respectively, and an accounts payable and accrued liability balance of $1.4 million and $548,000, respectively, related to Wistar. As of March&#160;31, 2022, the Company recorded $38,000 as deferred grant funding and $76,000 as prepaid expenses on the condensed consolidated balance sheet related to Wistar.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749329939832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies                                                  Leases<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately 82,200 square feet of office, laboratory, and manufacturing space in San Diego, California and 57,360 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of March&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of 1.7 to 7.8 ye</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ars, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of March&#160;31, 2022, the maturities of the Company's operating lease liabilities were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,074,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,050,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,139,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,749,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,164,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,725,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,439,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,673,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,766,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5%</span></td></tr></table></div><div style="margin-top:3pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:3pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the condensed consolidated statements of operations for the three months ended March 31, 2022 and 2021 were $830,000 and $850,000, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately 13,500 square feet in its Plymouth Meeting headquarters through periods between December 31, 2022 and March 31, 2025.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and J. Joseph Kim, the Company&#8217;s Chief Executive Officer, as defendants. The lawsuit alleges that the Company made materially false and misleading statements regarding its development of a vaccine for COVID-19 in its public disclosures in violation of </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. On August 3, 2020, the lead plaintiff filed a consolidated complaint, naming the Company and three of its officers as defendants. On September 21, 2020, the lead plaintiff and another purported stockholder filed a first amended complaint, naming the Company and three of its officers as defendants. Defendants filed a motion to dismiss plaintiff&#8217;s first amended complaint on November 5, 2020. On February 16, 2021, the court issued an order granting in part, and denying in part, the defendants&#8217; motion to dismiss. The court granted the defendants&#8217; motion to dismiss, and dismissed with prejudice, the claims premised on certain of the Company&#8217;s statements. The court denied defendants&#8217; motion to dismiss as to the remaining statements. On March 9, 2021, the defendants filed their answer to the complaint. The case is currently in discovery. On July 29, 2021, the plaintiffs moved to certify the class action. That motion is fully briefed and remains pending. On February 17, 2022, the court granted Plaintiffs&#8217; motion for leave to amend their complaint, and further ordered that the amended complaint is deemed filed as of February 17. On March 21, 2022, Defendants moved to dismiss the new allegations in the amended complaint. The Company expects that motion to be fully briefed on May 10, 2022. No hearing date has been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class action complaint. The lawsuit accuses the Company&#8217;s board of directors of failing to exercise reasonable and prudent supervision over the Company&#8217;s management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of the Company as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12, 2020 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et al. and Devarakonda et al. v Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name the Company&#8217;s current directors as defendants. The Devarakonda complaint also names one of the Company&#8217;s former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 28, 2022, a fifth shareholder derivative complaint, Schumacher v. Benito et al., was filed in the Delaware Court of Chancery, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2022, the Delaware Court of Chancery entered a stay of the litigation.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to defend these actions vigorously.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#8217;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. On June 3, 2020, the Company filed a petition for preliminary injunction, which was denied on June 25, 2020. On June 26, 2020, the Company filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, VGXI filed an answer, new matter and counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from the Company. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, the Company filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. On October 1, 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Device License Agreement, or the </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement, between the Company and GeneOne. The Company terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from the Company. On January 29, 2021, the Company filed preliminary objections to the complaint. On August 23, 2021, the court overruled the Company&#8217;s preliminary objections to the complaint. On September 13, 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#8217;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 18, 2021, GeneOne filed its answer to the Company&#8217;s counterclaims and new matter. On November 8, 2021, we filed our answer to GeneOne&#8217;s new matter. A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#8217;s consolidated results of operations or financial position.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749330116584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Agreements</a></td>
<td class="text">Collaborative Agreements<div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#8220;Advaccine&#8221;), which was amended and restated on June 7, 2021 (as amended and restated, the &#8220;Advaccine Agreement&#8221;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;) and 33 additional countries in Asia. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without the Company&#8217;s express prior written consent. As part of the collaboration, Advaccine also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2021 amendment relates to the collaboration between the Company and Advaccine to jointly conduct the global Phase 3 segment of the Company&#8217;s ongoing Phase 2/3 trial of INO-4800 and expand the existing collaboration to include the planned global Phase 3 trial. The parties will jointly participate in the trial and will equally share the global development costs for the trial, including the Company&#8217;s manufacturing costs to supply INO-4800. In certain instances, the Company will have the right to convert the exclusive license to a non-exclusive license in the licensed territories, other than Greater China, unless Advaccine agrees to pay the Company its full share of development costs in excess of a specified maximum. Notwithstanding the foregoing, Advaccine will be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. The Company will be fully responsible for its costs and expenses, if any, incurred solely as a result of its activities in connection with the performance of the trial in the United States. The parties may continue to conduct clinical trials of INO-4800 outside of the territories covered by the Advaccine Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that a global purchasing entity desires to enter into a purchase agreement for INO-4800 in both parties&#8217; territories, the parties will enter into good faith negotiations for an arrangement to supply INO-4800 to such entity. In addition, the Company is permitted to enter into an agreement with a global purchasing entity to authorize the entity to conduct a portion of the global Phase 3 trial in the licensed territory outside of Greater China.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, Advaccine made an upfront payment to the Company of $3.0&#160;million in January 2021. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $206.0&#160;million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China and the additional covered territories, if approved. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#8217;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for ten years after the first commercial sale in a particular region </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the first calendar year following the first commercial sale of INO-4800 in the licensed territory outside of Greater China, Advaccine will pay the Company an annual maintenance fee of $1.5&#160;million for a period of five years, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, the Company will supply Advaccine&#8217;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#8217;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months&#8217; written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in the licensed territory, or 18 months&#8217; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808 at inception and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606. The license to INO-4800 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the Advaccine Agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the Advaccine Agreement consisted of the $3.0&#160;million upfront payment received in January 2021 plus a $2.0&#160;million milestone payment which was achieved upon contract signing. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $5.0&#160;million was allocated to the license performance obligation. The Company determined that as of December 31, 2020, the transfer of technology had occurred for the use and benefit of the license and accordingly, the performance obligation was fully satisfied. The Company accordingly recognized $5.0&#160;million in revenue under collaborative research and development arrangements on the consolidated statement of operations during the year ended December 31, 2020. For the three months ended March 31, 2022, no revenue was recognized from Advaccine. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the June 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement is a collaboration and not a contract with a customer and therefore concluded to account for the June 2021 amendment under ASC Topic 808. Reimbursements from Advaccine will be recognized as contra-research development expense on the condensed consolidated statement of operations once earned and collectibility is assured.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company has granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to an upfront payment received in 2018, the Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning one year after the effective date for any reason upon 90 days written notice to the Company.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of March&#160;31, 2022 there have been no significant reimbursable program costs under the ApolloBio Agreement.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplate preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of $56 million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the three months ended March 31, 2022 and 2021, the Company received funding of $2.0 million and $2.4 million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of March&#160;31, 2022, the Company had an accounts receivable balance of $3.8 million on the condensed consolidated balance sheet related to these CEPI grants. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded the Company a grant of up to $9.0 million to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of $6.9 million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of $5.0 million to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3 million to support large-scale manufacturing of INO-4800. During the three months ended March 31, 2022 and 2021, the Company received funding of $510,000 and $2.4 million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of March&#160;31, 2022, the Company had $2.7 million recorded as deferred grant funding on the condensed consolidated balance sheet from the CEPI grants related to INO-4800.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Gates awarded and funded the Company a grant of $2.2 million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1 million for the project. During the three months ended March 31, 2022 and 2021, the Company recorded $80,000 and $0, respectively, as contra-research and development expense related to the Gates dMAb grant. As of March&#160;31, 2022, the Company had $304,000 recorded as deferred grant funding on the condensed consolidated balance sheet related to the grant.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Gates awarded and funded the Company a grant of $5.0 million to accelerate the development of the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device for the intradermal delivery of INO-4800. During the three months ended March 31, 2022 and 2021, the Company recorded $0 and $893,000, respectively, as contra-research and development expense related to this Gates grant. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Defense (DoD) </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#8220;OTA Agreement&#8221;)&#160;with the DoD to fund the Company&#8217;s efforts in developing the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. Under the OTA Agreement, the Company intends to develop the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the device by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3PSP device, as well as large-scale DNA plasmid production for manufacture and supply of a specified number of doses of&#160;INO-4800&#160;in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is $54.5 million. The Company has determined that the OTA Agreement should be considered under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is outside the scope of Topic 606, as the government agency granting the Company funds is not receiving reciprocal value for their contributions. The Company will record contra-research development expense on the condensed consolidated statement of operations in the same period that the underlying expenses are incurred. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#8220;Procurement Contract&#8221;) from the DoD for the purchase of the Company&#8217;s intradermal CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 device and accessories. The CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 2000 devices will be used to inject&#160;INO-4800&#160;in the Company&#8217;s planned later-stage clinical trials. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The total purchase price under the </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Procurement Contract is expected to be approximately $10.7&#160;million. The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Company determined that the Procurement Contract falls under the scope of ASC Topic 606 as the contract is with a customer and the Company is able to satisfy its obligations under the arrangement as the Phase 3 clinical trials of INO-4800 are underway. Performance obligations under the Procurement Contract consist of the delivery of a specified number of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 devices and accessories. The total transaction price was allocated to the individual performance obligations based on the determined standalone selling price for the devices and accessories. The Company will recognize revenue on the condensed consolidated statement of operations upon shipment of the purchased devices and accessories. During the three months ended March 31, 2022 and 2021, the Company recorded no revenue from the Procurement Contract. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022 and 2021, the Company recorded $3.2&#160;million and $7.8&#160;million, respectively, as contra-research and development expense related to the OTA Agreement. As of March&#160;31, 2022 and December 31, 2021, the Company had an accounts r</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eceivable balance of $0 and $3.6&#160;million, respectively, on the condensed consolidated balance sheet from the DoD. As of March&#160;31, 2022, the Company had $2.3&#160;million recorded as deferred grant funding on the condensed consolidated balance sheet related to the Procurement Contract.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company announced that the DoD had notified the Company that it will discontinue funding f</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the Phase 3 segment of the Company's clinical trial of INO-4800 in the United States, while continuing to fund the completion of the ongoing Phase 2 segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749329912968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.&#160;For the three months ended March&#160;31, 2022 and 2021, the Company has not recorded any income tax provision/(benefit) due to the Company&#8217;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749330096984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc.<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">Geneos Therapeutics, Inc. <div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In 2019, Geneos completed the initial closing of a&#160;Series A preferred stock financing. The Company invested&#160;$1.2 million&#160;in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;61%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Geneos completed the second closing of the&#160;Series A preferred stock financing, in which the Company invested $800,000. Following this transaction, the Company held&#160;52%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Geneos closed an additional&#160;Series A preferred stock financing round, in which the Company invested $800,000.  Following this transaction, the Company owned 47% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217; economic performance.  Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $4.1 million, of which $2.4 million related to the remeasurement of the retained noncontrolling interest investment to fair value.  </span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. Since the Company&#8217;s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#8217;s common stock investment and will therefore be recorded as an equity security under ASC 321.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the deconsolidation, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's condensed consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217; net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020. The Company has determined that its Series A preferred stock investment in Geneos does not have a readily determinable fair value and has therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $1.4&#160;million in the Series A-1 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 36% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continued to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share of net losses of Geneos for the three months ended March 31, 2021 was $1.5&#160;million; however, only $434,000 was recorded, reducing the Company's total investment in Geneos to $0. Of the total amount, $819,000 has been allocated to the equity method investment, thereby reducing the balance to $0 as of March 31, 2021. The remaining $4.2 million loss has been allocated to the Company&#8217;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, thereby reducing the balance to $0 as of March 31, 2021.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Geneos completed a second closing of the Series A-1 preferred stock financing, in which the Company did not participate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following this transaction, the Company held approximately 35% of the outstanding equity, on an as-converted to common stock basis.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Geneos completed the closing of a Series A-2 preferred stock financing. The Company invested $2.0&#160;million in the Series A-2 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continues to be a VIE as it does not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continues to not be the primary beneficiary of Geneos, as it does not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 24% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos&#8217;s Series A-2 preferred stock was based on the per share price paid by third-party investors in connection with the closing on March 21, 2022. The Company has concluded that its Series A-2 preferred stock investment is a similar financial instrument as its Series A-1 preferred stock, and therefore remeasured the carrying value of the Series A-1 preferred stock investment at the Series A-2 preferred stock price, resulting in a gain on remeasurement of $165,000.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded its current and accumulated share of net losses of Geneos of $2.2&#160;million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of March 31, 2022 as shown in the table below:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-2 preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remeasurement of  Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,165,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to exclusively license its SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapy and CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span>&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749329912968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsFrom April 1, 2022 through April 21, 2022, the Company sold 2,502,269 shares of common stock under the 2021 Sales Agreement for net proceeds of $8.7&#160;million.  The sales were made at a weighted average price of $3.52 per share.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749334649736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of March&#160;31, 2022, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, the condensed consolidated statements of stockholders' equity and the condensed consolidated statements of cash flows for the three months ended March 31, 2022 and 2021 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three months ended March 31, 2022 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year </span></div><div style="margin-top:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended December&#160;31, 2021, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) on March&#160;1, 2022. The balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of March&#160;31, 2022 and December 31, 2021, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC.  All intercompany accounts and transactions were eliminated upon consolidation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss attributable to common stockholders of $79.1 million for the three months ended March 31, 2022. The Company had working capital of $340.5 million and an accumulated deficit of $1.3 billion as of March&#160;31, 2022. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $360.4 million as of March&#160;31, 2022 are sufficient to support the Company's planned operations for a period of at least 12 months from the date of issuance of these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has a history of conducting debt and equity financings, including the receipt of net proceeds of $29.4 million and $47.7&#160;million under a Sales Agreement during the three months ended March 31, 2022 and year ended December 31, 2021, respectively, and $162.1&#160;million from a January 2021 underwritten public offering of common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three months ended March 31, 2022 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.</span></div>The Company is, and from time to time&#160;may in the future be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARs-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company continues to closely monitor the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will continue to impact the Company's business and operations will depend on future developments, including travel restrictions to, from and within the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, which remain uncertain.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Agreements and Revenue Recognition</a></td>
<td class="text">Collaboration Agreements and Revenue Recognition<div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. Differences in the allocation of the transaction price between delivered and undelivered performance obligations can impact the timing of revenue recognition but do not change the total revenue recognized under any agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For collaboration arrangements that include license fees, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For collaboration arrangements that include milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. This assessment is based on the Company&#8217;s past experience with its collaboration partner, market insight and partner communication. Milestone payments that are not within the Company&#8217;s or the collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment and could be material.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For collaboration arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue in the period the underlying sales occur. To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses - Clinical Trial Accruals</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMAbs. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Impact of Recently Issued Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Standards Recently Adopted</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2020-06.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;), which simplifies the guidance on an issuer&#8217;s accounting for convertible instruments and contracts in its own equity. ASU 2020-06 is effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2020-06 as of January 1, 2022 on a modified retrospective basis and recorded a net reduction in accumulated deficit of $1.8&#160;million, a decrease in additional paid-in capital of $3.3&#160;million, and an increase in convertible senior notes of $1.5&#160;million to reflect the impact of the accounting change. The Company derecognized the related deferred tax liabilities of $1.5&#160;million with a corresponding adjustment to the valuation allowance, resulting in no net impact to the cumulative adjustment to retained earnings (see Note 8, "Convertible Debt").</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risks and Uncertainties</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749329970600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Summary of Investments</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of March&#160;31, 2022 and December&#160;31, 2021:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,648,717&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,367,983)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,280,734&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,772,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,139)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,664,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,986,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,986,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(333)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,093)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461,623&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,935,569&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,336&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,566,548)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,384,357&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,966,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,614,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,193,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#160;than&#160;1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,608,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,712,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,195&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,648,668)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2022:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,280,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,280,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,664,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,664,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,986,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,986,103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,384,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,945,284&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,439,073&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,369,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,369,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,753,425&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,314,352&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,439,073&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2021:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.796%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,622,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,077,736&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,529,746&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749330083256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Summary of Intangible Assets by Major Asset Class</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth the goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:18.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.918%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:45pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,312,787)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,305,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject(a)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,798,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,301,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,735,556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,862,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,806,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,974,176)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,499,585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,847,406)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,974,176)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,012,956&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,847,406)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,139,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div>(b)Other intangible assets represent the estimated fair value of acquired intellectual property.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749329979416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Convertible Debt</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at March&#160;31, 2022 was as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Original principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,085,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(296,051)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,207,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.328%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">534,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,549,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749330098104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company's authorized and issued common and preferred stock as of March&#160;31, 2022 and December&#160;31, 2021: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:42.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding as of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,510,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,510,720&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,382,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par value $0.001 per share</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749334378856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect: </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.170%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.263%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,097,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,826,472&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,491,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,610,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,305,035&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,153,244&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749334347016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted Average Assumptions</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.88%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.88%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749329886424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of March&#160;31, 2022, the maturities of the Company's operating lease liabilities were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,074,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,050,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,139,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,749,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,164,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,725,000)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,439,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,673,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,766,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749334375192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of Equity Method Investments</a></td>
<td class="text">The Company recorded its current and accumulated share of net losses of Geneos of $2.2&#160;million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of March 31, 2022 as shown in the table below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-2 preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remeasurement of  Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,165,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749328363608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Liquidity and Risks and Uncertainties (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 79,073,719<span></span>
</td>
<td class="nump">$ 54,402,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Capital', window );">Working capital</a></td>
<td class="nump">340,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">1,287,103,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,209,855,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">360,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="nump">29,364,538<span></span>
</td>
<td class="nump">$ 162,105,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Sales Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="nump">29,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of stock</a></td>
<td class="nump">$ 162,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Capital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of total capital as defined by regulatory framework.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117337116&amp;loc=SL5958568-112826<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Capital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749328305800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Impact of Recently Issued Accounting Standards (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (1,287,103,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,209,855,522)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="num">(1,642,419,819)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,609,589,797)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible senior notes</a></td>
<td class="nump">16,207,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,959,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">32,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749326471304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 199,074<span></span>
</td>
<td class="nump">$ 371,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from deferred revenue</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_OtherCounterpartyMember', window );">Other Counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">190,000<span></span>
</td>
<td class="nump">321,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember', window );">Revenue under collaborative research and development arrangements with affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 8,842<span></span>
</td>
<td class="nump">$ 49,949<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_OtherCounterpartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_OtherCounterpartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749328477416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 307,935,569<span></span>
</td>
<td class="nump">$ 331,712,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">15,336<span></span>
</td>
<td class="nump">107,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(6,566,548)<span></span>
</td>
<td class="num">(1,648,668)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">301,384,357<span></span>
</td>
<td class="nump">330,170,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">178,648,717<span></span>
</td>
<td class="nump">192,966,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">87,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(6,367,983)<span></span>
</td>
<td class="num">(1,614,411)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 172,280,734<span></span>
</td>
<td class="nump">$ 191,439,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual Maturity&#160;(in&#160;years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 84,772,489<span></span>
</td>
<td class="nump">$ 94,193,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(108,139)<span></span>
</td>
<td class="num">(9,921)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">84,664,550<span></span>
</td>
<td class="nump">$ 94,183,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual Maturity&#160;(in&#160;years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">39,986,103<span></span>
</td>
<td class="nump">$ 39,967,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 39,986,103<span></span>
</td>
<td class="nump">$ 39,967,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual Maturity&#160;(in&#160;years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 2,976,544<span></span>
</td>
<td class="nump">$ 2,976,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">15,136<span></span>
</td>
<td class="nump">15,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(333)<span></span>
</td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">2,991,347<span></span>
</td>
<td class="nump">2,991,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">1,551,716<span></span>
</td>
<td class="nump">1,608,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(90,093)<span></span>
</td>
<td class="num">(23,998)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 1,461,623<span></span>
</td>
<td class="nump">$ 1,588,647<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale contractual maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtSecuritiesAvailableforSaleContractualMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749326031032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>position </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gain on investments</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized loss on investments</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss</a></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="nump">$ 848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities in a gross unrealized loss position | position</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of securities in a gross unrealized loss position for more than twelve months | position</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares) | shares</a></td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749325189432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">$ 301,384,357<span></span>
</td>
<td class="nump">$ 330,170,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">172,280,734<span></span>
</td>
<td class="nump">191,439,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">39,986,103<span></span>
</td>
<td class="nump">39,967,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">2,991,347<span></span>
</td>
<td class="nump">2,991,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">1,461,623<span></span>
</td>
<td class="nump">1,588,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">301,384,357<span></span>
</td>
<td class="nump">330,170,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entity</a></td>
<td class="nump">3,369,068<span></span>
</td>
<td class="nump">3,906,796<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">304,753,425<span></span>
</td>
<td class="nump">334,077,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">256,945,284<span></span>
</td>
<td class="nump">285,622,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entity</a></td>
<td class="nump">3,369,068<span></span>
</td>
<td class="nump">3,906,796<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">260,314,352<span></span>
</td>
<td class="nump">289,529,746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">44,439,073<span></span>
</td>
<td class="nump">44,547,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">44,439,073<span></span>
</td>
<td class="nump">44,547,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">172,280,734<span></span>
</td>
<td class="nump">191,439,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">172,280,734<span></span>
</td>
<td class="nump">191,439,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">84,664,550<span></span>
</td>
<td class="nump">94,183,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">84,664,550<span></span>
</td>
<td class="nump">94,183,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">39,986,103<span></span>
</td>
<td class="nump">39,967,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">39,986,103<span></span>
</td>
<td class="nump">39,967,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">2,991,347<span></span>
</td>
<td class="nump">2,991,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">2,991,347<span></span>
</td>
<td class="nump">2,991,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">1,461,623<span></span>
</td>
<td class="nump">1,588,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">1,461,623<span></span>
</td>
<td class="nump">1,588,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available for sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749328529656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Indefinite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill, gross</a></td>
<td class="nump">$ 10,513,371<span></span>
</td>
<td class="nump">$ 10,513,371<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, net book value</a></td>
<td class="nump">10,513,371<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">10,473,761<span></span>
</td>
<td class="nump">10,473,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(7,974,176)<span></span>
</td>
<td class="num">(7,847,406)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, Net Book Value</a></td>
<td class="nump">2,499,585<span></span>
</td>
<td class="nump">2,626,355<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsGross', window );">Total goodwill and intangible assets, Gross</a></td>
<td class="nump">20,987,132<span></span>
</td>
<td class="nump">20,987,132<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsNet', window );">Total goodwill and intangible assets, Net Book Value</a></td>
<td class="nump">13,012,956<span></span>
</td>
<td class="nump">13,139,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">1,323,761<span></span>
</td>
<td class="nump">1,323,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(1,312,787)<span></span>
</td>
<td class="num">(1,305,600)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, Net Book Value</a></td>
<td class="nump">10,974<span></span>
</td>
<td class="nump">18,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember', window );">Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">5,100,000<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(2,798,889)<span></span>
</td>
<td class="num">(2,735,556)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, Net Book Value</a></td>
<td class="nump">2,301,111<span></span>
</td>
<td class="nump">2,364,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">4,050,000<span></span>
</td>
<td class="nump">4,050,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(3,862,500)<span></span>
</td>
<td class="num">(3,806,250)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, Net Book Value</a></td>
<td class="nump">$ 187,500<span></span>
</td>
<td class="nump">$ 243,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average Useful Life (Yrs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average Useful Life (Yrs) | Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average Useful Life (Yrs) | Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average Useful Life (Yrs) | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749334286120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Aggregate amortization expense on intangible assets</a></td>
<td class="nump">$ 126,770<span></span>
</td>
<td class="nump">$ 136,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Estimated aggregate amortization expense for remainder of 2022</a></td>
<td class="nump">366,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated aggregate amortization expense for 2023</a></td>
<td class="nump">276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated aggregate amortization expense for 2024</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated aggregate amortization expense for 2025</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated aggregate amortization expense for 2026</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Estimated aggregate amortization expense for 2027</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749325008840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 01, 2019 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,287,103,438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,209,855,522)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,207,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,959,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,488<span></span>
</td>
<td class="nump">$ 513,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,642,419,819)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,609,589,797)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt instrument, convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt instrument, convertible, threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt instrument, convertible, threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 592,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,000<span></span>
</td>
<td class="nump">463,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, contractual interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,000<span></span>
</td>
<td class="nump">$ 267,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1858045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares) | shares</a></td>
<td class="nump">1,009,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, contractual interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Bonds | Initial Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="nump">0.0002147766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_InitialConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=ino_InitialConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749326365048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Balance of Convertible Bonds and Notes (Details) - Convertible senior notes<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Original principal amount</a></td>
<td class="nump">$ 78,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleDebtConvertedAmount', window );">Principal amount converted into common shares</a></td>
<td class="num">(62,085,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="num">(296,051)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">88,915<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 16,207,864<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentConvertibleDebtConvertedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Converted Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentConvertibleDebtConvertedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749326480952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Schedule of Maturities (Details) - Convertible senior notes - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 16,207,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 534,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">1,067,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">16,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying amount</a></td>
<td class="nump">$ 18,549,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749328347944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares, authorized (in shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">226,510,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">226,510,720<span></span>
</td>
<td class="nump">217,382,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749326333176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 09, 2021</div></th>
<th class="th"><div>Jan. 25, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>May 13, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan', window );">Number of potential shares authorized for issuance under share based compensation plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized', window );">Increase in number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,491,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, other shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,701,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Maximum contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember', window );">2007 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, other shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,395,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Maximum contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Maximum authorized amount</a></td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage', window );">Sale of stock, sales proceeds of any common stock, percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Aggregate number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,480,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementWeightedAveragePricePerShare', window );">Stock sale agreement weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Aggregate proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementRemainingAuthorizedAmount', window );">Remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of potential shares authorized for issuance under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateNumberofSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Number of Shares Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateNumberofSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement Weighted Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementMaximumAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Maximum Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementMaximumAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementRemainingAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Remaining Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementRemainingAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749328493288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">21,305,035<span></span>
</td>
<td class="nump">17,153,244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">14,097,063<span></span>
</td>
<td class="nump">10,826,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember', window );">Service-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">3,491,330<span></span>
</td>
<td class="nump">2,610,130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">663,353<span></span>
</td>
<td class="nump">663,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">3,309<span></span>
</td>
<td class="nump">3,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded (in shares)</a></td>
<td class="nump">3,049,980<span></span>
</td>
<td class="nump">3,049,980<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749327348680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 28, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,711,151<span></span>
</td>
<td class="nump">$ 9,595,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.48<span></span>
</td>
<td class="nump">$ 8.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,200,000<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember', window );">Non Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,000<span></span>
</td>
<td class="nump">$ 429,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.88%<span></span>
</td>
<td class="nump">0.88%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation cost related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, restricted stock units (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="nump">$ 11.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units | 2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, restricted stock units (in dollars per share)</a></td>
<td class="nump">$ 12.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">663,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units | 2016 Incentive Plan | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units | 2016 Incentive Plan | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749327424408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,074<span></span>
</td>
<td class="nump">$ 371,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAmendedAmount', window );">Collaborative agreement, amended amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedExercisedAmount', window );">Collaborative agreement, awarded exercised amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember', window );">Revenue under collaborative research and development arrangements with affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,842<span></span>
</td>
<td class="nump">49,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementExpensesToReimburse', window );">Expenses to reimburse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeArrangementTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedAmount', window );">Awarded amount</a></td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Contra-research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">$ 230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Operating expenses related to affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,000<span></span>
</td>
<td class="nump">$ 318,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Accounts payable/accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">548,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliate', window );">Deferred grant funding, from affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember', window );">The Wistar Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedAmount', window );">Awarded amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedOptionAmount', window );">Awarded option amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences | Available-for-sale Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related-Party Transactions (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAmendedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Amended Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAmendedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedExercisedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Exercised Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedExercisedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedOptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Option Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedOptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementExpensesToReimburse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Expenses To Reimburse</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementExpensesToReimburse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_RelatedPartyTransactionsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_RelatedPartyTransactionsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749325837320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>ft&#178; </div>
<div>agreement</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease cost | $</a></td>
<td class="nump">$ 830<span></span>
</td>
<td class="nump">$ 850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease', window );">Number of agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember', window );">San Diego, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Area leased (in square feet)</a></td>
<td class="nump">82,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember', window );">Plymouth Meeting, Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Area leased (in square feet)</a></td>
<td class="nump">57,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseAreaofLandUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area of Land Under Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseAreaofLandUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseNumberOfAgreementsToSublease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Agreements To Sublease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseNumberOfAgreementsToSublease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749328320552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2022</a></td>
<td class="nump">$ 3,074,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">4,089,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">3,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">3,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">3,139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">6,749,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">23,164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(5,725,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">17,439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(2,672,974)<span></span>
</td>
<td class="num">$ (2,603,956)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 14,765,868<span></span>
</td>
<td class="nump">$ 15,459,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749321113336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Aug. 30, 2019</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199,074<span></span>
</td>
<td class="nump">$ 371,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,283,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,559,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Revenue under collaborative research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,895<span></span>
</td>
<td class="nump">39,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AdvaccineMember', window );">Advaccine | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved', window );">Additional revenue to be achieved</a></td>
<td class="nump">206,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementPaymentEarned', window );">Collaboration agreement, payment earned</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementRoyaltyPeriod', window );">Royalty period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Annual maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AnnualMaintenancePeriod', window );">Annual maintenance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AdvaccineMember', window );">Advaccine | Collaborative Arrangement, Product | Revenue under collaborative research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_ApolloBioMember', window );">ApolloBio | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved', window );">Additional revenue to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementRoyaltyPeriod', window );">Royalty period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination', window );">Period from effective date for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination', window );">Number of days written notice before termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | Lassa Fever and MERS Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment', window );">Collaborative agreement, period to receive funding for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | SARS-CoV-2/COVID-19 Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement, Product | INO-4800</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">893,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill and Melinda Gates Foundation | Collaborative Arrangement, Product | DNA-Encoded Monoclonal Antibody Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department of Defence | Collaborative Arrangement, Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Contra-research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">$ 7,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Deferred grant funding, from affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department of Defence | Collaborative Arrangement, Product | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received for research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department of Defence | Collaborative Arrangement, Product | CELLECTRA 2000 Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeArrangementFixedPriceContractAmountAwarded', window );">Purchase price, procurement contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeArrangementRevenueFromTheProcurementContract', window );">Collaborative arrangement , revenue from the procurement contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AnnualMaintenancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Maintenance Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AnnualMaintenancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Additional Revenue To Be Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAdditionalRevenueToBeAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementPaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Payment Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementPaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementRoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Royalty Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementRoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received for Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Number of Days Written Notice Before Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period From Effective Date For Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period to Receive Funding for Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementsUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreements, Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementsUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementFixedPriceContractAmountAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementFixedPriceContractAmountAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementRevenueFromTheProcurementContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement , Revenue from the Procurement Contract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementRevenueFromTheProcurementContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123366838&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_AdvaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_AdvaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_ApolloBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_ApolloBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_SARSCoV2COVID19VaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_SARSCoV2COVID19VaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_INO4800Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_INO4800Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_CELLECTRA2000DeviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_CELLECTRA2000DeviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749321010536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,999,998<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,165,213<span></span>
</td>
<td class="nump">434,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment', window );">Stock purchase agreement, commitment of additional investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of investment</a></td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment', window );">Loss from equity method investment, recorded and allocated to investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount', window );">Remeasurement of Geneos Series A-1 preferred stock</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Series A One Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of net loss in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,000,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Commitment Of Additional Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749326463480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Preferred stock Investment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022</a></td>
<td class="num">$ (2,165,213)<span></span>
</td>
<td class="num">$ (434,387)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember', window );">Series A-2 One Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning balance</a></td>
<td class="nump">1,999,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount', window );">Remeasurement of Geneos Series A-1 preferred stock</a></td>
<td class="nump">165,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022</a></td>
<td class="num">(2,165,213)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139749330030600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Common stock - Subsequent Event<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Apr. 21, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="nump">2,502,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received | $</a></td>
<td class="nump">$ 8.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>ino-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:ino="http://www.inovio.com/20220331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ino-20220331.xsd" xlink:type="simple"/>
    <context id="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia337f4f8221049bdafddfe7f7f369002_I20220509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2022-05-09</instant>
        </period>
    </context>
    <context id="ib30ea824035a4f29b36bdddc9f77f71b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7d6d1124a58448ddb3c672fffdeb679f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i21d5e20142404b77b5d380c961472ef1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iae8b8138e63644098dfe464495c5f147_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i00d50bf6cf7f4ad2a522a955df7010fd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i998a91031a25433790f82a700988c0b4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if5b13173d5de4d16982a5e2c1dfbfd2e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iec9fd62a63dd428f8b7307aa6489cfd8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i804e05de6cd241ee8b38b4028e3fa675_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48c5a28f11784bc08ca5f019b88b0a82_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic94dcc9ceaba4c73bf5498290cc2a8f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c094866746944c190a5cb5e6ec38207_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a5ff34a96be4b01892682db87c0bb82_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic3d2aff6e7174cf6990e9cce3126b3d2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3a5dd7608edd4c9b81f794075e1bf7c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia20aee050b564621b0904ff547d1603d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8a58b7a2eeb4d1b8fa8e40ba25ea392_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8289efe5fbaf48509196fa46a48e5ffc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia4a41317c5a64ca1abb762b294f27a77_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie499a30eb95c4720b752a618011da9de_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie50284eae13a4b7db5e6261db6e0f911_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic282ad05383d4cf390606ef8b610a75a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i33a11834f7f947429f551d48915db764_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id541689a86584fd08a1e5666a6539c27_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i09c58eec38c84e9ba577bfb58d9de2c6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib931e527febe494c96c6bff98a6bc8c8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i197e743baebd4a54a1f59b2ead228a4b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5a964ed0569a4e2687266fee8d3eb2cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic378134c645a455f8c29cf425649d9b4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if7fbf9be64024e8389236deb05644f9a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i37a14c64016b44eeb0df3bd03a9c7261_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i01903000ca0941ae93dc226d9b97e700_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5c88a6a27b9e44eeba42ab6a651cc57c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i495f9f8bba37406aa957bb1fa1bb6b82_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i706e11fcf7b840a68346dcb076a72fe7_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7b4db7184a6e4d539bd893221daa7b6b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib17ceb956c2f426eb2b764885c99a7e2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5f8d19094f794192baacd56f29fcdae7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5a7141f817b64eedaa3b9d245abc6c8f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="iafaea1518ae5419386ac2efc6b2ba187_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idd921433e3a44903b67d69cd507b789c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2676a854bc50429cba33013cd2fd88be_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if2af437e174542f6a96a9dd371a8e151_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i13070eb515fa45c694edb66f1cadcb21_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5188e2afa230429fab7f59ddf2c594b3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifdd8f1364df749e5b75e252f613f37c5_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i5998790341a8497ba20d32d62e49492c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9acea0aaff494ae8956e27ef9faf34c6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:OtherCounterpartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib186138d47d74be9a37ef0b9377767e2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:OtherCounterpartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7dd96d739d1d4c6ba7fd44457e650877_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i200d0433fb874ceca8d01b4202a59cf7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7d5059c8d38048299da6be38015206d8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i96212faeb6564d55b7a90168c62339d7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifea821ceda2b46c5ba64c5b0a9ebf7eb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib3b77e32e0d54bbe98f98ad16cfdcced_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7d2dabcc2e274335be3e08c2ede5ec0e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i15f4645750d14b1d8727f373d9bfec66_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i35afa32f29f843dabd62652947f0eeb1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3dd02c8047614f899869c90b0070ab8d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i11ad7b0c63c34318904c5962edc5336c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c1de2f49204499c821a49656c3c3db0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i256e22e1c0a840458b2307e674601335_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9c26ca99f7cb4cacbac0e8bc0ed494ed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a46ac477e0c44908926cbfd89796968_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie327610064114130b6724b61e0aa0b11_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1a7a4020c94941b4b6acc78d93b58453_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i471805632a1c4b1497d106f7f6d32bc1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3a3922f5859d40ef8c8a2487c7e981b6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3bad7403c49c468b8ceafcdd73d058f4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i910199c871b24e7281edfe262f9e595c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idcdd3d9daef249babdd7610c465d9861_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9fd176d27ac94f388085f5b57e2f24cd_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if6e6180b331b4e71ba67ae40963d4a03_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibc7f88e09b444751aad08e36afbd151d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7763d94f5b7e483eb2aa063bff3f4fc5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i37fe9e79f04d4894a64245d5e39a5f1e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if05223ae01d645f69bb34279da86b5c0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib091b9b6d4f644349ae9a24d2bdc827b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibf2144065280473599c7afda89ad1694_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7d6412688827466ca20d0eb89182015c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i20a3ba1b8f6c4fdbbc57d85e7c759c66_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i62d964321f9c49ba80f2d28a540dfb8e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i05e130a7d4404dcf9c53ef79a503f2d8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7aee826afc7f4bb584c9baec2cacd2ff_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i02b127be22eb4b9a9750afaa61f1ec0f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iae1ff7cfb12549c794647cdbfea00698_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i50d2be785b7e4c0eb3075ccc1b52f222_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3ab217ecf956405d9cf37acb90fb804c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i735216c789474c09b2396fda353fb55e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib92f6424c666449486766a5d1d0e1832_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a4147a900d44007bcbaff1d2000a812_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i922d453abb054b1c959336166486250e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a00852361e24abdb75f61f00ba8440e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia0927a0eab1d4d2ea57f80d09385ab14_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2346a1c5f64c47f39444b2604e34bec9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff609476032e4fd5850ace07b081d978_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4df03a74cdb1441981e64076b32bf6cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf4907bded604daa8b4f90733b4960a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic01a2bc151f341de9e5bc9ca12685bd1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4acf182b26a44980bccfb7dc1c75de40_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i10431da7c03644c9875fb73a741719db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5cee4483f4e345c08e931ecf9ad3260d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idaca2ffe0ede4c7292c889e48dba76a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0768b2ff10a94d04af660988ce14766c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia45b882b6c5449a098b1e8921b30765f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8fc8c9fb3dda470585109a269277aa90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iddcca9c2136e4da798d1e5a739c72a2b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id97388b64a184cbab4a4fa6e23803d1c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4284e75eeec74588b5ab75d6c01392cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia11026ef96064c518d5053ab32d38a62_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5133a9aa6b974cd6be58671085bc9222_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ffc37c7b05544bb97a430265cc2bef9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd3476330236483c98b0ec3070d9e333_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i937bf2eba10942f6be46a1071b4f10d7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7ac1da597f7b4340893eba51de04ad26_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i851991d1186f468b82660c9a9ba18e50_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3175c5ab2f0d46d7883309efb700f354_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i72f5235c51804466877805e8fd527626_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4ee1c54551f24453a3c895ffdc0bfe2e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f93349007644f839f68fbed0c369c0d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9b2a0788492e40989bb27421d1bd2073_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic060851ec89c42658d3355959c413ec0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6fece0d322b434c8593f46a8150a928_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia23c27fd3cb34cb7ac69f9e4e67b758a_I20190301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-01</instant>
        </period>
    </context>
    <context id="if641e7664fea4b26986aea56c1df79ee_D20190219-20190301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-19</startDate>
            <endDate>2019-03-01</endDate>
        </period>
    </context>
    <context id="i89c242d635e34cc2882b5b395b26a546_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i11fba970b3414270a4d7e4804a06e0e9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if239e019c41f41df87d6fabeb16a8209_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i93f4fe9cdb954509a29e6972a23d8717_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie10fbf5fad8743a6b390d426979d8a2f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib3c3bc6efec5497d8d3e271600131a3b_I20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-26</instant>
        </period>
    </context>
    <context id="i257d1ac432f142b299c0fe356311ee8a_D20191226-20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-26</startDate>
            <endDate>2019-12-26</endDate>
        </period>
    </context>
    <context id="ib7987401764743bca11a6fcb90ae347c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ide3610d56f684b5fbb8f7fff6ee33eee_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6cd8ee10514043399860125bd7812d5e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3b8f0e3e81bb46f2b223a270fb1bfb13_D20191226-20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-26</startDate>
            <endDate>2019-12-26</endDate>
        </period>
    </context>
    <context id="iee0415add3154b6c8fca72404d201bb7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e2be23d00d345b6bed7ade8e6494fc7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9a881011504441e1a9c61a374bf1ccf4_D20211109-20211109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-09</startDate>
            <endDate>2021-11-09</endDate>
        </period>
    </context>
    <context id="i5e2f4f4898364123a256c32ca33facc9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ief33ee4c2f9d472ca203587fdd030959_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i49690b96047544fa998f0502891752a4_D20210125-20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-25</startDate>
            <endDate>2021-01-25</endDate>
        </period>
    </context>
    <context id="i2d07fc0fc7734f8d9a8aaf0c1d8877ec_I20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-25</instant>
        </period>
    </context>
    <context id="i506a7271caec452a979fcd2973d994a3_I20160513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-13</instant>
        </period>
    </context>
    <context id="i74e4addc1ab747f6b371d1e28eef2596_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i7c114109f3fb4d2e9bd8f37900a7cf35_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia7964dc3a17e4cfb80c440f5e98914ba_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i53998403d9a644378e830ed35dde9174_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i74c8f3b2f8074de68c07442296de5eda_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4e593faba088418ca3470ba0e2ef170a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic1f7c31d501f484e8655d8e19138ea45_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8eeb39a62cfd45a19b16ff2f77b29ea0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9d5160a767ac4bafba1dc028690dde9c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i64c8814591c9419e86db1db17a0446e7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i450d92211f544cdc985d06e7fed62e63_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6079656cc273434d86458c6aebd9dc67_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i404ce3ef99524755b77883e75ca4a739_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8f5a82e0fe634a5cb2409168cbd8cd88_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5454fcab37d841f7875d94376e14df0d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5244cd2065d44efa8be7f4b42dc1fef1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i131de56e723d441a8b4d29a66a9f0297_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ieccf6f95500841c6a3689f60a52eee48_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib1c041808f3c4fcdad3091644d6b6568_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i12c8e38f5a5d4faf8e21cca6e3048613_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i466990d2769740b4be6de242e03e8e59_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i82e293c63e7b45f497259112c8856cf3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ieaec0500407e4460af3ae9824374aa5f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i91452942e5e5451087ce0e121faae465_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7c416618392046e181d9a033a06b4af3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if2ec2de8f8e64ef6b6eb20c42e3919e2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7fdb61060a19450e8b33f7efaa1f435d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i76d9cb0a9e604a1d89a1ce39c1ba9ed3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1fb6f216bfa54b49a624c469d5203ec1_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="i491165f321fa4e9eba5d2778f326ed0d_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="ie37803101927413c9caf0a2b10452612_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="i0505907c69774e2f9b14cd272f6e78ab_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i113857f5676c45c8985e00527eadd700_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i54c2b2722e924db1b3ff26d952a3e88e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a14a4908e804611b1eb9dc197afef27_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="ic38879a67ed2417892b510c2282934e9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i154ff5c5f70146429ef3ca2399396227_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="i1c89ed0e5b044d7e82c20c40f333fc2a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0034e9c906a24164ba01742d7b986684_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if9fe7623f5234877ba048ec3fbd39a69_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic40026348a73461d8f5be933afc8a40e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i598d38fe89f5401ebb28138691b4da4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i93b7902a9abb40beb532a03c0df4ed2d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic80593d7532d4f61b66a6152e7a7552b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8bf07160649541bca2512ad124da7853_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if296892e17fa4a3996048fd9a773bb41_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9d671d2113a6459188a02276cfc2a5f6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia01bf7e261dd4db5917be920fa366418_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2db1017a46a040d6861a567a358dcdd1_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="if8516f2c2e834670831af151ddee24ed_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7bcc9760314f413bba4b5e3b026f2e41_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9818436ba9fe436cb6d8b574154f1b3b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3e370c4fb7ad47f09d71f49dcf34f2f7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i071ee78b7166461a9fbde479b660be3e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i506a148e81644d5482e7e9eebdf0b1d5_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="id2be74ba561d442db493dddcc92ebd3e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8b96bf9a8fc445eaba5ecb1d140390f6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5e1c9fb9467945ab9163eda017d1f2da_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8f8f17f12161403fafe2948a7f9f402f_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i152a732fccdd4dbdb5a4fc5c6458a1ec_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="if9442dd1633e455b91a66f5a6ab2ce25_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i32bf53bd03c54fc1a9176c9e8bd73481_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i2b14e2287928438d88d281f85c7278a8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5bfa9631ac274759b1b56aef9adc496f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if5ba8467f8d240158db11dd9beaae7e2_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if5e81165a16440ebb8326d8a24d15995_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="ic2b5bc317c764378a3de78871886838c_D20190801-20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="i92f8729b1391467aa54b6475bbefade5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6295923acaed47d1956bd75c6c4c0edd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4b11763ebe53429599cade53585833b6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie62aeb4d7cf747aeb6d6d6c6296bfe0a_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3e16f9f97cb444ca9d3dba5ea73d1d90_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4518574f497f4fa2a453bf07d6721aa2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1204bafe5467488693dda8b9e96a2774_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i17c519d2d2f7427e8cf34e5097504c60_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA2000DeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6c0779eaba8941deac45ec2a70e681f7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA2000DeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8ee8e99d45ce4685bcbfe7aa1f6ef9ac_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i74796e39acc84dc198e9df9ff90b38c2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2125ae0ebb6c4ac58e7f4bb7948cf2ee_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i76c6ab34cb86461fbeae30681dd72330_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5a59d1c482204129ace354f666e93b3c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9287e5231b0c44c2a4df39c192522f21_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7ef6b938867e49d4b6bea20f92003696_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="ief31b251d6394afd8f91a7cc96c6f6f0_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="i358168d3fb3e4081afe3f8f55ae73934_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2998f9f06ab149b7a5203f1dd82fad31_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i072b718ce60743018ae014282340909c_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i35c4e31704a040e18096a49a219271b0_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="icdd6b2404d2348d6be3af54fee60364d_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i7b0adeeead5e4699a63cb480fc0a0ac3_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7af4410be8f148b5b8314f57ad7a668d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iade08220a0f74869bcb1f820413ac244_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie1f4de57b99d45e7878e83e0a961478f_D20200601-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i39108879adec43dd9ce939da4a9133c8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i240a06710e7f499c92f922af74aa1d72_D20200601-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i94cd371c1e2a482189fbcd1fa606ce5b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i99ae48f06acb4be0999de4734437d7de_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i37c604731df5488385ee8ef0f5eaa642_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="ic757f5e350bb42269e2c1e8b10f57ef6_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idc03d9886d82421ebbc554d6ea904cd3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if6bb6660938e47b0a2d5df1338384e35_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6c48be9a581248328538c7ec76130395_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8c076c415b0c4d348c148ffabebaa199_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic58ffceb77ce4063a7894330d50f5c66_D20220401-20220421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-21</endDate>
        </period>
    </context>
    <context id="ib3ee9fcf6611452784c45ad678fced93_I20220421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-21</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="position">
        <measure>ino:position</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="day">
        <measure>ino:day</measure>
    </unit>
    <unit id="krw">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="agreement">
        <measure>ino:agreement</measure>
    </unit>
    <dei:DocumentPeriodEndDate
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180L2ZyYWc6NzA0YzNhZmQ2YjJhNDVhNmE5Y2RjOGQ3ZGI4NTNjNzQvdGFibGU6YzlkOGFkYmQzZWU0NGFhNjkwZDY3Yzc2YjZiOTVlYzkvdGFibGVyYW5nZTpjOWQ4YWRiZDNlZTQ0YWE2OTBkNjdjNzZiNmI5NWVjOV8xLTEtMS0xLTMxNjky_113148a0-daff-49e5-bbb6-3c21fd52b5c2">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180L2ZyYWc6NzA0YzNhZmQ2YjJhNDVhNmE5Y2RjOGQ3ZGI4NTNjNzQvdGFibGU6YzlkOGFkYmQzZWU0NGFhNjkwZDY3Yzc2YjZiOTVlYzkvdGFibGVyYW5nZTpjOWQ4YWRiZDNlZTQ0YWE2OTBkNjdjNzZiNmI5NWVjOV80LTEtMS0xLTMxNjky_007d5b7e-ba37-4057-9c1f-bb9b26c24e54">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180L2ZyYWc6NzA0YzNhZmQ2YjJhNDVhNmE5Y2RjOGQ3ZGI4NTNjNzQvdGFibGU6YzlkOGFkYmQzZWU0NGFhNjkwZDY3Yzc2YjZiOTVlYzkvdGFibGVyYW5nZTpjOWQ4YWRiZDNlZTQ0YWE2OTBkNjdjNzZiNmI5NWVjOV82LTEtMS0xLTMxNjky_680041c5-4c00-44f2-9b58-ff74258a8463">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180L2ZyYWc6NzA0YzNhZmQ2YjJhNDVhNmE5Y2RjOGQ3ZGI4NTNjNzQvdGFibGU6YzlkOGFkYmQzZWU0NGFhNjkwZDY3Yzc2YjZiOTVlYzkvdGFibGVyYW5nZTpjOWQ4YWRiZDNlZTQ0YWE2OTBkNjdjNzZiNmI5NWVjOV83LTEtMS0xLTMxNjky_cd776983-f742-4168-8cde-5a399f3c31d7">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180L2ZyYWc6NzA0YzNhZmQ2YjJhNDVhNmE5Y2RjOGQ3ZGI4NTNjNzQvdGFibGU6YzlkOGFkYmQzZWU0NGFhNjkwZDY3Yzc2YjZiOTVlYzkvdGFibGVyYW5nZTpjOWQ4YWRiZDNlZTQ0YWE2OTBkNjdjNzZiNmI5NWVjOV85LTEtMS0xLTMxNjky_e29a1fc4-3b83-48f4-9b7d-36da11d9e589">0001055726</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180L2ZyYWc6NzA0YzNhZmQ2YjJhNDVhNmE5Y2RjOGQ3ZGI4NTNjNzQvdGFibGU6YzlkOGFkYmQzZWU0NGFhNjkwZDY3Yzc2YjZiOTVlYzkvdGFibGVyYW5nZTpjOWQ4YWRiZDNlZTQ0YWE2OTBkNjdjNzZiNmI5NWVjOV8xMC0xLTEtMS0zMTY5Mg_c60e6f0c-400e-4986-a6a1-b1157d55452f">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="ic3d2aff6e7174cf6990e9cce3126b3d2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNC0wLTEtMS0zODcxMw_3e7c1e5d-af94-4a9d-8491-3f37d7a30ea0">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="if641e7664fea4b26986aea56c1df79ee_D20190219-20190301"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182NC9mcmFnOmQxMDYzYTAyMmY3YTQwNzQ5NjdjZGVhMTdlY2MxNGI4L3RhYmxlOmM5ZWQ1NDhiNjZhZjRiZjA5NmZkZjNjNTZkYmYwODc4L3RhYmxlcmFuZ2U6YzllZDU0OGI2NmFmNGJmMDk2ZmRmM2M1NmRiZjA4NzhfMi0xLTEtMS0zMTY5Mg_baa924e4-6443-4be4-aff4-b2f5f9f93f01"
      unitRef="number">0.1858045</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i3b8f0e3e81bb46f2b223a270fb1bfb13_D20191226-20191226"
      decimals="10"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182NC9mcmFnOmQxMDYzYTAyMmY3YTQwNzQ5NjdjZGVhMTdlY2MxNGI4L3RhYmxlOmM5ZWQ1NDhiNjZhZjRiZjA5NmZkZjNjNTZkYmYwODc4L3RhYmxlcmFuZ2U6YzllZDU0OGI2NmFmNGJmMDk2ZmRmM2M1NmRiZjA4NzhfNy0yLTEtMS0zMTY5Mg_4b8c2e80-8f79-4ea2-b95f-ead0b2dda7e7"
      unitRef="number">0.0002147766</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTEz_d5cf483f-b60f-4bb4-86a2-4c4d3ce07235">10-Q</dei:DocumentType>
    <dei:DocumentType
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTEz_d78f3682-4bc5-4b90-91c5-906d0ef857a5">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGFibGU6MTcyN2NiM2NkMzcwNGMyZGE3NTY5MDc2NzA2MzMwMjkvdGFibGVyYW5nZToxNzI3Y2IzY2QzNzA0YzJkYTc1NjkwNzY3MDYzMzAyOV8wLTAtMS0xLTMxNjky_4d1dfd9e-14fe-4e8b-8f6c-b0af110d0328">true</dei:DocumentQuarterlyReport>
    <dei:DocumentTransitionReport
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGFibGU6ZjJkMDNiYTBmOTYyNDVmYmFkYzk2NTliNGYxN2YxNWUvdGFibGVyYW5nZTpmMmQwM2JhMGY5NjI0NWZiYWRjOTY1OWI0ZjE3ZjE1ZV8wLTAtMS0xLTMxNjky_19101b24-f067-48b7-8ca8-548cbda5fd68">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTE0_38eee5d7-2636-44b1-a798-01ba5a2aebeb">001-14888</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTIw_5a326a8a-e71f-4d55-ace6-9e675222c79b">INOVIO PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGFibGU6MGY0OGExNGZkYzQyNDQ2Yjg1M2M2ZmQxMjkwNDViYjkvdGFibGVyYW5nZTowZjQ4YTE0ZmRjNDI0NDZiODUzYzZmZDEyOTA0NWJiOV8wLTAtMS0xLTMxNjky_1bea5435-e996-438d-8d4d-e04c80ffc3f1">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGFibGU6MGY0OGExNGZkYzQyNDQ2Yjg1M2M2ZmQxMjkwNDViYjkvdGFibGVyYW5nZTowZjQ4YTE0ZmRjNDI0NDZiODUzYzZmZDEyOTA0NWJiOV8wLTItMS0xLTMxNjky_522422ee-cab4-42d2-8379-fca5faf9b6ab">33-0969592</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTIx_2f82e584-3b95-4726-a45a-d5aae1ee0791">660 W. GERMANTOWN PIKE, SUITE 110</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTIy_9f7ce997-9a14-4a2e-b049-ed9f34d05383">PLYMOUTH MEETING</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTE1_ec78e188-8442-48b6-bb54-afffa2795fc6">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTE2_fd5eaad4-6747-4143-bd28-0cac6925083f">19462</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTIz_fc094a2c-1bb3-47f2-abea-2064c6ea29c8">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTI0_185137ff-2cb8-40de-81f8-916c4ebcb35b">440-4200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGFibGU6NTA5NTIwNDFhYmIzNDFiODgwMzc1NzY3OTIyOWViZmMvdGFibGVyYW5nZTo1MDk1MjA0MWFiYjM0MWI4ODAzNzU3Njc5MjI5ZWJmY18xLTAtMS0xLTMxNjky_617e16bd-0548-4a14-958e-8352e9e7b14c">COMMON STOCK, $0.001 PAR VALUE</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGFibGU6NTA5NTIwNDFhYmIzNDFiODgwMzc1NzY3OTIyOWViZmMvdGFibGVyYW5nZTo1MDk1MjA0MWFiYjM0MWI4ODAzNzU3Njc5MjI5ZWJmY18xLTEtMS0xLTMxNjky_a87ad73b-7916-4264-92a4-4e1803f50fdd">INO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGFibGU6NTA5NTIwNDFhYmIzNDFiODgwMzc1NzY3OTIyOWViZmMvdGFibGVyYW5nZTo1MDk1MjA0MWFiYjM0MWI4ODAzNzU3Njc5MjI5ZWJmY18xLTItMS0xLTMxNjky_373af2f3-9d57-4ffa-83ed-24c7b9b8108d">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTE3_1e87fe85-a8d5-4cda-90f1-763a186df520">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTE4_056bd5a0-5a56-4216-8bf7-c7e5098e9802">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGFibGU6MTlkY2UxMmM5Yjg4NDcwNmIzZjhkOTdiYTE4MTJkMDAvdGFibGVyYW5nZToxOWRjZTEyYzliODg0NzA2YjNmOGQ5N2JhMTgxMmQwMF8wLTAtMS0xLTMxNjky_72cb8942-a7b5-46d8-9927-50cbe73558e4">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGFibGU6MTlkY2UxMmM5Yjg4NDcwNmIzZjhkOTdiYTE4MTJkMDAvdGFibGVyYW5nZToxOWRjZTEyYzliODg0NzA2YjNmOGQ5N2JhMTgxMmQwMF8yLTQtMS0xLTMxNjky_b670b75e-2973-4c24-8efb-4172e4c67b65">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGFibGU6MTlkY2UxMmM5Yjg4NDcwNmIzZjhkOTdiYTE4MTJkMDAvdGFibGVyYW5nZToxOWRjZTEyYzliODg0NzA2YjNmOGQ5N2JhMTgxMmQwMF80LTQtMS0xLTMxNjky_ab8d6c71-67e9-4780-981c-16be296f4c52">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTE5_29607103-1b9b-4313-93b5-2fed5ae24e10">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ia337f4f8221049bdafddfe7f7f369002_I20220509"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xL2ZyYWc6ZWU4YWNjNTU0NGQzNDQxMTkyOTNkNDZkNjZmMGEyOGMvdGV4dHJlZ2lvbjplZThhY2M1NTQ0ZDM0NDExOTI5M2Q0NmQ2NmYwYTI4Y18yMTAw_27fb1473-cdcc-4222-9fad-0d2194d6bed4"
      unitRef="shares">229041114</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNC0xLTEtMS0zMTY5Mg_f521b5f6-69c9-4ff8-b944-affa11be7224"
      unitRef="usd">59009491</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNC0zLTEtMS0zMTY5Mg_9a334c61-51f7-49b4-9af4-d4f05256941c"
      unitRef="usd">71143778</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNS0xLTEtMS0zMTY5Mg_9f50a367-d606-40db-bb9f-77974dd04088"
      unitRef="usd">301384357</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNS0zLTEtMS0zMTY5Mg_bd23b132-76a8-4bb6-91e2-25b25e9cf2bc"
      unitRef="usd">330170940</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNi0xLTEtMS0zMTY5Mg_74ac9446-7e86-44c3-b3e6-1444a0be4d72"
      unitRef="usd">4003680</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNi0zLTEtMS0zMTY5Mg_d1dcd2c0-a2f5-4d4b-a9f0-621e9184b9f7"
      unitRef="usd">5466850</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNy0xLTEtMS0zMTY5Mg_d584e7ef-26e6-4250-adf3-d2a6e2d3bc0b"
      unitRef="usd">3487116</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNy0zLTEtMS0zMTY5Mg_ff353c41-43e6-4f10-80ab-900d4a350759"
      unitRef="usd">2565194</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfOC0xLTEtMS0zMTY5Mg_96bce83f-74bd-42a1-9f0c-dd04cdca8b2a"
      unitRef="usd">31946477</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfOC0zLTEtMS0zMTY5Mg_a0d95bdf-ee61-4788-854a-664a0afaab52"
      unitRef="usd">38836991</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfOS0xLTEtMS0zMTY5Mg_5d5b0bf9-02a3-4b4c-b8df-1f9c263c5296"
      unitRef="usd">75772</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfOS0zLTEtMS0zMTY5Mg_862ba108-f0e7-479f-ac1d-159061944e0d"
      unitRef="usd">261192</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <us-gaap:AssetsCurrent
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTEtMS0xLTEtMzE2OTI_5fa9f1be-ea96-4b9d-ad21-d0e4ad565304"
      unitRef="usd">399906893</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTEtMy0xLTEtMzE2OTI_563fcbec-ae05-45c2-9ee5-db474f178cfe"
      unitRef="usd">448444945</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTItMS0xLTEtMzE2OTI_63fcf12e-59be-402f-9dad-864684877f3f"
      unitRef="usd">16696936</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTItMy0xLTEtMzE2OTI_54ebd978-d78f-40a1-a066-cd36d8511297"
      unitRef="usd">17453206</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTMtMS0xLTEtMzE2OTI_be1ab8dd-5f48-4e2d-874c-80fc0c7f2514"
      unitRef="usd">3369068</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTMtMy0xLTEtMzE2OTI_3d21f4be-fb27-4106-bdf4-9540140eb61f"
      unitRef="usd">3906796</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTUtMS0xLTEtMzE2OTI_da57016d-463c-4fe4-b62b-003a79efe9b3"
      unitRef="usd">2499585</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTUtMy0xLTEtMzE2OTI_2f8cb186-e10a-41e6-b20f-97264c1e8d79"
      unitRef="usd">2626355</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTYtMS0xLTEtMzE2OTI_7f4107a4-82b2-464c-9fa0-d0a8b5469a6f"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTYtMy0xLTEtMzE2OTI_2e1f3967-daaa-452b-9013-580af7afdd4b"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTctMS0xLTEtMzE2OTI_e147b23d-7a63-42ab-abc4-056dacd5905e"
      unitRef="usd">11251440</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTctMy0xLTEtMzE2OTI_1b800068-ade4-45ff-a4e8-5497ee5f8afb"
      unitRef="usd">11571026</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTgtMS0xLTEtMzE2OTI_02cf0c64-8d8f-4438-aef2-500cdfc02df7"
      unitRef="usd">1273795</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTgtMy0xLTEtMzE2OTI_ff70c092-ed75-452e-a04a-8529b1ffaffb"
      unitRef="usd">1425794</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTktMS0xLTEtMzE2OTI_2748f4cc-ed23-46eb-87e4-b96f108137ed"
      unitRef="usd">445511088</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMTktMy0xLTEtMzE2OTI_c625b524-1a28-4e9e-820c-75fb2df75da9"
      unitRef="usd">495941493</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjItMS0xLTEtMzE2OTI_c4f72835-cfd1-4c08-aba1-35c28244c1ee"
      unitRef="usd">38115396</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjItMy0xLTEtMzE2OTI_1a23507b-a217-4e18-ae89-ae062701d8e1"
      unitRef="usd">47644530</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjMtMS0xLTEtMzE2OTI_8a9a0785-4007-46b3-affe-2ecce83f95d7"
      unitRef="usd">1407386</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjMtMy0xLTEtMzE2OTI_f7512254-5894-4eee-87fb-e342c6502458"
      unitRef="usd">548032</us-gaap:DueToRelatedPartiesCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjQtMS0xLTEtMzE2OTI_3dd9cca5-329a-4f6f-bb0a-884acb7142d5"
      unitRef="usd">11827755</ino:AccruedClinicalTrialExpenseCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjQtMy0xLTEtMzE2OTI_43b5ae4f-7421-4748-9a5f-3df412e22d14"
      unitRef="usd">10326266</ino:AccruedClinicalTrialExpenseCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjUtMS0xLTEtMzE2OTI_f33e7dde-7f77-4ba7-b02d-2417672bffd3"
      unitRef="usd">15378</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjUtMy0xLTEtMzE2OTI_1e5bd6f5-3110-4bc1-bdc5-31f6b95552db"
      unitRef="usd">21628</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjctMS0xLTEtMzE2OTI_ab1c731e-da96-4054-a2d5-67e1d6b5f866"
      unitRef="usd">2672974</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjctMy0xLTEtMzE2OTI_ffd42096-a766-4d80-9582-4652aeb6b01a"
      unitRef="usd">2603956</us-gaap:OperatingLeaseLiabilityCurrent>
    <ino:DeferredGrantFundingCurrent
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjgtMS0xLTEtMzE2OTI_cbb69522-ecd3-43ef-a682-434b3eb62ce3"
      unitRef="usd">5283271</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingCurrent
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjgtMy0xLTEtMzE2OTI_e8ff8db2-25eb-44d0-88c8-7be356d4160d"
      unitRef="usd">4559721</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjktMS0xLTEtMzE2OTI_4358b33e-26ba-4faf-b828-aab30376fe72"
      unitRef="usd">37500</ino:DeferredGrantFundingFromAffiliateCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMjktMy0xLTEtMzE2OTI_0392b9dd-0cf5-4a9f-80f6-28274addc7a3"
      unitRef="usd">37500</ino:DeferredGrantFundingFromAffiliateCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzEtMS0xLTEtMzE2OTI_4a453139-5c5b-4df6-b1b8-124bfbf12963"
      unitRef="usd">59359660</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzEtMy0xLTEtMzE2OTI_1cf27318-153f-4987-945b-f217dfbc5b0b"
      unitRef="usd">65741633</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzItMS0xLTEtMzE2OTI_b1f6dc9e-b950-485b-92af-0c4f3dfb4fa5"
      unitRef="usd">60648</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzItMy0xLTEtMzE2OTI_509401c6-141f-4a1f-83ae-ac3d2510a8d9"
      unitRef="usd">64361</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ConvertibleDebt
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzQtMS0xLTEtMzE2OTI_12981ebe-2272-4c99-a569-a0a19db11132"
      unitRef="usd">16207864</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzQtMy0xLTEtMzE2OTI_b5d588a8-996b-42df-ab75-d23a012c5b10"
      unitRef="usd">14959647</us-gaap:ConvertibleDebt>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzYtMS0xLTEtMzE2OTI_48470018-9aae-40be-be4f-a229126cca67"
      unitRef="usd">14765868</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzYtMy0xLTEtMzE2OTI_b33a9647-ece4-4669-acbd-59525fd8393d"
      unitRef="usd">15459559</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzctMS0xLTEtMzE2OTI_0fd1c72e-dc37-401f-b588-1b581ac74abc"
      unitRef="usd">32046</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzctMy0xLTEtMzE2OTI_73766910-4af9-4298-8997-ff9ab6f344de"
      unitRef="usd">32046</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzktMS0xLTEtMzE2OTI_47302764-2f9f-40d4-b4b0-4602c6f2c403"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfMzktMy0xLTEtMzE2OTI_be20b177-bf59-4d18-9452-4f22fec20145"
      unitRef="usd">14826</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDAtMS0xLTEtMzE2OTI_06edd6a6-1f8f-4591-acee-61d67f2345d2"
      unitRef="usd">90426086</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDAtMy0xLTEtMzE2OTI_dbda98d3-4779-4d3f-a30e-386d220b7a82"
      unitRef="usd">96272072</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDItMS0xLTEtMzE2OTI_d2cb4928-8911-48fc-85fd-8b1a304e38e1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDItMy0xLTEtMzE2OTI_aa54b408-5fef-486d-8767-609b70abcc2f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDMtMS0xLTEtMzE2OTI_00bbc0fa-1e40-41bb-ad65-f9e476a36a05"
      unitRef="usd">226509</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDMtMy0xLTEtMzE2OTI_dfabcb4d-2445-4ed1-aaeb-ad4dfdfa557f"
      unitRef="usd">217382</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDQtMS0xLTEtMzE2OTI_d2a962af-e415-43fc-afe3-2a665c4eee79"
      unitRef="usd">1642419819</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDQtMy0xLTEtMzE2OTI_80542ac7-d0db-47ce-be19-32e50b71c027"
      unitRef="usd">1609589797</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDUtMS0xLTEtMzE2OTI_eedf7bc2-c9d8-456c-9744-95113dd99639"
      unitRef="usd">-1287103438</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDUtMy0xLTEtMzE2OTI_9ac40e64-6bfa-4d80-9aeb-b55985b7cb7d"
      unitRef="usd">-1209855522</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDYtMS0xLTEtMzE2OTI_5cac9c82-4aa7-4973-9397-d5d00cc98e49"
      unitRef="usd">-457888</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDYtMy0xLTEtMzE2OTI_5830f866-1b2d-46f2-aebd-041ed804642b"
      unitRef="usd">-282236</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDctMS0xLTEtMzE2OTI_9916ac8f-df79-4344-9ff3-9b871ae53e5c"
      unitRef="usd">355085002</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNDctMy0xLTEtMzE2OTI_cfb513e9-fd72-4c32-b9b2-a872f9ad6472"
      unitRef="usd">399669421</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNTAtMS0xLTEtMzE2OTI_e5645bcc-f15d-49be-9660-7049f5862e9e"
      unitRef="usd">445511088</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xNi9mcmFnOjcyZThhZjM3ZDA0MTRlNmE4YTdiZGUxYTAwNjEyZWUzL3RhYmxlOmYyY2Q4ZTM3Y2YyMjRmZWJiYjU1YTIzOThjMzQxZWMzL3RhYmxlcmFuZ2U6ZjJjZDhlMzdjZjIyNGZlYmJiNTVhMjM5OGMzNDFlYzNfNTAtMy0xLTEtMzE2OTI_5d8d44e5-c314-4fd5-b7a0-76019a27412f"
      unitRef="usd">495941493</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21d5e20142404b77b5d380c961472ef1_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMy0xLTEtMS0zMTY5Mg_326bc894-ec56-495f-8499-640afa9f077f"
      unitRef="usd">65895</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae8b8138e63644098dfe464495c5f147_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMy0zLTEtMS0zMTY5Mg_7f56f6f8-0a60-4e2b-856e-628d78716b83"
      unitRef="usd">39615</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00d50bf6cf7f4ad2a522a955df7010fd_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfNC0xLTEtMS0zMTY5Mg_8473ad7b-aa6f-4269-ba6b-1d3d5a81b82e"
      unitRef="usd">8842</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i998a91031a25433790f82a700988c0b4_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfNC0zLTEtMS0zMTY5Mg_b4a247a3-ffc5-4fb2-b7f2-a90f0b6cef48"
      unitRef="usd">49949</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5b13173d5de4d16982a5e2c1dfbfd2e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfNS0xLTEtMS0zMTY5Mg_ef1fb5e1-1f26-4f75-8748-765fde2ae696"
      unitRef="usd">124337</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec9fd62a63dd428f8b7307aa6489cfd8_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfNS0zLTEtMS0zMTY5Mg_9f2de166-53ac-4d70-99cc-b7b9bd71e4ef"
      unitRef="usd">281556</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfOC0xLTEtMS0zMTY5Mg_bf790fa5-31ed-466b-ba90-04313c5f13d1"
      unitRef="usd">199074</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfOC0zLTEtMS0zMTY5Mg_25b79a7c-1c2a-4bf3-9156-aeb8b640392f"
      unitRef="usd">371120</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTAtMS0xLTEtMzE2OTI_6ba49846-46b5-4a80-9c41-f63e43c55ff0"
      unitRef="usd">55978611</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTAtMy0xLTEtMzE2OTI_5bd79373-ab8a-4b1b-a282-8940b91beb68"
      unitRef="usd">39044418</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTEtMS0xLTEtMzE2OTI_100e79b4-3148-46ad-8fa9-a484dabce48f"
      unitRef="usd">15953458</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTEtMy0xLTEtMzE2OTI_464d5428-c3a2-4a54-9884-ca4593d1cdeb"
      unitRef="usd">13881194</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTMtMS0xLTEtMzE2OTI_6bc775cc-d3ee-471f-ad17-23ec1db8b13b"
      unitRef="usd">71932069</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTMtMy0xLTEtMzE2OTI_d7859fa9-2cf8-4a96-abc1-68e04aa26c69"
      unitRef="usd">52925612</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTQtMS0xLTEtMzE2OTI_a9cce04f-c9ad-4c77-b1e3-e9b9c1ecfe1b"
      unitRef="usd">-71732995</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTQtMy0xLTEtMzE2OTI_cf46f297-94cf-494b-a1c1-6118c91605ac"
      unitRef="usd">-52554492</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTYtMS0xLTEtMzE2OTI_71021b12-3b25-4c79-b133-0864373184a7"
      unitRef="usd">669814</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTYtMy0xLTEtMzE2OTI_b15ed74a-c0f8-4a2a-8bcb-4f10b8747ec4"
      unitRef="usd">769237</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTctMS0xLTEtMzE2OTI_98bc3d15-faaa-44a4-874d-ee2f708b0fef"
      unitRef="usd">313488</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMTctMy0xLTEtMzE2OTI_18f7ce76-469b-4b98-93fb-63e4a4393c47"
      unitRef="usd">513034</us-gaap:InterestExpense>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMjAtMS0xLTEtMzE2OTI_ecb1a1a5-5b39-41ee-8abc-1d5b20d32337"
      unitRef="usd">-537728</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMjAtMy0xLTEtMzE2OTI_dcc3f8bf-e18e-4362-954b-1f6f9c75405f"
      unitRef="usd">-830475</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMjEtMS0xLTEtMzE2OTI_08e8cb6b-4f27-41ab-b22c-384bec572ecb"
      unitRef="usd">-4840641</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMjEtMy0xLTEtMzE2OTI_b6dd713f-41e1-477a-b330-63d7ac41060f"
      unitRef="usd">-847958</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMjItMS0xLTEtMzE2OTI_24677325-463a-4107-b496-f39fa273b0a6"
      unitRef="usd">-153468</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMjItMy0xLTEtMzE2OTI_c11703d5-52bd-4eb8-81bd-04b29f43f5ca"
      unitRef="usd">8978</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMjctMS0xLTEtMzE2OTI_3e8dee16-6ccd-4a70-9142-b9b2ac16b5be"
      unitRef="usd">-76908506</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMjctMy0xLTEtMzE2OTI_db757ca7-7a65-4d7d-ab02-13500b6fb232"
      unitRef="usd">-53967744</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMjktMS0xLTEtMzE2OTI_89e273fc-9caf-4ddd-bc12-676dae124baa"
      unitRef="usd">-2165213</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMjktMy0xLTEtMzE2OTI_08fc516a-61dd-4990-ab3d-e3fba93edff0"
      unitRef="usd">-434387</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMzAtMS0xLTEtMzE2OTI_3eea9081-cbfd-4af6-9f0b-c4553fd245ef"
      unitRef="usd">-79073719</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMzAtMy0xLTEtMzE2OTI_ff479c8d-ee27-4701-8be6-56e396699335"
      unitRef="usd">-54402131</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMzQtMS0xLTEtMzE2OTI_8e04dc4f-3a52-4033-bd3f-608c044e5d93"
      unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMzQtMS0xLTEtMzE2OTI_b3837ecf-3b13-4b76-98e6-3126dc8e52ed"
      unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMzQtMy0xLTEtMzE2OTI_08957aea-d680-4957-9b57-9a78d9bab202"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMzQtMy0xLTEtMzE2OTI_948ee088-d6a4-4fb2-8947-3bebcd779459"
      unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMzctMS0xLTEtMzE2OTI_60f3e8c6-feae-4529-8773-8e98a853ff5c"
      unitRef="shares">218940693</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMzctMS0xLTEtMzE2OTI_c955cf61-9003-445a-9774-971d1f6b564c"
      unitRef="shares">218940693</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMzctMy0xLTEtMzE2OTI_2d220722-7942-49bb-a30d-ce82d37c9713"
      unitRef="shares">202414445</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18xOS9mcmFnOjU5ZjFiYjdlNzA4MjQzNzliZjViZjY0OGU3NzFhNWI4L3RhYmxlOjQ4NWQzZWViMzAwODRjY2U5NDJhZGEzZjRlOTVjNGJkL3RhYmxlcmFuZ2U6NDg1ZDNlZWIzMDA4NGNjZTk0MmFkYTNmNGU5NWM0YmRfMzctMy0xLTEtMzE2OTI_79cd82aa-6be7-4f81-bfd6-2e314da4d68a"
      unitRef="shares">202414445</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yMi9mcmFnOjRiMjNkNTAwMTNmMzQ1OTE5ODNmNzIzMDllZjIyODdkL3RhYmxlOmE0MWNlMzQwMTE5NjQ0ZGU5OGE2OGU4MDEyYTU3MTA5L3RhYmxlcmFuZ2U6YTQxY2UzNDAxMTk2NDRkZTk4YTY4ZTgwMTJhNTcxMDlfMi0xLTEtMS0zMTY5Mg_3c565199-6619-42e0-a6cb-69fe67fe9075"
      unitRef="usd">-79073719</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yMi9mcmFnOjRiMjNkNTAwMTNmMzQ1OTE5ODNmNzIzMDllZjIyODdkL3RhYmxlOmE0MWNlMzQwMTE5NjQ0ZGU5OGE2OGU4MDEyYTU3MTA5L3RhYmxlcmFuZ2U6YTQxY2UzNDAxMTk2NDRkZTk4YTY4ZTgwMTJhNTcxMDlfMi0zLTEtMS0zMTY5Mg_8beb7afa-fc4f-4994-b007-d981f752526a"
      unitRef="usd">-54402131</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yMi9mcmFnOjRiMjNkNTAwMTNmMzQ1OTE5ODNmNzIzMDllZjIyODdkL3RhYmxlOmE0MWNlMzQwMTE5NjQ0ZGU5OGE2OGU4MDEyYTU3MTA5L3RhYmxlcmFuZ2U6YTQxY2UzNDAxMTk2NDRkZTk4YTY4ZTgwMTJhNTcxMDlfNS0xLTEtMS0zMTY5Mg_c1da97c2-770f-46b7-9bfe-b07b896390d3"
      unitRef="usd">-6555</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yMi9mcmFnOjRiMjNkNTAwMTNmMzQ1OTE5ODNmNzIzMDllZjIyODdkL3RhYmxlOmE0MWNlMzQwMTE5NjQ0ZGU5OGE2OGU4MDEyYTU3MTA5L3RhYmxlcmFuZ2U6YTQxY2UzNDAxMTk2NDRkZTk4YTY4ZTgwMTJhNTcxMDlfNS0zLTEtMS0zMTY5Mg_8da4e668-ff14-4086-ae55-bcfd7df95a74"
      unitRef="usd">-14419</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yMi9mcmFnOjRiMjNkNTAwMTNmMzQ1OTE5ODNmNzIzMDllZjIyODdkL3RhYmxlOmE0MWNlMzQwMTE5NjQ0ZGU5OGE2OGU4MDEyYTU3MTA5L3RhYmxlcmFuZ2U6YTQxY2UzNDAxMTk2NDRkZTk4YTY4ZTgwMTJhNTcxMDlfNi0xLTEtMS0zMTY5Mg_273ada0f-0b23-4d9d-b099-b1f2ad3d2ddd"
      unitRef="usd">-169097</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yMi9mcmFnOjRiMjNkNTAwMTNmMzQ1OTE5ODNmNzIzMDllZjIyODdkL3RhYmxlOmE0MWNlMzQwMTE5NjQ0ZGU5OGE2OGU4MDEyYTU3MTA5L3RhYmxlcmFuZ2U6YTQxY2UzNDAxMTk2NDRkZTk4YTY4ZTgwMTJhNTcxMDlfNi0zLTEtMS0zMTY5Mg_5873a34c-01b7-40c3-b603-4009269b5ed8"
      unitRef="usd">4861</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yMi9mcmFnOjRiMjNkNTAwMTNmMzQ1OTE5ODNmNzIzMDllZjIyODdkL3RhYmxlOmE0MWNlMzQwMTE5NjQ0ZGU5OGE2OGU4MDEyYTU3MTA5L3RhYmxlcmFuZ2U6YTQxY2UzNDAxMTk2NDRkZTk4YTY4ZTgwMTJhNTcxMDlfOS0xLTEtMS0zMTY5Mg_377a935d-468f-48cb-8c40-1777eaa8ac80"
      unitRef="usd">-79249371</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yMi9mcmFnOjRiMjNkNTAwMTNmMzQ1OTE5ODNmNzIzMDllZjIyODdkL3RhYmxlOmE0MWNlMzQwMTE5NjQ0ZGU5OGE2OGU4MDEyYTU3MTA5L3RhYmxlcmFuZ2U6YTQxY2UzNDAxMTk2NDRkZTk4YTY4ZTgwMTJhNTcxMDlfOS0zLTEtMS0zMTY5Mg_d1c4f159-10c8-4f9c-85ef-72c6c917f5ef"
      unitRef="usd">-54411689</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i804e05de6cd241ee8b38b4028e3fa675_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMy0xLTEtMS0zMzIwOA_9ac214a4-110a-480f-a9f6-117eb929a06e"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i804e05de6cd241ee8b38b4028e3fa675_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMy0zLTEtMS0zMzIwOA_1446e530-76d3-43e3-bfed-517c0d9ff2de"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i48c5a28f11784bc08ca5f019b88b0a82_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMy01LTEtMS0zMzIwOA_edf2f9a8-7e21-43db-878c-a255733b3235"
      unitRef="shares">217382887</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i48c5a28f11784bc08ca5f019b88b0a82_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMy03LTEtMS0zMzIwOA_713d1ea2-6eef-4c53-9528-0cb2fed464c0"
      unitRef="usd">217382</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic94dcc9ceaba4c73bf5498290cc2a8f1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMy05LTEtMS0zMzIwOA_ae996441-10be-46d0-9095-9ad5d11b41b6"
      unitRef="usd">1609589797</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2c094866746944c190a5cb5e6ec38207_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMy0xMS0xLTEtMzMyMDg_bb3ac70e-d45b-4ca0-ac30-e0a79efe4426"
      unitRef="usd">-1209855522</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0a5ff34a96be4b01892682db87c0bb82_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMy0xMy0xLTEtMzMyMDg_fbca0f39-f850-441c-95bc-52117e6c8021"
      unitRef="usd">-282236</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMy0xNy0xLTEtMzY3OTE_0e28eb9c-ccbf-4032-9a6d-d0757edc1186"
      unitRef="usd">399669421</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3a5dd7608edd4c9b81f794075e1bf7c3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNC05LTEtMS0zNzA2Nw_787ca225-03e9-4cc4-b2b2-a7ef89b58c55"
      unitRef="usd">-3294019</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia20aee050b564621b0904ff547d1603d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNC0xMS0xLTEtMzcwNjc_fa7c1b81-95ce-4949-a733-f5e44dfc5229"
      unitRef="usd">1825803</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if8a58b7a2eeb4d1b8fa8e40ba25ea392_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNC0xNy0xLTEtMzcwNjc_08922a79-4276-4b04-8289-43c0161a4cde"
      unitRef="usd">-1468216</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8289efe5fbaf48509196fa46a48e5ffc_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNC01LTEtMS0zMzIwOA_54731f3b-4446-47f4-ab9c-4d321b6c1084"
      unitRef="shares">8480483</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8289efe5fbaf48509196fa46a48e5ffc_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNC03LTEtMS0zMzIwOA_04387c71-f5e4-4f5a-875a-50dc4dec2eb4"
      unitRef="usd">8481</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia4a41317c5a64ca1abb762b294f27a77_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNC05LTEtMS0zMzIwOA_b553cd7d-2246-40da-a154-c096ca4acd53"
      unitRef="usd">29356057</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNC0xNy0xLTEtMzY3OTE_21fb567b-6186-42c3-9cb6-7c578c62e837"
      unitRef="usd">29364538</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8289efe5fbaf48509196fa46a48e5ffc_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNS01LTEtMS0zMzIwOA_59238f51-d065-430b-9fa0-9a6394095df6"
      unitRef="shares">647350</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8289efe5fbaf48509196fa46a48e5ffc_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNS03LTEtMS0zMzIwOA_9e2a2434-72c5-4f37-9048-bc1b4bfe1fcc"
      unitRef="usd">646</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia4a41317c5a64ca1abb762b294f27a77_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNS05LTEtMS0zMzIwOA_aa9ddea4-2365-464d-bbc9-8008c1f33fce"
      unitRef="usd">-943167</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNS0xNy0xLTEtMzY3OTM_dfb80fa5-1d11-47a0-9214-3b3ff309b329"
      unitRef="usd">-942521</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia4a41317c5a64ca1abb762b294f27a77_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNi05LTEtMS0zMzIwOA_114f422c-4802-4603-8b0b-50b2ab3a600e"
      unitRef="usd">7711151</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNi0xNy0xLTEtMzY3OTM_70e79bc0-c3e6-4595-9911-a5920598858f"
      unitRef="usd">7711151</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="ie499a30eb95c4720b752a618011da9de_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNy0xMS0xLTEtMzMyMDg_2b296a80-d66c-459e-906b-d822a2b51bc2"
      unitRef="usd">-79073719</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfNy0xNy0xLTEtMzY3OTM_1c585800-3b74-48b9-aca5-9d8b9b6c2579"
      unitRef="usd">-79073719</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie50284eae13a4b7db5e6261db6e0f911_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfOC0xMy0xLTEtMzMyMDg_597857cb-923e-49ed-a105-7378bf35d369"
      unitRef="usd">-169097</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfOC0xNy0xLTEtMzY3OTM_93da5f9b-feff-4ce2-ab43-ba4dd07a9ec3"
      unitRef="usd">-169097</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ie50284eae13a4b7db5e6261db6e0f911_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfOS0xMy0xLTEtMzMyMDg_0f8cfb0a-155f-4b2b-afab-0ee5c340ecd2"
      unitRef="usd">-6555</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfOS0xNy0xLTEtMzY3OTM_cc2c93e6-f3f3-45d2-9b9b-641af8cd23df"
      unitRef="usd">-6555</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesIssued
      contextRef="ic282ad05383d4cf390606ef8b610a75a_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMTAtMS0xLTEtMzMyMDg_ae042e51-4f74-4f48-b2a2-216fb58474f7"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ic282ad05383d4cf390606ef8b610a75a_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMTAtMy0xLTEtMzMyMDg_852888d6-5a6a-47c9-8290-676976b5fb8f"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i33a11834f7f947429f551d48915db764_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMTAtNS0xLTEtMzMyMDg_39ae7211-b025-4671-804b-263aa5d525ce"
      unitRef="shares">226510720</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i33a11834f7f947429f551d48915db764_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMTAtNy0xLTEtMzMyMDg_911824dd-99fb-45a2-b19b-b7ef45e0d7b1"
      unitRef="usd">226509</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id541689a86584fd08a1e5666a6539c27_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMTAtOS0xLTEtMzMyMDg_ec947236-3cc8-4001-9668-d555a081b5d1"
      unitRef="usd">1642419819</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i09c58eec38c84e9ba577bfb58d9de2c6_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMTAtMTEtMS0xLTMzMjA4_e0d88f3a-6650-4ee4-a417-f16156e71bcc"
      unitRef="usd">-1287103438</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib931e527febe494c96c6bff98a6bc8c8_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMTAtMTMtMS0xLTMzMjA4_93577bc6-631a-4cae-9668-fc302e6647ca"
      unitRef="usd">-457888</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjQ3MjIwZDY1NDhhYzRjMGFhZDcwZTc2YzA5M2JiZTQxL3RhYmxlcmFuZ2U6NDcyMjBkNjU0OGFjNGMwYWFkNzBlNzZjMDkzYmJlNDFfMTAtMTctMS0xLTM2Nzkz_95a72bdc-b0e8-4970-bd53-bdbb1fa26664"
      unitRef="usd">355085002</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i197e743baebd4a54a1f59b2ead228a4b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMy0xLTEtMS0zMTY5Mg_65f21174-88a5-4c8b-bf57-63fb8e550882"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i197e743baebd4a54a1f59b2ead228a4b_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMy0zLTEtMS0zMTY5Mg_cff89bc1-b5cd-479f-989b-57f8cf89e8f8"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i5a964ed0569a4e2687266fee8d3eb2cb_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMy01LTEtMS0zMTY5Mg_fb609d67-7b84-4a51-b966-d8224d6d911a"
      unitRef="shares">186851493</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i5a964ed0569a4e2687266fee8d3eb2cb_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMy03LTEtMS0zMTY5Mg_b70c2467-94b2-4e6f-b8fe-acb7d881d620"
      unitRef="usd">186851</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic378134c645a455f8c29cf425649d9b4_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMy05LTEtMS0zMTY5Mg_1f1658bd-f8a1-49a9-8ae9-4fe070dd3c0d"
      unitRef="usd">1367406869</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if7fbf9be64024e8389236deb05644f9a_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMy0xMS0xLTEtMzE2OTI_8bf4bca2-d792-44a0-9e59-4026a4197569"
      unitRef="usd">-906196812</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i37a14c64016b44eeb0df3bd03a9c7261_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMy0xMy0xLTEtMzE2OTI_401e529c-e7ca-4b34-964c-13d198d13995"
      unitRef="usd">-256150</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i01903000ca0941ae93dc226d9b97e700_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMy0xNy0xLTEtMzE2OTI_2e3aa51c-eee9-4dc9-9329-1ea82dd5ea5c"
      unitRef="usd">461140758</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNC0wLTEtMS0zMTY5Mi90ZXh0cmVnaW9uOmNiOTcxNzVlMjc0YzRiZjRhZWQ4NzFmNjUxM2EzMjEzXzY1_fa3612e7-2251-4c16-810d-114a05c3d82f"
      unitRef="usd">531000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i5c88a6a27b9e44eeba42ab6a651cc57c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNC01LTEtMS0zMTY5Mg_253b7f9d-9f0e-4b6e-ac72-a9d054a95915"
      unitRef="shares">20355000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5c88a6a27b9e44eeba42ab6a651cc57c_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNC03LTEtMS0zMTY5Mg_8de5bcb1-c61a-4ee3-96e6-9649d38f4ea2"
      unitRef="usd">20355</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i495f9f8bba37406aa957bb1fa1bb6b82_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNC05LTEtMS0zMTY5Mg_0af24370-041d-4521-8798-2fab9cbc55bf"
      unitRef="usd">162084675</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNC0xNy0xLTEtMzE2OTI_df6243d0-829e-41d2-8090-c9603898ba7c"
      unitRef="usd">162105030</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i5c88a6a27b9e44eeba42ab6a651cc57c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNS01LTEtMS0zMTY5Mg_10d88820-66a5-4c8f-acb1-81f3afd7ed88"
      unitRef="shares">1009450</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i5c88a6a27b9e44eeba42ab6a651cc57c_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNS03LTEtMS0zMTY5Mg_827503fd-968b-4512-885d-e10d1e075b31"
      unitRef="usd">1009</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i495f9f8bba37406aa957bb1fa1bb6b82_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNS05LTEtMS0zMTY5Mg_7af0667d-b7a3-480d-a5c6-47346a235ec9"
      unitRef="usd">4376883</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNS0xNy0xLTEtMzE2OTI_2ad12492-ba24-44bd-aa2a-279ffe17b218"
      unitRef="usd">4377892</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i5c88a6a27b9e44eeba42ab6a651cc57c_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNi01LTEtMS0zMTY5Mg_79cc957d-58bc-49be-9ce4-a6d6fc1625bd"
      unitRef="shares">1118093</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5c88a6a27b9e44eeba42ab6a651cc57c_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNi03LTEtMS0zMTY5Mg_7be43536-4702-4d24-a668-93f92a51799d"
      unitRef="usd">1118</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i495f9f8bba37406aa957bb1fa1bb6b82_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNi05LTEtMS0zMTY5Mg_2d32f3a1-90cd-48bc-b50a-388747164dec"
      unitRef="usd">-1202907</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNi0xNy0xLTEtMzE2OTI_5599ba97-43fe-4b39-943a-dc90c8b268d5"
      unitRef="usd">-1201789</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i495f9f8bba37406aa957bb1fa1bb6b82_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNy05LTEtMS0zMTY5Mg_b39682e7-e375-4506-970b-ad011ee8075e"
      unitRef="usd">9595947</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfNy0xNy0xLTEtMzE2OTI_bf1b7514-c48b-4f69-8da2-fffcde82ba44"
      unitRef="usd">9595947</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i706e11fcf7b840a68346dcb076a72fe7_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfOC0xMS0xLTEtMzE2OTI_2c45c9df-36fa-40b8-8e23-00c8a1a8e7e4"
      unitRef="usd">-54402131</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfOC0xNy0xLTEtMzE2OTI_e4f6753d-19c3-4c06-85f3-69c3cfd0fb8b"
      unitRef="usd">-54402131</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7b4db7184a6e4d539bd893221daa7b6b_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfOS0xMy0xLTEtMzE2OTI_d19e8ca8-1a6f-43ea-89af-e0046fa9c9e9"
      unitRef="usd">4861</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfOS0xNy0xLTEtMzE2OTI_d6198659-4c9a-4d60-bf17-88e361f7142e"
      unitRef="usd">4861</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i7b4db7184a6e4d539bd893221daa7b6b_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMTAtMTMtMS0xLTMxNjky_b4c01727-ef37-4f2f-b3a8-ff0cfa965061"
      unitRef="usd">-14419</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMTAtMTctMS0xLTMxNjky_165d06a5-e09c-4fd7-a391-0b28e9a4ed70"
      unitRef="usd">-14419</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesIssued
      contextRef="ib17ceb956c2f426eb2b764885c99a7e2_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMTEtMS0xLTEtMzE2OTI_628df666-524f-4bf0-a836-c1ff901d0107"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ib17ceb956c2f426eb2b764885c99a7e2_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMTEtMy0xLTEtMzE2OTI_2ce2f870-43c2-433b-8ce4-57f81315f2ba"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i5f8d19094f794192baacd56f29fcdae7_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMTEtNS0xLTEtMzE2OTI_ac00c91e-c16e-418c-a232-d3f1460021e8"
      unitRef="shares">209334036</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i5f8d19094f794192baacd56f29fcdae7_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMTEtNy0xLTEtMzE2OTI_8ad1ac8f-0287-4308-b2f5-08da6628fdc0"
      unitRef="usd">209333</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5a7141f817b64eedaa3b9d245abc6c8f_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMTEtOS0xLTEtMzE2OTI_efde530f-410d-4b72-8822-09b188489560"
      unitRef="usd">1542261467</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iafaea1518ae5419386ac2efc6b2ba187_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMTEtMTEtMS0xLTMxNjky_41f2eebe-227b-459a-96fd-c2548412c274"
      unitRef="usd">-960598943</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idd921433e3a44903b67d69cd507b789c_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMTEtMTMtMS0xLTMxNjky_59aec09b-9b5e-48fb-8979-076658fda481"
      unitRef="usd">-265708</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2676a854bc50429cba33013cd2fd88be_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yNS9mcmFnOjYxYWJhZjNjM2RmNjRkZjZhZTI0NjU5ZWJiMzNlODg5L3RhYmxlOjU4NjU5ZjAyMjE3NzQyZjFhNDA5ZGMyMTY0OTM0Y2RlL3RhYmxlcmFuZ2U6NTg2NTlmMDIyMTc3NDJmMWE0MDlkYzIxNjQ5MzRjZGVfMTEtMTctMS0xLTMxNjky_8e19c3de-9996-4676-ac0d-b200eb2d2f6f"
      unitRef="usd">581606149</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMy0xLTEtMS0zMTY5Mg_bc4f97ef-41d1-4b00-8992-62ff1e9178fc"
      unitRef="usd">-79073719</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMy0zLTEtMS0zMTY5Mg_cc945208-e38a-42bd-8816-58b492f8a054"
      unitRef="usd">-54402131</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNS0xLTEtMS0zMTY5Mg_b30f12ef-091d-41db-a747-d3e72336e7a6"
      unitRef="usd">929383</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNS0zLTEtMS0zMTY5Mg_d8958138-1893-4ae0-b776-492c82844cc5"
      unitRef="usd">660697</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNi0xLTEtMS0zMTY5Mg_2755fc59-0b9a-488e-be32-589910ea269f"
      unitRef="usd">126770</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNi0zLTEtMS0zMTY5Mg_e2dfe149-a39c-4410-a547-990f49014c2e"
      unitRef="usd">136770</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNy0xLTEtMS0zMTY5Mg_c39967c0-d5c2-46a8-abc7-e6c86bbdd3fc"
      unitRef="usd">319586</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNy0zLTEtMS0zMTY5Mg_a1a128b1-4c78-486c-9b07-ebce9cef419a"
      unitRef="usd">278290</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfOS0xLTEtMS0zMTY5Mg_4f60169a-72a1-485b-a73d-12c0ef1d85f4"
      unitRef="usd">7711151</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfOS0zLTEtMS0zMTY5Mg_dbeaffbd-1a06-4988-bbbd-7ab9f38f4043"
      unitRef="usd">9595947</us-gaap:ShareBasedCompensation>
    <ino:NonCashInterestIncomeExpense
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTItMS0xLTEtMzE2OTI_fe7382b4-e831-44d1-9d76-de24c7801b8a"
      unitRef="usd">219999</ino:NonCashInterestIncomeExpense>
    <ino:NonCashInterestIncomeExpense
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTItMy0xLTEtMzE2OTI_121c6675-2ddf-4277-ac67-684936780dd5"
      unitRef="usd">31281</ino:NonCashInterestIncomeExpense>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTMtMS0xLTEtMzE2OTI_5b9e59f7-42e1-4b5f-ba07-45d279fd4003"
      unitRef="usd">125810</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:InvestmentIncomeAmortizationOfPremium
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTMtMy0xLTEtMzE2OTI_a41af41b-326f-4763-bfa8-9ccc6a566f17"
      unitRef="usd">0</us-gaap:InvestmentIncomeAmortizationOfPremium>
    <us-gaap:GainLossOnSaleOfOtherInvestments
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTQtMS0xLTEtMzE2OTI_066dec56-6cfb-4075-b292-74f75e296e6e"
      unitRef="usd">-318684</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfOtherInvestments
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTQtMy0xLTEtMzE2OTI_4f4f0c0e-5061-4795-a9a0-37ac9caf7035"
      unitRef="usd">-10151</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTUtMS0xLTEtMzE2OTI_f0f235c1-b7a6-48a7-a96d-c959c212d232"
      unitRef="usd">-157666</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTUtMy0xLTEtMzE2OTI_f62296c8-b3c3-4675-b55b-2430f23e3069"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <ino:GainLossOnRemeasurementOfEquityMethodInvestment
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTYtMS0xLTEtMzE2OTI_2aa5b575-b9fe-4468-853c-94f179b1478c"
      unitRef="usd">165215</ino:GainLossOnRemeasurementOfEquityMethodInvestment>
    <ino:GainLossOnRemeasurementOfEquityMethodInvestment
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTYtMy0xLTEtMzE2OTI_753226a5-eb91-49b8-9563-795e09393fb9"
      unitRef="usd">0</ino:GainLossOnRemeasurementOfEquityMethodInvestment>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTgtMS0xLTEtMzE2OTI_2816e4dc-71bf-4646-90aa-c735398cc162"
      unitRef="usd">-537728</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTgtMy0xLTEtMzE2OTI_2f9f065c-1546-4a34-bc2f-b694fb55bedc"
      unitRef="usd">-830475</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTktMS0xLTEtMzE2OTI_35de1b14-b2e2-4305-bb76-1f7eeee6cc07"
      unitRef="usd">-2165213</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMTktMy0xLTEtMzE2OTI_1af6871b-59b7-4cdf-a0d4-410afc1442ef"
      unitRef="usd">-434387</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMjItMS0xLTEtMzE2OTI_6bf6927b-1ddb-4822-9999-26494c475a44"
      unitRef="usd">-4840641</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMjItMy0xLTEtMzE2OTI_af50048f-9d76-4e76-b91e-0d30e451fa5e"
      unitRef="usd">-847958</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMjYtMS0xLTEtMzE2OTI_9dfac862-6b58-403e-a4ca-126c42f60b1f"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMjYtMy0xLTEtMzE2OTI_420e9148-ff54-4d51-8cf3-7672bea842d3"
      unitRef="usd">176927</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMjktMS0xLTEtMzE2OTI_36f63754-ac5c-4f06-805e-0b4eb7788926"
      unitRef="usd">-541248</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMjktMy0xLTEtMzE2OTI_9d2ff146-6bf5-4703-ab6e-b54cb143a35b"
      unitRef="usd">-8804853</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzEtMS0xLTEtMzE2OTI_bf5f22b0-d0aa-4e04-a2a2-debff7115e0a"
      unitRef="usd">-7075934</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzEtMy0xLTEtMzE2OTI_fb33deb0-89a6-4af4-b569-3757b940485f"
      unitRef="usd">19108348</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzQtMS0xLTEtMzE2OTI_47e739f3-5138-46c6-bb13-d4723377a936"
      unitRef="usd">-151999</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzQtMy0xLTEtMzE2OTI_c9101a01-00b1-4f63-a233-dfb2b95ea718"
      unitRef="usd">-75514</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzUtMS0xLTEtMzE2OTI_6d316c75-a87f-47de-b3d6-c0e9e5e71e9e"
      unitRef="usd">-9859913</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzUtMy0xLTEtMzE2OTI_dc9c9d4d-a9e8-4f84-8476-0488d568b340"
      unitRef="usd">4735352</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzYtMS0xLTEtMzE2OTI_e586fdba-6715-4ebd-acc1-0588d8b4e10e"
      unitRef="usd">1501489</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzYtMy0xLTEtMzE2OTI_7712ebf2-ed37-4cd7-a189-4e2172a4ec81"
      unitRef="usd">-2579476</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzctMS0xLTEtMzE2OTI_5ed906f2-69fe-429d-96e2-f351bc1294f1"
      unitRef="usd">859354</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzctMy0xLTEtMzE2OTI_11d88447-771b-461a-8223-448184866269"
      unitRef="usd">125292</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzgtMS0xLTEtMzE2OTI_288f95ac-1ee2-47bb-8523-dc552b858a29"
      unitRef="usd">-9963</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfMzgtMy0xLTEtMzE2OTI_f9189d84-74d5-44e7-b116-4f32a6f0b228"
      unitRef="usd">-72463</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDEtMS0xLTEtMzE2OTI_f9f48eb1-90c2-4623-a0bd-50b77ad06794"
      unitRef="usd">-624673</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDEtMy0xLTEtMzE2OTI_5d88603a-7840-4adf-b797-b5918afa4b7b"
      unitRef="usd">-558140</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDItMS0xLTEtMzE2OTI_b9112111-faa7-4d84-ad3e-cc48f9642ac6"
      unitRef="usd">723550</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDItMy0xLTEtMzE2OTI_53d30ab4-869f-42c0-a11b-67e27ebd2f33"
      unitRef="usd">-2480826</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDUtMS0xLTEtMzE2OTI_104337c7-2950-4d75-bff1-f4cbd48151c3"
      unitRef="usd">-14826</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDUtMy0xLTEtMzE2OTI_7a338da2-64ab-45a1-ac00-c665fbfe7b06"
      unitRef="usd">6478</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDYtMS0xLTEtMzE2OTI_3e0dbdc4-b78f-478c-a837-1fb0df6b2c90"
      unitRef="usd">-61882102</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDYtMy0xLTEtMzE2OTI_e8fd920d-de05-4d57-a688-647172a5a498"
      unitRef="usd">-52867428</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDgtMS0xLTEtMzE2OTI_f8d204c5-d7fc-475b-9d02-15113a7c29fb"
      unitRef="usd">99722697</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDgtMy0xLTEtMzE2OTI_1fba48fb-a28f-47c1-9638-fc03cf44e234"
      unitRef="usd">275408976</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDktMS0xLTEtMzE2OTI_6f5c1314-f397-4d13-9b60-876c8699bb1d"
      unitRef="usd">123055048</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNDktMy0xLTEtMzE2OTI_8cd2045d-b319-48a6-90a6-4f7b4cfcdd35"
      unitRef="usd">504464</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNTAtMS0xLTEtMzE2OTI_f8b4324a-c0c4-4b14-9279-edfe44d11b24"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNTAtMy0xLTEtMzE2OTI_5cc2a95c-35d0-4cf7-a353-765225916daa"
      unitRef="usd">210824</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNTItMS0xLTEtMzE2OTI_252650df-1b20-4410-a932-6ff6d350d1b4"
      unitRef="usd">1999998</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNTItMy0xLTEtMzE2OTI_73b4028e-2c7c-4a91-9de3-d92fd53ce2dc"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNTYtMS0xLTEtMzE2OTI_913c40f6-f36d-417a-a149-2973bca7faf0"
      unitRef="usd">21332353</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNTYtMy0xLTEtMzE2OTI_53ae83a8-675f-41da-b821-1dd51b3ba864"
      unitRef="usd">-275115336</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjAtMS0xLTEtMzE2OTI_0e0a03ce-0c5e-48b2-ae74-517ca161afab"
      unitRef="usd">29364538</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjAtMy0xLTEtMzE2OTI_130a60bb-33b1-4e31-bf66-507477e0a555"
      unitRef="usd">162105030</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjEtMS0xLTEtMzE2OTI_f2c82a0d-8259-40a7-ac5f-d9670b68c0f5"
      unitRef="usd">83812</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjEtMy0xLTEtMzE2OTI_108cf06d-28a6-4185-a545-ea2c6e9d40d6"
      unitRef="usd">2632996</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjItMS0xLTEtMzE2OTI_484fd2f0-32a4-4a51-aac7-a20bc67976be"
      unitRef="usd">1026333</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjItMy0xLTEtMzE2OTI_2dce568c-9b43-4234-aaed-39c2ee3e304b"
      unitRef="usd">3834785</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjUtMS0xLTEtMzE2OTI_1f48b629-f19d-41f2-96f3-094663863b8d"
      unitRef="usd">28422017</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjUtMy0xLTEtMzE2OTI_c5a6e30d-3118-4652-b659-1b4c63b78bd9"
      unitRef="usd">160903241</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjYtMS0xLTEtMzE2OTI_ca3de3af-2b7e-4cf1-b5a4-a892c2ef6a4d"
      unitRef="usd">-6555</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjYtMy0xLTEtMzE2OTI_260400d9-8171-45c0-93df-1577671244be"
      unitRef="usd">-14419</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjctMS0xLTEtMzE2OTI_b7d4267a-0cfd-43e6-9965-25f1b6d2632a"
      unitRef="usd">-12134287</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjctMy0xLTEtMzE2OTI_4f3ae497-3449-41df-b3de-d30544c59950"
      unitRef="usd">-167093942</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjgtMS0xLTEtMzE2OTI_0ed33ac2-401e-4a82-a8a9-982701d212db"
      unitRef="usd">71143778</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i01903000ca0941ae93dc226d9b97e700_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjgtMy0xLTEtMzE2OTI_07699113-3e66-4b39-9d2b-5f3253b4587a"
      unitRef="usd">250728118</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjktMS0xLTEtMzE2OTI_0cee065a-0e66-4aa7-8a30-70ae86cc5b27"
      unitRef="usd">59009491</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2676a854bc50429cba33013cd2fd88be_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNjktMy0xLTEtMzE2OTI_b1ce785d-7379-43e7-80be-1f47438c9ab0"
      unitRef="usd">83634176</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNzItMS0xLTEtMzE2OTI_031ef378-80f3-4dec-976c-8a3505653154"
      unitRef="usd">330779</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNzItMy0xLTEtMzE2OTI_b1630367-44d8-4e4a-b4e0-d5070c9f009b"
      unitRef="usd">35370</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:InterestPaidNet
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNzMtMS0xLTEtMzE2OTI_897dc688-96be-4b02-9c7b-01b4a4bc59a6"
      unitRef="usd">533487</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18yOC9mcmFnOmNlOTdhMWJmNTY1NDRlODFiMGM5YzAzYjkxODIzMmZhL3RhYmxlOjUxZWEwNDRkYWUzNjQxMGZiODg1NmIzNTkyNGM4OWVkL3RhYmxlcmFuZ2U6NTFlYTA0NGRhZTM2NDEwZmI4ODU2YjM1OTI0Yzg5ZWRfNzMtMy0xLTEtMzE2OTI_fe33d174-47ca-4def-aae4-f3c80fb0c280"
      unitRef="usd">544315</us-gaap:InterestPaidNet>
    <us-gaap:NatureOfOperations
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNC9mcmFnOmE5Mzk2MDcxMWQ1YjRiM2RhZGRlZDQ5MDM2NzdmNDc4L3RleHRyZWdpb246YTkzOTYwNzExZDViNGIzZGFkZGVkNDkwMzY3N2Y0NzhfMzUwNg_dea64b5e-c9e7-47f7-9046-8b77bf3aba9e">Organization and Operations&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Inovio Pharmaceuticals, Inc. (the &#x201c;Company&#x201d; or &#x201c;INOVIO&#x201d;), is a biotechnology company focused on bringing to market precisely designed DNA medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer and conditions associated with human papillomavirus ("HPV"). INOVIO has shown in clinical trials that its DNA vaccine candidates can be delivered into cells in the body via a proprietary smart device allowing the nucleic-acid delivered gene products to activate functional T cell and antibody responses against targeted pathogens and cancers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's DNA medicines pipeline is comprised of three types of product candidates: prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies ("dMAbs" and &#x201c;dBTAs&#x201d;), all of which utilize the two components of INOVIO's integrated platform, SynCon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's proprietary SynCon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; technology creates optimized plasmids, which are circular strands of DNA that instruct a cell to produce proteins or antigens to help the person&#x2019;s immune system respond with antibodies and immune cells which recognize and then help block viruses and destroy cancerous or pre-cancerous cells. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO's patented CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;smart delivery devices facilitate uptake of its DNA medicines into the cell, which has been a key limitation of historical DNA-based technology approaches. Human clinical trial data from more than 15,000 CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; smart device administrations across more than 5,000 participants to date have shown a tolerable safety profile.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO's corporate strategy is to develop, seek regulatory approval for and commercialize its novel DNA medicines to address unmet global health needs. The Company continues to advance and clinically validate an array of DNA medicine candidates that target infectious diseases, such as COVID-19, as well as HPV-associated diseases and cancer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's partners and collaborators include ApolloBio Corporation, AstraZeneca, Advaccine Biopharmaceuticals Suzhou Co., The Bill &amp;amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations ("CEPI"), The U.S. Department of Defense ("DoD"), Defense Advanced Research Projects Agency ("DARPA"), HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#x2019;s Medical CBRN Defense Consortium ("MCDC"), International Vaccine Institute ("IVI"), Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research and The Wistar Institute.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its collaborators are currently evaluating the feasibility of, or conducting or planning clinical studies of, DNA medicines for COVID-19, including both homologous and heterologous booster vaccines; Middle East Respiratory Syndrome, or MERS; Lassa fever; Ebola; as well as HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp;amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis, or RRP; glioblastoma multiforme, or GBM; and prostate cancer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNy9mcmFnOmVmNzQ4ZjQ0Mzc3YTQxMjlhOGEwM2E2MTMxN2Q4YmY2L3RleHRyZWdpb246ZWY3NDhmNDQzNzdhNDEyOWE4YTAzYTYxMzE3ZDhiZjZfNzQ4Mg_2fd6164a-570e-4b7c-a6ff-7cefaadd05f5">Basis of Presentation, Liquidity and Risks and Uncertainties&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of March&#160;31, 2022, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, the condensed consolidated statements of stockholders' equity and the condensed consolidated statements of cash flows for the three months ended March 31, 2022 and 2021 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the three months ended March 31, 2022 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ended December&#160;31, 2021, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March&#160;1, 2022. The balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of March&#160;31, 2022 and December 31, 2021, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC.  All intercompany accounts and transactions were eliminated upon consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred a net loss attributable to common stockholders of $79.1 million for the three months ended March 31, 2022. The Company had working capital of $340.5 million and an accumulated deficit of $1.3 billion as of March&#160;31, 2022. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#x2019;s cash, cash equivalents and short-term investments of $360.4 million as of March&#160;31, 2022 are sufficient to support the Company's planned operations for a period of at least 12 months from the date of issuance of these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; has a history of conducting debt and equity financings, including the receipt of net proceeds of $29.4 million and $47.7&#160;million under a Sales Agreement during the three months ended March 31, 2022 and year ended December 31, 2021, respectively, and $162.1&#160;million from a January 2021 underwritten public offering of common stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three months ended March 31, 2022 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is, and from time to time&#160;may in the future be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARs-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company continues to closely monitor the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will continue to impact the Company's business and operations will depend on future developments, including travel restrictions to, from and within the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, which remain uncertain.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNy9mcmFnOmVmNzQ4ZjQ0Mzc3YTQxMjlhOGEwM2E2MTMxN2Q4YmY2L3RleHRyZWdpb246ZWY3NDhmNDQzNzdhNDEyOWE4YTAzYTYxMzE3ZDhiZjZfNzQ3MQ_26c54de1-e92d-4aa9-962c-fe1e83084e4d">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements of Inovio have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) as contained in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") for interim financial information and with instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheet as of March&#160;31, 2022, the condensed consolidated statements of operations, the condensed consolidated statements of comprehensive loss, the condensed consolidated statements of stockholders' equity and the condensed consolidated statements of cash flows for the three months ended March 31, 2022 and 2021 are unaudited, but include all adjustments (consisting of normal recurring adjustments) that the Company considers necessary for a fair presentation of the financial position, results of operations, cash flows and changes in stockholders' equity for the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the three months ended March 31, 2022 shown herein are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2022, or for any other period. These unaudited financial statements, and notes thereto, should be read in conjunction with the audited consolidated financial statements for the year &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ended December&#160;31, 2021, included in the Company's Annual Report on Form&#160;10-K filed with the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March&#160;1, 2022. The balance sheet at December&#160;31, 2021 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited condensed consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiary. As of March&#160;31, 2022 and December 31, 2021, the Company consolidated its wholly-owned subsidiary Inovio Asia LLC.  All intercompany accounts and transactions were eliminated upon consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred a net loss attributable to common stockholders of $79.1 million for the three months ended March 31, 2022. The Company had working capital of $340.5 million and an accumulated deficit of $1.3 billion as of March&#160;31, 2022. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#x2019;s cash, cash equivalents and short-term investments of $360.4 million as of March&#160;31, 2022 are sufficient to support the Company's planned operations for a period of at least 12 months from the date of issuance of these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activit&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ies, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; has a history of conducting debt and equity financings, including the receipt of net proceeds of $29.4 million and $47.7&#160;million under a Sales Agreement during the three months ended March 31, 2022 and year ended December 31, 2021, respectively, and $162.1&#160;million from a January 2021 underwritten public offering of common stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These condensed consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's condensed consolidated financial statements as of and for the three months ended March 31, 2022 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;The Company is, and from time to time&#160;may in the future be, subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNy9mcmFnOmVmNzQ4ZjQ0Mzc3YTQxMjlhOGEwM2E2MTMxN2Q4YmY2L3RleHRyZWdpb246ZWY3NDhmNDQzNzdhNDEyOWE4YTAzYTYxMzE3ZDhiZjZfMjk3Mw_7a21bc19-35c7-4649-9c4e-f9fec1db0f8a"
      unitRef="usd">-79100000</us-gaap:NetIncomeLoss>
    <us-gaap:Capital
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNy9mcmFnOmVmNzQ4ZjQ0Mzc3YTQxMjlhOGEwM2E2MTMxN2Q4YmY2L3RleHRyZWdpb246ZWY3NDhmNDQzNzdhNDEyOWE4YTAzYTYxMzE3ZDhiZjZfMzA0NA_8ed54484-18d0-4d35-9eb1-eb789dd5b227"
      unitRef="usd">340500000</us-gaap:Capital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNy9mcmFnOmVmNzQ4ZjQ0Mzc3YTQxMjlhOGEwM2E2MTMxN2Q4YmY2L3RleHRyZWdpb246ZWY3NDhmNDQzNzdhNDEyOWE4YTAzYTYxMzE3ZDhiZjZfMzA3OA_46508cf1-a783-4e41-aae3-d409ff353652"
      unitRef="usd">-1300000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNy9mcmFnOmVmNzQ4ZjQ0Mzc3YTQxMjlhOGEwM2E2MTMxN2Q4YmY2L3RleHRyZWdpb246ZWY3NDhmNDQzNzdhNDEyOWE4YTAzYTYxMzE3ZDhiZjZfMzQyNQ_adcd63b6-4323-4f01-bce3-5c820015b37d"
      unitRef="usd">360400000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if2af437e174542f6a96a9dd371a8e151_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNy9mcmFnOmVmNzQ4ZjQ0Mzc3YTQxMjlhOGEwM2E2MTMxN2Q4YmY2L3RleHRyZWdpb246ZWY3NDhmNDQzNzdhNDEyOWE4YTAzYTYxMzE3ZDhiZjZfMTA5OTUxMTYzODUxNA_29dc814c-5765-47d1-875b-50edffe3117b"
      unitRef="usd">29400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i13070eb515fa45c694edb66f1cadcb21_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNy9mcmFnOmVmNzQ4ZjQ0Mzc3YTQxMjlhOGEwM2E2MTMxN2Q4YmY2L3RleHRyZWdpb246ZWY3NDhmNDQzNzdhNDEyOWE4YTAzYTYxMzE3ZDhiZjZfODc5NjA5MzAzMzEzNw_99b72db1-e4a4-42f5-ae99-a8055b0d7ebb"
      unitRef="usd">47700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i5188e2afa230429fab7f59ddf2c594b3_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNy9mcmFnOmVmNzQ4ZjQ0Mzc3YTQxMjlhOGEwM2E2MTMxN2Q4YmY2L3RleHRyZWdpb246ZWY3NDhmNDQzNzdhNDEyOWE4YTAzYTYxMzE3ZDhiZjZfNDA2MQ_f6c7de32-cc0a-4780-83b7-e9508304289c"
      unitRef="usd">162100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ino:RisksAndUncertaintiesPolicyTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y18zNy9mcmFnOmVmNzQ4ZjQ0Mzc3YTQxMjlhOGEwM2E2MTMxN2Q4YmY2L3RleHRyZWdpb246ZWY3NDhmNDQzNzdhNDEyOWE4YTAzYTYxMzE3ZDhiZjZfNDk0NzgwMjMzNjA0Ng_463df0ed-833c-457c-a872-c5e912274168">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The global pandemic resulting from COVID-19, caused by a novel strain of coronavirus, SARs-CoV-2, has caused national and global economic and financial market disruptions. The impact of this pandemic has been and will likely continue to be extensive in many aspects of society, which has resulted in and will continue to cause significant disruptions to the global economy, as well as businesses and capital markets around the world. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company continues to closely monitor the impact of the COVID-19 pandemic on its employees, collaborators and service providers. The extent to which the pandemic will continue to impact the Company's business and operations will depend on future developments, including travel restrictions to, from and within the United States and other countries, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, which remain uncertain.&lt;/span&gt;&lt;/div&gt;</ino:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180MC9mcmFnOjhkMzQ5MGIzYjZmNDQ0OTliNzFkMGJmMTQyNGIzNzFhL3RleHRyZWdpb246OGQzNDkwYjNiNmY0NDQ5OWI3MWQwYmYxNDI0YjM3MWFfMTY3Mjc_74b04da8-a4b0-4cee-a23c-7232c60de9fc">Critical Accounting PoliciesCollaboration Agreements and Revenue Recognition&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, Revenue from Contracts with Customers (&#x201c;Topic 606&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. Differences in the allocation of the transaction price between delivered and undelivered performance obligations can impact the timing of revenue recognition but do not change the total revenue recognized under any agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For collaboration arrangements that include license fees, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For collaboration arrangements that include milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. This assessment is based on the Company&#x2019;s past experience with its collaboration partner, market insight and partner communication. Milestone payments that are not within the Company&#x2019;s or the collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment and could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For collaboration arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue in the period the underlying sales occur. To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses - Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMAbs. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180MC9mcmFnOjhkMzQ5MGIzYjZmNDQ0OTliNzFkMGJmMTQyNGIzNzFhL3RleHRyZWdpb246OGQzNDkwYjNiNmY0NDQ5OWI3MWQwYmYxNDI0YjM3MWFfNzE0NjgyNTY0MzQ3OA_e60f82b5-1e20-4350-8d63-3f73a5db5ecb">Collaboration Agreements and Revenue Recognition&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, Revenue from Contracts with Customers (&#x201c;Topic 606&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. Differences in the allocation of the transaction price between delivered and undelivered performance obligations can impact the timing of revenue recognition but do not change the total revenue recognized under any agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For collaboration arrangements that include license fees, the Company recognizes revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For collaboration arrangements that include milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. This assessment is based on the Company&#x2019;s past experience with its collaboration partner, market insight and partner communication. Milestone payments that are not within the Company&#x2019;s or the collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment and could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For collaboration arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue in the period the underlying sales occur. To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180MC9mcmFnOjhkMzQ5MGIzYjZmNDQ0OTliNzFkMGJmMTQyNGIzNzFhL3RleHRyZWdpb246OGQzNDkwYjNiNmY0NDQ5OWI3MWQwYmYxNDI0YjM3MWFfNzE0NjgyNTY0MzQ4MA_4558bcc4-b257-4039-b8e7-67ce75ae80c4">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses - Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMAbs. For clinical trial expenses, judgements used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180My9mcmFnOmVlYzA5MTBlMmM4ZjRkOGFiMWY4MDQ3MzE2NmQ0OGNiL3RleHRyZWdpb246ZWVjMDkxMGUyYzhmNGQ4YWIxZjgwNDczMTY2ZDQ4Y2JfMTE0MQ_5bce0517-6d2c-4994-9621-381241dd7184">Impact of Recently Issued Accounting Standards &lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Standards Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2020-06.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2020-06&#x201d;), which simplifies the guidance on an issuer&#x2019;s accounting for convertible instruments and contracts in its own equity. ASU 2020-06 is effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2020-06 as of January 1, 2022 on a modified retrospective basis and recorded a net reduction in accumulated deficit of $1.8&#160;million, a decrease in additional paid-in capital of $3.3&#160;million, and an increase in convertible senior notes of $1.5&#160;million to reflect the impact of the accounting change. The Company derecognized the related deferred tax liabilities of $1.5&#160;million with a corresponding adjustment to the valuation allowance, resulting in no net impact to the cumulative adjustment to retained earnings (see Note 8, "Convertible Debt").&lt;/span&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180My9mcmFnOmVlYzA5MTBlMmM4ZjRkOGFiMWY4MDQ3MzE2NmQ0OGNiL3RleHRyZWdpb246ZWVjMDkxMGUyYzhmNGQ4YWIxZjgwNDczMTY2ZDQ4Y2JfMTE0Mw_28fb9777-f0d2-4649-ba32-ea0274fbf536">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Standards Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2020-06.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2020-06&#x201d;), which simplifies the guidance on an issuer&#x2019;s accounting for convertible instruments and contracts in its own equity. ASU 2020-06 is effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2020-06 as of January 1, 2022 on a modified retrospective basis and recorded a net reduction in accumulated deficit of $1.8&#160;million, a decrease in additional paid-in capital of $3.3&#160;million, and an increase in convertible senior notes of $1.5&#160;million to reflect the impact of the accounting change. The Company derecognized the related deferred tax liabilities of $1.5&#160;million with a corresponding adjustment to the valuation allowance, resulting in no net impact to the cumulative adjustment to retained earnings (see Note 8, "Convertible Debt").&lt;/span&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ifdd8f1364df749e5b75e252f613f37c5_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180My9mcmFnOmVlYzA5MTBlMmM4ZjRkOGFiMWY4MDQ3MzE2NmQ0OGNiL3RleHRyZWdpb246ZWVjMDkxMGUyYzhmNGQ4YWIxZjgwNDczMTY2ZDQ4Y2JfMTA5OTUxMTYzNTY5Mw_2d940275-3e2b-45d9-a8ab-e90b55b68c0a"
      unitRef="usd">1800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ifdd8f1364df749e5b75e252f613f37c5_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180My9mcmFnOmVlYzA5MTBlMmM4ZjRkOGFiMWY4MDQ3MzE2NmQ0OGNiL3RleHRyZWdpb246ZWVjMDkxMGUyYzhmNGQ4YWIxZjgwNDczMTY2ZDQ4Y2JfMTA5OTUxMTYzMzczMA_9476901e-a5ee-4905-9a09-d5690fb6c782"
      unitRef="usd">-3300000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:ConvertibleDebt
      contextRef="ifdd8f1364df749e5b75e252f613f37c5_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180My9mcmFnOmVlYzA5MTBlMmM4ZjRkOGFiMWY4MDQ3MzE2NmQ0OGNiL3RleHRyZWdpb246ZWVjMDkxMGUyYzhmNGQ4YWIxZjgwNDczMTY2ZDQ4Y2JfMTA5OTUxMTYzMzc0NA_e27b2d15-dcf5-4c67-9566-1d442bd960ee"
      unitRef="usd">1500000</us-gaap:ConvertibleDebt>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i5998790341a8497ba20d32d62e49492c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180My9mcmFnOmVlYzA5MTBlMmM4ZjRkOGFiMWY4MDQ3MzE2NmQ0OGNiL3RleHRyZWdpb246ZWVjMDkxMGUyYzhmNGQ4YWIxZjgwNDczMTY2ZDQ4Y2JfNDk0NzgwMjMzMTE2MQ_7b5fc575-9ad1-4ba4-bb35-2e97c5991d4e"
      unitRef="usd">1500000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180Ni9mcmFnOjVmZDg1YTgyYzEwYTQ5Yjk5OTY0M2RjODY0MWJhM2NlL3RleHRyZWdpb246NWZkODVhODJjMTBhNDliOTk5NjQzZGM4NjQxYmEzY2VfNDY5_cb9af968-2d7c-4675-9f66-ea389fa01bfc">Revenue Recognition  During the three months ended March 31, 2022 and 2021, the Company recognized total revenue under collaborative research and development arrangements of $9,000 and $50,000, respectively, from its affiliated entity Plumbline Life Sciences, Inc. ("PLS") and $190,000 and $321,000, respectively, from various other contracts as a result of performance obligations being satisfied. Of the total revenue recognized during the three months ended March 31, 2022, $10,000 was in deferred revenue as of December 31, 2021.</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00d50bf6cf7f4ad2a522a955df7010fd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180Ni9mcmFnOjVmZDg1YTgyYzEwYTQ5Yjk5OTY0M2RjODY0MWJhM2NlL3RleHRyZWdpb246NWZkODVhODJjMTBhNDliOTk5NjQzZGM4NjQxYmEzY2VfMTQz_4aef39c0-6a9e-40d9-a16e-440b72d76f15"
      unitRef="usd">9000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i998a91031a25433790f82a700988c0b4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180Ni9mcmFnOjVmZDg1YTgyYzEwYTQ5Yjk5OTY0M2RjODY0MWJhM2NlL3RleHRyZWdpb246NWZkODVhODJjMTBhNDliOTk5NjQzZGM4NjQxYmEzY2VfMTA5OTUxMTYyODk2MQ_42584ede-3c07-4385-a469-0fa31eba7844"
      unitRef="usd">50000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9acea0aaff494ae8956e27ef9faf34c6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180Ni9mcmFnOjVmZDg1YTgyYzEwYTQ5Yjk5OTY0M2RjODY0MWJhM2NlL3RleHRyZWdpb246NWZkODVhODJjMTBhNDliOTk5NjQzZGM4NjQxYmEzY2VfMjM3_8247d34e-0394-4a0c-9c1c-58c321140503"
      unitRef="usd">190000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib186138d47d74be9a37ef0b9377767e2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180Ni9mcmFnOjVmZDg1YTgyYzEwYTQ5Yjk5OTY0M2RjODY0MWJhM2NlL3RleHRyZWdpb246NWZkODVhODJjMTBhNDliOTk5NjQzZGM4NjQxYmEzY2VfMTA5OTUxMTYyODk3MA_483f6d81-04d5-4f27-8d32-d65c52ce1b43"
      unitRef="usd">321000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180Ni9mcmFnOjVmZDg1YTgyYzEwYTQ5Yjk5OTY0M2RjODY0MWJhM2NlL3RleHRyZWdpb246NWZkODVhODJjMTBhNDliOTk5NjQzZGM4NjQxYmEzY2VfMzk0_fc59ff34-5532-40e3-a56c-c042b29af182"
      unitRef="usd">10000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfMzQxOQ_06294ae4-e0a1-4d8e-b087-82d893d6b9c1">Short-term Investments and Fair Value Measurements&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of March&#160;31, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,648,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,367,983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,280,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,772,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108,139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,664,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,986,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,986,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,551,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90,093)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,935,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,566,548)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,384,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,966,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,614,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#160;than&#160;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,193,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#160;than&#160;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,608,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331,712,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,648,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,170,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the three months ended March 31, 2022 and 2021, the Company recorded gross realized gain on investments of $20,000 and $0, respectively, and gross realized loss on investments of $339,000 and $10,000, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded net unrealized loss on available-for-sale equity securities of $4.8 million and $848,000, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the three months ended March 31, 2022 and 2021. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of March&#160;31, 2022, the Company had 29 available-for-sale securities in an unrealized loss position, of which 13 with an aggregate total unrealized loss of $2.9 million were in such position for longer than 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;March&#160;31, 2022&#160;were &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;primarily due to changes in interest rates&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#x2019;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at March&#160;31, 2022, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,280,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,280,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,664,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,664,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,986,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,986,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,384,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,945,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,439,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,369,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,369,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304,753,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,314,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,439,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,170,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,622,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,547,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,077,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289,529,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,547,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 1 assets at March&#160;31, 2022 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#x2019;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;rations as unrealized gain (loss) on available-for-sale equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;or as a gain (loss) on investment in affiliated entity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 assets at March&#160;31, 2022 consisted of commercial paper, certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no Level 3 assets held as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfMzQxOQ_d7e99c76-9868-441a-b937-48a0b140317e">Short-term Investments and Fair Value Measurements&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of March&#160;31, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,648,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,367,983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,280,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,772,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108,139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,664,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,986,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,986,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,551,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90,093)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,935,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,566,548)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,384,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,966,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,614,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#160;than&#160;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,193,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#160;than&#160;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,608,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331,712,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,648,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,170,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the three months ended March 31, 2022 and 2021, the Company recorded gross realized gain on investments of $20,000 and $0, respectively, and gross realized loss on investments of $339,000 and $10,000, respectively. During the three months ended March 31, 2022 and 2021, the Company recorded net unrealized loss on available-for-sale equity securities of $4.8 million and $848,000, respectively. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the three months ended March 31, 2022 and 2021. Interest and dividends on investments classified as available-for-sale are included in interest income in the condensed consolidated statements of operations. As of March&#160;31, 2022, the Company had 29 available-for-sale securities in an unrealized loss position, of which 13 with an aggregate total unrealized loss of $2.9 million were in such position for longer than 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;March&#160;31, 2022&#160;were &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;primarily due to changes in interest rates&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#x2019;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at March&#160;31, 2022, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,280,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,280,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,664,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,664,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,986,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,986,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,384,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,945,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,439,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,369,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,369,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304,753,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,314,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,439,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,170,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,622,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,547,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,077,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289,529,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,547,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Level 1 assets at March&#160;31, 2022 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#x2019;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;rations as unrealized gain (loss) on available-for-sale equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;or as a gain (loss) on investment in affiliated entity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 assets at March&#160;31, 2022 consisted of commercial paper, certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no Level 3 assets held as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfNDk0NzgwMjMzMjE4MQ_99353627-c642-4f0d-876c-ad9e79eb7f4f">&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of March&#160;31, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,648,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,367,983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,280,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,772,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108,139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,664,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,986,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,986,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,551,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90,093)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,935,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,566,548)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,384,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,966,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,614,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#160;than&#160;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,193,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#160;than&#160;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,608,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331,712,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,648,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,170,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7dd96d739d1d4c6ba7fd44457e650877_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfMi0zLTEtMS0zMzc0MA_e501eed1-9055-4d53-a686-83cee61ba9fc"
      unitRef="usd">178648717</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7dd96d739d1d4c6ba7fd44457e650877_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfMi01LTEtMS0zMzc0MA_0d90d9fb-ddd1-45ac-8275-8a072e4dd50d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7dd96d739d1d4c6ba7fd44457e650877_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfMi03LTEtMS0zMzc0MA_8b813a3d-822e-4708-af6e-58ef7c00b591"
      unitRef="usd">6367983</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7dd96d739d1d4c6ba7fd44457e650877_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfMi05LTEtMS0zMzc0MA_a4d6dca4-2a62-43d2-8c7e-f9bca25f8727"
      unitRef="usd">172280734</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="i200d0433fb874ceca8d01b4202a59cf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfMy0xLTEtMS0zMzYyNi90ZXh0cmVnaW9uOjlkMzAwOTVmNDMxOTQ1ZDI5OGJkZGI0ODc5ZGVjZDc1XzE0_7680567d-2921-468f-9c48-205ef50d3ed4">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7d5059c8d38048299da6be38015206d8_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfMy0zLTEtMS0zMzc0MA_d5439cf6-fc54-4b4e-a188-d4dc19105f25"
      unitRef="usd">84772489</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7d5059c8d38048299da6be38015206d8_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfMy01LTEtMS0zMzc0MA_28c65b49-64ed-4e20-abb2-61c815148d3f"
      unitRef="usd">200</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7d5059c8d38048299da6be38015206d8_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfMy03LTEtMS0zMzc0MA_df41fdf0-ea75-4c74-9821-93bad77b3dd1"
      unitRef="usd">108139</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7d5059c8d38048299da6be38015206d8_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfMy05LTEtMS0zMzc0MA_5c8c2bf6-c22e-43d7-b28f-04a1796f59a7"
      unitRef="usd">84664550</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="i96212faeb6564d55b7a90168c62339d7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNC0xLTEtMS0zMzczNi90ZXh0cmVnaW9uOmE2MzRkYTVlZGY0MDQxNTY5M2YwN2YzZTY2OTM5ZTNmXzQzOTgwNDY1MTExMjM_5f8d0286-9377-41f4-a82e-688cb9b65378">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifea821ceda2b46c5ba64c5b0a9ebf7eb_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNC0zLTEtMS0zMzc0MA_03aaadeb-fd1b-41c7-a9b6-181b05dc84ac"
      unitRef="usd">39986103</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifea821ceda2b46c5ba64c5b0a9ebf7eb_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNC01LTEtMS0zMzc0MA_7b0553ce-6661-4cfb-83db-672c05c3600d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifea821ceda2b46c5ba64c5b0a9ebf7eb_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNC03LTEtMS0zMzc0MA_da996336-2937-4d65-899a-d282e1bc15f2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifea821ceda2b46c5ba64c5b0a9ebf7eb_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNC05LTEtMS0zMzc0MA_86201106-6fa1-4861-ace9-5088c4bc92ae"
      unitRef="usd">39986103</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="ib3b77e32e0d54bbe98f98ad16cfdcced_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNS0xLTEtMS0zMzYyNi90ZXh0cmVnaW9uOmZjN2UyOWE0MWM3NzRhNGZiM2ZjYzAzNjBmZDlhZThhXzE0_a46a95a0-bbc1-4a8f-baef-9d9f967601df">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7d2dabcc2e274335be3e08c2ede5ec0e_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNS0zLTEtMS0zMzc0MA_a9050fe2-bd30-45ee-93a2-ef2cacd3b955"
      unitRef="usd">2976544</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7d2dabcc2e274335be3e08c2ede5ec0e_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNS01LTEtMS0zMzc0MA_e009af7a-2701-4634-ab2d-ab37237d77bc"
      unitRef="usd">15136</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7d2dabcc2e274335be3e08c2ede5ec0e_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNS03LTEtMS0zMzc0MA_e45afca0-f203-4c9a-8a54-9f653cffec37"
      unitRef="usd">333</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7d2dabcc2e274335be3e08c2ede5ec0e_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNS05LTEtMS0zMzc0MA_cf12f469-6e7d-47d7-a3a3-a33c4dd0c519"
      unitRef="usd">2991347</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i15f4645750d14b1d8727f373d9bfec66_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNi0zLTEtMS0zMzc0MA_ccc8f824-2b97-4c60-99f1-532304b7e8e4"
      unitRef="usd">1551716</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i15f4645750d14b1d8727f373d9bfec66_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNi01LTEtMS0zMzc0MA_c2fe6ed3-140a-413c-a1b7-891c85fd6252"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i15f4645750d14b1d8727f373d9bfec66_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNi03LTEtMS0zMzc0MA_422e1688-1664-4c1c-a8ae-e3cf4bdafa3f"
      unitRef="usd">90093</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i15f4645750d14b1d8727f373d9bfec66_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNi05LTEtMS0zMzc0MA_49319eda-9596-4395-a8cd-1aea74a5f896"
      unitRef="usd">1461623</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNy0zLTEtMS0zNjg1Mw_302af4c0-bfa3-43cd-ae51-a76219e18095"
      unitRef="usd">307935569</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNy01LTEtMS0zNjg1Mw_53a80a44-dba7-4167-b2ad-863cff80e5d4"
      unitRef="usd">15336</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNy03LTEtMS0zNjg1Mw_33723065-7999-4958-994c-f10b93129727"
      unitRef="usd">6566548</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOmU1YjlkZTY5OTBhMjQ4YzM5MmI5MmM1ODQzNDM4NmYwL3RhYmxlcmFuZ2U6ZTViOWRlNjk5MGEyNDhjMzkyYjkyYzU4NDM0Mzg2ZjBfNy05LTEtMS0zNjg1Mw_a7374ee7-d7cc-43fc-8f42-7bf40426a8e3"
      unitRef="usd">301384357</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i35afa32f29f843dabd62652947f0eeb1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfMi0zLTEtMS0zMzcyMg_ae7a480a-8b19-4e63-b760-076522bd06bc"
      unitRef="usd">192966772</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i35afa32f29f843dabd62652947f0eeb1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfMi01LTEtMS0zMzcyMg_4e1a1b3f-a0cf-4aec-b340-f3c44529b213"
      unitRef="usd">87069</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i35afa32f29f843dabd62652947f0eeb1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfMi03LTEtMS0zMzcyMg_23225f31-ed90-424b-a7f3-0cbcd63d1e77"
      unitRef="usd">1614411</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i35afa32f29f843dabd62652947f0eeb1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfMi05LTEtMS0zMzcyMg_eeabc69a-e09a-4a7b-b81e-3855f0dd6316"
      unitRef="usd">191439430</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="i3dd02c8047614f899869c90b0070ab8d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfMy0xLTEtMS0zMzYzMS90ZXh0cmVnaW9uOmE0NDcwNGIyYjAzOTQ1MzhiMGUxNjQwMjM3NTU2N2JmXzQzOTgwNDY1MTExMjM_0b419a77-852e-4b1c-ba07-a17f90dcf08f">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i11ad7b0c63c34318904c5962edc5336c_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfMy0zLTEtMS0zMzcyMg_dc36dee6-40eb-45a9-bf02-4e808539946b"
      unitRef="usd">94193441</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i11ad7b0c63c34318904c5962edc5336c_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfMy01LTEtMS0zMzcyMg_1bb7e42a-6a83-48dd-a4e6-72d7e493dc92"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i11ad7b0c63c34318904c5962edc5336c_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfMy03LTEtMS0zMzcyMg_633e34db-6e29-4d14-87b3-acf56e584dbb"
      unitRef="usd">9921</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i11ad7b0c63c34318904c5962edc5336c_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfMy05LTEtMS0zMzcyMg_676b9252-ea42-40f2-a4ec-a3367fbbf116"
      unitRef="usd">94183520</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="i96212faeb6564d55b7a90168c62339d7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNC0xLTEtMS0zMzcxOC90ZXh0cmVnaW9uOmQ5YzdhMTc4ZDhjMTQ2NjY4MTIzYTY2ODZmYTQzN2QyXzQzOTgwNDY1MTExMjM_eeb56cc7-7e23-432e-9869-8744d9d76619">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1c1de2f49204499c821a49656c3c3db0_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNC0zLTEtMS0zMzcyMg_336f9a35-6166-4ec6-b9ba-5dd27f045377"
      unitRef="usd">39967853</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1c1de2f49204499c821a49656c3c3db0_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNC01LTEtMS0zMzcyMg_92c1a0f3-5fb9-4c02-8ace-bdfa9b2ec6fd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1c1de2f49204499c821a49656c3c3db0_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNC03LTEtMS0zMzcyMg_92933c3c-47dc-4ae4-a30d-e275fda14c5e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1c1de2f49204499c821a49656c3c3db0_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNC05LTEtMS0zMzcyMg_681c1e68-f3ec-4f47-857a-43842f921d2b"
      unitRef="usd">39967853</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="i256e22e1c0a840458b2307e674601335_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNS0xLTEtMS0zNjg1NS90ZXh0cmVnaW9uOmEyNGNlZjBlOWY5MDQ3OWVhYTY4MThiZjFjOWNkMTgyXzQzOTgwNDY1MTExMjA_daa9446b-c97d-4d35-b946-71ccfbb90dbb">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9c26ca99f7cb4cacbac0e8bc0ed494ed_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNS0zLTEtMS0zMzcyMg_03218fcd-1f83-47fa-8bae-f9f4cea90f50"
      unitRef="usd">2976210</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9c26ca99f7cb4cacbac0e8bc0ed494ed_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNS01LTEtMS0zMzcyMg_63ffc9ec-60c0-4e84-9ed5-4135d8df15fa"
      unitRef="usd">15618</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9c26ca99f7cb4cacbac0e8bc0ed494ed_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNS03LTEtMS0zMzcyMg_9c472f0e-0ccb-4588-bfbf-192c7c93e817"
      unitRef="usd">338</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9c26ca99f7cb4cacbac0e8bc0ed494ed_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNS05LTEtMS0zMzcyMg_19bf8679-a058-492a-ac01-1fbde91460e8"
      unitRef="usd">2991490</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4a46ac477e0c44908926cbfd89796968_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNi0zLTEtMS0zMzcyMg_e5750343-4b43-4e33-8877-40500f75e584"
      unitRef="usd">1608137</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4a46ac477e0c44908926cbfd89796968_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNi01LTEtMS0zMzcyMg_80c06d68-48c7-4771-9480-44c50fcc6e84"
      unitRef="usd">4508</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4a46ac477e0c44908926cbfd89796968_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNi03LTEtMS0zMzcyMg_8fa79eb7-564f-45a8-be11-5468a61a8967"
      unitRef="usd">23998</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4a46ac477e0c44908926cbfd89796968_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNi05LTEtMS0zMzcyMg_dd97d989-63b4-4c79-a596-1dc060d8f6cc"
      unitRef="usd">1588647</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNy0zLTEtMS0zNjg0NA_f56e928f-0a14-4608-b549-1657f0def6dd"
      unitRef="usd">331712413</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNy01LTEtMS0zNjg0NA_8d193c5b-d99b-4274-8189-e39aedf9ed4b"
      unitRef="usd">107195</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNy03LTEtMS0zNjg0NA_5dc2822e-d198-4341-a419-5bc0df766b0e"
      unitRef="usd">1648668</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjc2ZGEyMzkwZjY2NDQ3MTc5NmI4M2YwN2Y5NjkyN2UwL3RhYmxlcmFuZ2U6NzZkYTIzOTBmNjY0NDcxNzk2YjgzZjA3Zjk2OTI3ZTBfNy05LTEtMS0zNjg0NA_3b065106-3190-4d9e-b86b-add0e7f3e4e1"
      unitRef="usd">330170940</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfOTYw_1c59a375-e1b6-4bea-8757-c85c9cbd79cc"
      unitRef="usd">20000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfOTY3_922acaea-45d6-48cd-9c54-52d55d6b93e0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfMTAyNw_767cb7cc-af59-41da-ab79-6d5152a9738a"
      unitRef="usd">339000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfMTAzNA_511a25ea-66e7-46eb-8fea-98cc5d9b7be6"
      unitRef="usd">10000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfMTMxNw_3f93485a-0b5a-4afe-af1e-8664180897c0"
      unitRef="usd">4800000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfMTMyNA_5f6a908a-fe88-44fd-b629-c173e476ffd5"
      unitRef="usd">848000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfMTc2Mg_b47f5de8-634d-4528-b974-f4e85c62196c"
      unitRef="position">29</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfMTgzNg_6a3ae7d0-a66d-4865-8174-9d9c518ff8fd"
      unitRef="position">13</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfMTg4Mg_be682654-9b3c-4d28-bfe8-45ca17b66dbd"
      unitRef="usd">-2900000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfNDk0NzgwMjMzMjE4Mg_c7e369e3-6be8-4556-97f6-04dd8b27b990">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,280,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,280,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,664,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,664,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,986,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,986,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,384,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,945,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,439,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,369,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,369,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304,753,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,314,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,439,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,170,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,622,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,547,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,077,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289,529,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,547,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie327610064114130b6724b61e0aa0b11_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNC0xLTEtMS0zMzk0NQ_8b14693b-51e0-43ee-951b-569387065805"
      unitRef="usd">172280734</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1a7a4020c94941b4b6acc78d93b58453_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNC0zLTEtMS0zMzk0NQ_203188ca-0147-4b3b-88ff-996c672e4804"
      unitRef="usd">172280734</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i471805632a1c4b1497d106f7f6d32bc1_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNC01LTEtMS0zMzk0NQ_4bdf38c7-8c0e-48b3-b066-c79988a43022"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3a3922f5859d40ef8c8a2487c7e981b6_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNC03LTEtMS0zMzk0NQ_fb228013-900c-4bc3-85fb-684eda6c62e7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3bad7403c49c468b8ceafcdd73d058f4_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNS0xLTEtMS0zMzk0NQ_26ec11b0-c531-41dc-bfa4-a414de649f92"
      unitRef="usd">84664550</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i910199c871b24e7281edfe262f9e595c_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNS0zLTEtMS0zMzk0NQ_b0c4598a-7f14-44f0-acb0-998bbd5ae206"
      unitRef="usd">84664550</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idcdd3d9daef249babdd7610c465d9861_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNS01LTEtMS0zMzk0NQ_47d6715f-5867-4938-b2e3-4939132fe9d1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9fd176d27ac94f388085f5b57e2f24cd_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNS03LTEtMS0zMzk0NQ_e8910c3b-112b-4d31-989e-902423a2b45d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if6e6180b331b4e71ba67ae40963d4a03_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNi0xLTEtMS0zMzk0NQ_39f99b3f-43ce-4402-9b26-e5555fbb1a37"
      unitRef="usd">39986103</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc7f88e09b444751aad08e36afbd151d_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNi0zLTEtMS0zMzk0NQ_db7a3cec-8ccd-4ef1-b03d-b228d17e30a3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7763d94f5b7e483eb2aa063bff3f4fc5_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNi01LTEtMS0zMzk0NQ_2ace0fb6-dbd5-4bd4-9cd1-7c53ca100b84"
      unitRef="usd">39986103</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i37fe9e79f04d4894a64245d5e39a5f1e_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNi03LTEtMS0zMzk0NQ_bea2c840-7350-47a9-b916-5c5bd06f84c2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if05223ae01d645f69bb34279da86b5c0_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNy0xLTEtMS0zMzk0NQ_2cf9c9e0-0acf-4c08-baa7-5f5d6e666e21"
      unitRef="usd">2991347</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib091b9b6d4f644349ae9a24d2bdc827b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNy0zLTEtMS0zMzk0NQ_2b2f7ae1-a1da-4d4c-854d-6e85075d0187"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibf2144065280473599c7afda89ad1694_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNy01LTEtMS0zMzk0NQ_58bc8155-9171-4e4c-a3b8-70f9bb843fc5"
      unitRef="usd">2991347</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7d6412688827466ca20d0eb89182015c_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfNy03LTEtMS0zMzk0NQ_d26c2c02-2491-4fdb-ad16-7204197283d6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i20a3ba1b8f6c4fdbbc57d85e7c759c66_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfOC0xLTEtMS0zMzk0NQ_f699acd7-6c7c-4c85-8f0f-284439cc84cf"
      unitRef="usd">1461623</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i62d964321f9c49ba80f2d28a540dfb8e_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfOC0zLTEtMS0zMzk0NQ_b453a512-114f-4f6e-b6c5-80212ac6fed0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i05e130a7d4404dcf9c53ef79a503f2d8_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfOC01LTEtMS0zMzk0NQ_53650604-6ebb-4a05-9267-9c503420e6fd"
      unitRef="usd">1461623</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7aee826afc7f4bb584c9baec2cacd2ff_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfOC03LTEtMS0zMzk0NQ_ca60a19c-f5ea-4d60-be08-b3c7f532e9bf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i02b127be22eb4b9a9750afaa61f1ec0f_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfOS0xLTEtMS0zNjgwOQ_ff2e530a-abfb-49f5-923b-8bc37f4482e5"
      unitRef="usd">301384357</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iae1ff7cfb12549c794647cdbfea00698_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfOS0zLTEtMS0zNjgwOQ_3648038a-7066-4308-ab35-62bc6d4b446f"
      unitRef="usd">256945284</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i50d2be785b7e4c0eb3075ccc1b52f222_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfOS01LTEtMS0zNjgwOQ_8a67d054-8e63-4a8a-854c-00ed7cbc70ea"
      unitRef="usd">44439073</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3ab217ecf956405d9cf37acb90fb804c_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfOS03LTEtMS0zNjgwOQ_18df8f07-a8ce-473e-a9b0-db954b0cc0a0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i02b127be22eb4b9a9750afaa61f1ec0f_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfMTEtMS0xLTEtMzM5NTI_e1e08fd3-c45b-4327-9edd-f40b09b69a8d"
      unitRef="usd">3369068</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="iae1ff7cfb12549c794647cdbfea00698_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfMTEtMy0xLTEtMzM5NTI_d30958b6-92c9-401b-8e65-9152e367f392"
      unitRef="usd">3369068</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i50d2be785b7e4c0eb3075ccc1b52f222_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfMTEtNS0xLTEtMzM5NTI_ea4ecf7c-3d42-4364-afba-718827db4ebf"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3ab217ecf956405d9cf37acb90fb804c_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfMTEtNy0xLTEtMzM5NTI_dafe1f21-c855-4bcb-ba33-998d4a4ed174"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i02b127be22eb4b9a9750afaa61f1ec0f_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfMTItMS0xLTEtMzY4MTM_a0e701da-7c82-4ccd-bb12-ab2539bdbcff"
      unitRef="usd">304753425</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iae1ff7cfb12549c794647cdbfea00698_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfMTItMy0xLTEtMzY4MTM_e6006363-5079-42a4-a7d9-74cb3152720d"
      unitRef="usd">260314352</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i50d2be785b7e4c0eb3075ccc1b52f222_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfMTItNS0xLTEtMzY4MTM_b50c6866-9e8b-4424-9d21-f59fdb7ad212"
      unitRef="usd">44439073</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3ab217ecf956405d9cf37acb90fb804c_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjVlYjE3YWY1Mzg0MjRmODliMzIwY2QyMWUzZThiNWM5L3RhYmxlcmFuZ2U6NWViMTdhZjUzODQyNGY4OWIzMjBjZDIxZTNlOGI1YzlfMTItNy0xLTEtMzY4MTM_29937bb3-a9e5-409d-9bac-e0581aabdae4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i735216c789474c09b2396fda353fb55e_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNC0xLTEtMS0zMzg2Nw_a1a26e5f-fcff-4d07-bd6c-d13759fb3ac6"
      unitRef="usd">191439430</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib92f6424c666449486766a5d1d0e1832_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNC0zLTEtMS0zMzg2Nw_e1074606-479e-485d-bef3-61c5f32b3b95"
      unitRef="usd">191439430</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2a4147a900d44007bcbaff1d2000a812_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNC01LTEtMS0zMzg2Nw_b9d8b33c-b35e-4b9e-93d8-bb4c98895755"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i922d453abb054b1c959336166486250e_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNC03LTEtMS0zMzg2Nw_666c93b6-73cd-435f-9ba1-cd8fc104873c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7a00852361e24abdb75f61f00ba8440e_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNS0xLTEtMS0zMzg2Nw_7f5e5b64-fa12-450e-a039-d22fd91b1fac"
      unitRef="usd">94183520</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia0927a0eab1d4d2ea57f80d09385ab14_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNS0zLTEtMS0zMzg2Nw_cd4f9a4e-cfa3-46ee-bb73-c52338c9acdb"
      unitRef="usd">94183520</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2346a1c5f64c47f39444b2604e34bec9_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNS01LTEtMS0zMzg2Nw_7078890c-28ce-4d83-9c81-8a4208e4e277"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iff609476032e4fd5850ace07b081d978_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNS03LTEtMS0zMzg2Nw_5b82ac16-6dc1-415d-b2ab-f01a974b0234"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4df03a74cdb1441981e64076b32bf6cb_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNi0xLTEtMS0zMzg2Nw_0954cf49-3c92-4bb0-9997-b4eb5469d02c"
      unitRef="usd">39967853</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibf4907bded604daa8b4f90733b4960a5_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNi0zLTEtMS0zMzg2Nw_aa4b5754-d024-4ff5-b468-9261ef9dc890"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic01a2bc151f341de9e5bc9ca12685bd1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNi01LTEtMS0zMzg2Nw_baf25404-1f20-4ab4-ab7f-7ca01371ee93"
      unitRef="usd">39967853</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4acf182b26a44980bccfb7dc1c75de40_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNi03LTEtMS0zMzg2Nw_e2e2813b-2f32-4de9-8b52-ef598d16960d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i10431da7c03644c9875fb73a741719db_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNy0xLTEtMS0zMzg2Nw_ae643a2c-f8bc-451e-b490-34c65ea6a7f1"
      unitRef="usd">2991490</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5cee4483f4e345c08e931ecf9ad3260d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNy0zLTEtMS0zMzg2Nw_c15185e8-d762-460e-82f3-aa25bebb0930"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idaca2ffe0ede4c7292c889e48dba76a7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNy01LTEtMS0zMzg2Nw_a54d1908-cdf8-478b-852a-7e929f8536c2"
      unitRef="usd">2991490</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0768b2ff10a94d04af660988ce14766c_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfNy03LTEtMS0zMzg2Nw_8f2ede96-fb8c-4575-8787-fbb4426f4455"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia45b882b6c5449a098b1e8921b30765f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfOC0xLTEtMS0zMzg2Nw_54519b59-ede3-4472-a0ec-102289f126ec"
      unitRef="usd">1588647</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8fc8c9fb3dda470585109a269277aa90_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfOC0zLTEtMS0zMzg2Nw_b2771bc3-e71a-4916-8b69-af568e8e50bf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iddcca9c2136e4da798d1e5a739c72a2b_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfOC01LTEtMS0zMzg2Nw_0d4dfb6b-4bc9-4c07-b17a-d03b5c71cf8a"
      unitRef="usd">1588647</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id97388b64a184cbab4a4fa6e23803d1c_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfOC03LTEtMS0zMzg2Nw_08070171-f987-4dca-8345-93ceadd3e917"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4284e75eeec74588b5ab75d6c01392cc_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfOS0xLTEtMS0zNjgxNw_dd9ee312-21af-4575-a44e-cb52697b1654"
      unitRef="usd">330170940</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia11026ef96064c518d5053ab32d38a62_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfOS0zLTEtMS0zNjgxNw_c0132655-4d61-4579-8865-e20ac36ccd1c"
      unitRef="usd">285622950</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5133a9aa6b974cd6be58671085bc9222_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfOS01LTEtMS0zNjgxNw_a8e6d0d3-9879-4ad0-b692-9a893a307595"
      unitRef="usd">44547990</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3ffc37c7b05544bb97a430265cc2bef9_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfOS03LTEtMS0zNjgxNw_e76b5c58-4819-4de8-ae10-f1e8d3520328"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i4284e75eeec74588b5ab75d6c01392cc_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfMTEtMS0xLTEtMzM4NzA_2fa377eb-c3a6-4c32-902a-1d321089700d"
      unitRef="usd">3906796</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ia11026ef96064c518d5053ab32d38a62_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfMTEtMy0xLTEtMzM4NzA_e2df35b4-cd13-43a9-b624-fdde7dcd4aa9"
      unitRef="usd">3906796</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5133a9aa6b974cd6be58671085bc9222_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfMTEtNS0xLTEtMzM4NzA_e00e3d8b-316a-4600-aca5-39e01100c4b2"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3ffc37c7b05544bb97a430265cc2bef9_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfMTEtNy0xLTEtMzM4NzA_de7bab64-13f5-43e6-8370-db41c779cda0"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4284e75eeec74588b5ab75d6c01392cc_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfMTItMS0xLTEtMzY4MTk_8afd1a81-0f9a-4025-8b9a-4a0e9bb99411"
      unitRef="usd">334077736</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia11026ef96064c518d5053ab32d38a62_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfMTItMy0xLTEtMzY4MTk_528f429a-2411-4e2d-b24e-a63cce4c7627"
      unitRef="usd">289529746</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5133a9aa6b974cd6be58671085bc9222_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfMTItNS0xLTEtMzY4MTk_ca1ddb84-8d5d-48cc-8b17-2a54e56932cd"
      unitRef="usd">44547990</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3ffc37c7b05544bb97a430265cc2bef9_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RhYmxlOjM3ZjIyOTc5OTM3YjQyZWU5NDNkN2Y2NTk0ZmZlOWI4L3RhYmxlcmFuZ2U6MzdmMjI5Nzk5MzdiNDJlZTk0M2Q3ZjY1OTRmZmU5YjhfMTItNy0xLTEtMzY4MTk_c53b64b0-d436-4d7d-8d4a-042dff864224"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="ibd3476330236483c98b0ec3070d9e333_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y180OS9mcmFnOmUzZjYxYjJmM2UzODQ3YjVhY2RmNmRhYTg1MGRkMmVhL3RleHRyZWdpb246ZTNmNjFiMmYzZTM4NDdiNWFjZGY2ZGFhODUwZGQyZWFfMjE5OTAyMzI2MDk3NA_68223bbe-ec35-4052-9b24-2bdae8094251"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RleHRyZWdpb246MTI4Yzc4ZDIzZDZlNDUxMjhmMjJlNzc0ODMyMDU4ZmVfNzQz_2689ee0b-8a74-47ed-a1d7-051d6963340e">Goodwill and Intangible Assets&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following sets forth the goodwill and intangible assets by major asset class:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.918%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:45pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful&lt;br/&gt;Life&lt;br/&gt;(Yrs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,312,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,305,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioject(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,798,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,301,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,735,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,364,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,862,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,806,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,974,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,499,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,847,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,626,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,974,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,012,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,847,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,139,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Other intangible assets represent the estimated fair value of acquired intellectual property. &lt;/span&gt;&lt;/div&gt;Aggregate amortization expense on intangible assets for the three months ended March 31, 2022 and 2021 was $127,000 and $137,000, respectively. Estimated aggregate amortization expense is $366,000 for the remainder of fiscal year 2022, $276,000 for 2023, $253,000 for 2024, $253,000 for 2025, $253,000 for 2026 and $1.1 million for 2027 and subsequent years combined.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RleHRyZWdpb246MTI4Yzc4ZDIzZDZlNDUxMjhmMjJlNzc0ODMyMDU4ZmVfNzQ3_ded4e469-c0ea-469d-8a13-4c1c2fc2828c">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following sets forth the goodwill and intangible assets by major asset class:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.918%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:45pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful&lt;br/&gt;Life&lt;br/&gt;(Yrs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,312,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,305,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioject(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,798,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,301,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,735,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,364,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,862,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,806,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,974,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,499,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,847,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,626,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,974,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,012,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,847,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,139,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.&lt;/span&gt;&lt;/div&gt;(b)Other intangible assets represent the estimated fair value of acquired intellectual property.</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:GoodwillGross
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMy0zLTEtMS0zMTY5Mg_c2787b5c-5599-4e4a-a78c-fb79c314a644"
      unitRef="usd">10513371</us-gaap:GoodwillGross>
    <us-gaap:Goodwill
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMy03LTEtMS0zMTY5Mg_a8a609a6-5fed-4649-a570-811217f7f67c"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:GoodwillGross
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMy05LTEtMS0zMTY5Mg_95221fe5-355a-48a3-a8aa-7637b087b259"
      unitRef="usd">10513371</us-gaap:GoodwillGross>
    <us-gaap:Goodwill
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMy0xMy0xLTEtMzE2OTI_6ac362f7-4013-484f-a553-f57496982d4d"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i937bf2eba10942f6be46a1071b4f10d7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfNi0xLTEtMS0zMTY5Mg_2af5a30b-8668-4979-95fa-c2dce4adf085">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7ac1da597f7b4340893eba51de04ad26_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfNi0zLTEtMS0zMTY5Mg_d268a7d4-0c73-4a4f-bb5c-17ef1dc275c6"
      unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7ac1da597f7b4340893eba51de04ad26_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfNi01LTEtMS0zMTY5Mg_119a9756-5227-4986-b162-20b95c313edf"
      unitRef="usd">1312787</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7ac1da597f7b4340893eba51de04ad26_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfNi03LTEtMS0zMTY5Mg_4681545f-7409-488f-884c-44960c1b06a6"
      unitRef="usd">10974</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i851991d1186f468b82660c9a9ba18e50_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfNi05LTEtMS0zMTY5Mg_12c5147b-07d5-4e62-9cf8-844968b763fe"
      unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i851991d1186f468b82660c9a9ba18e50_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfNi0xMS0xLTEtMzE2OTI_177f8474-f26a-4acb-98a9-3f3b045925db"
      unitRef="usd">1305600</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i851991d1186f468b82660c9a9ba18e50_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfNi0xMy0xLTEtMzE2OTI_e85fdda3-07c3-434b-8786-b5cd132558de"
      unitRef="usd">18161</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i3175c5ab2f0d46d7883309efb700f354_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfOS0xLTEtMS0zMTY5Mg_d900c6e9-ef7e-48fe-8705-3fd98424fbb2">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i72f5235c51804466877805e8fd527626_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfOS0zLTEtMS0zMTY5Mg_498cfec5-8547-46db-a3fb-2dd745c3a41e"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i72f5235c51804466877805e8fd527626_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfOS01LTEtMS0zMTY5Mg_598a5f42-8960-4a27-9ada-15a1a556b5e5"
      unitRef="usd">2798889</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i72f5235c51804466877805e8fd527626_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfOS03LTEtMS0zMTY5Mg_3c72c4cd-3cb3-4280-b315-2e4d4b3c8ad9"
      unitRef="usd">2301111</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4ee1c54551f24453a3c895ffdc0bfe2e_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfOS05LTEtMS0zMTY5Mg_6f767e53-7a44-45af-ad80-bc57f139396f"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4ee1c54551f24453a3c895ffdc0bfe2e_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfOS0xMS0xLTEtMzE2OTI_11da7a8d-3ee9-45cf-a151-e182186b4daf"
      unitRef="usd">2735556</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4ee1c54551f24453a3c895ffdc0bfe2e_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfOS0xMy0xLTEtMzE2OTI_4553ded5-4924-4a8f-ba90-33ddacafc83a"
      unitRef="usd">2364444</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i4f93349007644f839f68fbed0c369c0d_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTAtMS0xLTEtMzE2OTI_1f96328a-a9f5-4eaf-a4ee-65d9fa5ace63">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9b2a0788492e40989bb27421d1bd2073_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTAtMy0xLTEtMzE2OTI_18a3906c-f162-4b0d-b116-547179432057"
      unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9b2a0788492e40989bb27421d1bd2073_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTAtNS0xLTEtMzE2OTI_9f001e57-6fdb-4c54-88db-f59f6f5d4dc4"
      unitRef="usd">3862500</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9b2a0788492e40989bb27421d1bd2073_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTAtNy0xLTEtMzE2OTI_bd8f0f91-ff14-4327-9ed8-9983525edbfe"
      unitRef="usd">187500</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic060851ec89c42658d3355959c413ec0_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTAtOS0xLTEtMzE2OTI_09774e94-3090-453a-b8ce-bf957ffc69b9"
      unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic060851ec89c42658d3355959c413ec0_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTAtMTEtMS0xLTMxNjky_42f85e36-8af5-4117-ba3a-3c8fa1bef3cf"
      unitRef="usd">3806250</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic060851ec89c42658d3355959c413ec0_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTAtMTMtMS0xLTMxNjky_7578075f-88f1-414d-b0fa-0c1915ceb5df"
      unitRef="usd">243750</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib6fece0d322b434c8593f46a8150a928_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTEtMS0xLTEtMzE2OTI_8ad620aa-9a32-4dfe-8b07-ce6a3f80915c">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTEtMy0xLTEtMzE2OTI_4b2633ac-118e-46d1-8924-692b128ca914"
      unitRef="usd">10473761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTEtNS0xLTEtMzE2OTI_75cce7ec-6267-4231-87b1-d844d785b5e0"
      unitRef="usd">7974176</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTEtNy0xLTEtMzE2OTI_b9cd9d8d-3ac3-43fc-ba5a-b8cd4c91506f"
      unitRef="usd">2499585</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTEtOS0xLTEtMzE2OTI_cc863a10-bbf4-438e-85f0-532d6c2bab96"
      unitRef="usd">10473761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTEtMTEtMS0xLTMxNjky_bc35f031-e1d0-47ca-bd88-0bc7420bb49d"
      unitRef="usd">7847406</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTEtMTMtMS0xLTMxNjky_f50c751e-9980-405e-8af5-31b749cb9b47"
      unitRef="usd">2626355</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ino:GoodwillAndIntangibleAssetsGross
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTItMy0xLTEtMzE2OTI_896927ea-eca7-4c8e-931b-3f57a55c9de6"
      unitRef="usd">20987132</ino:GoodwillAndIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTItNS0xLTEtMzE2OTI_b5a52a84-6cbd-4552-98ef-327c16166cbb"
      unitRef="usd">7974176</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ino:GoodwillAndIntangibleAssetsNet
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTItNy0xLTEtMzE2OTI_e328a328-bd53-4324-9240-b8731e26c88f"
      unitRef="usd">13012956</ino:GoodwillAndIntangibleAssetsNet>
    <ino:GoodwillAndIntangibleAssetsGross
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTItOS0xLTEtMzE2OTI_82c25188-849d-405d-8067-3619bbd5790c"
      unitRef="usd">20987132</ino:GoodwillAndIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTItMTEtMS0xLTMxNjky_7b595f04-24e8-42ab-8b9e-260de0fdf0f0"
      unitRef="usd">7847406</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ino:GoodwillAndIntangibleAssetsNet
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RhYmxlOmExNzBiYWMxZGNmYzQ0NDViMzNmZDYwOTU0Zjc2MmJmL3RhYmxlcmFuZ2U6YTE3MGJhYzFkY2ZjNDQ0NWIzM2ZkNjA5NTRmNzYyYmZfMTItMTMtMS0xLTMxNjky_e6cc26f0-7924-44fd-a5bc-e7f726b9b675"
      unitRef="usd">13139726</ino:GoodwillAndIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RleHRyZWdpb246MTI4Yzc4ZDIzZDZlNDUxMjhmMjJlNzc0ODMyMDU4ZmVfNDQ3_22f3e7ad-a7c3-4347-a15f-325b479d64f4"
      unitRef="usd">127000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RleHRyZWdpb246MTI4Yzc4ZDIzZDZlNDUxMjhmMjJlNzc0ODMyMDU4ZmVfNTM5_0c8c29b4-998c-4a94-9553-0a5bf3507daa"
      unitRef="usd">137000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RleHRyZWdpb246MTI4Yzc4ZDIzZDZlNDUxMjhmMjJlNzc0ODMyMDU4ZmVfNjA5_8fa60e51-414e-4373-928e-8b313024a3a9"
      unitRef="usd">366000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RleHRyZWdpb246MTI4Yzc4ZDIzZDZlNDUxMjhmMjJlNzc0ODMyMDU4ZmVfNjQ5_0a8ba264-5821-4ae4-ad6a-648e7aa70243"
      unitRef="usd">276000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RleHRyZWdpb246MTI4Yzc4ZDIzZDZlNDUxMjhmMjJlNzc0ODMyMDU4ZmVfNjYx_a5151dc9-4105-4afe-bb14-56209d638a6c"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RleHRyZWdpb246MTI4Yzc4ZDIzZDZlNDUxMjhmMjJlNzc0ODMyMDU4ZmVfNjcz_e8583ce1-2e51-450e-b990-5abd4eca8a98"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RleHRyZWdpb246MTI4Yzc4ZDIzZDZlNDUxMjhmMjJlNzc0ODMyMDU4ZmVfNjg1_6b450b23-5fa1-4c17-8776-1d73cec49ef9"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <ino:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y181OC9mcmFnOjEyOGM3OGQyM2Q2ZTQ1MTI4ZjIyZTc3NDgzMjA1OGZlL3RleHRyZWdpb246MTI4Yzc4ZDIzZDZlNDUxMjhmMjJlNzc0ODMyMDU4ZmVfNzAw_506b50aa-3410-41a3-9f7c-5a763a073cf4"
      unitRef="usd">1100000</ino:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTMzMDc_25220d92-f0f8-4cf9-9e3d-7b81af221466">Convertible Debt&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Senior Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5 million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#x201c;Notes&#x201d;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $75.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of 6.50% per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate was 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.38 per share), subject to adjustment upon the occurrence of specified events.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days (whether or not &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Initially, in accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments, which do not have an associated convertible feature. The carrying amount of the equity component representing the conversion option for the Notes was $16.3&#160;million and was recorded as a debt discount, which was being amortized to interest expense at an effective interest rate of 13.1%. In addition, the Company allocated $592,000 of debt issuance costs to the equity component and the remaining debt issuance costs of $2.2&#160;million were allocated to the liability component, which were being amortized to interest expense under the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, the Company adopted ASU No. 2020-06, Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU 2020-06&#x201d;), which is intended to simplify the accounting for convertible instruments. The ASU eliminates the cash conversion feature models in ASC 470-20, Debt with Conversion and Other Options, which required an issuer of certain convertible debt to separately account for embedded conversion features as a component of equity. Instead, an issuer will account for these securities as a single unit of account, unless the conversion feature meets certain criteria. The Company adopted the new standard using the modified retrospective method, and recorded a net reduction to accumulated deficit of $1.8&#160;million, a decrease to additional paid-in capital of $3.3&#160;million, and an increase to convertible senior notes of $1.5&#160;million to reflect the impact of the accounting change. The Notes are now accounted for as a single liability measured at amortized cost, as no other embedded features require bifurcation and recognition as derivatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the Notes at March&#160;31, 2022 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Original principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount converted into common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,085,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(296,051)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,207,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2022 and 2021,&#160;the Company recognized $313,000 and $463,000, respectively, of interest expense related to the Notes, of which $267,000 and $267,000, respectively, related to the contractual interest coupon.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, were&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,549,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;December 2019 Convertible Bonds &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#x201c;December 2019 Bonds&#x201d;) with an aggregate principal amount of 4.7 billion KRW (USD $4.1 million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were $4.0 million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The December 2019 Bonds, which were unsecured obligations of the Company, were issued on December&#160;31, 2019 and accrued interest at a coupon rate of 1.00% per annum, payable quarterly. The December 2019 Bonds were scheduled to mature on December&#160;31, 2024, unless earlier converted or repurchased. On March 17, 2021, the December 2019 Bonds were converted in full into an aggregate of 1,009,450 shares of the Company's common stock, leaving no further December 2019 Bonds outstanding. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Upon conversion, the $4.4&#160;million carrying value of the December 2019 Bonds was reclassified to stockholders' equity.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective interest rate of the December 2019 Bonds was 6.2%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three months ended March 31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recognized $59,000 of interest expense related to the December 2019 Bonds, of which $9,000 related to the contractual interest coupon.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia23c27fd3cb34cb7ac69f9e4e67b758a_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTM2_d9230176-de4f-4898-9112-8ce159a07e98"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia23c27fd3cb34cb7ac69f9e4e67b758a_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTcz_49ee558f-706d-4b31-aa04-cbda8191881e"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="if641e7664fea4b26986aea56c1df79ee_D20190219-20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfNDA1_5dfdcbf5-7f4b-47cf-a231-a07fcd7a1070"
      unitRef="usd">75700000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia23c27fd3cb34cb7ac69f9e4e67b758a_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfNjE0_6b61af79-ac07-4987-b88c-5a39e4aa2516"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ia23c27fd3cb34cb7ac69f9e4e67b758a_I20190301"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTQyNg_052b6279-a0e8-440a-9399-6c9c17282413"
      unitRef="usdPerShare">5.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="if641e7664fea4b26986aea56c1df79ee_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTc0MA_09fd97e2-2737-46f1-b6ad-1558df2e3a9c"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="if641e7664fea4b26986aea56c1df79ee_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTc5MQ_62d5b352-90fb-4302-9a87-a8eab5cc401c"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="if641e7664fea4b26986aea56c1df79ee_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTg0Nw_9c582af3-ee2a-4387-8a4b-7a2a07d09c60"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="if641e7664fea4b26986aea56c1df79ee_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMjExOA_457d86ef-377f-4957-94ae-dc2ad5c8bc56"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="ia23c27fd3cb34cb7ac69f9e4e67b758a_I20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTA5OTUxMTY1OTIzOA_72c1929e-4c14-4e62-93f7-89f6516d5098"
      unitRef="usd">16300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i89c242d635e34cc2882b5b395b26a546_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMjE5OTAyMzI4ODYzOA_e3a22e68-514d-4963-936b-d50a0b67ad06"
      unitRef="number">0.131</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i89c242d635e34cc2882b5b395b26a546_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTA5OTUxMTY1OTI2MQ_92b6427f-6f3f-4542-b766-01970dcfc3cf"
      unitRef="usd">592000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i11fba970b3414270a4d7e4804a06e0e9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTA5OTUxMTY1OTI3MQ_fe5e16e3-5551-4b1e-956f-7300c2708a28"
      unitRef="usd">2200000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ifdd8f1364df749e5b75e252f613f37c5_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTA5OTUxMTY1NTE2MQ_48cbc980-fe0f-45b4-86bf-5c2f0e9fe38e"
      unitRef="usd">1800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ifdd8f1364df749e5b75e252f613f37c5_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTA5OTUxMTY1NTE3NQ_1a274f06-7525-4587-8e0c-90ea6ec34735"
      unitRef="usd">-3300000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:ConvertibleDebt
      contextRef="ifdd8f1364df749e5b75e252f613f37c5_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTA5OTUxMTY1NTE0NQ_2a5d5b34-310c-4e42-a524-2838ab37b63e"
      unitRef="usd">1500000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTMzMTA_55ecba2d-618d-4973-b57b-cfab70791f72">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the Notes at March&#160;31, 2022 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Original principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount converted into common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,085,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(296,051)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,207,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if239e019c41f41df87d6fabeb16a8209_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RhYmxlOjJiYzA2Y2JjMjY0ODRhNjg4ZTE5MThjOTZiNGFmYTcwL3RhYmxlcmFuZ2U6MmJjMDZjYmMyNjQ4NGE2ODhlMTkxOGM5NmI0YWZhNzBfMC0xLTEtMS0zMTY5Mg_16ff3913-2442-4a69-b6d6-0738f50479a8"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <ino:DebtInstrumentConvertibleDebtConvertedAmount
      contextRef="if239e019c41f41df87d6fabeb16a8209_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RhYmxlOjJiYzA2Y2JjMjY0ODRhNjg4ZTE5MThjOTZiNGFmYTcwL3RhYmxlcmFuZ2U6MmJjMDZjYmMyNjQ4NGE2ODhlMTkxOGM5NmI0YWZhNzBfMS0xLTEtMS0zMTY5Mg_38d4c224-e49c-4b51-be4e-44d28acf08da"
      unitRef="usd">62085000</ino:DebtInstrumentConvertibleDebtConvertedAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="if239e019c41f41df87d6fabeb16a8209_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RhYmxlOjJiYzA2Y2JjMjY0ODRhNjg4ZTE5MThjOTZiNGFmYTcwL3RhYmxlcmFuZ2U6MmJjMDZjYmMyNjQ4NGE2ODhlMTkxOGM5NmI0YWZhNzBfMy0xLTEtMS0zMTY5Mg_ddbd989e-4dc0-4a66-bc9e-b15a66c796a3"
      unitRef="usd">296051</us-gaap:DeferredFinanceCostsNet>
    <ino:DebtInstrumentAccruedInterest
      contextRef="if239e019c41f41df87d6fabeb16a8209_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RhYmxlOjJiYzA2Y2JjMjY0ODRhNjg4ZTE5MThjOTZiNGFmYTcwL3RhYmxlcmFuZ2U6MmJjMDZjYmMyNjQ4NGE2ODhlMTkxOGM5NmI0YWZhNzBfNC0xLTEtMS0zMTY5Mg_d93028d6-8cb6-4dd0-b7d7-2deb4705c91e"
      unitRef="usd">88915</ino:DebtInstrumentAccruedInterest>
    <us-gaap:LongTermDebt
      contextRef="if239e019c41f41df87d6fabeb16a8209_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RhYmxlOjJiYzA2Y2JjMjY0ODRhNjg4ZTE5MThjOTZiNGFmYTcwL3RhYmxlcmFuZ2U6MmJjMDZjYmMyNjQ4NGE2ODhlMTkxOGM5NmI0YWZhNzBfNS0xLTEtMS0zMTY5Mg_e8a125f7-3e51-4991-b69b-8f3bdbfce69b"
      unitRef="usd">16207864</us-gaap:LongTermDebt>
    <us-gaap:InterestExpense
      contextRef="i93f4fe9cdb954509a29e6972a23d8717_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfNDc3MQ_b011eac6-65e9-420a-a6b7-6e594f4562f9"
      unitRef="usd">313000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie10fbf5fad8743a6b390d426979d8a2f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfNDc3OA_c2b54d39-513e-436d-a8de-8cdda6e5ad0b"
      unitRef="usd">463000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i93f4fe9cdb954509a29e6972a23d8717_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfNDg0Nw_c17a439e-057c-466d-b1e7-ff156711be4d"
      unitRef="usd">267000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ie10fbf5fad8743a6b390d426979d8a2f_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfNDg1NA_262f7d12-3b6d-4eea-a571-28a8b1ec6fc6"
      unitRef="usd">267000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTMzMTE_389ee9f7-7209-43f7-b53c-fe95775f31ae">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, were&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;534,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,549,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i89c242d635e34cc2882b5b395b26a546_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfNTIzNA_a2a76a79-bd51-4290-af25-62886bc64d8e"
      unitRef="number">0.065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i89c242d635e34cc2882b5b395b26a546_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RhYmxlOjc1MTQ4ZmNiNmFmZTRhNTdiYzYxMzE5YzU4MTkyODc0L3RhYmxlcmFuZ2U6NzUxNDhmY2I2YWZlNGE1N2JjNjEzMTljNTgxOTI4NzRfMi0yLTEtMS0zMTY5Mg_6c09a17e-4d34-4791-bd59-30e1a4b31486"
      unitRef="usd">534000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i89c242d635e34cc2882b5b395b26a546_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RhYmxlOjc1MTQ4ZmNiNmFmZTRhNTdiYzYxMzE5YzU4MTkyODc0L3RhYmxlcmFuZ2U6NzUxNDhmY2I2YWZlNGE1N2JjNjEzMTljNTgxOTI4NzRfMy0yLTEtMS0zMTY5Mg_c7f365c9-cbed-4715-b37f-1cfa19888c63"
      unitRef="usd">1067000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i89c242d635e34cc2882b5b395b26a546_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RhYmxlOjc1MTQ4ZmNiNmFmZTRhNTdiYzYxMzE5YzU4MTkyODc0L3RhYmxlcmFuZ2U6NzUxNDhmY2I2YWZlNGE1N2JjNjEzMTljNTgxOTI4NzRfNC0yLTEtMS0zMTY5Mg_361b14ae-a2bb-4806-b29b-4c0a5f22d7d8"
      unitRef="usd">16948000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt
      contextRef="i89c242d635e34cc2882b5b395b26a546_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RhYmxlOjc1MTQ4ZmNiNmFmZTRhNTdiYzYxMzE5YzU4MTkyODc0L3RhYmxlcmFuZ2U6NzUxNDhmY2I2YWZlNGE1N2JjNjEzMTljNTgxOTI4NzRfNi0yLTEtMS0zMTY5Mg_338314ae-be45-43b9-a1a8-c9d02b8a8a6c"
      unitRef="usd">18549000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib3c3bc6efec5497d8d3e271600131a3b_I20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfOTc5NA_0962f4d1-4e6a-4c1e-ba40-7425d0e058d4"
      unitRef="krw">4700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib3c3bc6efec5497d8d3e271600131a3b_I20191226"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfOTgyMA_18c25ee9-f6c6-40de-a976-cc49440b2bf0"
      unitRef="usd">4100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i257d1ac432f142b299c0fe356311ee8a_D20191226-20191226"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfOTk1OQ_6b029faa-3f7f-417d-9b37-f0206a7e3df7"
      unitRef="usd">4000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib3c3bc6efec5497d8d3e271600131a3b_I20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTAxMTM_e17dc9a4-7a14-4579-bc05-ff52d075e17b"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i257d1ac432f142b299c0fe356311ee8a_D20191226-20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTAzNDU_effa7199-f4e2-488a-b517-1e000ce1e8ae"
      unitRef="shares">1009450</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="ib7987401764743bca11a6fcb90ae347c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTA5OTUxMTY2MzQxNw_37700e93-0adc-4b4b-81bf-1391259712f2"
      unitRef="usd">4400000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ide3610d56f684b5fbb8f7fff6ee33eee_I20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTI2OTE_ddd28c7a-ed59-438a-8727-40c4ee6d6832"
      unitRef="number">0.062</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpense
      contextRef="i6cd8ee10514043399860125bd7812d5e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTI5MTQ_9d3887d4-75dd-4a26-b612-34164c7ec69f"
      unitRef="usd">59000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i6cd8ee10514043399860125bd7812d5e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182MS9mcmFnOmIwYzdkNThjZWIwYjQyODQ5ZTJmMTk0ZjI4Njc3ZTNlL3RleHRyZWdpb246YjBjN2Q1OGNlYjBiNDI4NDllMmYxOTRmMjg2NzdlM2VfMTMwMDQ_c9d860e8-c730-4a8a-be7b-bb20af3f1d9b"
      unitRef="usd">9000</us-gaap:InterestExpenseDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfNDIxNQ_9d0d836b-9f29-41b4-831f-f3f5fe584362">Stockholders&#x2019; Equity&lt;div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company's authorized and issued common and preferred stock as of March&#160;31, 2022 and December&#160;31, 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding as of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,510,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,510,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,382,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 9, 2021, the Company entered into an ATM Equity Offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Sales Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with outside sales agents (collectively, the &#x201c;Sales Agents&#x201d;) for the offer and sale of its common stock for an aggregate offering price of up to $300.0&#160;million. The 2021 Sales Agreement provides that the Sales Agents will be entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. For the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three months ended March 31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company sold 8,480,483 shares of its common stock under the 2021 Sales Agreement. The sales were made at a weighted average price of $3.52 per share, resulting in aggregate net proceeds of $29.4 million. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; there was $221.8 million of remaining capacity under the 2021 Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 25, 2021, the Company closed an underwritten public offering of 20,355,000 shares of common stock at a public offering price of $8.50 per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other offering expenses, were $162.1&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options and Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the maximum number of shares of the Company&#x2019;s common stock available for issuance over the term of the 2016 Incentive Plan was 22,000,000 shares. On the first business day of each calendar year, such maximum number of shares shall be increased by&#160;2,000,000 shares of common stock unless the Board determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2022, the maximum number of shares increased by 2,000,000. At March&#160;31, 2022, the Company had 838,641 shares of common stock available for future grant under the 2016 Incentive Plan, 3,491,330 shares underlying outstanding but unvested restricted stock units and options outstanding to purchase 11,701,340 shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.&lt;/span&gt;&lt;/div&gt;The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At March&#160;31, 2022, the Company had options outstanding to purchase 2,395,723 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfNDIxNw_14bdf4c9-534b-4168-a006-2c421163e52f">&lt;div style="margin-bottom:10pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company's authorized and issued common and preferred stock as of March&#160;31, 2022 and December&#160;31, 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.095%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding as of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,510,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,510,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,382,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par value $0.001 per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfMi0wLTEtMS0zMTY5Mi90ZXh0cmVnaW9uOjdmNDZlYTYwNDc5ODQ3YjY4MWFjNjljYThjZTg5MjY2XzI4_42509f08-a79c-4162-a370-0d39adc1b6a9"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfMi0wLTEtMS0zMTY5Mi90ZXh0cmVnaW9uOjdmNDZlYTYwNDc5ODQ3YjY4MWFjNjljYThjZTg5MjY2XzI4_9e63a56d-556f-4164-bc62-dece1b154f41"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfMi0xLTEtMS0zMTY5Mg_6c47a2ad-d427-4fbf-bdd2-ab0c6535cb20"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfMi0zLTEtMS0zMTY5Mg_990c9a63-95e0-46bc-b85e-34f4c23f85fd"
      unitRef="shares">226510720</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfMi01LTEtMS0zMTY5Mg_6e8872cb-4fcf-4ab1-8901-ac694f042137"
      unitRef="shares">226510720</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7d6d1124a58448ddb3c672fffdeb679f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfMi03LTEtMS0zMTY5Mg_c67c7797-e5c5-4951-aec9-b937ca8e6443"
      unitRef="shares">217382887</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iee0415add3154b6c8fca72404d201bb7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfNS0wLTEtMS0zMTY5Mi90ZXh0cmVnaW9uOjBjZjU0NWZlMWE1YTQzN2Y5ZjJkYjE2NjBkYWIzN2I5XzQw_55055fc1-e1c4-42a2-b494-74b71dc2bca0"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i4e2be23d00d345b6bed7ade8e6494fc7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfNS0wLTEtMS0zMTY5Mi90ZXh0cmVnaW9uOjBjZjU0NWZlMWE1YTQzN2Y5ZjJkYjE2NjBkYWIzN2I5XzQw_cd91b93e-b091-47d7-9fd5-967e94eeebe6"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i4e2be23d00d345b6bed7ade8e6494fc7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfNS0xLTEtMS0zMTY5Mg_1dc64823-b880-4aed-ac4f-d1351794881b"
      unitRef="shares">1091</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i4e2be23d00d345b6bed7ade8e6494fc7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfNS0zLTEtMS0zMTY5Mg_040f1ff6-de96-411e-9ff5-369a3d811636"
      unitRef="shares">1091</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i4e2be23d00d345b6bed7ade8e6494fc7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfNS01LTEtMS0zMTY5Mg_0a421073-a8b6-4235-9af7-ea53aeaddbe6"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iee0415add3154b6c8fca72404d201bb7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RhYmxlOmUxNzQ1ZjYwNGE5ZDRiMmFhYzUzZDYyMjBhZWFhZDNkL3RhYmxlcmFuZ2U6ZTE3NDVmNjA0YTlkNGIyYWFjNTNkNjIyMGFlYWFkM2RfNS03LTEtMS0zMTY5Mg_d31e7a47-1e1d-4768-ab66-cf185b779533"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="i9a881011504441e1a9c61a374bf1ccf4_D20211109-20211109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMjE5OTAyMzI2MDgxOA_69fe655e-a171-4c99-b8d6-03a23e68e28a"
      unitRef="usd">300000000</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage
      contextRef="i9a881011504441e1a9c61a374bf1ccf4_D20211109-20211109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMjE5OTAyMzI2MDgzMw_9472ed17-189b-418b-957b-c763e7ab2d9a"
      unitRef="number">0.030</ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="i5e2f4f4898364123a256c32ca33facc9_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMjE5OTAyMzI2MDg5Mg_deb9d07d-2747-4587-a375-9526797eaad0"
      unitRef="shares">8480483</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="i5e2f4f4898364123a256c32ca33facc9_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMjE5OTAyMzI2MDkwMA_666846c1-b8e2-4f5e-8669-297c63b17ea9"
      unitRef="usdPerShare">3.52</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock
      contextRef="i5e2f4f4898364123a256c32ca33facc9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMjE5OTAyMzI2MDkxNw_6c30f90a-25e5-414b-b953-c276787121b9"
      unitRef="usd">29400000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSalesAgreementRemainingAuthorizedAmount
      contextRef="ief33ee4c2f9d472ca203587fdd030959_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMjE5OTAyMzI2MDk2MA_231de15b-9a96-4799-a604-39d105a51d07"
      unitRef="usd">221800000</ino:StockSalesAgreementRemainingAuthorizedAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i49690b96047544fa998f0502891752a4_D20210125-20210125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMzkx_b26126b2-e599-435d-8ab4-c9edd686984b"
      unitRef="shares">20355000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i2d07fc0fc7734f8d9a8aaf0c1d8877ec_I20210125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfNDQ3_e6b1a08f-5531-44db-b259-d34a4cde7b9c"
      unitRef="usdPerShare">8.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i49690b96047544fa998f0502891752a4_D20210125-20210125"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfNTk4_8ef2cd41-30db-4797-b319-ec81490c3e48"
      unitRef="usd">162100000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i506a7271caec452a979fcd2973d994a3_I20160513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMjkzOA_c12def94-c9de-4b23-b666-ca455785339d"
      unitRef="shares">22000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan
      contextRef="i506a7271caec452a979fcd2973d994a3_I20160513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMzA1Mg_59d7bea3-8e93-4ce8-8334-9ec7a32c3141"
      unitRef="shares">2000000</ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan>
    <ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized
      contextRef="i74e4addc1ab747f6b371d1e28eef2596_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMzMzNg_e367abad-4051-4a93-ad18-39d018f4f338"
      unitRef="shares">2000000</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i7c114109f3fb4d2e9bd8f37900a7cf35_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMzM2Mw_f57e3756-7738-4e96-9eaf-e01d1b8a16f6"
      unitRef="shares">838641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i7c114109f3fb4d2e9bd8f37900a7cf35_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMzQ0Nw_8e76928a-d5d2-4a00-adef-d34d44fffbf3"
      unitRef="shares">3491330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="i7c114109f3fb4d2e9bd8f37900a7cf35_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMzU1Mg_62aa6957-e650-4e65-b878-77a353bbcddb"
      unitRef="shares">11701340</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ia7964dc3a17e4cfb80c440f5e98914ba_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMzcwOQ_dadcb4b7-8611-4b1a-95e3-06a6f4f42f60">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm
      contextRef="ia7964dc3a17e4cfb80c440f5e98914ba_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfMzc1MQ_cbd82e6b-2412-40fb-8d73-cee0e42a91f5">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="i53998403d9a644378e830ed35dde9174_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfNDAzNA_702fe1fe-8c47-4297-9b7c-4c0741915891"
      unitRef="shares">2395723</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i74c8f3b2f8074de68c07442296de5eda_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfNDE2MA_c107c7a9-c629-476d-885e-dcc5276357ae">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm
      contextRef="i74c8f3b2f8074de68c07442296de5eda_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y182Ny9mcmFnOmU5MjY5ZDRlZWIxZTRhODBhNjJmOTQzMGQzNmQ3NzVlL3RleHRyZWdpb246ZTkyNjlkNGVlYjFlNGE4MGE2MmY5NDMwZDM2ZDc3NWVfNDIwMg_54e886d2-1fa2-433e-a11b-b8e22592158b">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RleHRyZWdpb246Y2I3NzkzNThmMjRhNGZjNWIzNGU5OGQ1ODIxYmFhMTZfMjE3NA_e46ce02d-9000-4ed1-a085-b95ff7468cad">Net Loss Per Share &lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units and refle&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cts the potential dilution that would occur if securities or other con&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes issued by the Company (discussed in Note 8) has been considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to the net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. For the three months ended March 31, 2022 and 2021, basic and diluted net &lt;/span&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;loss per share were the same, as the assumed exercise or settlement of stock options and restricted stock units and the potentially dilutive shares issuable upon conversion of the Notes would have been anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,097,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,826,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,491,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,610,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,305,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,153,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RleHRyZWdpb246Y2I3NzkzNThmMjRhNGZjNWIzNGU5OGQ1ODIxYmFhMTZfMjE5MA_438a83eb-bc0d-456e-9c50-71c21690ccf9">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.170%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,097,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,826,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,491,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,610,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,305,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,153,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4e593faba088418ca3470ba0e2ef170a_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfMi0xLTEtMS0zMTY5Mg_50908e25-811a-42c3-8899-d89ff9711a3a"
      unitRef="shares">14097063</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic1f7c31d501f484e8655d8e19138ea45_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfMi0zLTEtMS0zMTY5Mg_6f405125-c9c3-4e08-9119-85c5d8096617"
      unitRef="shares">10826472</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8eeb39a62cfd45a19b16ff2f77b29ea0_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfMy0xLTEtMS0zMTY5Mg_08dca492-bf0b-4459-a1f3-449c7e3024ba"
      unitRef="shares">3491330</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9d5160a767ac4bafba1dc028690dde9c_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfMy0zLTEtMS0zMTY5Mg_fa9f3cd5-6de7-4f24-a42d-3e9995cbf66a"
      unitRef="shares">2610130</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i64c8814591c9419e86db1db17a0446e7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfNC0xLTEtMS0zMTY5Mg_b078ae4b-997b-43db-acc0-986aa9696719"
      unitRef="shares">663353</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i450d92211f544cdc985d06e7fed62e63_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfNC0zLTEtMS0zMTY5Mg_8e037620-aae5-4a4c-acf9-1d9316f550d5"
      unitRef="shares">663353</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6079656cc273434d86458c6aebd9dc67_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfNS0xLTEtMS0zMTY5Mg_dfa6e162-b93c-4bf3-9732-43090901e24c"
      unitRef="shares">3309</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i404ce3ef99524755b77883e75ca4a739_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfNS0zLTEtMS0zMTY5Mg_d06da410-31b1-414c-bc60-25bd518df26c"
      unitRef="shares">3309</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8f5a82e0fe634a5cb2409168cbd8cd88_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfNi0xLTEtMS0zMTY5Mg_f0d6e8a5-58a4-4af9-8104-4f5b691aaa23"
      unitRef="shares">3049980</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5454fcab37d841f7875d94376e14df0d_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfNi0zLTEtMS0zMTY5Mg_a322b4af-2785-4821-987e-f6cba6612d08"
      unitRef="shares">3049980</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfOS0xLTEtMS0zMTY5Mg_d225e15d-c920-48ff-aef5-a54a356e45cb"
      unitRef="shares">21305035</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183MC9mcmFnOmNiNzc5MzU4ZjI0YTRmYzViMzRlOThkNTgyMWJhYTE2L3RhYmxlOjAwZjY5YmU2ZmE2ZjQxZjM4ZTQ0ZDRiNGYyNzIzNWEzL3RhYmxlcmFuZ2U6MDBmNjliZTZmYTZmNDFmMzhlNDRkNGI0ZjI3MjM1YTNfOS0zLTEtMS0zMTY5Mg_c08d224c-3bad-4cf3-94e9-f9978aa8c4db"
      unitRef="shares">17153244</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfNDA1OQ_56faed4a-06ae-4365-8870-d3007dfcb12b">Stock-Based Compensation&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurs stock-based compensation expense related to restricted stock units ("RSUs") and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total employee and director stock-based compensation expense recognized in the condensed consolidated statements of operations for the three months ended March 31, 2022 and 2021 was $7.2 million and $9.2 million, respectively, of which $3.7 million and $5.2 million, respectively, was included in research and development expenses, and $3.5 million and $4.0 million, respectively, was included in general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022, there was $19.8 million of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 2.2 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share, calculated using the Black-Scholes option pricing model, was $2.48 and $8.34 for employee and director stock options granted during the three months ended March 31, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2022, there was $17.1 million of total unrecognized compensation expense related to unvested service-based RSUs, which is expected to be recognized over a weighted-average period of 2.1 years.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share was $3.33 and $11.42 for service-based RSUs granted during the three months ended March 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the three months ended March 31, 2022 and 2021 was $550,000 and $429,000, respectively.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August 28, 2020, the Company granted 663,353 performance-based RSUs to key employees under the 2016 Incentive Plan. The RSUs will vest in two tranches as follows: 50% of the shares in each tranche will vest upon achievement of the predetermined performance milestones and the remaining 50% of the shares in each tranche will vest upon subsequent completion of a one-year service period. The grant date fair value of the performance-based RSUs was $8.0&#160;million based on the grant date closing price per share of $12.06. As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;March&#160;31, 2022&lt;/span&gt;&lt;span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, the underlying performance milestones of the RSUs were not probable of achievement, and no stock-based compensation expense was recognized for the performance-based RSUs for the three months then ended.&lt;/span&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfNDA3Mw_d09fff7b-5c4c-4c34-832b-ca4f9e401e1d">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.461%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.88%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i5244cd2065d44efa8be7f4b42dc1fef1_D20220101-20220331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RhYmxlOjEwNGJkYWFjZjFlMTQwNWFiYjUxNjlkM2IyYTNjZTE5L3RhYmxlcmFuZ2U6MTA0YmRhYWNmMWUxNDA1YWJiNTE2OWQzYjJhM2NlMTlfMi0xLTEtMS0zMTY5Mg_a9d30af8-5634-433d-b663-cda88c4ff783"
      unitRef="number">0.0188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i131de56e723d441a8b4d29a66a9f0297_D20210101-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RhYmxlOjEwNGJkYWFjZjFlMTQwNWFiYjUxNjlkM2IyYTNjZTE5L3RhYmxlcmFuZ2U6MTA0YmRhYWNmMWUxNDA1YWJiNTE2OWQzYjJhM2NlMTlfMi0zLTEtMS0zMTY5Mg_757013d2-b812-4ffd-8a11-88df84c9e638"
      unitRef="number">0.0088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i5244cd2065d44efa8be7f4b42dc1fef1_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RhYmxlOjEwNGJkYWFjZjFlMTQwNWFiYjUxNjlkM2IyYTNjZTE5L3RhYmxlcmFuZ2U6MTA0YmRhYWNmMWUxNDA1YWJiNTE2OWQzYjJhM2NlMTlfMy0xLTEtMS0zMTY5Mg_95d599f0-1528-4478-9c01-ffc0effbaa99"
      unitRef="number">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i131de56e723d441a8b4d29a66a9f0297_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RhYmxlOjEwNGJkYWFjZjFlMTQwNWFiYjUxNjlkM2IyYTNjZTE5L3RhYmxlcmFuZ2U6MTA0YmRhYWNmMWUxNDA1YWJiNTE2OWQzYjJhM2NlMTlfMy0zLTEtMS0zMTY5Mg_6c03cc02-5610-4bd3-9720-cd4e4b7d7336"
      unitRef="number">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5244cd2065d44efa8be7f4b42dc1fef1_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RhYmxlOjEwNGJkYWFjZjFlMTQwNWFiYjUxNjlkM2IyYTNjZTE5L3RhYmxlcmFuZ2U6MTA0YmRhYWNmMWUxNDA1YWJiNTE2OWQzYjJhM2NlMTlfNC0xLTEtMS0zMTY5Mg_04a59441-ce9b-433f-b7e8-f9e02b667dac">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i131de56e723d441a8b4d29a66a9f0297_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RhYmxlOjEwNGJkYWFjZjFlMTQwNWFiYjUxNjlkM2IyYTNjZTE5L3RhYmxlcmFuZ2U6MTA0YmRhYWNmMWUxNDA1YWJiNTE2OWQzYjJhM2NlMTlfNC0zLTEtMS0zMTY5Mg_72db336a-18a6-4bcb-8a07-1d37d4ef4d4f">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i5244cd2065d44efa8be7f4b42dc1fef1_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RhYmxlOjEwNGJkYWFjZjFlMTQwNWFiYjUxNjlkM2IyYTNjZTE5L3RhYmxlcmFuZ2U6MTA0YmRhYWNmMWUxNDA1YWJiNTE2OWQzYjJhM2NlMTlfNS0xLTEtMS0zMTY5Mg_6f483219-af62-4bb6-a097-6dc7ddf9d522"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i131de56e723d441a8b4d29a66a9f0297_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RhYmxlOjEwNGJkYWFjZjFlMTQwNWFiYjUxNjlkM2IyYTNjZTE5L3RhYmxlcmFuZ2U6MTA0YmRhYWNmMWUxNDA1YWJiNTE2OWQzYjJhM2NlMTlfNS0zLTEtMS0zMTY5Mg_27a30693-9ed4-4068-a91b-df0d74a7ab14"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensation
      contextRef="ieccf6f95500841c6a3689f60a52eee48_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMTU4NQ_f37e23b5-5526-49a6-93f0-4d18ff1030ca"
      unitRef="usd">7200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ib1c041808f3c4fcdad3091644d6b6568_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjE5OTAyMzI1OTYzOQ_2a5e44da-012c-4667-bf9f-c9d43d57056f"
      unitRef="usd">9200000</us-gaap:ShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i12c8e38f5a5d4faf8e21cca6e3048613_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMTYyMA_e7858b2f-c22e-47a2-afd7-4e0f84c42ccd"
      unitRef="usd">3700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i466990d2769740b4be6de242e03e8e59_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjE5OTAyMzI1OTY0Ng_3e323835-6c09-4de4-aaa6-380a5d21e93d"
      unitRef="usd">5200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i82e293c63e7b45f497259112c8856cf3_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMTcwMQ_dcde26ec-e080-4dc4-81c3-2429ce014010"
      unitRef="usd">3500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieaec0500407e4460af3ae9824374aa5f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjE5OTAyMzI1OTY1NA_3861ab82-3758-4f2e-be17-7b41e61e4699"
      unitRef="usd">4000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjEzMA_1dcb69e5-9e9b-41a7-b739-2f8eb889d941"
      unitRef="usd">19800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjI4MA_ff3558fb-2a24-4cc9-90bd-e315969f92a6">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjM5OQ_20ee04f5-0afb-473b-b5e9-14961b7b6f7f"
      unitRef="usdPerShare">2.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjE5OTAyMzI2MDAwMQ_408bbda5-06f6-4ab3-b10a-7657e483726d"
      unitRef="usdPerShare">8.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i91452942e5e5451087ce0e121faae465_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjU0NA_5f606af6-9c60-42f5-9876-2b0c72ff15c9"
      unitRef="usd">17100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i7c416618392046e181d9a033a06b4af3_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjY5OQ_58baebef-db9c-4a5d-9780-cdfbd6b97e34">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7c416618392046e181d9a033a06b4af3_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjc2OA_35a985fd-4952-49e0-8327-9cc0b2693785"
      unitRef="usdPerShare">3.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if2ec2de8f8e64ef6b6eb20c42e3919e2_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMjE5OTAyMzI2MDE4Mg_075d48a1-92ba-4451-8f02-9bc035769286"
      unitRef="usdPerShare">11.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensation
      contextRef="i7fdb61060a19450e8b33f7efaa1f435d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMzE4NA_48a64fe6-6ba4-4738-b584-c551d351c76b"
      unitRef="usd">550000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i76d9cb0a9e604a1d89a1ce39c1ba9ed3_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMzMxNQ_14aef346-04a1-4011-acdf-594b49ef59b4"
      unitRef="usd">429000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1fb6f216bfa54b49a624c469d5203ec1_D20200828-20200828"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMzM4MA_5af21d32-b9c7-4058-a811-197010123da7"
      unitRef="shares">663353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i491165f321fa4e9eba5d2778f326ed0d_D20200828-20200828"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMzQ5OA_5dcbfa53-4982-46fd-be58-890799acd38b"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ie37803101927413c9caf0a2b10452612_D20200828-20200828"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMzYyMA_c27c8dce-aada-49ec-8722-b33d87077666"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie37803101927413c9caf0a2b10452612_D20200828-20200828"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfNDA3MQ_e2326fce-f69c-4ae8-834c-ab94c89fa129">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue
      contextRef="i1fb6f216bfa54b49a624c469d5203ec1_D20200828-20200828"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMzc4NQ_01d42eca-9d01-43d6-8731-f16d51b0fd4c"
      unitRef="usd">8000000</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1fb6f216bfa54b49a624c469d5203ec1_D20200828-20200828"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183Ni9mcmFnOjYxZGEwYWI3MGQ3YjQyYWVhMmNmYTEyMzQyNDAwODk4L3RleHRyZWdpb246NjFkYTBhYjcwZDdiNDJhZWEyY2ZhMTIzNDI0MDA4OThfMzgzOQ_90b355e0-8167-4dce-9a5a-ee5a233e6ad4"
      unitRef="usdPerShare">12.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzU2NA_b8218d96-ebdc-4b51-9352-230131a60423">Related Party Transactions&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Plumbline Life Sciences, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company owned 597,808 shares of common stock in PLS as of March&#160;31, 2022, representing a 18.7% ownership interest, and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized from PLS consists of milestone, license and patent fees. For the three months ended March 31, 2022 and 2021, the Company recognized revenue from PLS of $9,000 and $50,000, respectively. At March&#160;31, 2022 and December&#160;31, 2021, the Company had an accounts receivable balance of $34,000 and $25,000, respectively, related to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Wistar Institute&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreements. In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. The Company will have the exclusive right to in-license new intellectual property developed under this agreement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, the Company entered into collaborative research agreements with Wistar in support of the clinical development of INO-4800. Under the terms of these collaborative research agreements, the Company will reimburse Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $1.9&#160;million during the two-year term of the agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In Novem&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ber 2016, the Company received a&#160;$6.1 million&#160;sub-grant through Wistar to develop a dMAb against the Zika infection, which was fully funded through December 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company received a $10.7&#160;million sub-grant through Wistar, which was amended in 2021 to $13.5&#160;million, for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding through November 2022. The sub-grant also includes an option for an additional $6.0&#160;million in funding through March 2024, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of which $3.3&#160;million has been exercised as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the three months ended March 31, 2022 and 2021, the Company recorded $1.5 million and $230,000, respectively, as contra-research and development expense from Wistar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 14). Research and development expenses recorded from Wistar for the three months ended March 31, 2022 and 2021 were $181,000 and $318,000, respectively. At March&#160;31, 2022 and December&#160;31, 2021, the Company had an accounts receivable balance of $3.5 million and $2.6 million, respectively, and an accounts payable and accrued liability balance of $1.4 million and $548,000, respectively, related to Wistar. As of March&#160;31, 2022, the Company recorded $38,000 as deferred grant funding and $76,000 as prepaid expenses on the condensed consolidated balance sheet related to Wistar.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i0505907c69774e2f9b14cd272f6e78ab_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfODU_11be6962-3164-4b8d-baca-c82bad257dcf"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i0505907c69774e2f9b14cd272f6e78ab_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMTQz_15c92e7c-ea5d-4fb4-8d65-63079cc268e9"
      unitRef="number">0.187</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00d50bf6cf7f4ad2a522a955df7010fd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzgz_4aef39c0-6a9e-40d9-a16e-440b72d76f15"
      unitRef="usd">9000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i998a91031a25433790f82a700988c0b4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfNDEy_02a4a584-9950-434b-af08-2c8d4b7a1fed"
      unitRef="usd">50000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i113857f5676c45c8985e00527eadd700_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfNTEz_65560175-a84b-4549-9a0c-eb6760aa7fe2"
      unitRef="usd">34000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i54c2b2722e924db1b3ff26d952a3e88e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfNTIw_137605dc-812b-4742-b74c-b203bed999cf"
      unitRef="usd">25000</us-gaap:AccountsReceivableRelatedParties>
    <ino:CollaborativeAgreementExpensesToReimburse
      contextRef="i8a14a4908e804611b1eb9dc197afef27_D20160301-20160331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMTE3Mg_f619b526-728b-49a2-b4b0-c025f6cc9e07"
      unitRef="usd">3100000</ino:CollaborativeAgreementExpensesToReimburse>
    <ino:CollaborativeArrangementTerm
      contextRef="i8a14a4908e804611b1eb9dc197afef27_D20160301-20160331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzU2MQ_f1562519-155c-45c5-bd4a-7829af4a4588">P5Y</ino:CollaborativeArrangementTerm>
    <ino:CollaborativeAgreementExpensesToReimburse
      contextRef="ic38879a67ed2417892b510c2282934e9_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMTgxNA_8f453743-bb55-41a4-b83b-66354809db37"
      unitRef="usd">1900000</ino:CollaborativeAgreementExpensesToReimburse>
    <ino:CollaborativeArrangementTerm
      contextRef="ic38879a67ed2417892b510c2282934e9_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzU2Mg_4931e6c9-9ac4-400f-b148-910e58826f47">P2Y</ino:CollaborativeArrangementTerm>
    <ino:CollaborativeAgreementAwardedAmount
      contextRef="i154ff5c5f70146429ef3ca2399396227_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMTkwMg_7ddfe1b5-8de4-4115-8925-be46ff81fa61"
      unitRef="usd">6100000</ino:CollaborativeAgreementAwardedAmount>
    <ino:CollaborativeAgreementAwardedAmount
      contextRef="i1c89ed0e5b044d7e82c20c40f333fc2a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMjIyMg_120c6348-4d26-4d72-afd3-ca13ff5501d2"
      unitRef="usd">10700000</ino:CollaborativeAgreementAwardedAmount>
    <ino:CollaborativeAgreementAmendedAmount
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMjE5OTAyMzI1OTI5OQ_771703ab-5c08-4056-babd-08ba15180040"
      unitRef="usd">13500000</ino:CollaborativeAgreementAmendedAmount>
    <ino:CollaborativeAgreementAwardedOptionAmount
      contextRef="i0034e9c906a24164ba01742d7b986684_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMjQ0Mw_0afbef95-2efe-4695-ba8b-52291a4ad037"
      unitRef="usd">6000000</ino:CollaborativeAgreementAwardedOptionAmount>
    <ino:CollaborativeAgreementAwardedExercisedAmount
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMjE5OTAyMzI1OTM4Nw_a87004d5-9725-42df-8635-6ed3a52dd61b"
      unitRef="usd">3300000</ino:CollaborativeAgreementAwardedExercisedAmount>
    <ino:GrantProceedsReceived
      contextRef="if9fe7623f5234877ba048ec3fbd39a69_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMjcwMQ_e32dfbbc-2704-411e-ab9d-163e491f511a"
      unitRef="usd">1500000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="ic38879a67ed2417892b510c2282934e9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMjc2Mg_215346d9-9be1-4ebc-983b-6f1fde59a828"
      unitRef="usd">230000</ino:GrantProceedsReceived>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="if9fe7623f5234877ba048ec3fbd39a69_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzEyNw_8055efbb-0495-4d69-9e45-dafdd83ebc23"
      unitRef="usd">181000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ic38879a67ed2417892b510c2282934e9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzIyMw_365c9a42-7ead-4bf5-ab31-da185a69a552"
      unitRef="usd">318000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="ic40026348a73461d8f5be933afc8a40e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzMxMg_49c30c49-b0a5-4460-b344-99e809864c29"
      unitRef="usd">3500000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i598d38fe89f5401ebb28138691b4da4e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzMxOQ_388f8f06-a1fe-437b-98ea-b4d72bbde4e6"
      unitRef="usd">2600000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="ic40026348a73461d8f5be933afc8a40e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzM5NA_3f5c4105-59b3-46ba-bc30-5820f58f913a"
      unitRef="usd">1400000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i598d38fe89f5401ebb28138691b4da4e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzQwMQ_e7837b60-ccef-4aa1-ae4e-43042235956e"
      unitRef="usd">548000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <ino:DeferredGrantFundingFromAffiliate
      contextRef="ic40026348a73461d8f5be933afc8a40e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMzQ2OQ_36eb77a9-bb0f-4a62-b1a2-4855d4fbbb40"
      unitRef="usd">38000</ino:DeferredGrantFundingFromAffiliate>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y183OS9mcmFnOjU2ZWVjMWIwYmZkYTQzZDA5ODBmNTQxNDg1YzI2OWQyL3RleHRyZWdpb246NTZlZWMxYjBiZmRhNDNkMDk4MGY1NDE0ODVjMjY5ZDJfMjE5OTAyMzI1OTc5NA_1d52c12e-5b19-4418-b844-833a12496d1b"
      unitRef="usd">76000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RleHRyZWdpb246YmIwMjI3YjI1OGY5NGJlZDkyYWNjZDFkNDc5Mzg0ZDFfMzIwMQ_8266586d-f4bf-4dd0-98c6-9bd07f8bd66e">Commitments and Contingencies                                                  Leases&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases approximately 82,200 square feet of office, laboratory, and manufacturing space in San Diego, California and 57,360 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of March&#160;31, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of 1.7 to 7.8 ye&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ars, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets and liabilities on the condensed consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;As of March&#160;31, 2022, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,074,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,089,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,063,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,139,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,749,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,164,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,725,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,439,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,673,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,766,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs included in operating expenses in the condensed consolidated statements of operations for the three months ended March 31, 2022 and 2021 were $830,000 and $850,000, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately 13,500 square feet in its Plymouth Meeting headquarters through periods between December 31, 2022 and March 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and J. Joseph Kim, the Company&#x2019;s Chief Executive Officer, as defendants. The lawsuit alleges that the Company made materially false and misleading statements regarding its development of a vaccine for COVID-19 in its public disclosures in violation of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#x2019; fees. On August 3, 2020, the lead plaintiff filed a consolidated complaint, naming the Company and three of its officers as defendants. On September 21, 2020, the lead plaintiff and another purported stockholder filed a first amended complaint, naming the Company and three of its officers as defendants. Defendants filed a motion to dismiss plaintiff&#x2019;s first amended complaint on November 5, 2020. On February 16, 2021, the court issued an order granting in part, and denying in part, the defendants&#x2019; motion to dismiss. The court granted the defendants&#x2019; motion to dismiss, and dismissed with prejudice, the claims premised on certain of the Company&#x2019;s statements. The court denied defendants&#x2019; motion to dismiss as to the remaining statements. On March 9, 2021, the defendants filed their answer to the complaint. The case is currently in discovery. On July 29, 2021, the plaintiffs moved to certify the class action. That motion is fully briefed and remains pending. On February 17, 2022, the court granted Plaintiffs&#x2019; motion for leave to amend their complaint, and further ordered that the amended complaint is deemed filed as of February 17. On March 21, 2022, Defendants moved to dismiss the new allegations in the amended complaint. The Company expects that motion to be fully briefed on May 10, 2022. No hearing date has been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class action complaint. The lawsuit accuses the Company&#x2019;s board of directors of failing to exercise reasonable and prudent supervision over the Company&#x2019;s management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of the Company as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12, 2020 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et al. and Devarakonda et al. v Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name the Company&#x2019;s current directors as defendants. The Devarakonda complaint also names one of the Company&#x2019;s former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 28, 2022, a fifth shareholder derivative complaint, Schumacher v. Benito et al., was filed in the Delaware Court of Chancery, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 4, 2022, the Delaware Court of Chancery entered a stay of the litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to defend these actions vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;VGXI Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 3, 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#x2019;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#x2019; fees, interest, costs and other relief from VGXI. On June 3, 2020, the Company filed a petition for preliminary injunction, which was denied on June 25, 2020. On June 26, 2020, the Company filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 7, 2020, VGXI filed an answer, new matter and counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#x2019; fees, interest, costs and other relief from the Company. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, the Company filed an answer to VGXI&#x2019;s counterclaims, disputing the allegations and the claims raised in VGXI&#x2019;s filing. On October 1, 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#x2019;s counterclaims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GeneOne Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Device License Agreement, or the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Agreement, between the Company and GeneOne. The Company terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#x2019; fees, interest, and other relief from the Company. On January 29, 2021, the Company filed preliminary objections to the complaint. On August 23, 2021, the court overruled the Company&#x2019;s preliminary objections to the complaint. On September 13, 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#x2019;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The counterclaims seek damages, interest, expenses, attorney&#x2019;s fees, and costs.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 18, 2021, GeneOne filed its answer to the Company&#x2019;s counterclaims and new matter. On November 8, 2021, we filed our answer to GeneOne&#x2019;s new matter. A trial date for this litigation has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#x2019;s complaint. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of our business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#x2019;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#x2019;s consolidated results of operations or financial position.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="i93b7902a9abb40beb532a03c0df4ed2d_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RleHRyZWdpb246YmIwMjI3YjI1OGY5NGJlZDkyYWNjZDFkNDc5Mzg0ZDFfMTAw_e571e419-546f-4269-bc93-9b36dc5a4dac"
      unitRef="sqft">82200</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="ic80593d7532d4f61b66a6152e7a7552b_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RleHRyZWdpb246YmIwMjI3YjI1OGY5NGJlZDkyYWNjZDFkNDc5Mzg0ZDFfMTkx_6b3de1c5-7d76-47d9-9d14-0e4a01b83f2e"
      unitRef="sqft">57360</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i8bf07160649541bca2512ad124da7853_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RleHRyZWdpb246YmIwMjI3YjI1OGY5NGJlZDkyYWNjZDFkNDc5Mzg0ZDFfMzUy_e8191aac-d137-4b8b-9744-25484bc44e2b">P1Y8M12D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="if296892e17fa4a3996048fd9a773bb41_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RleHRyZWdpb246YmIwMjI3YjI1OGY5NGJlZDkyYWNjZDFkNDc5Mzg0ZDFfMzU4_ba21879a-aad5-483f-b17e-4eb5a5a2b3da">P7Y9M18D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RleHRyZWdpb246YmIwMjI3YjI1OGY5NGJlZDkyYWNjZDFkNDc5Mzg0ZDFfMzIwNQ_e93dd233-8c98-48ed-807f-8bdbc6930e8a">&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;As of March&#160;31, 2022, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,074,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,089,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,063,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,139,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,749,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,164,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,725,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,439,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,673,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,766,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfMC0xLTEtMS0zMTY5Mg_deacc4ed-c791-4d90-ad2b-09785d3ab063"
      unitRef="usd">3074000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfMS0xLTEtMS0zMTY5Mg_e31e2433-bf66-45ee-947a-985afa43a3e5"
      unitRef="usd">4089000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfMi0xLTEtMS0zMTY5Mg_772778db-ff08-4ea0-bee7-8582cb29e8ed"
      unitRef="usd">3050000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfMy0xLTEtMS0zMTY5Mg_6627acaf-75a6-4c44-94c4-35d119c4239a"
      unitRef="usd">3063000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfNC0xLTEtMS0zMTY5Mg_ade494bc-d177-425e-9060-ed1356716df3"
      unitRef="usd">3139000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <ino:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfNS0xLTEtMS0zMTY5Mg_34e0353e-aa38-4b8e-b629-828efd5ebe83"
      unitRef="usd">6749000</ino:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfNi0xLTEtMS0zMTY5Mg_516ba003-4102-458e-89c7-fd8cd5f69e30"
      unitRef="usd">23164000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfNy0xLTEtMS0zMTY5Mg_c27b85e8-b293-4741-a601-6afde3d2f43a"
      unitRef="usd">5725000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfOC0xLTEtMS0zMTY5Mg_74b8f567-153a-458d-b111-6a081d8bdf83"
      unitRef="usd">17439000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfOS0xLTEtMS0zMTY5Mg_2f1e46d3-05c0-4276-8930-98a8d3b95d27"
      unitRef="usd">2673000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfMTAtMS0xLTEtMzE2OTI_0830d970-d0f8-48ed-8a51-ab40fb076140"
      unitRef="usd">14766000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfMTItMS0xLTEtMzE2OTI_ce71c21f-fea7-448a-aabd-ac859709c3fc">P6Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ib30ea824035a4f29b36bdddc9f77f71b_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RhYmxlOjA2ODJjM2E4M2MxYTQ2NmQ5NDM5M2QzY2IwMWI0ZWYwL3RhYmxlcmFuZ2U6MDY4MmMzYTgzYzFhNDY2ZDk0MzkzZDNjYjAxYjRlZjBfMTMtMS0xLTEtMzE2OTI_939f3601-e78c-44a6-80e5-bb8bc2822ab7"
      unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCost
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RleHRyZWdpb246YmIwMjI3YjI1OGY5NGJlZDkyYWNjZDFkNDc5Mzg0ZDFfMjAyNQ_3bcf132f-aafb-44be-957b-d20ca04cf06d"
      unitRef="usd">830000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RleHRyZWdpb246YmIwMjI3YjI1OGY5NGJlZDkyYWNjZDFkNDc5Mzg0ZDFfMjAzMg_abf1926d-5666-4051-8cb0-da97ee49f6c0"
      unitRef="usd">850000</us-gaap:LeaseCost>
    <ino:LesseeOperatingLeaseNumberOfAgreementsToSublease
      contextRef="i9d671d2113a6459188a02276cfc2a5f6_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RleHRyZWdpb246YmIwMjI3YjI1OGY5NGJlZDkyYWNjZDFkNDc5Mzg0ZDFfMjQ1Mw_ab849f02-a27d-4af0-8a68-8d4e7d5b797a"
      unitRef="agreement">2</ino:LesseeOperatingLeaseNumberOfAgreementsToSublease>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="ia01bf7e261dd4db5917be920fa366418_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184Mi9mcmFnOmJiMDIyN2IyNThmOTRiZWQ5MmFjY2QxZDQ3OTM4NGQxL3RleHRyZWdpb246YmIwMjI3YjI1OGY5NGJlZDkyYWNjZDFkNDc5Mzg0ZDFfMjUwNA_1e17370a-da75-4b26-8d37-1fdd595e8024"
      unitRef="sqft">13500</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjIwNTY_2bf2dd10-2dbb-4705-a94e-ef5e9e74f722">Collaborative Agreements&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Advaccine Biopharmaceuticals Suzhou Co., Ltd. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#x201c;Advaccine&#x201d;), which was amended and restated on June 7, 2021 (as amended and restated, the &#x201c;Advaccine Agreement&#x201d;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#x2019;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#x201c;Greater China&#x201d;) and 33 additional countries in Asia. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without the Company&#x2019;s express prior written consent. As part of the collaboration, Advaccine also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The June 2021 amendment relates to the collaboration between the Company and Advaccine to jointly conduct the global Phase 3 segment of the Company&#x2019;s ongoing Phase 2/3 trial of INO-4800 and expand the existing collaboration to include the planned global Phase 3 trial. The parties will jointly participate in the trial and will equally share the global development costs for the trial, including the Company&#x2019;s manufacturing costs to supply INO-4800. In certain instances, the Company will have the right to convert the exclusive license to a non-exclusive license in the licensed territories, other than Greater China, unless Advaccine agrees to pay the Company its full share of development costs in excess of a specified maximum. Notwithstanding the foregoing, Advaccine will be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. The Company will be fully responsible for its costs and expenses, if any, incurred solely as a result of its activities in connection with the performance of the trial in the United States. The parties may continue to conduct clinical trials of INO-4800 outside of the territories covered by the Advaccine Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event that a global purchasing entity desires to enter into a purchase agreement for INO-4800 in both parties&#x2019; territories, the parties will enter into good faith negotiations for an arrangement to supply INO-4800 to such entity. In addition, the Company is permitted to enter into an agreement with a global purchasing entity to authorize the entity to conduct a portion of the global Phase 3 trial in the licensed territory outside of Greater China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Advaccine Agreement, Advaccine made an upfront payment to the Company of $3.0&#160;million in January 2021. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $206.0&#160;million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China and the additional covered territories, if approved. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#x2019;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for ten years after the first commercial sale in a particular region &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the first calendar year following the first commercial sale of INO-4800 in the licensed territory outside of Greater China, Advaccine will pay the Company an annual maintenance fee of $1.5&#160;million for a period of five years, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Advaccine Agreement, the Company will supply Advaccine&#x2019;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#x2019;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months&#x2019; written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in the licensed territory, or 18 months&#x2019; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808 at inception and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606. The license to INO-4800 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the Advaccine Agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the Advaccine Agreement consisted of the $3.0&#160;million upfront payment received in January 2021 plus a $2.0&#160;million milestone payment which was achieved upon contract signing. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, the entire transaction price of $5.0&#160;million was allocated to the license performance obligation. The Company determined that as of December 31, 2020, the transfer of technology had occurred for the use and benefit of the license and accordingly, the performance obligation was fully satisfied. The Company accordingly recognized $5.0&#160;million in revenue under collaborative research and development arrangements on the consolidated statement of operations during the year ended December 31, 2020. For the three months ended March 31, 2022, no revenue was recognized from Advaccine. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the June 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement is a collaboration and not a contract with a customer and therefore concluded to account for the June 2021 amendment under ASC Topic 808. Reimbursements from Advaccine will be recognized as contra-research development expense on the condensed consolidated statement of operations once earned and collectibility is assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ApolloBio Corporation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company has granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to an upfront payment received in 2018, the Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#x2019;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning one year after the effective date for any reason upon 90 days written notice to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of March&#160;31, 2022 there have been no significant reimbursable program costs under the ApolloBio Agreement.&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Coalition for Epidemic Preparedness Innovations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplate preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of $56 million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the three months ended March 31, 2022 and 2021, the Company received funding of $2.0 million and $2.4 million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of March&#160;31, 2022, the Company had an accounts receivable balance of $3.8 million on the condensed consolidated balance sheet related to these CEPI grants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, CEPI awarded the Company a grant of up to $9.0 million to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of $6.9 million to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of $5.0 million to accelerate development of  the Company's next-generation intradermal electroporation device, known as CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3 million to support large-scale manufacturing of INO-4800. During the three months ended March 31, 2022 and 2021, the Company received funding of $510,000 and $2.4 million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of March&#160;31, 2022, the Company had $2.7 million recorded as deferred grant funding on the condensed consolidated balance sheet from the CEPI grants related to INO-4800.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bill &amp;amp; Melinda Gates Foundation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, Gates awarded and funded the Company a grant of $2.2 million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1 million for the project. During the three months ended March 31, 2022 and 2021, the Company recorded $80,000 and $0, respectively, as contra-research and development expense related to the Gates dMAb grant. As of March&#160;31, 2022, the Company had $304,000 recorded as deferred grant funding on the condensed consolidated balance sheet related to the grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, Gates awarded and funded the Company a grant of $5.0 million to accelerate the development of the CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP device for the intradermal delivery of INO-4800. During the three months ended March 31, 2022 and 2021, the Company recorded $0 and $893,000, respectively, as contra-research and development expense related to this Gates grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Defense (DoD) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#x201c;OTA Agreement&#x201d;)&#160;with the DoD to fund the Company&#x2019;s efforts in developing the CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. Under the OTA Agreement, the Company intends to develop the CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP device and arrays for use in the U.S. military population and the U.S. population as a whole, subject to approval of the device by the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;). The OTA Agreement is also expected to support large-scale manufacturing of the CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3PSP device, as well as large-scale DNA plasmid production for manufacture and supply of a specified number of doses of&#160;INO-4800&#160;in support of FDA approval of the device. The total amount of funding being made available to the Company under the OTA Agreement is $54.5 million. The Company has determined that the OTA Agreement should be considered under Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is outside the scope of Topic 606, as the government agency granting the Company funds is not receiving reciprocal value for their contributions. The Company will record contra-research development expense on the condensed consolidated statement of operations in the same period that the underlying expenses are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#x201c;Procurement Contract&#x201d;) from the DoD for the purchase of the Company&#x2019;s intradermal CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;2000 device and accessories. The CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; 2000 devices will be used to inject&#160;INO-4800&#160;in the Company&#x2019;s planned later-stage clinical trials. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The total purchase price under the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Procurement Contract is expected to be approximately $10.7&#160;million. The&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Company determined that the Procurement Contract falls under the scope of ASC Topic 606 as the contract is with a customer and the Company is able to satisfy its obligations under the arrangement as the Phase 3 clinical trials of INO-4800 are underway. Performance obligations under the Procurement Contract consist of the delivery of a specified number of CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;2000 devices and accessories. The total transaction price was allocated to the individual performance obligations based on the determined standalone selling price for the devices and accessories. The Company will recognize revenue on the condensed consolidated statement of operations upon shipment of the purchased devices and accessories. During the three months ended March 31, 2022 and 2021, the Company recorded no revenue from the Procurement Contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2022 and 2021, the Company recorded $3.2&#160;million and $7.8&#160;million, respectively, as contra-research and development expense related to the OTA Agreement. As of March&#160;31, 2022 and December 31, 2021, the Company had an accounts r&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;eceivable balance of $0 and $3.6&#160;million, respectively, on the condensed consolidated balance sheet from the DoD. As of March&#160;31, 2022, the Company had $2.3&#160;million recorded as deferred grant funding on the condensed consolidated balance sheet related to the Procurement Contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company announced that the DoD had notified the Company that it will discontinue funding f&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or the Phase 3 segment of the Company's clinical trial of INO-4800 in the United States, while continuing to fund the completion of the ongoing Phase 2 segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i2db1017a46a040d6861a567a358dcdd1_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjcyOA_8c9fa8f6-b02b-4a40-abfe-498201c0dae8"
      unitRef="usd">3000000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementAdditionalRevenueToBeAchieved
      contextRef="i2db1017a46a040d6861a567a358dcdd1_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjg0MQ_902a5754-dbf2-4bb4-aa31-b40f1071e5c1"
      unitRef="usd">206000000</ino:CollaborationAgreementAdditionalRevenueToBeAchieved>
    <ino:CollaborationAgreementRoyaltyPeriod
      contextRef="if8516f2c2e834670831af151ddee24ed_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMzczNQ_53405238-fc16-4ca1-8cee-e763b3f9ba39">P10Y</ino:CollaborationAgreementRoyaltyPeriod>
    <us-gaap:CostMaintenance
      contextRef="if8516f2c2e834670831af151ddee24ed_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfNDEyOA_91e5e4a6-aa5f-4429-8da8-e341b1cc4453"
      unitRef="usd">1500000</us-gaap:CostMaintenance>
    <ino:AnnualMaintenancePeriod
      contextRef="if8516f2c2e834670831af151ddee24ed_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfNDE0Nw_64aa01f7-357c-41f3-9e77-e3933759e136">P5Y</ino:AnnualMaintenancePeriod>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i2db1017a46a040d6861a567a358dcdd1_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfNjU0MA_bc1628ca-cf85-425d-a8e2-3c422f5f9571"
      unitRef="usd">3000000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementPaymentEarned
      contextRef="i2db1017a46a040d6861a567a358dcdd1_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfNjU3Ng_92ff6486-cb75-4344-806f-58f157863174"
      unitRef="usd">2000000</ino:CollaborationAgreementPaymentEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7bcc9760314f413bba4b5e3b026f2e41_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfNzQ0OA_81261d29-d709-4d04-9b74-ac18694f04be"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9818436ba9fe436cb6d8b574154f1b3b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfNzczNg_bca8a8d0-ab04-461d-857f-4cc82e683406"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e370c4fb7ad47f09d71f49dcf34f2f7_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfNzk3Nw_cb7f0fa9-333b-4e4e-8c39-62695e2af265"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ino:CollaborationAgreementAdditionalRevenueToBeAchieved
      contextRef="i071ee78b7166461a9fbde479b660be3e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTA0NDk_7c11a390-4c8d-4903-b7da-40baf96be7f7"
      unitRef="usd">20000000</ino:CollaborationAgreementAdditionalRevenueToBeAchieved>
    <ino:CollaborationAgreementRoyaltyPeriod
      contextRef="i071ee78b7166461a9fbde479b660be3e_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTA5OTA_41d7e970-e636-4ebd-afce-52a74f8c2992">P10Y</ino:CollaborationAgreementRoyaltyPeriod>
    <ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination
      contextRef="i071ee78b7166461a9fbde479b660be3e_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTE2MTI_46364715-2eb5-4f9d-9ce1-013d1d7882c8">P1Y</ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination>
    <ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination
      contextRef="i071ee78b7166461a9fbde479b660be3e_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTE2NjA_a8687671-c77d-4082-94c6-41b92427dea6">P90D</ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i506a148e81644d5482e7e9eebdf0b1d5_D20180401-20180430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTU5NjQ_d273eb7f-f56a-4f69-85c8-1e8ca37db423"
      unitRef="usd">56000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment
      contextRef="i506a148e81644d5482e7e9eebdf0b1d5_D20180401-20180430"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjIwNjU_bea8e95b-5f93-4de9-a1e4-bf9cf18beb9f">P5Y</ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="id2be74ba561d442db493dddcc92ebd3e_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTYyNTA_0a3d817a-4a98-416a-8f97-83873cb8cdb1"
      unitRef="usd">2000000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i8b96bf9a8fc445eaba5ecb1d140390f6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTY0MTg_85aa489f-5571-484e-9fe4-82ea5b40ed06"
      unitRef="usd">2400000</ino:CollaborativeAgreementFundingReceived>
    <us-gaap:AccountsReceivableNet
      contextRef="i5e1c9fb9467945ab9163eda017d1f2da_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTY1OTk_42d5140c-1cc8-4cd4-819b-a9a4d45fa7b2"
      unitRef="usd">3800000</us-gaap:AccountsReceivableNet>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i8f8f17f12161403fafe2948a7f9f402f_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTY3MzY_313b37a8-918a-4f4d-8a07-ddae79ef41a2"
      unitRef="usd">9000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i152a732fccdd4dbdb5a4fc5c6458a1ec_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTY5MDI_006879bb-98aa-4241-a1a3-ba54ebb0fcfd"
      unitRef="usd">6900000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="if9442dd1633e455b91a66f5a6ab2ce25_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTcwODA_3d458e38-0689-42cc-9b07-86fb26abc37b"
      unitRef="usd">5000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i32bf53bd03c54fc1a9176c9e8bd73481_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTcyNjI_62b4dfa0-f0ef-4487-b3e1-f7afdd5e821b"
      unitRef="usd">1300000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i2b14e2287928438d88d281f85c7278a8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTczNjI_fd94fabd-2bb6-4b5b-b571-f93f7ab9e37d"
      unitRef="usd">510000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i5bfa9631ac274759b1b56aef9adc496f_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTc1NTE_0641d8fd-48b1-48f7-a527-60d1151dd628"
      unitRef="usd">2400000</ino:CollaborativeAgreementFundingReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="if5ba8467f8d240158db11dd9beaae7e2_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTc3MTk_d0ee1eeb-8a72-4db1-8781-252f4d7d211f"
      unitRef="usd">2700000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="if5e81165a16440ebb8326d8a24d15995_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTc5ODA_e7e4b2a8-41a9-4780-9142-0d5e03b2ed03"
      unitRef="usd">2200000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="ic2b5bc317c764378a3de78871886838c_D20190801-20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTgzNDM_4eacc471-a188-49f6-bfc5-5247f093ed3e"
      unitRef="usd">1100000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i92f8729b1391467aa54b6475bbefade5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTg0NDc_9dd7d9c2-5261-4968-b05d-2ad4b542123e"
      unitRef="usd">80000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i6295923acaed47d1956bd75c6c4c0edd_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjE5OTAyMzI3OTkwNA_53705991-629a-4e4e-bf61-ca1dafadd3e1"
      unitRef="usd">0</ino:CollaborativeAgreementFundingReceived>
    <ino:DeferredGrantFundingCurrent
      contextRef="i4b11763ebe53429599cade53585833b6_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTg2ODk_49c86c66-a462-4a4b-85b0-8d930c352470"
      unitRef="usd">304000</ino:DeferredGrantFundingCurrent>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="ie62aeb4d7cf747aeb6d6d6c6296bfe0a_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTg4NTY_8afc24a8-11d8-415e-acb7-13f38f5f3eaa"
      unitRef="usd">5000000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i3e16f9f97cb444ca9d3dba5ea73d1d90_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTg5OTc_c4427a70-339a-48be-9476-acef911d8464"
      unitRef="usd">0</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i4518574f497f4fa2a453bf07d6721aa2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMTkwMDQ_2889b5d7-b3c9-4bf6-9e66-e16d0bd1acfc"
      unitRef="usd">893000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i1204bafe5467488693dda8b9e96a2774_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjAwNzY_e5857baf-187a-4365-a406-99691e1f3c89"
      unitRef="usd">54500000</ino:CollaborativeAgreementFundingReceived>
    <ino:CollaborativeArrangementFixedPriceContractAmountAwarded
      contextRef="i17c519d2d2f7427e8cf34e5097504c60_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjE5OTAyMzI4MTUyNQ_f7c52bd0-d4a1-42ad-a879-018ca2bb284c"
      unitRef="usd">10700000</ino:CollaborativeArrangementFixedPriceContractAmountAwarded>
    <ino:CollaborativeArrangementRevenueFromTheProcurementContract
      contextRef="i6c0779eaba8941deac45ec2a70e681f7_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjE5OTAyMzI4MTU0OQ_71780749-b9c5-4a07-8a18-7ac60e363373"
      unitRef="usd">0</ino:CollaborativeArrangementRevenueFromTheProcurementContract>
    <ino:GrantProceedsReceived
      contextRef="i8ee8e99d45ce4685bcbfe7aa1f6ef9ac_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjEyMjU_d490314a-1884-4f8d-bc3e-085bf3a5e988"
      unitRef="usd">3200000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="i74796e39acc84dc198e9df9ff90b38c2_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjEyMzI_e70d7955-7031-456f-81f4-dbd48ba756e0"
      unitRef="usd">7800000</ino:GrantProceedsReceived>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i2125ae0ebb6c4ac58e7f4bb7948cf2ee_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjE1NTk_d3267210-5740-4c0f-973e-7573c1682861"
      unitRef="usd">0</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i76c6ab34cb86461fbeae30681dd72330_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjE1NjY_7c125d1b-e4f3-4077-8b5d-b9cc01fa7d6a"
      unitRef="usd">3600000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:GrantsReceivable
      contextRef="i2125ae0ebb6c4ac58e7f4bb7948cf2ee_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184NS9mcmFnOjY1ZTAzY2JlZGE1YzQxNGI4YWQ5OTM5OTM5NmNkNzM2L3RleHRyZWdpb246NjVlMDNjYmVkYTVjNDE0YjhhZDk5Mzk5Mzk2Y2Q3MzZfMjE2Njg_43dcdb74-f75d-4d92-9473-4b2582dcc2f0"
      unitRef="usd">2300000</us-gaap:GrantsReceivable>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y184OC9mcmFnOjY0OWUwM2I5ZWI5YzRhYmI5MGIxMDA5NzBlMTg3MTQ3L3RleHRyZWdpb246NjQ5ZTAzYjllYjljNGFiYjkwYjEwMDk3MGUxODcxNDdfMTcwMg_930e9e2b-7e1b-4825-8e77-ea6f248dd51f">Income Taxes The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter.&#160;Due to the adoption of ASU 2019-12 which removes the exception under ASC 740-20-45-7 to consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations, ASC 740-20-45-7 no longer applies.&#160;For the three months ended March&#160;31, 2022 and 2021, the Company has not recorded any income tax provision/(benefit) due to the Company&#x2019;s history of net operating losses generated and the maintenance of a full valuation allowance against its net deferred tax assets.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfOTkwNw_0e98a05b-6de6-4a2c-a4b1-d2af6f269162">Geneos Therapeutics, Inc. &lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In 2019, Geneos completed the initial closing of a&#160;Series A preferred stock financing. The Company invested&#160;$1.2 million&#160;in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;61%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, Geneos completed the second closing of the&#160;Series A preferred stock financing, in which the Company invested $800,000. Following this transaction, the Company held&#160;52%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, Geneos closed an additional&#160;Series A preferred stock financing round, in which the Company invested $800,000.  Following this transaction, the Company owned 47% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial interest. Based on the Company&#x2019;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#x2019; economic performance.  Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $4.1 million, of which $2.4 million related to the remeasurement of the retained noncontrolling interest investment to fair value.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#x2019;s common stock. Since the Company&#x2019;s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#x2019;s common stock investment and will therefore be recorded as an equity security under ASC 321.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the deconsolidation, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's condensed consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#x2019;s investment and the amount of underlying equity in Geneos&#x2019; net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020. The Company has determined that its Series A preferred stock investment in Geneos does not have a readily determinable fair value and has therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#x2019;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $1.4&#160;million in the Series A-1 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#x2019;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#x2019;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 36% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continued to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s share of net losses of Geneos for the three months ended March 31, 2021 was $1.5&#160;million; however, only $434,000 was recorded, reducing the Company's total investment in Geneos to $0. Of the total amount, $819,000 has been allocated to the equity method investment, thereby reducing the balance to $0 as of March 31, 2021. The remaining $4.2 million loss has been allocated to the Company&#x2019;s Series A and Series A-1 preferred stock investment in Geneos, on a ratable basis, thereby reducing the balance to $0 as of March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, Geneos completed a second closing of the Series A-1 preferred stock financing, in which the Company did not participate. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following this transaction, the Company held approximately 35% of the outstanding equity, on an as-converted to common stock basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, Geneos completed the closing of a Series A-2 preferred stock financing. The Company invested $2.0&#160;million in the Series A-2 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#x2019;s assessment, Geneos continues to be a VIE as it does not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continues to not be the primary beneficiary of Geneos, as it does not have the power to direct the activities that most significantly impact Geneos&#x2019;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 24% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Geneos&#x2019;s Series A-2 preferred stock was based on the per share price paid by third-party investors in connection with the closing on March 21, 2022. The Company has concluded that its Series A-2 preferred stock investment is a similar financial instrument as its Series A-1 preferred stock, and therefore remeasured the carrying value of the Series A-1 preferred stock investment at the Series A-2 preferred stock price, resulting in a gain on remeasurement of $165,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded its current and accumulated share of net losses of Geneos of $2.2&#160;million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of March 31, 2022 as shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos Series A-2 preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,999,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remeasurement of  Geneos Series A-1 preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,165,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to exclusively license its SynCon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;immunotherapy and CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology. The Company is not obligated to use any of its assets to fund the future operations of Geneos.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i5a59d1c482204129ace354f666e93b3c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfMzc4_a11be6f0-cb6d-411c-b4cc-d3bb87e4a37b"
      unitRef="usd">1200000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i9287e5231b0c44c2a4df39c192522f21_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfNTA3_ebb5bca5-188d-44c5-afe5-85545f77e01f"
      unitRef="number">0.61</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment
      contextRef="i7ef6b938867e49d4b6bea20f92003696_I20200131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfODAw_938383c0-e118-425e-b827-78dcf349b470"
      unitRef="usd">800000</ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ief31b251d6394afd8f91a7cc96c6f6f0_I20200101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfODcx_c914126b-dd95-4c51-aa9f-6a787001a6f9"
      unitRef="number">0.52</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment
      contextRef="i358168d3fb3e4081afe3f8f55ae73934_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfMTEyMg_f72e78c0-40e7-4212-ba28-ef9d7d11b488"
      unitRef="usd">800000</ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i2998f9f06ab149b7a5203f1dd82fad31_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfMTE3Mw_0cdfdad9-a420-45b6-9b30-1a4e28e463b7"
      unitRef="number">0.47</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i072b718ce60743018ae014282340909c_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfMTg0Mg_5d1d697c-ff63-42a1-9586-631a80cc75e9"
      unitRef="usd">4100000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
      contextRef="i072b718ce60743018ae014282340909c_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfMTg1NQ_07564bb0-c290-43ff-a1c6-5c247d13c855"
      unitRef="usd">2400000</us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i35c4e31704a040e18096a49a219271b0_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfNjg4Mg_ca24c351-2979-48a5-b966-4e34548178bd"
      unitRef="usd">1400000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="icdd6b2404d2348d6be3af54fee60364d_I20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfNzUxNw_ae93bc25-a0c7-443e-aed6-e401e7c21dc2"
      unitRef="number">0.36</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment
      contextRef="i7b0adeeead5e4699a63cb480fc0a0ac3_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfODU1OQ_b4807b04-699b-4c50-93ff-6cf715ed2280"
      unitRef="usd">1500000</ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7af4410be8f148b5b8314f57ad7a668d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfODU3Nw_8cdc0f1c-2e81-4fe5-aa4a-a28b8adb3b7f"
      unitRef="usd">-434000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="iade08220a0f74869bcb1f820413ac244_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfODY0Nw_096121b5-ef54-43e8-a525-641a39493234"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie1f4de57b99d45e7878e83e0a961478f_D20200601-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfODY3Mg_90059821-6b37-42ed-b7d5-4830b5c649bd"
      unitRef="usd">-819000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i39108879adec43dd9ce939da4a9133c8_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfODc1OQ_c663d86a-b50d-44c8-a080-072bbe7b40da"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i240a06710e7f499c92f922af74aa1d72_D20200601-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfODc5OA_e8da989d-293e-41e0-ba4d-46d040ad74a3"
      unitRef="usd">-4200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i94cd371c1e2a482189fbcd1fa606ce5b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfODk2NA_a5c9ba74-b406-45fa-8a70-c689010078ad"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i99ae48f06acb4be0999de4734437d7de_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfOTA2OQ_8479fc97-b9e0-4361-9655-c4245620d663"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i37c604731df5488385ee8ef0f5eaa642_I20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfOTM4MQ_4580ce71-58cc-42bd-9873-14b8bbfb2192"
      unitRef="number">0.35</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:EquityMethodInvestments
      contextRef="ic757f5e350bb42269e2c1e8b10f57ef6_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfMTA5OTUxMTYzNzk2Ng_3d8f9667-9244-4191-9913-a44b2505475b"
      unitRef="usd">-2000000</us-gaap:EquityMethodInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="idc03d9886d82421ebbc554d6ea904cd3_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfMTA5OTUxMTYzOTMwMQ_4f360e19-1ab6-45ad-be47-c5995322e71a"
      unitRef="number">0.24</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
      contextRef="if6bb6660938e47b0a2d5df1338384e35_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfMTA5OTUxMTY0MjAzNw_31352e66-cc5d-4b27-a839-9f0d2cc03827"
      unitRef="usd">165000</us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfNDk0NzgwMjM0MTcwNw_7fa91eea-87ee-4d9b-856a-4d7810796e05">The Company recorded its current and accumulated share of net losses of Geneos of $2.2&#160;million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of March 31, 2022 as shown in the table below:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos Series A-2 preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,999,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remeasurement of  Geneos Series A-1 preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,165,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if6bb6660938e47b0a2d5df1338384e35_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfMTA5OTUxMTY0MzY5OA_61be27fa-32c5-4765-9679-8442b879f4f1"
      unitRef="usd">-2200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i6c48be9a581248328538c7ec76130395_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RleHRyZWdpb246NmRkNTc5NzQzMWQ1NDRlMmFjOWZmYjU4NDJmYzkyOWFfMTA5OTUxMTY0MjcwMQ_8e9fd7e3-0076-49aa-b1ef-aef7cb91cc34"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i8c076c415b0c4d348c148ffabebaa199_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RhYmxlOjNiYzFkYjhiZWUxYTQ2MWU5ZDEzZTQzNzRiNDE2NGIyL3RhYmxlcmFuZ2U6M2JjMWRiOGJlZTFhNDYxZTlkMTNlNDM3NGI0MTY0YjJfMS0yLTEtMS0zODA0Ng_394203ac-f5bb-4828-aaf2-6a127c4df598"
      unitRef="usd">1999998</us-gaap:EquityMethodInvestments>
    <us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
      contextRef="if6bb6660938e47b0a2d5df1338384e35_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RhYmxlOjNiYzFkYjhiZWUxYTQ2MWU5ZDEzZTQzNzRiNDE2NGIyL3RhYmxlcmFuZ2U6M2JjMWRiOGJlZTFhNDYxZTlkMTNlNDM3NGI0MTY0YjJfMi0yLTEtMS0zODA1MA_a7a57260-3b46-4936-a8df-77a31a5aced6"
      unitRef="usd">165215</us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if6bb6660938e47b0a2d5df1338384e35_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RhYmxlOjNiYzFkYjhiZWUxYTQ2MWU5ZDEzZTQzNzRiNDE2NGIyL3RhYmxlcmFuZ2U6M2JjMWRiOGJlZTFhNDYxZTlkMTNlNDM3NGI0MTY0YjJfMy0yLTEtMS0zODA1MA_48921ca6-39b8-4018-8280-53966c1bf020"
      unitRef="usd">-2165213</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i6c48be9a581248328538c7ec76130395_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185MS9mcmFnOjZkZDU3OTc0MzFkNTQ0ZTJhYzlmZmI1ODQyZmM5MjlhL3RhYmxlOjNiYzFkYjhiZWUxYTQ2MWU5ZDEzZTQzNzRiNDE2NGIyL3RhYmxlcmFuZ2U6M2JjMWRiOGJlZTFhNDYxZTlkMTNlNDM3NGI0MTY0YjJfNC0yLTEtMS0zODA0OA_12bc1413-a24d-4701-8fc0-ae611b6ef01f"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185NC9mcmFnOmQ0NDc5M2NiNTA2ZjQ4Yzk4M2E2YjkyMTY4NDZiNmIxL3RleHRyZWdpb246ZDQ0NzkzY2I1MDZmNDhjOTgzYTZiOTIxNjg0NmI2YjFfMzc_9a5a64db-3185-4b2b-80b0-5b599f7c0210">Subsequent EventsFrom April 1, 2022 through April 21, 2022, the Company sold 2,502,269 shares of common stock under the 2021 Sales Agreement for net proceeds of $8.7&#160;million.  The sales were made at a weighted average price of $3.52 per share.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ic58ffceb77ce4063a7894330d50f5c66_D20220401-20220421"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185NC9mcmFnOmQ0NDc5M2NiNTA2ZjQ4Yzk4M2E2YjkyMTY4NDZiNmIxL3RleHRyZWdpb246ZDQ0NzkzY2I1MDZmNDhjOTgzYTZiOTIxNjg0NmI2YjFfMTA5OTUxMTYyODA2OA_b7aae710-251a-4c43-a575-2c36d7b273f5"
      unitRef="shares">2502269</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ic58ffceb77ce4063a7894330d50f5c66_D20220401-20220421"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185NC9mcmFnOmQ0NDc5M2NiNTA2ZjQ4Yzk4M2E2YjkyMTY4NDZiNmIxL3RleHRyZWdpb246ZDQ0NzkzY2I1MDZmNDhjOTgzYTZiOTIxNjg0NmI2YjFfMTA5OTUxMTYyODA3OQ_6bd79cef-8aa6-4d21-b98d-e08c109309c8"
      unitRef="usd">8700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ib3ee9fcf6611452784c45ad678fced93_I20220421"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjZDkzMGU2YzdjZTQ0NGFiYjdmNzIxNzFmNTAxNjRjL3NlYzo1Y2Q5MzBlNmM3Y2U0NDRhYmI3ZjcyMTcxZjUwMTY0Y185NC9mcmFnOmQ0NDc5M2NiNTA2ZjQ4Yzk4M2E2YjkyMTY4NDZiNmIxL3RleHRyZWdpb246ZDQ0NzkzY2I1MDZmNDhjOTgzYTZiOTIxNjg0NmI2YjFfMTA5OTUxMTYyODA5OQ_6bf1aced-c716-4e4c-b36c-4d9ae659ba4f"
      unitRef="usdPerShare">3.52</us-gaap:SaleOfStockPricePerShare>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>67
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%
M  @ 87^J5/9WDHI:!0  =Q4  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6R5F%UOXC@4AJ]G?X6%]F)7*DWB "TCBI2F= 9-@4RA'<VN]L(D!J))8M9Q
M2OGW>QP@::MPDKUI\W5>GAP[[SGV8"?DKW3#N2*O<92D-ZV-4MO/AI'Z&QZS
M]%)L>0)W5D+&3,&I7!OI5G(6Y$%Q9%#3[!DQ"Y/6<)!?\^1P(#(5A0GW)$FS
M.&9R?\LCL;MI6:W3A<=PO5'Z@C$<;-F:S[EZVGH2SHQ")0ACGJ2A2(CDJYN6
M8WUV;:H#\B>>0[Y+WQP3_2I+(7[IDW%PTS(U$8^XK[0$@W\OW.51I)6 X]^C
M:*OX31WX]OBD?I^_/+S,DJ7<%=&/,%";F]9UBP1\Q;)(/8K=5WY\H:[6\T64
MYG_)[O!LI],B?I8J$1^#@2 .D\-_]GI,Q)L ^UP /0;0#P&6?2; /@;8^8L>
MR/+7NF.*#0=2[(C43X.:/LASDT?#VX2)'L:YDG WA#@U=,4+E\2#$2-MDFZ8
MY.G 4""L;QO^4>3V($+/B-AD(A*U2<DH"7CP/MX H(**GJAN*2HX8?*2V-8%
MH2:E%3QN7?B>F/VJZ'<T=I$C.Y>ST1S][2Q3)6':_8-(=@K)3B[9.2-Y)_P,
M/@9%%OLMKTHX'FZ9[>\(1;>@Z#:C^)XQJ;B,]N21;X54542XE)(91XAZ!5&O
M&9''92@"/:$(S.O*%.%*IRGTVZ=/-=/@JF"[:CAFDH&-Y2YT/EVXUHI%*9:O
MZX+I&M49)2I4>W(?1IQ,LWC)914+KF&:5MOJ7%]?(SS]@J??A.>1KT/]L4"R
MIBRN'#U<9SR=/8]GQ/OJ/$X<=_2T&+O.P_R"C*?N)8)IF:7MF4U QXDO) PA
MTZ-Y0>8*YAH1DK@B2Y3<P_^@DKY&_6Z$0;[Q9JL)Y(*]DG$ ,R]<A7Y.BHQU
MC:1MM\U^K]_M8U^$14M"VH30"0(H'.G%Z8 \P'-DEE3G#I?L]4SRXY)\&<'(
M3Q>S'U/BC;^-8&R>QHL1L2P3 R\MW;+_%[BKSV#@%V*75$+C<M[#S\GL:?&5
M3$:CQ7CZ!6,L:X2%N_Q'QF)V>E*\A(E?G5U<TW,PM+)P6+C=?T3S1*I81/X*
MM^<_&5S1ZG=ZZ)PL2XB%.W\^E [TM.=1< ':N\) RGIAX2;_('S(B;<1"6;.
M-2*=CMGN0%..$975PL*M?A$J*!1B12SZQ_)/,N=^)B%;E5BXDCN;3&93,E_,
MW&\7Y'?S$JH(\9Q'\NP\/*'N5Y82"Z\!4&:#,%F3^3Y>BJB2L;:(8+UH62LH
M[N:G-)'1J[]A";3*YXI:C=#4F=\Y6.-&R]) &Y4&-Y-2MR2'/B3/%IA$5MG#
MURC^_-CYOR<K2P)M5!+&"324AT6:[N#8";62#%>L(2L]GS;R?-TL084'+UT+
M63GW:W0>F(0YX/@^+$:A<^#!01)C+#V?-O+\><RBB-QF*=Q.JT<3UZEK,&EI
M];21U8]B+M=Z@GT!!;4!;XVW+*E.'RY8BU8Z/<6-^I2L#8=D84"X3"U0Z?@4
M-^O35RGB&)JTN1+^+RC;^:J:S#(%-3+1EE:YHCTH=W-EO?GR,J2T;W8LR^H,
MC)<JK-+V*6[6#BQ;@GSI<A^QJE^_K1&HS5!IZA3WY&(1=1^FNCK^Y$R2>[A8
M/<EQL;KU?>GP=DV__H'JN/H\RU4C]]W"J$J/MYMY/(!)@!HG 7\EWWCE%*^1
M,J$\F]WN%>UA9*7'V[@CG\K.VT'$ENHU<NVV1=MV9=*,-UM;VH'R';^4^'I]
M=MCE*JX6NXI.OI=FE(\?MB0G3!M82B*^@E#S\@J^-7G8Y3N<*+'--\J60BD1
MYX<;S@(N]0-P?R6$.IWH'RCV6H?_ 5!+ P04    " !A?ZI4FKP!3]P&   $
M'0  &    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;*V9:V_;-A2&_XK@#<,&
M-+%X%[LD0)M@6S\4#9IU^\Q(="Q4$EV)SN7?[TAV)5N\. 7V);'LE]1[*/(\
MA]3%DVF_=FNM;?)<5TUWN5A;NWF[7';Y6M>J.S<;W< O*]/6RL)E^[#L-JU6
MQ="HKI8X3?FR5F6SN+H8OKMMKR[,UE9EHV_;I-O6M6I?WNO*/%TNT.+[%Y_+
MA[7MOUA>76S4@[[3]LOFMH6KY=A+4=:ZZ4K3)*U>72[>H;?71/8-!L4_I7[J
M#CXG?2CWQGSM+SX4EXNT=Z0KG=N^"P7_'O6UKJJ^)_#Q;=_I8KQGW_#P\_?>
M_QB"AV#N5:>O3?5O6=CUY2);)(5>J6UE/YNGO_0^(-;WEYNJ&_XF3SLM%XLD
MWW;6U/O&X* NF]U_];P?B(,&B 8:X'T#_-H&9-^ #('NG UAW2BKKBY:\Y2T
MO1IZZS\,8S.TAFC*IG^,=[:%7TMH9Z^N35/ 0]%% I\Z4Y6%LG#Q7E6JR75R
MUW?<)6?)E[N;Y->??[M86KAIWW29[V_P?G<#'+C!1]6>)P2]27"*L:?Y=;SY
MC<['YNBX^1)"'>/%8[QXZ(^$XMVVK6YLHKH. GL;Z9&,/9*A1QKJ477K1#5%
MDO<?]+=M^:@JN$7G&ZM=5WSHJE]ACU=,IJFD$F)[/!P55R@0HD2(;!0>N:6C
M6QIU>[<VK3VSNJV3LGG4G:U#5G?]L ,')$4DHX2)F5>/$J0"PDK]9MEHED7-
MOLMSLP5[D"]R#<-Z7VF?4^;<GZ8IX5DZ\^GJ&.4\8P&7?'3)?]1ELFI-G:C5
MJJS*83W!()>VU-Z!YN[PT0R>-I_9=W68<88D]=L7HWT1M7_;ZHTJP>+SID\$
MW3"7C5WK%O+/X6+Q>1>N=S#$J9C/$8\PRPB7!Q/_R'TVNL_^'_<_]$@RQZU@
M0N!93*X*<X0D]D<DQXAD-**_C575*X9>NB,JI4QY)LG,IZND-*.42LK\5E$Z
MT2.-FOVC?(:AW)E\DS3:>@&1.@80YY)+,I_B/J6@C."4!YP>< Y%G7X8LQTD
M/F<>O'A](T]BX_T0SVU[A" 3,N1ZHA7")UQ;U3R4?4HY-<C8G8U42I:QN5F/
MD&-.6&@R3"!$<1+^:4SQ5%:5UQYQGVS*$"%B3K[7*(\-3NQ#<?A]VNA6V;)Y
M2"H-I5_2]C7>F5F=;3L=66G(!1Q"F"%*YX3Q*IE *0[-A F%*,["3T-.BYAT
MZ8:P($(ZS]\CI)B)$$?0Q$$4!^$N<T4LN@2CE#&$TLQ941ZI9)(B>I#=CFU.
MO$/B524@K/][2 (] V)U()I0A.(L&@N!C7H9JH">12K/VZV> .4=&)<D)(.)
M0Z23(%TE%1Q&D02*&#1A!\6Y\RKW2;'5B36OY2ART8-H*DCFQ.4*&<U2$F I
MG@"%XX!ZMP\@AQ_*'*:G;4OX&WL:V ,AE&$AV'PI^93@&;)I8+GC"5<XCJL;
MO=(P30LH*A]UL_76O=C%#LP9,5]+'AE&' <V$OA@)Q5GTSR;?E]/7I9B'W4$
MEH+.W?J$*9$L-*03GO )/+4*5OUJVQ2#YZA;ET$,9P0[L/(((:-)@0.LPA.K
M<)Q5 ;?^,M8?A&=?)E@Z9]9)V7$ $[!P'%C'=>Q!LO5Z]>S-)&&2<\>NJ^1,
M4,1)  QXXA>.\VN^YH9:*S&K,8@-[)U+TW@#<('%4TZ=M>B14<)#LV5B&HYO
MXJX-E+=@KL_;G6Y*TR:-L8&Q=O=BD Y2D7%G+7J4/89A?Q<P/+$2QUD93!X_
M-.@N#1'@D&5.A>Y3,LHDK-5 )!,W<9R;XZRQZOGD-/=LVG!*YS0\*3L^J)I@
M2.(PW-60)SP2%VKS->B1()J%:EPR08_$H;=+&:?\N3B3*05&.$6%3\FQ@*D>
M*"O(Q#X2/T:\LR;_NC95H=ONEY\RC,3OP]&??8D>*1Z<*<99==M^GU5=?R?O
M.+CH<9Y33'+L;.(2B7/IVM2U:2*V7)Q@S%DJY]X\.@258>C13-PA)PX-BZ+L
M$P;,I/YDZ QV^[G:E#"SO'8]NR%.,44R0XYEGS:%+;84,I 0R00?<O(4<5MO
MJX'IA5Z5>>G=YA,7(&<(9[#%))3,LYY?G,J,,89# STQA\29<^AX?^)FZDVK
MU_U+GD=(Z:;S+V"7*F>4B<S9!/J$.,.8A!+-1!\2I\\NT7QHS&-IDMNU:FN5
MZZWM-PC=&_@^/]]-<.\*]\;DV<$QEF901\U/#7U2"86.I*&BD4PL(J\Y.SQ(
MH,,F[@=#D<ZKA] NW2<-[-*7!Z^H^O>#'U7[4#8=T'\%;=-S >/1[EZY[2ZL
MV0QOK>Z-M:8>/JZU@A!Z ?R^,E#?["_Z%V'CB\^K_P!02P,$%     @ 87^J
M5-/RS!Z<!0  X!4  !@   !X;"]W;W)K<VAE971S+W-H965T,RYX;6RE6-MN
MVS@0_17"V(<$J"/QHEO@&&C2O138[A;)9OM,6[0M5!)=D;+3_?H=72PY$L6X
MZ(NMRW!T9H8\9\C%419?U4X(C5ZR-%=WLYW6^UO'4>N=R+BZD7N1PYN-+#*N
MX;;8.FI?"![7@[+4(:[K.QE/\MER43_[7"P7LM1IDHO/!5)EEO'B^[U(Y?%N
MAF>G!X_)=J>K!\YRL>=;\23T\_YS 7=.YR5.,I&K1.:H$)N[V7M\^T!I-:"V
M^#<11W5VC:I05E)^K6X^QG<SMT(D4K'6E0L.?P?Q(-*T\@0XOK5.9]TWJX'G
MUR?OO]7!0S KKL2#3+\DL=[=S<(9BL6&EZE^E,<_1!N05_E;RU35O^C8VKHS
MM"Z5EED[&!!D2=[\\Y<V$6<#P(]Y &D'D.$ -C& M@/JS#D-LCJL#USSY:*0
M1U14UN"MNJAS4X^&:)*\*N.3+N!M N/T\D'F,11%Q BNE$R3F&NX>=+P!]72
M"LD-^GLO"EYE7:&KYYR7<0(VUVB.GI\^H*M?KA>.!BB50V?=?O:^^2R9^"Q%
MGV2N=PK]"I^/7X]W((0N#G**XYY8'7[BQ0VB^!TB+B$&/ ^7#\<6.+1+*ZW]
MT0E_C^(@\E*H6XLOUOEBM2\VX>L?J7D*2Z;Q:,IU,]ZOQU?K]K#$4>0&;.$<
MSE,P-J,!QL3MS%[!\SIXGC74=G+D6R1>]M54L@;M=UY]:]"/0@E>K'>(YS$L
MRP/PS;Z:CZ;P&T_>65R>%P6AC_$@ 6-#&KF,,1R:4Q!T8 ,KV-]%#CE(:ZP\
MAE6:*%WEY"!,<(,1"NQ%'F5>.(!K,*1AB''$S'###FYXP822H[J9P(8C# &.
M*'']: !V;.B1B'@^)F:P40<VLH+]4RJ%-H7,3H"!A4Q H]'WYP$.*(DB;X#4
M8.D1SV,LFH"*W9Y,7?M:T#M1H"1?RTR@JS:OU[;U@,^(&EL3\3'7HA!*M^Z-
MG(M'H?E^%.(A$1CL C\B-)B(G_08R648V]"-(,DX_Q13%@ZGO\G0P]2E$],?
M]^2,Z=MS"GJ()#\ V(I6X!+QS29)DUK^X$FB$_.*:'V_AD6#@(SP&PQ#ZK+
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MK$5SG-C<:+FO3^164FN9U9<[P6&Y5 ;P?B.E/MU4'^@.=9?_ U!+ P04
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MM'.XS:#-EK?Y,D^:Y.2H,H^HLGC09R_:I&OE(4VRTIZ/ZZ:"3S.0:T[.3+F
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MU-'S)UVE6=VFX2;@9F4[9KW-0Y24"_2@Z\9F(*#>7=_4V]QLDB?HK!\W5.C
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M+Y<Z :)F ?#YG3'-IQO[??/VAQLG_P%02P,$%     @ 87^J5 KLZ\0G @
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M*!#$6BYG.#_>O!GNV=ZZ1U\0!?&UU,9_&!0A5._'8Y\55$H_LA49O-E85\J
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MY[>H_4'<TA9%?G$_\T\U@="SN?M"987 \5I]HYB&L+?106LBAV!/ LS/G-E
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MUO2VLO8$6JWSR,0S4F7^TX^P T^)@RG&BCKN,/!=\C1/)+%CU+(A#]A@I
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M\E!WZ6)TM7S<$.8*SPOP/U\\=E]80/^4_^5_ 5!+ P04    " !A?ZI44J?
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MVB!3BK:>E$ED@&4(>S6,$O*K59GD3NI!1H*F89@,9[SDD7F0'O KK+6J$8C
M".TUDH?\2AF)M!Z!>ARC!IG3(T8 9QI-5>9JN+YK.*P9^E[]WFFX\6M7;WJP
M03F9211V#CVO1(>&PYL]J1(HU<^E(1BC_3,TEOQ%2G)4'W6*QLLB&-4"Q?^T
MZT=>1YRPQ^->3$%GO4ZIU<A#@NNHFDS/DGE.53+0'AD7<.F0CN%#14T##>O
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MCV<4.Q0W24*X -XC D $ $3SL3<I@FLRJ7V>A$$T#8-Y&K)O?E+,((\@3:"
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M&LGHQ(^^T&C?JQ]F<RNR32GA<T/V<DV_3],7QO%#!#?>6<D2J8! W3%>W:"
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M .]7"E[V-\2@_>'L\W\!4$L#!!0    ( &%_JE2[I/!9JP,  (L(   9
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M]OE)/M>K5V;'*YP'U(P&]1T&S]7VH4'8*$E]*+HM>!5UM6W DF%[BA7?L7S
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M0_\64#L'LF^4L@?!!3C^_UC\"U!+ P04    " !A?ZI4TEL1IMT*  "H'
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MXGER1LS&\U%'Z,ME=)G,^0+@L)./1+*()O%%M%S,Q-NF-_NM592Z?-\5F.K
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M+89796D!OE\;L&#S0 JZ'R=?_1]02P,$%     @ 87^J5!>I-M*N!@  ,A$
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MW%N5?LV5S(0V+]C[;W5A-V<C"\NT/DH;*U?>2OR(E83=J,KFAKVO,I'MZH^
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;+U8;6_;1A+^*PO!ATL
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MVT'0W5&IG0F:/CQ24C%V\04)%7=P1J6<3.B,P@,HK ,Z&8U/]\,6[,-;$-2
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M=@)D[!X9>(TNX* G( V;![RIZ3"\;GAQ>;.X;[O\HD.2Z%X8B S]]@8G^]$
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M!LA)+RYCS84W9?ARLC3>FSS\S$ABM^$#>+XRH'E]P0;:3VD7_P-02P,$%
M  @ 87^J5,@/[8_7$0  8C4  !D   !X;"]W;W)K<VAE971S+W-H965T,C N
M>&ULU5O[D]NVM?Y7,-OT-4-K5]JG4]LSZUVG=6I?[\1I>F?NW!\@$I00DP0#
MD"NK?_W]S@% @I)VO6F3V^E,XI7X.#B/[SP!O=@8^\FME>K$Y[IJW,NC==>U
M7Q\?NWRM:NEFIE4-[I3&UK+#5[LZ=JU5LN"7ZNIX<7)R<5Q+W1R]>L'7[NRK
M%Z;O*MVH.RM<7]?2;E^KRFQ>'LV/XH7O]&K=T87C5R]:N5(?5?>W]L[BV_%
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MMXC\O5X\2O"]M#-Q.L_$XF2Q>(3>Z2#O*=,[_6?D%;?:Y95QO57B?ZZ7KK,
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M;B6A$I)34W:Q(R,S\1?XB;$:B:="PS+P7\L"N-Y.;/$EF=8(,ZS M02J*7D
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M@=6OM]AKM8G4,XW.4BG"X((&PQY;6T<Y.\\>W@H. Y:+S2CL*0!QN @J<1-
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M6SE. Y9NO*5<5-2:O&U_(]]Y <&Z:.5<1=W<S*S'>&BNTW&M5&'OV- '2*@
M&'0:^_U>=BAQH[#RX]UY$M_1]"?[Z5%G^;ZZYYTR/AY>X!>M"4;<7P\;T*X&
MH&ORA0?NTN2[O:LW</X=.GI;S3S&G]RI<\_W@*LFL,Z/W;GIYZ5@?Z;3UVO6
MM:S>30QQUV@>QAU8>Q!^:DVNETQX-+UQ762.2L^F\-W&[N\J4;$74I%'6<P-
M-S[GBI[E*G4!]15%X)UE1E3^#,6I<P.)IO:SC]>E3E4.OGM583M;I=0:NBP*
MB(6L*)#F&<#^;"#0=_-\>[>1(LWYZZO+$0[+;2-YRLRU7B=3X&PFM7%&W+HV
M9\.HY1T $RD6L)!MYOWK3Y_9GY:& S?#H;O<NT+J,"Y'(_J=X-L:CN>ZN($\
MXBP88TQMDJ\E)I<(Q,ETP]U&7PJ#G<#_R<8AUEKQ;2L'S-LB-]466\ X%T+G
M^NJ:+T-B)0=1>8GA"Y-].,O634I3XZC&9<!\Q#=I^5I8OTX?N<*)+!VEFX,7
MZC)SD["M=D1\_R(6L)N4C)A(C%0.8X"4%V"6NR# R9-0(-%X&*V8Z) TCQN3
MYSG71]G>QK*_K'8GUKD'XXQ@NX'M(3*;E*E\(D5^4%Z$YHG?D)$'P$C4,VS1
MR$1<M-79K74748+E1M<' Q3S!!&FBDI.? P^>-QB+#>*I$NCHQXD AD1CO6]
M&P0_5(49JUKP,5"@])W&%2G#T:T/GE.R":ZOK&.)YZ@R\YGDP6QRVIK)WM+'
M/\5O3VPQ2-IB+BE91!W%J;-=N9:.[_C^*%][!5K8CA\\B\3L[B&9JNZ8)YF/
M_Z4SV(G& 7Z(Z>UUU>1XC=9%BN%K9%%8OBO5#YY,GL7TXFL9+:B]+'A8R['M
MBPO#EQ!X==V HSX\N/QR>? H7%SY'0ID*3[X!]J%<-);A;-D>.3W#Y=OX9D[
M7FT#3C]#^%OQWJ,.[2==64>3C9Y4(^;_#E!)?:O'A$^E@Z5@M9 ?<XS,6/=2
M XZ_XT'X2'PMS+I &S]__>[=Z_/K3V?BE[\=/7W\7,RN/E^-0@,@WBONPK77
MAZB_%#%Q-)D-&0Q@TZ4:6[Q&T6O+1[O]=='BY&@ZFKK+ /LB11OJ=L6,SI6G
M3@ A?.>[M_<?/H#LIT&RX5 <@OC+\JR$P/8/Q(_0-XWB1BR!5D&O$ 7\(O/R
MN7@/]E"D4OQ&".8-\.U>: &__9C4AIHG!*AXA7==E ,2N<>+CR?''4](;XC8
M_E0 V\'OS^:6UZ1TNUY;V_"=+ET0>C6-#<"CI*9>:)2YA@.B$,1)<:/5\C4R
MD('BL[U'D%8-03$X(&M4\9UONKV]_.(VZCLD%<982H1;>ZTC@7V;)*/P LSK
MN4FI(*317BZ_*M>H"91)FD?091+8#:I9OI&BTS138^XEM*\\< AME@T@2]#$
M,Z\))WU9Q%?SP'./.G>&".Y4!FOC^W),MMD'IY$S3OLN>'?/Z;<ZF#FT"#:E
M.WO6;/J8"+IGK^J1YV@"E?B6'&:U'_:-W5EBP#W8IP="O,L$=P[T]VP!3OFG
MSV8H^/LR ? ]%J<3]076>[67Q05H%!]Y>&$N'A$H<MWMO:^902RC)L%U-"(Z
MXYO0-9=!5Y6I3;TI5;^KZ]Y4^GA]MOUN5PM*@)I0/$1DM*\-+> 0;K@X 83W
M0?8IEO*RM2;A5Y2PGME85PE0NW31&ZRU2<W5HN<?OUQ>C(^>Q2WC#B^]ENAV
MH7LW(IDRNKK0OCKRQP3JWAS[]0A;2U-B$S.*V[P@_AQG(>N5R52GHQ?W/)U_
MX,&N J)-WN!-?-SV D>+9VD.Z V'G=QFCQ3YYN*L?37ONB\-:H'B764TS<39
MY)W@SVUBZA1^\4[8.H="T$+X]XTY'[QWWS",>TU%0R,.S*/&JBVDZJG'%U(O
MSG;(DD4!'H IC- /73)U\9*;KWPO_T;J3+K,%5M.,VQ>*- ')X_;FZS=6>2*
M@O3V$*V[1WM+AJYCI.39?.#G9E[3!.O9R>GXR?1DA*\#C4%X8_!HG*2^=J_U
MB4]N%/B)YU<DY%$[U_?77*D?ZB^018-F=X5FB?5^P1VX)5W#HS#5>[N+)$=W
M$7",QV"6>J"@,[QT"E+&FQ(A<NN*8Z6>-P/W6:AIPV'W+YRW^5ZPS)7O801U
M1"/]\)X3SNS;=YW. @;)Z'VE77&91O ^3XJ%_J;2,0_KPZ@S]M8KOJ%+Y)Z[
M!2'Z!L"+T3> '?_*SXXW#^,<N>6OQP@@XK!&0,V-FZZ'/#QZHNVN46BF%Q,I
M@O4O:O5)\FT@ZO*/+<T[>N5G[)^!P_[]I2%AT9 KBF5XTPPCP#>=\TV.!T?3
MMB39?]MAYQD+T'K<SPW^T[G YETHB4C;,=:.1W0^V/!MALW6K=SVV+C=Y\[R
M4_A]U3P:,FVREE!%7 W>JK"WB=G=$VNC:IN3AV/U?DL:-#Y6__8UE\%K+5#5
M0<Q)<;8V?%'$=AN!D;*CRW\6$A:_5ASCS+U4;D4MNBP0;F+\7'#B>UPKW<'$
MWA'2W03=)]Z-KI.$R#-D"_>,LF=1&4UX^VG;7[R_LJN3<'>,>@A>]6[D'-W2
M(A7#/5)7.LPF3W:Q\E.=#T@$/]")F?U5G9B>;(>-)&Z,]J0(Z<#@/<,H[F**
M0[)Q-,>3VF@]3WW<:#;5MIU"^^:_<)Z[__7\O]M>H!RZ#-[I[Q* RL([#V3U
M41F$@_9,Q6/JWHO_GI#)T!]#.8S^*@TDAR7][1W+G1'^ S7AT_#G?<[XK]JT
MR_EO X$U+*$>$IE:P*.0\4X.^)*+_P5 )/V-F[FI(1/1CRN%. $7P/<+8VK_
M"QX0_NC1R_\!4$L#!!0    ( &%_JE1R&59/R ,  "((   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;)U6WV_;-A#^5PXJ4&R 8\FRTV2M;2!Q-K0/
M!8*FW1Z&/=#22>)*D2IY](_]]3M2LNRB:S;L)1;)N^^^[WB\RW)O[&?7(!(<
M6J7=*FF(NM=IZHH&6^&FID/-)Y6QK2!>VCIUG4511J=6I7F6O4I;(76R7L:]
M1[M>&D]*:GRTX'S;"GN\1V7VJV26G#8^R+JAL)&NEYVH\0GI4_=H>96.**5L
M43MI-%BL5LG=[/7](MA'@U\E[MW%-P0E6V,^A\6[<I5D@1 J+"@@"/[9X0:5
M"D!,X\N F8PA@^/E]PG]EZB=M6R%PXU1O\F2FE5RFT")E?"*/IC]6QST7 >\
MPB@7_\*^MYW/$RB\(],.SLR@E;K_%8<A#Q<.M]EW'/+!(8^\^T"1Y8,@L5Y:
MLP<;K!DM?$2IT9O)21TNY8DLGTKVH_4[79@6X:,XH%NFQ(AA/RT&[_O>._^.
M]QS>&TV-@Y]UB>77_BDS&>GD)SKW^;. [X6=PGPV@3S+\V?PYJ.\><2;_ZL\
M>)"N4,9YB_#[W=:1Y8+XXYD0BS'$(H98_,\,_G=O^-@@;$S;"7T$[WA#:$!'
MDHL/2UYH+Q1@56$L92!69?EH OM&%@U(%PNT!*YV/'1L=?:2,<X$' GR9.QQ
M] Y1RKCJ%!M+78/I.F/):TDR'.^$5&*KD$& F.).6&F\@S^]E:Z4\7FY<-C3
MH L5W#QBC F0X<=":+F&&8@<?/'"\EH=H;-F)^,KYR8S, V$T$UA@Y:XM8"3
MM9:5+(0F8".OO8NR"%MFR'?JL!,A%.-9+ Q;_\7J!\9#K*\X,KFB\#:J9UC8
M(@APQML"P511I-A*)>EX0ODV\PXJ:]H1GC4.G].7+V:OLC</'L-F<!:EZ6(?
M8NR[IT]<X+.?KF;YP,=B:W8,%\,<"NQ-/;\JR]8;N%ED5WEVM;B^N@F !2=<
MAC.AU,#9!> A=\S7V+(G=$YZP [$MZBQDL0Q';>N<-]1A !^'8,@QN<#W]="
MN,%PPY-OF&C#/KH./+I.<:T,LKE?]M$:BPAMWR(PM C@!UXTO=7IF<<;X ]>
M7I9.(QP'H'B;MHR5?+PHCG/5I#\,BGZ$\ISO >;EB]M\=O/&02-=+'O.DN99
M-\AB@4$U9Z]F##N\LS(BA)%&J(7N"T) Y3G;.Z&\Z >*XHD63T7-IHYB60=P
MG@IH+?:O2C \S\U_ZC3I1=]NT=9Q.CG.OM?4M_!Q=QR =WW?/YOWTY/S6C,'
M4%BQ:S:]N4[ ]A.I7Y#IXA38&N*9$C\;'N)H@P&?5\;0:1$"C/\6K/\&4$L#
M!!0    ( &%_JE0])>6%+0L  ($G   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;-U::W/;-A;]*QC7V\>,+$NRG#B)XQG'3;;9:;J9.&T_[.P'B(1$
M3$B"!4#+ZJ_?<R](BI1)V4XSN^W.M+$>P,5]GG,OQ/.UL9]<HI07MUF:NY<'
MB??%\^-C%R4JDVYL"I7CFZ6QF?1X:U?'KK!*QKPI2X]GD\F3XTSJ_.#BG#][
M;R_.3>E3G:OW5K@RRZ3=O%*I6;\\F![4'WS0J\33!\<7YX5<J6OE?R[>6[P[
M;J3$.E.YTR875BU?'EQ.G[^:TWI>\(M6:]=Z+<B2A3&?Z,W;^.7!A!12J8H\
M29#X<Z.N5)J2(*CQ6R7SH#F2-K9?U]+?L.VP92&=NC+IKSKVR<N#LP,1JZ4L
M4__!K']0E3VG)"\RJ>-_Q3JL/3D]$%'IO,FJS= @TWGX*V\K/[0VG$T&-LRJ
M#3/6.QS$6GXOO;PXMV8M+*V&-'K!IO)N**=S"LJUM_A68Y^_^+O*E7'B8Z*L
M+%3I=>1&XFT>C<^//<33HN.H$O4JB)H-B#H1[TSN$R=>Y[&*N_N/H5:CVZS6
M[=5LK\!WTH[%R70D9I/9;(^\D\;6$Y9W,B#O)Y-'T-":%-^L8*575CDO_G6Y
M<-XB/_Z]YY!Y<\B<#YE_"8=^IBC\ Y],GXR$3Y2X,EDA\XV@"E6QJ'9Y@^2\
M0=$50N:QB$R6*1MIF>K?E< *F7N]4OD1I70L"F6=R?E+K)5YI"S)QKE:N7$M
M<RT=!*$@8S@N%E+<2*OE(E5"U[Y4$.LWXMM?WK[^CC02ZT1'24=/DD+O"ZL)
M!\0"PI<:JME-;=FS47TD]"Y2Y7$:;=&Y]C!!1*EQ%$*SA!+7RD))<0F!:JDL
M:8:RB3Z)I<YA"=:-R8?-^3J_@:98=3@=SU!3R ; @\[YA/N%C2J3R(P47R\V
M<+  WI%;*N$&B?L&:6;6I*5/-"RV,G>2H:@;MD2EL7@R_1L90Y^3)(^0T4[U
M6PEOC@3!%_YS1_#^C;+L#L,QQ3=!/\11(ST@I/)<B#K"D9?U\MR95,?20TWO
M*E4!L)Z,KW:5J%TK+J^OQ-ET,H*2]1[R$8?G'S(O*6PHRLE F)S"67$[2@]U
M+12YFS#;@)U-)J/)9/)(YY[._AS.#>XK<[7C.[B)J@DZQ+$F&Y#A]SM+6(-@
M?7F7F76.??.G>WS6<L1#G4<EV#T5K_5J50$)X (47V.+#%I5.%$KEAN1FAP[
M0E2E:(-YY19XKH:BL7C%T&;RMI2OOSJ;39^^0 2=4\Y1@%I)W KH0E5J00OM
M1:QC*.!%(F^0W^62 (N"6SE$>F&U^T0;@R8A"[CG0$@1R;7V"3S9CK$K%\;"
MK9*\MC7 E45A+/3_P:R!X'9T!SU)D0$$W89FU*<Y[X)8R_R@X?(@J:6H3V!,
M9H#E3J]R#;F@BA0IA?.Q.@BOW"@H9";3$1$(=XBP?"PNHX@-6Z6;KO*Q:M5)
M/(Q"T!QV<*D$^D>U(*;HM"C66"?%"@TG+3J<CZ<UB'.%AF(XG(WG#;9;E<HJ
M,TD;JS(E74E_<&J5Y59Y2%3DJTZ7T#!;2U&*LM06])>6JDLNLBC2X$55YT:F
M$'D^?"N"[.Y6"2$*EAABW=V%3*I-;#B0G&VTQZJUM "C1%(' ]1PU">$E=)2
MKBZH>HDV$42GX1/)T9?YCN\#P3)NJ*9,VCJ.Q;6FS.XKIT&\ZHUO@@#+K6JP
M)]5P5D4S083"42-*8!T2?M"0/G4ZKFVI0!Y;(RNXN5'(6$6%3LAC8P(B0O8Z
M;F"QTM*++2>>S*9=(%6=E+Z#I1*%4%(0J1.B;!_2JW'- )ZG,OKD:L 3"^!(
M;)3;UK1<Z)14A3O4+?5Y3K7+%T*72%4*G@&B",QT!+(P@1RRA9X"=@#7H$7I
M:@,[61Q:04LA&#WR8(2QH!JF'G6=J':^P3F%83R&31D%!>E+C6##03?&MXO1
MU9_7^5K12SB@X"S*) $CVPNO*[&HV< 5*B+U4,.1KZA<VZC,*+VBNLIBA4#1
M6.!5^.#1UI*B5J,F8R9^0H9-KU.[.1.2T;7,"YGK$7[ 4)FG\%.G&Z8=JYQ9
MA<X-:$9@67MI)T=#VTSUI&/BC%;.17!257/;HO!#:/<->=P061&AP5$N(<B!
M^%QYD+5SK4ZA+5(W1897M%9)F\,WG?4=WOZ&LS]6.06Q0R*(FE<!*K&YRFPL
MV-6TB\9MA"6=K;K!P$\\3)6*9B>22$L62<2G;1T$)>$FJ]AH!!/':1-S$I&8
M-0##([=C=%%=FA!Z&4"''('#XE"-% EV%,P-ZSC9L(:9X(@*X0CVX3R>CRZ)
M1?6RPD<DN%^KJI8B:2TGF,P(=.K@[T+C#AIR6C<;&.I"FFX#U*5\"A<U3YY#
MBJUPQ.\<4V8XKC7X4-T6%"R&P*H7X(B0D^@?='/<&+:L@<"8J&ZI Q0/9&_<
ME.3:E&@$<[7MV&IMQN+G@I;N ^=M-OJ'\5>G$+9XPCT50#4D/WHRQ 49PY,A
M6FV0<R&MWS185W%_GE<74]095NW<4*MO\DXSU&TYB$QCS%XVX_XEY,\#3=I2
M,O-)TR=*03=\.MTTDGG,;YE/N9.$#KTB4KYIJR; =H,E4T@ /!#-X[R*1REB
M!$%(,\7]90C' .R-!*,>CS9-.8*FBK1TE&U0$"_0!&$^<*U6<6E-)@Q.L3=L
M0(A.O8XZ2,L)WQY,*K;F5(P KWA3=QMMU*BRT\F,2MJ5"C/_K\1K[1Q15 ZN
MX\31YRDUNJ^8N:U!#6 B^!0*8@>U$2*.[8(  ^4WJ %9OW5RNRA=T__U%273
MW$\@W&R!<MAS/]![?7,T_9P+G/G0!<X^<3U7.+OW-Q5]U)HRYG#$=X;8]4[Q
MM0;'G7D6H \_ONCBQE]P*FU'HJ,;*;)0?X[!U/5.I@Q:+@FL87SGTJ:^HGG4
MS1)Z.FMN8:M74.3DR1>Y9]HS/W?\70T7#Y\MNN/-G4:H,^><L*]([#![L,#N
ML$1QVAF7/O:D^9T^4;4[/S*(K/:)5<"S\*."HA\5Q#MI4;?5;P)3KCZ P&D-
M B]$4M^9F!P1.9R?S.GVBQ?6?$]7"7$9U:WXMD/TQO/]48_GX.Y#T.X_0W3#
MPM UC<3AV?09'T)TR."*\<A$[1N'(9>/ GTN-EV5%C+E=.53JTZH:WEP*PA6
M:NJ;Z19D>Y7-_>2P,H.C.T5\#WSVCZN4U0((QSQ2W9/^(:.:BR[B,ZI2EG+G
M5G5!OR>RI'JD#VNYB:"U38XM2\N7*KVYMG/'F/#M&J@QU:N VH2=R.CV%>X;
MM;#U%?BTA^+D/1?@^ZFI=_ZOL9(Z2>!IP6S[1Z#J] M!%=P1@DB_T3V*[F>/
MI_O9>#)(]WO$_27IWO71?:='_Q_RO?LLON]H__] ^+/Y?XOPW5^,\%LS4),'
M=PBGIV:IOAX^6!\]<+!N *@!J^JA@KN#-+9':1GWS=$]ZK:=SC?:U9S8_C7*
M>5N&4=9UQ=UA@5%](5,-U,WO%''W?J?QZSVDTAVC[T%+=N_ KRSYW9],#J=/
M3L/OBFT/=JY4D!^VOF5"ZI99&7Z%V=_\D>S9MIEI8_>=3J9E>Z=WV1^H;>_R
M>7W*C#X$J*P;$JJ:'^I(GH,1>PIQCVJ'8CIZ]NP9_C\3'W;=O+O];I I#K/I
MJ;AFKU(!#+B]YTKVH8WV3'P[&X6#3K[K-[#73X>":W[V8IA$U"W*S>D;@M,4
M&9B[P%G7F_P*>??U5].G\Q= _*S,37@@9<.67;W^\<?75Q\_7%9+^I[<.6X]
M%I4IN^*'OZC$ :+A":GFT^;YLLOP6-5V>7@X#8:M4,IH'Y;8.AD_/3T U?(#
M7^&--P4_9+4PWIN,7R9* A=I ;Y?&N/K-W1 \]3=Q7\ 4$L#!!0    ( &%_
MJE0\19+D9 (  #<%   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;*54
MVV[;, S]%<(;]A38CI+TMB1 TK78'@H4S2X/PQX4F[&%ZN)*<M/^_2C9\3)@
M+3;LQ1(IGJ-#F>1\;^R]JQ$]/"FIW2*IO6\NLLP5-2KN4M.@II.=L8I[,FV5
MN<8B+R-(R8SE^4FFN-#)<AY]MW8Y-ZV70N.M!=<JQ>WS&J79+Y)Q<G#<B:KV
MP9$MYPVO<(/^2W-KR<H&EE(HU$X8#19WBV0UOEA/0WP,^"IP[X[V$#+9&G,?
MC$_E(LF#()18^,# :7G$2Y0R$)&,AYXS&:X,P./]@?TZYDZY;+G#2R._B=+7
MB^0L@1)WO)7^SNP_8I_/+/ 51KKXA7T7R\X3*%KGC>K!I$ )W:W\J7^'(\!9
M_@* ]0 6=7<7194?N.?+N35[L"&:V,(FIAK1)$[H\%,VWM*I()Q?;MJMPX<6
MM8>K1_JZ>>:)-AQF14^Q[BC8"Q03N#':UPZN=(GE[_B,Y R:V$'3FKU*>,-M
M"I/Q"%C.V"M\DR''2>2;_&V.\'VU==Y21?QXA7XZT$\C_?1_GO ?*:ZM4;!J
MK)#0OP/XVIJVJGLOZ]TC\B-<&M5P_0S.R!+8:):S$3LY!U=SBP[,#@JC%/4
ME5-Q#RW])QMQQ#"&#9<4M*HLH@H*J--!TSAHK"D0RXA_>Y:>OGLS/LG?*R$E
MM5,*\)D(7,3NT2(598G /7 R0RM@"?P1+74V,8D"(\TDG3%HZ/8H+?W3ZV='
MQ:S05K%E'670:M_5]> =IL*J:X9?X=U(H4*JA'8@<4?0/#V=)6"[-NT,;YK8
M&EOCJ='BMJ;)AC8$T/G.&'\PP@7#K%S^!%!+ P04    " !A?ZI4;ZIZ<4X4
M  !B.P  &0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6R]6VMSV[B2_2LL
M[]1.4B7+C[P\>54I3F8G>R>3;)S,;M76?H!(2$)"$;H :47SZ^_I;@ $:5F)
M;^WN%UNB2*#1C].G&^#SK75?_4KKMOBVKAO_XFC5MING)R>^7.FU\E.[T0U^
M65BW5BV^NN6)WSBM*GYH79^<GYX^/EDKTQR]?,[7/KB7SVW7UJ;1'USAN_5:
MN=TK7=OMBZ.SHWCAHUFN6KIP\O+Y1BWUE6X_;SXX?#M)HU1FK1MO;%,XO7AQ
M-#M[^NJ"[N<;_C1ZZ[//!:UD;NU7^O*V>G%T2@+I6I<MC:#P[UI?ZKJF@2#&
MW\.81VE*>C#_'$?_E=>.M<R5UY>V_D]3M:L71Q='1:47JJO;CW;[FP[K>43C
ME;;V_+?8RKU/SH^*LO.M78>'(<':-/)??0MZR!ZX.+WE@?/PP#G++1.QE*]5
MJUX^=W9;.+H;H]$'7BH_#>%,0T:Y:AU^-7BN??E*>>,+NR@^..UUTRK2U:3X
MW?R],Y5I=X5JJN*C\5\]?_K<E-JUL'5KM"_N?;"U*?'I_O.3%L+0D"=EF/B5
M3'Q^R\0/BG>V:5>^>--4NAH^?X)%I)6<QY6\.C\XX#OEIL6#LTEQ?GI^?F"\
M!TDS#WB\![>,-RM+VV&=S;*(RRS^>S;WK8,G_<^!"1ZF"1[R! _OHOI]BOPG
MABD^K30\OK3KC6IVM(:N41T,JJNBM-!XX^63Q](J19<7IE%-:51=>(RA$7@M
M#_NVL=?&%BMUK8NYUDV!X-\HAR=,PU.X"L]I^&V[*CY/KZ;%4C?:J;K>T<]Z
M0X.K7ID;9S#-IB;_^==_N3@_/WW&3_W;;/:!OY\]NU\H3\*1H\D\+9;S:Q(P
M,\U5"[=4KO+%*XM_Q;VC7V=7KX[N[[_GTE9F84I1T;VCV=4E[@2R88I6.[/.
ME& :03R&#G@^+\\T,'_'>.*+UA8$#,79Z?%_\"TSUYJRUKA >ONHEUTMSU\=
M_]>4!7(5Y*EW$UK/KJALT=@6@Y9U5\%<=4W/T5+'DR^L;7$K5.8T I.4/]\5
M26V\!+)UK5N]UY!3=HA;+#]7-5M0LH!BJR.:RE4*)Q;XML>'[H)TX5AP?X>'
M2':G5X3U\++:^KL\#(PLOZYL76GG?RY(/P&V?GQZY5?% OG)LR;IN7;EM"[6
M E&:(&JD$IX!'\X*Q$(?79-BW@U-JJHO@'&9ZQX)83Q[)>9MR,@U;%IVSM&U
M[-[[$$&U+,NE1#&OP- JBT:7VGLD4997%0ME',5E'__!D7I?V%AO!-MQ&U+6
M#6-E2J"EE2O5+.%P"+Z]"HZ*P@C&(K3"[+H25]L[R1VTZU=VVQ0K[32A##1,
MD1*7;0 MIJDXD.$O8:UQ2M;;6NV 5H7^MD'Z)W0+,^^T<C0C:?LUAEO/M<O<
M''>Q1J%MB]M=6!ZOR6=FWAMD$U:<Q"D]K%L[H85T=46R$&<B=<*,7[I&2 FC
M"LF5@?-W('F\$MPW7@C^!@],X!E\Z&=?S)JFPX@?]<:ZMH ,$<3^AOEJ7?4R
M,;Y<D7,:3O>TNC??Q#%HP+7QS,TBC%^]N4P CLMBT:!:\8H1TK0W)4>>\9)F
MX&TP+I3@['J@HKU:X5#!'U*<Q&!E(?+_*[X.'.0N639*V(:DW0U3[X>5@K"E
M[I!>5 TW>]N44Y;;X#[?S8$*!F" '+,'N_G&/1XR1I8D(@VZ1;C7NV/$((%E
MFB%*-/-&%;__?HD9ZUJ29Z :O?R,P$XU7H5\N45$%+HV8+$\3[>Q338S[IEF
MO/-3)A[T X D&@$(:#D_P."M,["SFB/C(A5C?N#) *M(%S\]^65Z!N)<UV3K
M'\:?Z6#^%0*7B@L"C5)M3*O8DWYZ\/!T^B@-3@M63(FZ-65^#(KR ,2QY9O/
MI@^*>;QUCYW&4_I^V;1@@6*M\ 1'OC<42$:\!R0K2B"(YT4EQ'\Z5@^/A8>6
M#1.@IN4;&Q_".F TUA?FBIK"?_BU9BTONK9S.D!8HT<(1O?Q@F@\9(,21)7\
M5;))_%+I:Q2"&_)[4@')OW&V J>"9@'+Y()^H J"E+,GSSPGJ)"F*$BO5:VC
MGP%D77L,+UQ#NFL=TRW;Z/'I]&%OH[T!@D7Y;D&F(K&@+=]M&!V'R+D!>%$\
MC!*:"DF"1@8"U5KYMC@[C^Z5\(N6QFOVOF,4%##RMR'*6V1Q!S\>FW+1$6*)
M+09*SW7+U2X\#[@]#/4M-($HPC)HG5I_!>FHF!E@^N#<I'_4%)1#;4E^@WBQ
MW7)54/'3ZJ4I"4P-+X(F1G5$U(T(C'.4'4(Z7#IR-+5$L*VCK4XHQ8KPFVZ.
M)RGGHB:X)NU4>M[2]\@Q1"_-,D(D33&#H5?Z&#;\"BQX(W>^7RPT,Z@K187%
MK)\R):?1#S%3W0P[56#QK07:,3-MR#EI:!:.0VPLW2033T*AU&;##DYX!0<O
MH7#QQ_-?<G?$:#\]?#)]DJ[ MII<:B1N474NCOYCU/0P/8#?$$P@P5(UPF*<
M/3[/D9*\5A7_KD 6H E.S2S;%F2@I2HP&"\J7EA\@N!B6OQFMW!(-\ECBWR7
M[B;7HMP,6J2NE:D97P)5$>]@+F86_<^3R.DP!45Z('H9I($55J;N*,J<T+>M
M072I"E)X3>4HA"TEJAUU:]@B^EL@Y'GJ0/1AZ@J6)K<DJ7UBH9E$>6#QDD)<
M5;I6.](R?$?2NB^!&LR&X>T=\RZ:"O]9VC5@-N)A#IPG'!P]EL*5$%3K6Q!2
M(;^09^: 02-F@(6PKO2&_ +6X Q,-V0/VCE5W7M 86@>R7;ERL#$)-7"2";N
MIQH&UBUIR9%9J%SI6BIM"F\[!XY/JDCA1?>MB2^R<H(P#0=4K/*&-KBF"(JB
M<=F##ZF\B53M+@1M7*D3S\G*.@C(-L82R14+M>XI4%DKL.38=."5X8(.OP)$
M6?4,T]N5012OR3/)S_LB+]00@7S-F68FVA.4R<"UM$Q1+'7IFH$!?O9W6K#D
M2:'&/UJR[>D0$<0-A:(6JDEK)>DU:+4*)1/52+7Y*Y6PF:98P;IM:QVY0Z8[
MT315)&UDU/Q *+#!2 $ ],R\0YJ"5@_PFYL)08-J=-(V !,&)I  <"Y6U*+5
M,M*PMN%D']-FROZ4D)']=142_QU,,CW0<7R4.HZ/#K8*;^GC[NLY_E,#L>:6
MM9T34N%7O48P2%E.+L YY?+]GV]?'Y_]0DRN\U)H@=9;9"*F%Z:15.* /=?&
M=?"5J]E'?WQI_SQ&@4[V" \V*@ 4R1%FU="CI5G9=9,:UT(6*N-=M\G0R<#(
M92M$#,B89$Y%J'3^P)AJ\Y6@*L<N;B^TH6<%L=<,"UYPCOI2%CFOW45?IS%%
M%Z%U&H?.Q^2E#6AZ)G/$F<%:*7U3;46=)I_\.X9$0$M9/Z4PVX580CU35T-?
MCX((2J,0H!4CXDT;@B57ETZ6[-46L@E%M-UI@K029:2:6Z0$ZP)5U^X:=)%R
MQK615$LRL":9>XNVN+44Q[VAIB#(D)ZGV,X*&JX[Z6E)>B1AR%\961[R-Z?(
M%6$IU)>ITSL)A"@T@@.\?&ZXU+]J&;]X6FX:<07L&-,C=&FF'O 4EI"@+8ZM
MOL+/?G3 "/DJ.% +P!0]P$]0>.CH;4[3CAP210C/0_#Q.,''XX-1?YF,2? \
M&]#ZXB,!(JSS$6X)[[UM+^-_=X:!^U*R8,_?KC1KC?G"8,2\%.&B;_Z%":&]
MPW;!)[N!2UZ<7CPM,G$! ;.L]DEE1[H[=<9H#Y$=,8K)>P$H6VV-0;X@6;99
M.1[JN)CCXC-S^ 7BP_$/G'AE>U.NE68C,@>WRJHRX6V..Z/6ARHP@QN7D-WI
M+2D!X2FH$R,T=J7S01<H!WT>&8GNIO7?X&I$"(A-!1Y_TUBTE(;,*&T\%;9#
MJ:+(QPF-9VJ$E:2376(P2@AX)!.WULJA$\*</SV?RO;]0@4HCD* \(@8J4DO
MMX<R:B#YH"';]\N$D< FO0S[%+K743]OF%Y$IYM=?4[N=GYZ]O#X%.DVAH]D
M86 ([6/*',5ED&_LMX]/'^^ODZG3[XAF,1[E49!W &3PH+)@YW:WH4J&._C"
MIL-RN3@:5D-"T&J0=BSW:7'/W ^M!EQ&>GF&*[@4^T?4M,&P(<'(K_@9%2VP
MG$9.>D75P3PK&#'4"E&(S#54344<[^-9M^.2E%BF=LPJEE;5F(;<Z9ZYOE\X
MNU,U1R0L3X6_YR*>J6HI-"_(BJB:L:NP$?H.WM"S$Z!QTK>TRP(!XOH$S$(;
M-7@*MP?3L!SJ/$;"#;Z!ALI&XIJ0:^#P3*6IO@8T!W]DNQ%F )6X;\[-*Y3_
MRWV5'GNX$XS^2W,@NN!ZK&RNC:)ULP8Q-8'*,!DD@HO8,K=2W[*X10Y:)&":
M.G*\>W;K?1C=XY-?&-JMFGGVT"A1ME,=:@2O1VVM0<6)R(D>4\#/S#JE;JB^
M6T?F1JL*>PO%EZY:1F>#<"J */<->LUKZ;?4.^E-8,1C59,;@Y;582.]Y )&
MK'JK4H@.I(&1+9#T]ZM^H'78*?2;]@\L1F>Y]HE%E7@,<'":=8!GQ3BG48S3
M',$OH-(<CJ%#3<2 +AO/UBA<TBHB:-[7?60T7:[Z1G,?K30A%= CX JUG#^H
MM($I#+5EJ#M-C#\Y#K5Z5;'A=$T8#:&Y[43-!_K"_=O819D4U\H9+C*'^8'=
MAPJ)5&+NF=IP[2[%$4W<5!/97R153I"^PE9?2EDW3#LM7AMJU.FFU*DX#K;.
M=HMONL1<MUO9C*L1>$YF9\>,WV_!!-971M-;VO992AH6,' 9C9/].D[S87N1
MG[$M[XX/[O]+5[%)2A 9"=V4MC'';"]/18(KP2/S+#(9)?($7-$[1:^-;8ZA
M<4PMK;]N@\M$?;3> U9Q@FU,]_$";,E:AC'<C=MU(DGI L5D:/5094B_SU%#
M+. 6R=SA9E%!^.)[U)Y#YK2O&W:U\2CJA=':NQ9A12M/ (590P+A;HKBRBDX
M"Q+AG/WQ1V(HX[K??3"'YSZ>*+CVA!P' \(DW2=+4ALL$2Y,K&B-J65W9HT*
M2?KHW$>-?:!-YX@+>_%.L3_=%!S@-@"A>61$UDD:DH'%\?8Z3R6;0U'0U-6;
MA!;BS8$RM0BD"5O9$SAW\_H]3.C>?ERZ/W2,?LVY'=-P4DS% 73$Z%HZ;EI4
M":4$].BS9,8'I)\R/K5P$Y Z'[=!UA;0&=HR81"Q-/-X@<TDB 3#L-))ZJ3M
M 0#-EINLA$&\Z14<R5,;A_7?JX_4P:'Y77G#3IH$$8<4OJ4*,--QZN%O:/>0
M*A*4^^E8W:W%T22VM@R43WUC3I&A1B&JVC6A?IT6[VZ:/V$$K3JK-L9"V1BY
M>T3H]V>)=]IZDC)]EHLY'J_Y\ )-UY\09,@_Y#F!G!/H YX"(TW#\6B\W7;-
M7$Z2#7=Z%A*(6<MV')-CY#\>QG;/-';2L"%!F(QUW*;OO9\W_G<I4%.R;J7_
MLS_JN5,60B%B*J$8'5/9XT>S9A<4FVT\A-73-G%HMH>S![+CT9:KXVXS;+F+
MEX>=L) L)B/+QNVS/@5RW"K7A+W8R OCKG<2*33BPXDG6AK@I;X;3''5="Q!
MDDJJO$6W!\<&(543F>0.+(TT2=L8?6<QR\85\8<JX(^875>6SJA0L(*Y#GN2
M?8TGUOX>>Q@I:TSKI4 DN.$^2W5C1.H:4XQD[(<G8C%V&8@-FNQ\?FTQAHU1
M=7ZH)?@DM02?'-X(R'LJKS,2_R:>+CDN+N/FY2<7#N^Z#J&[KSOX?S;9:"LL
MZZIQ\ZQ6;AG:^W0\4U>'^T4+>-.PC1!^)@/P"P<@']'1 U7>2:%B:[MD=W[]
MQPQYI"RET*%OAM":XTYM8K^O>C>;^Q ^<64MKRP>WYDP6PMQQ/LBU <07!'\
M#!J(6ZU]^B7088I=6M]FQXU2,*5F(BVZ ;;7-,TD'H4+E8-O$9:#=K7LC4U%
M^[H:BR[3C1JP\&3CN7)07N[SB5)-J7D5?R6JL2)[L>*#&D9A9IHL9!?<YV*(
M65(,.#H4D)H*,BZ"'XO2Q=?&;I$J?^,#(-*GFF2BL;-(./8;.1'ETI%97LWA
M7N,S*L-EHQI$)NLRQW4XVUIZ&X30=:P_<@9BAW7=;Y0FU1+TBG2\R11T->I7
M_ARWHD8'= ]!PD6"A(N#4?HV;1)]1-+C4QEO9<]S7^MR'PH<'O]3.&##AYRR
MMPIL8VFW(^0#>MN(FQ#2'!^>?)/D9\<G8_<?P_KXO;D&) KC2_M=W%-F3Y6P
MY%8Y,#YJ0NX3@[:'#Q_:MBZA$/5*:DM%1']4A:YUX)[5='_?.%EH5EE^3V-V
M];GXPTYI0__T^/0Q-S%FW9*Z%'1)<A.]81'WL4</ ,GTO&5*>/Z,/H;^LFV(
M9,<C3^\9)=Z'WMB]JV[><KOYX9/3X_/3^P'?^4P8 E:0Y3==+2%\&+KO7\/)
MWV!9;4]6WV^;>"RL'_KB[-'QP]/[3W,]$"<0R5I#G/,MO]W1;S@-)E$'Y^D;
M[U$3L6\>>9>'"]3PP-C.[8R\-L,J$6WV5'K4A"PS(<U(R#(7D@_[0"PYH38M
M,GF(ZZ1-R%#V\@DN3:LRX<CG @X#QZ/#8Q1$T'C#281/.:1S9&>/XCDRIK?A
MW9GX)D"J(RP?;>P''!;2*G.Y**,<.XF'SN+!$B:V@I)<!B.[IE8P<]M0)@<>
M+(>$^ZT?<^A,[D4\\8:UX*?2T29J,3P M5&F.J93K_G1W^F#[$DY^8L$FA[/
M3>9U8Z!;.6 NT_:GACE9+.IX+FVXQ9[Y@227H0JI9DJT4-)96F/H+ZEO@W,R
MX]DY.A4=MZ#VNI7#>1F=#^ D=1&'+^W&D.-.,LZ)]3:6M1X[?O)85HP,QX0-
MI9>9:HI[U.SZ QHJ+B;%41Z5A")']_=FII/LO<>U1IJCMSN][);+*Y#I:GJ!
M=";O3?:WR]NG[Y E$5JH'19X]'3ZY-&1G!&,7P C_!;EW+:M7?/'E5:P -V
MW^D5@OB%)DBOU;[\!U!+ P04    " !A?ZI4,FB,<IP%   Z$   &0   'AL
M+W=O<FMS:&5E=',O<VAE970R-BYX;6S-6%MOVS84_BN$-PQ)0<>B2-W2)$"2
M7E:@';(ZZ1Z&/= 2;1/1Q26IN-FOWR$EV;)C>^Z  GN)*5[.^<[E.X?,Q;)2
MCWHNA$'?BKS4EX.Y,8OST4BG<U%P?58M1 DKTTH5W,"GFHWT0@F>N4-%/O(]
M+QP57):#JPLW=Z>N+JK:Y+(4=PKINBBX>KX1>;6\')!!-_%9SN;&3HRN+A9\
M)L;"/"SN%'R-5E(R68A2RZI$2DPO!]?D_":P^]V&+U(L=6^,K"63JGJT'Q^R
MRX%G 8E<I,9*X/#S)&Y%GEM! .-K*W.P4FD/]L>=]'?.=K!EPK6XK?(_9&;F
MEX-X@#(QY75N/E?+7T5KCP.85KEV?]&RV1L% Y36VE1%>Q@0%+)L?OFWU@^]
M [&WYX#?'O =[D:10_F&&WYUH:HE4G8W2+,#9ZH[#>!D:8,R-@I6)9PS5^-Y
MI<S0"%6@#^63T 8<;C3B98;><:G0%Y[7 GT27-=*-&LG]WR2"WUZ,3( P(H9
MI:VRFT:9OT<919^JTLPU>EMF(ML\/P+@*_1^A_[&/RCP$U=GB!*,?,_W#\BC
M*V]0)X_ND==S 49OQ,0X1[S]6DOSC,8BK94T4FCTY_5$&P49]=<!I6REE#FE
M;%\(@&A9G0M43=&XX88=]K#L\O1AF?=S@:95#I23Y0Q)"&A'.RN:/W&9VR .
M@=5#S4&W7AO'M=T#KDWG*]\Z/[P1J2@F0G6SY!Q=[]I["T&VSJEY#F-MT'M5
M:8T>2J@:N?Q;9"\G7*Z!F$<H0VW*U>[\M"XSC8;#(?H9D2C&(8MQ1"+X^N6G
MV"?^:QB=A)B&$4YB>NIV^=B//1Q1AA[.QF?(*)>]SWT;/PK0;^:\1 3%#$=P
MAL4)P/?0"?%B3&AR:A?"D.$@\,",HA JE8!HP1?@@KX FH#N$!./KD!UO[VE
M6Z&,G,J4&^&<EHE%I:79D.3C) IQP!@B 6 (T0FE8!1,)P13%C4&0;$LTV=4
M '-G,!Y.>/H(/NR9]PH1@$W 4^$*RDGB82\!:02SD.#0I^ LZH'?:("#,+&N
M"S %I<ZC06B!Q*=N$R@'9] @:@/^(A-^7,P3,!Z@0(3@*XZPYY">@ &$84:(
M"SEXAX&K&?6."WG",$DH9HSTW(,3'Z39I9CBP#\BZ)!T<; [Z.W2\4'WB6?]
M'Y+8!CWN@LX2[WN"'KK<C1!DK0>"? I"8AOR(+;<L;RAU.8%Y#NQ"4 @ 4@2
MM"X%<H5A$W/J81)Y.&$>>O5;A334$2@3T :MNF>4@45G!XI?L"I^P='%;]UP
M,.29%FT?^BCY1.:-C6TCRA T],_6=&7KVPW7<F>1/*C;WG?.]8*GXG( %QHM
MU),8;%5.8ZLD<JNV]1E8A*Q8\/+9!3MZ;<NE0PK!-&@I%/BHPP@34VO2DTMN
M>P6!:TR'>6(Q8T@(VWL!6(9J[31N5NYR49O=)?E\;X,&O5L5^;XRD,2_UY4!
M/7=*IN#*L9R5+C5+LSE>WPAD[T:PP<W-*KO]M:[,W6@O*7LEMC?<)M0+(NZH
MN#NF]I%O74Z[G2]GCN3<NI9V!U_.-,[7N]W:KZU^$ +? O D0XRYBN9%:SGK
M"P%(0'PZ!5)P&U"8L92DT 7A1!CW1MN>;+"T*;LG46W!AY880'WT;6'P0P]3
M8B':$MP#MH[O_Y@T.RXM!WCSLK'] .KTNM7VUW=0I]>H>L.CJ+/5MW9,'::.
M;4J;U.G/'$V=KB>MJ;,]<Y@ZO1;EQ] Z?< "U0,R-&!PK>E!^G?J)![<,9*P
M-_J/U*$,N!%!);3W*#].("H)CEC84*<#MH[OKAXZZKWG('HS]VK5**WJTC1/
MN]7LZF%\W;P'U]N;5S4T@IDL-<K%%(YZ9_8=JIJ7:O-AJH5['4XJ V]--YS#
MXUXHNP'6IQ5D?OMA%:S^77#U#U!+ P04    " !A?ZI4_/-T?*L#   <"
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M%J>)7S8XOKEV#FC?*&4/@DLP_2%8_ -02P,$%     @ 87^J5"-3F6\X P
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M"JHH=;,%@2V9YN<7Q(T9UN\@.-W'E;?1CA9H/';TQ4(3%.B]U53=O1 <C-_
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M3Z!V!O2]4N36L'$7C'^>U6]02P,$%     @ 87^J5$'6L22Q @  FP4  !D
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M4[13[>XFNXZ1=7-:SZ7!L[]IKO ^!\H&X/>%1&?:CKT =#?$R1]02P,$%
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M4)9Z?#%,Z1F&VFV@[RNE['[B'-0/N\E/4$L#!!0    ( &%_JE2US]D)MP<
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MS>@R4Q_%XSM63\@W>(G(RNH_>*S'>B.0+$LE\CI8,\AYL?JD7^I$M )0.!"
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MU@'G-Q+O:V?8OM)_%?)_4$L#!!0    ( &%_JE0K9<K;F0(  *H'   9
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M9S7\11/)11U)>""2:Z9Z) H^D)"&80=\\@8X=?!@]!SNFYJTA0G;PH2.+SK
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MZV#6E]*TQ<:P[;I]GK-?4$L#!!0    ( &%_JE0F.S0@[@(  &,*   9
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M%+$ES1-USW>_L')"@;:WX(DT_]&N?-?MH44N%4]+,#!(XZSXI<]E(!H ['<
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MTDT[ M-1 BLJMRRE-Z;V9G 0*"U9JF%HA4,U9UJ-Y"GNMHFO23[L]?76NZB
M+?Q0&!+$F!#O2, SAGZ$/3PP/*0P.#+P* 7(CNT?^/^7$?O]9OY5"=F7=DPN
M*R0YT2>*" F//\3W[0X)](< 'C\%EH)OJ=3L&0YZ: '75,J]?F,)ZFLT#J]*
MN;ZRX^BRRD6GGR#QXF/=WK$Z#+ZO_WC\ !BJQH4^[KH.4?NBC*=7I55?QG%\
M6:WB4Q6\((ZG)^7R?<.&@CMHMDLJ-_8.HJ#]J+EN&M5NM;OGW-GN_FC]WMQ_
M;!/?PS27)VA#-PS:FX*N =*[G4!4LKF/-!,M*MO2/PL-%P0[S.$.1Z4Q@.=K
M 6]&.S$;=+?"Q7]02P,$%     @ 87^J5"K;_/30!0  <AX  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#@N>&ULS5E;;]LV%/XKA+$!+=#8(BGY4B0&DKAK
M"ZQKD/3R,.R!D6B;""5Z)&W7PW[\2$H1Y5BF'2P;G ")+CP?SX7G?#SB^5K(
M!S6G5(,?.2_416>N]>)MKZ?2.<V)ZHH%+<R;J9 YT>96SGIJ(2G)G%#.>RB*
M^KV<L*(S/G?/;N3X7"PU9P6]D4 M\YS(S17E8GW1@9W'![=L-M?V06]\OB S
M>D?UU\6--'>]&B5C.2T4$P60='K1N81O)W%L!=R(;XRN5>,:6%/NA7BP-Q^S
MBTYD-:*<IMI"$/-O1:\IYQ;)Z/%G!=JIY[2"S>M']%^<\<:8>Z+HM>#?6:;G
M%YUA!V1T2I9<WXKU!UH9E%B\5'#E_H)U-3;J@'2IM,@K8:-!SHKR/_E1.:(A
M .,] J@20$\$4+)' %<"^%B!N!)PKNZ5IC@_3(@FXW,IUD#:T0;-7CAG.FEC
M/BMLW.^T-&^9D=/C.RW2A[,KX[D,7(O<+"=%7$!>3:@FC*O7X Q\O9N 5S^]
M/N]I,Z.5ZZ45^E6)CO:@7RYG78"&;P"*4-0B?AT6_T1D%V#HQ%&+^.1X<;@M
MWC-NJGV%:E\AAX?W^6I.)#V[W_75I92DF%&3#AK<;T!SW W9N,>7:R(S\/NO
M!A)\U#17?P04PK5"V"D4!X-73I0V%&KS=(G4=TBV&*S&@P&$,#&.635=NCMN
ME)C?>%"/VU(UKE6-@ZI^$9IPL"PD3<6L8'\]T=C<*&WJ""?:O-'"C%Q19:^5
MM1&(A1VEV@R+=Q2&HV%D?]HU3FJ-DZ#&-U0RD0&QHA*LYRR=&[5>P@:3X)R#
M>PH:,*]8 3:42-668]=A/5$I"1#(1:'G"D $,K)1@?75KUW0#T)_=U73Z$>,
M$PP+@)E9Y]J@:PJFA$FP(GQ)G?:9X-QJL3#>4G;]MUI23C=HQ IUX^&3%;@[
M:-C%<7LP![4E@["3(M@''XO4I**A&7##21'PS[!&'9Y&01C5"HV"9I:@=M6Q
M8F9C85=P>'&% 7$I&5 -1IYIHB#6+54&R^01*3(PH2NSYU@X5[S[83U'0Y,T
MZ R>1DB@9PV(PD'A7*2N)JC&I%N5@[9YH&)(M%/?\&"[O%5<N#LP08$Z"#W+
MP##-O*>%27_NXG:9F4T(4UH2ETA'A,XS!(Q/)'2> F"XMO[+T)7@23-T26OH
M=@?&42ATOH##< 5_ER^XV%"JRJ1CAG.T".>S+ZEP<"+Q\O48#E]L0U1!-9T^
M0*W1V1TX"B:6K]8P7%U_,\YZC%!H?^I++(I.(R3(%V0$7RPD%=16"4M:(M(R
M+D:CO0%!C0U^N%0[9<'G:J/V-WA^^B!?51$^D5CY"HS"F_1;IA[.II)2P I-
M);7;65/]6D,51H+=X?#GMH[M@%RT*[=MBR_=*%RZ+3.EMG*OA-F0,\[TIM6.
M,,H(=Z.HW9 #@FA7<-L27\/1@1K^: EG4QN9MBU994P8**DZA6&P4ZC,.PYJ
M5$,-#S4=R!,+"F_6)VS%,FH2;L,HSUH-#0-$>X/V;+EM$SP1H3 1F>;1?9,S
M'4>5NC:;)$M].[@LF [ZR],(&IU&)<&>B'!XK__?M?O5Q%O]_@ &Z!A[JL)A
MJCJ=CO^ HH\M/RRS#_0/Y1[V#(C##'A<R_]FSW)^QJ> 2H]FFX^[&#_]&K4[
M"L)NC/:$NO'A+-S2')N?9@_PO$\'V),M/I%V!WO.Q&'2^K^"?U7IL1560YC]
M/6'U5(G#M/3>ZEMEEYN]-;VN*I3FCK[?QSC!>^;WS(7#!/*^S5^M&@QVJM@P
MU/%ASSSX99BG?66;IU^,#>F<@L]%J"?!GIWPB;!3[-DI#K/3-_^!S!IO5GI;
MC Z )(=V"[$GGO@@\;Q,S+ZL14@ASP+QB9QTQ+YBQ^&*?63,PB"'8]8XSPAW
M*L__U'IU !$ZT3;E>HWS/7L:^XG(&3/["DZG!BGJ#DPED^4!9WFCQ<(=^=T+
MK47N+N>49%3: >;]5 C]>&-/$>MCYO$_4$L#!!0    ( &%_JE1]_QG^4@4
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MV?P3ML7:7A+ ?&.=EB68%$BABF_^7!IQ!(BZ)P!1"8A> M@)0%P"XI> W@E
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M$O/\XXRSD,ML@/Y](H1:7V035"_O7_T/4$L#!!0    ( &%_JE2=ZB[SV00
M !X6   9    >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;+U8;6^C.!#^*U9T
M)^U*;< .Y&651MJ^I]V7J+F]^W"Z#PXXC;6 L[;3;*7]\3<& J$!%YV:B]0&
MPCPSSW@>9C#CK9#?U8HQC7[&4:+..BNMUQ\<1P4K%E/5%6N6P)6ED#'5<"H?
M';66C(8I*(X<XKI])Z8\Z4S&Z6\S.1F+C8YXPF82J4T<4_E\SB*Q/>O@SNZ'
M!_ZXTN8'9S)>TT<V9_K;>B;AS"F\A#QFB>(B09(MSSH?\8=[,C" U.)/SK9J
M[QB95!9"?#<GT_"LXQI&+&*!-BXH?#VQ"Q9%QA/P^)$[[10Q#7#_>.?].DT>
MDEE0Q2Y$]!</]>JL,^R@D"WI)M(/8GO+\H1\XR\0D4K_HVUF.^AU4+!16L0Y
M&!C$/,F^Z<]\(?8 V&L D!Q V@)Z.:#7%N#E *\MP,\!?EM /P?TVP(&.6#0
M%C#, <.V@%$.&+4%8'=7.;<UI"AV)KI,):G$+JFFD[$46R2-/?@S!ZE.4SPH
MBR?FEIIK"5<YX/3DAB5,*/3'BDFZ9AO- W6"IDG01:?H"Y62&L6C=Y=,4QZI
M]_#KM_DE>O?;^[&C(;QQX@1YJ/,L%&D(=;=)NLC%)XBXQ*V!7]CA7\13%_7<
M1OBE'?Z92H!GT4D-_*H]'-? K^WP2Q84\#KR-ZWA>%0#O[7#K]FBB\BPD?RT
M1>$L*W_W"IPFUMSO6\#K9>. V O%DT+Q)/77:]11$HA$2Q'!E4?0NF:2*8W^
M_@2&:*I9K/ZQA.D587II&*\AS(P^P^31"FD!<^/'ADN&:!AR,TAHA/@N+$]@
MG"T4#SF5G*DZ86>!^FD@,R*?)GAD/L.Q\[2OX$,[M["HY. 5.7C6'.8K"JS%
M$B4PVR.AE&&;=8PZGMY!?(+[/L&]%SPS.W_/SNMYO>&@GJQ?D/6M9!L[F:68
M_<)W_YB:&11A!M847H39:>0$B6W"I%KQ-5HS&8"LX&D'+9[1&NJ3Z+I>:@_4
MZW==]_>Z&MIQQ&O W=AQ?=R NWV%I]^ N[?C?'*(JU1D6%1D:'7TM6;AZQJH
MW8LW>(7.J* S>G.-8[=\%'"/J7*\]\R!_Z?>>)%'JC1'SS6?:M.YJ3,D5<-J
M-N4\P<3>);4(OJ/U1@8K>+9']%$R9M([08&(8Z[-L6FBE0R?(+^X_MZ=YO'V
MJ0YK4KI[W:Z:43FZL'UVW<!6#,%^)V2@!R4B'M)T_P-)6)F?X\,1Y&$;I7(2
M8?LH^F2FSU**&#'0BWY&,=,K$>[Q.8$=7B!DR$)$$_B+(A%0#6<@,BOK*WPX
MD$ZQ;Z-=SB1L'TH/H 2J-I+M1)#?P7-F!(T^GF($.^$EDQ*(*B.DVF7U#R>K
M9^-7SC7<?\L)GWOK5T=W,X]R\&%[PYX6!3($FDI<SVEP4+T7-\J5U:3*N!P,
MV-[3FS=.OXKJHJ_0-V=%?>>']:T&+\< 'AVS4Y-R)!#W#?5QG7NK="0\:M0'
M*2<&L4\,VVI?0)>%YE1S]U2#[6T0CKI#(&6?)?8^^]]5?Y5[;B%I4O988N^Q
MMD6>V;I4-5[9'(E_U'4NNQQYRRYW36JZG.U1@91MCARMS>6>]TF=9J1>=KL:
MRY?$G;T71N;-Z6<J'WFB4,26@'&[ RB<S%Y&9B=:K--W2 NAM8C3PQ6C(9/&
M *XOA="[$_-:JG@E//D74$L#!!0    ( &%_JE0GYX7$ P,  ),(   9
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;,U6VV[:0!#]E9'5AT1*\(UK!$B!
M]!*I:5%HVH>J#XL]8"OV+MU=0_KWG5T[!A)P^U*I2&#O9<[,.3.[PW KY*-*
M$#4\Y1E7(R?1>GWENBI*,&>J)=;(:64I9,XT#>7*56N)++9&>>8&GM=U<Y9R
M9SRT<S,Y'HI"9RG'F015Y#F3OR:8B>W(\9WGB?MTE6@SX8Z':[;".>J']4S2
MR*U1XC1'KE+!0>)RY%S[5U/?,P9VQ]<4MVKO'0R5A1"/9G ;CQS/1(091MI
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MP> !  #L(   &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=H[3L-
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M_?^DNIS/3=?+7Y;?.T<WU 7G #\W/'X!4$L#!!0    ( &%_JE04U''DT $
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !A?ZI4  58$/     K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !A
M?ZI4F5R<(Q &  "<)P  $P              @ '. 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( &%_JE3V=Y**6@4  '<5   8
M  " @0\(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !A
M?ZI4FKP!3]P&   $'0  &               @(&?#0  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ 87^J5-/RS!Z<!0  X!4  !@
M         ("!L10  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( &%_JE0*ZDL$ZP(  +('   8              " @8,:  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !A?ZI4L(*KXE0'  #$(0
M&               @(&D'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ 87^J5 KLZ\0G @  D@0  !@              ("!+B4  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( &%_JE292GF'"@D
M %,E   8              " @8LG  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " !A?ZI40YFA1K((  #?$@  &               @('+
M,   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 87^J5#K[
M**_/"P  \1\  !@              ("!LSD  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( &%_JE12I\!2& H  $4;   9
M  " @;A%  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
M87^J5.*8B:*M!   H0H  !D              ("!!U   'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " !A?ZI4*W7$JMP"  !J!@  &0
M            @('K5   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( &%_JE2&&%:<_@H  $0[   9              " @?Y7  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 87^J5+ND\%FK P
MBP@  !D              ("!,V,  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " !A?ZI4TEL1IMT*  "H'   &0              @($5
M9P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( &%_JE07
MJ3;2K@8  #(1   9              " @2ER  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ 87^J5%.?$F'T!   " P  !D
M     ("!#GD  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &%_JE1R&59/R ,  "((   9              "
M@9"T  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ 87^J
M5#TEY84M"P  @2<  !D              ("!C[@  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " !A?ZI4/$62Y&0"   W!0  &0
M        @('SPP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( &%_JE1OJGIQ3A0  &([   9              " @8[&  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 87^J5#)HC'*<!0  .A
M !D              ("!$]L  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " !A?ZI4_/-T?*L#   <"   &0              @('FX
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( &%_JE0C4YEO
M. ,   \'   9              " @<CD  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ 87^J5'H/PP*X @  %P8  !D
M ("!-^@  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !A
M?ZI4>=S?IA #  "%!@  &0              @($FZP  >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( &%_JE1!UK$DL0(  )L%   9
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M970S-2YX;6Q02P$"% ,4    " !A?ZI4!L_<].T"  "7"   &0
M    @($(_P  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M &%_JE0)PRA<O@4  )P<   9              " @2P" 0!X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ 87^J5 VDZC=* P  Y D  !D
M             ("!(0@! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    " !A?ZI4M<_9";<'  #V/P  &0              @(&B"P$ >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( &%_JE3#G +3PP0
M 'H7   9              " @9 3 0!X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ 87^J5)7-P\C* @  _@@  !D              ("!
MBA@! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !A?ZI4
MK[;^'X\&  "@'P  &0              @(&+&P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    ( &%_JE1S2S]KC@(  "$&   9
M      " @5$B 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ 87^J5"MERMN9 @  J@<  !D              ("!%B4! 'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " !A?ZI4)CLT(.X"  !C"@
M&0              @('F)P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0    ( &%_JE01_%3"#@4  "X4   9              " @0LK 0!X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ 87^J5*L]<H!\
M P  (0X  !D              ("!4# ! 'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4    " !A?ZI4*MO\]- %  !R'@  &0
M@($#- $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( &%_
MJE1]_QG^4@4  $<6   9              " @0HZ 0!X;"]W;W)K<VAE971S
M+W-H965T-#DN>&UL4$L! A0#%     @ 87^J5$B6)FZ$ P  $ P  !D
M         ("!DS\! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
M    " !A?ZI437=RL'8#   0"P  &0              @(%.0P$ >&PO=V]R
M:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( &%_JE3Z9\BO'0@  ,@O
M   9              " @?M& 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL
M4$L! A0#%     @ 87^J5)WJ+O/9!   'A8  !D              ("!3T\!
M 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " !A?ZI4)^>%
MQ ,#  "3"   &0              @(%?5 $ >&PO=V]R:W-H965T<R]S:&5E
M=#4T+GAM;%!+ 0(4 Q0    ( &%_JE0=\I>UEP(    &   9
M  " @9E7 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @
M87^J5-0=:\Y. P  8A0   T              ( !9UH! 'AL+W-T>6QE<RYX
M;6Q02P$"% ,4    " !A?ZI4EXJ[',     3 @  "P              @ '@
M70$ 7W)E;',O+G)E;'-02P$"% ,4    " !A?ZI4M_'D#90$  #()   #P
M            @ ')7@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 87^J
M5+P!UL'@ 0  ["   !H              ( !BF,! 'AL+U]R96QS+W=O<FMB
M;V]K+GAM;"YR96QS4$L! A0#%     @ 87^J5!34<>30 0  K2   !,
M         ( !HF4! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #\ /P P
)$0  HV<!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>252</ContextCount>
  <ElementCount>301</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>76</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/OrganizationandOperations</Role>
      <ShortName>Organization and Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties</Role>
      <ShortName>Basis of Presentation, Liquidity and Risks and Uncertainties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - Critical Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CriticalAccountingPolicies</Role>
      <ShortName>Critical Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2106104 - Disclosure - Impact of Recently Issued Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards</Role>
      <ShortName>Impact of Recently Issued Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2108105 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2110106 - Disclosure - Short-term Investments and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements</Role>
      <ShortName>Short-term Investments and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2115107 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2119108 - Disclosure - Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebt</Role>
      <ShortName>Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2124109 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2128110 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2131111 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2134112 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2136113 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2140114 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2142115 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2143116 - Disclosure - Geneos Therapeutics, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsInc</Role>
      <ShortName>Geneos Therapeutics, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2147117 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies</Role>
      <ShortName>Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CriticalAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables</Role>
      <ShortName>Short-term Investments and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2316302 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2320303 - Disclosure - Convertible Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtTables</Role>
      <ShortName>Convertible Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ConvertibleDebt</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2325304 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2329305 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/NetLossPerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2332306 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2337307 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CommitmentsandContingencies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2344308 - Disclosure - Geneos Therapeutics, Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncTables</Role>
      <ShortName>Geneos Therapeutics, Inc. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GeneosTherapeuticsInc</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails</Role>
      <ShortName>Basis of Presentation, Liquidity and Risks and Uncertainties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Impact of Recently Issued Accounting Standards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandardsDetails</Role>
      <ShortName>Impact of Recently Issued Accounting Standards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionDetails</Role>
      <ShortName>Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/RevenueRecognition</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Convertible Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtNarrativeDetails</Role>
      <ShortName>Convertible Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Convertible Debt - Balance of Convertible Bonds and Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails</Role>
      <ShortName>Convertible Debt - Balance of Convertible Bonds and Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Convertible Debt - Schedule of Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails</Role>
      <ShortName>Convertible Debt - Schedule of Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2430414 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2433415 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockBasedCompensationTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2435416 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2438417 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2439418 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2441419 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CollaborativeAgreements</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2445420 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2446421 - Disclosure - Geneos Therapeutics, Inc. - Preferred stock Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Preferred stock Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ino-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2448422 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SubsequentEvents</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ino-20220331.htm">ino-20220331.htm</File>
    <File>ino-20220331.xsd</File>
    <File>ino-20220331_cal.xml</File>
    <File>ino-20220331_def.xml</File>
    <File>ino-20220331_lab.xml</File>
    <File>ino-20220331_pre.xml</File>
    <File>ino-3312210qex312.htm</File>
    <File>ino-33122x10qex311.htm</File>
    <File>ino-33122x10qex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ino-20220331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="627">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>73
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ino-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 28,
   "contextCount": 252,
   "dts": {
    "calculationLink": {
     "local": [
      "ino-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ino-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ino-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ino-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ino-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ino-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 504,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 3,
    "http://xbrl.sec.gov/dei/2021q4": 6,
    "total": 9
   },
   "keyCustom": 52,
   "keyStandard": 249,
   "memberCustom": 33,
   "memberStandard": 37,
   "nsprefix": "ino",
   "nsuri": "http://www.inovio.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.inovio.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - Critical Accounting Policies",
     "role": "http://www.inovio.com/role/CriticalAccountingPolicies",
     "shortName": "Critical Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106104 - Disclosure - Impact of Recently Issued Accounting Standards",
     "role": "http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards",
     "shortName": "Impact of Recently Issued Accounting Standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108105 - Disclosure - Revenue Recognition",
     "role": "http://www.inovio.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110106 - Disclosure - Short-term Investments and Fair Value Measurements",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements",
     "shortName": "Short-term Investments and Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115107 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119108 - Disclosure - Convertible Debt",
     "role": "http://www.inovio.com/role/ConvertibleDebt",
     "shortName": "Convertible Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124109 - Disclosure - Stockholders' Equity",
     "role": "http://www.inovio.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128110 - Disclosure - Net Loss Per Share",
     "role": "http://www.inovio.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131111 - Disclosure - Stock-Based Compensation",
     "role": "http://www.inovio.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134112 - Disclosure - Related Party Transactions",
     "role": "http://www.inovio.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "ib30ea824035a4f29b36bdddc9f77f71b_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "ib30ea824035a4f29b36bdddc9f77f71b_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136113 - Disclosure - Commitments and Contingencies",
     "role": "http://www.inovio.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140114 - Disclosure - Collaborative Agreements",
     "role": "http://www.inovio.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142115 - Disclosure - Income Taxes",
     "role": "http://www.inovio.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143116 - Disclosure - Geneos Therapeutics, Inc.",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsInc",
     "shortName": "Geneos Therapeutics, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147117 - Disclosure - Subsequent Events",
     "role": "http://www.inovio.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)",
     "role": "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies",
     "shortName": "Basis of Presentation, Liquidity and Risks and Uncertainties (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311301 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables",
     "shortName": "Short-term Investments and Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316302 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320303 - Disclosure - Convertible Debt (Tables)",
     "role": "http://www.inovio.com/role/ConvertibleDebtTables",
     "shortName": "Convertible Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325304 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.inovio.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329305 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.inovio.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332306 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.inovio.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337307 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344308 - Disclosure - Geneos Therapeutics, Inc. (Tables)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncTables",
     "shortName": "Geneos Therapeutics, Inc. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties (Details)",
     "role": "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
     "shortName": "Basis of Presentation, Liquidity and Risks and Uncertainties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "ib30ea824035a4f29b36bdddc9f77f71b_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Capital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "ib30ea824035a4f29b36bdddc9f77f71b_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Impact of Recently Issued Accounting Standards (Details)",
     "role": "http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandardsDetails",
     "shortName": "Impact of Recently Issued Accounting Standards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i5998790341a8497ba20d32d62e49492c_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredIncomeTaxLiabilitiesNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Revenue Recognition (Details)",
     "role": "http://www.inovio.com/role/RevenueRecognitionDetails",
     "shortName": "Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "ib30ea824035a4f29b36bdddc9f77f71b_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails",
     "shortName": "Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "ib30ea824035a4f29b36bdddc9f77f71b_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
     "shortName": "Short-term Investments and Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "ib30ea824035a4f29b36bdddc9f77f71b_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i02b127be22eb4b9a9750afaa61f1ec0f_I20220331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "ib30ea824035a4f29b36bdddc9f77f71b_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule Goodwill and Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "ib30ea824035a4f29b36bdddc9f77f71b_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "ib30ea824035a4f29b36bdddc9f77f71b_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "ib30ea824035a4f29b36bdddc9f77f71b_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Convertible Debt - Narrative (Details)",
     "role": "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
     "shortName": "Convertible Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i11fba970b3414270a4d7e4804a06e0e9_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "if239e019c41f41df87d6fabeb16a8209_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Convertible Debt - Balance of Convertible Bonds and Notes (Details)",
     "role": "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
     "shortName": "Convertible Debt - Balance of Convertible Bonds and Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "if239e019c41f41df87d6fabeb16a8209_I20220331",
      "decimals": "0",
      "lang": "en-US",
      "name": "ino:DebtInstrumentConvertibleDebtConvertedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "if239e019c41f41df87d6fabeb16a8209_I20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Convertible Debt - Schedule of Maturities (Details)",
     "role": "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
     "shortName": "Convertible Debt - Schedule of Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i89c242d635e34cc2882b5b395b26a546_I20220331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "ib30ea824035a4f29b36bdddc9f77f71b_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)",
     "role": "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails",
     "shortName": "Stockholders' Equity - Summary of Authorized and Issued Common and Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "ib30ea824035a4f29b36bdddc9f77f71b_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i506a7271caec452a979fcd2973d994a3_I20160513",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i506a7271caec452a979fcd2973d994a3_I20160513",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430414 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)",
     "role": "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails",
     "shortName": "Net Loss Per Share - Schedule of Anti-Dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433415 - Disclosure - Stock-Based Compensation (Details)",
     "role": "http://www.inovio.com/role/StockBasedCompensationDetails",
     "shortName": "Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "ib30ea824035a4f29b36bdddc9f77f71b_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435416 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ino:CollaborativeAgreementAmendedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i197e743baebd4a54a1f59b2ead228a4b_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i5c88a6a27b9e44eeba42ab6a651cc57c_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438417 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "ib30ea824035a4f29b36bdddc9f77f71b_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439418 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)",
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails",
     "shortName": "Commitments and Contingencies - Summary of Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "ib30ea824035a4f29b36bdddc9f77f71b_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441419 - Disclosure - Collaborative Agreements (Details)",
     "role": "http://www.inovio.com/role/CollaborativeAgreementsDetails",
     "shortName": "Collaborative Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i2db1017a46a040d6861a567a358dcdd1_D20210101-20210131",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ino:CollaborativeAgreementsUpfrontPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445420 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
     "shortName": "Geneos Therapeutics, Inc. - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "icdd6b2404d2348d6be3af54fee60364d_I20201130",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446421 - Disclosure - Geneos Therapeutics, Inc. - Preferred stock Investment (Details)",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails",
     "shortName": "Geneos Therapeutics, Inc. - Preferred stock Investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i8c076c415b0c4d348c148ffabebaa199_I20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "ic58ffceb77ce4063a7894330d50f5c66_D20220401-20220421",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448422 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.inovio.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "ic58ffceb77ce4063a7894330d50f5c66_D20220401-20220421",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i0553862169f645a6b3b2aa0590bb8662_D20210101-20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Operations",
     "role": "http://www.inovio.com/role/OrganizationandOperations",
     "shortName": "Organization and Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Basis of Presentation, Liquidity and Risks and Uncertainties",
     "role": "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties",
     "shortName": "Basis of Presentation, Liquidity and Risks and Uncertainties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20220331.htm",
      "contextRef": "i57d2bddd4afb4efc9acb228ff1077bf7_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 76,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ino_A2007IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2007 Incentive Plan [Member]",
        "label": "2007 Incentive Plan [Member]",
        "terseLabel": "2007 Incentive Plan"
       }
      }
     },
     "localname": "A2007IncentivePlanMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_A2016IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Incentive Plan [Member]",
        "label": "2016 Incentive Plan [Member]",
        "terseLabel": "2016 Incentive Plan"
       }
      }
     },
     "localname": "A2016IncentivePlanMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_A6.50ConvertibleSeniorNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "label": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "A6.50ConvertibleSeniorNotesDue2024Member",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AccruedClinicalTrialExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trial Expense, Current",
        "label": "Accrued Clinical Trial Expense, Current",
        "verboseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpenseCurrent",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_AdvaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advaccine",
        "label": "Advaccine [Member]",
        "terseLabel": "Advaccine"
       }
      }
     },
     "localname": "AdvaccineMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AnnualMaintenancePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Maintenance Period",
        "label": "Annual Maintenance Period",
        "terseLabel": "Annual maintenance period"
       }
      }
     },
     "localname": "AnnualMaintenancePeriod",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_ApolloBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ApolloBio [Member]",
        "label": "ApolloBio [Member]",
        "terseLabel": "ApolloBio"
       }
      }
     },
     "localname": "ApolloBioMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_BillAndMelindaGatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bill And Melinda Gates Foundation [Member]",
        "label": "Bill And Melinda Gates Foundation [Member]",
        "terseLabel": "Bill and Melinda Gates Foundation"
       }
      }
     },
     "localname": "BillAndMelindaGatesFoundationMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_BiojectMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bioject [Member]",
        "label": "Bioject [Member]",
        "terseLabel": "Bioject"
       }
      }
     },
     "localname": "BiojectMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CELLECTRA2000DeviceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CELLECTRA 2000 Device [Member]",
        "label": "CELLECTRA 2000 Device [Member]",
        "terseLabel": "CELLECTRA 2000 Device"
       }
      }
     },
     "localname": "CELLECTRA2000DeviceMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CELLECTRA3PSPProprietarySmartDeviceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CELLECTRA 3PSP Proprietary Smart Device [Member]",
        "label": "CELLECTRA 3PSP Proprietary Smart Device [Member]",
        "terseLabel": "CELLECTRA 3PSP Proprietary Smart Device"
       }
      }
     },
     "localname": "CELLECTRA3PSPProprietarySmartDeviceMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ChangeInValueOfInvestmentsInAffiliatedCompany": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.",
        "label": "Change in Value of Investments in Affiliated Company",
        "negatedLabel": "Loss on equity investment in affiliated entities",
        "verboseLabel": "Loss on investment in affiliated entities"
       }
      }
     },
     "localname": "ChangeInValueOfInvestmentsInAffiliatedCompany",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CoalitionforEpidemicPreparednessInnovationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coalition for Epidemic Preparedness Innovations [Member]",
        "label": "Coalition for Epidemic Preparedness Innovations [Member]",
        "terseLabel": "Coalition for Epidemic Preparedness Innovations"
       }
      }
     },
     "localname": "CoalitionforEpidemicPreparednessInnovationsMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CollaborationAgreementAdditionalRevenueToBeAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "label": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "terseLabel": "Additional revenue to be achieved"
       }
      }
     },
     "localname": "CollaborationAgreementAdditionalRevenueToBeAchieved",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementPaymentEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Payment Earned",
        "label": "Collaboration Agreement, Payment Earned",
        "terseLabel": "Collaboration agreement, payment earned"
       }
      }
     },
     "localname": "CollaborationAgreementPaymentEarned",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementRoyaltyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Royalty Period",
        "label": "Collaboration Agreement, Royalty Period",
        "terseLabel": "Royalty period"
       }
      }
     },
     "localname": "CollaborationAgreementRoyaltyPeriod",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementAmendedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Amended Amount",
        "label": "Collaborative Agreement, Amended Amount",
        "terseLabel": "Collaborative agreement, amended amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAmendedAmount",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementAwardedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Awarded Amount",
        "label": "Collaborative Agreement, Awarded Amount",
        "terseLabel": "Awarded amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAwardedAmount",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementAwardedExercisedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Awarded Exercised Amount",
        "label": "Collaborative Agreement, Awarded Exercised Amount",
        "terseLabel": "Collaborative agreement, awarded exercised amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAwardedExercisedAmount",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementAwardedOptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Awarded Option Amount",
        "label": "Collaborative Agreement, Awarded Option Amount",
        "terseLabel": "Awarded option amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAwardedOptionAmount",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementExpensesToReimburse": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Expenses To Reimburse",
        "label": "Collaborative Agreement, Expenses To Reimburse",
        "terseLabel": "Expenses to reimburse"
       }
      }
     },
     "localname": "CollaborativeAgreementExpensesToReimburse",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementFundingReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Funding Received",
        "label": "Collaborative Agreement, Funding Received",
        "verboseLabel": "Funding received for research and development"
       }
      }
     },
     "localname": "CollaborativeAgreementFundingReceived",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementFundingToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Funding Received for Research and Development",
        "label": "Collaborative Agreement, Funding To Be Received",
        "terseLabel": "Collaborative agreement, funding to be received"
       }
      }
     },
     "localname": "CollaborativeAgreementFundingToBeReceived",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Number of Days Written Notice Before Termination",
        "label": "Collaborative Agreement, Number of Days Written Notice Before Termination",
        "terseLabel": "Number of days written notice before termination"
       }
      }
     },
     "localname": "CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Period From Effective Date For Termination",
        "label": "Collaborative Agreement, Period From Effective Date For Termination",
        "terseLabel": "Period from effective date for termination"
       }
      }
     },
     "localname": "CollaborativeAgreementPeriodFromEffectiveDateForTermination",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "label": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "terseLabel": "Collaborative agreement, period to receive funding for research and development"
       }
      }
     },
     "localname": "CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementsUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreements, Upfront Payment Received",
        "label": "Collaborative Agreements, Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "CollaborativeAgreementsUpfrontPaymentReceived",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementFixedPriceContractAmountAwarded": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded",
        "label": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded",
        "terseLabel": "Purchase price, procurement contract"
       }
      }
     },
     "localname": "CollaborativeArrangementFixedPriceContractAmountAwarded",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementRevenueFromTheProcurementContract": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement , Revenue from the Procurement Contract",
        "label": "Collaborative Arrangement , Revenue from the Procurement Contract",
        "terseLabel": "Collaborative arrangement , revenue from the procurement contract"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueFromTheProcurementContract",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Term",
        "label": "Collaborative Arrangement, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "CollaborativeArrangementTerm",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_DNAEncodedMonoclonalAntibodyTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DNA-Encoded Monoclonal Antibody Technology [Member]",
        "label": "DNA-Encoded Monoclonal Antibody Technology [Member]",
        "terseLabel": "DNA-Encoded Monoclonal Antibody Technology"
       }
      }
     },
     "localname": "DNAEncodedMonoclonalAntibodyTechnologyMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DebtInstrumentAccruedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Accrued Interest",
        "label": "Debt Instrument, Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "DebtInstrumentAccruedInterest",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DebtInstrumentConvertibleDebtConvertedAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible Debt, Converted Amount",
        "label": "Debt Instrument, Convertible Debt, Converted Amount",
        "negatedTerseLabel": "Principal amount converted into common shares"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleDebtConvertedAmount",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DebtSecuritiesAvailableforSaleContractualMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale contractual maturity.",
        "label": "Debt Securities, Available-for-Sale Contractual Maturity",
        "terseLabel": "Contractual Maturity\u00a0(in\u00a0years)"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforSaleContractualMaturity",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_December2019ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2019 Convertible Bonds [Member]",
        "label": "December 2019 Convertible Bonds [Member]",
        "terseLabel": "December 2019 Bonds"
       }
      }
     },
     "localname": "December2019ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, Current",
        "label": "Deferred Grant Funding, Current",
        "terseLabel": "Grant funding liability"
       }
      }
     },
     "localname": "DeferredGrantFundingCurrent",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate",
        "label": "Deferred Grant Funding, From Affiliate",
        "terseLabel": "Deferred grant funding, from affiliate"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliate",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate, Current",
        "label": "Deferred Grant Funding, From Affiliate, Current",
        "terseLabel": "Grant funding liability from affiliated entity"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliateCurrent",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DepartmentOfDefenceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Department Of Defence [Member]",
        "label": "Department Of Defence [Member]",
        "terseLabel": "Department of Defence"
       }
      }
     },
     "localname": "DepartmentOfDefenceMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_EmployeesAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and Directors [Member]",
        "label": "Employees and Directors [Member]",
        "terseLabel": "Employees and Directors"
       }
      }
     },
     "localname": "EmployeesAndDirectorsMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Estimated aggregate amortization expense for 2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GainLossOnRemeasurementOfEquityMethodInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Remeasurement Of Equity Method Investment",
        "label": "Gain (Loss) On Remeasurement Of Equity Method Investment",
        "negatedTerseLabel": "Gain on remeasurement of investment in Geneos"
       }
      }
     },
     "localname": "GainLossOnRemeasurementOfEquityMethodInvestment",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GeneosTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geneos Therapeutics, Inc. [Member]",
        "label": "Geneos Therapeutics, Inc. [Member]",
        "terseLabel": "Geneos Therapeutics, Inc."
       }
      }
     },
     "localname": "GeneosTherapeuticsInc.Member",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_GoodwillAndIntangibleAssetsGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and intangible assets gross.",
        "label": "Goodwill and Intangible Assets Gross",
        "totalLabel": "Total goodwill and intangible assets, Gross"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGross",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GoodwillAndIntangibleAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and intangible assets net.",
        "label": "Goodwill and Intangible Assets Net",
        "totalLabel": "Total goodwill and intangible assets, Net Book Value"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsNet",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GrantProceedsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Proceeds Received",
        "label": "Grant Proceeds Received",
        "terseLabel": "Contra-research and development expense"
       }
      }
     },
     "localname": "GrantProceedsReceived",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_INO4800Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "INO-4800 [Member]",
        "label": "INO-4800 [Member]",
        "terseLabel": "INO-4800"
       }
      }
     },
     "localname": "INO4800Member",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) From Equity Method Investments, Realized And Allocated to Investment",
        "label": "Income (Loss) From Equity Method Investments, Realized And Allocated to Investment",
        "negatedLabel": "Loss from equity method investment, recorded and allocated to investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInAccruedClinicalTrialExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "label": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedClinicalTrialExpense",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "terseLabel": "Operating lease right-of-use assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseinDeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Deferred Grant Funding, Current",
        "label": "Increase (Decrease) in Deferred Grant Funding, Current",
        "terseLabel": "Grant funding liability, including from affiliated entity"
       }
      }
     },
     "localname": "IncreaseDecreaseinDeferredGrantFundingCurrent",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_InitialConversionPriceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Conversion Price [Member]",
        "label": "Initial Conversion Price [Member]",
        "terseLabel": "Initial Conversion Price"
       }
      }
     },
     "localname": "InitialConversionPriceMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_LassaFeverAndMERSVaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lassa Fever And MERS Vaccine [Member]",
        "label": "Lassa Fever And MERS Vaccine [Member]",
        "terseLabel": "Lassa Fever and MERS Vaccine"
       }
      }
     },
     "localname": "LassaFeverAndMERSVaccineMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_LesseeOperatingLeaseAreaofLandUnderLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Area of Land Under Lease",
        "label": "Lessee, Operating Lease, Area of Land Under Lease",
        "terseLabel": "Area leased (in square feet)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAreaofLandUnderLease",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "ino_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_LesseeOperatingLeaseNumberOfAgreementsToSublease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Agreements To Sublease",
        "label": "Lessee, Operating Lease, Number Of Agreements To Sublease",
        "terseLabel": "Number of agreements"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfAgreementsToSublease",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ino_LicensewithAffiliatedEntitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License with Affiliated Entities [Member]",
        "label": "License with Affiliated Entities [Member]",
        "terseLabel": "Revenue under collaborative research and development arrangements with affiliated entities"
       }
      }
     },
     "localname": "LicensewithAffiliatedEntitiesMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_MutualFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mutual funds.",
        "label": "Mutual Funds [Member]",
        "verboseLabel": "Mutual funds"
       }
      }
     },
     "localname": "MutualFundsMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NonCashInterestIncomeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Interest Income (Expense)",
        "label": "Non-Cash Interest Income (Expense)",
        "negatedTerseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestIncomeExpense",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_NonEmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non employee.",
        "label": "Non Employee [Member]",
        "terseLabel": "Non Employee"
       }
      }
     },
     "localname": "NonEmployeeMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of potential shares authorized for issuance under a share-based compensation plan.",
        "label": "Number Of Potential Shares Authorized For Issuance Under Share Based Compensation Plan",
        "terseLabel": "Number of potential shares authorized for issuance under share based compensation plan (in shares)"
       }
      }
     },
     "localname": "NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_OtherCounterpartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Counterparty [Member]",
        "label": "Other Counterparty [Member]",
        "terseLabel": "Other Counterparty"
       }
      }
     },
     "localname": "OtherCounterpartyMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PlumblineLifeSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plumbline Life Sciences [Member]",
        "label": "Plumbline Life Sciences [Member]",
        "terseLabel": "Plumbline Life Sciences"
       }
      }
     },
     "localname": "PlumblineLifeSciencesMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PlymouthMeetingPennsylvaniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plymouth Meeting, Pennsylvania [Member]",
        "label": "Plymouth Meeting, Pennsylvania [Member]",
        "terseLabel": "Plymouth Meeting, Pennsylvania"
       }
      }
     },
     "localname": "PlymouthMeetingPennsylvaniaMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.",
        "label": "Prepaid Expenses and Other Current Assets from Affiliated Entity",
        "verboseLabel": "Prepaid expenses and other current assets from affiliated entities"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_RelatedPartyTransactionsTextualAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transactions.",
        "label": "Related Party Transactions (Textual) [Abstract]",
        "verboseLabel": "Related-Party Transactions (Textual) [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsTextualAbstract",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ino_RisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks and Uncertainties",
        "label": "Risks and Uncertainties [Policy Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ino_SARSCoV2COVID19VaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SARS-CoV-2/COVID-19 Vaccine [Member]",
        "label": "SARS-CoV-2/COVID-19 Vaccine [Member]",
        "terseLabel": "SARS-CoV-2/COVID-19 Vaccine"
       }
      }
     },
     "localname": "SARSCoV2COVID19VaccineMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Sales Proceeds of Any Common Stock, Percentage",
        "label": "Sale of Stock, Sales Proceeds of Any Common Stock, Percentage",
        "terseLabel": "Sale of stock, sales proceeds of any common stock, percentage"
       }
      }
     },
     "localname": "SaleOfStockSalesProceedsOfAnyCommonStockPercentage",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ino_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Agreement",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SalesAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Agreements [Member]",
        "label": "Sales Agreements [Member]",
        "terseLabel": "Sales Agreements"
       }
      }
     },
     "localname": "SalesAgreementsMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SanDiegoOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "San Diego Office [Member]",
        "label": "San Diego Office [Member]",
        "terseLabel": "San Diego, California"
       }
      }
     },
     "localname": "SanDiegoOfficeMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SeriesA2OnePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-2 One Preferred Stock",
        "label": "Series A-2 One Preferred Stock [Member]",
        "terseLabel": "Series A-2 One Preferred Stock"
       }
      }
     },
     "localname": "SeriesA2OnePreferredStockMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SeriesAOnePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A One Preferred Stock [Member]",
        "label": "Series A One Preferred Stock [Member]",
        "terseLabel": "Series A One Preferred Stock"
       }
      }
     },
     "localname": "SeriesAOnePreferredStockMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ServiceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service-Based Restricted Stock Units",
        "label": "Service-Based Restricted Stock Units [Member]",
        "verboseLabel": "Service-based restricted stock units"
       }
      }
     },
     "localname": "ServiceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value",
        "terseLabel": "Grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award maximum contractual term.",
        "label": "Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term",
        "terseLabel": "Maximum contractual term (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized",
        "terseLabel": "Increase in number of shares authorized (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement, Commitment Of Additional Investment",
        "label": "Stock Purchase Agreement, Commitment Of Additional Investment",
        "terseLabel": "Stock purchase agreement, commitment of additional investment"
       }
      }
     },
     "localname": "StockPurchaseAgreementCommitmentOfAdditionalInvestment",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSaleAgreementAggregateNumberofSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "label": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "terseLabel": "Aggregate number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockSaleAgreementAggregateNumberofSharesIssued",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "label": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "terseLabel": "Aggregate proceeds"
       }
      }
     },
     "localname": "StockSaleAgreementAggregateProceedsFromIssuanceOfStock",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSaleAgreementWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement Weighted Average Price Per Share",
        "label": "Stock Sale Agreement, Weighted Average Price Per Share",
        "terseLabel": "Stock sale agreement weighted average price (in dollars per share)"
       }
      }
     },
     "localname": "StockSaleAgreementWeightedAveragePricePerShare",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ino_StockSalesAgreementMaximumAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sales Agreement, Maximum Authorized Amount",
        "label": "Stock Sales Agreement, Maximum Authorized Amount",
        "terseLabel": "Maximum authorized amount"
       }
      }
     },
     "localname": "StockSalesAgreementMaximumAuthorizedAmount",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSalesAgreementRemainingAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sales Agreement, Remaining Authorized Amount",
        "label": "Stock Sales Agreement, Remaining Authorized Amount",
        "terseLabel": "Remaining authorized amount"
       }
      }
     },
     "localname": "StockSalesAgreementRemainingAuthorizedAmount",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TheWistarInstituteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Wistar Institute [Member]",
        "label": "The Wistar Institute [Member]",
        "terseLabel": "The Wistar Institute"
       }
      }
     },
     "localname": "TheWistarInstituteMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten Public Offering [Member]",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://www.inovio.com/20220331",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r49",
      "r51",
      "r107",
      "r108",
      "r267",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r114",
      "r125",
      "r131",
      "r205",
      "r394",
      "r395",
      "r396",
      "r412",
      "r413",
      "r444",
      "r447",
      "r450",
      "r451",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r114",
      "r125",
      "r131",
      "r205",
      "r394",
      "r395",
      "r396",
      "r412",
      "r413",
      "r444",
      "r447",
      "r450",
      "r451",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r114",
      "r125",
      "r131",
      "r205",
      "r394",
      "r395",
      "r396",
      "r412",
      "r413",
      "r444",
      "r447",
      "r450",
      "r451",
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r173",
      "r341",
      "r347",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r266",
      "r306",
      "r367",
      "r368",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r548",
      "r613",
      "r616",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r266",
      "r306",
      "r367",
      "r368",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r548",
      "r613",
      "r616",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r173",
      "r341",
      "r347",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r171",
      "r341",
      "r345",
      "r551",
      "r612",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r171",
      "r341",
      "r345",
      "r551",
      "r612",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r266",
      "r306",
      "r357",
      "r367",
      "r368",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r548",
      "r613",
      "r616",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r266",
      "r306",
      "r357",
      "r367",
      "r368",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r548",
      "r613",
      "r616",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r50",
      "r51",
      "r107",
      "r108",
      "r267",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r174",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual with Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r524",
      "r526",
      "r529",
      "r658",
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average Useful Life (Yrs)"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "auth_ref": [
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.",
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "Accounting Standards Update 2020-06"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202006Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r117",
      "r118",
      "r119",
      "r121",
      "r178",
      "r179",
      "r202",
      "r203",
      "r204",
      "r205",
      "r208",
      "r209",
      "r248",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r412",
      "r413",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r452",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r472",
      "r473",
      "r501",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r22",
      "r596",
      "r647"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r9",
      "r22",
      "r175",
      "r176"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedParties": {
     "auth_ref": [
      "r21",
      "r105",
      "r506",
      "r509",
      "r603"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.",
        "label": "Accounts Receivable, Related Parties",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r45",
      "r105",
      "r506",
      "r509"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable, Related Parties, Current",
        "terseLabel": "Accounts receivable from affiliated entities"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r55",
      "r56",
      "r57",
      "r600",
      "r624",
      "r628"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r54",
      "r57",
      "r62",
      "r63",
      "r64",
      "r111",
      "r112",
      "r113",
      "r432",
      "r619",
      "r620",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r23",
      "r398",
      "r514"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "negatedLabel": "Additional paid-in capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r394",
      "r395",
      "r396",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r117",
      "r118",
      "r119",
      "r121",
      "r131",
      "r178",
      "r179",
      "r202",
      "r203",
      "r204",
      "r205",
      "r208",
      "r209",
      "r248",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r410",
      "r411",
      "r412",
      "r413",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r452",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r472",
      "r473",
      "r501",
      "r553",
      "r554",
      "r555",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r369",
      "r371",
      "r401",
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r371",
      "r386",
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Allocated share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r90",
      "r227",
      "r233"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Aggregate amortization expense on intangible assets",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r103",
      "r159",
      "r163",
      "r169",
      "r200",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r430",
      "r436",
      "r462",
      "r512",
      "r514",
      "r574",
      "r598"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r48",
      "r103",
      "r200",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r430",
      "r436",
      "r462",
      "r512",
      "r514"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r453"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "verboseLabel": "Gross\u00a0Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r186"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross\u00a0Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r183",
      "r215"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "verboseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r182",
      "r184",
      "r215",
      "r580"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair\u00a0Market\u00a0Value",
        "verboseLabel": "Debt securities, available for sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-sale Securities [Member]",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r373",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r7",
      "r110",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Basis of Presentation, Liquidity and Risks and Uncertainties"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertainties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Capital": {
     "auth_ref": [
      "r594"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of total capital as defined by regulatory framework.",
        "label": "Banking Regulation, Total Capital, Actual",
        "terseLabel": "Working capital"
       }
      }
     },
     "localname": "Capital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r94",
      "r95",
      "r96"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Amounts accrued for purchases of fixed assets"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r8",
      "r31",
      "r92"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r86",
      "r92",
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r86",
      "r478"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r100",
      "r103",
      "r136",
      "r137",
      "r138",
      "r140",
      "r142",
      "r150",
      "r151",
      "r152",
      "r200",
      "r249",
      "r254",
      "r255",
      "r256",
      "r260",
      "r261",
      "r304",
      "r305",
      "r309",
      "r313",
      "r462",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]",
        "verboseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaboration Agreements and Revenue Recognition"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r423",
      "r424",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Product"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r111",
      "r112",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "verboseLabel": "Summary of common and preferred stock authorized, issued and outstanding"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.",
        "label": "Common Stock, Other Shares, Outstanding",
        "terseLabel": "Common stock, other shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockOtherSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20",
      "r514"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r59",
      "r61",
      "r68",
      "r429",
      "r438",
      "r585",
      "r609"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r330",
      "r331",
      "r342"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r330",
      "r331",
      "r342"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "verboseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized from deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r17",
      "r576",
      "r599"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r262",
      "r263",
      "r264",
      "r266",
      "r276",
      "r277",
      "r278",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r295",
      "r296",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "verboseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r304",
      "r305",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostMaintenance": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered.",
        "label": "Cost, Maintenance",
        "terseLabel": "Annual maintenance fee"
       }
      }
     },
     "localname": "CostMaintenance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionByUniqueDescriptionAxis": {
     "auth_ref": [
      "r94",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.",
        "label": "Debt Conversion Description [Axis]",
        "terseLabel": "Debt Conversion Description [Axis]"
       }
      }
     },
     "localname": "DebtConversionByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r94",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Debt conversion, converted instrument, shares issued (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionNameDomain": {
     "auth_ref": [
      "r94",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Name [Domain]",
        "terseLabel": "Debt Conversion, Name [Domain]"
       }
      }
     },
     "localname": "DebtConversionNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r99",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r280",
      "r287",
      "r288",
      "r290",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r14",
      "r16",
      "r17",
      "r102",
      "r109",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r295",
      "r296",
      "r297",
      "r298",
      "r490",
      "r575",
      "r576",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r265",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt instrument, convertible conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r39",
      "r265",
      "r321",
      "r324",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt instrument, convertible, conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Debt instrument, convertible, threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Debt instrument, convertible, threshold percentage of stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Debt instrument, convertible, threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r263",
      "r295",
      "r296",
      "r488",
      "r490",
      "r491"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Original principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r38",
      "r293",
      "r488",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument, effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r38",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r40",
      "r102",
      "r109",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r295",
      "r296",
      "r297",
      "r298",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Debt instrument, redemption price percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r40",
      "r102",
      "r109",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r289",
      "r295",
      "r296",
      "r297",
      "r298",
      "r321",
      "r325",
      "r326",
      "r327",
      "r487",
      "r488",
      "r490",
      "r491",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r276",
      "r487",
      "r491"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "terseLabel": "Debt instrument, unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Number of securities in a gross unrealized loss position for more than twelve months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r192"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Realized gain on investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "terseLabel": "Realized loss on investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r189",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of securities in a gross unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "auth_ref": [
      "r434"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "verboseLabel": "Gain on deconsolidation of investment"
       }
      }
     },
     "localname": "DeconsolidationGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount": {
     "auth_ref": [
      "r435"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.",
        "label": "Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount",
        "terseLabel": "Remeasurement of Geneos Series A-1 preferred stock"
       }
      }
     },
     "localname": "DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r33",
      "r276",
      "r489"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedTerseLabel": "Unamortized debt issuance cost",
        "terseLabel": "Unamortized debt issuance cost"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r405",
      "r406"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r90",
      "r237"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r341",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r34",
      "r105",
      "r252",
      "r254",
      "r255",
      "r259",
      "r260",
      "r261",
      "r506"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "verboseLabel": "Accounts payable and accrued expenses due to affiliated entities"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r105",
      "r252",
      "r254",
      "r255",
      "r259",
      "r260",
      "r261",
      "r506",
      "r582",
      "r606"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Accounts payable/accrued liabilities"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r69",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r134",
      "r136",
      "r140",
      "r141",
      "r142",
      "r146",
      "r147",
      "r451",
      "r452",
      "r586",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r69",
      "r123",
      "r124",
      "r125",
      "r126",
      "r127",
      "r136",
      "r140",
      "r141",
      "r142",
      "r146",
      "r147",
      "r451",
      "r452",
      "r586",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r478"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost related to unvested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period over which total unrecognized compensation cost related to unvested stock options will be recognized (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails",
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r62",
      "r63",
      "r64",
      "r111",
      "r112",
      "r113",
      "r118",
      "r128",
      "r130",
      "r149",
      "r205",
      "r320",
      "r328",
      "r394",
      "r395",
      "r396",
      "r412",
      "r413",
      "r450",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r619",
      "r620",
      "r621",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r32",
      "r160",
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "verboseLabel": "Investment in equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Schedule of Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Investment in affiliated entity"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "auth_ref": [
      "r459"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "verboseLabel": "Investment in affiliated entity"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r197",
      "r611"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Net unrealized loss on available-for-sale equity securities",
        "terseLabel": "Net unrealized loss on available-for-sale equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "auth_ref": [
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "verboseLabel": "Unrealized loss"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r453",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r278",
      "r295",
      "r296",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r454",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r453",
      "r454",
      "r455",
      "r456",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Short-term Investments and Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r278",
      "r358",
      "r359",
      "r364",
      "r366",
      "r454",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "verboseLabel": "Quoted Prices in Active Markets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r278",
      "r295",
      "r296",
      "r358",
      "r359",
      "r364",
      "r366",
      "r454",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Unobservable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r278",
      "r295",
      "r296",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r454",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r278",
      "r295",
      "r296",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r521",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r187",
      "r188",
      "r194",
      "r195",
      "r196",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r217",
      "r218",
      "r219",
      "r220",
      "r289",
      "r318",
      "r440",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]",
        "verboseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "verboseLabel": "Financial assets and liabilities that are measured at fair value on recurring basis"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Intangible assets, Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Estimated aggregate amortization expense for 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Estimated aggregate amortization expense for remainder of 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "Estimated aggregate amortization expense for 2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "Estimated aggregate amortization expense for 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "Estimated aggregate amortization expense for 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r228",
      "r229",
      "r232",
      "r235",
      "r552",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r232",
      "r559"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Intangible assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r228",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r232",
      "r552"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Intangible assets, Net Book Value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Indefinite lived:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r474",
      "r475",
      "r476",
      "r477"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Unrealized transaction loss on foreign-currency denominated debt"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherInvestments": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) included in earnings for investments classified as other.",
        "label": "Gain (Loss) on Sale of Other Investments",
        "negatedTerseLabel": "Loss on short-term investments"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r221",
      "r222",
      "r514",
      "r573"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "totalLabel": "Goodwill, net book value",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillGross": {
     "auth_ref": [
      "r223",
      "r224"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Goodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Gross",
        "verboseLabel": "Goodwill, gross"
       }
      }
     },
     "localname": "GoodwillGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Deferred grant funding, from affiliate"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r159",
      "r162",
      "r165",
      "r168",
      "r170"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before share in net loss of Geneos"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r66",
      "r90",
      "r158",
      "r198",
      "r583",
      "r607"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "Share of net loss in Geneos",
        "terseLabel": "Share in net loss of Geneos",
        "verboseLabel": "Share in current and accumulated net loss of Geneos for the three months ended March 31, 2022"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r104",
      "r407",
      "r408",
      "r409",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Payable, Related Parties",
        "verboseLabel": "Accounts payable and accrued expenses due to affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, including from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r89",
      "r549"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue, including from affiliated entity"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets, including from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Definite lived:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.",
        "label": "Debt Security Category [Axis]",
        "terseLabel": "Debt Security Category [Axis]"
       }
      }
     },
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r226",
      "r230"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Schedule of intangible assets by major asset class"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r65",
      "r157",
      "r486",
      "r489",
      "r587"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r75",
      "r284",
      "r294",
      "r297",
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense, contractual interest"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r85",
      "r87",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeAmortizationOfPremium": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization of purchase premium on nonoperating securities.",
        "label": "Investment Income, Amortization of Premium",
        "terseLabel": "Amortization of premiums on investments"
       }
      }
     },
     "localname": "InvestmentIncomeAmortizationOfPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r629",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Investment owned (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r630",
      "r631",
      "r632",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r630",
      "r631",
      "r632",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r193",
      "r572",
      "r589",
      "r646",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Short-term Investments and Fair Value Measurements"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r498",
      "r500"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total remaining lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r499"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease, remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36",
      "r103",
      "r164",
      "r200",
      "r249",
      "r250",
      "r251",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r431",
      "r436",
      "r437",
      "r462",
      "r512",
      "r513"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r103",
      "r200",
      "r462",
      "r514",
      "r577",
      "r602"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r37",
      "r103",
      "r200",
      "r249",
      "r250",
      "r251",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r431",
      "r436",
      "r437",
      "r462",
      "r512",
      "r513",
      "r514"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Revenue under collaborative research and development arrangements"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "verboseLabel": "Licenses"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r17",
      "r277",
      "r291",
      "r295",
      "r296",
      "r576",
      "r599"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceofConvertibleBondsandNotesDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r109",
      "r246",
      "r282"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r109",
      "r246",
      "r282"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r109",
      "r246",
      "r282"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r40",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Noncontrolling interest, ownership percentage by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r46",
      "r73",
      "r428",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities collateralized by real estate mortgage loans (mortgages), issued by US Government Sponsored Enterprises, such as Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac).",
        "label": "Mortgage-backed Securities, Issued by US Government Sponsored Enterprises [Member]",
        "terseLabel": "U.S. agency mortgage-backed securities"
       }
      }
     },
     "localname": "MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r153",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Organization and Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/OrganizationandOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r86",
      "r88",
      "r91"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r6",
      "r58",
      "r60",
      "r64",
      "r67",
      "r91",
      "r103",
      "r117",
      "r123",
      "r124",
      "r125",
      "r126",
      "r129",
      "r130",
      "r139",
      "r159",
      "r162",
      "r165",
      "r168",
      "r170",
      "r200",
      "r249",
      "r250",
      "r251",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r452",
      "r462",
      "r584",
      "r608"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r5",
      "r115",
      "r116",
      "r119",
      "r120",
      "r131",
      "r132",
      "r133",
      "r180",
      "r181",
      "r206",
      "r207",
      "r352",
      "r353",
      "r354",
      "r355",
      "r397",
      "r414",
      "r415",
      "r416",
      "r448",
      "r469",
      "r470",
      "r471",
      "r502",
      "r556",
      "r557",
      "r558",
      "r623",
      "r624",
      "r625",
      "r626",
      "r628",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Impact of Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r114",
      "r117",
      "r118",
      "r119",
      "r121",
      "r122",
      "r125",
      "r131",
      "r146",
      "r178",
      "r179",
      "r202",
      "r203",
      "r204",
      "r205",
      "r208",
      "r209",
      "r248",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r410",
      "r411",
      "r412",
      "r413",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r452",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r472",
      "r473",
      "r501",
      "r553",
      "r554",
      "r555",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Impact of Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]",
        "terseLabel": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r159",
      "r162",
      "r165",
      "r168",
      "r170"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r493"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "netLabel": "Long-term operating lease liabilities",
        "terseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r492"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r497",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r496",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r7",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Geneos Therapeutics, Inc."
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r53",
      "r55"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on short-term investments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income.",
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "negatedTerseLabel": "Investment in Geneos",
        "terseLabel": "Payments to acquire additional interest in subsidiaries"
       }
      }
     },
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of capital assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r373",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r19",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r19",
      "r514"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r10",
      "r29",
      "r30"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "auth_ref": [
      "r581",
      "r605"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.",
        "label": "Prepaid Expense",
        "terseLabel": "Prepaid balance"
       }
      }
     },
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "verboseLabel": "Proceeds from issuance of stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from sale of stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "verboseLabel": "Proceeds from sale or maturity of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r81",
      "r389"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other revenue"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r238",
      "r514",
      "r590",
      "r604"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Fixed assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r365",
      "r505",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Due from (to) Related Party [Abstract]",
        "terseLabel": "Related Party Transaction, Due from (to) Related Party [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedPartyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r505"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "verboseLabel": "Operating expenses related to affiliated entity"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r365",
      "r505",
      "r509",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r503",
      "r504",
      "r506",
      "r510",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r404",
      "r550",
      "r660"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses - Clinical Trial Accruals"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Performance-based restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails",
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r328",
      "r398",
      "r514",
      "r601",
      "r623",
      "r628"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "netLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r111",
      "r112",
      "r113",
      "r118",
      "r128",
      "r130",
      "r205",
      "r394",
      "r395",
      "r396",
      "r412",
      "r413",
      "r450",
      "r619",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r155",
      "r156",
      "r161",
      "r166",
      "r167",
      "r171",
      "r172",
      "r173",
      "r340",
      "r341",
      "r551"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Revenues",
        "terseLabel": "Revenue from related parties",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/RevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r344",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareScheduleofAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "verboseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Summary of Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Summary of Intangible Assets by Major Asset Class"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r507",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r373",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Weighted Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r42",
      "r100",
      "r150",
      "r151",
      "r300",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r313",
      "r318",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r301",
      "r302",
      "r303",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "verboseLabel": "Schedule of Summary of Common and Preferred Stock Authorized, Issued and Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series C Preferred Stock [Member]",
        "verboseLabel": "Series C Preferred Stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, restricted stock units (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Number of shares of unvested restricted stock units and options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r370",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r381",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r15",
      "r578",
      "r579",
      "r597"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r98",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Critical Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CriticalAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r100",
      "r103",
      "r136",
      "r137",
      "r138",
      "r140",
      "r142",
      "r150",
      "r151",
      "r152",
      "r200",
      "r249",
      "r254",
      "r255",
      "r256",
      "r260",
      "r261",
      "r304",
      "r305",
      "r309",
      "r313",
      "r320",
      "r462",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredstockInvestmentDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofAuthorizedandIssuedCommonandPreferredStockDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r44",
      "r62",
      "r63",
      "r64",
      "r111",
      "r112",
      "r113",
      "r118",
      "r128",
      "r130",
      "r149",
      "r205",
      "r320",
      "r328",
      "r394",
      "r395",
      "r396",
      "r412",
      "r413",
      "r450",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r619",
      "r620",
      "r621",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r149",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r43",
      "r281",
      "r320",
      "r321",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of December 2019 Bonds to common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r320",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock for cash, net of financing costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r320",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options for cash and vesting of RSUs, net of tax payments (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r44",
      "r320",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of December 2019 Bonds to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "auth_ref": [
      "r44",
      "r320",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "terseLabel": "Conversion of carrying value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r320",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock for cash, net of financing costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r328",
      "r372",
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options for cash and vesting of RSUs, net of tax payments"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r26",
      "r27",
      "r103",
      "r177",
      "r200",
      "r462",
      "r514"
     ],
     "calculation": {
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total Inovio Pharmaceuticals, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r101",
      "r305",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r485",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r485",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r485",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r485",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r515",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/BasisofPresentationLiquidityandRisksandUncertaintiesDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r187",
      "r188",
      "r194",
      "r195",
      "r196",
      "r289",
      "r318",
      "r440",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instrument [Domain]",
        "verboseLabel": "Financial Instrument [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r117",
      "r118",
      "r119",
      "r121",
      "r131",
      "r178",
      "r179",
      "r202",
      "r203",
      "r204",
      "r205",
      "r208",
      "r209",
      "r248",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r410",
      "r411",
      "r412",
      "r413",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r452",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r472",
      "r473",
      "r501",
      "r553",
      "r554",
      "r555",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ImpactofRecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bill Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r106",
      "r358",
      "r366",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedTerseLabel": "Unrealized loss"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/StockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r135",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r134",
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Weighted average number of common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.inovio.com/role/CondensedConsolidatedStatementsofOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL6284393-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)(1)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=117337116&loc=SL5958568-112826"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.10)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r661": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r662": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r663": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r664": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r665": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r666": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r667": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r668": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r669": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r670": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r671": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r672": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r673": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r674": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>74
<FILENAME>0001055726-22-000034-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001055726-22-000034-xbrl.zip
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M%YP:2Y ^HH\ ,4C.59AC19NJP_9XFD<#C<"2L(P(8=&W9M0)B]Y;0)%%3Q9
M0D_)\!\QR6P.Z#.@@3@CB)#&,TXTY*2SA"(Y7"23. V&/Q5[: -3P5F;=/ B
MN. =TGKC\8\H\H*.1="V)V?XCY@:/6?""P(]:Q+RXL*<.#CX%(W55EEE%D \
M,\WP?TJ25P<O5(C#7OGR%#ODQN.+XTH>?(P=<(;DE! E*!64$Z\T$UY1(,X1
M3^D<>W_?YS,\_'FN*#^ZU@!>732&O9P?^;J$_PR@$RYNX_*J\(VBO9T,S\FL
MGYE,A,!I)P@CP:(UIQ[AX4+0)EKNI1&2+S'R%QBY^O@O? -7AJ.+MW *K:_
M9*MS,NCWJA)T"=@?'O T-40JSAP-PE-A=:1$)9U4Y,R'I5&;"&#9$K _'"C*
MV:59DD;:* @D$XQCPNB@P1KJYSD&.\. Y4O _C!@O8M:$!Z$#4(9;P*X%&+4
M/!)ITAQDF?R."-B#HU]+P'P]1$ )S7$X33T3H)FA$!,PQ9(%:>4<K,N=%< L
M">44,K>B:>/11@>)">N=SZ?34(*F3T9KU#P3RGE![Y)=_KCM39%J%9EVZ,$G
M;@PQ,DDO-3"$<XA+]"ZIYNRB-RG(9T-XA*='YD"]4]J!(%;Q*!R9Y^C3CTWE
M+;'R]?6#02=C@%@OA-"2.A>) :Y<\I%*N@B6;O)861+,IP>NUFC-<'"67H,P
M.>VR<T1QGQ)/(EWM.ET"=\DM9PNX7">PH&TB(A\R(IP23,@H@5LG$UV(Q;VS
M"]PEK?QQ6DDD8]P!H5$)F93UG@NFT<<WRLM %@&X/[!F98F8KY-+8JFW7D61
ME!!<6 ?6,1&9C\$PO1"[AIX(,4N*.07X)D:%($JRO""=2VN#=@G-G<T;K.PB
M3-G,/'R71//'/20<IBE3QJ"I%4J%G-B%@#>6&D;H0DP@S3Q\EW3S)W(W..Y=
M/E)<!9&B]T'J:"3HH*5=[K)[P!K<);B^"B[%HE6",YILR-.3AB06F7%2D)B\
MF0<G?*:XX1+ILXIT(H%RXG1$)BMB0+Q+#DE;)PE'S"]"JI09!->2[TZ![SH
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M=,YXD? 'SKVPBCBYQ,J28,XD< .A+N=DE#1Q02/D(W>##2ZO]9<^SO.A%7,
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M\ 66<)MQN-VT61EPK$[M VS676Q^G\VZPF9T%U\ ,W<__O[=J$1ZP02+BDM
MVQ=87D8M/;<R;SJ58@[\]%\>C!/AGY0F[ZPF.")2P31Q(N9CPXEP1 $!._NX
M6$2I),8MH!E!)R )'#>,CBHY#YXBS61D#J0R,6V=%1%ESI_ ANBM%#+O%+"@
M;%X_S:/1=)XF-W]YRSI]UP0H23[)Y! [@CN%(S.) LFCMM$XEBHTT3&:Z!)-
M\X(F^G TT4=#D^>!^Z @09#"ZF@B!Z:I0GESZK@?.KJ4,35O(-J 4-V3VW]#
MD*^ZCY@5>68(!;H1E-5O=.R/N;B?R[,OW8A>5S"J7_Q[Y]-WNQ),ZDA=$)PE
MI(R>61M( BX5IQ3 N*&#F]%57\)L9F%VQ[6]!;2_=FUO%?T9*Z4M#G:$:B5P
MS//!4>I4RL?N./11=5@ !O6+X6@ZW"D"5Y1$J9(RPLODO4DZI:0 . <8S7 O
MX3.3\+DU0_-HAUB':  IM:2"",ZM-8I0)GW4AK(H80'8]"\ C>GS:(Z6A  '
M0[T7*B'78=PQC:X:]?@_7S*=!S][6'?^_=7%AT[QGP&"IA?*XJ2//UTW9PM)
M9^%:UZ7?E47XUF3D/ )Z.I0+@ @J78R<2N%5,"DXS?+YY_@8[^<@?=5N'U\]
MWU,M*MA.U>:,VW+<Q?Z WOJ[$OW?LH3XD/T;/SMR/=IB,& >&(^$1"ZD5QZB
M=A$,*&%%"GKV [\S*:!'#/LZ8Y W4$F$$!2HLT%1Q[7PB8:0A@NE*:7$UL<?
MYEA2$]@ M3OPO2(6KKS8=2VX]=0\ .0?>U?+YR=.*BB2A8?,Z-XM^A,V6 )+
M(@EC#5>"9D(A5> L.,Z3"\'.D=N[1-!T)@M2]FM%8,E&H1$Y"!)I=(J1<&+E
M',P._I+ F<SR?JLL\581H:40R:&OFX@DS%BJ)7-B[.HR61]_F'E0;/YG@.U"
M )QT._BU-VU@?.A$*,_*HM^'SKN!Q\JV$S*7B>S2_M+I9?*!3N_-HC]A75@D
M.@6"9%-SD4Q$QN-<(H%&8[2&42:9)9!F'$BW VLWL?$S"4>(0G]1T^ @"#0O
M5ML4(K.:1VN%JS884$4DY;.*C7<MUVFZ-MR8E\Y-WNJ$7/<IY.L3G=-3=2+K
ME#^",+0 @:Y\H,YKH9/R7--(@1F Q*158T6=W?6ETQ;&W:CBSP@C4"K0V4L\
M^7PTI_71)*XM(4Z'Q.7L<[*I"^/Q2)'35HD8N*,::7+RA@0A2))@D18)[^;(
MQ9J.5*;OX\@\:R,(CBM."<&U <,)1"YC!*2V8D[UB>AYU"<M AHSSY(A6D10
M)N#?@C&K(DB(<Z]/$Y?*]/5)0-ZEYKPCQ@AJ@N-"$_P&#!+59)Y$N(8UQ*(U
MR.*ZSG>Z>1Y:@PCQ==EM9\8_0"< ;]M.FZ[L(,/NO8-R]\B5\.KB_@IN.P>;
M[9-6]P*@8O#;U2S5(L(BT*0#IU$2FH018)24T0"UE!MP0L[13/F"PF(J$]_H
M0GB.(R\+*0KIJ/54I<22UIY9<&1I+6Z$#:$\+0*\<CV(.]#KET7HC^:T/G2*
M2>QJGK[9L%&BF^^TTBX@GT[>T1@(,\J2S,_"TFS,##ZF8C\4$D9#A;0T6$$M
M#BO14_Q/NYPD".9I<\R3#"OWX6)G]\,BF@XA2;2,49JD$"$&:V0D"(D$43%0
M?&DZ9@$:T[$:1%LE50A,<\%%-$I($Y0#'VT,:FDUOIC N%JP-NFU-#-@-X@(
MP"%9*YG04GJ=DQ2"EL&)?'3-TF[,!CBFXZ\DZ0P#DG  $4X&SP2Q5)G@HPG1
MS$-*GFF!(R]UO2ZVB)9#"BE2<)[K: 1-VF@9K>!: 14QC1+L+2W'U,$Q%<N!
M@PFR4$:4C$) <L8C%15>L!AH@D3GR7*<N3)^N:S]^T-6WWQBSA>V5_3S"H>M
M3BQ.BSAPK6N/=_S$WAK*I2@A]+OE0EH6RFD$B<X+XX@>BN 1D5FGE+.),*OG
MR;+\RN"9BN6!$))*5DI"<%A"-X<K8Y,B3C( $// 6690E%.Q YX&(J@A)O&
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M9+,GS<FLO0]$HY"HS N@(A<F4&21R7GPZ(E:.[N+&V=:0(^WV#!(%$< KW4
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M)E.MUC;/CPI?+*<?%TB^4C\YV5F&%!Y#>)*NO-S%KG7]95AQ830R"U7^Y9*
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M';E3R!++!]3&6@]-3I'0]T'4MKH(ABS-6CZP%W^X %<BHN#\9*0+U6VW[NG
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M0RZ9W<23$S1BE=$;A*/J;/B;CZO\)O33JD?G<P< /F>_\!LO,@0K,NS.(78
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MU,\ETA=/MK9._%X_]Y*:,V1-5[>06FDH) -Q(43(XH: N/H]P-Z6'5P4<V7
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MDN,2KS;&<-4JT:H=+LA[2=^&[6NHRJ?&U5&\Z90S#@/QTG(0O/: ,JR %((
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M*9'""E2Z9P -3 ,IX@N#SM(XQSC:;V/=KBIT).MU_?1:4TT10<(RS:G5*'7
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M&AN&C,71@%$%%"1:,;DT\/*H\LH!;H[F6J9HK@SB<P/Q22\4LDPR"2$@1E!
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M7A3%JKS&V-- \]$,*P/GC, Y0;-4%!JFS@&E@@&416O4(&6 $3Y0YJ$3!ET
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MSQB4$E=>X*'>(3=SU.!5"8!Y*2$N3X.L7(1A87!V/@%G-@2IC$7 ,.L %2H
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MT_ON+_(KLA-N04ZXG:LY'X/>[7B4]V/I9 BL#@*;4V2&&>69"B*BGT^9K2P
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M_3 6_!W=K_Y^L3?5WU_ /9]99]=^[?SS-CD\>5=T&.C6K]YU/^["\W9!Q[Z
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M(J=6%Z,V>%[IC:-6 "6Q6Z CL#4Y'>O/L3=\K:_.E*"HE2*=(SG5#(6*K_%
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MK)@(+&T81[1#X'.0?4-]7@N[^L7S=F@4@*59M][$'DU0A([F#6R05]%6'+7
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MU9)&XTDT(O#R17$2R60*TS/?J!F@2W/00P4,"1#'>>QAG^H/S& PPFVKO50
M.X5S(-)?Z!%RY>BT&):"#FQ6!ZJ9CR/MO'CW_FGK+Q  H+"!:!P^;;TP@ZY^
M^@T1@0[ATELX/T(;Z5^#AOEE N0T;%>.2%0'S_'P?E3 4Y<>M>8Y(#A=!9P
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M?GF@_:W%S*^98PBW-L<2")RWU6' DPFPV+ \"?POO3%C:0$*@.GRO[[O1<@
M5.(A'[#Z<[1Z8G<PO38)8;TM=B7;:O6^[ZOPBRJ_RJF$N3+/,BD2[[13B<QI
M[L!TT"QGET;PBGOTG94 O!8-D]J].5,C9V=3.WU8JRZH9Z>#X1@C<!?4N?_7
MPG-8-T.WJ&2]1^$<VV='G*P;\N!3>\5H%/7*2JM]_^+Y5)^%C^?TJ JI2U5L
M2><:7S*16=@ D!\@FRL/^>=A=RW21J4!?B 8E]J(&_C1':J;WQ/_%1++^S01
MOZ<.+$C-Z]A/]1*/*W-LLFA4K8\QKP]"1A,#"EX!>AW8#)?IXF7 :T4RK1G9
M+VN*TW'BD\] ?>N>$U!14/F=OJ8>ULZHT*V__GJ^W<)#N-(XJ@/6I[.(*O40
MUE57]M 9* LMC^$L_?BBR>F@/_=JN.8'_?*K6W]IO9G[<QO,O' /:(Y7/ILK
MJFI-8%ST :70) -D&0\+ )0HV,8Q"!HTX@7S &GV/^ZN@@F1EW9EV_-CX*U!
MS_\%0[]:V8#TD7D*.R>?>>?L4Z998FRB")<V(R(5BB@K/ DJ>)LX0T.NMYYE
M:GNU9'L+J+!;AU)<R4Y:#,\Y!ML"0QSBF699,NRZ%/1CC060<-96+&LH92VE
M7.S0O9U/N7=2B%R0)'>4",<E4=XDQ)LL5\Y)8%U0?+F@VZO5(::D4IY4HUB9
M]-!+AF?&/A2V&-_1UN>78L8[7SH@7^@AQA",=F9CW"V'>#7R4(^///C^SB>1
M2IK;D!"=Y1S+S258/H03)Z@*@4N>2H;YI'R5.$Q-')=I/<NX,9I)*)1-I:/*
M:T":Z&$8%:AA%Z5"YD^GZFWI7AF5TJNT@_#W^*Q(%=%;W!_'"_MU:%[E$ *0
MJMY5PQW\"ZJBCP(Q3#"+M7*5]/V2IV0X'\J#01UU>,I\,&(=,%E'EI5'_<OI
M4@M+,0WY0O==>Z5-3WS\Z!C,'0(J'68%?O&U,_+>@':E8<%.W[W',1[ $%_/
M1MA@\7IF>WN^]_:3=M:EW*1$< ;,%D!#,A:83=H<PT6DX9D#+$[IMO@&%E]N
M9  ICR884H(!;<@CH\EI-)L73>H8;^7=LL]45RY(?#S8HEV/@5$)JS6#J24;
MXVZ1TD>C232*2[-T]*.VY4-1M5_W6S%*:AF(P@1M\!))%B!C'AEB/FHQOL_@
M^**.O:P1^0Q#<#$ .Y(*AGMC7:<JRK-2[1"XBE'T= \L BYHBX/)T7$=-HXI
MFD"7TQAML,/P1 C/189#=+I4_NJC(2*T/@)5LU>#W!_H R_7[71BX,XRPZ?,
MVW7>C/'O^NBB)"T0\'.A<#N D,>>=,H\[!?EE?LA^'@P\U[C\>7.[)53G\_2
M%[4#: &DU^W4O9-@%**ZRC\Y+T_AII&4<<6BP%Q>LOGPP5*P65^<1G'5CPGL
M XMA^->5+H'I('CFDTQ(P4*J%?S?.9XE.O>)3*Y@""Z*F3?50%X"U+RNT&4_
M/(\FZ_MQ# MYK +D8$?N'WSX"N^_V-_]\!44>Z:<S1-AB<Q2243F$I)GTA!)
MO0,6X$F2F:UG3'U3E@"U7&?'$TXSZHU,9-!"VE0)[TR:AL2":#,L6:H4N-PV
M](=VO-$G5LEA?]?*O9,=&-_.!7Q^L7?V22F3,8>&G="" #M*HKU21.=42D-=
MY@V0@\BV+ZM+6M-$/#H!D%E"R9:;#&O\N-I!>WT*ZM>Z/C&L&!5N$)'G[6L3
MHDSRW /\:,:Q$5?0)@L2L"<P*Y4P_#:@IR'$-8%KNSNL\_932&WF/&?$6JH!
MBW)*<FXRXA58E[A#N;)@1:9LC3]JD?JBEJE;_];]"?JZXZ%*I,BS83$>8V!3
MI2G44KZ,1)GZ-.\U<;_UK\$9Y@BTY]5P5 ]QH*A"X8&. 47IBRZZT0"MCKM*
M+2@&!11A]G6[CC" V:$I6(4=S-F\6'2FZ,;4DV$91W!6C##S$3-8L"2-#IB3
M4TI]'&H4\OYK%<\R[P;>;KV&5SM0'JJR*6XTC8F8&]&\ AFG5.F/SG?U.;)U
MS"G'JT86#(P8FX%]=>+9';X*_HVCC6F8E<$\;UG_4:9Y3S\"[024Q]X/5EZY
MWP"598-?5VDP\Q8$SG_.$@-EVWGLP("T$T]G\(*Y&P<&'5YK5/5%8BI]=O:X
M ((L\U7+,X#9JQ;=,Y=X689(1!B;-!EC'%-K-)@,;=T>J=(O8RTD/!>-6UD-
M)B9V3D.Z%BGF"PJ8>F@QM..+G\4RU2$PUSG"6X[-PS.PN1BN*L%[5E6F-SL>
MLUT]&DT##N/,RI9/E3U3+GTTGLK4\!YN,G+E+**K"KVI3N9,/(B<'KA4BQDU
M]Z-!=)L/,.J[O[ !,2?WZA,NO0#EZ>]5PYW61(>B#K@XJ);1,;6GG&L4NCVL
MBU-&&F%H4;<N1;:X4G&!_7A<=E[#+^?6;IHP7(SK,]>RG%,936>!JD81#4R5
MRO -=]VJ6[%*.*N.20'!< ! 7'&A,+"FK#6U<(8?O1BU,3MU:Q3CZ-;PKO)H
M_'B=T1M)T;EKS%H?G_+]>).%4\@J.JWT%\'H(O?!OY6@U^=+0&4\RDMS$N74
MH/5%#V,*:=<?E>B/>EDT_"MN+7HHF(KH9*B>%"-UD1%7"6F16I!>HS>XG"5F
MX!:^RGM'"8M9II$8/.J]5>DK4Z,O#B Z->(7 X -I,IXSAJ;QPTP9@BI(K:4
M*Q&Y3);\'NVT=OHM#S*Y%R^)3YR-,*;FUUWJJAE?(:HAE-1<S:#K2^5!3]GR
M?!:M,CLYKABY!,@ZX*0<3UG-#0!@-$!T.Y\->+OUU_)FS;L<$ *.JCR8HP&
M?S\B1.G7KKXI=]=C9(OU4X]9&>0:L;4,O,3IXRMCKK4=C-"UA'ZIT_.%DP!@
M!%VZGO"^2F25+P#A"7<67XK*C3^,H1!=S)K4W1+F$3EP^>8%%^8TXHN[6/S!
MHSHTVBX)>J=_/HW<!:R:@FF)0S;2VN($D#F1PC&NI!9-RYI"3;Z7A/Z6'#;=
M]FF9O^U5W&FM9!'=0G9/T1\\B4E-.WVWD-+TR/-Z=C_3O8NCL\Y)YP+L=;IW
M]$FDW 7J'1A(W!(A,0<MS\!RDEXEC&4B2?,KY.QL?(;.I2ENURX5C&I<$<XW
M0*]/9*775S5,X.UE(8J21Y'QH]2;):A;'0N'FG.,R8G54=!O7O1+LW4(0!I+
M7K5;[W?>C<CSP=^$M2,L5S=.JSS@0E9O]<"T@UZLC3B/ 54U4E>,AI/3.06_
M &"Q%92C-*C'/*MP%!-GNEW Z<^(;_/J?XQN'U<Y'A%[HQ M307,XQB _!R?
MSU=-*M>BRCRJ'SW_S#BU!;B>&W.-APMS/5\HR%)#X[0&2VEPE/-'U0 =]/$A
M9X-A]XJY#5>AN?NJ=RN7XKP6"N1@<V/<-5#\BW&E,\]ON9]2XVSK*Z,2%?O!
MN?=1QBZ4<\ #Z+)<!\KT+T7I'\ Q1&J(>EJYXS&=I'[NRE97 UD\?IRJ^'/'
M]#$T$>\N;5\<8:4=SAVB+9YC##6R$_:9 4%6TTZ[<B!5N6"5LO2A'V-"WX^C
M&1-?&U,N8I#D<%J1%"_UT5\"U!Y'B!9._6S].2I*5WM@;?GIB@G*(KU1LRPK
MH[2G]?!Z>,VDQL@U5L25\RRNCIF7I/Y?,=U>T$U.M^>WGF[_?@9=2VG,L/,;
MHNK03ET/_>3X<^<"[GOU^N+PY".J+73_H%O \S]W7OV[USEX>XYUSN'OXV55
M9_\5J#B[G\\.3_:*O=XAO.^MW/_G->_\\_8,5*.O>[NOZ>%)!_Y^&>"]O'-B
M/V7"4.%T3C3\0@38 T0ST'0RQIE-J?,JV.6$!FZYE-0*D],@\LQIF2:9X)QF
ML%.4KN0P/\?@?KN88UJO_[=SZ!^@(K7>)O_^DBTNL< @(*]YX+D13OG<*)]E
M20I[D@>;R%O/^W\^E3  KCNSV(#E0@"/C&WV+E[0O9.C\SUX/[P/0_)\2D/.
MC"2)9\!!7%*2NY03'C*NI3/26[.\O4Q1RZUPF=1"!!MTE@$C9D'E'N@C,2L<
M--N-6(EL/BRC]0X-8!#@[\I:K65J_7<%T7>Z[#RJ[#_59/]MQECN,/OO:@B[
M>M]W67?3/<<K]LG4R7IV[*-:O%@P+@:>S"%.C%J<NG^O7A+B8' *<BJG^9/6
M@G!IS4F76=#7].IINE]9MA<#?JMAQBH/1?_+H L/.1D4Z "=1A%7 7SU649]
M3ZP[%RO(^E%YP!(O]+.JLN5.EW;#7$Q<>3XWC-GC@U$5@S=G$P^G_I.A/\-%
M /NK-(UK$ZPN-3#_T*!CJ>V9Z3,]A)W.?^5,#@]^\-1LKJ''XF95Y4'1EQP/
M@UMV@I7>\)Q[_CE5-8%164/N5)]/3ZIT>2Q<'QI=&B19!7#'D^CI_=.XT_6#
M6O2?PK.K84PK+Y275W$%"R-?2#6=Y<R5)T^P)[,QK%O0M83ZX30>(]5$M_/^
MPY3<0#T2A*KV5+R6KB+@+(R$*-_1>EZ-;YEN4YK.HA0?4MV\%7"(8KDJNFT7
MV'8^8+1<C6E=VI+6ST^KZK_U,6^U/]$UOAA44'KCJ\8Q3UJ_%;]7D:E8CA*+
M/_Y6P$=UG#Z&2<-CZPJE\5OX&E;"PW;TYP@A*BTELY;9HO$0NQ[$'"UC(<99
M\>2JZ&5=+[EU--#=45D5\;?BR^^MX>"\/'Q .,*0S%$,OHIGJ+8\?ZR;VVRW
M=B)M1ZJ994HLLN(4@:,K;8"U/F  ]?Q*]*UR/RO2CFD8T\=&;(K/F )=O  ?
M-?>D&*P00TFJ>^8/T9"!RA.G8:PX$L.G8KBXZ=:'/HN'<Y$EIPT"1F49RI)7
M5L^DYK):,6;85B_#DS+8=CN_2[-0LTO&@9,$N8(Q\+&&RZ77P=-'\-LH%-X]
MJ#JND0UWRDK/]0K.E7NJ#MM'?BEJ>R%T Z"IIO#IT=^H)I5)K_;?XBY4>>BM
MDXD[JIEC[DQNY;BU5-C.RY D>"+H\,AV(]_M5M6H;%DA.%+AI9N(#K7I@T$<
M#\XN(94%*@&ZJN(:US^X)-(XKG7#*@^T2T JQKXWFM90Q>- JT?XCHJ.84GG
MY1V>BG?+EDG 1G$W6L/IJLY.GLM2N&6'@6D"TEQI=GBA73GJKH,B1M]<M(6M
M*(^,JX/>*:&WXJGQ:=2'4 CBD3Y&FV$4#_X!XGH6CM2.Y_=1D5X4P)%\\#AA
M&JNQYM5%>58>CTC*T^BRF93'I6R#?E!5B9CJ!"M;N]W:+3 TL#QYK=6N<J_G
M:BRMDH3QX[.R<$/=4PP7&0FS_OL2#(OK->?HQA8M95QB#5[#F1U=U7:(>E15
ME"+>,QC'FE(+UV.?ERH8%R&]UI@?'NZ\C,)O0?V?%_55?YJ2@^:E='M)LYL*
MAIJ;2CKH#_H$* 2KQL<(Q<DI?(RZL/=KA$']@K-:_ZL_P/8'2!5 /,.5RZ?M
M:F8?((94,5YXGA7[EOF^#T#&4_*L+M[&HB7U'Z.95#0PYFGUDJH*%-Q:C);G
M7K4R&\T %5LCE (ZAE'%;IPU<8.B82+_7(7GYXR?[]XX+_YF_!_[!JU"1&1>
M8.OI=>648AL)8#E4DWOPZC+?K.?UJ(POC^&>=0#8Z62(QM&HY*9R__&BB@ N
M SQ\3_G$.H2G?&0$PF&L)!-?5::[U0.=AO.UJ]C!U0?-+4L)P:4VN(;1?VTN
M7:,9_[8>]W]?).39'LW3W?1Q527YZ@'>S6*7,*++EUN/C75*=)YI(7/Z87EJ
MO5Q0:!7P)Z,ZG:$W -%4'7Y7#RDI,QJBZX.H%DSUZ?9CU#4 ^5D,^$&,CSES
M%>'/ZJW/E@^7(T+)=\=;)>*53%_&3XUF+HQU(42GF+^))O4P-DRHBF->9MVW
MZP"" A8? URC"E(9V6BZ3/J5 V:[U5G=_BFFX:SGS.7E00UJI%DSA%E>--HA
M@^Y\-?J5-C1X9@NOFY4QC2+U6Y13&6LH5 %.*PME^KCXM)@8]P4#VG9*81[/
MHD,)''.QI<L8LBRIR"(6S<<0QB-E'$A4=B<QGGA&_;'.POD46*;*T+@\H5Z/
M4O$LOV*%6@8@ZF+)J#5TA %KY<+.14A7L\<$URHJN"JC4(9FC^TQF9PNQ@:7
M5%XE&%3"K;VTLW56PDQD1[ZM:C74Q#Z7=SP=4A4Q7%4TK&/^?FU8C59_U4YL
MZA*8#WI8@[L+$-!%XR+&Y>"3VM/X\%FLQIRVXU"?=!5>EF3JW0"C(1%<L+??
M0I3'S$=14N?WM+.ES5TV\TH'!\)C=&RZE2=B+!'R])PV'%\4AW$^![H+H5>Z
MC,9<@KDE[])W0[5O]RBT;A&STW>[,VOP1>G\;$Y!L5;_SB<A96ZL%<0PF1%!
MN2(F]QE),^LSJ7U.[55JF]\''EPW4G+>'3Y'$*T7=3T3TGI>9T.57:9VROCR
MZT53;@(:+B:\S)VIQ*.3+O9HZU9%DZ/?Y)NG!0&@;=$G6WV-:."[(); TJA1
M=]H=<MJG,6+K8N/J-<VJR]=BX^G2BEOJY%C7G&E'TZP"]1BZ64PC^DOEH]RQ
M:4+53'=%B1WM_QC//HO%GR+[7(-"4$A ,>KB:]IU3<?*K5'W3)I%HY49,-LE
MM7BW//3R=4O';P"KQ:B,,!_5?=YK^VD;CR[J;U%//\;]B@M?+<,2YA?].?D1
MXBE'E'='",C8:WSFH2V?"Y((R[^U/O<'9Z!G_FO:9[,;4POKET=B*67#+-9T
MEA905<&.L_GV2=-3]!&6Z6A@!<R=,=;S& [& ^"-J)HLKQ\2 YJ"W>XL'6JZ
MM(L1_[I:JZ73JO^LHV67HOM_)@APD?-O)MZ/;W*\G[CU>#\8Z%R4TG#0'V"X
M9J^J@O2\)+?7_?EKZNX)&Q,-.$M\@'MW9.?@SVZGUQ$?3]Y]WH?W=/XY%)W=
MM[QS\8+M]4#(O]HK5A,?_C[I['[^"F,\/[PX[NV]>BL._WD-[SDZV]NU%_ N
M]G$7/F/_#IV#%[3S]I,TUE.9@-1VS!*AE,"&)@GA><)$XER6K*EN+'3F#<U4
M  GO4JTE!8),' _,9?EJPYW7TV#G=]Z6#>A>ERE\:T]H?Z#'SO='M#B#W'H&
M3)0EJ<\%T)@17 LF;992#KH+N_58NV\0[ 9VV[D?XCS[!&MJ5)9E)%#'RAJ:
M1G-&O*8L$\$$R=.5]DF)25-K* @S*3351CBN/?7> VWD0E^]V\Y&EU*.CI"8
M@S?7$6:>C$!0=P=G\>RK#'I9+,17^@0&R[6\UZ<^OOO>NQ9\2]AB/H;5E(I'
M^?;I 4SI<BB[>RR=U:\;QC1O[M(.&X/A5+_$([KN 'W!L\((^-ED-+I*!XU-
MV/=K6B9K 72*LCMN@&V#FL80U^*NA-Y#;.@Z_>]&Z'2MO+R:_%O3/^%[X'KW
M?+%>Y=QY_Z&U-]C&J@J4T'3[/HO.X.'[SN0(3]=Q.*4/#=MKU84,E@;;;MWR
M:*^),;O>C*/CGSW%7ZLPN$$_MF"N2I3M1W-VOXHP^>W]Q(QC5)S(*.A OU>.
MDU@X$%"C-('_Y1W0[E'UZ%F8'5AC+X#PQK,CB?VS?ET[</;H/)%$T-^?S"N1
ML?=P'-DX)OZ_CHW&9G'S"R_1WWC/O=++7&QB31-U:&'MV1^!-.V",*\#R"9%
MV3TN;D=)5[/#FJ4P(CNW0,72 MGY!8IU;V!)RFJ%VZVY\:!W>IJ(5QT$QZI/
M6%XANHOPLU!@T:U89@SU$=CMV$2Z+/@QK3B6R+KB6#Q J5K(U1VPIB=5@UB^
M=/; I;(1I:A;&&-9@:4N5%776(E')Z4K(1X,CX>#:?!9/#VI#HZKDY:R4O\L
M.K:XD2+;P;D\)#P5+F1">6DRZ9ED(4UXX)F55=E?,"&^713MIFIKWW-5M'LP
M,&;5&O<.#B4:&TX),"LDX2 ;B9 .*_-I0[RB1DJ3YI9JK+.=?[L^&E Q[A@6
MX8C.MKDJ4*>Z< 0K6?]83?X?IYE+"K/O3(?V!D;VNO^0BO7?*\5T+N"[G4]*
M9*FBB2=:>D^$HI(H315Q$CX.)K495M[A:RJS+U-,6;R_Z,_(9AZD1[Y? )J6
M#83N"6CFI"HJ 0V-7(%&L+F#9YEA#E059P/H*S;-B))I2A(G!#-.I: \(ZJL
MMG98K+H87>6A6U<*7*P?,"?@2]?ZHFS$<(OI"6WIS)\*KRJ43G]=J 5VW7XS
M2N69HEPD.A<J,YI1QYE+F1=**&:O6L1^MQI/V6+F0'_]:S:F/=\0W5JBFZ]@
MTSEX@<4^,R.#E1G"D4N(,%H08[@DS"M@>:6 ^*Y$=%'3UU@&!0/T!V65S+D
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M9CC1-LC4RQR^0A'?5NQG?*P-KS\ZP=YX#^^ FY>]AVF6&L4D(UX+4--I8"C
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MJJY%U8SV%?.U SH ;2/$ #9$L%8[L#6Q8LQQ([$5E?ZQDBP][2*PECNA!$?
MNQSQE 1PL]2YQS2)R00/QL8JQBLJ?EXR/WM0.*GS1)#$. G11.&\\990J84+
MI)+3J\O4,SD2-E'!,4<D48RX=1Q9IQ)2WF+"%(G1L$I.OPV^YM8GHJFCTG)N
M-';>)Z? V/1*A,AQ):=7DJ6G_0211JH)<X@F!JHWX#/23E 4DS Z$ DZ5UA%
M.?W&\PI^R\/,9PH'L:@Y$N)IM]\:5&D%B^"*8,Y(L,IC)GG.Z%,"X"H[$(@B
M)E3N@I7%K//94R]1<F:I1TD[C[@@$6P+@Q'C7HIHI56)K&W0NLGYY*:*/KYB
MMA8P2<XU2SG<*#S6H(&27(;-!D9!=%5:R$IR]$Q" 9B'6D2-@I*@A4@<D0:%
M!%E+A8O.8<.6WN2UXN<5Y.=@O:4I11S!AO"*&NJU-I'KX*P"8*_$].HR];2W
MP H>B,$:^9 TXDH[I 6U2$5#3=*"24\K,?TFV!HKJ1WP-<'6\("Y35)BH[6/
MA"LI?26F5Y*CIYT%.E' 92-1<CHKWDH@K;2"/QWG5";.EWA&JDHJ6.HA!'L8
M._Z\=M+M#0[A,\J3CN%'CR2\"5>GY<)I39WT@G-C ;@<B=I0D@OG2Y$JI61%
M(6QGMF*&X((8)PP"(&.(<T61Q=$C@BG5)A$JHU_;('6A=5URM4(>SRJ"L62V
MULEKGXNDA&"YPD(+@HVETE"EK#55!&,U.7K:=^!@NXCS#$5%+.*&2*2=-,@F
M(7744> E]M2M^'EU^3D$[ZWQE# 9>; JQZ^BL(H9KZBEE8M_A9EZVG>  P_)
M29?;[!K$?2YL191% 3,GO"(^:5N)Z;?!UD8Q#8C.+='<.^NXY<G*2)G&+)#*
M=[":'#WM.\ :*TP40<EHA7CP%FG&!3+,1Z!?%@U9W@&C*M'@OMVS^_<KOGL'
MC^;":JRO'*\XU3PJ$6/TBH-\<L(Z)8+TF#!#_>/B5:6&_ !H310P:!X??@?0
M"L'$R A%E-A4.CPMS^>>G0 [43DB!5_;8 S7B<)UPY<5Q+@;[[R@\,9;!0-+
M"*8R)B.QY%X0'03.Q9@8#4Q;616Q7&$PN)@"@PS@5 H!RHLD&0P,TEH*%"FV
MGDGO01E=VZ!:U"6E=2,J,*C X'JR$F',&FNE,_G<HG11:*D(UOE$Q+CO;@4&
M*PD&9 H,K(XRX, 06#,&<1LP<M)09*PVS.:&RKFB+>=UP57=+"V[H<*"5X(%
M+"7/E%<."\&Y T2PG(&J(+RG#O2%RJNQDC# IF @*NF$%QIQ34P^/J&1C02C
M1*(.3%#,J%YV1L3C8L#(WS$>Q9B^1<'ARW9NWN$9M\_V1YY>C?!%CO#5.^6V
M+WUPM5:G9E-JM5LV=\F#;UJ#\^J<SR-[W][_9PC+?"4_/WQKMBI]>EF"M%$*
MT5$C]@9O7FP>T&294M$ASZQ$W#/0I3&UB 1&P40R"N>#B*QNL*PK(U<HN[#*
M%EY-IUG%PX_.P^?7>3C2D)AP'/E &.+,&C"**4<IA*B"#]Q:4_'PF^#A)?FZ
M;N?ARI9],/LVIT1PQ#BRH!UB1-I\"@\CZZU S$0,D(P]=W05T_LKYEU-YU3%
MO(_)O%.R%R2LL[G6/F%)@.R-$FFF, J.$Z^4\<&NY!':5W\VI\ROL?U^'/1K
M)T4G$+#C[:"6;*M7^V;;PWC?O*:1MZ1<R'<,5CYTAZX=+YL=_X!7_>7W<5K6
MZKP:.%]61E)!PA^ :O_.1+O5ZOMV-U-S950M#]BW)QPC>[RQ^_5 VQ2(U03A
M9$ KPU0@[?(GBZ,!V6PX(3D'B=>Q4G7%?MBL6BX;K7A?NX?/LD+3^R[0JP'4
M965U58#Z)(!Z?AU0!=6)4T!0"LB)>*2Y-#Z/R$H&>BWW2E*5\[A,75!35_SY
M ;7"U I37SNF+BLYKL+4I\#4YI22ZBT)P6F.0!0&Q+7WH*02A:@5/ II&/5A
MF>EP%:16D%I!ZA/E&-X-4BM?[L/1=$I#]8(YR1U&@3.)>% !<)5;A#D-*6G)
M*5U>\Z:5@=);/,&AU3]MV_,\U7@S^E977K^R6MAJ85_6E=7"/N;"_FN03PS
M?T/KV\98?#2')Z"0^(W_*KXL98?K_6OC4HX4W\,_X\<7X-[JA-@9O*.JT&:?
M6!\B O2A?\=OL5TCXP";'=0:MN>/2B'(2+T&.@[->E&_U<\)M-U4.QD.AK9=
M2R $X89.J!4%\@:](C9W/E$2KW84VZ'FSFN#HUC[K7L"T\N?X1VV%\O071')
M^\^PFQ]]8GM?XZ!V"LL8^W484>TLMG/H;_+^0FJK7_H3Q^QSBF\KCWTZS;=>
M^_/?,++=B;=;[T%XP\6@>A4W77_,0NVP?P1#[D_WV@J,*\E )V22:^:-=CAZ
MAA4.)C+&"@618G9=0=QN?IA6$:_2E7?..C'\:MNVX^.GT3M?L>'=CO_]%ZB%
MX=11+O=WFR?-XP^MQLG>Q?YN@S>W0/7[\N%X__<]NO_[AZ.=K<]G^[]G-?)#
M:AR_![5R\[QQL4T;6U]9<_- :DJ9<Q'!%@C$L:#(P&,1=<%&C0VG@JQM"*/J
M&NL9K0]V]N0$=KS<Z$SF0#LU9_N9YCL%!6:U'92TDD#S%?G+\?7E)?_3!2XH
M6//]=W]D.X<QLU.FZM$%]O2T#1I<5@Q=N<OPA B_!Z#;]=KG#MS?!O8-M4/;
MZI3L!:_M7[UB1,G_[-=BD1\RR6^9K7KQM-O+/- :C1I8-^N:!5_T!_"?@MAA
M^-W3R\CY)/(L5'&?"I)Z-N](/S/^\/IZU'[*:_%S7@H[/KF%@#U0'YA@SGK,
MF]Y3S0+P!29@I\?=NOEDPGIMH<  >#QL=0H#0HS=#\\J/RB^E!_T/O+#3S5I
MK=?\_'8L5\+EUNJK-XN:%L XO*Y]/B%T\H6#'LQ\!/4E5^<W]H>N#[0$"WMY
M0WU\1^P44XC6'XTXK4 $6+LN7#0X/\WF&=PV',"^7N3?1E*M"\_L?2L8'UC1
M7I=*73<HN#V_X2JM);\HBZBI)4Z][@G0U6FOFV*_#T//ZPB#SR_+[X!IU&MG
M1RT8X8F%D?3C7 %;2L!,/GG(-?C#Y]'TBB'"8 :]85'#IIY_:G5.A_#J+@RP
MEY>U,W[DZ%F7*STQS=@JK@ZM7O1Y)8O'C/\JYW_3'(!Q\OW]^8//^W2=4S*@
M9^G<Z@P+_)CWS00WC8B8TW65N:F@-[CF72^VX>)O\9>S5A@<C9U&$S>.+'Q\
M=8MU +##P>);)NQX#TL:>\_$JX1.+=G$OT>71Q9/"P8#W/V*;(+!OK/M,WO>
M7_O7=30"*)I:P^GI+U:#RW^GMJ=48#3#7B7JN8^*.^D<EEJ#<A69RT4)V=J"
M^PSEGA$:E'>">TNLIX1SQT0P(<7<+',QEC[3=DSPRHB_1JS]S?9:$219YO].
M& (KGA>@D?GE&[!LKU^R3T:)<@D&T1]U6H!9_<SOH3;HCE/EYF#*=2UBC"ZI
MU0%U)(/R!/.#!@Z/@#<"1X1R>* T(9<9^0K;,KK'3G_8GX$#W^WUNJ[;*R2<
M.Y^$A]&]>5[UQ0#5;\'"V]X,((W!XJ0;8KL/D UH!^(6;+9"OX=G>=L_JJ5V
M]VQB<:ZC+BQ(H1:5N#MW"*,%OY0L\#5<<#Z#5?!SB9[YRT(M+'_X9[] [7Y_
MK'-=WXW^['9,Z =9NB10W;J7JJ(ME,+!#SZEE#;C_;19)P&!&PM5HM;O#GL^
MKK\P+02V%:BM(-9.=T32;"PP"]7 %JLT1S=9_R$Q<K?E6.0**)!+^& 8CM(K
M'SGGUCF5%-BX) E,)/<'0J\MWH@KA_.UER.^_A3 IN;NAEH?&](CK\A4J%H%
ML,E"X#8Y'I,WUCM*=6YOH91+ZF"K,)L))NC*?KYN,/_>[8:S5KN]V0G;G0'8
M62V E#+0<A5?V84W_MKN^J_/:QN3G=]&MO'Q^_.=WQML!VS8!OU(X3VDL;O-
M<YAD?]>SYM;A1>-XD^S\OM^>MHWS=7L7GN]O;5_L;^VWFUN?OS>.CTX:QW^T
MFQ<>[VPUSAM;G_G^R=^I>?'QXH!*;6+$#FFK..(J!F1)4 @+$J21C'$<2W<&
MT'4,F]F_$*V(AC$E'<A?IT%R&A8M9\I3HZ+6:[78]Z"Q@T;3&\:UC?$N%-K8
MU3[4RHV8\8Q=(_^Y0OSV 5P?L'? +#%[7G#D*FE#C<$Z,6NETD39RW#?8]'A
M)W\4P[ ==](T&0)ECI=G-\N[-TR,[  D*(]<&N1QS">C3 "RS$<</?$T>:JI
M]M-[*[$3DELOM5)<9?^: ](P*;<]8I;3:6)\$4(*=)HVJ"2EZE!Z(0='A>P^
MG.2EUA4OC608*!@G]KCP*?2SQM6&_[Z;$2A+GI>YT[2FXJ4W*PRY"$JA_EU:
M4T54%(;:MJ?]^&[\X9>Q][W5*=Y8W/3+=9F7MW;ZF$K>Z?+GD3EBS+J0)%LD
MHWC(Z,4C8V6],%:F@KRCW_2Z5HM_QNMD\:TW/%:N"R8>]-2;?Q.,+WVL!*]3
M+%_.8"57+V>P6#Z,N*K!WC98@5_*8,VZ(?I.3UU05XK>4%?JGD?\'B<M2]^C
M =?"LCRS<[JI6%*O>S9]$/G6VXBXR[*5WKOG6;@94ZM8N,*@K8UMV64LX$M=
MB:WHXXF+O?%BD&N+,9]]^$UEV5XS^[R('?U2_!%#;1,&90]C[7,_IF&[\*7\
MNY5B\>&GO5[_YSO,_#[I=ZN]++_WNOW%G07N.>.[%)U[-2NWZ?WP9-C.SNB"
M=C9S/+%U43@@J@5]P((VP13]M=O]6JSFW_..XC]0A+^ZE:J8MF+:%5G06YCV
M#=0&#3'EC)!8:^>PYKN[4-&]BPG?E[P>7&VI&F0UR&J0JS+()95C*@\9FE6&
MT7%TZT'HN<32UP\]$OH&#G6^SF.9CN%H->68"<L3-8[)',7U)BF5%''SL^YG
MCF6.Z;?0S%]$DOU#8[?E><R3]_#^7UM[7QK?]W]OGNQ=P-BV_FXU+IHG^UM[
M9SN[GS&\DS9._CB9/H^YM_N>-7[_XVCOXL/7/;I_W-R">[]L7S3H_M?F\:9H
M[OX%\]L[WSO93XWSB0[3NWNB<7C@J=+*"8^$, ;QR"VR2GN4G#*>$6XEYVL;
M!-<%876FR IUKZRPZ UBT>A@<$5U%=6]"0E8";\E"C\V)?RLMA(;*Y%(,2 N
MN4%6*(PT(93 ;B6I?"7\*AA:E;G= X94D &HF%NA.=<A..:EHC#?$)U4)MVQ
M/DJEB#\6%HDI+#*"4I*B0$P(B[BV# $\6:0D4PZ#CDZ%J;"HPJ)5F5NEB%=4
M]Y8D8"7\EBC\OE_5K7U/=W:W#V3N,DZ30ASGHP>:)]#$!4-)*&ZDT33PL*+2
M[]7'9+>6%Y%=E=A1]8SJ&2_V&54!L>K*I5_Y=F+C_V[YV.G'.R7\/:!!TU/F
ME-U/:9Y[SM8PY1*-SI)<A"M)%[F$SXHXG@@.=SEG^Z'0#OZ=E8.I@[9E3GA.
M![^F/<,\_+LP[)U'VZOTY5OUY69KI"M?.8NH3<*R?(!<2HVX4089D2SR-/C(
M;4A8BZPN+SSF_1CY(#>U%KRK,?VR+4[K2;#"J*0<9QQKPX"Q! D1PYY0><?0
MSV)^ZE=NV&5SUG0^!&R3MBIPA+T"0]2"(>IR>@11,9'@J1)> F?5&65U)5?)
M#JW8^2[L_--*\?-$_OQDZGS%X4OD<#+%X808:Y202%"J0'9JB1R1%-0;9X1G
MA,60"@XGM*ZTFN'PF0-M%7.O"G.O%&\WXZ#BXR7R\73R!I>:""X24AP;Q+5.
M2&ON$>=&8D\<EE86+F.C>"6F7R\G:T&,(8$0+1/0A--4POX#QH--JZ/ =XSS
M5%KW$_+R=/(#H5X0KAS"*@C$(XACXY-&.C.S=DJR%"NM^^6R\WVT[L?GYTKK
M?@*/U56KYS+"2Y1*FBN.$I6YP;-WR&AK$$O,82X,%<$5+(Y%7>+9)GJ5VKVR
MW+U2S%VIW<MFY*E4C:A%"L$RD-6>(;"='-(J&]'"!\*H$#ID6:WK9*4$=14U
MK:Y\ZJCIZ@VXNG+UKUQ20MD+",7_VNH>1S_XR=ZI2-@#$NE>6#">$26\L(XF
M'+@,2FO&L(G)*8P3$[P*QC^[1K3S:288'PS&7D:#8E(1<9TB*$18@&43C.:4
M)^=HV=]E"<'XNR:7W61IS.&;UV=I*)H$9<!.1&/.9:Y4KK&(.@5!E:R"\:O(
M6=/!>&ZT3]$+I 57"!#1(<N20S0$Q85GEA.0FJ(.Q%''<WP&][0V;I"CC^4X
M>-OL?*]@_*/S<^46?'P.GP[&"Z.M2)PB;21&W%*%C T6$6&)%4(Z$<7:!JTK
MH^M:FQ_P"E;,_99E=>457"X?3P?CF5>Y+6! S#N&.-48.48$HI$'[IC7-IC,
MQPR3.B$_[!>LF'EUF9G'2+S@0I!$.1?,PNX;D5+PV*5(8Q6/7SUVGH['RZ2D
MBH(A93E'7-B$;,@\[85*A!EF9*H4[Y?+SO=1O!^?GRO%^PF<5C/Q>!*LLAHD
M=HP&6-P#BQ-!4"2:$BUS0]]4:-Y,U$$1KS3OE\/=*\7<E>:];$:>BL?#YK$0
M<]J<H2"KK4[(68,18R%8;Y/7S!:JM^1USG\X%7:)W/QVSISN#(YB[R?WL##7
MJSMSRI-AC!N,E>0\:6:2U,G%@#V3QN-0A;F>'6@:NYN#&8TA&<FHMLB:E)-T
MLU$ \@-)$4RRPOHH64[\J0Z=/J4$-XY:K+0&](\<&VV<HXI3$H@+%"M6Q;E6
MD;6F9#C1EADL/4KY)!IW."!'B$2"*Z(,9Q0+M;;!ZU@LQ=ZN,F17V-Y^?(:N
M[.TG8/'FE/0T"6,2A4(R!8<X&%U(:_B4!*@_200>/%_;8'4M:5U4^>\OB;M7
MBKDK>WO9C#PEJUW0"2=#4$H$[&V60]8Q:&2,9H**&%QQ5DVKN6Q<2>I7P\L>
M2ZP%B5X;SZD4.C FA!'P%V'15P=/5Y&;=Z;$,C9*\6@X8MA@E#V@R&D?D4M&
MJ)2\-,Y4FO?+Y>?[:-Z/S]"5YOT4QG49RP8V;\!<OYX?<)JTB$PB;;/CBA"%
MG 5&9UXG2UQ,S*="]<:R3D6E>K\@]EXI[JY4[Z5S<N,Z)RNA-%8B5WI)!#B9
M!^1PL@A[8HCPT8E<NXER5E=S^'AE#Y^^HB-=N]V!;==:EYQ1LP5K/'H;YY<?
M%7,R11]Q8)3FBE1>"\,2EU83@:VANHJ*K0 FO9^)BFD;),76(F,913SDTU\.
M*^2CM"QIG'%I;>,JY7553G_=F:M>GR:PI!9]E>'^I'PWG?;BJ&3,>D2(COEL
M&$$Z)\!(0QVAVEM#RL:U7"VE9M0#A-%+27%[;5!P'YO_\;&@LOF? !VFHVU*
M &VKZ)&D4B$.1AW2RA$4-.=!:>%$Q&L;*M>&K!.UA.S6"A=6'Q=6"A8J9\&R
M(6 Z3F=\,"$GN-NB3E7RR%E1N/<#]Z"68UDDN'-CZD*+2C^H<.#1F@A6IL)3
M(L%TC,][+9DE&#F7<L0>[ 4M$D:"T2 ]==8969D*;Q(*[E6!XM&QH#(5GL*1
M,!T>=)X!&K!\]"U@Q)4''2%HC;#SBE/L'#<AVPJ:JSK'E:WP)H!AI7"ALA66
MC@%3@<4DL%>"Q)S%!QB 12R3!1AQBAOOC.,J&PN2RCH3+\98>#LG[,JXX^&H
M67?-=L*2@I"C%;G35CVHU>LM"1QW'%BY[^\8C"UTAWG.X\']&#*__.[V2UR@
M5R.R?M"]U>ITW_T^8K7-3F72/K; VIZ)?FDC#571HNBM0MR#26M 5B&6A+)"
M>!,BF+04UXU6=<+HDG)AEL=+SYP65Z%JA:I5,+$"V[E@.QU,=,(*:C5'TKN
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MY%HY &9 K!,T51\YAH>==NSW@9QZ[1;</9) ,>0X9HB@A *!]W+ZR1!NLWT
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MS;,#XX6F-C$4([6Y&8!"&O8$*4LM5@$;+_':QAQY59N@@^LP%3NA]+#41V>
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M5SW/\O&#48F/G\O"VT6RL:W]3[<7+2J?DHN3MP;#4?'A%H!4?]#MK=?R$5C
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M>-*=Y=M++\0Q-T7T,1BPS &]TFE?1B3UA7#E=)LDZ;FRU 84>$Z]22XAV$#
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M+@N>:JY=;AWEU*7,"9?=U+)E+0;?$2W2_9-CYAAE@F5);E():L+Q1"G0&DR
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M'KNL((Z#U9;Q'+0.S<&^-Y(E:%9; Q:V54A.3;MTF>DV^L\$F:8]FF'@^@W
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M+3-+"_  NWFQ_,!OE3FUCF5]$Q -^B=)[,EZ>\OJ^UI3SS^%_O;/_[01^ND
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MMZ-W,AZ<N*!R@@9J70A;1[5Z/WHW',9( @PM?BPX<S%$J.(8PIEIZUP$X^F
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M:S9TOQ7UQJ]-?>GVVG0Q8'(Q&==G*^U ;)T44ZWB4(78/VB)F<OY$,0*@SH
MJQ0/1<AU.#/=^R'&'L\>^S-H<*O]WMD"<42T"%'<VGN;FE@AL(N9,\\UN+O"
MYE(GL%U'HZ@)038PME4U+FVVVS@&Q^I3^T4A#_LA*MR6O5;;<_ =U_,S'UXN
M/4]P2N]HX$V-D^=KXS49C0T<U$_U_6R\^ZJ<ESM__;7S\O#MUG=QYG+,W+IQ
MTI8DFN"B)FQS2=-1/#7 "P22M(+_]IA.*$8X$3O_@K_ZH"FVIHJ[@K]U\LWU
MR3?RZ2??/,-DFI8<UEG6\WD:%2+-GN%6W;#KJ'ES&;3?:EM"UG[%\N!6I?)0
M_4><B:DUT4[K+O72NF"T>E4=A%<N1O=Z8W;6];N#\P8F#BC7$U=GUX&^]N7X
M-A;O+6Q=- /!$$4?;38W8=;D:OMR WWFJC#-8C)$*UC,%A-8\#QO..FM<)_O
M<I-ITA!AJX<]8\#.7*3M%747W:(9&5MNMU0GOU%?U<IR1D]-93'D+L5CK6N%
MK<K?692WGS=HNL(3;';'5-JG*7#UQICZ%ZX^N@Y.X,\[FVT'2]3[9M;2*X.3
MW-XT-VP#/'-M]E+8G$UF6W.+R_KJ  .MJU=W;J[<OLX2UZP<K7VSY;[9LHA.
MO:RW==%:=X#KSB]-"W[_ 041!T$K[@51&SW%Y[EV]*^"&B_/8ZD2_#NK^ZH"
MJW:A40S0S*8'3[<2ED/W8MDR9B!68C0L1R$R-1G/%?^4*RK%<&_7542P?_OU
MF=6HD2OX;,_B82(J]YDQXWT!FD$X>Z$ IR%X .D-(>/>3%)'YP3$<Q@C\FC:
M?*YK&LIQP 5EW7\F"!P@V9-A" V%.V#:TSE^WY;>NW HVE1,M6JUNV%;3;]K
MU'!88E(P3BWFU\9+(<,- %,H:L!<*1@\V"_CT70%FG' W6-.X0@F<>2O0K90
M5&(QG3O45,'.'O?J[-1='R$OA/'@^Z<8V>I7F:.Q'BS$N^!"HPG8$=5EXAR'
MFJ]6K9>R,%Y8B&G-5VLV_WONZ'YYS5<X/6Z*OFK'#1:Z24;"2K5F.'5L\/+4
M5;FA :WA/63#A\GH5D.M9F%V/$,74]^KI)ZI6"&9_L4XGEJ/S+#4=:+ 0GTB
MWJU=H]BO9>MB6MP5OU1/#H@ZP%R0Y7!(@;NEE1'78.'@HNR';0-@4'XN[20(
M(DI"E7:*$(ZUC?#TX1%U*RFO3CN-H=P[K5,+C.]6H=<LUAU\^]LIS57\,L$-
MS8R5+'6Y*8SCG"NM"U_ $Q"?I23GYEAD&ZMAMXH1L!\ L\M+ 0G?[%Q'ZG8O
M@I=9LH^7@UX/I'<8HB5;0T";*&K;37'4(=SN]][ ?'KD@N_]=U7!]]D1^7BX
M]?6(_MG[^,<..?KZYLO^'[O\Z,.;[.!P+_S9/]__M/]UC\X7?.^?_=W;0T*E
M\[\_'1W^?;:_O9,>G9V>PKAA'.$/A3&QO:\?_=[9[N7^X=$QU9Y:2]*$6JT3
M7J19HB1WB?.9DZ[@(%!TOI;(>WC36UD4RG$EB-1$65;(7!FBG2\V.@ =Z@*#
M2L.)VW@QLPI3MVVT0+\T(^9+(R\WWWIVJ+E7J9#*FBQG7&@A/".<,I$I*E.?
MJNLB-3<;)"OIU![/\MJR=6W@[^7@8C9;L?-N\O5T, &XV^QV_AK;!S0U?\1,
MW#K&SI8>;LUPFZA.2R@K);@0LHV'7'>;T5]0B=#TM^9;X7?RV[_:!_-UW42L
M*@EY[=-C^GA"0#J_K/A@?*KYVTQ'7=]PL_.^R64--#?UF?V2[\S.5%.=-&A]
M%C_@OH!Q.PI!M9#X%M*+0FEJMW7>ZJI(P/DY)LR#W'Y=GC!<7]G QX.N[>SN
M'R1<I&F8^$K9P]"')9;J1ROR);RNNIU#55XJL!#^9P F]/_%OR)#A%&3SB_M
MW).9I!28T6K>_@![ 0_LP^7J&0O78*R=_AU<OW!O&,[6J%2;WRF^<,O@QM*[
M/_KFFTJ)'<2T_&AXX?HUDA*D*A#(Q'T&QF$,GH)C$<H"E,=SZK 7D&<B.@HH
M">@B+1,@,/30E0>#$X^<+T%,P,NO,__!<!X%Z[06>]/>\-V69(?L\Y;,S\3%
MX6'ZR53NJ['7E6286KN]O]6(\FS203"$1_"D#T?<\.A+C5&5F#N$&!7P*4!E
M\'!=*YK<1M=5)PXM=!ETS@9EJ.Q#NHM)Y;Z>] 8:Z2).L?Z/@?]V4KMER^0!
M8&" \QX_3O_-JA 7?+Q!EJJ8M\Z;<%\J!K+9 0?*E$ [5A<2]C%C>FXXX>I5
M;0Z2C,#C7Y:]7O,DD7FDO(B.<D2SZ(7T;?PD>J_!:\74Y?83MRO^8V)-0ZF(
M5VC'&5:4&;7D,%X@L#>%9*)Z,I"EH1%CC%$%!I5971"&N;B989'P$'9.*[1V
MQZJ-4\U#]:MMP_L,'LP -!X']7"GMS8MJJ[P4."KS[JFXUB\64TJ)K$L3"9R
MPX2N<;%,J55'%;ENL 1QC-"#<]+,,BR!"Q+61H\P04U)(_+>(:T=%H?ABE7"
M7%\A+G^Y\'C3U8SQQOFR\RGWW,SAW/7W7GXIN%D(:G2;:R*[?*4=5>7MUM7:
MF"_\.19EE0%9^\[,IOLMR:%L'G*AGF-VKV 4I[;6*YD*&]\ ZJ!U%2\TFMF^
MH I&F)I5WZIE'(2044S!6F'E_(-@N&*3 L'&$!M&YE0-'1>3H0& "N4)J$8Q
MHC8JAW&S!".X-H&K3[:R7H/<-),-2Z@'X]-ZP>ICT)DM.YX'O]8=3@8#BQ64
M<(D^;)QQV6*'Q:/#J3^^!)SB2V PQX<(6%4;9@NQJ L\I1Y7^KO]C/WY;.%K
MI@D_/P%K8U@;K-/7:]%4=6>J6@"7:825&'?5%M\9!/@'2>;4Z5CJ9TQ?#)0X
M,/#)A1\.L.=7%7.=L\!@JN["%TNM)BDI%,]5RE.;BYRH+"\4RX0UUI)YOE@R
MQQ>;M3D%9\-'3=SB?1QQU2GY+;B=\+:]';%@_M/%F<S5P=:Q,-(KX?-$IU0G
M7/$T4=J[A$M!4V)2JYS8>,$V5_5/ 4'MA2!0*Y\"EF\&%6K)F1.H!; (V[H7
ML6(8%P^^TZGAHHHM/Q7!&_0;P9N>!+Q%X)^XP\'O;LN<XOG,6OQ6B-])NO?F
M6*94947&$ZL]3;C6/%&*D02;^)"T("XS9.,%3?,;!7!R49T9J#COM3_2,B%+
M,%7'@[X;54Y1XU2V[% \$CR9]&(62LCA_USY!>VX29/47RO%>;M_Y2#Z#EQM
M6/' L>E&6!4Y6E#N,RJH226?B7Y$DVI&XY<5X^OGI=9H<*:U6[K)P+H<7*D>
MJ-3@]T0WX11T1P?5<,\EMCPIQZC,,0,QG/ZAJ=K'STX?J.9UA FL+=&5"K<[
M/0S%8013/*+(U'H*^4'GT](://S5Y:#.^8<GQ:^%^ZHVF61U_TC84+DNTP68
M(:7<[,R$ Z.SVE!;UDY,G)S&D*I-XVXDLVX>KAI0HJ^2^=<JCNL8+<31X8>J
M<8:WND$&KCMT\2(CN:>&.L%X7J2"$>5)1JQUCG)GKSET60U<;^.ROPXTKTL[
MZ#0\S3\7.GTU7_??'&>,IQEE(O&&Y DW"LG6G4M<D3/-O-2*R8T7&-NJ>M[,
M=<()&;#10PUT6%,("5MFE>2N$Y&O-61I^O03D6\\WIH[#I/>>99J9T'E<4.$
MRBV5A2^\<(:KC-PA<?G1'8T*^&>5V& 8%!2JW6&W(HZ),:J+<JC:GEM/C<;P
M:$EX!WW8<0P/@<9#[0I^(LAU?P%VXV:*[\5]] _RW7['$I%^16[7PA, D;X%
MX$#X ?3N]0:734QL*>*T0S9W]X87PFOS(;Z0=QS, B2W@(4+X2?O[FRTWTO;
M+3/:IPD'H_'>=$QKHWR9VH/WT">48'8[[.:D5.83SJE,A%4B<8P338SA/,->
M[4OZ.LV:Y"&<5''(!W;;[V?>; 6I:RWPVJ197-MT__(XYTJEQ!<)RPJ3<.)9
M(EU1P-I*QHI,.L+RC1<>O8*E-DU]6HY[NHYR&^2D'T?>M2JG%L%@:C8#3(1W
M]=4,@(Q/ZW8T(:88G(AU(&[AD*>*ORYZ*DT\?@AN&^C*IN'7S*&:=54E-BS&
M:>CJT [U7<WD!S1?;(XIZEM,:E9L%9*S3<@FZ 4ZO'%5#(^)HBV'"B,Z\R<?
M^&SS^0C5X\UHIIB@';X0&U$LK1]'ZMMPE-/H.!CE9N<]1@(69ZO%#HCS%4HG
MQG.G'G4T'%WBD;O :A0WG0,8[;]G[S=/ O D&P'<>&R\1 QG/5TT%6"F\22I
M'XZBEKFPE5$WO5BL4VA1T-9!AG;S"*3 FC1!@\W.3CEN>F"$)6GJW%;MF,XO
MY;]F P?X4ZN5!IXWUF>ERQA- OMQ:TCX31?IYJ)\PO"L\PJ/WUJ7:@SX2L]-
M0PR5QHO>7YW]T% BPL4'0;9_*6'@3=A*J_ZGX>1B;*J$VA'FL/=-PW\TVQMD
MU9'+XHRU""K"O69S,N*H@FD^G5J<4.,"ZQX^[0S)_7!)'*QU&!FF8ARZ=8T[
M_0 Q ^PQ.!/OJ4^V74AIQCGO-O-A<()=_Z0B _T,=X'GO.IV7#](8-5E/22-
MF\&%JS/!:]J3X"V,ID;M7,N0F<RIR?5 O&3$3<>/&:"[G9BJJ!5#^4)U OT9
M>6#00@XKTYJN^D1O7GAF3F#"J@7IK-[&\[:&[P)Y0]VW>@)A78BX850HTD'8
M?YO>?TFCA2LL\W0]-ZQG*>9ZH\=6'?B'AZEGLG5P &"),S@]3(15[:G+ARI\
M>G2+H!VL=2#RDRD9Y@WY@94,;[U[V3D<7)1FU,G3/,"62 6*7-FO]EAE"\39
M;2]0HU@Q ;(ZBC63T1B)#.K8\S!*T^BTSNJO"G8K\)L;!(ZAXO>=YIW,"UL[
M0P#O7.+J1/RL2$X'?2S9"FE 9CR;SS -T5;]!&&<JC=HF@FJ9LZFS[]Z$F>C
MY3 ?55_#9HKJQPC<3?6 0CQZVGJI:K@TF^#3MF^F&F;V?C6'^+*U@87ICVHJ
MWR%NMFLQJ^[<Z&S]M$_AH&Q]0GM/C^WL?;JW=:P-R:DP*C'@(R><9C91PM&$
M&4ZIS[S,"G*;$]KYX_SJ\,?.']UV+GH33#AZ"J+3.JJH1&9'#?MK@5DI,&S_
MY%A2[W,N\L1H[!7(.$]$FOLD$YYDA<@9*?C&"WJCP#3GI8W(M!+EJ\/M:+DT
M*F14GO0#H14"7-V"KH'(Z05CG[JJQ ^SDMN]9)<"7[?2"E?Q.]$NG0)FJWD!
M8B#VE^WC,>A<JG&E7%OJH&W<5L=S]>EOZ[RXN>:<?[X,L^>/?M&F:5VJ'%6>
MPTE0WSA]56E@\++BG,UGVLV-K#Z7!KNY9E*HN@RB%U89JYN=5S<O0%6PB=UT
M8>6^1N4[C$D,-]G'+;Z[^,GHHIB9HJ*A&[E "UR%(J:3/4TRBV?7,/#VRKUU
MY;F>#$?!88?'/1FJ\RIKLHX[M4:-7'LQ 2PV.[TN#3(,MA=:Q31$<@/4O[T2
MFY:$Q-3AY*1Q[I'#8EAETZ*(-F0B"T+ZCPM2->9<M\F[&RZS2NX8W2^T,;+(
M4T:XYX1IK;C.'-,IS3UU/*J+M%87Z7Q[V<7H?I5V@_7A+RLL^@ 2\+(R8W>^
M5+D96YCT#Q[.H?JR5B%+5<C7-REFA1%L_4ME8HM4)MRF/)&ZX(DR1.22^Y1K
MM_$BNU&%!%71ZPU,.]NFMJ:76_2SQO$\P$;#?D5!69!+'UMHCYTY[0\"'27R
MJ U,E5)=1R'K>*8&Y].7C8*HQQ8VO<$6XY@ <]5=Q)*I"Q+XR5LU[N5\_DWK
M0FW,NLN.D0*$@>5:2>_@7Z-S*W16<))Q3S33ZQWS>#O&? 6C2QLEE+"8/0F;
MA</N2416^(0;(ZC+!>-I?IL=4_;GU.\]U&E=/3]3+=\TZ9FKE[?14\7/AU/D
M6->XL,/ FJCK7$)_CA@1JCX]TP":=E>W&E\4;.98D1KN=:$L+WPJ;4$\E]9X
MQCU=44N^M#7]@TFV+[\XFWQUP\&3Z3K^XX7Z$]N_/ 8'PJ=>R80QIA/NN$N$
M83+):2XS1Y6G>;;QHK^D.7TMPY?!G&P@+YA.C3'Y-!EU;BKO6%9LLZ3P[F9'
M86F) F8\@H$^K:6;EDF$UN-FH3HZTGU,HWC71O!:P:U!'<1K=.*R\L'YT)Y(
MQ=0VK^!F=E67F>>Q1PH,,&D K U>50E4"[=L#$3?"L$&J(]=B M4B;JQLK@Z
M*0CA0&24N&=7GZ=%X+1U@5D^OY<#$"UL51?EX"D^V&U9 :+^BR2,V*RQO6UF
MJ0'ZG:U6V?W;NC[_KY;--DL>T#HCQ*MN3">O>6?C7]T?PTNWG&KE44GQ(HO"
M4H'Z93I7&__J5J#2GY[81'8ZY#R./7]""T4B5E,;+,[\[$KC87&;WJ#Y_&PA
MZSR]P2*C012GO__X?PDC(2\?  HKP<OS\TGLHJLNKIJDP2G% =;BG52QI#%F
MGL0+70Q=8D)CFE%\P:A)=:[X/Z__[K:SW -25Q&QUNG&<Z/GFRO<65((UHX<
MXZK_H$(>+ =QA= %R7,PL,$5TM;Q0NH\3[5C[M8Y@>M"GH=,E3_<@O%\.BX,
M(8K)%#P>81,N4Y;HPJJ$IUIYF6M7^ )SMY=X0)W*^>EV0BUYE<V$XH6L9'&/
M8:%,[!=1%Z.K+YC4]"UE/\LJ?09^%D#B;V6_<N*#[]^8?4M0+>1FS%8 SUXP
MV"-5F4ZPO  %/KE(?;R0^K6B7J=.I*DV9*L]J^J,RZ QKZ_5J1 ]Q*9;GXP]
M,R*<Q5'W!I=)_&D\J!U5FXP=*-QN_/U6=3R!M3"D?$[K>>:+'YJD@\WIO-Z]
M*.?&.II[H<BWU]&@;_WS(0-<:^N8$ULX6:2)RUD.7J2VB?+&)1E5!??"4"GI
MQ@N2+I3/A 34.Q?1M-+8;UMS4,GZ3.%!I?[GJ@]FTF3:%6CXQA1S6K*\+N:Y
MOIB'//UBGAN+<^:*>0HI*,U4*GFFN#:IS(3("R85(3G SAVX[1Z7I'F)>EN5
M%UKE?C9?N$WNY\W)GDON?XM$SX4<SWBZ%Q,XJ^_/'0M&[MJ*BO2VN:#U+(SN
MDP ZE\,Y?=3;34,[F5 WQ4$_1N^U\GFBPL-0ZT[M&6[#L%\-AH?3++YU$49+
M)>[0O</=8PZ:D!<D2ZC36<*]M(DTCB0I81:TI1#4B(T7>%"/.O":NM(YASP2
MN%Q5N>[1./[A0@%WTFXX\-N T!^B\.\'V?\]Q"!OD@RKKGY"J=@_VSI6(A<%
M:(C$% 6X4*F@B>0&3":B)>6TL$[E&R_DHJ$$4S:Z/E?XN04A,'&GCBY%2ZP^
M78H &E/P0P<$4#,A[<B71H7@Q,J\D58^RQ+'[9I(G'.TH/Q[/N[36YX[QJ5?
M#E1OV@)UYZ*T[AS0YO40JVB<#1G>N_W^X'.E6)]=Q!K4]=;%$(R<Q8C7;)2Z
MR76-/O;+G=>[722U&DU4)%&*J5HS(;-V5^@8UUS@8)WVM_A+C4:JX]WGRBC9
MVWG[+B8<G RF#6!O1_2(H\.(1(M*:^41\V@0SZ[*_F<WJELHH!<V'IA/%QAE
M:1W]*'L5JQSJ3#;05/"ON:K.N<8NTCM6Q\_3'#5;CK#T! L!@\%?94LOF]:H
MR[ ]QQBWNJOO504FQA,;>%%:>6KQK(V$1ZO(*.=S[;I5KD@(-H6V"6#KE1>]
MJAYR(:6P39;6GN6JK*P;1QIZ,\3X<.B(@ VSOCD@FJ6Y(EPX07+.;<8%=>!H
M.W"P?:J)S5![$Y'RH+WQ!Y;.!$3SFW7YJTE@6<0PZ#I9^WH=_C[;/WMS;&G!
MG"Y\XK-<@667RT1D1B3$":-8836G;.-%EJ\,@D;:&U170?K4]4S\]Y& VQGU
MXT&UX)4(P**_K9 !=L_V%!?6YOTL=__9^V/ME' RTTGF)4NX=3)1Q/%$>VD\
M$=IIZ6.1=;+4OJ_\QZJ9> -0RQ"M9L"]%;+%-.D*Z!>+X^K#\R@2@V$=)O91
M N(Y?X"S)MZ\)/+>*N29AMXW.]O3/*,;,XC"2!9[VS7G3O6 [HB7EFI7<*VR
MG%C.*>Q%R:RUQDAPP^S]#Y 6\7*-E==CY=$5C/<X5<P*4@!,*BG RP' %%X6
MB6"B8$8+8S597JC0@"4*REU$0&B9PRY4PB.+A5,@#,X 4A*>,IGZ?+Y092T"
MWTT$TKW#DV.1*<6%]$F6@=_+!7<)9K@FH,A4IGGJ+*9-TDU^S:%AQ2$1.@ET
MY\[X  =#5D%=0H%G>"$'"YO%-\=G2]*3YHW?*D5I<[5C.I_/8%N-34<5=D46
M#-6KXXYWLO8<,=)KR?," \M:DIPYJU)26.*I5<>[MV/"V:J&]+89T;X;KZ5T
MA922@\-/QZ K,D (DQ #IAPW%@242)THJ;CEF5>%IEB")ZZQZJY-;:M%8G3J
MW'A1A(/.C7+\/',F6_6%:>41A:YMLPUQD;\K]** G1&]HSM!NQ>>%)Y0DB.:
M>^4=E5RHPDO/4^KG4N3O4[ZZ]H9NOW'@WZ-C1IAFA1*)) *](6X3H=(BL5:Y
M0CK/B8*-(Z_3\!4!^0 \[K8M'&S5^I<9AHH6KT'-'E,;QZ>3<^QH4H4>EA/A
MM^(\MY75NT@IP5-O1KTQUG*KK<X4]R;#GN4"? 1322FOI73>9U]+Z8-*:;:W
MO7N<IKDHI-:)% JDE'("[IIB"1B'W&F=>N/_?_:^M#EN(TG[KW1H9W?LB 87
M9P,8[3J"%BD/9T12%FG[M;\H"D"!A-0-] +=HJA?_^9152CTP4,21=)FS-@F
MFPV@4)65E<>33Q;/?ICLI%=**;B\[WMHT$'-W$@<(OM51?,.:A"]!;:U_>[9
MP:\'S[XWY+[_;EHI1D?Z@OZ+(%__E$C=!)?\^^C@GW#-#5LR@'R?-$NXD.X]
M_ER)+5/TE0JP-@(91A'8'6(R*2,Q$9F?2S]ZDMAO*;'YQ?'>[ML K(Y$!HD#
MDIN"Q.:YDV:@5Y-)F?FP,'D09YNKC6R)M>A85C2HK>G^CNVIP93@SK,*N@6V
M<B&I#:Y$K#U5W_+?F&YL/'I?-Q<U6M8O]E^]VG]Q^F;W3J#.$S1LKC5"-F!I
MT$QR KH:&^;@)E)X& QNX V>86E6'#Z_3XCV*'A]\GIL*C3LB;?KE7L:<BI<
M_+R-'OA9&059X09Y!&>2)U(OGN2I3+(B#L+$>]KHWW2C7QZ].W@[\;.P*(7K
ME*Y$*LXD=K) >DX9B[(H(IGX7H94G,&-#*@I> C2H2E=(:JQ9.A!A.K\S NE
M[\.Q["=AD!1)4OB)5R91'OMQ(I+K0G7!'<5I_FJ%@/#\3RB'99&&I<@*Q\^R
MB1-F4>9D&+$ITP!$,4ME$(.)%'GN&/3ANBS>-DP79:5()X$G<C\.XRC-O"R:
M"%DBHW:83LJG,-TW6W[OZ'3_K3L)O2(I"U 0&8;IRM@1D1\[$[?PB*1WXB>W
M"]/UN81M ;M!4XQ!](Z[OBL&DSN*W=W*0HXRD823N 0E!:=CE!29!W.29E*
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M\.PMRD\J_<R))=@'8>)'#IR:L2/%I/3#I"@BKUQM(!H&L [P5YA]#Q:B2.(
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M5PN-^W0*?@6!R#^^S5,/;.!)YA1%&CEP"'J.$&GI3$2<Q##18E)B7?:ZN?6
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M)]DV3R?"+4Z$HQ?#P,+Q[EO/SW(O1&BOCP6-,1SJ29F[CI 3S\LFLJ26FX3
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M?& YRP(^G$K&U*C0*Z@"S-$^3ELO;UJ*1$LR.L!]HDJN/H@Y'G52OM^4,*)
M[6K(D@/%=0/7KBAAROD6+6)"EO5,+D9GTR:#NW#(;U0C5IXB$QKII++$IHV,
MUK#3RQ%%$AD5 H93*RZUI:0?9\<J..I/KO_F&(S&DED1&,1B8SRA&_WS]:^.
M%5S15UF!@T=KOK2+6JJ8Z#".K9./NW.$@_Q8-:,72DH(6+"+DO('G,^Y@%\*
M'1Z"[\W/13L3.04*,(QTLOQTWBSAZC&AW'_$5H__)6;SYZ-#U!*%&/U$2_02
M*\GY\/V./@'7_T4#BTP?H9SMSZM"8G.AUZV$D<N"P$4'-4B:VL_?/7NQ__K@
M&5RY1U%L24.#!:(DNB0$Q&N&5&&YAJSS2[AF;_?-ZUV\Z%1#*_;P_@M-^*;O
M!=]L]O![_SSX=?2K#O>=TEE_)!<73?M^W,,S]%6GYQ2^>X-DW/0J_%QCB!^B
MN&+._\<W1^8B+-)H0 DM9_#4PQ=[+_"QU&RH%BK<I08 GW:+:@$F 'SSX%=Z
M^7^+6KX7H_UEBP$N,%G&HR-]V0L.'9JKK#^9S\CI^"?MR4U_QK_N3D$!JFS5
M0;^A]LR&.B8;">2APXAQKB)("+5X;S^>%E:/R:YZ'H]>3Y>SC )9KZI2CDXP
M+4KW>2/1,&QA*E\/90W^!%8=3)+S3SF=X<-?-6=5WM'*MK-F]++J,!E"MUI@
M*$JM5XTF9:?R4Z]E77>74Y";2O#??Z-D$CP7Y&BWG5T.IT)+%D? 4(9^@R-&
M6"_Y"+7#;W)CAHU=5$8K@@[65'DJ>EO"VE<FT3?FS%I-<H\PO!8=WIJ:HZ_E
MR.GK:T8["8?1R!:>H,'P=C-#0[Q1*9]S[ BG/\B:IL,ET^%+4#954<!QO2\Z
MW(O=O&KY)#NYK LPNR2-]G#_S<GST2O0]6",P=G7/A_M9\U4/+_B-,#D  >/
M[1'F)/4"/(T/2Q"E=JSBTO#*Q2626W<5W'7E5AON<X[ .5:7H&M!O_0WQILA
MN+,&NV/XF \"9 K1')RK7S^^B(+#.O5:J1&HK34U)G.P:*C%.$S0FS>OG\.A
M7349O &X(F(TPZY &&3E&?SIQ\/G.F-'4);'>T#N<MQY<])[)#2$D, 1?+1P
MP,."PH!_*?M,"R%W47/1,G"?D0^2N#040HB+P#0D07N^O*@7<E1POS\&G:)I
MI.]&7Z?%[._8$$)A*E'@&2?^<0%V'):131D802.#'VI]%0]#LPV44IDX,+?8
M1JN6YGM#<Z'Z<,4<],GHG='QYJFD[L\MMCN#.;6Z#-H-$K?>7Y;PIHO!GH$7
M58B0K; BA1_9P7-LTY!,CE_9GIC86L6>#(:]R3:>MY4"#1OC&-D0QGW+ZTTO
MC5@$7KXU&  MV&9@DD+H73]-2I3H+B@,O0Q9V",](WJ]F=*"?!RBUGE\;LYN
M3[?&2,_ 5()?X/8LR(VP""P+ZJ')+<V\G6"4Z5K-WZ2U 6T_!01PB="I#%$/
MA'Q14&B0%=4>2&/^&+1?\'5\R,YFE8*7-%>O9(^OXUMQ*T3*YZU!S\8;47NV
MK/:-/C6N@N4/(1DD&"JA:CG.'^S^H+>3A $9QX,!-1P0DJ0;0$F.:])6/RJ@
M\5U0CES+H_7-/$$-*D:_6NV'#RSE+=G<!5=L@>'0+N<::S 2"KBGP=IF[N#=
MR$^[[\;P6)XA$/<W7ATNP7\NL9@#=N3@M4#654Q"?:<[![TISF2W>6(*.167
M7 Z2(5:0(+Q4WF:V(D.-X/H>2D??4I^;<AE.8QL-38]"Q82 /[3/\ B_&(%"
M+M 0IP-"X1.WW K/_W.8$:S@P3)M.(%/<&@W&@=V=L1[P_\U:E?-".6(>G!D
M'Y#'D_,+],$CV"D'M4&4: RS%G9<L@J%;<8)(3'"> !;5.<XZ_,&M-%E#W>1
M\.7F$FVLB_.&$7/#"S#^!DO?4+("J_<(0(XQ,H5.HN_C^FCW[%(G0ZC+M/IK
M=UZ5',:D?F!2X6RH%(4HJ0A6=":H:QA*VQDC!A'\4S/(&.1F@2%1;OZIF%3H
M[.Q?@L0U@Y.EYD>!=-5ZCAHT+ @L"/Y"4X"E@]*4G\-XII9]3-4FU>P^E8:]
M?C/1O8=O<]T0W)F"C27C(.%=X+Z+P4EHW@.34/5(=0WHK/U[W;F.<2GKCGKA
MU]:YHOE6J:NF/1,UI9/[):8&Y/9Q1@VU5570G6[1;QF]G%9@/2.8E":#;6*8
M$%T0:YJ4\]30\BDX>W]"[?7 [6MYR5DUZY(NO&RMIHL.B580XNIO?KH3CA3'
M!UWZMS#>B?4GU%)WSHAC/':K>D@9L^82]E0TVF(T=#2:Y.B9PK8S;O&9:2&-
M=^CM1E71\R\X!A#=005"%]P,F?Q2!A9?M-4"_*C1?)F!XL(]+%ME::X^?\QG
MPF#XQ/S&UO/$W_%6"$^N,,?IYJ([5]%U^ '? OPI4UA$1[*#Q<R#EMG$G/*W
M8.):LZX,;G$&7B@RTH$FZ\FS8(BK"]RO'KH#O?OYMZ1?. MWK4O"[5G7=5,;
MYOY/L?-.J0AZH2:0\^C#@Q ]VX%CI)#:5N$>@[3[2E&ZII!S61,&5SM(O7H<
M./B@S3"WA#6#K2I4A^>,==D)PUC4TO]2D^URLA##0E'J\-X:X"*5=NL" %VT
M+/2]2:'?](;:+]25(PS?525Z&!T?&Q0-65C&E/HS^%)(* 62L6>MW",1^EN6
M AX<'3MA@NVM'\7;71?L)\,%*9\*=5I6G=G"!T='Q[_NGNZK# X&-4?!*MA%
M'0O&XE@#C(]'>LJ8,Q3,&(I2HV\RPW,(]OZ\J6KC3^K'J@=@JUQ0 <@3P@18
M'RH*]ZMT,!;R5^T,H5AJ"'3*X%5<Z-HI[#SOUM5Q=OWP0+N=5QE[/'U<CL#_
M".'#PZ%G6:!,1"V7H)*FU2<J/"*L,]L'-I).X\]A,,>@)C%]A>72HG_AD]TW
MG?.B^=7Q&4*G:MX$@>GZMSJI:F7%%Q5%9<ZIWXH]!$7]@#=^ B'9(*3X<8"0
MOJF&OY&: ^?_[$QB9+!:<''DM'J/)C9!4)E0N+N<S3$GA!4"?=:.;(/5+7Y!
M2:</9&EQ</E&6YO2%]+:"Z=D=B'DOQ;J6E4&TE=^-!FFH"E^H5[!U(":MX,W
MLM^'"W?TEE5/5:?WSNB?S84DQA3#X0).8TLU0Y(A"GKPZ'2(\1J/C-%L9/:H
M8#XS]#2FOI@S2Y0?*"Q_G6B3R!T8C(I"7#S5Y$:B!;M88!4XQ?:5[8(@Q]Y.
M@0_9$#'CJ3HKN9M)2F1R A?+>]#'NEC1B5,TE0@Z17:V]4B4"L0$P)>8-Z;
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MT:DFA+K9*-X(SZ>5.U7=\#*PFVO,4V+'7$.LTF&]&)<.@?ML/9%2!*KFF=H
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M 0"?ER;VROBC<[D^]TU;G:G!8UNLJ9W,4KL(]G ?.>.*S;Z;G69AZ'N?6PX
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MF)F4CFT)4X>'\TJ6\-XP!V0''&-:7[9CG*D7^\?\;/Y2G^D9?.GE,<\0PB#
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M.#+P&>BA-#K2C:TV+D=9"XK8A-GQY6!J)97HK<A/;*$'5U:V'\?*'*(N!:7
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M5.P)!803RL*XK3M_W&'S02O+AXO+R.'+(OCEB^"#IX:61EYVD F*3*GD\=Q
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MV/7%7C[F:E5XVFZ/+=85KB0AC[='C+"K!I8.8N: =+;<PR]/3M1R-6QX[#.
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M=R!D7)Y>29$F[PD+HCN27&V>+WE:.)W6;D\N5K=]O>7F:.L^/'XQ2HHK>PS
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M8T]OJW>,[VG"V+0!;DM":/AUZ!BTJ)+1=U;$E)-*R(;=",6U;2 'B!.XTHG
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M*GY_@?KD(6U[6M4[PR/B)]<&D<G&WH!=C/@*2<*>2++)?G=]LWU'Z9ZB3;O
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M+_089Z*.[Z2S &AG!$/T^%Y<.8F ;=W"465G/>Y"#GI&14@Y:,?Q+0?BV^Q
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M2DA:66-0@@K5)LJ,S%E<@!+ 8$[-!"H)$CZTT8%'JT9&;;[)=HX0X^Q0"#]
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M/D?)E&:QF0?<"I-.YQ1WRYK07IR9H^_IX,;^M;QQO J2/I!V>LKTHP5:LZP
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MC15PNAB@6O+*-UPZKI'C%YTT_0Q= 8#E98I^'0DB!>/'\%"SE[Z")T>E^YW
M[,IZ1YZSL&N@N3C"DMSETTN[")4%-G,3DT\A6X8*ZUCO<:XK:"WP)\OM6I<*
M0>@4$J6]O"VU/1%R_ SSYC\5,A]K+:FN=68X/]18F4F;#)M6)>@9%;D"L5+L
M)#F58@<P"2E#$;Q\WXVLUZL,0U@RZOG^MJE   IM2F ]=Y*U1/6WJ#-I-=-#
M70%^8%L7UKR9F-G7>&,%,".8U)2SXY7GM''H=Q5%FLGCRQ<U&F36LL3]F&GC
M-F"BZ"-O0%%$F4"WL F&=9:+#TAT4&L!TEXG!?IDG>$<L*+D>E6 -QZ=-_<
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M/ <D& FK6RP[L[HD,I*#J"1:8>"N-U.Y<8_J-V*_EU[+^O.L'NI?HP'O1>$
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MCBT=[$(VQ=H;D^,#'R,,4X4.3>,TP#E2R\ZQJ4&CAJVV1.+9.("ZZ(<!T,I
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M#5"TME$/@_TM*49R(0@4M1R)E 6(J:4D<31 )FW[\7DPR;5?E7>Q-'/N/HB
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M\%'TDJ0@J$]8FW:W['.WQ$-I>:P:.[5#OSM%9L++8<NLN6H4<&-RD :BX)%
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MN-Q#(UCX^0)I&;VG_XNRHWGAO!+H S"/,PZ?<=>PAT**PTJP7)^)I.;^I=Y
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ML \#I3W$I!$&:Q.]U1_ 7*:ANA_QK4JL+C(( \N;JG;9V+$ ZXA8?4,@N6-
M*6HA4G92K&R-31+:0H%/T" O:XW.[$#GR,^F^FZ7^Y_8+3XV]NDGJNT[]&)8
M:7)?$?P$;_").4*QK/@D7V1DX=93QMS:J/<'@RKP.V]/9.2X2(XLR,'< T^@
M"\=PR#UTL0;(OY'WW' CWW5)MY$(3@!IH>WZKI1%-9,$'('49!Z5'!&;1.R6
M=,1]@V$VN;4"&M@**'SV@5R=6'VBXW]-X:R]1(;_I] UWM*.93E:,NM*OE^%
MVL<;FM_5"K8+WW,LE&*> G\?)Q !42VT54-;G[;0U@W#@\:OQO@#^D.>&0?L
M]@X*Y-S2>57#IB*I&[<X=$ Q"<-Q[(<KX,X@-J)<!__@VCJ5[TLH+.$:V_ZD
M?3#.R5MG!%73!%;:9* F"N:78_\!#/4@]4_H!/E]E3DB6?-G;=Q90?:S9CPX
MPIARKZRZY<0C)F2VA\;T\)R;C^/MFJAA,V_KZ1%:B>$H07,+'EM:UFLG4F9(
M)L"=4)[7R^L<SV;59XDN- 2/!T!HX%ZMN4DWNEIW>]P\V \-EA.Z'8P8SXO
M.4%N16(:;MRHKT GGOW8)+:#93^R^CVX]4JOT.VHJ5?<AEU&9<V+NWOA48>P
M GA+=G*6'D+_B7(B@9 MP>JRN628\YD=&D6WY#9)<!#S3!,YO"&R"T-,^]S:
M&&[8XHOL!GKEJ"L!"@H)A@YVY+8UMI.V9WFQI(U-ER-G8YO;#;$!1M.T"J45
M:._4=-I9'5KAZ!YR#J, 1[Z6H*B- KJU0AKBV#C Z-?-3%[4K8P"Z!^:58<U
M G,H?J.X8_%$+ MR.S)F82%3B@],Q(^'?3*"W*X?-[M&(8D+R/9)G)4AN PW
M0I*"MT6M?W$M:?;) =IMB" VTKR9O_MO>\M*,76K&?S]V<E)YX3^4]S=%88$
M?;C7]-DZM9<8;M@1%_F\7*52E%Z'A77TWT04)58Y+-WHVB.L$'>1X@+"V[ X
M"![NU<0T "M%FX%LAV]=67_),(5FE^$G&%)"?#+ )_@\JGU!!W$,QE*L:*^L
MWMBOWV#YZM6[[>(ELA".J]M$=4V-H&L?+'/N>Q< ,E=8MSXW)[9F*W[0H9F?
M7Q$X"F.M CY,C[ >"%CNDC)_2MBD!IH>&%1=D89-PN0Z/+.!Y);P+:1Y;%,B
M"G?2ZO@AOJ"C!0JU6G<Y#P0E,G,C8F&JY>5*TK86JV.5#['#\<(^AMK=Y&L!
M0Q9Q^Q1[$T_/([J(\BO2R?+&H#-DXZ6J,#J]I:_=@+F^OGK%MX2M8 ,U0:4'
MNE<$N4 OP+V9LEM^Q6&%"E'V2L0'716P)T? ?J^F2+XFNN_GWA\"2(5&_60=
M(JIV6B,[ V*6^U)'K^H.^W)::"F%MM[P5$..,A&LP^XB&#O[?>@$<U.E";Y5
M6HJ?C*.EJSJ0!L8Y@(<9Y D*G>%F%-(8"^>X#JK.TB_)C!KA3GYF!"0KB1&*
MZU5+;>'%1/KDHN2F,:^F,/-,Q\B$(Q #)<S:2BX >-/PIY+' CXTGS-U$P^&
M@F@[1W2/>4VH*3S(_"_09;5^.KRT(WZC[>:6?[5Q@1GX[) L2+7)?[<3S YK
M>Z1,4'%!$*UBW=M= 87JD9J<Y]!=X:X=M?=J#-^PKE5M@"F/0IX%R=,@P0,W
M;C.3N=)$9=S;\^7,<+G.FAN8<6UQQ,VA(27$E2,U+/5W).>#CS% KN"0F[H/
M0;#?SBH(1ED+E]MMO.1<$:?D);(IQ(0'W9FA6["WU^[QD;<8D_B45.'E4A3Q
MB1Z7B+)@?EP2K]L-%?!N8NJ-(^31WRM[HH^@"D<JZ26UY"[  *UC.G<BU#."
M5/#<&-]NI9$;#@ZHF0Y,P=J1-KK56F8'Y]F\4C@8X,0 PXCGH)YE6.DQK<\H
MKDP=E)R@3UW9-[>&#2]KUXO#G.I3$58=PD#<;ZE,8[C:4)KY?,(*&&S2=$]L
M[3?BD*.G\MH,<3%%_9/>>8=FP#Y'.1&1+7"?[0S\EN6+3'J"?[2?>E7Q_OPA
M'Y312WN3A?VMR6(JV- SAN* P@^%2]R-(TH;M_'VH "2PXE#I+@Q1=U.)&SU
M]<L:=CZ^%5:T\J@ H,%'I^9K\H3!7_#$C.VU9A$M,' %.9(]?2IT4S06$90W
MW2_[/?EEA\Q=K.\$UT_<[4=H^[B?*I_O<,E3QV>EE,2_*G2!A;4>/89\_(PL
MEN.L8@=XV4:F?-)T^_#6C2PX>_N+X/9,ZCM"FFO(..1"<"#3LX[).HB'OZ%%
M-!RA\L2@51R-RG&N>/E0HI"CH\"2L]U%UFI.N JQ&!M>#V:)VZ0PLQAP][A(
MTRE((\)\N/<M@[$"'R7$V]GQC<DFA]](C"?6NQER'B>KH%KW<;1D9)A]$!-/
M*%UM@Q=GUM1U\?3#0K2=R=JJ9!%'_SU8,"(=H-[ DPU,&:IWXEE:^(!)/@ S
MR5].BNJ&7J^(\02D;KN<8V8DP)-N]$O-ZZ.<NJP@OK[?.XH!6: D [*M/V&Y
M*#R5I8HD)P-XZM!$DQYOQ9%;<R1LKF$'X1I _O4M$ "6D$F&<L MYI6!7P6D
MMI)0#IB8LW>#LK)4MVL/SAY'<_Y0>;1POOMHU 4HBNTC]A=-GI)1^4J,VR!K
MTW%"2358"%7-[5,HI##M<=%,=;-[</X(3A3%63 '3"0N<UQ3:"\@OS6'R49F
M?HF6 2P%:>KCKAV#7!S,R^&Y(]?Z33$8E;&8+#F!5)7"/)M.JXP2MU0(8QP)
MUB@Z 3G0(_PE?]@@4.N1.=[65,6:ZR@]VH9+H;6GQ^6O\_X!/0A0Y=3SR=D"
M!\8>I'FMV1XWU@N1/YQ8J*5M@U0.ICQ1IYRQ? 0HL';9CM&&VO9_)43C60O1
MV!@GV-T(2XXRXT,4-E&'%>/,4+X!_*L\JQ<<@D2++SYPCMU7KBGA1.DWI?:C
M,R_BHKBT2C=Z ^KBMS&</=(J(;7#Q-5JV .!$86#*S,3R0N1@+649A4P! ]Z
M^QO"P=GSAI2^ Q(EQ@@Y%S81"#<!Q=7$ ^(@MN]&OXY-1EO2IU"MB1G:TU'K
M8"@)#)6 LN%%*LD.G6=1(QG<CA\'?2IU3-HK*!5S<$IX#A(S,G6/AF,?ROLZ
MB1B(T*BEJXL*%(]D*'+#D0=-4DS(]7E[87QOSN^1DQ#,#0M_P(6+E*<:RD(\
M(O#P)<  G,V_BX46R%Y->02338BFGQ7DF[NIXH0'V#7$92*.3[P6R<]3GBB&
M.44AM)R! ;S&2@_9@.IBYM[<QB.+O/@-IFMA!O8>!C.:C/\/4D0+0]DV7#@\
MH;Y.&R8L5TM]M0(?N5B4V7*YLP[-X^J.Z_@T&#=_C<GI#!3'MG$ZD.*P(8O9
M9!CA2FGRUT?ITV%R>7IBG@W/A^;L["P>#,Y'YW9Q]D9/3WK/SH;_WSN[>-1P
M?VO[AD?0^<.^SO.RFMKG6;[@A^*3ZW1O(B?1VX]7/T?/NO_W/[UG)R]6_[SZ
MY]_??O_VX_7>/=J-Q\3C^,G:%[A%D=?]*[=L?(%5I^B[O\QQZS@7I[#!U1'R
MKF:E>2Y_>0'M:R;Q\GF:X57Q2[75!6L>B^/6*K+/@UN ?LT^PN5E]_SD'-R$
M>6'_2^3&[$%TT8,XGB>KO[OH]B_.UO[VI-N[X^^>GI[>Z9L;G_6B>WZQW66/
M<1QH+.QHP_3\]='I(^^2(7?J>7]V&_7$J-#@ IVJ/N TUO?L@UY\S@2@7\@[
M9.T&>1"/2>.;F"%C9)X3Q\Q^ZM%WOU20S:VYLSR]&V;N!.;MT58?;9AD&HJU
MT_R@!NBU*8=%.I.,XFONU>%&;(OE+F;&>MAF\YC]L4^VC]$^QF$_QA<>#-;O
MN/.I,!KMQB7YC#GY2]SHVAHZ1U[L_0&C<6%&?WTTGL]GSX^/%XM%USYF]R;_
M=/RR&(Z!Q'QLDINX.+8!6WS<.WGZ]+S_[-@^;J]W>=KK/^V=]<_/>Z?GQ\GY
M6?_LV45B;D][W?'<VO73;N\OQW$]=;+KLV;CNFE7QX-9':]"4._; -1+,?%D
M0D5>"LL?>]ROP+ 8= OA+3MFD5UT7F[X!LL6V=PE1MY !>;ZZ-3]#N^&91I"
MJXY2J)#;?_L!FKKT3SM0]SY[TEVSD-F\U9*R/8J-OMHJO^M'6^/[K6ZOD\NG
M)[W^::]W<O[LHG]YO+@X.SD[-[>?3A=],;[]UOBVJV/-ZGBIFN%\D&8XWU,S
M'#3&^:<TC]X'):ZR T:ZBUT2DNAE=0/-L'HG:"%[6UOGOM2HUUGGBZ,?73&:
M\_7.*,M-^W33;],L/Q#7O'V,]C':QSB@QVC=N7T_(!_8:98?G=KHIW_;._D=
M AZ)AWMM0/R-3[$/:CE]_&J<FI%U?U 2\).)WC$)XGU5 -0/<;]O;? 9/3OI
M/1X\>7S:>P)?^^!JP#9:_9'@SDD^PUZSZIO2TO'TI"]![W5<#.+,E$?O;B=F
MB;AKP!*?V$\\)C\*:NH07S_1:_&>ZWA82^E^:YY;:X'W_8#U[<F[L^\,<!L4
M?],SO,;^OG&8[YW87P)/W,T(?Y,A;&L(]_V :_R4OKBB_= 5W<?Q'_VYM</?
M[ );,<3(T%OC#$,6<IVAUN:V=X'TE%<,P NL;^_TZ<EV=OKRY-E6=KHJ6(W3
MV^H__Y<9ZV;<#NV9?9B,WDFO^_:7ZP"+LQ^+L8^W_^?W'WZ*WF; HAL:!TR*
M'L^1D,3_G,@_)SGW=(IG,R!<,OP;>;4Q4;!>Q_/8;KD)]B6,I9DHWF8>WQ!#
M!LB_"90*8 >X:Z#@&7Y0[O>DVX20:G?$/>R(ZU=__R_=$7HA?HQO21_Y"CB8
MJ&=R/1R;:;P1PM<NT'M8H*]>_M0NT*8%^BJ>#"7._"G-?AN PI(LU]:@[FN]
MOKYZTZ[7IO7Z&AJGI^UR?3@3!LOUIY??M\NU:;G^% _,I%VI#V.N8*6^_W#5
MKM2FE?J>9"):3^!!+=BSO2[6W="CMGSY5RA-]!YD]9HS!H^)6XT]5LL@(T#T
M=Y35(O$@ ?]9"_"DI5%M?HQCY*1^IZFM-&"-7.OO[IGW:M=&]X3T,;Z4^'K6
MO;B\&_%UTU4O^]W+DV=[H*CNSRS]^0N,TE<K@NSTC4BWA(U$"<I(HGR1&#.U
M-@2;/]HG@,HI_KWW D7'9E4!DE8(60Z+ 1<NP^]5SZ]8T5C2_+W+T[-00%^I
M(6*/1A9;2.D.*/=1TFTZ]@D+?M94/^IZ%'1*8A+0C!44DJ1?IWY"_V"GC0J'
MGWF9\#NB;#>%3A,#,P)5/! G 4D<4E "Y@W4-G+2,$L+ZX3,6)V+6Y>*BG H
MN3^Q=Z[@: C>:<M./.<H*Q%VT^QU^W6MB2/^QT<;5'AV;KQW?_$5>U]SZ^Y%
MWZE1=./!B#Z=KQ=]^@*YD:>]1]\]"*FH^Q_7-6(F[4_[T_ZT/^U/^]/^M#_M
M3_O3_CSXG_U)CVT96%R__=LO+S_^X\/55CJ(EWN3$=04 "*D_UZEA2&QD>W2
M1YT:DST:QV64@'((PNFX6Q.SV.UMH..&G1\BLP/6;F#&\60D&NR8%*(/L-IL
M!=WY\(*NS6&R79JE=T;UH /113SKGO:??O7T\.E%][)_^=4OV^^>];[^5<\N
M[<.>?\U<]M<H]SU[R!GR9HW&3>H5VU12SQY&)77/=)Q]5 )>QW/S?%?UC7V\
MT,_QDB52^OUOZ;V^7_ZQM[E/0=#+K=[HN#Q>IXK\0S?ZX=WUU?N_1S^^_7G=
MA];]^24%[[T;%W80T'^8S:,RGZ1))$/_[8CXPH3FI9F-HQ_3Z0.0\L4+;M6
M!A__O73GZ6QD5+V6YHN[^GG\+HN^)P>6W>4/SA-^LC5+JM]KC]OVN&V/V_:X
MY3_?7WV\^F"/VJOK]GP]S//UO0&,R8^0-3F\TW4=$?GQ^R+-H&'11/T2SMF7
MOA\??W;MX?=EZ+Y]0$$>#.KC8CWJXWB0)TO[/^/Y=/+=?P!02P,$%     @
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M$C&MAEX.G7[&G5DJE[2!3\S$6./2:M77FC_%Y/J)<FYG%ZL<(%HY&T93QH,
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M%*P3RV,,8]7?.#_61M/\QIC[0GP?]'8'@Z 3 LX[TF4U4](QT >AQY8Z&-R
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M$/Q'D53/F13.%+8H7W_Y?U!+ P04    " !A?ZI48E5,\I(=  #L(P$ %
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M820'59*N21@2>)#6E)R9":GO%#J#LJ5%A>^*(?L)OJ/^><K,:TM#X9$&%7,
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MQ]7% []]P7D:DR1&T85D8JCWE6,AEZ30OW@68$J(W.5BLNK3G?%>:$/:.GX
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M/T]1?\WM'UVQ+VW3<TQ+51^9J229I)H^YPH6BP>%:1)0)T!5:9[^>"0 +B!
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MU+?Z<__QTYIXT#_Y9Z66 9_FT_C/+]-S?/YL<2=<M77 ?8^KWT)@Y\6NM1(
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MP 5)APXM;H!YBM3I4S,; HP]Q*<S-(N<N!+H>C6=+<IAA/+,.^$(>(\N8PB
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M8TMG1*L5$":TB2FEZ->;60R7I+" >!I,J:.1#=SI.>ZY*, 3F:K(,R/<IC9
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M3PS+BDCE-/&Y-(Y/&4!YQUREC6 OF*=B7M33386RYQ)T?9]?I&F[%:XFM^^
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MJ_)6/+//T[D_O_GS5]/9_-UT_G]A_A'B]&S2#J3((DNKT<C6*G(B8\SXUOA
M1!+ -)<ZB3JN6;4E/3L*/PYR5)A!6&UABS[8OTR;Y5^5WT/;6YKD%+[9%IU/
M/$!0_#Y+36A0I0%)3(S6N=(8=IU_OA^/AT851C8>+.SEP(MVP,OLS62QN+61
MV.T/7^-Q>67"CR++$ASG)#"*RZ6>$:>,(BR"R!9"#%"GU^G "WUVK\UC)M)C
M&F/YX B9?05AHY*,0B9%/41*PT@(-N%[0(,QP+T-=5R$1R."/]^U)T&^'F=S
M#BV(D<Y.YZ Y@<4-@\5]1P9'RB *HZ@.GIDG_9+]^0X]!NKT.5FT\_7#S5%
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MGPJ+E51"<A.(HC'BF6-BZ1.D2.# ?;#2"E>IT>^38>]#71<>-WGW4?"@O15
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M+V9?ZE\_ES)3"$I[K!! .LK6L2B=)0^1RZ1CP+1^3]O[G.PLS"^XC63(EDR
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M9YS#%[R^FJ3%ZVEZ5V\(EQWK=J8\Z?;=O9E/=A!_C0!%0O9"<! I",T->&]
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M$G]1H$G+6X'M8;   #NP$T152I126T>7$G$$  - !B  V   8Y#C)P4U277
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M%2;RCP]'*XN_C!-35:<$.4-<_M3]L2T!\  4 "8 %T $( ?0 -X F 'L !Z
M . ]0 (@"U "J -T (8 $, 28 >  *  3\ 70  @%! %B >D #(!.8!"0!F@
M$E ': :T WH @X!?@"G  F 5L 4X )P"K@'W0" 0$8@.Q $2 2F KX&,0'8@
M+U 8* &4!ZH"=8 ?@19 ,- 9Z GT!88"8X IP._ 0F %L '8#NP'C@'G@&O
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M-P\WA+N,>X^'EN<C3QK/#"\NKS)O&&\?'SR?*)\/7S/?+3\WOQ-_)?^) +.
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M*>(+Y4V.6ST$>U3=N/D(=EA6\P@24MK),R<0F-!&+80[*GG[Q\5<C-7F=77
MU*;]NSZ'%FG4X9PTY*# _5[,2M.5-]&\0(_9^@N#V^_<YA%O0 G&-HDZJ<EA
MWL[8'DO?@A]21Y]^S&WZ_*KGJ"^SD^/$64QI!AV^-\-.?<3N0V]_5]?@)Y=P
ME]N[J[>BYDF_*LQPIF?4/\ZKRZGGI2$X+*<]=5)9(BAK9FH3/J/(96JJJ#GW
M&L6F+/2DHE!&N:AH@;%H46O=<V?'"X5%Y2MX*%7-[NK$ '+2='AT<F XZ!B\
M6CM(H>(_P%-%X] _VH[:Y%E*<,E]L=,_^Z1DD\ESJ.WP%;T3%5#ED9PDD=R:
M[<;!P7/$<\!B]D/ J/#JNJH\A_-(J]^4]8/@F:@%[KN9D.IHSM],L\*"*/$=
MYFZC\VMI[C1\I(!2M3F:QCHI2^7"Q"F5Z:F[,FXB03GLY(\.L1YW#K-[R5\7
MH]W>K?2+0QHP0PUKZ.GA#S?*C8]Y)W@KCTF&^SM:4]C.')EGBC+D)CS3<NF*
M\@C&)*ZWVCL<$K@T(!\*!%C*FJAX?-?*$*9N J9,8IV<'(?Z(.>,*\7^#G(K
M%:QGSCD)!QD:/;+BJ"Z0XYW%EIY3NU\="3B(5#P/+06BMLY\'VZV9;%(#9MB
M(T<'K)U'LI/2O"O'OX0J@/NA[RS1""5 6IN5_+V42XBTL%-^'<'(SH+&JB7C
MRTDB^T.'IOIF^ >$C V\G+V =U5(5>]".?XB/&A#PYM#R_H\?<MR]YJ^G<\
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M]96@F7OGR96]K#P),:B#?9?-8Z.U_>68&G4Q9G#;O5C),^ F0.F^1P<#Z1D
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M"#>6NXY.A&SSON1CDU/$3GDXF7A1:W/Y_BN^F7@^.26@4J<Z=2]E^7;KYK%
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M;S;^PDGZ/WHY!KMN;2"FA!W1EM W2J;OS1Y?XG_ '@NGL3?^^7 ^0Y3>&"L
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M],%#X7C-$;XL4A0LF34^@TB55]40+N)JE% 7T*_7,W)R7I$ND^4&E]PH3WL
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MI:-#>%#&<$3Z<XHT'"9\U_P5OR&"IM>1F^N4['"J7(K!=[@5\1T>PO* ^];
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ME")0?;M)AJ=RM?RY964*[+W.T]SY;H8L*?XCRLN&BT(65!,GYT$\)SRKV]P
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ME/395//?QC6'6V[1(==LD(WGUS>?P1_J10J/GGLBUI',]D66V[Y/JX'B#ZH
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M9R\9<&_O;@SAUN?^_GGV&9O8W^_BK FX6]5+]$OB64NF&:O\N761"UB74BG
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M^F8( P<SJ!=5$'Y*@25+Y*!^=HQ<] \''E2)O5C$!S:LZ_#/0,A(CT#GLQH
M,$@C$ =<J42@6V >.RP5-'XCO+DA5N>62VJ04CC>T%&OG^%7NRS@K0E.VIJY
M 5(83G!UMW");^A?^$&7ID7TK'-&\%F+Z(<]3544*KS35%]OEDG5G,XB6(>/
MM^_L;TU']_QR'F;>'WT[II/6L*B<=$)MF911&'U5 PEHCOAF4%GN@*'V<7/Y
M(QN,4,JP_H+!=Z%]'/%H/PY>&>C#@4K"7,![?-T9UQU\!?O.7>?\UD%/[$ _
MT:R!P:'A_0MK?L=1%MS-DF=S]/95'ZV[_.)&2>LA-QF \395;U?=9AW=+]-
M=QJUYQ'GB@=@-=(O"*K(1H(5'A_IW^M\N!H;^-3$E>!$E]"LX"2RXXW%A,BM
MV,!XS?((TWV8.0>EIHA8:'WF;X)I='0<E0^!(YS'Y4RSX5I%9JGMSMF2;)E?
MY< 036KH9>T5/+.L(>GM__!]:M%<S()I1)\(FV5XTAX[=\I[[LV=B<0F-)+-
M0)#\I\]CZD:1?8Y>,: R:'^!7#,M!4IN[@K?2>%-\1[PBOZ>LES97\^IXA5I
MGKUK?LBCER=&7Y[I4\;=P*T=?W'3IS:A[=>G-IXW^!N/,JTG+4PE*\R\V1IT
M!H4&<?P3(SWD+.[?*X0*/1>_GX(3#=29#-0'9I6N_1!)NGV)_3ZZKSUC=/"Y
M]0QEIFFNI.$=KV6/X,?J2--<_$E- >+7M7%#6*8\T34B:O7L(=-JGK:<SE.-
M%F_2<?8'"1"T8X-,K(K\(ZR\AT>F&&)(NVI@:(&')%!G^K)5T?7G3%KP':B"
MQ]VS2C<E],1UO%9PH4R H%M8?H:#)M-.41H]EWDUZY19N.SH^G):XJ>O81X6
MI=!-9#SEA@>9PDK.R[$^&U;_CL\07+W^L%4QPXQ.6>*-TO>CSV1Z+X9>>GG4
M'%]DBO,EU:X<:A;4>QUE))_4-$N,)F=Y#__2G?1@*G<X!1>BQ&I?F?I .WRU
M3:%15QYE+HDFB9)L=(=I2TFHY/:SG<^TB=6(RKI6?<&[VE3X$Q.AJ(VB8J=N
M]*0N8.]<^2^Z-P8'T-++CPB2Q,12L0.-)5.8[SY)Y<?ZA9F0N@U+@:B4WB^T
MRSDUO%K?^X;6)R)56.4F)M-N+DU/9FI_,RJZTTU>P3T$J1%:Z_6B+_L7>NWV
MHM,G .Y66]K#%N[H!Z (+V:]R]O?8*,(Y944,G7OA+ FTW<C60\\Y6N.WE0O
MC8F*Z'6#;]S2>+AAU#OZ 9Y< SY"20X0%4-X(HW'<2BM)9\2L3":7_W!F^VC
M[<:PLR3G8H-;D/+"K()TCH)X7K5AJ(6VU0!CU8KOJ-U)EYWUDAG^FY!"@UX3
MR2[)T]=A=M@V9=$C:N/=6%5*=/YVS72IFD,?E7,0,"85,JJ(G]^+)Y\]G"BT
M9%I^(;9'1X<WL4.A9_^"MN0D0;(ZQU*'M;\-.AP,@^NCD!/IT7,, X-4B)@?
M_!(X-OQI5G&M&XD8J"%C/34(M)NCT:1;)/=<*F/C($&W[O"7;0V@.5N,A2$E
M8;Y\55=QR>+YSVQX7*NYEGI ;A/W H"I<N-\P&*#!N6J*69(1I?A=TC#_<6S
M<CP)HO;A+!?NG=;M1,&SZXFX1TEJ&*4XUC8L=<0W\WO>@QMKP0K?[IO]WLFL
M[E0C[)R%TZM4\<07$<9BT8%%+\1;.Y3&@:@JAL_.#W-5,]4N$T*?\+Z,VHM_
M0B?VB6\02[ *66'_>MX_-)3U[:U"9EC6?%K:THV]_M.YMIVV^O1MFK*2J$E=
M@E*)EG?@Z;A.TW@2N!EFYE^%43]#EBQJGSAY_@2]IN#0-5ZN63C+#I^C'?%Z
M$A^A=K>7Y0+,/_K+WSNOV,JK,:[R>,):K]JBPY7"W2MFS@#G<]IHN%-W#AGG
MX-K^N=#!\B,'&9+'J_6HL@55VKNW[2:0>-_HN'2XI4"SC0F.<IVL,!9:8=&L
M<O(*O)SF[&"?[O#14$*F0 _,1F^5$[</41UGKO:'^VU6ZW$3;5DPW9<C 1KD
M6,2'4=U1_D28@=+<<4NI+,R1LWS&KR'[$/Z5 V3S,21U.EW391P<H:DVHLQP
MA]D>> Q*168'_/ ZL[;Z,'-JG);6FI81<DO5] =C'H+/55%EQ2^R1XRM_DL[
M@;*FEQ74W40);-3U!)  Q1->P6K$<H2I]DDZ #P<'#Z/DLCR@4M7+TT##S:4
M]XAIU?R6N1A3FQ:]#S^T\7*BUN!<>F(K,;,P1W-BZ3>=#.97Z/2(_E>JZ$("
M 1LVT(R)*'3OY>7SNTWV:QCIQ"="*<^3 *D+"JJOB_/S\^<M2"UCF'G42Z2C
M7_G[X\F(3F6V6"JIK%:@!!4/C6#CV\_6@H%&4^(.I\C]1VT#X'G6U]3@0^6A
M;CIU%Z_]1,8G5]9/L+S7R,\ET!1"S  1:/;.82R>:&*_X^[[#YNC_91#ND#W
M4ROW,Q4<*;-(=W*!NEQ7@9YH50JHZ^?MC<\W :<4E!\DJ>\6_?UL*APS*C;H
MQ-3K335$$0'-D'/_").5PMVZ#;Y8I,I$>T;I[H*U"F+8)"9P20?1&Y]IQ;9/
M<T:F?XDJ'(6QK:4D*LRLHYY/ L>K34PM-QBH2L#?%U]9^Z;\I<@;(R-WC51<
MC40^ZT@)PSO&&QH"*##"A(YLC0XME7JF!"N[1_J*!$B8">"GM3S!4RBL94"E
M0Y\:S+0RFKW! <!0NBO>/'>U;K\QF13I;\:/Z*\4G;1ER-]/!P?H.'F.Y\\,
MLQNXU55YA52/'=NPA.%X6F1&CVB9_C1:X9(C#'HHB([L9<96N $FMAJ9/3_0
MP'^]%R-^QO*WRW/M_@=#&[5W_]#V!T/?O-=*YO$*"_7HK;.8_OD]# (Y3NWZ
M:!!O<]=8(M[&4S5*.\#*XA1B3\,L%7D>VL?P/LR4Q\-;C)M4='$YNMA8S.#1
M-(;<;[L6MS98PM$I (7\!HTH]'<Z^!I1GJU%L% 2Z3^J,9A9@/U@$YW$[U"P
M2WWF<W?=K[W 7;89-)#R,[!<E%G<^2V)/&/3 .F7GA>C9T#9ZWG4<$[H/XB\
M^("-H\Y%<RD/HRXE0T,;I>)/I[4B_C^>R29H1=6]F3'S$2N>:Y[M3OAF5EV\
M.VTDE4P]/H8<:XZ$,XSK]QND9QXLGHR,&V$/][2M6X]@+CL?C2"S%W77CDE.
M&LS=="8]^?ZVJ#Q>_T9<[B_M)1ZS]NP!?),27=JZP:FS WTJ*BK"Z1$,H1*^
M>A,CO7!R[10553Z% 9D8>%X;9']^5H+O'D LTC>*U!Z9X2GM=<OE;K>S)_1+
M"=TZEG(Y _A?MBTRX.TG0J&'=DTTQ@%''X;E/6B(^MG\" %MK?1*W1R!&3=I
M2_N)V?9\CN1?+M0A> 9YI_B1C47-9Y6-4PNJ(6\&Y0E?(C)N3DYZ-/]@/&C?
M4<F:993MT4 .'J%79K_WHNNL)[O;N:WGR]^?]47<I-"'V=IWU==9W8&>%-!>
M/E\!DO$NY0W;B[J<)_6$YH-=4L\B,P^B?EX)5&J8TN?X%&:VNT@O'!4T"U!W
MM\OB-IF:EWT,*9]L^/B[:-"*M43SBO<WT2_+VK.WSGU8:RN]5&%P80C^WL'!
MYK5\22XMUH2$R0Q81]KOU<@0WV@P(TTDW$<0N^-=QPP[Z [YHM:7^="0XXF3
MH%C3^AV_Q".IUB'@T6K?K6HTP9_Z+%-(\ DMA)!OBO4-XZ.KPES&?FV;E.7!
MY:]LWO7Q<G<0A4VO/O;A!=5TJ?5L:U9I:SG74FSQ>S,T>X&%0G664]%X,HHF
M.:]J5#?+:]Z?/TOOEEM;6Z-S4$<3'&&JYM,!IVA '=TEQ,U'-@9:.E\D&VJ^
M/TFLL(2GP^)N#%FLC1DK)_4K,)3H)2G7?6RQ@C>Y6)L8S=7I"1,2+@R.KV)F
M%O:L$W3W>&ZQZ98V$)A5AD3//"5PY2,KUG2MZ7W]?9B3!\*^J@EG/>MQMKE,
MUH$#%:#VH"!1#BJ)L^N.,+9M]/%UI0(]>DOBO(;J%'UH\+GM\ _&^V</B]QN
MZXAK\5;KZ2)>=4VAM<6*IXEEW9-\H]-UO=1YI(ENO7WCKHC^%#& ;O] B\.H
M'1O=PM3-%^IV"V&P3,;CKID/#^*<0]\,WI"X9NXH*KWB)[%P$1BBG!#TL^FQ
MTG#T&]W9JUM9?(:.T(T4473SM<?FLMJ/S47GDJ#9MS*:R_H;=X>C=;W;O]W*
MVXP]LS6U<AM<1COR;0@O,;P?"TINP(](0J*Z@SD[NSTS.G-PY4(!Y9Y)6T.!
M,YMIH@W=<X-%W160XTK#?L!40/Z)8J"HG8_INHI\QB(417Z;N[%D,\R7$$1W
M[S_4- M0M":J^[3$*!TXUJ$FUE$6RWYVR_ '@VQB7D-%E0-Z&J*T$4+9%/?0
MWG0FNP*UFQ1U4Q/(G*2"^3R<R;&[50YI=0?.XK:)!L'H.V8G,';IN%*'NFR9
M9W/++T_EI]2EE9(:]$_7NXZ6W/9E@:#-^6 3/I;[U'39*=O36/)-V_7U$I?0
M@@WM?)L^78=A\V)[5)9+30ZW%K*(P%1!?% @(R!69Y5&)*KT8+ !*<&\8<!.
MIB&<H:EIH#94.\MO5+AA[L :KW*T8KHX520@0_D1<)_9BKQ?D5NI&!#;/VD[
MQ/UQOE#&94E85&-,>V0R7MVI1&?BY-$A<*CL0MDT6XD_,&P-BF@5#%<3KNG#
MU)"4SH;''JFL6BPNR=-]>(@ZH;962G?-X3BIV"K_1=2GM2443)V #???VCV?
M >3!Z'+J7)<W3$GRJDG=DQB*^C@QT<W./48F:O.X'-+[$R?#YT@#=O9 ;ZB!
M5C#87_KD+MS&W>)S,&TCEGG:6-1A>^]>K8ASLWFQ[<QF8M*K^HT[0^X)Y?0;
MV4Y#G<@DD57]VJ7Z+?2POUA"0D30-GNFY4W5-\&K-T>@BG=E("_[#Q"2$Z'.
MO ^J6HK,(!!HV#:7B:>W&RC]TIS,.'S!230U6WR[$3^X**;,(D:FP%'8\>TK
M_2)5[-*I"CR7B5>S51C?7O?@;Q+U/7TZW T0*$"</=JAE5HU>F_OVI:A+D?#
M&6>[L7 %KCM]G9T6Y\P<D?AYCQ%3<D*%M0=SF0X!Z@*ZJ^V:^YFYV?+MI8?<
MAJC  QWLL/H$X2!B7/&F!$%<6 V@D7?]M^;(BC9J933E99YY;IV@0[1/6;4F
M/XN\A/L/:_H81POP@#8[^1F1I"%/*@ (>P( G PN'OU@: MU"9#7?W^ISM0C
M<0"VJ:!Q'[JNP1RE21#+,4L\Q+B4'<<'DX,^+.DPN!$0^"QR19?.DA^.B[S<
MMK%(-=ZU-O^#T1OP0N-.48A3Z5I.2N)1L,O(I,!]"_YFZJ==/ I:[4GY2'S1
M</AX?2>C<:GZ.D<37EQFH]F!/@O::E.4K>RH+/IM>5\IX_$PPF/<%01[('A>
M31,AB5N7_6T*HCJ]NSQHO;O)SD*9^]*GGW720-,!YXXY0I1S*W.XYRD3%_Y\
MLT@J78W?FP$X,!3$HF-,J+Z:KBZ3'KZ83L6-$)1NA2D^O$8F9YI8--I_+WDC
MQP(],3+A ^K8= BON\#<T?BIM!DK_:00K)S';%@0ZIJW9-P'6_Z9%J.TM"&W
M H]_ID3?,HL8_1%A28=QNP*J4G*]O/P/!N8#\Q0X(\EP9W(MLYD/97"R5#M9
M[9AP.+C?.Y@C\'$G=B\K^D0M3*!_59.NQP-%G_G!$+)2GIW1_OQ=4'5>-)7+
MK ^G3&:1U7OA0#7][>H%^6<4D7'(Q8A@Z/G)NDU0SF+U^NBX228^6P96-UR>
MZ*3'#!<5:R^:0?&SKH]%S2KO?5YXZ>NZ&%XADVI;G<4V68*'.;BCBO/0$?I\
MP+PE*RW1S.L=U,E7' 7,2 U^#)+%F9Q\P]%>B9__,.FO\#AA5Q3U@DMBSU'D
M5QXT9C/+@W>HX?A)TW,'7\?A%AJ[[2XA,^1R%=7]F"6'Q\*\YSX#EW2F"3]%
MB)3$A;]7EC.T@Y\'J=7F709Z?N8E7)[2QUTY#!AD/MGS82,90]KNZU18HP?6
M*W3RA>9A]AZ4/ZLL,+C8LXWQYVQB.'NB_@Y%%+*6'I*8[CN!UJ8KTIU X1&C
M"YG4Y&6@\A0S?^2[UG(*$=IQ=UY1@ 6F3A>[ )N9NWZEYH1T"-?/8Y=#.0E*
MV_E%_&9*5WR?^MY2R$?94B+ARXMN39FYMD+L"OL7_"G<((M(Y*3] 3YFRZQ;
M]0V^",0DR03XYM701&N\"B,&9?.]3IH[/8.AJ1A^MZ?/V5&# $ZKS^HC2?CK
MBR%T3DJEHV0,?VSPA9DO1_!G*903PFMSTSQ)/3'S4%^K/_=6'WL$*&:;Z.06
ME:D;J.&UV^*__E/QF+]O0;>!3O_5@D &TFEY+Z%QR0_BN2-ED36X?=;4QE-8
MHA(_M,4O'],W\;D-+KK-'P<*%(]A="WA2&WWPB0:$([II&F!7UO+]-]$IX^E
M/O*\68,E)F:PE<"(>E9],@].%<F=X3E"=^5/:#^>GM(T?M7$SLA7S]\2 J;
M7R9G]S8<.[8HT.=-Z:%#575J>R;6ZM#9V:UQ76;"$G@GGQ)=Y<X-NEO?LQ'9
MNOXJFDY37Y;RCKM3XMH53W8+#K4YWZ8XVD0K+3E]O$HR>K1A4#'9YB\5&7"V
MP+WQHQ/ M]^4OS_GYM;>LKC40U8>KP$#I]IL"(PN7!W2?-[J+V8^[:6?>ZP4
MWAK:0:97R;A(?_$J^-REP!B\>/5^78)GK+P7&>7\2]>\;E5[HH0V(0-8K1B
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MC- <>,UP[(Q;^PTP*B8!GS'YD]V+)LF=VADW@:.MDX_4F7H5ZFHKMD;INU5
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M[<*2</[-HA^$)GTEAL-=V<ZWTE5I3 C B ^V>M]"1SM\1^6_*DLH;XPS?B4
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M2PDAE6,I/R7>?\PM(T*1#'I#=#I"GL!O]14M8>N0E'%$\:>@^F$LWW'F  F
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M\'G>>Y^=?M "H,[9*>[0$25G&(RU0QNR;+D:<"GE^\,SELFM^P=X%:<$#-W
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MG:8Y6-**=/D65&*V(8_+1;UBH6DQ6KN4K?=(=!4:5[IED)(D^/K C-L688/
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MG@DBVTJJX]M^M>Z(6-5?WI[CJYOSU!Z= ]XG],)TL1/;NJPM96JWJ(6G%'-
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MKU$^2+V?]?)^GIRVRRUUWHL+=&DU!LL2S?I;,W=V*D%^#VB9>K*&^_Q3UJ4
M695-/H/P_C7'VMPBQ]*FN*>21KXF1@;-4\2AC,:9-4<-PP;=#J/8057^_,WN
M;A1TI UL631T,ZY@-]CJ ,U51M),A,>![$'!N]:EE60)<#39;5O]P''S35*T
MUF%(SR7;C"&.?;XW8SK3JX;4_M[^ =L)[500_Y$5:C(6#OX]MW^DP.,0+R&#
MT,;NZ55-_-!H3E)G+:]N.Z$"S))I(C)LO7'3!=7JE_(IWK.KKG"XS'6:'\W)
MD_9Z>] \QWQ?K,*NT?_%[9#C<<9S@8_S_IEL6E(E#%,5P0.(DVL_CDG'RP7"
MQ6SKFC*$9A5%,_1&_ ,F0%6)T(GR=TH/[7?R9Q'NS9(+46F1YK)^";=6TEF[
MAYVWOO5<9T(&HR<C!IB^W%_NECG#&C;/DD4?T'1AYPD*DW<1MU:)WE#G?8+Q
M-V[UF<3EK!.<D?S>L$0_N7S?]:9.E>5(5Z5&YD6Q.&7G B'3M<Y"C_0SJ>UG
MRB%MVY+#JYP_[[M\3S_KUC,-[;O54>U3^(DG]RU,J<3T[3CX_QPT.;J$"="F
MHAA^NUIJD[Q"?-ZMC\;58('(CS+,Q$=W'JWO[EDM"P1$E[Y=BH M<V63G[AM
MKR$L@-?\%7+5XQ_Q[E?9;.*@9Q)2]5(3Y9LV'%L"(Y8FZ)<7 U0#:6>7%-\]
M')!]$G5[ZPV8IK6N53'I)LW*.3[R#=>H![0:#9V!Z"ED6-;R9M=AWJP7OY>\
MM7IG=*Z] +X=M9S97 )'1*H"R*.I\JP8'JOO5EXHZ];V>VMZ%P!8NRF)LF_&
M(N]]#9C2,S<[EQ.2&Q$BV/!9B*2O1\58BO4?R,,Y#F%X_+T""AHQZ88KX:9\
MO5C(C-1SV>E, ==C*]I@;/\KVN\X!:%5BTI;':;E^@,[^E)JJ[HG<M:W%YRU
M+:V[6!V4T]+A-A,PEB0L7I$D7(Z#+E[)I:(E)958$XI&5/H/191J5!%MV!_\
M*7DTX_XUY!X&K;_6E%FJ[AJ0>'Y S[+:UAS7/G/BYG9RI6_NO+RO<H1% ->0
M#5UBL=A1[_0^4!ISL%CO:;UPO]+Y%D%!A3J_>*M<M#<&:,"YI/@TN4F^<]UZ
MA2TVY> 83W_GW<Y=O..;N2%\_S3.!W: 48 V8"B_EEO+P%NY7MW2H9]U;6G9
M>V"B<7W.5+RW?YC1P'1[SH!2;Z8J=\E1CV/R+(_J6BC5*5&?#^K#"2CBCO\&
MZ1A'#T_8>V_2(L/']F'_DXN4&[>H/1E5>L1^U[[P=-J"27#IC.JZL\RTR.6J
M;4?QCKXVA8A@5T&Q5NA2(C]8@NB3?D@7+8C;I8(P(;P>-J<4.[[@DN^@(R&]
M:K7R=H.D02,;DLO82<\!=YI-E10A!6@Q>]@MU7-,[XW(\H7EQ8=FPNPW@Y9>
M72KI5;E3O.^"AEY1:3I@VNCDYT7.KU>UH#+]7F\#8KLF5L-"\PX,%1R."][8
M&P8G"WK7=9'+@H_JP*(1$MBP,H>DBL0?N<V <3U=*!=0GZ)&6( X^RTS-:4X
M%A&Y<^B-ZS$ILV]SBEY>-9CD7OEVY$2GEK=1I*&'2-J U3BZ/8;$/R'!_%S;
M92*C;D%(VSQ1;M I/?,X/??",3[-KN["-IF!^*\\7*R<JYSK1WKZ6_S*_^,0
MD509'-QME='5H3TQGT-%M:/F9:\XU.%&996VZ>8PG6P@GR@%$4;XII@Z50@J
M/([]X-,;T5.XW7 5KQN1H*1--C/SNN+GELQ@6;F-E62_DN @IYL23; &I]N,
M,*B<9,I,CZ/<X7,0@@D:^?-"B6]KT.9\$85=S%_GP53)DCK.ST+7LZ/SF^*Y
M$\M5C^T0;:_@37G/*C?A=5G?CN=X5=Q,.#>P^)TT921<<9]QM"NB_IHJXOP*
M[#<(,P&"GZBP*(](,&BTS@O0"9\7S8>RE)E@R^9_S ^6H?V.JS_7G;)P,U32
ML>#7V*EQ5B974W7Y:\1I;JR.!?R*SLU1(N7&E2I5*R0SNU<_)1=]YY6&F=^S
MM"NQ#.BQ*/=(_\01,B;CEV>F5'\BUK29A7V=3QD[[QN3QKV1<<<7X</= 9E
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M1M?^))C:6PC!925[W0?E/%+6\2U2KQAO:;*06>;B3S'(O0<5<L&;!]2[N?U
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M"92*FMB#ZK]:@**LSIF:57+T7]D 4P_:SW,"I0GZWV$JXGZ@E[FW?;0^M/&
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M(!6)'WCDRZ)O,8?&>G[1/;$L^2 J1(H_Q7!;P1BT[T@Z0^]V1?%G8]T'S!C
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M)SW]DB+]T-#0'Z3ML&]8_"^Y!(Y_Y(Y+S_ZIN.6=:LQ_5EV!]Q$T80HTH.O
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M%;AH6;Z]]],=2(BM!Q!LMQVL-#V@]1VPMYD!^L$QMNTZ*I;W!A7'$6(MZIA
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M"YV%U?_@[BV XNJ>?5$2$@A!$B!8L. ^,! 88) $=X*[P^ .,S@1W-TEP9W
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M&<A--5D34I'_75%Y!*E:P]?(.N;-K,F.5?D@3J ]J0^U.;)6 9T)UE+(FXE
M!(Q%<Y_'62V/A%5(OTE2Y87#]!U>W0#Z/C4VI%%>X>90I<0<Z]9G9BR:2I+*
M;L;(+PMAR9#1LU_NKK\1+MB?]B/OP;!\FIJLVY38R^6N6:\7X%G71ZQ1EB4_
M]CJCD*R5B<0PJ5!0K*86A;(TL:4?.#["M/4Q?.7J:J^Q8.T9KVW$M'=4?UB\
M]WJ*_@^&9IZ)5W\^K+Q.SFC:E\%\J6GB9]0EP!:WC[L2^#+<\\4/]2#7V:D+
M"9"K8 =PT\(F*#^474/NXE=B+9F]J%4-.#AZUD=&LCRM>PP@#@QMXGV/94VV
M!VPP48:8TIU\PQF%/_+LWQ/<#_;B#/.Z\*%U<"]A/M([E!I?N-#>K)B(5I0Y
M;'WC'F-._IA3I8IUQ266MMPTA(4O[<;\.6KWX#A:%@,7WR=35#O5B[A?RT%<
MQI73(C'2C_H%?S=LD']H+=U0>^9][^GU=*&EV-2:A=/ S9F'8VYZS*(560?S
M'XP74\[P:['82<<&MT@4;;U*TE(TYJ=%46K;K9[-7X%$=4$O8,0)50\TLO@)
M,;S,(0_"R%=\F"<S8E0G%^_?2NFQUU_ Q"[;I]N204.7XX>%E#[VRG;#=>2.
M>I%#35]LLU5,^8]?E]759"4[K%4A=/J,FK7EV=%]>L6)(8,AG.:YIFF)8#[X
MZ=CFZ)+#P2E8?&CL5'Q*C2S<\.6YLB2RS!B*I4FJDAM74$P)W)H7L_1'C59.
M63'>7[4<R,O,Y;,5;WI/'\Y,1F[4BC8D7,/D?U][&H>>AT6(BJ[\*]MY9N%'
M_=R(8^'9O"H/M=?^ ^^,P!C^H-0,O6M,3X#%V>[$%93N,KU5+C1U;1"J\(9_
MXE![R?(\YNN(K=^4,8'!HX3&B'9\Y)<Q=?7PC6!T\&C;)[,:?5G(B3WR518?
MT0J[/_@"S"_&HK$"XJ/&Q,=7Q%CA6R+GP],;=B'\V<P02^,MXLR/1C?9 AW6
MI: 4&8__(6AK+QR^/V X4VY,.6>6Z!Y,_@GU87L;/)RP4U$ U^V'@T\W!6\#
MFF-IW:4U6;M&.FM$Y4GM?OM!XQZL$.7%_-3I\WA<<%'Q4JKP/N8?&^M!+#6@
MM$89X<6WM5F(6[%")#SV0QP90OKN$Y!/\-\(Y7\=UW!X8R*\L?E!VV3BOXV6
M'WE-#[&&02&0#?1=>GIF*BS0G0^$/'PG&>L/LM49OX6\5J45EW$VT1,Q^XX
MSD[6/RT:1IT&2.\G3O;VC8Y,D3G(]8ZX$16?<=X= 0[H#=(1^E\8]*&IF)\3
M-^U5PE(UK63)I4@/(V_#3_5 S0Y*TAV\R7*1I2M[G$_^4;*;(W'^T2[5#(/J
MZ@K;J?=B(9Z8&*&3GV(SAYI&!?<ISQ4<-YWX^T<@15,8HI%"(W71&55?3] T
M=$@JT:C-)]7)#Y1]P]<KEH^4Y"'L.3I*)(L\88R_R^$;U*!;S[[!@+-8WV?U
M.UY&3OKPO:*?.G\ /%<R7_3IS;7S_:TZF+W1$6 /@K! W%+<6<Y@1EW_LPG[
M/Y;.PLI\-'9 ,\=%$K[0PG>^[ED8:SR$(5Y/FM.M&Z)-890;1Q6B,;T6GN65
M(:PC'9[!0)0=&B#RH)JZY^\I!3AV^KD\P@?E5_E:#8H.+7?X+NR7EKW&*4 C
M;_\> O!:%0EZ@"=@F6%O-W ZSO0<8I'^6W,A^ML6$Z7ED?63.0<C]\9$Y')Q
M5/]T=#.8S'DNIE)7NKTB40$3B7@&;R;^#D<\$FGKHTZAY,@9.FS01E!SB9S]
M.D?*C4UX(SR[5Y0^@E2QKNX<0XJ)FP7?-E,,!F]689/DITI>6LZU4-I_/9^)
MZ.=IU57RDC8W<Q[SIL2"GJ8:W;Q''UJRP"U22:&VY%Y.%)GM_R^%*?Z#*+'L
MKV.5,KT02-/2IW7"-_^TH,9JE<R[TM:7F?:YS#WG X,%?OY0)-DY^XF)%SI"
M'8>=N4%\XX2_>@HNLPZ<*W5KG7;426[)SVD+&V++BPOXD,#WAOE:#YV,[6L)
M]8;7+\26UOE]=53(7JO_DH6Z:OS8?F1-PD<,!V9IC93JN9Y2)CM\1(35")+W
M_!LNZN$;=2OG][2*%^$=EYM/66%'O:^JAOM$/Y:(V@K7$^R"XM2I@">"$7/]
M6F'O<F!TGS>0E[?&EG4-L!>E/*=70DJD"D7:GRY>1LX5\B@1#OY<=<9#<S]9
M91QUD7_CAI;#CV)M.;(%<=-6U/5A:YG'5M.6 #5KDS-+P_(I79Z$&LO26O=5
M,F1[I[=FZ$8%2,_]KXQ'2?V2X\GOY@YK]@?,GO*),BY8II__H3-JJ./C"2O>
MJW^SW?\IZ41MZE_C%P.X;7G_Y?@1,3?<8=3RE];R ;P6R<#D4=_M]C>>+*AL
MIJO!&,V^?]1H5-P"7B66#H2*XRUIINC8'L9<!8V;H&.[07%$*O_E6V,2W4(N
M93N/:*+KBVJ[J1V""& >AX[YNS7!2#Q+PE& "%4R)VZ;7[ L-\'PTS%%W9"Z
M&K5RZ&6FZ+=Z&AV%73N6V.&5_63?#ZG<K[Z<?S HY0BKC]!>=:U1[P0I?4_K
M>*PD 2;2U(-E0S$J$?..9[KL)])-PM""V-#,TCPJ]$OZ'"-QC^5/USLB">;[
M<G>:"#J<E]KU5C]?M4H?60%3;/7@"AO>98O%YCXINW-1>37ZT[;/*4FVPE 1
M0E^3"-@PTL.4Y+/343ZL_\0<GQT>'B#C4?[ZO'H<I.?:4)LWTX(EZ.%\K.LI
MO2$@\?<[AMC'ZQ]]:"YDA(L<E U78CW>.;A,9)139_5]&%X%O(_KW6!_'TCK
M4Q'-Y:O%)</[0T1&3(I(1D+YM%'DK[T=[O94/69'Y>1%&F<2V+VBZKM-16^Q
M [/$#W&9].'%W-+5!%F69]_3Y0OHL]%I-LOB!O3D#@9O&AI97[#^;V]+]+[M
MY:O$0I>^"@%49:5?JTR6M4YPLFY%"\4)M#1__K, C"E;<G<"%F)KK@/[E(;R
MAUI!GN(3]XVT%J=_,*+2DYX$_^O K>!J#AI?'><V9?A"FT[E 1_EKQ,W>1G$
M[>$F0)Y&'">6=&6A[,$8+1QUU/DB<I;NB3E$+$M$D1=0%F&^Y7@ID?$5,81D
M_/:L.C-1[JZZG5\"JES2U?27:WY WBLDWY$@7_O=Z,JHD&F1J[__P(ET12QG
MH9_C==#7Q++Z;*T UILN;5J(_'</VJFO9 ]?W!Y4^#;E!LQB\)]^ UA66=1=
MYO:K^MSOK!;&]$^%%=9 AGL[P^!NAU)W6;69WS%JD'1XYE*+;M45@UR+(1(Z
M]2G#)LUIPXL!>>!TP^1T@'$V^IK7FTN5#018OU=1.912N>P^K-IGH_GRH[NJ
MGI^9VKZ$#3%5#0;2Y'3I_5JMP-P<7W<CY%&-$[A>![[R$**)Q&=:F>'/4GGY
MLZ9F-=]R)S0Q5ONNFAL@/[I7W-A:?L;$P<)]XN)2QIWQ0:718M72E:#8,M&E
M%)DS^%MS(I>3OHUJ43V*X7>&N[V5 $+Q.P@&);/=EDT?#G;H:T-@W"S)=UI5
M!L6\MTZD"'*GD?*^=%P7I#@D]H@-UI5A27@@2]*L-ICEK:?*Y#T]2&[4O6F<
M!YI 7L;:Z)!,\,0,!G UFIVC!:(4S&1$[5I^M3"A._3D?R<5H@<O C\:"QJK
MF:MZ[R[FXX?%X!+*BA!%!L4-/^)4Q[WM61-X PQ,DL]NKPT'3*"'$6J5;9"'
MC"I?S]S,,IGZ8KK87_+6 8I52YD,$9% LJS8*!'+D$-UBJ2"S4(TJ;/$JM(]
M[S(8$[!O(.R\H5PRYC0TM'2Q0(NJY8T=Z+/+$&!V=*IH]:FEFRV,5^X/."2Z
M_1 H*-B1+D\S3KU@@*QW--_(XMN]%S*I0(H6K,'CGY5C>EY=4\D&'Q?]]:4I
M_+@BM9W9YN4H?E;7^VFZMFG_XZT1O>H&$@P.@#?^[C@U(&M2NY_W18!L&U7[
MFU,Z[W!*+,U=I^8M\WNM_&1WH6!30OG8H1=JX+1U6Q1H/4>('G3R>L@EMBXK
ME4MXAEMX.\>87OY!P$*^X($W65O6ZM+6^9M)4S7JB&:6HZY\231[6AN$[.@2
MZ*]:?H;"\3QZ&Z&WTSUB.QRDU\:1/FAZ&@=^)43%M4=^:[I_%RDR;1DU( 3;
MY-N-:H;206%6/$99X-.+RU2[JX.1;JSF?NE)PLT3,PW"TCX!YDT]^S"=+LN-
MES (%AYXL--SSN*$40Q_GJ^Y ^I!IQH_WD^PNG.5MN[R=?SGU(4968"( U>X
M'V?HH\FM\$;(8&8J^=4J-C\IF1L-/H)\N)>#_"Y:\MAQ F&L#[-7[!:7CI@,
M<NMQ8NP9831?9^Q9#,=M14&X\5TAX@)SZ3NR![VG5N/'*HK(H?SR6Z*-J!9G
M"JZP/(I%M:Z94Q3EM,&=T$Z-7^)F7O]9I)L)2[-WS$A;2T.WYRK6^$U.853B
MEZR6P#<'45,\/*&&,;J94GS#A*!SQ5?W$+CO/(R,R ^Q89^3J/ (B=]"G"5@
M/\ W4V.L\7E$[UO@2Y;/-EF0$%U#G[44(HIWZ5FT.:]2H- CV!)U"_L47PK]
MHB@8$X])XP.%;.9G#--'/J\_/_*5,GW436!,E3:P-,8?/03[U(1 (>BK[#W\
MDN,)*LTW!&?=%B9:PPJU,F^\X[]QZ[4-9@;=!70-S;=)=.0;C(,Y5#XLSV84
M7\0M7!IEWA&Z6ZJEHA+;,FU C%_[[WCU)=60G7>/RN: 6V]SE"=CD9ZDM&\.
MCSJ[23I;5YGHU)\ME,K'41(#^6J ?&!B\%^GV^CHDLK?'MU&5Y5^7W!Z\?SV
M2!^"=/HWH.K#IDDEUBSGVG$65=X])8N_N$8_LM(@VA,V\W#AKBY_1X,V?P F
M*/OD/T/T7E;6.XWN";^G-:IP$JQ_RLWL1DD.NCC=AEF[>G-(FQ/M7$8($8B[
M(MB%(#SUA: ,,?LAX\DL0USBCEQF*@_B#K%QL&?'^3+[7'= DK9I1MU)U'?=
M"#GF,%088\0'K_6HWKLL)9R>]+OL;)3]_)(R"2!YZB96:7A=W93/6T15KU$>
M24WI]@.O9WAX63R((;T)<B,.FRJ@&6^5K':I:LYSE<7?39^7L9K[;7M-MF+$
MOF;76V-IH96L?1C54E3K1AN?J#75P23TOB[&[A:Z(]0"@7>W*A:90+F:=9N%
MM;7JD"E\7M!^#E*R[GTC2H;4Q$,]G!]E/E7QPBW> ^^D"O9<G'**3[?&<KRN
M1>]<EI2&1[:VQCPNG:=SG^SZ@]+<71U4*GY8XJ#NQS4'QN$<@6@>BB>M=RAT
M\TW:0<!6QQ^,ZNO C?N+@7/-0ZU3O-']M4&^2 08W-OM\G )==W(75HR40N@
MZ6F5SZ[P0H27[**T(=9[GO838X,UTJKTB]%\@ 4FUEER+9*1)VN&=,^_?B/O
M D99D!BT8@\/I))8;*)!X,,;JY2Y"16H,!<<FI=/?CMNP%I(7O W\Z+FPMN$
MXVF\?5+I@C61O98]RAH+BFV[@J/W(S+!+*!*.AR-:MJX-M$R8I,NFMR>M'U@
M/93P+9BUGGXB98(]\-_(*&*'==G39+1PJ(83>Z74ZI5*YEKFM!+^K'!:>OAJ
M#T6UU\5>4"OK5U;[')9>C(Q^_D*KZ>4O%/WQ2^Q7.-0>5K"6XIQ7S25Q"H.<
M77M#2I?F[]X=^XE/[44U6Y=LV%X1^A:VY"CQ.L8:WTV9SV<801TOY.-RZYA&
M7!H\"8]2(0+B&ULRU]6CKP8#\&*>#?I^--DR8><U7H<T!6N."KKFXAV,'-[Y
M$Y0N1UL?R^36K.0J9QY.?0OP<B&VYN#]@W$CO.H 6-HA  4"M&I\:QN #7\P
MK#Q4F'7UJ4(47[].! #0O'X,)>1N3%2+C3KAVG7U.W&)';+EYR\>/QY1K\3_
M9N(!0TAN$[Z@I?+.^&"9MQ:7D!W@=KTEX"R.7Y.L4G.R2<V;Z WFJ#VB^8-A
M$]W<*Z:CMRNBG=DO10OVG?P^!L;TJ-.TZ9I8:N-.?/9>H?4T\3SL"P+.O9V+
M"NPJ/2X.O@,6W],XZZWA,O6]3G:I4A_PL)I^_9;*6*[8FO/M5)5'?9NWSKIH
M8E9,G"^IE[/VI^X4ZV5RK8"O#ZG^\'F1[RW 9)ZDC49.^]YH8M3!H-6LG][B
MWN=#YLV= X;(7/XR/MUA+&:XWRU=2O-3]JX[<)0%XR8^YX0'0OJ)D;N"\;!K
M/)AO5K)N.5 985P3@1H1FNB=?KE[H*>;/N>7.0/,\&!ZO!?(]UFI=?5')TF6
M9LP6QH^^S3U'BR8]F=$]M&SBE$Y_]8]$%HNR-B!H?:U_'"LF^UGD8!B;3G!X
MD.[U#@U ]9FOZ&YZ:\HNG[X3>'?/5B^5:=F9C?\Y[* -OA6YN^.?M=?;+F"K
M[Y;$FCIQ:% X<&VK>GUO)=[5U(2\&#=3F?2_NV)GL2:L:PEP5/7PDVNW/?L&
M *OV^0GB-=UY(:QX*[ //.<<M-S,R((.9%ET.ZO.G/O6G2HG.II>%]-E!(\4
MA))*O75YJVL2]US0QP*?G$9@)>.'-!?*1ZH"5</"*ZXI[TP=0^:ZPT)Z1K^2
MWN0<^'!TOY'JGWV+<WAYT.9]OIDC LG)OO97*S$\T=4.STY?+^FG6!X2XD/T
M".Y"Z4$[)RR?>4_T![?OR+JSN&4G#%VW70P4P0(#"M?R@)^U(TE,W*=>)]79
MA76,$QP/W_KN9'L:6H <S5HL+65I"CQJ_B"76#WI@+8).[%*!J*<'/'77&/R
MB$A*$$,W7V,J]^E#1Z(_Q.CL.SJ]D<]SWZ<]>.*WTP<*$;:SAG<U\]!R.)Q2
M/O4[IKZM^4:.0EW.="<9D9>PDM%^+"J_6=7Q[:?9(7OBFB:AN1;\_,'8<MNR
MVK!8)A-LBMS*U+ >(V][G7QGL]7*1Y'QPS+<)-K17G;JE4^%DSO-J[4K@+/5
M3R37@=U/) A[,&]>/B)TCD\RZEV:(+]@T\BW: V_,%$85*\*>N"?R&B9/LLJ
M1=VC&/Q7G*V;5=0Z= <<CSKB#31R5SC$$ZN/@QS0_MOM/]^C<IO@"BM+>"D[
M$%5]R_1YB1]KSV>XE3J5]O>)%/I)#3B[MP8'=+>MG)YLPX' 48+PGX*B_#'5
M89--?I 7)!^PV.?VI5_/W7R0X>J,\BSK?R4QO/S!.Q $"S!RF]**#!<<TYC>
M/^/'0SJCCEXOK.=UG'N\ERGQV&F)Y5-<2O17I/AV/(J5J5^-^[J,=$%(VMGR
M#T:N96-6!S97:IX</?T,WO9?1L]KQ6]XU"E'N&+6C71/K=B01I'T4)7$[J?,
MTEF&=QA]%.6-.;-S59Y!';>_\>CV1(WL([?-7YO?S,DJB\RW"%^U&^)'2SKF
M]<LMGO8?ZUF.TA/%F(;=I3A+KE3<*XQQ8!+=E58VMY8M?L._!7/N&-EO6>:U
M0T#J,T"7E4TK2RTI?^I$-;=K&7$[YXU7RP/G8#2BN.XORW+ Q-7J\);GMO1S
M\62AY]MQ05EHJX;/<(:%B*O@H!CS+4E8F8HSVZ\CE$.TUV;D+)O1A6\"0G_C
MXF%6]^<-NFH:+9H\@+5D/QQ@D#+L'FV[:WK:V"IC"Q$)%O&/J%T68.Z([[6T
MIJAPTZ#B<.[W??B]MY610SK-U=:E@,;44/ZDF)8@9H0^V*4<A@JC<PN7*72(
M\&@&\:H'.ZQ^:W7'3_H,_U80"5YH<+!VU7\!"SG(!#E8OEUJ2<_[^;JO-[S5
M=J.YZ**>PRNJXI+9YLTD:K:#,7FM=^X"B5URY5ANX5(E+=Q6-VANH*V2KLEX
MV$BPP%C>2 ,]&%S?.&,O+VI6P05.\C,6BJ[Y<_?B<_#I%F,3J"<W]DVSM7VC
M%"D!PX+$%ER#6$!LK&)R2,\%>Q]Z^@K&NO^\FV$!+D?VKTT\!!8T;:[)7Z-W
MF:SQ33-S-4=_0AO#LW-#7;'K7[ZW*/Z<4'!);^U,B/X 8XBN4>F-@*X*<FGF
MV#5\C6]*P"599RT.6E@77'_\V#D>A7((TEP]2MZ?FF?Q6)]*,CW^GAE,==V4
M%OBM-Z?JN+^$CI9Y95^9W^$;B.EL,:H-0-_U^(G,O_G"QTJCHV.;?[=>U396
M>^1YN/,P,=*$4(Z(V C-%,_/$>5*M\7)\7Z<[)5+Z-?68P8C_Q YJCS<R(XF
M$V*,D/3FU>P[##A@G7_AN;-RI'OL(GQ./]EH&#[/RHNV9LZI<SSG'(-*]C5W
MG ,'6X,DR6E!0O]MH)ULM?>RK>R"<N&84;'U]-E-"-^DL%=/<-'?_II%30!I
MH%_:$+[=OO./9W,1!#4N,"LZA>RV,W3!@MYAZ' ;I1B S/E;+E$7P<.KC!"4
M) !JO8:*VQ-Y=9)U^H"7M/_Q.^'(U)-W<)?%P*,'V%G@PK__>,#W]XQ%A-(4
M2,XB8.\K\RW&V@$EPGYR$$"6#H&!"V)4&5YRJHZ? \.S?(WJ;RR4Y%^9I?B8
M)4W)4H+&W%$\N$*/W'\/D>"%TN+%C,P^E0O_+!#PJ?S(0Q72.+L CQE$?^F=
MO*'"5ELW[$_;&NB3IL%*36M"I$A&!7W>O]<ZF>B[YV8E-B*,H_F?TKG_3S4-
M?_2Q;=/H:T?ZZ)B=7Z%W*V>[^9M)<D J)'&%:E+^2:+LU"A:T_5;(-TIN%XE
M'LK[5.:3$T7F+MOJT>)R=7!] Z9SF?*TCOQ:*%?RHT#F$>OW,77,2ZJS.B^H
M?6D<E,>3:%+-]ZPP_V$>L]4=OM]?/E-N EW,2,!I."2TL;ZZ8;:ZVQF6*%([
MXZ#3Y$Z:5NKMG'"&*+@LD,7ANB%$V0_PCAD(#'8S/'($^\WGN[RX6#X)<X%"
M'R (^2*>2U-R=V_AD1)/7&^A&!V>1Y9E \IC:A9V;0[N"$+,; W!Y0+4HVR;
M_U?*'OVK^)6CPP#NW#5O@-.LNTUQ9.N+'S;::C8X\GE(;JG4<D /_8 WY('I
MMOB6 DQ$R"=!?[;;1+!S, K6V6D]3$'VKUJX7Y7/97Y&BUK@SV]A(HD3B9\<
M"T7]E)\XHAH/BEJ,?,,_D[=ED-NH1TU7<I9A *"FX!)/:HYH[A:,2M!,R[==
MLSZSJ9#Y80[PNQ.2S*%-<7K^3R:&SF^BRX]^?1%C!_<[+8<[5%\L796D!TDQ
MWQY*/VO,/)'D(FET@T%L:DG,'YF%3QV7O859'2$/+D]M18+.O'2ST)\GKMN]
MM^V\VS,N*L@Z"DNM#&@=Q@J1TZLUY">K+:TM_XNI8?^/"#+[>5FDT>8RK6_F
MI5OU+Q$%S*?_MC;EJCVJ)\D: A<N8,>^Y4F>_ZG,T>.C_UJC]/GMD:O8ZO[I
M$R91:1M*5NXY_X(O_Y-F\A\1Y&2FY'G?_':ZMSJ_+8Y'UI\D_M= ]5\?5MO]
ML2BZ.KW:'>HAC>77)ICC:!M:C#W&6_<M//WBJ<WJF4CPLWS(H PP'EVP5+?)
MIR%0K[,9X+<PTK;_!T.KO0Q%(S$Z.CJ\?]#]=WSO%H7ZRZEMS=:$M>4CNJ]S
MUC<6N6B5OTAN.G[< ![CQ<Q;\#G)0ER=GEET;; (O*Y:IU,XCWZGEY>3]OUE
MT;^_U?'^7T;^$+HRG0_^BNAYH*E4M>-OERP'J[!$REH=*DDS0X*]?!XPX9Q9
MK>E*?D YCP(AX:J?6%^*9]@]]<KS;LBSZLM(]XSS(3XP6]V(:;!G 6N%%MRP
M3Y?S/2OXE5OW&[R/YONK$J,?41@1W+ZUOO[:2]2\5Q53WP@Z)K4XL*!DY"MX
M(\8BY/7XY-UA-PX#!$+"QQ_Q<?N&@;+JTRQ"$O^[>P*AZ+^@P3K<1V570:/^
M.1.YH>QE-O^HJ!H?K7K>X=@_=]>QQFREMO&O8/%CB?A_&5=K_VAL:8;\;<SB
M3/Q-!:'=78^#RLBO=U#7)L%UFA@\JP8*1<RSL6Q%"6+6:U;E"L;=2'3=[]Y&
M7'=^:"E.AI('BH+-G-'Y1?XO0[F;&+$/7CW2:SG/1%WD%RKG^WG!J8"B6$S!
MP!V?_HE"ZMW)/9A?ZRVH*OBJNJ*!>T*+7OB$3^=&+'>]]P!B>->1FTQ=:'\G
MUD,[-*:R^39$YD+H#2)*(.*"@_]@.NOKYX%N\XH?YA3/VTJ*RL%X\;BM F89
M.!0MS!%RB\$;RY:WES#BQ\>:LS<&9!6E+^04$WH5;GP%,1;YAH]%!$YTU@FM
MK_M#(VR56B(6)= <K^M3H5BWYBYS:%5)%:TI\N$B#MID.W+.T-B</EEH$G0I
M1X<XH%T,TF90D5]#PZN4Q?#&X\FZ"OW5HZ0A>9GSJXHEX1EN-LTT+HM3+4C_
M.@?Q-5RWV(8NAX7Y5VA/E$_H9QKIA4QK4890KYA8P/(W.][B;"$=.]A:PV7"
M5I%K>V%+S$X]15W.! <-I+DG@T#IH"SSY&1_?5V%9J,F8AE&2;]7T[;1L'1N
M?KD][G8?>F2%XO+<O0C5^E'H-GG^<=4S-?1C4A$W\V?*2RL_T?0P='X$*R\V
MY^8^3Y_3_I!LV4*$5Y<-8XQ- 2GK1EB?W#K9[Y?DX'#<NQC _IZ1TM5KLJ=W
MO+2VN2@Q\=:'R\#2K0>K15_9>4I/@:F/=6(-HRL<?:MK,13Y@V9AT@\?OZ-L
MG%=OJ+,R427,HI9J:;1/QK&)?-]J<6T5;"DTHM4RFO?VMJN+V%T5+TOK[RSE
M#,$'9)H9U>I]ZZG6POZ#S@\1_4CF!V MQ[K) 8GQ);AC%AQ[;'<(#8OE(/96
M3A^OE54Y4L4_&_O$.Q.2-.$-3@LQ3R-.I>_L'$^:<,#V&AUS4M2)5+6G\O<K
M.*#TP\P._'CV_FT6J#Q:\8C<(,DR$#?+;Y8N#K6$4TB0R(H=+@*<?5ME:V6J
MOQ/[<")Q(TT94%>LPU<IKBK WQ$OM.WG6KC[7%P&6::1>E7: 1AY>,ZWD%YM
M+,MTQO>)+$8G^6NFJ904=J@N<OY%S<S"8;0SMOZ.H9/Z &:_"8#P)L<MS?N8
MWYU?A"I(#=ZA\_$LV4T,;X6>$#I89]S*>7M2$3WWVT#ZIV_7O#7[?NR*(#_3
M&>I"'"_+[C"HO*7)P+!%@52&+RAUE%=9?%$KOP[D"BWOS([*F;%3S=#'G+$H
M.NO% HN2@\%4_'P8)^:UAI%Q?0)[JW*R10PI[F[9D@2-/^SP.>)%F.LGF_W!
M26$1O,69W\R#^L?7MW2WHLR;#3,_1TS+<VIE@"C,4N2BE"]?N[2,>4(M%.RS
M#)L<38I/]$,I6./:# OE*NJ<E/LC]=6=:0H_G;+N3Z=0ODR+BI<CPDA4O6,X
M("DU=YLNG::62*X]RT>J&)JW ]BTH.C+)#,AT>NJ70D_O5\JJ=DC$.8K'4];
M@.W4QBGZ.OGHEM=5L3X@I#W3!QJ]LLF"#3O;!@C=5\=?78LU$BS3(U7&J%L;
M(VU&67E>)XR:/")\(6RA01W51V5!MK&:OS8ZZ_KF(: /@-:ERBI@)9#=U2"<
MUVARIQ2/C9^GEM'E$&GN+_*4CDP][AD]/,(W_"4+ TIGIFQSQ$&\S6R&OY1N
MQN""$!8P7'O'8.H?$[^/QY$,W3H,;X);N=:LH3O%:67J$RD2*P-OO/._KXX:
MX^)R4!:<A!*X2HO+;O8/N!NYN-,]6R9K])JV\)N(V-NT&+(32V%.?[)U7$SL
M,M+NS]O@\>,/!I?2!JO;T;A0+U?BP:"'60>DP=_!&Y7?P>#D*?D^=O9\:R%J
M\KL,U''86Y1+I$/B5#8MHI5OK7,P;9$WZ5<(G%9R*8N>XRE6VY[FR?<C[>)!
MLZ/)P55/+A'FPF]Q_?.5T.2!6L$YBQ2[&3M%3F*)RW(5!D;(JH.HWZUA.RF)
MDO_)]4(8(:CY:NT/1GKN=:"_2VM5: ;S]>#+2/<)^KLO;BJJG=>1GH1"XOB;
MAZIC@,.RW+K^&BXJHP).?TSA-A!O5!-D;3)W$_U%J*N\S .\IVUE(6.WB8ZA
MB!8L^-;H2-N[Q(2(.A?VB.I7$7 "> K-78,DM$H56MQ8L[7+IO*2X]LZ>%ON
M9Y\>*L(:L3OLEYH?%HFS.</]<C@B Q Z9+ _&.(W =+3S2V).DZ6--@Y0DY>
M&W\P3%)7EI'#N2/W1Z?0AMEIOI[1D\BL%):L=Y1+,IWC&(VS]+\,]A[F\V@&
M O#M#=G6\%^+-4=2.1QP*$VY<ZTWD(Y#!&1HXV64R;2ON8H&K=ZS3*@E9$.[
M$/99#-A>:EUZKP-?=F6%]>K%QL9;K"=D,>%,K%!(N.ZP#LZUXXNN,19D&+R"
MKCW$F@9TK?[!\.ILSKB^RL!4K[3[-CFNW\K?7>"#743>)["#!=MVPO[K;VAP
MDY-?ZD]MYNM2%3>CK(+97PO6%KLQXQ$!\8J_N3[3<P_<_N>\]/_G(G:HEO@1
MUG!;Y=8L$[*IUYE04^^N1;\HNWN6V<E[)4*N0+QD745IN&>X\N-^Z>\%<^0?
M#/[['QOHJREM@]2S4YNO$.<9R$IZN\Q?UV^TZ.<U[<03[$;%/22Z?S!>GQ](
M /]@^-+CGIP&WL )7NPCQ;BJ8P$""@L/B,#X<6!NLT]SQ93NC?:1TIVT2MT,
MXQD$9I//L$,3*.4TC#&V,:6$/*T&<1T9X<^;J-_DY#XW-51,KB.Y:\W^]:G5
M>WGY''" )]TO/AY\E^[NB]KJICC)I3SNQY563-6= 0+=#$&;U:I1=_<*VW?;
MDSN#S8%\D\W2]2K/8J 0?AQ_H]\2O/8MY?X'@5'V&H'Q4]39O_=T;"I5W75V
M],IFIA+'!]4CV2!)>IB][::?*A?[I:UBGAWY-"'5*8HBS"+J,Q^MD&EXW!LI
M ]S5UZU&=^\.=<13LA<W![9X26MU<,+1=X(;C9S5)"XWY/;O5V9"!,B_1@AV
M2K<L.#O7^XQ+/N'5ZPA8D-9O)22)%&!D(3>M-FXU=QL1J;UXZRKUE#-(Z<WH
MX7#A+3S4 ^O@$&=F8!<:Z?QVO8(HJ3ELJ*\ CB.N@<^)YT13L4XC+6",)OXT
MC&>[Z)I ^#!^=O96E*#$<KU5A$:?H[^TJ4_@GB;L0)O_99319%5)VS=EM828
M(_3N0I93]RR_8?C.O!6T'Y?&KJFO/?E]21]OXK)=^1Z-%EO]82_3N$=DNMNY
M+=\3>A8&!(\W7SSQ-2Y&(V!=M9L/!#A:'QE[_LX7]-O\B'1'A,RR-R=TTEVP
MHSNCJCXC<0P'.XS/@H?QY_J1C,2OXS$.M4)QW580GKX$+M>EZ>'PO&/%<=7J
M=X;,*5,J^=(+.@$=EJD[3U%6*]HO-0Q(EV6LR4JV%_@B9XF>I8_6K@.YS\MN
M^V@F-%)%A0$@^H/SX:9B[KX*RT6=/MX6-V7_,HUM14.6_=M8C>CYRC'ZI<.,
M]>M G,6)Q.N^IFYGQ=='I$:IB#R!?*<V [J$;V?>I:;'5GY])=7&O<*7JY<9
M?MI/YPT#Q(M,<G2$V@+V"8#BU?*,CNQ)36NFI(000M*_3PCD%/)WN8V_*VY8
MW>=5ZL^^A.R"P&>U54/U1W65F79L]W.2!1RQ721]0..P[\*0^,A@_6+2B.U*
MQ\-9$NK+B\1;C=0#^69Q;4)"L^$P*4,#W3T_@>S^L90Q*^"5@Y79;DT@B]-S
M?GHG:E2$+S:5OW3W=VQ1R$$GCCA>^\^@0B;RWB%U6QF@\F#CW^3U#JG8BH*\
M3$?&E(/&6GF?AAM&M^2U9!SJ;^!S@6YE>3&PM-J0$ZDVR,5>\PDP \( "? Y
M(POD-_R5165"%M6L+[-'A,#[-'$<W4&]=;O1S,+OG/$B;?C5L.0Q<USTR:$K
M(A7?73  X#9XCNBS>#K_=@.+C%W48?/T#P;N%76UG2$\&_=QN,/=(GHO,W;?
MHE?A\G*W><605M6?I9G*E39B7B"KH#"NEC-F#]EO9Q^8'5TV<74ZI!Q0:G_X
M4[19H-P!(U37GE.9\XN,NO3G<K!E_9-5SCL1+SL:T5^84!>*?>FGUN)66^:G
M'VP[VA[T,GM%\<O'XW]^&<94M]L1A: Z=/ \/2Z([(Y?)+Y4AK&91LGW*?D]
MX53%Y-F1LTA0!%EY.RC3*8M,#+CKYJB?"4&2%@M2- )Y$R096,Y88"9U+9^3
M=9Y]BU*0QV,(TVLI2) ,B(OA<3(<'IR3>B(7C@[26PXVOS)!'<ET;<#Y4:6&
M+1U"U[J#=Q:Q!NCJB):%K[=-U7+8)B>W:DBW<J7\@2^^;#_<QYRSX0;<?4TR
MBA.REH=+1X> #0/?^3.=S;,U9))FY:(@SS1Y]G)1#FGCIXBR.S"./(E,CAJ&
M[69R;[AGCV"K)_-EEEQPYL#_Q=U;0+75=6NCU$NAI3@I5ISBD.+64J1X@>)6
M+'CP!*<M6AR"!VG1XA(@0' +3G$"!'=WA][W.]][[OW><[YSSOW'^>6.FS$R
MQMH9R<K::^X]]YS/>M8S=9.;FM9N S-0 &Q8(V7H+TS4/9JH-N6%Q-:Z'OD#
ME9/^U'2%R9!"O3Y5EG>2 40C^;CRPWR84L!YE@#EHQFG:A&?[[7%.\O(>RRT
M;^/(<C*>YG6:+&#1Y)$5 IS2[;,?S)W)MKJXWHE[Z$>FWM8NYCU=U[RA0=E4
M:!9G!>=.&*9&^$RLU)B-3E@"='&YWR-P<\]MVZ>VK[=K,3(NF)Z^Y(%&B_-N
MA8V]"4L*^Z--+5%PI5;!.%2.],=QHZ7:#(/5K!B72$?-@A]4LS?SJ4J <B_O
M9(-I/2$"T?T2<5CDA85AQVI$G@WD=>]2U; ZB;0I=N<=OE!XE=VC+[1-T35L
M7$XN*R(8"N#4%*)+V*+43=4S 1''@BM]@UHW-M7,'(52P>34>#P=<J0*54]B
MRA \QV^UA++ @&3XES,@WPH5&Q;M*[:Z.6H8&!6FQ4S=+0M6GHOA!^2CYZ9(
M)RJS %P*,TM,=67I-0PMRI+OZXIJ]4&RALH]Q+<J-=T=K:J)'BI>G>I&QQ=Z
M/I_<F#O )'I9"J8(PO?#R54S;JU;!X^=D\0"ZVF, *K9PNF-&M3.]3O#6*#,
M2Z?MDADU8JQ;W8*M&B1R&AEM4/T;QX??KM+T]&U6A\T&7+*=!Z\IF*"-;Y6)
MY3=.$4)LY?!"L2*XQE_EDMEB='L4&EBU-]?=50(@$3QRG7[8'48S8"5S^^J6
M%\QW^RI 6L?L]-\05]?WWF^/70]#$OD?B Q*^"GQVJ0^"B3N!>E33!V);WOC
M2XH)=INIC#E]IKBVY=2< B8(I9H;ND/>V(+OFH(@1Y8@".1,5-1YH/=2=VY6
M!H.\2 (/?&\;*YW_=+@KDJCBBAS0)X]/L(PM,GY9+<I .L5)[+30AG^_F5>1
M7.CEWT="8)K37=A+&GJ82L;>2[6O#!#JQM^'RY.4PSR^H5]^^R:8%(VH:(PR
M:1Q2 T=.;OAH+=/B*LJ77YQ+IZ8W>@$N8(R#@Y5T()VI&PB+\XF^HYNDL?H/
MOK3&):[A0/]Q79^:+I6=B+&3#*8@(J<-?S7316CZRY4.3(5[;LQ@)/*@/#[
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M+L;YMFB96C5A*RK3BAT3P-!F%I9AFUORVBPU\'P#"5E"5BAE7_@ZM;^DQ^'
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MX3R>:*)/\S*]W&P%D*V>E8:H_1+1_ELV46]=2=L'7N_.HK=/,6)5;@]+\AV
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MB<C:=.0]^)<DG9S]5\J_%I2%CQTFB<5SE$@8"Q(BI1S+\=[32ZWAQOE2#9T
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MIA#]WKS?.(U^SB=7 = G<',HNP+Y4T\%3]L/TM?[:WK"SN<;@?!(Q=;H>2[
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M-V'?9.<7[^BT&9\./AW;-S(_4'\LF$P9I&(M=/@X/#FIT"]\ICFY'3>I*RU
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MWVJ=WEY,*%A@?,ON!TQ5&_(D#\+Z&@^SI_O$2D1%^$)P93O<#PC9TTJ /&"
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MAIR>QT]:AY#W<O8_8*1]*6.FU:Z]3.M*UQ%[4^)1 %G*3K#6VZ:2V- Q?W:
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MR#9K$W '![N[^81P!X=0?VM+C+SKX"*/;09?!E8/!E_TPL*5KV^HT)]FPON
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M#X=5E5U!@2N/0SN']1$K(-32[&N,WLK,&A^YK:V/FR!WP?90X@+0!S+VTM/
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M#$&XE&]$J-.YL)_D$2.ZX_,F*.9(^%KE9296$HFPTF'"WU]KF' UL"E9 S0
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M0@/>/.KO#YW[K?5FA(1D!LBD+H7.IV8N!]9-WF'0--Z\O%W>$U?^1+^-3\#
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M'A[<AN;M$=8M[.)I^@5D7F)K3'XR6+K^M+$:'25DGR=[O<ZLU?F_^T1X!7^
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M"%KK>>XM5EFK1Z5:?$ TE"0K)WA>[Y48N#R]I1X.?_0J%BKW4&KC=JHF(7Z
M/3C<<]G[]K?FC'YWZLP5=&)-:I>>!)>\8$F,:2Z81[^ U$9R^[52U1A;G"T\
MKPP C88V44IEG6T4J>0ZF)F+1YZKTI] U-NZ+SFK"_%@0?OS )&&.XR!R]\/
MK/KR!VYM.[W#B/^#,M+DX1T&ZK=$!Q:<%5QDV1OWGXS^!J%;2DKLTBJ=M)RR
MTGOT].*.TJI=V(*_C]M4]Z3^/=G\)3$I164;'WLT>^:J.ZFI([G0O9XBB)F9
MT],*D3VI-?CWM\8DW"3T2?*Y<9-7=DMV]720F;JVQ@KF;U/"NBM)MP4YC@AQ
M'^7^U/X'JC$Q'V>^R/E!VA\.QS@^';9>^[4K57XD2+E]*1%_,C \,DNM;Q-A
MY9Z$F&CJ5?\2"=JM34@&J'"K@Y(FY![_$@>6M)2%588X#;NE%PO"):DH$I95
ME7.S4+[J'UVG%POWD)B"!?--) W*HSJSE8]0KJ,$%)Y7W3YH(SSPRJ E8Y"Z
MO.I :GPLX8V.N_OFKJ^L>BN"'VZ:,3?4) [0W+ZQ*MS78RTA\LD2J:SL>T)X
MH77<;%'A-1DC.++,%$[QH@!TQ!),CL(UC;3UUDFM[1LQ_YR-3%.A:C/AB<SG
M0IZ^2.^Z#&(&\GL*:>AHV"($F!B7>][QJ64PMIJS]E0%C;J"=5_85$Q;,?%%
M+[@F>"(AE5>GJI5+;8>Y<CK#K]!\L%NW^$;$*&'_WIE#_!W&_!?.[%F@,&7F
M;>W)T[TA.>"U-6243<%T&9FFYS\=D4>SL+)X#3,-=/KIP2NTJ-RGFG;KVTK;
M?EM$&'2FMI]7+E#U7G/(9N]TC[_1*->N?BA*F.VH:QRF+EXZ;VC:3CE;_P)Q
M[_LHGE)U#Z-[R,'E8=1$>C[I/J!\,"AA9N;^8ULEOI/M8;4/\P&J^$ =KO=-
M'S*S1)4'UAEX?VT;-!IWJ?,9G,F_M!TPQU3%+>X9*-'E$V+_B&X!#3FJ2_%%
M)_@Z@F+Y[HG:.]&:,R\YUK<*VFS#R?*_\36JZJ'M7C _H;2(PW2W(HR8O];U
M"LSXW"_"B%Q^NU:%<W+C4G02=EU>W&=;^TK!"+=MR'+>2-^I0F.[UL^P+'V#
MKX6CEPA1#E5HU2^+\Q3B\V897G@GYM,TP *SH&%<6#!H;$QW;)+1N-VG1NO]
M^F56E[6QOC%LH_"#KG-70[ ^IK-7I0O7?KY]%"54G#K(W*PJH$C=R?-.H"R:
MG\,J:D '8HSMQA(T;/"^QZP^#14PO:>302YO]<5Z*2_M91Y=G# #_8/[! 0@
ML)N,Q^@7OCK1; 9.BDZ?D8@0Q^TV?%]#@UVR/K<-+8XBS)GMGE[UU#IEKXC+
MI1T'%3&.0E_V4I,G<BO-W@H?O?G'"Y.;0\)5^=[^^W2>1ZC:U 7=0; +&9M;
M\?L"G"1'HZ;7;J735<^;%%X?#[U]H2;+O@ZTH.?8.&@C;E_"X4SJ0HSN4$8:
MJM!08(^ZG Z0"YEBK@2VJ0M;")*N! D( Q.^"'T:"C#.N%GU19+M+S=QXN&<
M_3+PUC9F6S6\!J1NFXE+,62QPKY@@9^\7$T)>YH]SN)-W*R"._OE@H9-KZET
MLHJ\B<E/*>E7<!4CB2KO#/2M6-R"!BAJ>)O2ID^WF?_EW/52F<:E^&OCR2RX
M\,9O235-@G!P1!Q]28 L,D.[O5</=R3;\P32X!'&&>!JU9?E#$=VEJYFU]V@
M#\N;KF;50>(,8INF T8/[@=6CW_V&O931=QAF PO[T"OX+=E?V (M/%Z-OH.
MHR"YT._4V<,IZ.AU,[$XDRW^O/#PWGZS79%8[;RK8AO,DK0R)L*\YE52?;>>
M5^8A ^>(I]@4;;..IK]ZL2/:?-SQW"79<U!]QXOE#B/YEFU<PN4\^@Z#ZUHG
MUQA9-[M]AT%=E%2U)R8L;K)XAR'%)>GDM9]9-G^C6.GJ]OH@OLMH>(,+'X?H
MI30*@%'K43O*DN"V\T-\Z<R*]6> Z#H/RBIC*3H/4N*T7]^%;BF)7-K^Y##9
MUW=/L2 /,[CDET[-&[Q8"@%&]R>NFCEQ3X/H>=ZW8K^87.6OY)[\V*1%N=>\
ME3@1%J"?L#F(0%CD&%JR3I.TG2FP?K01F^G=[KKF2\U:/]I.* NZGFD'UT_N
ME8C'9<%SJ):UVF ENE1V32^.S-2"E<LB#SYA?XZ\<*3VI$C"BY^CM@"CL;*T
M*7>&%5Q9S/N:V%)Y +*X>SV/?Y_J+^P/Z)>UKOL;'7,Y*:+.]HF^D\/LW63E
MY'9;B/8P_:F5U+6;*"ZT=_N7NF)[EQSMUH]F]-!!I\), 9'Y7R2CAO@ZJ 66
MSB$W2,;M6\W=P'H5@<[^DEE[QH(GG0I"@P11V[T*!VD._#L*^@+AQIRWN^#*
MN(R9"=5:!8GO;6SM>?;HP]_+</DBXMSI/&DW:G@!LI)Q3R%UHHD/8SJ-?GJ
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MDQH&OFE[S:KY7GIBV'Q)?1I^^YGFJ#B3KH\-UYKJ',TA80GI'O\S=B4" RX
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M!=7/?^O?<^+]B/G#;HWS4E=@O?='_UQ<.) T')C+MP[32S/]_[8O9C8OL'_
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MKZ<'#^NF#,(OTN<=M@P'FWW$WI:.&YV2KG![/T@^[NJQ@F;"LP-%9M*O#61
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MAE4#*>NWVWV5:-[4R5W;-'.@- R71\ANE/H-+ Q#+0P%5(__I2*7X\/>S(3
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MX<K\K&N=E'T6:@(BMVF3F8+3WYW,^;+&4XU:1*,DHNM4;(+N<+Q@PBX6?0B
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M3.YCN=J"=9$_[KF2N" _;?I17FQE) D)(5?$5!!N\X\F/1'G?J)UT8&Y*(V
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M##U DG1!#(HZBE42)::P)B9G9(0RL@7299NWY.3DI4(/H4>VEQQ]BW),+Z4
M95-GAV<(W;EM?%3!;]&-Q84<997R]=V'W_C_2.%?]DZ^Q]@7WY]H$L=C[M9-
MWNJ/*[4Z2DQJ!&Y9KJ(.I<_.<S(JX^=CZF&6(@CRS2'\A1"71RU::+R?/\D%
MN0/<4!.Q;$? _5S:4?W]N2F7_) RO;[?IGJ.9L5>G$$"Z:VN/.E(L]Q;=?9
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M.$_P)@)?B%J8<RD/##>+GWN?KJ)X)\>?:9E"U_QX"LBV.$4HSUR8Q[/RE$3
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MF/N/O<8:2^;^YES?^E:R+C#TIM!].-?PY(T#&AM 5Z?!1-T9MQ_5T;Y86#X
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MM294YN#\].G[?MQ+1INML8G\UTG/MKK?FC)3ZV\AH%FPE!&D@(?$4WX^N?T
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MYQG^4SJM_MFS8?];Z,GW+,/MV[_1=<VJV13IRU99UWKA4*TM,U+[_KI<8!Y
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MV3(:F+7Q%K#(9J#!++N@5- "H\V]L2RGY/PU1JW?1R?\*X=\B@=F\"55G(5
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MLG>])(N4@)Z&+7'SJYT!IYZSMF5QH[!63CW$@4MEB"BL*RXG_RKU3%M>\(*
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MN:?+A9TNW]GOEX%?;3EGXSB"OSYC^"2":7'RPEN=0[OS OE:!& 7N&*N(W>
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M[3^4OV'LEYXS%[D9OY6@46U"<F6G^BVJV$S7"DD-@1:T%K)GE.&N=9PDF-I
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MIJ0&)+LUM/(X]W3"JR:36NJ7:\W!4\E'M1CG"SGIC1W PB.F?IAG>X-R[II
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MC#'MQ/?.N<S>5)+/S(0-C\(I0+45XR1*YJ9](8U>+MJ+\!Z+;<_3E6;Y&,'
MC8-3/;T?,5CM0=(SO'8+O(P=AX9;U+[DKP,#@8W1"+S=XV_8\OFU V6%:U9A
M!Z[W!$$<EB-#]M]O#&QO6XIGFG,"%?0; 2>][4I?)A#*!WH$!75(81ZRQ8TY
ME[D;YWNB2*UK7F&7'N<N++>YU+8PUEZVS7T*BWV025=6#+<H=V[I#JJ*LG5C
M&9>F#$I+R90TG.K"%'*X'_V2[5"-',/_F?,Q=K9W$4^GQ#;5CPEK/\E3Q1G"
M9OZBHI+EIQI07.5Y*S5]/*ZHX(5*B@;C3&#'^@O#?+W\"7S^,7PGLB:-0'
MXT/\@(\)4<8O,X/S&:E;F $7TMVNC4\21 T"L1@<RNHPM%_QKPQ.U.@Z:GN.
M#<8(MEV4EAF#K@VLY#GU9:S=_7:.'$86%D$5DX@L_N0P8#_P>*:FH;,W,JRB
M1Z/N\Y*1 D;3",$)DD?NZ:(H;QGYP>8<8!+6II!_RNUBAQ<+_U7U2!";58J^
MOM7YQ+&$O7,<V!HU/"'%IQE3J[S[$;\\T-]Q6(#<9(7_F[6/K1V64;41%_&G
M*W.T\U]Q&Z 3<RBX47;5[5?AN1VE6!U#?\X/#CIW6Q*;R93IS9G]4L$%.BH.
MM925,?G4C6,/F5\-(U>E!=>I]4!9WZM)C0RE.QV(K.#=D+=P ,6)_V "T)E!
M<R2B:&S:Q(:&P__@."-&LK'_8>AT$A8%)F"(&5[ET._;J!&TLW!)>QFZ,I\?
MD-EI!BD[<=[CD>'"^GPPRK'6B8'9(NE[R(&=.S+"BLFU"&;%[F^!?,F-:V^!
MR:Y*2K)%%A?FGR<A@Z)C48F)^75Y$S9%#?$V9W;--I!TNE:CS36,0Z@M9_[>
M;S2HU14Y9@M$U&MJ.:N^,+6>P:N^,N?UG+\;N)(*73;9VGAE</K+J'0,678$
M78NRS[HU [F[F ).8LB)9OV$IP6H&UJS  F=TH0S#;=;?Y^\F:B&"66_1*;^
M1MO@1/<K@'[)S&!XX@Y+I'&M<,1USKI@'F_#3C6K,='?JC)CWOKJI6P18FU)
M+%08\<X3@RZ>A^#)"Q<:1AI/*Z/?:,>AGV?"2QO?@WZ,;'80K "0WG/+ISSQ
MZ[_1^$4F'165,Z\  (/4A],;5,.W',DIZ'U=]I\?=>%.S3XM;;A*ZG]JE'+*
M,\57*;9%)F]%U"O&J@"GT]9)OU>9H"\9;*5K_<4DPLU"SP-Z]8B6"6AYT%*&
M\-P&[;XE"@+RM<V0IZ'GME3NZR;-&S;M2!7U[W0Y!WX\^2H52/OTWN'=6^G5
M8PO<Z/P@+]U[*_7\YS&>PWZS@(;CO#"'30#G9E&B[FXV7!JCF-ZL'F+2RF;'
MP[8[V! LB$"8+R=C'B^ +GQE%0'NM+>MNZW$FV>HVMQO-6RBGL7V%#X^Q0JR
M1[TUNQ$."CX\%]E*M(=4/!A/3;(E0YF[ILL5WYX@JAZU"F5EZSD)7M8YG ?
M) >6-B];)%,DDX;:T=UC<&F\<>]S!"^RVAOAYP]0D9MF41EBC>(:EMA>$EA:
M&VP]D&=E>9%F?=/DTA-([=;B+B_U\_CLSI;+>5>]*-6UUWU)K;6B5H'#CHE]
M0]@>5K"P,T[D%";TQ<D1:)EER3!\N[<^]0E=OA+NF$^T0]3BRSA:Y^SJ2>OI
M&2CH>>KY9PWP/[P_3[T/N:6P$H2:K-6!V0O+HZ/['HI'JJ&]09WO325K]EV9
M0 BN\=[9'<[7>^.)%40T]6)"&^8?%L2"26_XV8P:03W\UI/E>&.VR')\+!W4
M;#!I0;KW!E<$:6=FU+!L1KRE?_M^=H][@XS3VY4-,)D'T&%E:!<K3.B#Y@8.
M'NEQ[+!8C?E1C>A4":T:WM"N'B#-4=DRUPO2W_&]FCIY<FQPJQP?%_A]P@3X
M/@$@-%%(I3VI6:L>J2IV:]]*D,^N>S7D>68X9=^@5,SC>Z*=DU]3W([,);.?
MW%CF: BU<K_X]F=&3UU4<VQ^)*3(_;-8'0 9Y:)B2)\*'M6%  2%#PS2!@$"
M#,D&'\*0TS*B$Z*O%*"&<Q[$6:4K#IM5]?1-XY$I,6I;V 4UGF@J$R.4!D_I
M6T("BN\&9UB<);XS\?],40)]FXMZOK&#-1,YE33O![0M[]FDY11G=7DUHL2@
MO#S*FLC^5-=N@&-IRO_9,-#LG+<[Y]4)GXK63K+JD#4\A2/W!1,+ $,%CIR^
MG9UF41P0N$P^#8K758C_C4;N;/FZ(8=-'EW:H]_/P#Z^4E&4V=V8-5V11\&^
M#6&_B,_,XK+!J3-HOI4,N>&=A1E.NQWMZ33J2F77E]!3"VU\=<8PXS[%>!2Y
M;NEZL#>ZJ'.9\OZ)Q6:(N$>1-%9 10'6^$UG"ZG6F$YDMK\:.X4:_5>V-=TK
M0.E0L(L"@TQC$/#\^;2=T6CPU/&Q&YEHO:_]4W[7J](/.=0IQ=.'$)_GYCL;
M2VU?LDM;AHQF&?Z,7AT(9,ZL$,2WF&S/IU''OH&SE_GCZ,>]1,M HH^A<20)
M76"?^-0/TTZSY7;=G"\**G'#C0AB>FZ4V7N3W."5'04[UWAVR;U"+"*9.5<5
M82>0!:-D9I6SJ,2RG% CG4 LU.2/$2TP>X('@(RIE<*R-MZT2LFIV,1:6-;#
MIOP*6L4*$? %'8D<JICQ.Z8WDQS!FN,6BX6.^MB,HNHKY$;5G@TF8"5!9IE0
M(3V:<B9F+>QNJ!LF[2WCV$2V2LW@%;XU9E7V/HU$4QWFNDFU,CN@,6H_:HVL
M2U$]7C,J;S(JGZ'9IC*:?YH?254_&*<?H<\4(?PKG3?DSQPCGB4OUH@^0G\D
MC![\CHG@B14^B0LCR--2>>D4_ ,D - $%T\2%;#73WEBE''A*9QRIJ2"-3OU
MM^*Q_(9[&?%=Z9RP&')9L))^L>J)&@<V^WX*FO'Q92\\9T!W]5)&"C.OLPR/
M3-++=SZ-2Z%41U0Q]YL5AETEUZ?F9>.3T3UV..T&2PS\Y%V+P['C=M@( 8KX
MLY=*)$3X$TT[;FAG(S>>3S'1::P%X/3/5!?'V"K.E8JPVWD:S>_=^\'V$F?A
M"AS6^:8<TN4F$:(>47E0C*<K;(P:(X3C! I81P,X3!0U'YZ\(4T@)0V/K.$5
M!<@TY[0J>RIAGY*7[_>1QQ27G;+%N_?<E..^>/\IK5)B(%NN@X[*MDYY\<-*
M !<I6Z+';O@"0:UCH%E]S[POS9KQ).QQ^E+\6"R!;%(?-RY_A:C@.\N:]C=Z
M [,DOW*Z&LF]B,UWMC-Q"H=V6OM8]6P $VN\J0"-I7YDI1$%09!0++D@-H,O
M'F'27B<3-P+"]E.1'I] ?'R-BOC'ZCYM"W-MH[#NX>3)Q"U!_"[&V9;.2*^>
MOXJ;M(9*_S"$ML Y!@]X!(:(*9>,;4-K=#PT S+.7)R*^;2VBGSWF=L:UY,W
MN^OTV>=(&C9)?/G<O?7%7HKDX_/OH/8E\(6I!&E=4F3+?O@I>D45!_%=(8;*
M0S!VX#3SQ>91VU9&]]-U%5$4&34\94G"A"JS?[I<09O6/C.<GUF1O<_9)1$0
MJ=S21#9M,6DB2Q"=!" 24N7,5[M)]Z?/T8?S3=CD4XNJ@JPF;FL*7%_+Z&@?
MVP)(XI.V]>7I0N!R8Z@T(XMUAA5 A>/HZIZZX;?U4D<6E!H?DP)XPC_= P1'
M(=PKRT)[(1^+4]2VWCR^$M4P^RKWJEYG:)1< RM./KX_H_7,/D6>5R^^OIP$
MY1$M7B[*LF.\/ &J:RBNW.OI%V#B-#*_4GL6O^T22A>3V(N(,IZSUY.P0P:5
M8:*]VUMCNM):S9K'D2[:8G4?VFJ;YJC-<[(\BR#9I4_)P)GI=9BPY3%\$;9$
MN;:;.H:,XF4-TD:,LQ1.ZYA?.770MW2I!=0XB%!:UM2B*;A1\]47I[>5A3BG
MR3.5&5?QBT[#%QXJI_"'3#X&B.2QT-&X"%KB DKK9]R1[:&HY.""A_)/"R--
M@=L$HKR\BFQ+:F<\N*G7->AC3-;87Z<!@A4<UDC D[@7O&8GQ]UL7B-2D8*K
M%& 1F5T2DM.(:2?"S5QK"X@H#)ULK?+7]FN#"*U'/02SF911E&F+IDNCHTMF
M9@\?';HC&[5$VJ_(W"UU3'3Y=AO*=Z-6''SY+42:^"Z6+5O;9F?8X7S9V^44
MW#UIF:(9[)(2 MX4!SB\AR3M"Y ;ED)$%<A%P6-[BJGY 1M&XE0VNKQL.2^:
MU:![MM$%EJ(K9$DI,U@;R-AN)?,Z(>MLS6KK&YF1,%86_]@FF]X[6'FSXL&K
M56FCR!-YT%%3.2)1"LG1ML\Z8%JD';77E2##K5365?T0?@?[!%]S@>4Z/EO4
M]QX@45-"OYTS0,"\,W0JSIP\6!3R/*AHAK8\C@ .\6'>GE;Q2^2LBI-0W]1O
M-4E/82"FC8R83U>UZ5LD$5>LU&'UBA,()5K!P.N(\K8_?QKJE;G%)HD#?U'R
M"Z*ZWV@_C2U9KZ0"I/ (O>QS_W?0:Y)C>C.S=V9]]*/T],.KTBJ=&+PG_T:X
M]:"ZI+;>4?=.@[=5!NJ]'[!KJTS(U>JE''Q8PH>X/I.@?BO/JVL5Z&+.X;/$
MCT#"U\JQ#KIX/S?@L3I?+E[87I<N#/JL4;[0-9="L#@*H<$0D\)4J;7<"8W/
M#V,:^&KQ6F!/G9^_,Q04GNO+_V<<^V-/?%#\E:"ZU44WC>5\9>[C*1$?.M!.
M#'=,Y?C&;L_!WKU>C?-L_4JCEF"GZP :AUN:WK[;?>EB%!@\-8>M%\Z#!<X>
MTAS2V6'"?;4SBI]E#KIA=NB:T*XA<\6?3=<O((@:,,*.8&X^M/'D):^H&WVA
ML[)!5I,>1*+&HAZ<FBD]14<CQ90@-&(H+W)!1T-&F\U"%XO6$^S[]Y8SDG3V
M&!55_GAR$\G)J]?WB7OFQ+,H0#QB:D5X8RT%Z$:#$TL%*%F4S^%[YMIR):HH
M=EEW,&-NM?GVHTB&%A=)G&$:&(OHR<V1U*XWQK<[6$T,38"TE"V*8W+I?@%N
M-V):4@_6SYGUP-&=>;^*<GT9JT17+\(%\[XB9(DB7-D*]?J%SVD#7R[_)Y63
MRYPIM.8 O&T3S>R<V%1;>VTLK3PV3OR$9-+L5E%Y[*<@YH^^)]=NXMLR)4;-
M&7C3E;[1HOSM+V0M!4GH -T#NZRX:J].GO#%[;0:%9(KXSS,/5=C%+#<^65H
M.,VB3\(5+_B12:[>:P4LE/<(S/S9',Q%_ K]A_X[-$ ('AX0CQCXIYC6_C<%
M1?[O)1?]J;X$>L) [QT:%A5XF]+'B)-FXY%#X];]$5=WRV&\P&.5B6&N+TH?
M7?ER3W#UZMGX$6L%GP@U6(\O)O9Z94 7MX(%]E?JZ_3!E3MWP=][CQP#"ER)
M188Z*%4>#1SJ;@?5P!5[/Y.8N8!R-RLF8!3$6G3?AJ:2P5H$H#Y)&M5/+O'U
M@_&)O#W*>XMGJ1T*@K4?5\T'$D2>Q/R[=R!^=,]D@<<!IPG<KNOJ@%=F^16<
M'[V8R7U!GGI\??6E-;5DP('H@#R-NU;99"KI%]%KZ\\(/,U%K5["HP\$,GR?
MV'C?2[LH$7[MIXA+;0G_$E3S*+(IMD54%'K2]LT49Y-J"3LYE_@GJB4/P28+
MO YO UJY#:Q^Q#]VOR;,OA7R"E9[S69Q:BY2+H<'YA.S>_']_TW2T=LVSVG0
M+_O>RWEL?KMRLHCL-HB5+<D%A^5W[AJEYXQCIP/<%C\7V_JK#7#UOCQX2^O:
MZ![R[\.?CVW/0B+2Z69%TED)S_8=<^GZI;O'G=01,5^!(:'ZT5Q)J0[K+YD1
M8%*'5NVB1D<[_"&SGHFY&K%:-?'P=>'B;._H]72;C;A!!6"R- M#+'QX."Q\
M,0OY:/<?KAK1WV@'G^&. UD9KJ(U5=4^/$%P+.(-W[3R<:YS<R["04'XDI7
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M<SCM1SLU@RMT(=B!Q78?K@!/5UX!67@S)W9N)U*PN(>MZ)MVAE-MC05W057
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MN;Y_KS9EH7IP</>72&(:U8YJEQJ,['AQ!*!N.?[:=0>,_RT,N3KE T[,/YW
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MR'N L1?ONJE;8H^Q\>X<#6[;6^%P-_>T((&&)V3?OGZR2+BC3+&&I6>-/OO
MJE<^@"W[_U79K7^I0"Q1M!YNE8,TZ>>O*#TK[<_,$2'+W96V[=$F+RG$J_'M
M=_N[>&KDZ/Q\%46F2?'C+[WO 3G7@9P^'2I.>)G7'?/HKHD\//J,&Y^13%]2
M-G9P3Z9NFZ XE6-7<K\&T/(41/HVQ0[=8_[V&R+3>+C8>!"&464($ #];8'\
M'I[^F0T>H*@ V@ ,E3UZ-420(*8Z,*MF +V:H"-B-Q[863:@L#S0'WNT:<&A
M"CG\7CQPP"$)]P:!4(@.*"H0@3K?L8R1.GZ!^,-6UZG2);2I9.")LG32'%4'
M>IZN-^T&0F+%C$CKP@;0^#E3&&/.J4N.HDZZ!E="):PZ/E\K4ZS-93;7J]^=
M.4EG23AH%7J!/9VAA?*2B\965M^+!6<77PR*94WSS"\S!F)87.. L75#HOGN
M\)+TH-IF[P5:K\M']N;@RASEL[7D.*[1?+8:E?ATDR/,OC2 AT?G"@-2F5EI
MNQ]72!?[V3N%?MJ9&:T(.QYK/7/',$@PC3%_$=H4E0*'-)%"O\CUA:B;7O$G
MN'LO9 ]"OEQ&7"9L>4:*&(5/[#B&AO1IY3)\B4DG/]<"D;WS?M&#WSAG;PA.
MMM;VC':<,QW0"T]E>N*%8/S^4G-PZ1]5<NX!$DN^?P4/_>)'U9,V&C0EN*1$
MJR.+%Q.G"+X'?"HYVTD\&V@(<.]"M1<Q%P]@WGL5_I73:1_[S.0<]KKO&"WC
MTO1[ #'6,OJ:?>9$U6GQF3)656S_+'A%^N#W9)E:N11?!G]Y:H]1A36-::(=
MX9 )D:HTAQ7ULV<HY$BC;Y5OR[N%<MD]I*X1CGY"5O&FH#!N5X$+F)+NZE5P
MU;#H8*B .7SIZ=M7+N=,STIG3QS<@>ZSH%V;XE+'RK7?IM/:N12O57"LY585
M/]<0W@.&@._B/\F(^Q!>SV40;I1"/IPM90<^]+U2O8Q98??GUK*^<<A921F&
M\-#@%RINW(P;).W'/6V_YH HN5;L18(<LE]<Z=7?;);L=*D((<8T&%K&R3F2
M$OTK$@,. F%2YPL.Q>209"G=X8>D5-,M511!L"T>W:B&FJ9,)59!2K#$5CZ>
MGH9--XA=KX:Y%=?E(ZX5=5(G+DWSP]) OQTGLVE=&Y"3](KKKW7D2675+,AY
MV+)4D?Y%=J2JYUY^:+HX*5-/C\X0KH?QUWXX/U#LT5I;C.?GLN=9F\:H-""R
MS3J/W6UL;8=]BB5NI595Q?I4SLY/L[?>1@>$6)IM:2RE.#BHJ0*Q;K6.W$B)
M'9EO;D*-[2DK;_>O4=T7K-8'S&-QXW,1E'.F^5.T'*93*A.KSRWEN6K$J:?5
MJDHW>V/*,B?/LE,G=$4PQC@_ZV<$48+PZ2:7*1O8]$C&*QZ4Z]GI>I<>0>)(
M*_ZOCWKDY?('+Y,JB0DE(XLV"*MS)#LY>]Y' <>%[[*-K\M4/24NGB=)KG>F
M2U?G45?PL1MQ\;$]:KNQ4]8E@]-P)61T#2$R(H[.PK-\LBNDEF,J:E8XV#8H
M7[P<IWYM%VSH@:90@:U6-*(Z?7P=F*79K^?Y/9.<O+W!,CX./2W*5F1VKHV[
M"G^JZT8'6IT\I!3RXMPS%H<+1<&+R$%L<N1<7"W#6\LS478^J1]UD-KQ+3YE
M2R8_;OB.>?!3>,_T]/O?Y0?G+AZ%B1(5\@*]T=O,/T6Z/AE<39VSGG)S# W6
M:JWZ)]8NTJ^H)2V?'20BR7XFFR:;)LJ1QF$]+[>URPMGV2M\6=DD4V]&7'L-
MW5M<AK8Z-,X9#XJ_5>TT]/; \S]!-RHX\GZP7A:USIM)1U'PKH,)=R'8161&
ME)6Z<+E("BV_CWV; E1%B79:7U.+A4E;0\]P8]2%*1Z]%EY,, UR.IA]<J3[
M5Y6;-C$K&[6R@Y$_O<]CM,HI[6JK?+45*7/Z5.J_=-JZVK)NWYQ1D[:;-7X\
MO-@4PWKBU/>[A<K[Y*H_2$9HOGQ1&)8R>LMQ,DB0)"9,HC0E5O)XYE<GD,AE
MS4*$?G^F)MT31TMA/GID(;7-G^G)D)WVD2)QZ>Q3$L^M[7C=U=@'S31K4LM-
M*ZDP6&SA1%-X]2-<TR4>(%Z/\\JVB:, VE+KU:'L@:O6@=Y*EIQJ)OF!&2\1
M3]A?I**OSU>L@]UDR7E=1<XYSO-"6<N2G#7->%E?'"M8P-_;QM5TJJ2OXJ H
M)45TR;OQB-5^NV6[ TZ<&+G 3)2$1<$:=16VXC00$SM<"'6N;.(;]RN+8_<H
M6G%\;E0>$;M@"'9$:IGV1;8[K9/+*)AP*WGD'W?#+TY<.N36J!1.102'YH7.
M!6GYRXBHJ(G:'4^D3TY1K*#+/61U0PQV:9^X::^W$M!YSG_[#3F+A 4J0?H:
M'[OC8ZSV-;E&MFT5.9'%F6K"(TQ34A0&FL'Y-LQ/2E1%M@?>4&)HX0B4HX.V
ME(R6T=?*<7B^\ </,KO_D?63*NQ_]'FPK\)U&KM/4P9T4>D<O4FTJCU4,-RZ
M/]GIMD%D=U$ FF8E/AS/EH?:Z(0B6%6%HQLJ->.MRBQI+J/C5<@4R(%-75E9
M34;SGSH9P_[J2P0:T5;B--GB_]H_9]AJO"HB.N8>(-HIVG@G?D/!Y,OKA$OQ
M#;H@K#=K\G*JQ9<\&?Q.K*;*U:=K_USGK@6M=3Q7CNAQ/1%NY;D&>C%1GP4"
MLTY;)5,FD@80;I*V=GQY#T&>]OP^#$.;,:ME8)*VZ_0?(D!%]_XP#N.(%8/E
MS3>D9Z"2K)#&\7R&@5E,J$IVV/4DDSB\X355[EFYB%_LX5 >XN[\<*Z3N>1=
M>/XPE-%;>M7>@32,ZTN=7N.()X0X_T1-6I?YVBE+=W#H\,2DIO)P] +),\SD
M<1.CGXC35].BG)"4Y<?E_*>.YI;J=V73(<;5J=Z$>$8]Z7/0/@-$?1$"T20>
M6BQZO1_G+7?0(>?3>$L'=3B3JQ/C$6SQV@-S;K'/Y$K_E!$M@UI%5LA72X^J
M*9GV;A'T$.!X4":2?85F) '3OXW.BJ)?OY5/B9:>_XP7F$I5O,I'AU*;X!UI
MR]RL?9D"WX]"/_O\>JK 4=$U9J*+WL/WBV>PH^7%<L8VA$D'S<U3GXI^$T%3
M\;T0<+1.G.#(9LD!'$]IRTQR'T9JA&8J47*M4TCUX_6W(IS*[@%A2']-FR;@
M+Q$](LZ9BANEY;>_BS/SX_2/ACW&$;7SG#HS^Q6\LWPUO@DO.C<T,E*\%!)
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M)X_?I)>I2-)2B/ _"*G8Y.Q&NZ/<Z4';%!X,:S#8G&4,HDQ83L\[[SW?$<W
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MJ;#]&O5GC*#U#NPBD?AL-;%"5D[3+.7$(%\Z4I._<_A0X*M9+!=!['L20#1
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M"9GTO>M;;U_-TJC.=W!I7.0'_2ZSX^$@;%QT"YT0H%1.FYPR[5MWKL_-C2O
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MVX7O.^@=(\XI@W$GS7*]KOMV3VBV@EWB*5(:42?<(/:DNX-W9%N(#RN\)_>
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M/)TDP+") D[E9NT:[C0*V"'9URL&=W*_>7!*10[_>K6U&+Y4@_"R+X5-^9;
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M[]'*V^FUB.IZ?P;/.B@,O7;J:1@T%FZ(T0[5I@^G\W4=)OH=]U%F,_2+7:P
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MF>.R/VU!MR3=.ENIY>#^:29H]L77*W>.XE6K)YMIQ+(ETW YD?"Y%P,,@&F
M)^_H+D6'Q6[W-9IF)X\G@U^/B6^OG<KB9,+G6]LT@+">'IAV?<.82-#@'23-
MM:7SNF37BIC2Q\!R(88W?VR*:>W\1IO$J#%E1/%M;Z"G,<T#OZ4.)?7;UTO-
MC.*4ZWAVJM$]18VI#42'0],"S2Z%>1:<]8T8 C^PF_6\^+_\S@[+X@0TJ5=<
M_J#P)PZ*3I'GY-"NX(@'G92U'X27:%X7?ET-R5WNMZ8E'$R,(<U]E]VR..G
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M3>5^TL#;6I_!!G4*_TF9(_!)CW-6'\$2 N8C2D.M!/-.DZ4YDY6)J\]J=7)
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M$J$QFLK^PTQ9C7LY,U;R#4?;SQ;F=)0HX?6]:K0D>AN$I?:%;'$#(_='F!X
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M8AY]%_8/KBJS+8L.TD;*)RR6S[!<,>#W$?MK?QYU>S;RL\YUR%<UT+L5B^>
M8S/_G);YE:\^SR[%;-QAJ+S]7,0T;:"7KF[1[TX?W.%EZ:_)1_P_5QE0'VJ
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MVSB(L1&ZGDC/]\TM6X%6R#V==U^QKG0_"B[S[BW;+JL2TL)8(%X-O5Q0!J^
MI&%>.PZ-QL(DE9V7?AXCUUJS#(,S%T%!?HUZIU4X-O]3=6:^U^<@ZR*=IDU0
MCV59 YP#[E9R4"7@CAH434$$I5JG01/Z=9S]RJ<E$P+(L\9>ZNY@V3^NZ*WN
M=H%WAA26F.ZV9G[: -=J!@]DS$G= !(WF>5N "K]$R&<F.$SB:7<%6SS>=EA
M!8K+(C=SM(C>J^LTG6ZX;VKQ96Z<8GSVV1IB(/"*M6,J;O?%7'T6>X*9U 9'
MK68_>X(5N<5Y(/6*K9;@&>K19%'A6I;[>(+_I*XTDS.:J8;L@_>>,HB-75?!
M=<A&/]401FUQ>"PH6>-0EC[;UQA>O,#'6"9*+SE)PY-&<8#M&I3;NP[>"1"]
M/PUB\0S,^2$MC4DKUG\ W()IV3AEI5\V03XR+V"1C]L3$"5!N&L-R2N+M J@
MT9C0CT&A-DTJ@8RJH=7U,5V1"OD,)S<XZCB@,F[3A6EZ6L]@3_B)^W1F7NA1
M?&PY?XBQLNW7.;/VY_>A>)!Z3N$OG@CA$K ADM+%C&^R8%-J8S(%Z@A=9 -$
MZGT#^)(Z0AP<L.A+M-ZNX\CJE4JI-6$UW">CPUPW@;B]F*<F+8'< 9(D'[1A
MTGR+I.E;!5@RV"RW;$ OPE%PV=):4(ISRFP&1U/G?B";5U9/IRRPNF^*0!(;
M<SF"[G96*N2&;P=1<9"3NQ%%7IJ,>D\(*0HV6S#O/ZGWF;TNJVP'J=T D#*8
M"S71CU+.-%_T_X@-I?M5^6$=D(-1.KL=<BTCLD>>I;+MF46##86/!X]O3\T@
M68",)O1V;BB([_ZX,R(-D0:'^?C'4#_]&'CF56/S-*9Y/T?2T:&>Z\T-0%V6
M,#PA)<2[)=8TFNN1'!4?NHWE&5X@OG]J\_MS@MR9#^3DTU 0/0\]K!FE[MAP
M1VW]X:.8T7,H_8=R7'>?,5-9"KKI>->.D\?=.O[<K%4+PLGYELR1C(QJA\JH
M*/KJFP_QA(S8=.M#CE8KI&.J5'LVW?P34(<12NS8LT&6O#*WTR! 3P'KM7OH
M;UA%&UAX TAN"RQ/J#A.=F/04EGG%TSOF>ATNK3B5^!,<F,TISG?GZJB$)7D
M^$V,!O=?SXWUKXGAI;7$(EC(Y.TN-@)X)"A,#.<LK: ,UM5OBM)I?F7(G*=D
M/1Y69!UBVVN0(8M'H2)Q?YI%XY-V1F><O!V=!*)[06K1PQO$>7?4$ZN&M=CE
MDHF3P4[[)WD04"'O9)B(!+,TB]];064#ZA@IDBC[0N?Q50N>D3*[S6&WYD%O
M-,>JSBX\:RLA!E&)3Y)PGW<<ZV:B,*],#.;0CW:OY-T6_"+\Z8@+VS6J1J4Z
MF/*7$E>U?'^$-G@R_7UE?]EA%LBS#YH[XR^<8ZSLWYAK-[R36FH$]HUJ$#XI
MR_0<E??R -^'@)KLF=*_)06E?TN0#NTGMCKOG2<:ONQ(Q=\ !H"T;]0\HY?J
MEJ1Z/;/,/9/LFO.XZT=[-0HSUL?FOADYCY G<69Q$6I2?$SY$[TX9T_+-:$I
MHJ.A@,Q3D]R<H]6R&E)?^QK@UN77=!T=-'?15G5]LE4[++CE(;=ZAE,0L=8;
M]Z$%WH: W>^0?!FPM]D,)@K_8JZO)HCK\B*M(1F5U)[I#+A*P1RU=IS@SQ1^
M;.E05\#@+A7/,AIU3?W-M)DT&1IX0=*1.:P;,+6?-X!)PT9KC6+KB)3]XID$
M2<]]:?>H_8K&.[+W&O) :IQ&KS4#BGNAAO:>J[.0/-H!K1_N'6"]Q0H+IJV:
MLC;0/M@)4>36W%#JF5T=!ZK]DJIGQ*/8DEYK3R5XK(#3"YT7((R8;)+<:W-]
MV&!!Y<#A2)1>T0W=;S!KO89R(5UT^E1+#:;JZ4^]1 8Y1ABVZ3TK&YG.L4;C
M9KP5E5I.RAX@D:A+NIT6\0F)J#[5O0;2VF8>94^#CZF.5(TZI(\V".W](;//
M7SDNEN_(2>1^EGF95U#@(_9"B"+D!0GYH=J+W3&&4 H/[%.I25OV*YH4]U+D
M=1D?V;E*NJYPIH9*67A-QH2DOW_0=8$*&;"LZE!>D=!S[%RA,N1Y64E)7%>W
MU\ZR--$-H =O,O:3U\_7D>P&D-0H H1SSMP ]D)NIY[B'"4ZM!6-,%47-(B+
MD,\!@K^DD*]1\D51$:"*]C\I@>C/-P")MZ66:RGXI<M@TZ#E.:*S6H3]'ZN,
M9[C8V>R./MB#>D:R I[JC\&D44:_7H6FV=P RJC6%VVO[@0HLNY,J(K#6X?F
M$+)GZ684"YAA5^Q50?^8RTIO7\3FZ.N0/$N3X[N$V5= \M.%QO+[NZX_,L7_
M77,F4/ &,,/(? 6IVG(@B;D!_**+.Z_H.-$LR;T<O7"_CC )^:?H<@D@Y$ =
MUW'.:'4#@ .7F5V"Q]=O !6\M3ECBHMMLE<!-X#4ILK@$2 >;7@6=W5(O/A"
M52O*^0W0[UH<YWIO\XYDEKEU0/EEHL?IEA&841NSUG_>^.HRJS'WSF!^>W9\
M'+,0/]KJKV5V?3&/.13$[9S)9:-0"[&9TY#MGF1T OK\YX@!HL%\ZQ>3J7_1
M(]'$A%O@$$[')*6H7,&<P-GYXH@\DLKXQOY]Q>N%T[+<;83#.2@/N+FF%C+6
M5Q%RH;B$YX76)='![B$/G$+45F\ I:H5LI^\F& PO\U+_"FN'SG.M=B\ZLJ9
M-G#Q8F<;A(MWW&2BCW@+V2*'9JH"J]0Q?"-1<]%0!:.C>JTKA:G43KH 9I.R
M<Z#+8B'(8N8XJ,H^U)32!$BUCC]--([KXQJZ 124PD/V$T\BH'X9G)E"USMY
M5X2:S*=ZCTN2%SCR^LAF2-A<7^0Q*A7579ME_TJS3Y J[-6VT>E*K5?Y?N:X
ML;XT?-7E96\<\E+HI;R;;7W&5W4$5^BXKW3^&4%U,X/5^4^@M1IR[ND9<V=B
M*H@^.Q=U Y =7)9Q67 OL+4W/,5/'29UG ;GBM[%4)'#E0<V.I)ERJ_P^(ZK
M[X0-)UI"W_ ^XH5922KRH6&XR]?7(%*K0/O!_:%.91S+BX/3'_<4:$D/21,I
MX,\CC[P;7R=H6A\D.#UV*I \X.'(4.;A3$(D))@]R!?E$F5EA?HA)I,S>N5D
M/F5I2MYQ+QT9$;HZAKX* I<H\5<SCRKQ?TV\,HB<%[D!['_ZRY/APZPHF<D^
M,4F7,B'4V]6DE+6W!&[WFI@NMS%@]UF !%X,U2+<[F?TB5J+*P6$XJ>EWSNP
M>_)&5P_B91]$Q5-41T9)DU%TW&;E'UEYL3/$.K2SLSTTLM6)M/[9E@[.#"T7
MUA\KGLQ/Y+HG26;9W2HKG=Y/)VWO2;Z<(R(9T#"<EB4#:-%XWW,#D"M/,[3$
MU6J25@J"DW(&A;^@&Q;L$M =JN-I7B+)XH.]61DH92*<F5TN/]^7HZ25<9/=
M0X&0]17(L[/4,5IT0$KQL!?'"%6Z#@U\@#WT;O1H*(4L R6J>/E%Z#Q;3L,+
M2S]JMJ''LXQ] 7Y-:XZR/W0%6B9JDQ(UQWD),BSXA'THSJ_IA.ZN:X,]KN&?
M$^Y1^3WLH>\974* ^G!,DDH;<H\3NJ/\<RB8'ZFE%KS'3;_=:O37=PS)M:HS
M-$MNR?Z(]:3>H,+4I\KY("G$";?2_1L>ZS3M(*1Y]2_(>\OF"JG&Q'E7LTSD
MODL-\'%P-@2(>G4N#5I3^I[Y=*+:<"W6[4%Q&2!RZ\/7%BL?=((L;9EZFX+'
MT1\;]1S=&/QGM6:KHC>7&PKZ1%?JAG]Q>=Z/$["4XTU(////T>:>=W00,O:-
MY=%[; W<%2CPBQ:7BS'; ):8'_$]W3<K 3\HGZRAOR+5(>CTU"3!]M/(^@4D
M<1P7[5#.,(*/\70JDQ"DK*S.TY3'G,V%*S"V>$*=PFV=)^+?;$.<V^DF.3E)
M'(1C+L?7.IE&?2>Y)\HQK7Z'0,V>Z/+OUQ-)[GQEIQT""_ @MKN___CH/7:\
MAXUP3&>Z-JI0Z\%'_WF5>J%)'VC! S"VV/QKTYZQSD\UTR)Q$EQQN_S-5.,0
M>Z^]H_O%BZ40503';!61:"+#3/"X$?Z7D):HQEWN6NT_J2]$3:GVF9AA1R!;
M-QT5#MU5B2M;[NU7_48Y,3-XDGA5FX*FY1KBL&MUAIK0J#.IVAHZ(=(WSJ0'
M'N!]_/>&W8%:T23)*U]WI,69KG (FT['RY;/8/3KK9!ZJL1K%YS0L87Z:,H-
M8.H:?ZC%KK+*OGP#,#O]Z]0VV#3>>'FUM:85L%4^>F MA+A6Q.Q++SHW?U@8
M90N"+-T VN="LG./FH$&[<V?FO;9GITO;[M=!^<>"N8FG$P!%;1N %:!4H7!
M-X"\/,&M RO%<UI:H!D&L6"?%U)L\_;J9&/CK_67BJXHYLG];5$.K!#3^^LX
M/WP#".MV$@H*5DS%7^//QJRP08SO3OT9@$X:P;**E[F74-%8OOW+A AF<R7,
M9<_UIQW_E<  @_LD:SAZ6<63A0C36QS7<NFG5^X<ZUJ)0E[I?D$&(4*3Y[E7
M6IOKP+VPI;]<Q-X;P/CA=3Q+54()=?JPN81[0-+7O_[W;>AV/7$\#B3QN$-!
MT#C1<Y<TS4'BS-?C0[=@<*,>WYVZ'6JN['ZE+YVV8.FA>MB[TN6]0P$L&)(O
MQ!+;]I!TNE$N#D^@3^N)]Q@$!W#[R\+/FNR-=TH_,-?+!!O8I(P4.G84#Y*\
MZ1#>" S\9LW_WNV/M&4.RX]E=0D>MB._9S*K'45.R6<MX6XT-;.^90[)B5H=
MJ0:K#0N=31K'ZP&>O@(SQP99%^X#! F7%F#]RW.RC43<K8]5VU/T)L2?W]^3
M:A46E7QSBSRY.S(Z^Z-JZ #Z]"TKQ%Z(,1Q>#&T,8&IPD5;3^3Z[@<HGGG1.
MG)Y(_[*#67O_T^K(*XQ'J?_;X"J?<4E?A+R42#5Y;:Z--98Q#B5:EE(0%F1;
M[O+LZ^:5#:G=KE&:&0K;A6EEZ5YZ= ;97Q^G'Q%<A!++)PMJE^G1!:B BM0B
M5,(O^C90^KHNR^N]@:- FI%K4#8CF9,X?".8:7ERO$JWMZ586J)C9O9=QR_U
MJRH5R@N>8]'9JXS.0*(?'M=5[#AZK%<S(=UQWL@P#4SL++#FO8ZB%E[_]4<7
M3*ETID&!J?8G? &9L=S<5JU;]AD5RF=2*P/AEIBUQK7%H]%P3;38H/5#\KPT
MQO/51]L'JFXT/=P]0F%:/QY$MA:M_S=C;VZ]!EV.#(?<<M$VQF 6UWNWZ)9B
MAWS?L#&81U'>US9,U6.@TB(G/9-JM)S>(F^F'0I44F[O  6/>()RIC>MN)9"
M[?++4?P$!2M&!]-] 5('MY?FS'^))7%!,*45"#(XC![^JL&7_8L&:X;(%]-\
MJ8)(5#<F1<0C091ZJ?MG3_<G5)9&=N[P5^:$?Z2"?+33@>.4=8&;:D'YQ0.I
M"C;^-(]]/7\:UJ[;S907# H*I:/EWAQ@7^M2,M"R6Q5.RM9?R3T-$3H($0Q^
MSC[5EEGW88=JQYYOK&9YT=O2OJ"&C?9(A2,#1KLF1/(8LVPV(#WNQ22SB=F
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M- YOJ3$6WF2<1(I5M 4#,VDS'^VX,'XQQ=*?7US8;5#QGC#5_K1JII;A&+;
M7:&(%W;9JV)1>")_/?Q"MIAN?#]50;Q'S)_P0#P7"M_\1#;%,7$F[5?/J'V2
M?Y+/)KK&GKW3L_,*/O#C)W;?,.<B*G=4'''SV>L91);4V(5*8LS\U@>!->J)
M)M,6";#Y.44O,]UC1#OFRG65/:*Y>[_\./3]V*W!BHADKD&Q5TR49+6ZF[X8
M&1RGVH,-MK#53!S6X(/E<2!)^  H;O7IQ&*^Q'\S91#A\R65SBP,:E,!QC6W
M_U)+84CN(&/$N#IY8%%7)'+8R:9-(01M:GJ7*;WE&91[,5O"I"APRD?8'Z6$
M-SUUK9X=%V/L'5@;6R[LU-Q %/+4^U>2C+)3BK7\LIMN ,6HYSN4FNQ"G=]D
MVJ"5FH]X27^%>"/]L4C6-6O8]@9[;.K]3/VM@A/UUMUY.3>.UY/@D.!D UG>
MWNBM9R[7W(?58] QL8O#U>A+.U.T2_,]?::M"7!"/['[[8W-MX#Y%IG6DF--
M5G1!8<_]-F9% U\)H&WARU9TIV2GM"2MP)_QAE:MN;Q7K+D::;IW7TP0BZMG
M*7PRES;'XA_LI[@> +])*Q)V9"A34-U":"18+?PL\="D5/+>87I<"-@3XA?I
M%5V?T"]%%GEO,#[^C,+[:\-)G&CTJ96PX+8;57V1R>1-D ,-B1 OG\=$%>WK
M>NSQD'$">]!,A<*(NEYK>(WB_O[M(08AFE21I3?'$8-JO'F)_B?3.BM"7N/3
M2Z;5SF8^J]R+ZXJ;_1%G'6D>OMFBUG9=MP? @HW/DX(Z1TB=W]RL0N2O67'%
M;2%K3-(NW^ZQ/I&O/1-=/+7+:(5 =KZCO+B@Y3D$K)$H7J7G"J_.H1H^#(4>
M, TK.L9=#JC:U)]8]^?%PNEBD4F2N+C>,OW_E@!#KI^Z#WR0\!.49B*NB=)+
M 5%/0EYZQF<K.#"10:'0HL/!3AOP%P<ZS/X?Z[1;8+N,/L<>$B^D?NJB_7D2
MJ^B;A:JLT7*&HJYPD&N=>60\_6&;&%96IB"BEZ>'C*KWG'6JF%1Z\]=GE->C
MKG\)J7QB?F)^#1OXXQX.C6T_!SE].\IOA\L[(Z+W+,+U3%H_6"LGU=VA_F>-
M4BD<!(DC+DCE?VEAJ09!X^;)> ^FQQ<=\4I->[>G(#\T>T_H80#%RFU1E1GE
MT2H,RE4:\_:JQ!)2)3\ROU"(^W'+KYJP]L]VUQ]2T&GO_&!N?;*"[2C6T76I
M2?$UE^8_-LJ+\[WB+Q/%YL]0#^2%4N@Q6W]/_A<\ZPT$#%0>89 W"V<[+2P3
M#"EE&Q3$3SF<*0#KE0(*'4_L]P\<6G!C3.P&]!QC"DEDF(\OWBB:CO>I1\#A
M\TK9W&">_8I.1 >0V4-&=<FOIDI0(" UT4C0<J&8%E(#WAX1=02#2<A2X'6T
M;'Y[*/ XR?U LA^I,%1-)D"5J'#&$RPU(LYZ;!.BF$=GJ:HW3:FTAP7 0Z0,
MC^+2DM6N%*M7C7#N6>^L^Y2=?&TY*#?7#<C,8T&Z^6-2-^X!D'#DO& ,07&]
M+1A8#5BV#R_7*8P,*S()4;JO//!X (RL[1V#[I9^MR\63/R*D#]/@/:DC&N'
M)Z(RH4<%>1#86CJ>AG#R.,33L8JPR0^K;Y)0B8DV0..'P*X'P]/)A(&1[5V_
MIER7**+\MSF,:HGK63ODER>#^SG"G'Y<)PH9KZ\E(C:&>YY]^=H2^=,E#;FQ
MW,(+:BH@XS-61%T252)=9A=L=AS7L6(_M'UWFP6C](:&\7/YVR)'LD ?&6@^
M2WPV[G[&UDWWFY:/QL\B@?RM[ ^/P(2FUI"__0&8EW.",.6<E3,?,I><M=Q1
MO:A7?B^@U?3XDA'(P(C3O98YI--&"^&I5GD1U\_2J68_])-H2TJ[/.[@M!T[
M0,W^5%+3! B,X\UGX_7 [ (-)K-D\6XX^'#'D@T!']G2EM(V,UG#[T\BXJ9L
M,)QJ>[FQW5V,R&R+^,;K,B664U^O05OPRSY*WCTBL'*4I:VG8F-C6S(?8-?(
MF+&6YM9,95KA,T<SBJ8/A\\E@C@<7IK_I8#!!F/_.2OCVE! >LB,I#8B.",E
M)6UH?OXV):5E?A%J##X";\\J/%/M*N9=R*KTIO"4EV*N6G>DTG/H8F G/J^8
MWKU[I!U*#(7#HZ"73UA&-9/<FV\/$PQTYKQR*H!*03BP':N(X+QG/4@H!4.Z
M"[M^1$=+IU5RR-.L4WD1,O&#2K?$X]WSQ+;WFGJ=QNL.FWCY+^115,.3 U:J
M@.GE<8UXWP1D44J/IY+Z(U$9S#^SSK6+UM?5VYB(I\X;1A3::R,X\1?DZRQ5
MU^%?.;5^UMJ*R3896.%VZ3""F3:#!?G\%7^UWI&@S;H+F^3GY*!,$YN?Z?*F
M2;#WAT_:QY?QNFXLSZPRU^]U/QL<&T\G[]&TE'T^F,=%&[U8-#@_.-A>P,WH
M0'.]O[][^=9%[/0\>.HFQ+ER5T$N;F3@)7[M<B._P@N@_,J!#"F@1R+M-"Y(
MW7W)"WML;6^MR>AW,QLO_I&7EWCAP7JE>J_QMD[_FIT\[_:OW*>)Y;/IC:#0
M5E?)]?CY%%@>RB6A@S=*QAQ/,XV+NRWA(1RM"A\=LT"RI]P2T6.QTL-Q!J(R
M[I@5Y$XT ;(5%65](X&@E#KK=2S 1:,]'FUAIN>Q^^7 6658Q C?:ZP;!^H-
M%;!1:+U)0P]D^Q8-N8Y@^RJ6O#"1F!=N]E9RQ,AV'4A46.(2*V:*%SI)CF[P
MDXRU#Y5TQ\H9D6HGEL0B17)+M-K5:OEEP5+)1%Z#H?Q%[;9*.8J0,W5DJTYM
M3N2+L^_!KP2R?8F[34)?_]22X"#$)00"@;9$O_ZOER85JY:YU0-'[V'U6]00
MS?P_A/Y3)G[]OUX\27GD>R>W0NX72]O]YO5RBS]4.E6.$]7YS)VY''J41A-Y
M_.UW>@3D?PCMQYQ^,>KY=D<)(B1W%$=6'/Z_YT&SDI-+-T/H/=*;I*68Y?>!
M_ZCH,OXM<?Y^U\3QM(LJ=P\'G@K-#SN6$58D\0$]X:ZD/*Q^PA-0E:1%S%DU
M886G$?UQ55(<T*?5W4Z&>VKP..4]MJKV/&> :P"Z^Q0S$S'.Q) Q/=>KQE<5
M]PJ38T>ZE1.;JC-RCXX'GWD IO# NTB3P(4(<CY"J(R,LDFF7),)_Z]NUUL_
M=$>#OL>;#-Q4-),'/Q>\V BI5WI<9;_F2+"9-7AXI8RY#6:F3PA<';F5B39:
MF#(I#DWCCXJ3O_V\3G:V09%2JNT_C,X[++@4O1*-=FGY>^%2B3FO=-INTS=S
MV[[*8*:R;D#:E+7M/1=5=>73*S_P6"+FG^XYHD]V&K#MNY_C;J+,Q=N\"$55
MBA"4#-\>[:[82O=XA*!FLZIBBI4BRQW=/ ,CKBS)>1/['"G#@'5 K:+ZW*=5
M(:0?*)WQ63Z)M%Q)O(X"+SPKX51B1K&4FI2YFLM_F2>?I%/.0EK%ZY5%S?A^
M* 6X =E>#+;3D"LX&=1@FK%@_<P=T[NL)AB!MV6Q8OO!J%&_WZ1?U<&-^:.$
MPN33L_4X<LN-U@4?%4/46FP@)GNSCNI"PB1!<';2YB4R 0B +CM0#?\R!4&2
MXV18[)!#:)SO;)NA.OUD7#@E\N 69%(9GZ9J)K;J-!-H*B^]YCS'E]\:Z![/
M-K+2J2^S,YWS)&H:!*&,TI'80<VLZ@+JKBZ+AY[N.O41O5$N52^AN!62%@2%
M[CJCYVS,E=?TE?$Y^AY?2V1>ABU_JMFE]^8Q Z+$7AAJRU&H>KVIO0"=5O2=
M-TD;/ "T[2WAE17#BRJW<R.PD0> \^CUW,<("X/Y=RMY4=#>Q;M*:O'^!4])
MI5,*[ZX;"H6QMGSKQ>E[0UC 10X,P_>M)TZ:0'0S=PAZ/=;P@C5R[\"NJ,"B
MRP=)B\FJ7[BX,9$67A=1>ZX6ZG.1VVR?.$^I5+V6153;(&C]?:ED@TNC4FV\
MX0'P[; *'K-F#62?HJO&MXJKUYH(M3!];>1"]16]*\27[[-UQ"R+3\4^!4(=
M2W]]REVV+QN><2LRC]:2<=MP+KBY;NMZXAQ&DDZKR?Z2XN-CE]7UU_.WU_KW
M*E=/%W<YQ46$+V2 "EU]%N4^V2>-JRF'R9@*(0.&A]G,JCV*^=\3C0,!8$$]
MDA;I8,JR)M>(](R PZ90YV6S277OD[Y^Y\Z&NU)Z--B77N:RLK3%0NV/NFUE
M"_0%FAD9A3L$<V/-)9K2=K66R@IU<VL)*KH";9%H/%.P-&-2=F;_O875S[6V
MKR*SQ[5UW,K8%'&JY*BE-1+1<ADV@XY-0K469U);NLB#Z8U#75?C/Y"FL7W6
M_93-) &*9T03&'ZIR!6><PZ*UU'D4K >ERT<37+ 4_VH8JEBP3.NP'-=\#^S
M/OQ_)A)JN=1_ -0(B5_O&4X-F?R;/#)=P;^I'Q?"]@^ LET#C;*<B;.IFD(D
M1'/J5>8C(QJ^SQCKR\]VV+F6B+7G;^?GDES6I[K,W@Z/)R_Z7>0Z,;5K#O,N
MY%):^X?-015H'98&Q;;%I.W8&6W5,\]-VJWG5=NG>OLRY^[S(5%V2:F:BU]"
M!6M*&.OA=?T/@(\U#X##EX((NT3WFY&B8NYFWCULL 2EB>\92QTG?#'+#GX6
MQ1;%SK][]Z(N($REBRQVB$H*_ZVJ'(L_-1GH:R-9+(GP<P"Z( G>CS#NYF;N
M-Y87'W9V7,EORQUI'=K$*=R%-:7 >]#L<M5:G;,=,V#F9-HS7$U?ZM[+V(_2
M+!ABXS\$09&M9Z)7,HVYL;,16>VB-JV[J9G%D_8UM<A=,-'A"&F8@^MZ93[:
MK$854R_W9LJWOLY>9\P'@%U(&P5P-UUW;?5];(K1BFY<TNMZ#5&/.8UC+T%D
M;'%)B5*JC=>,M&.@9D>$!L'A.I:2"[JMOW&6MKB#EQCZXGR[4D^>O>)=V\7B
M1GMBEB7X@,IPL.N1*SIO8B55B_N!L+1M0Y[O!T1332^#/=YW-H7#3 EQ?[I@
MH])WPTT-9*6CK8J[W,V3M2B1B=YDJ232,L]\')U_--PIB8NS:?8!KT@:KB.N
M%S;L;L5;&MGBQTC(UF= ETW5NK7<]0",0=P@EA&6XW;<KN<>P[+/);7;-,'F
MU2W<7:ZI8IA: M%K!0DM^:R->U5[&X;638[:)KKULYP?<50J<$-G'(\]%[E<
M> =6)M(\I#G@I_.GH7(^AF%>NMR@&RWN"3)@:H]!?5(3JT'S;"@E%I/I,5'D
M\X+TO0]BYWA?EFV%\AR>,5@W("UF3GAC1Y1[)\K@K1XE+/'6BEXJJB2 POI)
MD^S;U\R=7/ ! Z-M8A/J< ,.0-P:^#,REQ<]ONHRE)"7L H6/>'/U+4R<"R_
M=Q5%3OKCDN.0Y9Q5_NT\C<,0"T%/MQWVS),?WOSF/V*UFT"FM15 *L]A94F#
M5QRGO>_]>XC>IJD$OK5@3+[W<)_^U#.J]V;:3^J(O[N$1T]F8!6H7A7;T[=8
MMM;D5D=_(!TZIW  J9.#A2FE*D<*F >\AK;M\,SF2]/'A==B3*TSL\LA)]'D
MJN>\M:3HZD]8PK9)+I1,Q6 "7OFCIZ<;_#D]5Z^$W?U81T?9#-E4@D=,AA"K
MI43I^,S"1P8_@IOC\UEBS;AHOC<%9H/5S]?6M)EMFQRJ8?0+JG'SM['ZN035
MX:KAJK(T/2O&TU+*!46O-?4^43\_5]%O)]J9VUG8JYLSPB4*/_VW*CI_G:/;
MH9N![AG+6^,58X7^Z#AAG#CQ. BD65@\KOH.]Y&DP6'FL%3M37FQTRU'BZMN
M7)V+(I[7(Z/J80W:KYXI*4=3=W;$[]<.=DR8N65>LS!IS!ZT(*=TLNR*=LN<
MR-ULT+]$7KP]=MQ.CPO7G(,V.O3-O](,F)^1*#45"1X4*'[S>UVENJL*U=QD
MGG5X7$@RE[9WR+1:^]C6->I1V%95["[HY%GU")80UYH/C\%7XNYP?6/WVBA0
M%+"O8PM1L;K&'.^&:2)H<GA !2'>'E3W#2_$TBU[3YL0V7$;P8-?HBBJDBZ]
MI-BC4]6!;_^>6 J#TU]%BOA''QDH#"#]&,'Q%9TC&/*7=)=N[//_=+_^]QW'
M_QV4PK8VV&9M1]37IW3TOF+64APVB^OM&&:DY\="7GF^)G,>>,]XM7XM5NH$
MO_H!;J(%)*R]53:I632^ZYP5;JLLX\@G)P&^MK D \EZ*)FB9<$MK["?$?EJ
MH\SX%DB\T-1O:JA$4BHRLT:]\E-2AJE"(@942V/ZYOU+YW+!S\L_U3ZJ1\4_
MV\ +U8*MXQ'9.1[!7K/LZ2-<"B!]YIRU5X1C*8+/U^.43 WDA"P=P2Y&^:^?
MIF (QUSA0!8+!E=^39;]O*<BT)&:OUF&-^OMM;T[2IU6,+57:Q3H$%G"6[6%
M"'*38^2_SZ*TE\N?3R5%>7VXR@)*CL;^\(><!%WU8HJ(^@D#E4<(89-9;/TO
MN2_'W)N5/Q,+; >1QT$(E!@W@W*DG09E[X,5&]'J8R#UL;$*10=-"WI$081>
MAZ^F?K37N;&8:H7'H/-CT#H^Y2G^;4"<R8:F2OAPQ5PY8W_X6G,^YW+])<P
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MXE@RNU:HGP#MM$\W.(JG)TPWS?HTKL!]TI2L32+1WVN?"HJGB\]]W1;!<Z'
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M)&HJ-+?ZI-0GXW]7V;^=/CP*N^GV:8'=2*)N+J.>YCX !A:O&/W%QZ(NTAX
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MD@9]]!%+<_<C'H3YG1;6X,%^8 /^B3AT'5]>^M[;0*(RNU#X$3*1::;$QB"
MFVB-KKV0LU'[;<I,<FX2$PJ4E@%\3$7-< ($FX.U20M/GZ'BX;T+[33FC X[
M_K5Z5+/=/7*F(_2K%^->86/HF.HU9YX'\S[0#?[CQJ>,_<PCE%PT#@=\G]:=
MV&(T_@"P@!5&B;F>:*OG>.2ZW/"\7<\QZ=2,20O31IZ_^([-,K(W4>I]_TG
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MS<_K+%G>G9$V?ST#A.&T:S\_C7EDYJ_^N7[;!ZQ*B=W1NX^85_T*&PXNQ@Y
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M+V[T&76EJ58,<0[ F+"0;U!H3CRK/7#SWY=@>VCBWX^O[(^$ILL;-X)9@UF
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MHR9HPBKRJ8J 5S#.<ZYS9N EC@OWX@!G",[#4#-I$AK&9B03*3$A7[!O>K7
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MBXJ,QGO.Y; @#(S7VE@?L'*"EAE4#L46Q,."NN&<ZEK5)3J74SP'B5Q+DG6
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MKN&% B2S9#%;^X)R2GFH3^+9I9)UR5RQ/)<]#WR^3?E(!D=J0J%(B(6OS$R
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MVY# %V)?93<HL)''"T3%_-;.OO#UXG" :RC\S)!;C;G,?K./U:E#1:P=[W!
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M/@<12AAO[QP$4/K^=KMK/[G,;*V%]HO&+Q3E6^7 \'G+E86DD'8G!CKL&.>
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M[%8*O6AFW5[+\3(&4E2V;@@:!#*ZB]"^+QF:(1GFYENIEE&[H8.]>VK>"$#
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M9/S4,)DQ7JLSF/&SK0)6E&[QS\(,NIF(#6&/<XDZK(FQK!(4E8?5C3(T 6.
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M4$+>^K'/9BI&1GDEVKI!$GMXDZU=AS:E;BMI)<*],3#%.QOO/*$Z>SX@#;1
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M+?.R?F'ZUG+Z$PN5QTH:PPRT3S^1MUPS@!D9&9+D^!F35'"R-I)4</LWDN3
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M+K ]\!W!E2#C2+<*60=1\8=JB6J^&C 1? 9!B6P_:_TF!*+%4:/4?:7^?KY
MJ<Z,P#:1*AQJ>X[UO>\%=J@DONF:&(Y_A'=D>\#%?R>XA+X;^(/D/YG64&S
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MU^"$+F8W$X][[5<Z8$V?6&7'!T7%BN(YC\OG\X/[M%P^R?:/_&6O)G] %97
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MVM*7-J .=]BIYXSF65[6W5;I>Q/&TDJ%>].=%%M+Y962GJJ *G;<;!&XYY%
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MV &,$#[R8$:0W%%DEYP,W0I6/:F%_R38'36_KOY]%I:2S:B% #<>3DR@W?3
MEK4(P>%L%38 )= %KD'(W&(H/2X.[_/068JNQY(&^\(]=/][CNZKCR7JP?Q7
M[]4KL'L,H;;G*'TO/:CAPHGS<%"V<. )"2V-_JUOK$;5%/,)7U'':\.3$X=*
M-JJU3.KP>'G\=Y%L2-L']TP ^>#6<8S-0P4+[>.DI)9-"1!=;/5\?E+=9?[
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M@WK@6;:_DQ=_'\I H'#"WS)]KBM4/(V_H270$W+7,/]DL:/Z<S+BM-W'+GH
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MSG=+/=+,+$MC-]:D=DG3OQ2_4]2,P3CAGKXE.367D6U$NSF[IF7%+0'8-Z@
M5W(6*%C&,[,X-8,@VJ:S.L3YL_<75J%F6?W5,RH]IH^$O'"T]LR\Y_>N1>$3
M;R=[9E%1MG$YDNB0:K#D.JKU8"'66+N9H97G!XJPRKO4%]*A+O=[:*I9PJHS
MR&=!:0)]UN?WD<0%6:H=;IR_X'A+\3=>=S W/3T+?EZN([+",/ ?F+%[/2 #
ML(.]$J54W\F>GF5N71A<\8C;&M\HWS[;P[ZZDG5$#2!ATJJ:+BYMW6(RH?)!
M]Z<7+E><67F2WGA<WO[XHL@= #I.@'18^Z!6,2W$,S.#]ZV?/.#GQ.[%577+
M-*\V0U^LJ74NO]+Y@80 B"'G\FBFJ^; W'Q=GYO%NQLLDD8B\B9<.]+\]S%'
MR+L=V;6B@$X>BF[0&[2XN)J9%,9'BX>+8$G]&U/XN44T8$Y<9;9F.FA>6K7X
MRK=E9K 3>\-.]>9)E>UVT3YDU*8N#9H>BA%R1O^VT8,K%3_>5,0T, [Z<JL1
MQ&8&H^R&HW16'_[G0OM5>P58E_&.$XN"5<^$G'+5K_\R@*@>?]>4/9[483;V
MD,J:W^YH];.@:N&G[ZX,1J'!Q=-*+>C+L4N1$%P^MSN:PR4H;?[UN_1\R\$D
M8<49!]'"?C$0DO<UWEQ.T?P48O(78E=9?&9V9KUN?8@PYLK#0E!OT+,*]1_0
M=/$;.A%9F?Y&3GK=7CR/!ONL=6W,MYCALWD'V#?N/%8GW^^Z>]3 2V@?(ZBK
MZHP'L$+4*+E&RG6KE#2I=NECT-+KYVSG"2-+3=V(F]>P0O#=QE_@I/QODMJ?
MYFSC?SJS_38'#0D-,WI";831YV*KL B?YAFM-C/]X]Y$SI48SC90[1*-[::N
M/)N!TZ;LFP_1:UG-BG-"+#1H=*8W_2C0+R5\)UXPF!TD^A?<?E0/D*.OH*CA
M)WLC ?QR5TN>6^4LRX2QT=J][\;TS*R"OCEJ#2N6VCS4EJ1SQ3%BUP1"P,%Y
M:/Y6.WB5=/9;D]*J&XDQ5'5&7- +6PYSBPX@8<+DBM:8@OW;1;]H3_LW<$G;
MT2;? &*$1 _8&4RT.B<I!7'WV9!]K!34R;1(/2PIJIGL5WBFNI]N.VH?XN1M
MUJJ062/P)*];MF66CAO==N7+Z!NJY?,>E[HV8HVKM7@3&:SUSM'NCG0ZE0]'
MT1$6=BQS<G+B"KRHH#[0NPD+WG<29,Z>3NX?CUI,CN6HU8J+KE=S<872>N?4
M8,5%I_9-4&"39P</+HU+*<#0.=Z74PD SW>?%4;,?\'E.JU.<B_#*)3!7()P
M567N_C\2$,DBE>U(ZV_W?L'%2:G06P;X2,9Y-1W0$-+<<BM0C8L;TU>])'TH
M\WJQ#90]#8Y>ND4:]0!J4O)4NA*DWI^GD6)QV0"FT5M#YVMB2<I^["M)CO*A
M5]@$\V6QOKBA.U@5E,:)R0OOUPB.YB%1JA>FE*OF_'0P582B5::),C#,:QS
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M[%8K_2'GU;Y?<'F+Z]6+RFN ;YS:_TQ8O/M[PY:J7/_%A_TEF%#FO,^7ZB6
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M"\=(Y6I"R\J)<E;0<KWLZN<3VIS5P2^X35S$)IS_OWEL<-"\>]./G4"5_8/
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MX02Z)4UZ^:8$^Q%">;E>7^N\JY<]-19.'39 "$( 1\P3R"XU/I2S-I;M9_;
M.88+^R7M-&.=E3^ BDVT"E%>U PR#GNZ:NH_A;,GQZ_,NMU3.S79;R J$'6H
MEA:Q0@.3,2OWK=S)WR6NUZI!0QRS4'#S%VX"IB%D&JX.;A/E0:S*F($7L;%(
MGS$P^&%OD1?__-K4F<:I#Z-F[DO.6N<G%V3?BF5]&?.,9W'=O&ECB>^>C,=,
M[$[4M)I*)_0?&:0-;L%F#!,P@(C@4+'A#02J12HCE46?YGB7^59X45\>E+:M
MC1]%#;X*<[-D>=E$:E56U=B2><4D;8L3/D4LV6=YKVQTO<']D->[Y8BGXM_[
MN11E>BM?Q;VTAZ?DA*R RND]ZS:0^+]P;_YW4_U,].O[Y^%KU7+_<@K#9 GH
M,WH9#/R?,=*F:6)W4T<Q=$>)\QD""*E<P6Y:>L"!6^6^%NWS)EBVU@?:GOU,
M;5<=#&D5_-:,7BD<4H#A>L@ F2N'^_YT)SX2 TF?__HH:6G'C:+WSRLH9AX7
M><;%#BMO/:[FQE;?(:H4N8&.LT)T&YK$T,?QO@&<KU,OZ=[83T=TZKC2'.I6
MG0SRH!?.O*7J'&(>&A*6&UKDXO)*3=\$FZ"=E7W8K8%K'@C/S.M3N7S7TO;(
MYP$U5#-A-H"^/9N8X.^COL&+T_:,[&7WM93N=$1U#>QGJJN3O*'*A.S\6. I
MXHOFD2O==HNF1#84-&1/$\+,+VB3Q6=Z;XL@\XAHB1@!,0:*'FYL]LKIT>!-
MQK;7DU!=7UM!M:#I./#AIQX%;O1@ O-<:C=Z7SKPWM:OH#N&Q-?KC"^A]L@*
M>C%:FURKA:V/D]I'BB>HO''F@_^RP"@,X,N0>W*2!(X!2(0M7A32>8 31AC4
M>1>'O5A+)V^RU>0.3_<S98MXF)NO1?1R!A<'XW^%<8-"(Q0#V4D_P9>LS_W2
M1*1*JYN!\?,_+3@NUC!.;E0IO1SL)%Z?]]KD6O$L:L<#OX6*%]%US4=D1C;+
MK#(SFZ "G4!-1^(45D*^[F[1FF1&AOD7!\A^(2&:RZ1O!Y4572+(.V[D2G<'
M\5PX/KN;,;"GI/);*_\738^@(5I.OSI"@QRQ@!@J1);"6=UUZM@:X0]\(K<=
MUFJC-31>GU%7;O!3S9*+D)7'7IG]N// N*F(KT"^[HNO0=V.VO$H:\J2YT</
MNZ^6-\GR.P?IL+.VR@.BFZ^(:>&Y/GAR\[N99XV@@$6=I.C151X(B7HP6YY3
M@XUJ:&IHS_K WE"FSC"R$86YI\UXZ%*?OZV V5:J@]JU(KXT&K$WQF?DATJN
M\$= Z@_2"6=):'%VYSK7),;W*"O"Z,%Q^LM$N41I6W7ZFRVL]J/S&0;EBL6]
MQJH#G$%M[")K^8TY6)VG'E#%!<\!#!%F_G0B0('R@)4HP^J]W)><_(?,LZ?D
MWO"E..,5G)$%:#TRF5G\X)Y5<LUB'*9(Z7X9,L1-?JCGAQE1DCXYJ"4NY)-8
MH5"*9F@^)>.+]ZBA:!A(BW1ATG0180*E0T_)IG8BL@1*1XFKR9PZ&!)4):U[
MGR-A5.,#V?[0 I[>TK8.N>8O>;/H58,ZMJL5*VJ^A3N0KO)4#Z0<&]GFTD63
MI@M.O_@D98%1&<E4'>$O\7P7.SPK6-W*<3)=JJ+.E]HPFK*.)*W5#IW.:/Q5
M_(RXXP]Q(F!S_"?B8@[-Z331ZR7/1F9YLR@1@YV&KU/DNR.N#=AE"-W<DTM$
MH@[._G1E72J!DX%?U;4'=6UN%'AM<4170JOUU3>N</?K2LZ='/?Y];_W&T&^
MTDQU- ML<]J.7.Z#;-JJEF&UKK>R1#+'PSBJ&AIDND.!=%W4-0TZ&-M<2N$!
M?3P1GUZ:,OAW?<=7JMV\,6[YALG5 '.IO-J;+3)OQC]8DFY'=.V3*[AQI+R5
MVNP=-_[&S:*?H)\2)23ZOF-9P]3@20I[-X>?)':[7PBFUQ4>&&RK/SJ0OJ4_
M' KA'Q';*6"G9A6ZIV)5[)M92X;G93>A5<*]$/,B5G6'""687V4&N42IE1R5
MDF+>V;<Z,PZ5_O20#]IT4P?KS!*3]-S$&-2A\RIH!KR.EQ07P@]&Y*F\75*:
M)3Q.]=^Z2L^5:NS(\HMYK.JL7A.\S8U23XO1K(@ IV9)&^9B@WQQ 'A)$FO)
M"4CJCX!Q?7@8L'A.5D>_5*W,K*XQ=Q$N@/**YW-%P4;*.;-2FX:@/&]R.NLI
M/G?4!B;F>Y.-'C_"@5'#-YN[2[U+@=8J_1\K)1=1AT1YM.TSO?"(XOE_C5P0
ME)'?',QPQ*;?F,S(Z/;R$?30Y]/U?=M#!8VFS<),%2(R83ES>#YU(X[_3 ':
M%MGK'DWY(LUG5CQE K_R^P-SKK&"2:4JUND)#=R'HQJOJ3OA=T \44?F]7FN
M5;ZET<1DU+K5^FPQYL4&;72JSIK6T!Y3%B&;H L9*1L$2C."H+DBK13M5NM&
M'2M5U_^:/[]SG>F:69%K.W=LG][WN3)O"]DWDR"OLS;C(IES6V,# UV*+SJP
MWX0KGNKE5[2X+J<:Y;_[)T]\XI(MKWFKJ\"KJ&]W2BRQ.\^QZSMCY,8TB&J%
M/@<H:U3TC>K)W&@)CB%UK]O+V0]/8Y$5P[7VA3C*I^FSER)A<TU< \>N*WNA
M+E&.''SFX,GY7@O&#<,DOLOAD(G9W"S&IS?2/,PY<E+X[@:J,1)!J?^VI4/
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MT"T]6WECS&B3@7+OS^ON@<=FN@+Q905),PL?85U]7J%H>-CVH=W^0:+D((8
M58NTE':.WB"(JBYGBJ-],T3O2T3.B;W,,6\]7S89($L?7=C%>MA:(HA#7"^:
MYLE :)2>=+X_G*]2&Q?=;<L+A0L==L&P\8+@+][@:OC#3S%FX092J(+F0$"
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M:VCR%S+</X4!\B_4N;Q LMG- >,U.8_/]W"EMFNJW&[F@<EW8R^'51?9% @
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M/H]"793J#@C/3DD),A\22+".//"5@W.L8=KC,ZMA56C4)ELDLS&,RM5&Z^A
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MJE@)+"[9Z.D;O"XH6&QU3<]E"9E$7J_B*V0P(QP'('% T/GWX=DKPV1>?@
M@&1L2YI]XRJ3FZYU^O%5Y%-S&<@-[G#,.7:H)CU3/6PG@A(#&U\%X[[[N$\M
MS_F7.]8C9C?7 PP.,1OFL]>-"@O 'LMT$=!'UYAICR[Y8>F Y(7@"V*6Y(AN
MO^14_0(',EMA*-E_D6_<?W3<^%!J$4%Z!"W:6"J'O>W=?2D3\YD!\8XX,O/
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M;PP*-T83*"O(XL:1EF069UAS=#)EK0UH\]QKV-OF9I?>4)'U@T[O)%]"T@S
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M?./ED:0-]O@N_Z5L[5O@)/TA$7Y9R0)3204W[D5=9=;;E0\-FR?SS+D<CKR
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M(F88;_,;=6=./0N+75Y XHM(Z9DE-)65=J82,UMR(.&=?0FEUD<S\C2&6<E
MA.K?AS*>AWO\:;2F2^7%89C_PTYXGZ^MATP/TD(I>%;MT]LZXS5U>7;2][S>
M@X7*ZT\5HM^VZDY7C?NZA\H KX-)G&Y.G7Z;K=P:45*9B%4,22*.\V8J1&KW
MY1["3N0=D+L,84NRJPT7=Z&%"5CJ1Q@-DJW7/6$5[ZW&%:,Q[DLD'#9V!S9Z
MXY<O;7\E"$E4]*[ WVWU/BGQ\>3%$,=^UO6A]UP"1Y>\W.YP B%]<C'LO.>&
MA+$@TI0=)3,$'93HE!D4K+V2DIH.:S=*FY?=!EQ&1M/4ZU9!>!A<Z[]"S#"-
MP*7K[7446BH>=;1(CC[8Z>S^]>NHG%PT+*X\!!ERBIZ6+D*D!G/'UC\1+.$X
MPDKS4U-W8:J/<UL;,4U,89;RKUAV;@H9C''<+H29< UHMIWNEVBI'9Z%R;8O
M\?W;_HO4%<^;#N7D=+R_C[KPT;;$/.(Z(H0=J"R2>' *V#GS8N$4 F!"[\6?
M177OL8A']*GUK%CS/"E5-S<Y_3#E2\KNS?@.)W2$-E^PD?2K6<U>"PE$09!I
MX0KD2@FF:BD\M]6OQ)$[F++Z:+J'SZ2HOKT9_B&9%Q0-9F>7F9%R)]3/<RD@
MU8,W)FDS)#0R A,R-M-471D!"0,PL+;BH"Q&9O]P:-BO6(48[S-6U4*Q$.(B
M,HC_:X1ZEN1YD O,V7,7Z'I?O*V:]>C[N'Y\#KI27D-2W57H]2CE/56S',XR
MVNE+:#.WT@HN(V4 ._1B,8-6R6N.^Z4"]LP)<AT6=A5)%C0*\FOT<AH;;_L^
M6)'G&;FFD^CO[61P?5'8,,!(L!=GDWI@YI#GBL103<7&M_TU"_\I[L32)O^!
MU<=G*GH1Z6"P<*T7$1'GS;%W$.\#S0'5)8&%CX^M7-[:7T$-WS9+:DKTX$/6
M!_+1A^!![Y-,)[HN5X+':*!WEYF(VZCOA-'?$_M;IA__3&@@61+D0L[3MJ/K
MO'RNYV(UWJI/_$7[Z>\NJ4C7;,; ?\@[VY)E9O\/W,&LS&12\U#^T?CF;NF@
M+N4$LVBFT5Q7W<C2C\V<3#>Y^@220H.S'2&W*S\IQ7W?4Z6]I"P=4ASS%>]2
M_2U%@ZY/X$P*<VOJ=,J@>RFR#YD33FKW!A7)JVJ^I6,R*Q?F3F_I5^/]GPS6
M;#V"NE,S?2>\V^(1J1Q^C1K@2Z"M=L]2"!!XNKH SVPU3%1D]:IWEG*J!F_<
M)F+WF_%D:\I;+L-WK0Q%XJA"PW5U1'BMG[X_NY:1XPAWIPE8+35Z=HU04!'W
M?+S!=]YPN^=J6;:<_5R0_W#+Y<?L=2AMM#4WN<(\8*8)%"65> ZY"S9,NQ#.
MKL ,>SU"@QG9^P1[SY.?U&R/Y]"_5MTB4S&N<Z-J(8/[3JNTE?I"(8N)04K5
M_U"$1LJ^YO<QIE'^O3%".:RNB(;SE!A^] /50\RCU%Y0SCB6__3L&Y7E*+3H
MG!<UO0@M;A=X2'O%\KJKN?3F&V7Q<8TO;!/%DU?>5=4Z2>LDR;^X1*@DIJ;D
MWK[]0Y=)?;SE#UN\(K2JOU 993+D8.6IFLHV,Y>^8_4*_*7SWP6($O')IEN'
M"Q38F5V;IQG^Y,6?-[#Q6C6:SP4?4T=,K@C''GFW\S]R6XV)M^UDS(HX1/Y$
M6/<.%[6N_?>U0LGK^=UMX6CJ[;?)MT%=Y[_F34MUV(M'\"*?D'A1)8AW2N7I
MM9!X9N>PR),=Y)UXG*1&,,_Z"M*Z?^E!G_;)X9Y(KCW///6T],VGQP6?A245
MGVN27],30>)F"^$R_"Z@]8ZIQ#$]_9N-Y8-F03T654@R"ZA5N"RX3[O'N-KM
MMN(%3^:; U(<'7JDXXP1&"QJ*.D3<^1?8Q:?P>K!+(KFI],TJX]&)TT!RH#B
M$7&6X*$I_T=!*B6'G21(4Q+":AJUG3"&?G>*@GZHY)+&#Y\CQ\9+W5EG"'UH
M\&9+TNSL"S(ANG0>1P(ND ??1M9H[*!^K9,N1%5GY<KY4@-V-@]!6.J#Q\\6
M29I00?2E#3T)3&#>=R!/V$-# \(<APZH5TUIB7[CI*E"J>&',_P:)O'U4S2+
M6*TF=51[N4DA-)K_"8FC )(B,2O&2ZP:+C.,]D-<,4-)C/8'CFX#Q0-I&FR"
M>/>(BM>8.<+AFE81@E$+X62,B;67G+KOBVVW@2=HX19<, CC#Z[2S2[.:P?5
M_OG.WE/!06!@R@!,!K5TM AQ6]NJA'UWY'X*XUZMQG=\,3!D:+%>DRJ[%TTD
MF64*,QEPV>!=>'JZ:?CP/S%8PX_UGJ<@N6N\4H=%]RFLP<?_K,EC$Q[6"=T2
M_T3 )HF]TF^YSL]/:I#\LRCO6__M/U7Y:?):(JJXR')X4.PONW)9@TX;D@8L
M=#E0H1,S\XP!+(76O4H.SBX;;_J4^EYV<ZI"+&O[=L^&Z0K*>^3Q-I(@@U-J
MC3K:5GJ%QASA/8*)&Z]9/E:]\G_Y6_$T#BV/#1>-AHK])1"P/ N)OE4C6^0X
MH#_UX1[ACC0'_4H:]^?;W/;0N0B]!H!ILSDE7"J^0>806BSR+_DT-[K]]\*]
MZ\R?U/PT+FR^2YPUUY'5PV#@KMUT&T-96WAG_XZ5T^BJ(5[#=)$DJAJ;2*;D
MB]+.<>+W?!FF"Y\UZ'.>'L4B%:O2'9I4:Q1KEX&B2E[9J=08')!,;PI<;L.+
MV;2*';^>0&6??4NB ?>X^\VOI;'%Z(=J([;$OD*Z>N;:9>*I;%-DS$W6_VE9
M"$F:0EQOG#T<NHOZCO5)5GV/Z(N)3.:.+AHSRG)JOM(N9;T<__Q(IS&1?P-3
M,",<,1]A3+2D7E;P-A)72]6\>S+-U9H1K-5']PW"4F#?9_P:,08JU?L(B6]\
M0">+\)\9X'?KY$<H9\CO6-8A-I1<\^3;L?IR&V!/C;&\,O#T8&W-68B_X^3:
M??W)+MH%2)77)ZM>NH/PLZ\SOWX%L\ZIIBLH[@#GVY65@659_^S-DP'+*,/D
MFJ2!L:%KO$7-3X61.11/V$S8N?Q;>4GT$)#?N.0"R>LYO&-%R:Z!KJ=VWWXB
M,)S^1-C3??^ 5][5!X%G6.YEM+"J3]]-@83,>,-(@E)J$ZA8%''U^E,C.B#A
MC-Q/V<_&6;*H5R-'TD+A(W"X^XLIP9T"+G;-Q'-;>G-NX0U3I&!P04SO0F1A
M'Q>XN\M5=<'\^&/(UPRIF9),.C(B;5NLSM7=]>+IO@E_@=JB6?],@?%H!>[=
MV5"JBJ=BR^*D*@A22*>H-93":?_CZ3Z)R$HM-#U-"IXX @G4W\.!3/4"U9^>
M^ PW2D7S?BT;%-_O(].=/IL_XW=G! Q_",5X)QSVVK2>\JKS4L;K<'\!*O $
M8E^349]O!^#Z0D%Q7J\8TM7D_#1LWL136P!;A3$L*B=\8K!3 J,6WFLK1KLF
M>CA\B RGQSH-]'\T_G0?%O& QEG?[WNH-*8+CU]2],R]PGUQ6J<LOOOY;>$W
M; *)FGM<#Q(>2\3'H",UDE<9#=[('=[5\'R(9W3XK("AXNX^69&=$;<&"E;1
M\54)B;S!%BL_N"*^;]%?ZC2.!(]%G%D*QNX7QAM?1A1A$9([LEC+2U!=GCV5
MQ,#H)"B;V%9?[R_-$>, :>)H,H5%9I>+^%9SO^E6J1$G47N3<S 7(X&.9G5@
M!Y[B8^[-&U::<= BU=_OE>O@XQ27)M/1!46GHB+%!N/N&+,#WY(4-VY:L!X(
M+J(S04FBR^MY>:D&XN8\"MF+S4PX1=3+8NN $;W=/PZXK95HS=>^(=4XJQ>B
M0AU'CZK7)S,.''6M%JPX"TXNFS$>#[?,S9][/9MB,Z*SX+BM:[_Q$7]'+F#-
MWP"5)6U,H<7Z0DVF4^K+$N$=HFQ:/77WOMPUA$8EMZ51X)L"_A-C"EM]NMR@
M[8R5SS=]0/6Q(JMKVW?1'29,)+5PJO(SI1WK+%<:<,?JFP%/[HS^\<[58HEA
M5=C09ED7N/=C6/; 1A5H&#M L,:%Q,4>5C8/!]_QFX!"K+A>+!AKD2>%339X
M"7-(;8@;>W"M@S?K&)^:B>@VKB_L)3:KGKC'PFXS$>-D_C%J&25WXD'"\2RY
M=6.?JV+X%7.K9\]YOE$B_EC!U+/7ZC!(@<^GO;/-^S(_CK!'+:0X*[[:J2I=
M465;>/1\OT+3$R3O!*H;ZB%=[),!.*24J*&GF)P]%M/>^M J4$NMBW-BDJA&
M?I:E91_ CKG.*&->4!""N4#=8)G:YALG=0<FU<Z%MJG%IN9:<9FW3KR-^26V
M1%_BP;K?>'=<;<D0]W<.I'TP8_L #IRW=9J8,7G)/=IG]R/Q/8O!E\)]R6T=
M]09$9,TW1JL+"]>ZQ7=HH(R<YCO>.F@^V,'<I3RV:\M:K)<#C[DT,1ACF4,-
M$9OQ1#O%;MWZ'!U)JX0&*YYCTK^.SH.,K%Q7!))V!W#$SS@E<2JBF4[AHZ7?
M8V$I4YH^PR"3V#"25ID<J%U[,C&+$45>_GR(']&1'T/BOPM'AV8&!>J.]&?"
M4U/31^#WO[XLBH]L#O1Y+D Q<+CG>L)U"7$;0^%Y&ST \6MM9AC7)<*:"< M
MA$8C8&O+KQ'5ULP&(2-RF>H Y:CBP'F);B'"Y:+%/9AY8H5"?L?!!R-<4;&4
M6;R0G9Z]WZ&V:GVC/\M@!8VK++I/+XZ>$4'R_%"<0A3U5'*264CB/M8>YH)[
M_]7@U"?Q5WIR6S)]2]02URO+"_Q<,05TR\^O(P9,QW)"^<3E52UK2IB.1>GV
M=!PAP<BOM_@(2=/DOK)(W*G5JL@RU4"EB=)K/.&^>IGIV<D#MN*'SOOA2Q0+
M4,OSIQ</ANRZ2N_3ISO7Q*DLO>0D,T>O.ZU[.;H\SA/E>!W-=1#].=SRHA#I
M0_^KATW6+PN=]X("[Z!'%,?1Q1J[DOEVS9X[D0=H5Z[+(JL4JE_81OX488'L
MEP4N!U7T!%\_3-K[A'^,(9#[3RN&9X)"?X %23W?__">HD56N22Y/EAH:RI?
M]N99P]^?^3I4^;W/=N1A!G1V4H]=#_@797FDSFFT[TMU*COD\TL/H<%LX400
MD. '<5+K+L+@LDD!NX_Q4IW4S"QOC=^#\%=,35!<J1B\VB(T-/.M"HQSEFA4
M=:(+2WCK[SP3,P/U#'O#P>*HH[:'^X!CHR^7"R$_; @=^EWX\+HU6<Y9(3!(
MO9VG\Q _%U%FXY3V%#[#)T;GV0)(=%0_48:,+[=I*?W&*#.@L[M7_]6D1LRY
M!#>GVH%:0LXLM794\0Q;)1_1JRAYUL*W@FC15201OO'-61++_7<RF!FH_U^4
M_G__2XI;Y<R^9GQ@[>&DL?ZHV$7+RF3*XNBA,?93NP:MM,H[#(>G",1U7[%K
MZY:EIEG6M$B+E3\_VULJQ@O-]W?+RT);YP,$?R*B3F-\UBF3'SGO+[/QQ)Z-
MQX'*]240"!(U3S(& O[&TE_5U/<?G J*S!BH)S]0"V\LD66ZN-LJP8T-;T*L
MF'*I#*H2HNK3OL$F8W<65BF! 8IF1)WZ+*: #*;A.7L0<HIFUV<JG:?/9H4(
ME>XJ4JT:LD9(JE)!4^Z"K)H6+L*J<Z/'_"1/>\A]VP!VKZOXB;+$)J?DF22E
MSJ-\D9]?.JB\K]1/"IU"IE^]N7FW )/-S(ZEH@+]^AB__%V%H@*!@+IO6TAL
M[_J^8PKA#]MZ*Z"[.GNS4: E5SOTT:]9Z.!PV;@\AO1,7_.9H%X@1+B8,B40
M?2%@Y$#20R?\#^(/9=_)*EH97:4/7<O:\*NM9(3_V9JFXY9=1.9QR+L?+K*:
M;C];V%.'-1%V*WVI>RFU\Q,!8RG8-VOZMVA"RUMPCUEY'2<2E*\I_ZT3P EW
M['/N2YID"<NI/I,+)+GA3V2$^XFDR/J%,?1O9G:^AR-&5<QS6\_,W575$>K;
MY%^0@Z<3<@<L'M0#!BU@<+2><)*4TA'&DZN]=)$!%JN7*"P=Z%!L*"YG)3'G
MW.FG[E':83&%-;']T=%1F*"@2'Q-?7S-C2 S]&!S_HJ_4K>E')3\P6U2>U(;
M&$(2DYK^J#N5G!--5<@9V]]!J+! *IF6;[J.@'K*OERDTL5MD1.-$T.BT4)L
M\+WRR!#P(.(W8.@IL Y<R:F_S>7?=YLK-2E2?UWK#?)NR^XG^HRIM2+H^*X"
M2!<QR#Z?U,U#R,Q<^^#*XIJBOP]M28DR,?^1_'X7.T#A4$, G_&Y(K=0;!PS
MW)PPJ&# PE/B1L#W:$9(;$#EQ8L]09N-29T:HJR>]1HWW9EJM\@6XD9F@%1&
MGI#\]-M._#>Z96R"@3'S_J))G 0K@:GCI$'_$MH(BKWO\3ZES13G5NC4<FA5
M&;LCO_[DC^U.EV:AV$T3_KH;+(L1*/HT-#,U<QPG]CO6,J)XC6V7%6:[(%MP
M?HU>[:Q?'E7OY :D#@#)Z9;&<,2(8C/)\U]VW'-3#36ITMB(><=&5ZBJRSGL
MJ&S9/7N@3!N_6 \03QN!JJ7*&\^D?J6.L\('<*:Y_[K05MC@H&9@R!:1D6]Q
MN9,_/%GGZJF.MZ@;[;GG"7=@,(?@*VF$8SS6L('(J?N5D<8[.$\-G\R"=["S
M5'6.1>40_F.8^?S\K\E#[^&_IP+PH%UURCW(NP\C%V-KO2H66%V/SB5WY%BP
M(,1SC3]-E=#5!);8MR>]:)<8[BCT?-"(.Q %_S41_!+2=M6BD0S(S&@S1(D-
M%IJ'O7$G15Z>) BWTIKB\V_5U);7:DHMWDEA"0KO^T0.R1A.603@8E1WKJ@J
M3]H<_" _O8P9M!BF:X?D@3R:TVAPN-W3=!;(Q#8Q6\P2(@-^2&%O:K%AR]"Q
M?EBEJWS9#%KDVZMND_V1I$V;YEY0]>YT0"@"GY:_5*N*/:%FOHH+K*IH[*ZP
MF6:!^C5)C1$C= #^$X$+V<S5_5*MI>7N>YV@KAQ2$IE:B8/*#U/"Q?=Y7ZLN
M308L88&="B?G&E,7=I%43)$@5GG5Y% 4<S3;A*XU)I-=]1PYPCVU?)WGB4S=
M</8.G5IQ#.S>Y<]/?R47F&,Q$1QY]3E[\"M HA!P45#5Y)YA6.J6P";+?DVM
M1SWSQRS_=>I24EELOR2X4^6M:,2*=2D8Q6!$UN#,_#<[^"=@4!=5II>5I#D5
M%'>7:HX%YW[R!"+W)V#PK;A$PX/"4/%%P1UX5Z37B]QW(?2?7D<;/PTNP4N<
MW[N"O_>Q@<8$!$#@KY@-/ 7YB!3]1,BEY,ZYE7GH]QF65M%>+JOHX3N@+Q\8
MH,_K'/=-(VN:(6)2IKEF1Z%"CAM;S'S$1!7C8W.]/<G$F<RFF/@(:9YRYNE#
M+./:<I*U+%5_MY4^G0)ML%ZFH4(=4Z:)ZA=U*5//H@8"B:AC4D,]E#AVXCB(
M$&0A[*ZSKM*[Y(.>J=RHU#5QBV7:QCWPNNE3&0W,/83:>JX"6TV<UY 73T,#
M9>[?#ZUF):DRO=3]G*^#(,X<&Q81AHX=+XC]*V\8._JM;ZA+X$5D<-<'BQ0B
M'_.L2-V#L?""46N1\P;U]FK*SP^%7P*[8%5&]_("%4I3@62;<=JE/QPHK\)&
M-TG]!LH3'3%I2CA2,%H9/GRJQJ_B'WZA!+9"2\IC"'(E2.K5!B\+/\BZ@=#Q
MK'M(JZ!AZ WG*2DXZ'XM[_]T@=+WA$E^)X@\4*FWTQ6B8P8=;S<=:\RY"3RP
MB<<'#;7GEU9"/#)"<%) ^! $ESJ&-V?K_5FL'Y.\._\+/YCYW\0/GM)ZB+:T
M&=;\1  \:"=U+Z%RM];9CPL0$G] 6QL$YL5PN*>T-WVEFEKT?E>@I4?#SC3^
MH82Q';_9[8(:X7@8%FN_;&JZ(?$3@1$'MQ%'\"86%QH/_=5*F&]5]5NP0% )
MY1QV@L\V1-47IE/<>>'2;^8@F4<O9LL&">2;'1-%AHF]BVNR XY!HGE4%S=^
M)1]\'VEC1&4&%@(E^S/O4U-TDUT? $"?15WM%N+R]LUJH?3*1M(6L8HR7N-N
MW:!B';?/3!\M#?-TZE(Z"*@95DW88KK,VV%MF^_*5;7@N2D(W,>N7)>XCV[E
M$\0$=K:S3,0ZI9-[9&[,A]0ZO(K*2@I!LFBIU]&<,?7A[4,_2)JUM8GYQ>S0
M9M?<*%%]J4.1^=9Q4-<1/R$@ + 1$ $X./A&./@ ?,"O)NK]IUS!FYQ;'?U
M=/LZ7C*HEH"X<,%":=CW@02'"^WZ^H58RR8P%<C6<,6S*VSZ'8XSY T1&X(@
MKMB(54\/I#>\9U>!1U<9R-@3VP5TJ+>_L<2]<.-U6"">G(9J2#_!_935/"FU
M\12965]43.%MNWF#84956!@B[X=XOGB1QOGT$.#MZ&CU7+VFJ5YKE^TA=%%O
M:(BY29!7Z)W93GK D 7TG=Z4MO\:G]]FOQ&@F*7M.;N_X($MH5Y>J$P5/R*D
M9J+VX(;^^M*N?7+TNV?:#ZNM&[^9EXI, Y8/>L[&'KJ\G*D#5.3R2IF$Y7)F
M9_MES)'^.!(.W3Q/=?*]B$>7VX;E:[,(")):=IM879FZZF\#34&6D#,-%JY;
M)G::1BP)""?#6Z*OER$S+GAU?/V+1)2+T_]W=1Y^]W+]J^XKGYD#NLJF(3N3
MYU6[H26?Q[<5@E+@O<&5G6&+/8AR&&?BFDS=#7J!L>PQ$_W*# &"OIT>;J?7
MOY4Z?KV+FHG^=5O=/E-S;:P7(Z1!Z"^G6Y3:1<:5-:8Y.E[?U)#:=4'=R_;1
MM7XBY*O#X?>#]9TL<^T?W9QM+S(C@RHC=6>J=/VB2K0X+P+\@)'<>"K1*KW(
M6YLQS#M2)DCB!@AOEBM&MGVOPI/$\;YY\NQZ[E_:(]%7+XE5B7RL8ZMGEENL
M419#Z7 V<D119I<P823: ]CU3.@P.PM7O4^,T4\0E-W%S(2UX#01&ZA%<^=R
MXXOP8XC=(TMEO+QV_\P2[(C\)A7VKK[RLF>8[$L3D#1FD'T8P?90<I(L[>Z]
M1=GLN("\P[G7>+]%BUE 7D:/%GD!O3],X50C U5TK5ZJ?41N_R6"O '<_4O"
M$YE^W:;"#&JD.''"]4B9C9@!7P3$C,CA7[GV;Y>F7UEV)OS:])G/ \WA2<&\
MTMB"M2T6Y84KEHO49=C$@8$&^% X/PV\F*TFH3C03<C\\8 4'S&EBS6NNX^H
MV[%VPC(FG H1&W]%5$NR]4L$)Z?W%"='FM)CZ_': <$BB>J6 VBY-V"\#RAN
M<QV!W6-"%%DSD3)6@WLJ671F/]^H!S/YB1!'U>TG@8NQ2<OZ123N+='W$&_A
M]P34KC=/_^8BU?_K.W,A*!.>:A-S#H)"QWX%/N!G)&#5R12,K,=^CG@I!E C
MIY"@<.NCK,R0'ON)35D)\H7@.(3IK<R:$Q+1\PAR<*&KS*7? 7IH57K)G@"*
M)3I)^46D%&E7;..S8GGIG1OY(NG.0>#KEJ58J.P>7RF/5*KTA'E!B+5H#>=O
M4_EEQ</5UD)4K/^",3%)[QY._!HH[)KF3K+?-&6">G\B?/YDB[)T"+D'#I87
MBEHGGG-[)T7UWK7M*J^,6236S<@*81KFYSFT'MW&7W,NFMG4_I:?:UOR7--U
M;=V\_8EPHL9<&_V/$F"]_>7R=1+\J-&[[?[C$ O-_#_KSXEOSSS00LGNL'1_
M(J"EC5@:Z)I[$;=]339I,]KS6>74_L(@])]* ?]'Y0ITYEM81I<3+QY/5BY-
MD!Q*5RX=T:QW<?VEWYQ9P:7E2J=F-B3STA1%_.+*M,/ 1A4^#+&Y1\^^)1MK
MJA[Y'#%V@ P7FK<:ZNET!>KI2*^%H.T*-G,9,W4EV<7-,6%<^>'=-?>,:4D\
M-S//-TFP1XR16406Q[0W+\A-6(IJ;M!.%V"72I= [H3J_4L.?KW,U+>&C:SD
M8FH+:;("2*'K!.;K.)%/M5[P0 V-+@U9&HE_2!T<(C,"AO<RU?PF4T[\,D<9
M:QK?7)_5'78:D/)=TR<]E""/8.I @#7\TD]5980^E$MO![GZC!1?8:E=^DT3
M=EXCV>WAIX[7E2*Y\5XD =#6IWF+:B[X6S,Z7GTTJQXAM3%1(7.C3=.96RM]
M]A,!I&SA0(PN;6&#XU>!I_<V=NHZBC_"GS 8-2\O)._9\WWL@ :),=(G!H30
M4.CQZ/Y0[=^>ZO\A R9T0]<"UGEO!4#YN/Z7$SRRJMMX"F3XGEHP[G8$?YAG
M(R9C(N2U'Q*Y/![W/6T(5^Q/A.%Y-TJT%[*A(-12FB.B??6  _0:@76+L\Q?
MR4\OFC''NQ39X.D&*/:F\Y8Q(PTPQDN<7>EK'0T^9;W\;-%\N$==H?\'+DCA
M1_\U!WE:7"EQ6AXJ#K#E6:^"_7SP>Q#?EK\*FE$,&9@?04$_5'N.!S8"&35O
MD2^JM2W\J@67_WJ6JLB;_47O3(TU&,J-?H*>_.+#]?&KQ$T0(*NJB^_T)7KY
M2U\8%:Q^F42MMJ!S1]^.)459<\VOMF!5%04Q*:NR2[.<UYJ4JB_$D%=')W61
MMH,4J$G]! &+J(>TDD56ORMSMT[P[1$&SQD(X%4R%Z2,TC#=;2#5%VC&MNKB
MI;5P32+@,1)_\9BT-?I\5$S$TISQW"9KZN:67^=5=<J0R]&ZHSJ3*?O5-SG<
M&:C4!A4@OVFJ=Y-T9K^#UDF<V?0]+8#^[=K^-E;YOZ 7$2^ACI>#DX+/(+<E
MSA=E(=$X!3LN'7+4%/HC6\SQFETK#K'Q]1$Q0X9\EIW,HQ.(LI:V:1=;;$\R
M6U,*[=@3SEF![S"7/5!Y41R>,)($FP_LF6<P#].-,7":GEWZ]C0):3X7E>!4
MP)0T@S_D>TI8VBS!, T;/0:'M*>;YOB=^./<X \&A6"%5U7.08\!%"%]?9IX
MT5B>'PO1TQ/  'U*WQ]WRI"%3*=OSLOA4Y6)D9?EHVOG6^38D9NN_68'/7)H
MS_FZ-UY;O:NP[)/!C7(S$TXV<FFZJGG1;0R"VG*]A7WJRL/-J<U"DE=Q-3))
M8Z;G@*#4"T9PREJNMH,.A@_FA%+S4^"C8JYS.]LQ5Q[XC?!W=8] B^LF*XO1
M65SY=Z5'SUJZAXU%K<<F#SN8=EHXDSV?('-$:IXU+.6M+.1K2%;]K:[Y_PV+
M\1M+4SR SO=)'%TN[@I5S=7JS!((J2^BQS[U05VI'N?,XA0)R>C.*E<C !9X
MG$9C4M8F%IJ4&9N/?0BQ6^X46*\)WMJZ[-+OG-3KPUWL^+'7P<Q7IE\(X+ &
MY79?9^JSSR,?5TRZTR7CQ8%'A9WB.\'N]1^* H\2#C.G]$M @_I"[.I=A\B9
M%Z4%<,L%B:65TH[.=7K6U_9]S+-<RS;! @L>>:1]N$&?$_D>/** HI;/M3$7
MY"%O:Q?TVZ<\D^MO9-EUTA7UP<,O>FV4&24BA7': 50H:UL$G%KD65+%-??[
MP2.NX0>6=51[9?.+-HI?+GA<)?<46%H$OYV/2EDK>:)Y=GD2W@=Y"ZRY4_%3
M5F'XJHQIP"W,RAQ+*Q<JF&,&GSY\]H6-P9.767/OE&QL&1R<$ZIF&HZ.;<NF
M7FJ!];)BI\>EZ%QQ/DO[NT6%OC4^=,;09C:]*.LY!^#TRTU%PP67W;_=O3E,
MU'<(1">R84T$8TBM["#$Z C)%P8#$[\636%W&'Y8W:"I#VR6I*C38)^ELR1"
M5ZC; _E\;V%L(N94VGO 2@K@SW=1XFC5Q(JK&/H5LL@-^'/?TI;9UD:ZE'],
MD?*HRTUJ[N204FC_,/9_2W$#\B/G^_FH%45#K\])F^2;G!(##[*?" I;57>1
MP)\().>J2&:Y_[[X/L6]/ -AR!54.NI-IZ0BODLMYOC0B!@2\2*O>C&)__U7
M5Q_41P(?S 48J>[\#OX.V7")=G+^U$*N%\.B&FX#MNA!*%P?*Z+2J>:.I;C6
MHA6)!2D '<-8BV-REIJ!@0F7;&V'XEE_^[>U)M><J$5R 1*_YG0U2R?\Z31#
M](K*2J(3E#*+R.CAQR_'"]_](<8%.5.]$]'(ZB=UM/A4P<;/M8J?'Q8>?(%G
MU_]$L*V7&A@D?*>DNU*F-QXF2V5^?UW'^T$&!RNC4*S6+Q&,8]NXT1>)L*9:
MQ4:2&NOA=A^(O^(_HYU;HS/,/E]FC/;$G/D]&T;,"$95HS2S:J^80_]3T4]B
M8H>CHRW=?ZYQGMT,8:?$$(;Y183Y<6+'Q-N+B>WOBRG\^N6OMK]WKL^^R MZ
MO2W4-KLXQV#.:'*>E3"VRP3: &%7(-,06)X,*AT.#V.BO#W<'SF%4G)EVTEJ
M4<XN+C[O[M/!M"K)*1<3HE9?FW;G6W4@)_EJP$X>"P#@KZ:F!\WNP0>V"@9T
M&^,KW^)S)-N:[B-!XX,BHU)M1X64AH^FF+=@4%X1E9:1'<JWKMMZW<I-@CL,
MRI4"*#*(!,D8P*+J;IH+P]@G/J[)Y-Z7/XR^Y27G "$<R-G?HUQ8C G+=C'I
M\HIT5V]IF97H9UV9]+.W]5:M+ZG% &?(*?K? P!6O?]JZ/OGY23K$M*ZCZOP
M+C3V>B=#M^DO4 @2V6Q?F[CA&I*C\%Y]VZO:ZCG4OT A,?@7_Q$S,;JR4^I)
M4Z[%G[$<^3;+CFO"34;.N/&)</D1B?]#6B_!!Q,Y47;T^9)5O!AC G"W(C=_
M]YY6&N?P*U$+Z@.O!1%M:^_UW:B*N83G23E3!&"4U#RV_-2>P2-ZA@]K"C<G
M)]K?]/%W4S*BT5Y-6V/#BBU?GU399![U'IJU@TK&<X!XNVZ*RY-X-B,Y$*[2
MDRX/SB=)-C1%&/PG;.ZZ2#C2G_QECZ\DWGZD LM7+LX(-0GJ%CL+YXV8/Y@%
M]%N4J1?:#H!'/SE67A-4S5&?N6WB.Z(9Q^@!2FP;AU0/3,)G9 LJF!VQR?P6
M FH/ZQ=:7'QA7M 1>?\9'="0HE)_E?RO']E?P(2-TTF-XCHWJ;$T^]>WZ(GR
M'))H_&%XI1T0UR:*U@!;J/J.EI!4CQ!W$]\WFK=52R6\3RO4^"*-TMD+!^V>
M6R^G5%%)V&]\"MOXHF&<DPB&S.[$JW#\@.HVI:6+[Y)JE$TT[I<G3U\+8EKA
M9G;JQ8'E @\VCEZ=B$!>!>QKE;$-:4PK'2\$:X7ZM2\#PA-:9EJ30!G3V.O.
MFA8-1I-I(:&[<_!W^A\PR9+H"7W-9@@'?R*(3-87B&!O-DJU9 K<7Y"L^OG3
M-":%S\[;R(;U_:B]U*3(Z#2SDG8B2NJ&5<3T&18S.9&%NUH.L'ABIWMAQ,K\
M&GVPT]'^%Q_^WL\87C]A';3H9&.D90?S=8/%.8P0$(#4G-0@'!R *[4K  !T
M!=EQ:Y:?L\J1F(/L'8F5+9=;CP[9I&VA0Z&-:.8LG*"7YM*K#Y(87V\$A9E2
M^\*G8@T9B$_O:3Q?<4PR^2KZV D?>U7MK^<<6)4-C_9%%XVJ5S;HM."[O"@:
MO#:CU<H4B3 AJM#A(>#/OWSSH9S!]B%\)H^?1*W"W<?==N4R'Z;-?=A(U:>2
M]W0>3I*[#<N:Q94R,DOOBROCB#%";_3<8"/W$;YX,S\LJY%AA^E!>.\BT$*U
M^*-.8_.HKKJQ_$K^(WSZYD[(09V(T,J8S1EU/@"GT/[8>;)KG7H'^=@J8,R\
MH\RT=+G9<3&></Q9OS,X=G 7HXX3R:\7/OR#TW5W[7@^TAK%\E&9#J02G/_&
M91W(#\Q2-<(!&.%O# >S<5($87#(TW[H(HU7?%?5\11;RDGYW1EA#P:V.'9"
MC3+75QQQ#%%5>2H,AS B3N&^[]),#0IU'OED9\OO/M3M;5KTWTK+P_!%MNQ"
MH.A]="5?NH^3:H9F8_R73EC;"6](R Q4&H&OM]$4#GD/BW,6@.96QAR(JK.;
M5EAJ8[92QM#:O.,2C9WB0G,M$/"=<%JX=O'TCA%XI-&1B('BY0ETA/@?(>51
M1BNU.S7S=VO\F^&,#\/O_>6K,L&6"WB"/,#SP^%65'#Q;)?N-&MI;5<#=I=P
M]FPE<D[0'FZH7X\T@QU3D BJV.L#X](N0@R'$,$PO%</G :#B+N>LJVOK#Z?
MDER!NE3&"'GI,&_K(6]3XCIX:56ZA'E%-%[2H^8FW4EM."Z%:CTG*P%X4,*_
M/9JZ'FG8)"XIXK.ZG(<J2Q'1;D=>*(4DP6\549.%-*Q73A<F7G?XYH._9 2O
M:_#-*,SY7*H<H"0NVHPM/8QV5@W$CGM T8ISOW$*@?IG^_0B3]TL /BNX#JG
MEYJ5LQ$A#F4>FOB[ -"3+H.D>JNM.:_<DSN'J#I.(QY/18T^&*J94^!%4C&J
MDWM6:Y@<;CQ9L)>0J'LDL,2\&C+<DHM0PG'X=OQN*A$6Y57FBL0#<->W^,:I
M$[=.&LTH=B,_.5^AF \"QK!?/&]!C5K(6"TC$N2$EF>*:EE-!.W'WD\+JEO
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M69OV-$'@EG([E8M[J> E+YK,Z;3"C^\_ (T'I[IU6@K/P:R]:-39[.DUJ$/
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MNTN'%"VH!  (T\W,7\USU8SULTE>_-C:&K".?6A]YO:T?BIGE58+)X@V]71
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M17)*V#VX3SM:6#Z]0BNE7Y?>7*<:U8]NLF=X-4Z;(B2:,7A8VXQAB3J,)$Z
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M/"X'6%_ID>R7S2XP6+])%LIJ4QB3%M#$G7R[9T3/081.XTHS?N&^[2B"5D9
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M06V_NO>WQN$\1%:]9U17H+1,&39KML,V ;0OG>6AZ'35A5YY.:2]V[Q))NH
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M-=-CO?[<N<;PQ\/C(#U1J5L$]4A/8Z*% [O[%9'OWZ+>P#:&.^W>H@V66HW
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M'8A<6UIB(M>OPB<-[V5H\_,;\'ZOV0T"@4BD>D&6;6%]O5=Q!2,O0MVM%S*
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MQ#D9>%UHQ *57* E=.T9KV:G:@'2UJ=N _+L5I\-0+Q@Z[DQR&4RC=PPQ N
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MU ;IZ"A3LZ*V0H)B)Z5C^-)1+.W(XF*$!F:('3A[ 6> *CTOX&JQ6'TQ$:1
MK0KPNI B7X/W*Q\[)2MT_$8R'1UIW"BF+F4/(I@Z+^[K136'2W4/-LE,%&5-
M-9\E;VJ3[_Q](<=QE& ,.5=<$T6HMUJ8IMH:"056,D0*.3I5;8>>&GNT)*_+
MK[864K 7_P*OJ_6DV#IAAX!Z<)^L-Y1[>&E= ?/LM+4>?F0?KBLLARY=YR=X
MK2-B\M!O"[V"W<N;I6PV^B$/<<J2 ,9$,HA00"")PTS_Q$2&)1&4.W6#<1A[
M:M36R-?9AN1BO.U(:R 4A_9&':NUL:^-, ,MA <(.NP!VAA%-(Z./X7R&%W
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M5&A[XVPN[V?7;;.56N:B'N,5+?/R1GW4WXWME\94<*\*N,\9)9F,$J(WB(F
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M_JC5'3"OI.DP_*ATZ [+2Z+K\82>G4VU1J8.T&JA+[JKG(#Z9=R=F&<A2F2
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MV5QVLUF7:_V#WODX-ELY,TEVI.81^(&I[!GB%:+L&ZBD;4HK@D&.GRT!\MM
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M1ORA4+8OMST8VB,5X+Z]EY6303]SLUA7^=5K_9$VX'.]\=1S8'[CNZE1-"_
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M TZ1:MX(#@2JN8\Y6IR:M[G],#7_0?S<RSO]V"?5JWS6.$%92E,)4PE8Q@B
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MQ;BI?(!!4=%4B*Q$)99NE.&AQ?3HY&ZUT6](W9KBN'/VF0:)-&,KKK<0I,
M%E4.*(,*0(D()%5!]5RXK(B1)V&<1E&-">V-=-W=G?YH+][B3TC!:4JX7D4K
M7.BEE&05P*P2>BF5,$ME7A*2SY9R\[+3L4N6VHPS&2, ;[?.1OY^1UZ#GWVU
MM_HG?\Y-J\#.@IMD9T.R-2)L\](K( RZ?OOH,>K:?@50A^O^-4/Y%#?I9?_>
M?J^EW-7GEZ)+/805K'!%,> PTSR'10J8WD68J/BT$D7%$+1J5&@I;VJ+3*=<
M0H=S#+V@O7R*%1BPR*QUD(&^5?<FV8)X(5'3"T27(B-!P1RMK,AUH#I6$;&&
M:+!NR.511JP48FW2\]H@]H^Y$^_'U?+MPX_%ZDEN@Z5+E;(2"@$*QJCI,P !
M0Q@!A&@&\PH)1JU#]X]&GQJI:@63K8;V;' ,VF4"O0J*R'391\$C]OX8#GLJ
MO J6D8C/P",[)?\6AM[.FCU 9L?/C$9=9]7M$]7Y#_F=$6T'ZS5HZKY>#)80
MF1BLG$D.H.EQ3RD2(-4^H""9TEM>Y'82=%;6],Y[NE95IBGR#SWF/5W+A*\>
M'O27=&VT=]OWG@=9"%C(JE*@0JE)X=([(LR8QCR#)GLK5QEURCP( O$H.5S]
MMG.AT+0[*PB"4>3%XF3#OGWYH)L.N8#Y1];H!-WLGY<VZI;^HM&'&_?+#WC>
MD-)YW43=OGK:_?A_Y[+6 ]T_?9 _-0KF\HFJW+2BR@!B906@$A0P_2>@J4!"
M*8JD<FIC9R=V:AS2:PBQ4[:)S_IX^W>_NSX[].UH)CRFD3GG&CC=;P2=T E[
M06@G>MS[0B<XCJX/W9YV;U7PIML#_'^/M-9O]N+IB_RQJC<SALH*EZ+4VUC#
M0U4& 94% 2K#IM=-B:!(;9L6G)$Q-=+9JIGL]$Q:1>W[&)Q#<YA7 F$4F43<
MX7%J<G ! .]V!^?&':WQP07#^BT0+GW4+YRUU_SD)YTO3'*C6M6FSL7V9N*1
M+GZG&_.AIYDH4BYH)@$M\A3 K,* *B)!F>6<BE*[(!2[A+@Z29\:)?143+8Z
M_NN_9%7Z'[_,E^T/3Y+6ZU_=@CO=9N3RX5A4G&/3B@GZ['?KVZD/M/Z@*;=S
M:AIB(NX68AL-^3'#;L_/P-K, ._-P$-G2J"S/&\(+X3HNHTY:MBNE[F'H;Q^
M@US?=[TKD&2Z^=W)^J'7?FM&"E2@E!2 HM(<+$(%*(8E$(6 A!>"5QBZYFG9
M")[>*>/S#N/-*[2J=V^.R:2>[]7W;]$^,!=V6]GP^$9>+IX#NRO&=K*W9)Q&
M[I=ABM;4?4#TBS5XOPS'4+-WBZ?]&.MU<Z3?'.)U1\BJ(F7.D  E1DSO:&D%
M2$HJD%4PPQQ*++!3>X8C"=-S7GUO-8[!LV.3JR")3!P=&EU;K^"'ZV=-#TH&
MQU)&?>_/&GGXBI__H-_;O"LD_G[)5P_RPVJ]GG&NL")9 3(((8 ,5P 74@&<
M2P$ERB1.T6QCHKOMWN<3,IS>Z)VD>-]AHU.[\*U^=&4I'9V'4T#:O=M7PA/Y
M[=YW&FC52WXQ"I[?ECN_WP/F!WW#3\D9]1T?,/3P+1_ZJ&>!+'XOQ:-Q"79[
MFG?MGF:_V_FP*WB29:EF@%R!DF8Y@*24@)FJ,H@JG*&T-&NZ4X$L%^E36^UM
M=O'^56?<)L:.4:+!_;(G5O9(NY?+\D$L;+DL)PW&+9?E \Y1N2RO0:YT:IYW
M1]F67%$,E;#,)2@*R@',BP)@A13@1$(3#,!99M4VW$[<U.ALOZ OC+K[+B6>
M_LYIC'&1"Y4A#HH*$W/9D0-F&@>HO(*8Z-TBXGS;,VLTE)_WQ8KM4C8ML;;E
M@\QMTU"]>A^,'=W+J[^=HWF:QSVM@M<+LD,EC@-Z6N3+^**#YI]U2X>?\BP\
M?; L')S$<_[X\-@DL/Y6:W?XV[*6=#'_'_T:Z]]>F0-Z:5(?$529A(0#I?2V
M%5)& ($5!BE$F4@9*[E,W7@GB%[3HZ=&V_:B=:]S8I1V+E0=9.+LR&R\R9B,
MQ]L4Z]F:E31V)0<S=I.PQK:PR:U!L0Y;)SN(9N-6T0X)YE&-[:"#^UX+]+/!
M]F'7;^9KOEBM'[4,^=?FE<;DOV<55!12Q4!9:-\;EN9>DRJD_\A%A5B5R<+Q
MPL!:]M2\\3.YBXX4[ *^[85#%$BC7T6<:_"\USOYPVB>-*H'O:9P!BSP!8:]
M_)&O-IR!.;[T<!_"N]K:?*,]VY]-_38M9ZY9M:V >?M@MG#_T]P-="4R_TO2
M^N[/U:RDG&*<,D SG -8" $()Q3DBA"2DA*EF#C7#'/78WK!&F_7F_E#X[?0
M[YK:C%]KR@3L]-\6W$WT&I3H+S9TKC/F,5MV!!A]!B)38:L_: Q(]A:T%7AO
MFM*\?-/FQN^,N4F,'8DV)&@9,W\<0Q<Y\]!D[!)H_F"=*)!VQ6!^_/E^R6MS
M-O!&MO]]WUY5WZ\6>HSUVW\^SC=/7S2;:T?5U F8095R)64&9"G-15.> Y)E
M)<BHP))AG(G2J1.+H_RI>8-;]9-?M@;\FLR[T(K.AO^3M%8D?Q@[DLX0QTLG
MUVFRH\R(X$<FRPBX.Q.E)WI!*=)5AU')T1.@0UKT'<8_ ^R==E/IPA#L._TW
MZQFG%!:%(D!FE3(E9E. 69H"1+E(*<S-0:5K!MB!C*D1VR[%J=6S]3,:3=U3
MP [A'":G0"#%/@=TQ\<K!^P, E?G@!V..WH.V!G#3N6 G?NH9V"-J3KPRA0=
M>+UZ,)Y4F]I2%$BDJ?9I2DXP@# E %/.@!)2R3S39E+D%$%S4LS47O.&2;L2
M#+RGIV-(S&E([9R0ZX&*_*I?+%-A>C31]?VV>TK ()=!:,)&LYP6-6[8RJ"Y
M1_$IPY_VO-,48FZ&H8O/=*YW8:_IC_F&+KK0;\Q*1B%&0 K]!\RYWOQ@60&&
MI,I, UW$K#+!K:1-C2KVRB:FZ0S0[C9O]76\?1R$V/)6,11PD:FCA]GG#K-.
MU0AQ]U:@A+W6&Y0X[G6=C?%'UW!6#WE>K^D5X78IS'_,%N4G79A;HMO-ZZY?
M:U._8J9IH^2\RD!6$@$@*B# HDJ-_T'+JFJV%VX'T59RIW?P;/1MZK T*ZG<
M:^YXKV:%NN6-6F@D8]^E;2%L?NBI?)/03;+5NBU^$_ :S06EL!=H5I+'O3IS
M >/HTLSI83]6>B-_U)+/6_\\IXPQKC<Z'$D)8,DE($1#;?8Z$JN"(ERXD4]_
M^.EQ3%\[-UIY!IL=>_A"$?O<P@8#9Q(X96S0=_V9@%%?Z5.F';ZY)S]S==H/
MUR102W'^5NC5T^_T'ZOZ]8*NUW<FFFB69EE*:45!";$"D"@"<"524#+%$"HE
MK7*G2IM7:3.U#<S6&),EOS4G&;QU3=A3TAB5-%8E?S1V^><+><RHY1G*6/,4
M^Z@E^A1=DVCD#VVLQ",/C5XJ$<D?O('$I"L&]:/G#ZOE=U-;PP1LWNDAWJP>
MZ'PY([@H4)69Y!FE>3=GYKP058!E$@N]M9-5:=4,=UC,U C5:-E6&C%ZWB1&
MT^2/5E='DCR#JQW[78]69%KS \J9JH9Q",I!9T2-2B[#YAZRQH5/>QX7[Z\!
MUGKK]G&UI/N_N=,_K2EO2A-TIYL9JRJ6<P146I4 8LX SI@ 5.8BSS#G)73R
MSQSE3XU SD?_FF.,_N]M,_K-/5TFSQ_RHQO7>;,\E8XW&[&/CD:8"/?S;#\X
MPYYP.^HP[IFW'T!'I^">P_@&'*I5_=!LE5\]O:8;^7U5/WU2O0R8IZ;^>"ZI
MDF6&0"7-?7P&"T"RM  8DT*FN9*\=&J7;2EW:A39SS=[2K9Z>Q5^MT7>CNPB
MX!G]Z,L'2H^P0"=@ H<#VLD>.0S0"9#C\#^WQSTK4)AU35/?ZGDAGRZD8U9*
MA8N,4I!24\Y34Q,P=76 ) P*C)A*2>E4@6)0W-1(J%WTYUTYJ2X%Y->;9"DM
M"\);HFS'/.&PBTPX+6Q]37<EN3IE0U;ELD(E;'V$89'CUD>P,O^H/H+=4Z%2
M*QIQ^YH,73F&N5S/*%3:U\%Z.YB;^EU0YH HO44L()(5)FG&V)5I%6=E3Y-L
M%GL%K\V4.(^ZK:<3!<O(Y',F0Z)%MU>YQ0+G )D1%Q&+G!5Q7OX+9T1<!.9R
M-L3E(3PKG;>QKNN[57?._KDV/+EY^JR_:!N]4S11"C_,1V9EA8I4( @(1DU6
M& 6$4@)4)?*,9(B50KD5<;$7;O7.C5JIY7/73'%MKK&Z&,F$-GE\CO7-[6?
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MOMY[L>L[B^NY<-=OAR4@/TKM;O#%HY@OO_^V6HD_YXO%[M1%:?^+%S0%E)O
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MSR'&)&,%ATX!FU92IT8O.Z7-5=');K*^A6SM)L&.>8)#&YF @J#JT9?7 :7
MK7IM)(_<O=<!C..&OBX/^Y%4.]CO<G._$KU[L7W=K)2FLLI1!E@!"[VG0A7
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MI/PI$.40,):4-SB$>_3NZ6[+C10IWOXE:S[7&G0UJC*3BH$D Q75_C(LS-F
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MU$GJU'A@IWAB-$]ZJB>-[DFKO$,JFS7^EP_GHZ :^T#%#E"/OEKVR#JD!,9
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ME3-5U=ZOUX]2O'FL=VY"6\:_+<FVUK[&)]4KS_95ZO>Z#7WEE10R+S$@A'$
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M*1E)<Y%S.F"Y'G!RQE^T3VV.'(\=@C\/L0\A:O#:"C#O_@X_OK\#1[/;[[*
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MMS,GJS(:MO?+"G,>/^6>DAUF<KOI<=P)&U5.NCFNL3XU"JJ@]JI]8&/W,9H
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MKQLYS2B2C!4DA5G.4D..G,-2*P:5UERF25:6VBL /!]B:LS76 @J$P<V KL
MI!MQW09/9%;R1,:;;*X['Y1)+@PS*DU<=_,Y!W1\<M@#_F&U_&X#Z#>*5]W
MJDX8BC&68YI!1 L"<483R%-2F(5>REE1DBP37FI/EP:9VD-N;:R7$M;*.V#M
M].HKTHFHV[-^*TZ1G_8A$'D_\ET8!'WH+PXTZF/?Y>KS![_SLT/% U;BGS]6
M"W/%QB[$MD\?5UMU:8=3HJ3("$H,%3#S1Y$+R 4JH,"Z($1(13#S*W5Q'MOG
MZS].M4O;]'\'M?&^X@"NP+O11A0P(W/))12!-3O^MK,W7('U %Q''UD)P!.4
M<PT WQO<U%MTM3QT7[N7LNI4PQ9-"<BWU2MU+W[,S=_D#+,4(UXP2&110BQH
M#DML_IHC52094ADKG0Z\!HX_M3#G:"Q8-P4SVQ7@"K#&X$&-)9UGHYO01L X
M]FYUV_IVD\@6[OM"I6\K\$J!^U%P']2^,P;^XS?K##4/0_MR^J+HUH73^:XO
MT7/3U^4K'3:];Q.J6W6]M;;2;]C3YA_K^7:KEN9E-A?JE=(K^RI;/\R7]:.$
M%4Z0E"FDBIG7B]($<JDD5(R664F2+-7LMD;5[L9,[5USW**6QG;P9VT\6%;6
MFW>.-1]LC_;?VM/88]J\WD/1)V.\E])IY^+C!%E_0.,0J#T"M4O@VXM,T*W]
MIN-,U$NWF@XV80&:3/LC[-U?VF.(%VXM[0]&?U?I ?<<N!$D?BBYLV+<]\OM
M7-K<:&/'5YN46!6]OOU++';FI?;. &%EW7;U]_^3?LO6MFO39J^'>]RXH*DJ
M%:(ES+5,($Z5>2V*0L&<%B1)DQR+7'ON& 4W<H);2XV/]@%O>PF.;H*]G\!^
M+4'+4WO1WE<'3>FQO@F.6U@O.KNQ][K"3ROXXQNS*C%Q-LBB34;8G;3P9HZ[
MY18-YK.]N7@CW:Q;;-/ WBU6?VX."3TL5SI+<P)E3AG$]MS!O$Y26&":H$26
M6#"O[*NNP::V9#K5R;5)CY6Y(72(SX%V/5T( U_T X7!R-VB*WP5DE@BPN<#
MOI1B\%77.^2!KU\SC$@^KI:VMSFS';+J_/BW?SU:^9;#EUR765*FA$.-> 9Q
M0CFDTH2C1&12IT4IJ.)^D6COF-,++#]M?YC(85[7=ORB:G-_]=3IZ\?:C5""
MXA>95=JV[I7*?VG,_34*MSBC$Y1@^D<=E66<07A.->X7^O'-9KV=?5%L\79C
MN>Q^*>^%V#WLJF2L-^IQK<2\"IG>J(U8SQ_KZ.GSVMJR?:HR@&1*,X%(#@MM
M-XJY)I#EM@!829XG29IICERBFILMF5K(\]'\SKZS]S9Z)5W=/B_=G#4JVK&Y
MS!-H9^H*!E(7I9E!6G1F_O:<RFZW8A2*"P;6GOK"W7!@[>"";39-'[\/\Z5Z
M;V*]S2Q#)6:B(+#D*84XQPB6*=,0:2K*M*0X15YUQA='F1J5548>&E:"/ZRA
MH++4<]EV!=.\H-J&LE+I%&*$">0D+V!24)5(@@1#GHK3-Z,Z4HN+N+BZA:TW
M8Q7[E&\ 2/X5D5T@A"U^O#C2N'6.7<Z>E31V?CBX$OUO[']6ZVI,^UIO*DH4
MII07AAL$LWG[MCZ':U381ABX+*A,"NE5FN,Y_M3HN$]:O?(!U,]-%1P-*^WQ
MG24WNHF(?60B"@][2''[+O#&4KF_:,-4Y.Z[ /+0O>^\S8VZR<U_+,VBF8EZ
MJ% ,08P9@Y@E)N9$7,*B9*K0G"6(.<FF=HXR-6I[+@7<_ "JE_ZGY5#9Y!-@
MNWDJ&%R1V6@P4L-5DR\A$48T^>3.+Z.9?,FYJY+)%S\\<*=?;>WA@5FX_IQ+
M)5\]_;ZQI%-+1<R7W^_%=OZS.LV<H0QG64HT3'):&EJPZR1;N)0@K)E*J9 H
MGVU76[9PW/!W'MJ+)@X&1-SR4=M:H.:QL1WP)_#+SI@/YLM?&VD:N[7-#BYX
MG@FXSXKCX4 4K&/OK!F8JR/'SVV8?]_#?# >W/?#[']@X(U8V),#]^''/4+P
MAN7L+,'_#H,%^]:*;=0;5?_W_?+3_@SC-7N<&YHXG+!A)AF5&8:<,5N933@L
M%<D@ED6"LEQDF6\EIOO@$]P7^F&;]VS,0P:.IW1UT\-*'VHQ9WR^J*;(\ZS3
M8TK<>"T.S)%Y;6\T^&5OMGUG@(/EH#$]RD&H/V*AM0)=AQ];.= 3E@LZ@KYW
M"!JR'48[$N@Q]XNC'+&4P(+E&N)<)Y!2\U,J.!,I+K(<(<]L#6\C)LAS-K;0
M53I3E1[:(KN#];[)'/YS<U, %PCOEPWDCL1W]").$LA@$,>([;K,F$*,YP"3
M8ZSG<J=AW/@WM32W7MCC6ODP7\[M36U2;I.NTBB6ER1/M0GY8%Y*;=6:.:2"
M%888!4D+21AU:PGD->K4]KH:HZN([M1LT-CM1WUNT+NQ77! (Q-</Y81I..]
M0 I*8&XCC\I97F \IRF_BX?NLG_]H18+6P? ED\S+&B2<XQA2FTEE](,LHQK
MF A9R"+-2$83O^WU]NVGQC7-;G%E(FAL]-U+/X'/=1-]*"CC[)Z[X3%@Q_R2
MVS=NE9_<<N0]\DONG&^.7_S4P$(:6Y7#S2).VOL9#JAE$XY=C5\]'3_RF3U5
M6@I_LK4\]*&XWVQV#U56V,:RB-@J:2M+T0RGJ4:",%A*I,R#7V20<O/T(Z0P
M3Q U 0CU*L.)9NKD2*0Q#BSF6MD-DR?%UIX;ZQ$GUBVRF<9T1::WR@-8N0#:
M;H*6GW8)V/Y<XRNHG+T#Q_X[H.7P'3A\":S/ 4N/HD]+V,*E>.:.6_84'?:S
MHJGX(PY4C#UNJK_>K==FV)G$-&5,V$)_FX+!L8:,Z1*F(L\8+2@N"?$Y<#T?
M8FH'J]_L&$#4QK7/&3RU8L^Q=&/GVQ"*S*HMX^Y 8UY @=BKKH>5AST?9EQQ
MV*MNGDG#7O_D@.;4:8+R]\;"I5U7?C;SVNR',)Z6PK -S*GMR%J4)ART*\)$
MZ)1IRE1!A7-WZBN#3"V0LV:"@YW &NK1>?D:DMU/>"A\(C_C%Z#IWSERQ\BC
M/74 K$:2=1J$F5^+ZAXPNGI47[MTO";5/<:?=*GN^^SMM4Q-MG:6E@4AI(0D
MYP)B:67P,[,@+EC*9*ESSH<7,DTS;?YY(<F@I/@+2+I%-K?A$YGU?*&YJ;XF
M8F[ZA6%>K+*F.\.\XY/#'O%FJ;1I.FE\6WUC?_UCOOUAI:OGR^_O5K72S:OG
M*Z\95QE+$XHA032%."DX9(CGD.4)%@5E)2_4;*F^LWJ=Y<H'0^UQ>BIH_52<
M615Q862;JX)'-I=@W32'V:[ 4FWK[F!@H[;;Q4&G1=6Z[\RN6SV73H/GT8V&
MHD[+.&35N'!7-7-MV7YW>3OKN+,0CLYN13$HZ0TV9E1JO!6RYP1Z\_U"R?1_
M63VQQ?;ILUK/5W)6)$HP*5+(B"008RXAS:2$+)%IKA,N)''*;' <;VHQ5F,<
M>*RLNU7[_13:_O5E8,!B!UW7M-SW('Z. .*M@OF#P7QI@7Q'4 .HX5^$R%O]
M_O0N+ZQV?]&E?G7[RY?Y$^_GQ>Z!F]^I#W.MOHJY,FYLFAT5)$M$&+:"0XD]
MSLTE+!&24'/,2$&D0BQU)=R.<:9&M =3@;45[(UU)XLN3/N9-A!2L2/%RR -
MV-#K0LN=4@.A-A*5#D;/BT,=,.G@SJZK1^-,!Q?:7.GR<7\5MT]_+@WM_)@_
M-KM21<D)+0PO2I(E$.>E;6=+;&U5H91,$"K< M$+]YX:%Q[,\]S3NP1;-_7=
M"$9DNO/ P4L#[8K'-ZN:/;_O:#IE5QQJ*X]=^XA_[FES=OENOA%L\=^*K=\N
MY1NS9)TIJLVCR2CD*"UM+P%;_6@>V"0A1*-4,J25:P;JM4&F]J@V=H+:4& M
M!<948&UUST>]"FGWTQL*J-CKPB$8>>6H]H$P.%/UZHU'RU?M<ZV=M=K[6?^5
M2K6?_Y4MCMU.GG6W_[R>"[67G9\E)"6R3%)(\EQ G @&RX(6,,V)EH(4@@@G
M"O ?>FK$4!\\;8SY@.WM!W\V#@!6>P >K0O@E_D22+O@7&_L1E.] _^K>S#O
M.4G]JZ%XT$>FFAIU:WE[JV1O/&BL!Y7YOKU7!B#MOI**A_A(BZM+R \'WFO%
M-0R[CD68YPU'6Y<-<[2]5!MXAP'I:8^&SU:OYJMF3P'34FIIW@0TI11BFY!&
M<\UARC,M>(ISF3FI:E^X]]28_V">1WK5,[3Z&?H&#")3\,&R(6EFSW#PR"X;
MCL=(!.F!BU\JV67/NS+(GETQ7N+895-/\L6N?,2?@=XOY]LY6[Q>+0VS;<S4
M5M36?+$HY5RJ1$*=6E$>G2:0"4)ASKD@2#&1,B<!UKZ!IL9-C:W@:&S]2G9_
M1#MA[>>M4&!%)K%K. W@M$[ W DN%' CL=UP +W(SP65#B;LO'PT6G1QHLV1
M3I\?EG3W1O'M^^5FNZZ^(RTM9)D5!4FDE:@F"<1(F?A-:00U5F9)7W FN/3)
MKKTVT-0(T]H)CH;>W:(_?17<;MH,"5EDVAR(EG>Z6A\40=/1K@XV:KI9G\O/
MT\EZ/W]C0\BJK>F,:<1(0@B4FIEE'<LEI$0*2&2I"HVE4MRIV.CR[:=&!L?6
MA757UZ$]'FOLW)[ZX8A$WVIS!6-XV\83G^,T:JR'>)G6C"?N76W&>/JI6SN'
MG[8P/^82;^Z7\J.Q_\JOOYF?-E;$;K7<U%_?3""9R"R!$ME:8I05D.K" (T+
MFNJ$8\W]9">"FS@U^CCQZT2YH%)Y:OV];@.Y_<&6X/2B8;P3?O(=N>M%IS0R
M_XTPFS<T! \->*2&X,',?*&&X*%AOMX0//A(0Z5B_[P78K5;6K'%S^O5TOPH
M:D,^KQ9S\53_>>@_/F-EQC%!"A*4IF;U*%)($660I2S-"*6:JLSG->%KP-1>
M N\?S"^JFJHORE;%+I[ ^\UF9\_(#FX!\^Y?2O]2*^_)<:/QF)!')FEC>AO7
M4^/O0&TX^*/YK_4 5"X$E8@=AEY@@5A/(T:6AQT&T;DX[,#[#-\L^ZK$;EWK
MS?YD\X5E6%NIQ1;J]<J:L5OM-K\OUXHMYO]2\L-J8RS9S"T=H_0W\XD?FT_K
M#RM#UNN/.[M_]TGO?[^9,9;GLA!6Q['((,XP@:Q(".02H02ELD":^>ZY1;1W
M:DQ;&VB9=G-PVHJ\,?!];?P"NX.;8&'__M@X O1J#1Y6:U6';-L_U<+$:@^5
M\_X;?C&_(.[[AA.9]C&V'X^NWH&#L]#,*;3)6'?@Z# X>@RLRV#OTQU *:C=
M-H0 :L?OP/$+=7 ^[);F"+,4?&<TILVC;["., &7]FG'&';8*^[MP^-B]:34
M5[7^.1?J<@7RQU75:4?)2M9N4TFNM7__>K79?EQM_UMM3<B[^KZT3LQ(RLN2
M90A2*]*".3'K I8CF.<<Y7E1\E1YM4"-9NG47FNUHIU]>>TM!**MB"F,#VU)
MAUWC,MA4&7JKQV[B&OEKX/8*F\3DQMY/[]9Z,*^?O7][15/KD/G7+7A26W#T
MR;SV'FP,'.[=%!W^H&^E>-:.^CZ*#OKS-U'\ ?V+ +_8K__]7_/-+"591C(N
M88D3 7'."TB)F?\T+3,EL= 4<=?RO\-=I\;M]LQGOMG.;9G,;XIM=NOFA,T:
MZU$$>(2MFU\'@S'"V>( '+R* ,_\OKG\[WC'T0K_SIQHE_R=_W+@X>&.;]3_
MVYD)>/O3_-&DKA')D&*(VVXWMJ>SY)!*F<!<EQ*3@G!-<Z_SOTNC3.X!/1@)
M*BL]#^(N NEXEG8K/+$?V6?(1&A/TPE!V .JBR.->\;4Y>S9,5'GAX=F^ICE
M@A6?,H_5VTK^S;S7U:')G&!(9#E-($TS:M['%$.:%.;U+!073)=*NW5S=QMN
M<CS0LO;?06VO#<652Y>Y(7 [DD0P$*._X&_ ;T ^D0LL@?.+.H<<.=_(Q?WS
M_".GJP:*>QJLU7JM9#5*\R(L<DUTGA(H"D3L43&&3.@$<HY4B;7&:>:EX'MI
MD*D1R<'&>GO&4UKS$HIN3'$K-I'YX0A+(^ ;/)CH B"LFN6E@<95JNQP]4R%
MLNNSPY[U=_/E?*L^S'_:1IU;,\MSOK ]3]1V\U%M9ZQ(B; -,S/S\$,L\@0R
ME&&H!>%<*YJGRJLG2?=P7L__"/U)CB8V_=#O@.UM^VJU^F?=K,B/$7JP=N.&
M< A&9HG:4%A9"EI(WA^1#$<8;J@$I8Z>(4<E$3?WG].)XU4#6_.N5O+/^6(Q
MDX2P7*H<(I45AD)2!2G1&N8X21+,"RYHYM>,?']KGR_[."W&]Y9YMM+=0T6H
M(521%)!E$D',%8(E5Q0R6184%ZH0!?=AVR% C<&K>[ON*DES;NGTIS^='F!S
M(\XA8$2FR-ZOBW^3X&=.ANT#O+_YN*U^G[ETULWW^>^'-F03K;[5:48Y8T)"
M6JK,5E0J6#):FL6/XD2EG.3(JW3JY.Y36^9\43_5<J? ;FG@ B?)RL",HPR6
M/ZJ\>6D^N%@]UGGTK2QGWW9M;:3='M[!^$5^@AN[(BR!+GH<N#=;>X21V[)=
M<.Z\(]NE#PTXIE1L\79C"[9LQV\A=@^[*O_BC7I<*S&O3T[-''_2G]>K1[7>
M/C65O[DD@A?"YG3:%$^.,RN+(V"*%!6%5EE9.)' +49,C2NJFF&;9-=8.4 $
M=?!\=%/%6"A'9A1_@/T.5F]$Z/9SV*$&C'=L>R-$)Z>\M]YK6#!S3+0_%*O\
M_BC-P&9"DB3?RWYID0G-['*#<(@ESR##60YU3I,""8W,PLTGR'$:=6J$=JFP
M!]1F VLW3'*_\,8->[>P)SBBD<G+ <P(H9(72D%#*+>11PVMO,!X'G+Y73RP
M2)%M=VM#>)\,W;&Z5")).*62EY!@9(^KM>U@I!$LM:)EBG*SY/*J5C\?8FJL
M\VG]G2WG_ZJ3@NW2ZFBJ9U7A.9INU'(;1M&#(&N<#8..YH$_XE0 7L4A;(W?
M^3#C5O%==?.L3N_Z)P<&(_)_=IMMM5'P;6433Y=BOE ?U?;]4JP>E*V8^+9Z
MS38_3 CT<RZ5?/7T^\9N23<6++_?B^W\9UV"L4^YD&G!D2XSF&#S!Y9% 2GC
M#$I$4"D4PDGJE'$:T\BID4[+1UM[L-Y[6>W"5E5V39-)8?P$.YOK/E^"U=Y!
MP X>_J=G2!3C&^ 80;WPO,8.N$ZG].!@=4Y9NPA^L4[^:G]M_01[1P%_ K_\
M7D_RK^#@+CCZ&R7=)^:$A(WM8A@Z;B@8$>JSR#'F6$$RH[^9NU19]UJ7A*=<
M09YK$VU*7< 2*_,'UXFB)OK$I+@A-WH_SM38_RP'V!KJ5;S0!ZP;(P> *S*I
M#D+JUH3IYSC$3)D^C/622=//'>Y)FS[[N+_H] >UV2AU()P/BFW4OB;W(+EO
M:,J,O+"_FRE-,RVS%.9(<H@U2B$OBQ(6&4-IFBN.4^?VNKZ#3XT^CO7UAXXI
M'OT?O:'OYI+8@,8^-:Q,OVL%797U!Q&#3_K8IF,#OJW WH>(@+N+7<<$?B0!
M[/ 3X"6,/13!#K%L[UN.)J ]U-FVJ/;@>PR+')LN[Y_9>OO4UFA[,]\(LT[>
MK=51I8L0DA)=)#!+L8282 7+-,-0%B0I=,XRK!*_]#:/T7T>K7$RX!KC064]
M:)OO%V/Z3(%;W!D)ULBOBNMX@J/AD;9&!R 6-&KU&7_42'8 ,,^CVR&W&!#Q
MLLV&O5/FT;]?RM_>?OGZ=R;$?+G/O<)YF2AFM8&)S"%."PD93Q(HL58*94K2
MQ&D3M7^HJ46SE;6@,K<Z?K$&@\9BCR"K&UZ'&#88:+$CUA9>]\_P&M!VI0<X
MCU@T&(!C19XW >D793IATQ53=M]@O C2R9&3>-'MBA!M6'XWL[U:;ZV4BN5N
M>WP^8ZG*56EB0IT4&&):YI!9E=T2(8Q0EA327QNR<\2IT6NE]3=OM1K9'6T&
MLC'ZEOXLEU!W"P.#8AF9=<\ZMK3,!6_Z8+RQ<4L'-!$[N%P:]05;N72 T-W3
MI>O"8;030&/\@Z' ]UOUL)EQ7 I-%8(HK^H;$A/Y(4R@+LJ"%!E79>DE\!?2
MN*F168A> M8Y4'GG>=82=-;=&/*EYC(RF8XUC=ZT&P/OH P=U,!1R3P&M,]Y
M/\H8UUX1[6^=N>J?__5O^W\Q?UAYRO_ZM_\/4$L#!!0    ( &%_JE2@["%;
M3XX  !I:!@ 4    :6YO+3(P,C(P,S,Q7W!R92YX;6SLO=F6FT>2)GC?3Z')
MOAU+^;[4J:H^(5+,YFE*Y)!49]?<X/AB3J(R"+  !"76TX\Y$'L@@EA^Q^]4
M3:I*"D8$X;9\;FYF;F[VS__CCT_G/WS!Q7(ZG_W+7_A?V5]^P%F:Y^GLP[_\
MY;?W+\#]Y7_\ZW_[;__\?P'\GY_>OOKA^3Q=?,+9ZH=G"PPKS#_\/EU]_.'O
M&9?_^*$LYI]^^/M\\8_IEP#PK^N_]&S^^>MB^N'CZ@?!A+C_T\4_:<:$YDE#
MX:6 BKI 3%&"4+HH(5E0AO_?'_XI<65C0 $AHP&5M8"8O0$GT'NT0;LLUA]Z
M/IW]XY_JOV)8X@_$W&RY_N.__.7C:O7YGW[\\????__K'W%Q_M?YXL./@C'Y
MX]5O_^7RU_]X\/N_R_5O<^_]C^N?7O_J<KKM%^EC^8__YY=7[])'_!1@.ENN
MPBS5!9;3?UJNO_EJGL)J+?-OTO7#H[]1_P17OP;U6\ %2/[7/Y;Y+__ZWW[X
M82..Q?P<WV+YH?[WM[<O[RPYG<V_3.=_3?-//]8?__AL3F!X$SY48M=_>?7U
M,_[+7Y;33Y_/K[_W<8'E7_Y"?Q6J4IG<K/C?;_[NCS>+?U[@DO"R9O85?>/R
M(^IBAQ""?ZQPEG'#WM4:Y_-TYY?.JW#GBZN_>1XBGJ^_.\DXG:P_^2PN5XN0
M5A.1HS8</92@!"@1.401"W@"5>+:Z)C57;XKT4NB>JV+)::_?IA_^9$^F'0B
M^'^H^B5LOEQ+Y<&2&^D<1OO5]GM/OSMQD=M<& /A5 )54@+/70'+LW5HF<G1
M'TWZ[17O4GY;LV>+],-\D7%!-N1JR;!(#[1\%[^7O_'CY["@#X+T<7J>K_YV
M-29#Z&PU'T!Z&]40N7_Y@;@NN%A@?K71S*/,K3E;D67%]6\.H?7_YR(LZ!//
MO[[%S_,%R:'X((L,$&STH$(F.7AO@4<DIH@;S^U@ +BW^$Y8$/UCX1B9=@*+
M-[B8SO//L_R<3N1)%-9XKS0$5Q@H%@C7R7A AR8EE[))8C!0W%EZ)TC(_B%Q
MN#P[ <3[19@MIU7PEZ#.4MKB$H<0. ?%-8/H)((F]RGP:%+P.-Q)<6_UG6"A
M^H?%45(=&1D_SU;3U=<7TW/\]>)3Q,7$.NZ+=P:$]W3Z9<_!^\P@%QU(3%%J
MGXY&Q/U5=T*"[A<)1TFQ"P2\Q0_3*H39ZM?PB6R;X58;BQ1621)$)$?(QY*@
M>.N-*44CYH%0<'?EG9!@>D?"$=+L @TO*=)?D"E;"_X=R1^?S2]FJ\779_.,
M$\]22#%38*D9@5NY ,[H!%P&B8%A,.7XR&@'0G;"BNT=*\/)N@OHO ]_O,PD
MOFF9;A(9EQ9180XJ"P52!DON,\'?.Y;!(DL88]%*RX% \P@).\'%]0Z7(>3;
M!5#.<B85+"__\VHZ0SYA-G*>D$/2CIC@U63RZE*G('G(:#WG X%DR_([ <3W
M#I!CY=H3.)[1EZ\7[^>_SR9"22,]^=3D42E0UB!XDS4P9W+":B;=4![)@\5W
M2V^Q[P09!PJU)URLC\G7BS>+^9?I+.$$R=1%3]+(E7K%2$(4E!L(K"A9P_,D
MX[#@N$?!;@CI. ,ZF'A[@LF;^7(5SO_?Z>>U*Y6L4B%F(KMD,H)"$]AE)']*
M$,H)_\&I@2W(G?5W@TC'B=&!1#LR0*KU.UM@6-.M4&9+<3J4J!P!F_[E&=%M
MC4>I."JMC[\HN;WB;B#H.!5ZL/A&5GN]5CU_\W$^N\K0"*6-,R&03;,<B-((
M(5D#L=@BG/,9E3E:]?=7W4W]':<\CQ+CR!!XA^EB0?#E(KZ?KLYQ0@P[[@R!
MUEOR?I@4$!1W@-E&I[@QS(2C(7!_U=T@T'&N\R@QC@R!]XM0"UC>??T4Y^<3
MI;DJF7N0.B(HE1S$Z!$TR]Q$D1S/Q^O_SI*[*;_C].;A NQD\__\1_H89A]P
MG9?UW,AD4P$MA0%5;"+D$OTU6$XZ.>F5&\P W%YY-QQTG+H\6IQ=A G/+A95
M7)M;NPIKTL'%<B)C=L8; <F6"$KF#!%10^:\2,MD\FRH5.5V"G:#1_>IR@'$
MVP5,7L[HTT@<TR_X/*S")5N3DM#:X R8S"GH,9K"'^$09+!,%$W&SPZ5K-Q.
MP6XPZ3YA.8!XNX!)O?Y=/ LK_#!??)UX+Y(JB4-!BHN5-R0.]!9L]%Q:U%FF
MXRLKMBR\6_E5][G*PX79!1;>?0KGYS]=+*<S7"XGP@HI1"0 8\S50_80;"B0
M,4B.@D?!AK(4=Q;>#0O=9R4/%V876/CY$RX^T/'WM\7\]]7'9_-/G\/LZT2+
M8!BJ K*X0&PD!9[X(M^)21F\L=X,91^V$K ;-KI/1QXOW"XP\NXCGI]?4>_)
M7;8^2CKOI .%P4-4V0)WEJ3CK"8W>RAS<6O=W1#1<6[R2%%V 00B_%,M YFG
M?[S[2');OKY8U4<B->J><)<"X9@!5TI2O$U\Q1PD>!>5+[7@3!Y?P?MM.G8#
M2L=9S(%%/3)PSC[A+-<ZU!?GX<,D2\%5Q Q,67*5!/- 8;<&.B)Y#$8'P8XO
M_;^SY&YPZ#BC>;@ .RGK?C%=IG#^;Q@6+^@[RTDBYS@QKH'%0%9/(@='3C*D
M5'(VIF@]8%7WO<5W0T/'*<XAA-H5+C:O%C9,L$#0%B:"" E!:8JL*8)B%%0K
MSUEF]=7"P,BXM?QNV.@X[3F,8/MP-(B-13A_.<OXQ__"KY-,]BUFHIU)DT#5
M^QS'-(G$Q^BD-0[S4-41]Y;>#17]9SN/$.C8-1&;E-N-Q;MZXN2+*!IM )/J
MF[>L(I#C7 "-EMJQ2#\[WEP\MOINN.@XO3F(6 >#QC__^$".K^@;A[X&)YC/
MEICIB^7\?)KKD_^?PGE]S4X!&*Z6=^G?\9GX-S]TD/?C^Y%^Y,/RBR5\".'S
M9%U35\^.U^7%=$:+3>D F6^>C5TCS2L=C%<&M$OD8T1!2 NUH,:&D'D(M<[J
MB?U6PC*N47"YZ'K3_8CGJ^75=]9[#QB_[ 7PW_>A[E +<[7&V7))PKWFU4;&
M=,0$G&(M4'1.@I<.(3J7$.F//I8FO-ZE8YRGZ\U0<65_!A#ZP9:';&><'WDL
MW:7_TI)>LU&L$MHR \0% V4< Z\# \P4G2FNL/BG$B''8N<>.>-"Z!@-;P7+
M,<+N C//PO+CV2S7__S\'Q?3+^&<V%F>K9Z%Q>+K=/;A?X?S"YPPBN52\@)X
MDA3GIU @E* IJ,O6%&9TD4]=RAR.H9W(ZP%31P%AWEHG74#MW<?Y8O4>%Y]>
MSK[@<E4M^7+B4"M;F"81T3Y46BH(*#0PD6@GJA"T>ZI^Y(A3? LUX[3C: >D
MHR7>!6[.4JJ//)=O,2%MAGB.O^+JJO+!Y>0]I_" N5H@([0F;M! 9%KGQ*(W
ML8T7^!15X_3P:(>CP330*9[>XGD-;-Z$Q6J*5Y*;Z) *%Y&!<8D,K"H6' L.
ML!03HZ"(UK$306LK@>.T!#DERH[7RXC)HBNVWBSP<YCFG__X7"-I.M=?KS[B
MXH[X)M(H;AA'H)TDR2873F>Y59 "USG*&+-]JKCV<*CM0-PX_4;:P6QH?8QJ
MTZ:S^3V&EE<<7<ELS=@+$NQ9*=/S:=U0FR0L2=$R'JV'P&K6E8=JM-'1OZHC
M*21:>^\EZ(,TU#'KC].^9'A@G4P'?9R>=S:*YCPI;AVD8GRUQ1E"B YD](%G
M5JQ6C<[(O4W4X%=E#4_"@V5\^'DW7X7S@<Z[^6=<K+Z^.0\DCEFN(>SG&GJ0
MSS@I*+GSFD[L6/O 23*Q0:H('*.1Y#H:K]O@Y2FJ>@C[!LE)#2;Z+BQ-I7[U
M]?+U#/E_+[[\.KW:9;/\ZWR6+C>(D,JZD"U85I_<^VC ::X O4Q:2NN->JH&
M\'!0[4IA#_'@( !KHI(NP/:2%#+[,*6@8R,NVC$__Y'.+VJ!V]_F\_S[]/Q\
M(DQ!;SBGR$-R$IVF<]IC@:Q%YD46,M1MW/1=J.LA'!P$9(.KH@N 75,>,%OI
MI0 *,'+-OTEPCLC73B?&BG8B/=5'X7 0[064Q@'=($ Y2*1=@.$U'=.A/O-[
MA6&);VMK_]?EM^4&\!./W*/V G02M7NRU>"%+%"DSB)%X85K@Y GR>HA7!L$
M-L,)OX/LTJWDQ:WCUVEAE.82,LNA]C K$*-$<(QE5+Y@:G10;26GA_!L&.0<
M+>PNK,^&@TF.5GE5!' 3"BC4IO;N-Z3:I)V79#C94U6,Q\;NX[28;%8)L)<X
M.PC37TU#G)ZOO7ARW=<O.S[.STGHRXV3?RT:78H)W#E CJ$F,BAN-#8!UJ:J
MR7 ;S%/]X@Z'R:X4CAN^-Z]*:J*H+NS0+<[N9\]B$)(+'B&7$"E^1-I,Y,2!
MU"E$&W003W8;&01T754NM4'!XU [1B%=@.OJ-O%-^%JO$DEH])W%!5'R@,F)
MLK$X3WA B\2<]09B3AF203K2:^L-T;:(8 <BNX'?4<AXY,IW:"5U@<#G%_A^
MOOT*VW/#5,BULS ="BH( T&K##Y+J42)6IJG'AX>#KC':1KW%&V$KX%4,/H5
M[^6N>$8_FZ9P_GY!3L;E7>,5/[G$I+0C!D+M+&<YH^U!QX#0P0EDRB5S[\3<
M>IG[[97&368/#)0&PNW"]CR;S]9"^?MT]?'9Q7(U_X2+*]%=]9J:8%&1JUK;
MP!AM 9=D=14RR"RD%4$ID]O<F^Q"W;CI[$;V:'"U= &VNPFU!_P8+!15T[X1
MT6E0/%MP!16$(#,=W;8(W>8!PM-TC9L&;P2P 54Q8G*S6N7GETO^K4X&>G&Q
M[C1QQ0:7:%5*#+2NC71C;5E3L@3%K"]6,9^"WN&L>V*)<9/=#0ZYH<39(2KN
MU%5=\41_+5O+76UF0YS(XNL;\PR66V54J1V8RX$0V;;>N"GN$^'E:$%W<%^R
M);!TQG-7DR7):K\1D3.V0%+%A128\:[-^71@D-\L)][H3#I2Y!WDRI]TVV[=
M!*F4F?<D)5YD?0J!=:J#D\!MX2H*Y8UZJI=,(X=ZSXNX4\3X[5*8+535A9--
MC-''K6I9S'.,%)+&A$E0(%K'Y](6D@Q<%!H21\6%2<J$-K=W]PCI)AW0%%,'
MB[Z#(^^1F.#69JBI,!\CKR$F4E@0"SA4#E(L#!WS5MHVZ<AODM9-%J =NH95
M3P=XNW(=Z[#.3_@^_'%+C+40.3HZZ[UP4*PGCS'%#)%CAE(?I#(9D3=Z\OL-
MPKI)"+3#VI"JZ>)47%?DW&;B9M<8P4H(V8'3L0Y<2@&\=1JBET&E8+SP;2[U
M'J>IFZQ"0VLVC$(Z,&.WF)A8LK$Z*$D;06GR%@N=^"0A(#_1QIHX$[+- 7F+
MB&Y2#">I/]A+Y!V$B \E0C9V4[/^ID[T("VM5HMIO%C5B^[W\[HO:J@R/Z=/
M_+ >ZX#+FWA;<:83"D'Q=J$C/[ $WI<$EB)GIXPROK1I^#0L']WD,]IA=D3%
M=W$"O[E:>2V(36L:ES%'C0:$U!D4UFMU-+2+%4:F%6KQY/30HYZSWR=F[)YE
MXZ'CX;OWHQ35P9%\JPOYAG[+!#FLQ@-SVE!DY,F;4#%!#LZACL;0MQLE0>Y2
M,G8-:C<H.TI%71BTLYS7Q;OA_$V84J3T+'R>DI<P8=DE-)Z!%M[5V*A>T+L(
MT4H5G!>ER$8]&+<3-&[BK2/(#:&P+I#W%E=A.L/\<UC,2$C+LY0N/EVLB]<H
M<)^F*07H4DFRRG5XM">#';, [PQ"2B9D)F+*C1X/?INV<5-U'>%Q8#7N#TV_
M@>8,5T-54E_1OVEJ,O]$A'S$V7+Z!3>9I%?S9<T?O2[OPQ\3[9S+ABR^B+6E
M2=$*8F &4$6+UJI<6+.^6?L0.FZ^KR/ ME1P%X;UH:PGQ7F4DBAGD:=--PQ7
M#)T5W)L4G+ \M\GH/*1EW*Q@1S@\4DT=9(&^E7&8"*^=E2Q"'8U3VSTY"$Y*
MT$H)*[.(A3\U1KO=8[J=0#CX_("QLHO'*V<PL+4?-7#]0G$Y+Y>7C?33WV:!
M-CG]^"Y'AP\?^-8RK<81[,7>0 ,*-H?B]<K7\.3%\JB2!*MJ5Q*G'$3#+$BC
M<J (1%G1IJ+^$8*./S@O/_!]-?Z3G#-#K2T4CXHB*JQN*_FNRBHFL[=H9)OH
MXRX=XZ;TAM#]PY/O8#F/F)9;+E:UY5B^2*O7BW>X^#)->/;'=#E!'24Z0;8Y
M"$VG=L@0H@Z0%/(8L3##=JJHI 5N883^=!\?CU$P=M+W<&W.!Q1M']!8'[8;
M#I;/YY\H-)X8C:@L4KRK#&T5N^EH2#YCMLJ'6(Q1.WE!^^#C(1GC@&08S3Z$
MR9%B[B"[_XI(I\/]%_P4<3%)ED4A@P:?1!TJ2N*(/B!XRT7.,3@O6W4 N$7&
MZ!@Y5JT/?.!#93SRPX]+PG^?KC[>ZZ%+[OPE.SE%Y)E[6,\+6T^=]%HS,$8[
MQY7UC.W2SWB'I<:Y[AD>%BTDVX$EN132C8S6::U+7D1*N03#8-VS26D3P!F/
MD+4N+KF45:/G'D]1-<YE3CL[,Y@&.D#3M3M'H2J^I"^7$U_(;0O10E3DYBMO
M#03)"S#IL7!FLLQM>B(]I&7LF^>C7=V!Q-P!4-[B%YQ=X$U7L<"=4+)FD%)M
M6<(24DA(7Y40LT"-U7PVNJV[2TDG\="!FGUPOW:$F+NXC[CDH+ZGW/9>Z;K;
M;>TL1_^7UY<NFL<DI8$<.1W!C!MP/D;(CHQT]A(1V]14'4#LN' [#A_;P=9,
M55W@\?H)RO7\BBO1.7(!2LR23GY&9MS(!(%Y!;QD*Y6,H<@V;S4>):F3\VX8
M4S:,X+O T%M2!)%0!Q<^ISUS/E\/'KCD:\*-B%XF"RY3V*!83A1IV@@F21<$
MTD],FY>Q3Y(UKIT:2/D/#-90>N@"5G_#&4GIO':&RY^FLVF5T&KZ!:\8HOA$
MB, 8Z.)K[PK.P25.5MZ()#1+.J0V%:#?(&Q<,]4&6D/JH@MP/1#3));D17T'
MCCG1T2V\J).8 MA$\:\+CJM&@[8?D#)N>6<; !TG[P[J.ZX9N*F*F@CKE-,^
M@/>R4*0;!3AE-'")RCN11;)MCK8MQ(Q=$]S&.3I0V!W@Y=?Y;'Z7BZNQ@]?U
M4CJXE.MCV^+89GIJU"6!")XG+70RC2H&ODG:V/6\@V)I6$5T<7A=E=YMV+G>
M+).$QFEM/0AO$)2T&:+(!:0K6JHL1/&M:E"V$C2NDSVPXA^.*CI:!QTD+J_8
MN'+D:JF;3#E"Y"+1&:\I2BB%U7H6P[UB+L<V=3[W"!G7B3X-= Z1^1%/ C[4
MV[WW@US)/OL89A_PY6S]SNMUN35C_N7LYB:Q%I.'V=<)"RDA19W #,6;2DL+
M7BH&002T,KA2U"X-^?9:=%QWJ U^VDJ^BY-MVY3!WV8+#.?3_\3\MS"=K7W!
ME&30%&6"T<:""D@L64'^0.#9H!92Q#;O3':C;US_J:WQ:J"A#H[!]1WUHX*;
M<%=XU*9 ]K5IH65(GBAG(!3S2#_QTO(F>'N:KG&?,;7%V8 :Z0!?-W'LU772
M='9!3-U4K?^$9;[ Z^Y,N/R%S/UB_2;G\IW-+-_]E,U._ 57'^?YUCDPX2C6
M<@<GF"(/U#-P)612@G(LB1P"MKFX.2&3XSZ<:NT>]HF5#I(JNS%EA$8Z9CQ9
MA#I_':.#H$V=P(7(A&'<YC;6>CCH-FOF=$KH#J&?#FSWK[BZE89DWJ?L/.G>
M;NHA(SAMR+N1F)%)9DNC /D.&>-V5VH+HL/EW8&%NGKY_P87[SZ2,'\*RVFJ
M%[+3\PL*S&X*4[S@GCQBX.N2?R<I^I>V@$XQ9%5BRJ9-*>J.!([]0G[0%' +
MI71@F+:R-7%TB$L?#$1F$RA%09>S%H$CMU'P%*)H<X^YE9QQ4\!-%+\+N/;2
M0H=0NA301&;4KF@&F&LA.(7TX)524+R2022>C&ISVCU"T+AIX3'@=(@F.@#4
MW[$.5R>9?"$_X0/^>E'+_U^7-4O+UQ>KY2JL!XML1'@]+#<P(;5UD%+-5V9#
MYCZ1S3=(HBN),\W:A*X'D3MV]XY!S\CV"OO>4#E129=<, %R3>*T*,CU3 ZT
M\C+;[)*,;9YZ[$7FN"?L"6!S#%#WTF&_ +T\!![P.,DY*8XIU>GBA4Z:(,%K
MF2 Y';-VD@5Y4H@^1NBXYW8W(!U$CX/!]+3]9^ZT%JNA?=,V-$^L=HIN-+LR
M.U!3FNNEZXUP39V04[JEE=LUM%/AD<420".OE9PVD,M (8J5/,H@B\=&#4WW
M)'38U%U*W#KA''##R2UGP8&7G$X%#"PZZ9AE;0K&]T_=M7^0UP I3R?R]I%^
M!R?Q+NT0*4:;UM1V6M3Y/<]Q\]^;>FGE&*LMR@1G$E1D&7P=>E>B1AFT5EJT
M>;=W/.V=/+4Z 4A/K.?.D?UBOB#/9;89UIB^OE^$V9)8K'J?Y?6?SC<HR/]^
ML;G.N6X-6I03:R=;L$R[6@</41K:Y-RHQ!V:)!O->F["S\@/Q$Z,RCTVQ8D@
MTO%&N2EW^I_S\^J^7U4]O9[=U$6=+:9+^M%S^N/LPT95UW)@2!K@I@#'FAR.
MSH-+B@$K443A@B=QG'2K',O1R$_>^MPL)X5)!]MEBPBN6#FDK_#$").MY\1^
M'4NNO&?@159  ;&7?CV;O,W=P\",=/(RZP2^U)@(^$Z[\C[L1=PT+?+4<J?(
MB^S,[O")D2=:2^? <F0^0T%I08E82Y-0@TY:F^!4Q-)F7N1.Y W<R;=8IZ64
M'I*O+5%J0[<@:V[3(;<L.7-KGON?MI/O\+CX1E_??:3>P5E^3?U&(M6PSV=U
M"V_ZE>9$CKPMM8L;.2:L<'#%![!""JY<)B>_3:CW)%F=(.H ?3\&G:.%WP&2
M[O%PV6 PRT0^;!:@F0R@<N+D;PL#+!B98W:1-_+MMI+3"7*.5_?6MSK'R+X#
M -T=7GC5E=0BVD@[J\Y+@GJ7"PXUN8<\U4KV*%313?"SC9J1:]R.5_*3XR(/
MD'@'J+DUC/"2@:)%G33MP+#ZU(&HAI!H(^4BHG3)QM2HB]X#4D8N8AL<+\?)
MN@.P/#)&\)(979\L^B*!I"!!H2ED@7.=:^2R%445H=K,BWJ2K'&S"L.#:#@=
M= "H^W, +[F03*OL0H):S G*2E,3>@IT8"6@4BS)-J?6=GK&?:8\/(0&D'H'
MV-EA)-\E8Y%E&6*V$$+F]9%-@(A:DN@\^I"]=[[16-I=21SW%4D#(]5$-R,/
M:WFV8:EV\RL%TVIS"_&ZG.7YY[6J:A@B8_+6B0C%&0^*#G"H[_M!1J8QIB)%
MVLE[VFENRRX4=5*A<'BTWT3TG4/I<@LZD;D(HDZ<SP:4PT+B4O6.(3&O0[3&
M[]0W;Q PC3T1:'@,[ &P Q32.<1NR@XN+;&3S!E>W^%82[&(862)!3'(G4^I
M"(;"#C=Q:E_J^H7=(<C8Q[(=HZ8.O+0MKV^DUH75-O,YN%K=DCTX8^H07"Z,
MT"GR1MU #YP,TO[*><!4^&%B[@ H]TM.7LX>7CB]G9^?OY@O?@^+//%*U9MW
M2_%M=4_K&($02@;C(C.1]@:Z-FFJ/0GM)&=^("X>]JUHIJ0.,+AY;_)RN;S
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MB^'S=Y/]'#.2U590>%#DP&9.D5>BT$G9K+)S#!L]Y^IH6D!KK3]YV[*/ KK
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MT#KN87_J0'PHI?7A==[RIJ]:N]<!UY\^S3=#6R;<6=J_R4*JK914<>1(R^)
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M(D@J5@BTT36!V#<(^]Z+JXZ!W) ZZ_7J^"U^P=D%_7J:?YBMK?<!-R%;/F2
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M[;,O87I>Q?YBOJB-N&_6J@[U+*WO8NHP^_H[-UO.T!X6*2,866@S&^_!&<V
M!=ILCN=@2AM;>"SEW\V)O@\*'_1/.J5Z.T@XW?![;58V7@D)^%;A[Z6IR:]G
M;ZL8:AOX]63%>\R[*+44BO@F1P64-K$^K['@5/04K'(F6:..7T.R\=WX!<,
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M4GH3/N/BDHE89"G&!3 >,RBMD)A !D)9KGW4Y+>T*OS80LZXQ6_= .]X5?6
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M8X[1(V7?'7J>A15^F"^F_QEN#0\UV5@KR9\UFJ?:4-.!-\1@\1'1UF>1N_7
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M@;L\:++_A6'YX<_%I4M6ZTPS"YY4K#2M3A=] &$CU]R:($2;0_]CI.UIEYX
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MQEZ+D94W/0"8W3<'43")0 LXZ7K"9 6"L\4#MYPB]F!B,4,BS\>^/VUP,1X
M3E=>!YO#[3GC]L;CQ>+SE\6\<J!M/*/CC*'6#DQ"\HS&)O*,V4")244L4AC1
MZMG\$V)-6]78_%C_9$MT *L'<[AI;J&*83Q$6F*\WKV+#('6& 1+>D$KA IM
M0H^]XG1RP'^ZN1=CZ[X# /UX_.R#=:)V"$13:<.S"93R.0&AQ!!9<9XRM_^$
M<_X1S/O3H_Y#=-T#6/8^'919D[P<:>4H5IF.&67QSH(62A2!4@K?Z*G1T2]]
MFU5 M]JT3M?\I#5^FS/#39W8]P>'X:_9Y^O/=V6RNY;7Q01K0[25V$J1IK"
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MD3E-HM=V+$715AQ,!%'58I)D)K0ITKTGQ+1/>?O8:XZU23]PVBVNK)#BKN*
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ME6#R;H:[AZK2)QNP.)!>;,H0*M4D"\#J2S"?8D VB'YN-'3NDW)*SLZS >A
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MP $..ZS-&(Q$&2&F#2>D$A0:B 1""R]H43(?6U)HCG&(/D&%SRDH'-\NDUZ
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MWH1SWI@=9-N?\B8<HN@.D/+0[](_VZR?5$3E!/%0%,7IRFH#SGF:D-+6BDH
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MJ4K%O!N=2'Z-W!\J-[$_]1ST]&1VJ+U7R*O&,1S,-B0W%[#0R7EN;X!'U:/
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M".+*K0YYX)NI^AJ^X/+?DIW^#U!+ P04    " !A?ZI4__:IPVL&  !U(@
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M:<CN/U!+ 0(4 Q0    ( &%_JE1R8E>Z8YX" (//%@ 0              "
M 0    !I;F\M,C R,C S,S$N:'1M4$L! A0#%     @ 87^J5&S!R&<'$@
MLKP  !               ( !D9X" &EN;RTR,#(R,#,S,2YX<V102P$"% ,4
M    " !A?ZI48E5,\I(=  #L(P$ %               @ '&L ( :6YO+3(P
M,C(P,S,Q7V-A;"YX;6Q02P$"% ,4    " !A?ZI4 WG?KIUC  #C1P0 %
M            @ &*S@( :6YO+3(P,C(P,S,Q7V1E9BYX;6Q02P$"% ,4
M" !A?ZI4P2!5\1XI!@"'!0< $P              @ %9,@, :6YO+3(P,C(P
M,S,Q7V<Q+FIP9U!+ 0(4 Q0    ( &%_JE0]$ H&=>T  !' "0 4
M      "  :A;"0!I;F\M,C R,C S,S%?;&%B+GAM;%!+ 0(4 Q0    ( &%_
MJE2@["%;3XX  !I:!@ 4              "  4])"@!I;F\M,C R,C S,S%?
M<')E+GAM;%!+ 0(4 Q0    ( &%_JE3;@OL560@  ) G   5
M  "  =#7"@!I;F\M,S,Q,C(Q,'%E>#,Q,BYH=&U02P$"% ,4    " !A?ZI4
MR&3^&U,(  "F)@  %@              @ %<X H :6YO+3,S,3(R>#$P<65X
M,S$Q+FAT;5!+ 0(4 Q0    ( &%_JE3_]JG#:P8  '4B   6
M  "  >/H"@!I;F\M,S,Q,C)X,3!Q97@S,C$N:'1M4$L%!@     *  H D (
' (+O"@    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
